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About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) is one of the European Union’s decentralised 
agencies. Established in 1993 and based in Lisbon, it is the 
central source of comprehensive information on drugs and 
drug addiction in Europe.
The EMCDDA collects, analyses and disseminates factual, 
objective, reliable and comparable information on drugs and 
drug addiction. In doing so, it provides its audiences with an 
evidence-based picture of the drug phenomenon at European 
level.
The Centre’s publications are a prime source of information 
for a wide range of audiences including policy-makers and 
their advisers; professionals and researchers working in the 
drugs field; and, more broadly, the media and general public.
EMCDDA monographs are comprehensive scientific 
publications containing thematic papers prepared in the 
context of the Centre’s activities. Topics cover a wide range 
of issues relating to science, policy, epidemiology and best 
practice.
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Introduction
Smoked, eaten, imbibed — or just talked about — it seems the world has a strong 
appetite for cannabis. An estimated one in five European adults have tried it. Thirteen 
million Europeans have consumed it in the past month. Globally, nearly 50 000 tonnes 
of cannabis herb or resin is produced for consumption each year. Little wonder, then, 
that cannabis has become a controversial cultural and commercial phenomenon. Today, 
cannabis has a unique ability to divide opinion among policymakers, scientists, law 
enforcers, drugs professionals and consumers.
This EMCDDA cannabis monograph addresses one basic question. How can I find 
quality information on cannabis, amid all the bias and opinion? During the editing of 
this monograph it soon became clear that the EMCDDA was entering an area crowded 
with general guides, even competing cannabis monographs. This is where the idea of 
a cannabis ‘reader’ emerged. Our audience — researchers, parliamentarians, drugs 
professionals, students, European citizens — is currently faced with an overload of 
professional publications. Added to this is the daily flood of information on the Internet, 
often crusading in nature, and sometimes misleading. This threatens to obscure the 
genuine progress made in cannabis research during the past two decades.
The EMCDDA cannabis reader underlines the point that cannabis is not just a static, 
unchanging plant, but a dynamic product that is subject to gradual evolution in potency, 
prevalence, cultivation, legislative and public health concerns. In this monograph, 
leading experts provide short, sharp insights on a range of cannabis topics while 
offering advice on further reading for each topic. Brief editorial notes provide concise 
introductions to each topic, occasionally drawing attention to political sensitivities and 
the need for a ‘critical eye’. So this cannabis reader has a value, both as a shortcut to 
researchers entering the area and a synthesis for experts.
You will find a wide range of views expressed in the chapters in this monograph, not 
all of them in agreement. The arguments, tone and conclusion of each chapter is the 
responsibility of the author alone, and is not necessarily endorsed or supported by the 
EMCDDA. This reflects the wider discourse on cannabis where different positions and 
perspectives often lead to different conclusions being drawn from the same evidence. 
We believe each chapter represents a useful contribution to the overall debate, even if 
their individual perspectives differ.
Introduction
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Two volumes, multiple audiences: policymakers, 
enforcers, researchers, professionals
The monograph is divided into two volumes, each comprising three sections. There are 
a number of reasons for the two-volume approach. While complementary, each has a 
slightly different audience. The first volume centres on political, legislative, commercial 
and social developments relating to cannabis. Its core audience thus comprises 
policymakers, sociologists, historians, journalists and those involved in enforcement. 
The second volume is very much centred on drugs professionals working in the fields of 
treatment, prevention and healthcare.
Volume 1
Cannabis in the past•	
Policies, legislation and control strategies•	
Supply and production issues•	
Volume 2
Epidemiology•	
Health effects of cannabis use•	
Prevention and treatment•	
Changing perspectives: from global issues to local 
experiences
What unites both volumes is an attempt to fuse general chapters with specific case 
studies. Within each section, you will encounter a progression from a ‘top level’ to a 
‘close-up’ view of the subject. So each section begins with chapters providing a general 
introduction to a single cannabis issue, often of an encyclopaedic nature, together with a 
summary of the current state of scientific research. The monograph then ‘zooms in’ with 
a case study about a specific aspect of cannabis.
In Volume 1 ...
In Volume 1 we can read an autobiographical article on events in the United Kingdom 
in the late 1960s, recent cannabis developments in the EU’s new Member States, the 
cannabis resin trade linking Morocco to northern Europe, the closure of Pusher Street 
in the Copenhagen commune of Christiania, and information on how coffee shops 
developed in the Netherlands. While these articles focus only on smaller pieces of the 
cannabis puzzle, they provide insights into the many different ways Europe has dealt 
with cannabis.
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Foreword
Cannabis is Europe’s most-consumed illicit drug. An estimated 13.4 million European 
adults have used cannabis in the last month. Cannabis also supports a multibillion euro 
market across the EU, with the share of cannabis resin in many markets losing ground 
to herbal cannabis. Moreover, treatment demand for cannabis use is rising in many 
Member States. Such facts underline the importance of having a clear understanding of 
what is known about cannabis in Europe, for example its impact on public health, how 
cannabis controls are enforced and the implications of cannabis use for public health 
responses.
Cannabis is also, perhaps, Europe’s most heavily debated illicit drug. Reviews of 
the health effects and legal status of cannabis have been carried out by numerous 
governments and agencies over recent decades. And there is frequent, sometimes 
heated, discussion about cannabis in the political arena, amongst others in relation 
to mental health problems, the therapeutic potential of cannabinoids, policing and 
enforcement, legislation and sentencing.
So it is with great pleasure that I introduce this important body of work on cannabis. It is 
the most comprehensive publication the EMCDDA has ever produced, and the first time 
the Centre has attempted to review a single substance in such an all-encompassing way. 
We must extend our gratitude to all authors who have contributed to this monograph. 
Excellent work was carried out by Sorad in Sweden, together with reviewers from the 
EMCDDA’s Scientific Committee, and two independent scientific editors, John Witton 
and Wendy Swift. The result is a ‘cannabis reader’: a genuine navigational aid to 
research, debate and policy-making on the substance. The reader approaches cannabis 
from many angles, and will appeal to a wide audience, ranging from ‘beginners’ 
approaching the subject from other disciplines to drug researchers and professionals 
who are familiar with the literature and who may appreciate some synthesis of the state-
of-the-art in current research or practice.
A cannabis ‘reader’
While cannabis is the most consumed illicit drug worldwide, politically cannabis is a 
great divider. The illegality of the drug means that the evidence base is often patchy. 
Lobbyists, libertarians, prohibitionists, think-tanks and commercial interests all by 
definition speak to the issue from divergent positions. Even research in this area can 
sometimes appear to be influenced by a political as well as a scientific agenda. The 
information base in this area is considerable and this fact alone poses a serious 
challenge to any reader who attempts to navigate it. The goal of this publication is to 
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gather knowledge that will provide a base for improved policy approaches to cannabis 
in the future. In reaching this goal, leading experts have been asked to clarify what is 
known and what is not known about cannabis; on which issues scientists agree and 
which issues are still under debate.
In the development of the monograph the EMCDDA has been keen to provide a non-
judgemental, non-partisan approach to the evidence. However, our aim has also been 
to enable each author’s ideas to be fully expressed. As leading experts in the field, they 
are qualified to make judgements where they feel fit, and while most of the monograph 
is analytical and descriptive, the nature of the subject matter means that, in places, 
opinions and views are expressed which may be perceived as controversial. Not all the 
views expressed here are in agreement.
Chapters have been peer-reviewed by the EMCDDA’s Scientific Committee and further 
edited by qualified scientific editors. The EMCDDA has introduced each chapter, and 
where opinions are expressed, references to counter-arguments are given, together with 
a reading list, for those seeking to explore the subject further. Authors have also been 
given the opportunity to adapt their chapters based on peer feedback. Nonetheless, the 
chapters remain very much the work of the respective authors. They should be read with 
the proviso that any views expressed should neither be considered those of the EMCDDA 
nor the EU institutions in relation to cannabis.
Maximising the shelf-life of the monograph
One of the challenges with working on illicit drugs is that the field is in constant 
evolution. Use patterns and prevalence, use context and even routes of administration 
and potency of product can change substantially over time. This is particularly the case 
for a drug like cannabis, where our understanding of the public health impact of the 
use of the drug is growing almost daily. Another example of this difficulty is the field of 
medicinal cannabis, where a number of new medicines are currently being developed 
in various parts of the world, with considerable uncertainty as to the scope and range of 
potential therapeutic applications.
What is certain is that this will not be the last monograph published on cannabis. There 
is a publication cycle of one governmental or think-tank monograph on cannabis every 
few weeks, and this is likely to continue. Around 20 major books on cannabis are 
produced by commercial publishers each year, in different languages, with many more 
in the specialised and scientific literature. So the first volume of the monograph includes 
an Appendix that sketches a brief history of cannabis monographs and grey literature, 
referring to the large range of monographs on cannabis. The EMCDDA monograph 
hopes to (i) identify the producers of literature on cannabis, (ii) illustrate the range in 
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thematic focus of publications and (iii) provide a one-stop research resource for recent 
major publications on cannabis. This Appendix will reside in a more dynamic form on 
our website. We hope it will provide an important stepping stone to information on 
cannabis, published at national, European and global levels.
What this reader adds to the literature
Each chapter is preceded by a section entitled ‘Setting the context’. These are provided 
to guide readers through the monograph, to offer suggestions for further reading, 
and to draw attention to the cycles of reporting on cannabis — often annual — by 
organisations such as the UNODC, the EMCDDA and our Reitox National focal points.
Readers will be interested in knowing what they will gain from this publication. The 
first is the multidimensional approach to the subject matter. It describes cannabis as 
seen from different perspectives: historical and cultural, pharmacological, sociological, 
legal and policy-related, and treatment- and practitioner-related. The second is 
the monograph’s supranational and European focus. While numerous cannabis 
monographs have been written at a national or multilateral level in Europe in the 
past decade, this one can claim EU-wide relevance. It is backed by the EMCDDA’s 
epidemiological statistics, based on reporting from the Reitox network and the Centre’s 
privileged position of being able to select a strong team of authors for the monograph. 
Thirdly, the monograph reflects emerging trends, for example in legislative approaches, 
treatment demand and provision and cannabis potency.
We hope you will appreciate the effort invested in this monograph. It provides a step 
back from the EMCDDA’s annual monitoring activities. This wider perspective is both 
refreshing and eye-opening, even to those of us who are seasoned experts in the field.
Wolfgang Götz
Director, EMCDDA
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Overview of Volume 1
Part I: Cannabis in the past
 1 Cannabis as medicine in Europe in the 19th century 
Manfred Fankhauser
 2 The re-emergence of the therapeutic use of cannabis products: recent developments 
and future prospects 
John Witton
 3 The pharmacology of cannabis: issues for understanding its use 
Desmond Corrigan
 4 Soma, the Wootton Report and cannabis law reform in Britain during the  
1960s and 1970s 
Stephen Abrams
 5 Cannabis’s role in drawing attention to ‘the drugs problem’ in Sweden  
Börje Olsson
 6 Enlargement 2005: cannabis in the new EU Member States  
Jacek Moskalewicz, Airi-Alina Allaste, Zsolt Demetrovics, Danica Klempova and 
Janusz Sierosławski with Ladislav Csemy, Vito Flaker, Neoklis Georgiades, Anna 
Girard, Vera Grebenc, Ernestas Jasaitis, Ines Kvaternik Jenko, Richard Muscat, 
Marcis Trapencieris, Sharon Vella and Alenka Žagar
Our understanding of cannabis today is bound up in an understanding of the past. We 
begin this monograph by looking back on how cannabis was used and understood in 
the past. Throughout human history, cannabis has been used for many purposes such as 
recreation, therapy, art, religion, medicine and as a textile.
The first two chapters in this section examine the role of cannabis as a medicine in 
Europe in the 19th century, together with more recent developments in developing 
cannabis as a medicine. In the past two decades, great efforts have been made to 
assess the usefulness of cannabis as medicine, as cannabis is currently being used in 
a small way as medicine. Nevertheless, the role cannabis plays in medicine today is 
modest compared with the past, and although there are reviews on the subject, well-
established and secure conclusions of the extent to which cannabis is a reliable and 
useful medicine remain uncertain. Many have pointed out that there is a need for further 
research on the subject.
Rödner Sznitman and Olsson
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Moving on from a historical and contemporary perspective on cannabis as medicine, a 
general introduction to the pharmacology of cannabis is also presented. Although the 
psychoactive effects of cannabinoids have long been known, it was not until the 1980s 
that the first evidence for the manner in which tetrahydrocannabinol (THC) acts on the 
brain became known and, as Corrigan’s chapter highlights, important advances have 
been made since then.
This section proceeds to focus on two case studies that discuss the role of cannabis in 
youth cultures in the 1960s. As Abrams and Olsson show, cannabis became widely 
known as a recreational drug with the youth cultures of the 1960s. Government 
responses to the increased use of cannabis were probably as much concerned with a 
response to the youth cultures as they were a response to the substance use in its own 
right.
The section ends with development in the more recent past: the enlargement of the 
European Union in 2005, to embrace 10 countries in Eastern Europe, the Baltic States 
and the Mediterranean Islands. This round of enlargement is an event that remains fresh 
in the minds of those who will read this monograph in Europe. Yet with the subsequent 
addition of Bulgaria and Romania, and the welcoming of new candidate countries, these 
Member States are beginning to become more firmly integrated within the fabric of the 
EU. Time will tell whether the large variations currently seen in cannabis use across 
these countries will evolve to reflect those in pre-2005 Member States.
The different chapters included in this section constitute only a limited presentation of 
cannabis in the past. Nevertheless, we hope that the section facilitates the beginning of 
an understanding of present-day processes. As people living in contemporary society 
with contemporary concerns, we sometimes neglect the importance of the past. We hope 
that these introductory chapters illuminate that although much of this monograph is 
based on up-to-date data, our understanding of cannabis today is partly a product of its 
past.
Part II: Policies, legislation and control strategies
 7 Cannabis control in Europe  
Danilo Ballotta, Henri Bergeron and Brendan Hughes
 8 In thinking about cannabis policy, what can be learned from alcohol and tobacco? 
Robin Room
 9 An open front door: the coffee shop phenomenon in the Netherlands 
Dirk Korf
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 10 Cannabis policy: tightening the ties in Denmark  
Vibeke Asmussen
 11 Cannabis: a harm reduction perspective  
Andrew Bennett
There are three main UN drug conventions, two of which are significant for cannabis. 
The 1961 Single Convention on Narcotic Drugs provides for controls over cannabis, 
as well as other drugs. The 1988 Convention Against Illegal Traffic in Narcotic Drugs 
and Psychotropic Substances strengthened the international scope and framework of 
cooperation against drug trafficking, including trafficking in cannabis. All EU members 
are signatories of the three UN conventions on illicit drugs, and the EU itself is a 
signatory of the 1988 Convention. Consequently, all countries within the EU have 
adopted some sort of legal prohibition against cannabis, and the UN conventions have 
played a role in constraining national legal experimentation on drug law and policies. 
The international UN conventions on drugs are unique. There is no other issue where 
one can find a universalised discourse translated into such similar legislation around the 
world.
Nevertheless, and as made apparent in this section, the appearance of harmony in 
the EU is to a large extent not a reality. Wide room for manoeuvre within illicit drug 
legislation has been taken within the EU. Individual national legislation is possible 
despite the UN conventions, as treaties allow for discretion. Additionally, national 
variations in drug use policies are accommodated within the EU organisational structure. 
Although the EU has launched several drug action plans, full harmonisation has not 
materialised. And though the EU takes complementary measures, there is no coherent 
holistic approach to drug issues in the EU. The EU considers drugs to be mainly an 
internal security concern. This implies that there is little overarching influence from 
the EU on national drug policies. Individual countries are relatively free to experiment 
with different drug-related policy regimes. Especially prominent is the case of cannabis 
liberalisation policies, explored by Ballotta et al. in this section. The chapter makes 
evident that many EU Member States have gone their own way in terms of how to 
interpret the UN global control regime on cannabis.
The different approaches to cannabis-related issues are often discussed in terms of a 
philosophical shift between zero tolerance approaches and harm reduction approaches, 
or in terms of criminalisation and decriminalisation or repressive versus liberal regimes. 
This is, however, too simplistic a notion of the issue at hand. Clearly, as shown in 
Ballotta et al.’s chapter, there exist multiple approaches to legislation regarding 
cannabis within the European Union today, and specific legislative categories are often 
difficult to determine. The Netherlands, for instance, which is often thought of as a 
liberal regime, is still a prohibitionist country. The Netherlands uses roughly two-thirds 
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of its budget for drug problems on criminal action. As noted in Korf’s chapter, although 
possession for personal use and use of cannabis is decriminalised in the Netherlands, 
production and supply of cannabis are prohibited, and criminal sanctions are enforced. 
Seen from this perspective, it might be informative to think of the various issues related 
to cannabis control as continuous and blurred, rather than a case of dichotomy of 
liberal or repressive.
In terms of the effectiveness of the various cannabis policies which exist in the EU, 
evidence is scarce. As Room points out, the drug field has much to learn from the 
tobacco and alcohol fields, in which policy measures are more rigorously examined and 
there is a relatively well-developed evidence base on which strategies work and which 
are most effective in terms of reducing the harms. In comparison, the policy impact 
literature is relatively undeveloped with respect to illicit drug use. Indeed, different drug 
control regimes are rarely rigorously evaluated. Despite scarce evidence, a modest 
research literature exists which remains sceptical about the effectiveness of cannabis 
prohibition. Korf suggests, for instance, that cannabis possession laws have little 
influence on cannabis prevalence rates and are thereby not an effective way to deter 
use.
It is also generally agreed that there is a gap between formal policies and policy as 
implemented. As is shown by Ballotta et al., the most common penalties for cannabis 
possession range from fine to incarceration. Nevertheless, reports suggest that in 
practice most detections lead to a fine. Additionally, evidence of a ‘net widening effect’ 
exists. Researchers have noted that a relaxation of policies may not have the intended 
effect of less severe consequences of cannabis prosecution. Some have suggested, for 
instance, that cannabis reclassification in the UK might have led to offenders that were 
previously dealt with informally being subject to on-the-spot formal warnings, recorded 
as such by the police force. Since there are few long-term data on cannabis policies 
as implemented and the effects they have, it is difficult to determine the impact of 
‘decriminalisation’ policies.
Researchers generally agree that the harm to the defendant in drug cases extends far 
beyond the cost of the actual criminal justice sentence or caution. Exactly what the 
impact of a cannabis prosecution entails is, however, far from clear. Administrative 
measures do not necessarily mean a more gentle approach than criminal measures, 
as administrative measures might be associated with additional costs for the individual 
user, for instance through a reduction or withdrawal of a student’s loan or difficulties in 
employment opportunities. While evidence of this is available in the literature for the US 
and Australia, little evidence exists for European countries.
Harm reduction policies, as mentioned by Bennett, start from a recognition that 
substance use has been and will continue to be part of human experience. Acceptance 
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of this fact leads harm reduction approaches to develop strategies with the aim of 
moving people towards safer forms of substance use, possibly with abstinence as the 
ideal. In this way harm reduction is a radical move away from more traditional illicit 
drug strategies that solely aim at abstinence. Another distinct feature of harm reduction 
is its emphasis on respecting drug users and on moving away from paternalistic models 
of care.
A strength of harm reduction strategies is the firm focus on secondary as well as primary 
harms of cannabis use. In addition to the attempt to reduce primary and adverse health 
effects of cannabis use, harm reduction strategies recognise that harm also arises as a 
consequence of legislation, policies and police strategies. Unfortunately, the secondary 
harms are far less researched than the primary harms of cannabis use, and this poses 
a challenge for future research efforts. Indeed, and as pointed out already, the current 
evidence base on the impact of drug policy regimes is weak. In order to learn more 
about the relation between policies and effects, there is a need for carefully designed 
studies that are able to determine the impacts, primary and secondary, of cannabis use. 
The most appropriate way to go about such work is through quasi-experimental designs, 
and where possible true experiments.
One criticism of harm reduction strategies has been that it sends out the ‘wrong’ 
messages. This claim can be countered by a variety of responses, for example, that 
public health approaches in other fields such as sex education have adopted a harm 
reduction approach, that the community understands harm reduction messages, and 
that they are not an encouragement to use drugs. But symbolic values can be as 
important as evidence and the emphasis on symbolic values might be a useful starting 
point for reaching an understanding of how cannabis policies have developed and how 
they may develop in the near future.
What the future holds in terms of drug law harmonisation is, however, impossible to 
predict. What is clear is that a possible harmonisation, if occurring at all, is likely to 
be very slow, and national and regional distinctions within the EU in terms of cannabis 
policies are likely to continue to be the rule rather than the exception.
Part III: Supply and production issues
 12 Global cannabis cultivation and trafficking 
Ted Leggett and Thomas Pietschmann
 13 Monitoring cannabis availability in Europe: issues, trends and challenges 
Chloé Carpentier, Meredith Meacham and Paul Griffiths
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 14 Understanding cannabis potency and monitoring cannabis products in Europe 
Leslie King
 15 Multinational export–import ventures: Moroccan hashish into Europe through Spain 
Juan Francisco Gamella and Maria Luisa Jiménez Rodrigo
 16 An analysis of the significance of supply and market factors for variations in 
European cannabis use 
Leif Lenke
The market
Current research shows that the main supplier of cannabis to the EU is Morocco. This 
claim is based to a great extent on research efforts made by the United Nations Office 
on Drugs and Crime (UNODC), as shown by Pietschmann and Leggett. Gamella 
and Jiménez Rodrigo have provided an in-depth analysis of the cannabis trade from 
Morocco to Europe. As they point out, hashish is generally taken from Morocco to Spain 
and Portugal and is thereafter exported across Europe. This should come as no surprise 
in view of the geographical location of the countries. It must, however, also be noted 
that cannabis on the European market travels through other routes as well.
Although it is clear that Morocco plays an important role in the European cannabis 
market, it must not be forgotten that there are other significant supply sources of 
cannabis. As is mentioned by Pietschmann and Leggett, cannabis in Europe also derives 
from Thailand, Afghanistan and Pakistan. Various central Asian states and former parts 
of the Soviet Union are also suppliers of cannabis resin to the European market. This 
suggests that there is a strong correlation between poverty and the drug trade. In a 
poor region such as Morocco, cannabis production constitutes an important means for 
families to reach a sustainable standard of living.
It should also be highlighted that over the last decade, domestic cultivation of cannabis 
has started to change the shape of the cannabis market, so that home cultivation has 
in some countries become an important part of the cannabis supply. The Netherlands 
has long been known to be a producer of marijuana, or ‘netherweed’. Netherweed is 
produced for domestic as well as international consumption, and in the last few years 
‘netherweed’ has been seized in the UK, Scandinavia, Germany, Belgium and France. 
New evidence also indicates that the supply of cannabis produced elsewhere in Europe 
is on the rise. Switzerland has, for instance, reported a sharp increase in illegal cannabis 
cultivation. A 1999 Swiss EKDT report argued that in 1998 more than 100 tonnes 
of cannabis were harvested for the drug trade, and it was plausible that Switzerland 
became the second largest European exporting country after the Netherlands. An 
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increase in domestic cultivation has also been noted in the UK, with some arguing 
that cannabis cultivated in England and Wales may now make up well over half of the 
consumption there.
Owing to the illegality of cannabis, both use and trade are mostly hidden. Carpentier 
et al. demonstrate a certain degree of uncertainty when it comes to measuring and 
researching the cannabis market. One can never really know if seizures are indications 
of general trends or of the extent of law enforcement. The trend of an increase in 
domestically grown sinsemilla at the European level is possible, but currently relatively 
undocumented. While international trafficking, mainly from Morocco, evidently occurs, 
it is unclear what share of the market home-produced cannabis actually comprises. 
Although much domestic cannabis cultivation is small-scale production for personal 
use, it should not be neglected, as it contributes to the European cannabis market and 
it might make up a larger proportion in the future. Seen from this perspective, although 
continued attention to Morocco and other international suppliers is important, there is 
a need for more research on domestic cultivation. Too strong a focus on Morocco may 
indeed produce a partly distorted picture of the European cannabis market today.
If cannabis production is to an increasing extent produced on European soil this raises 
new and important questions. Apart from the issue of THC potency, as discussed above, 
a geographical change in the production of cannabis is also connected to questions 
regarding the relationship between the industrial and the developing world. As Gamella 
and Jímenez Rodrigo point out, the cannabis market is an important economic asset to 
poor farmers in Morocco. A possible turnover of the market, with a shift of production 
to Europe, may have negative implications for peasant farmers in the developing world. 
Further, European domestic cultivation has implications for national criminal justice 
responses. At the moment heated debates regarding cannabis are usually confined to 
the issue of possession and not cultivation. As the geographical production of cannabis 
changes it might, however, also change the focus of the public debate towards more 
emphasis on appropriate responses to cultivation. Indeed, EU Member States might 
increasingly have to deal with criminal justice issues such as cultivation for personal 
use, and commercial cultivation, as well as medical growers. We might expect new 
policy initiatives, and with these a need for scientific investigation into how the market is 
evolving and how it responds to new developments.
Potency
From time to time, a wave of media interest across Europe contends that cannabis in 
contemporary society is stronger and thus more harmful than it was in the 1960s and 
1970s. Claims have been made that cannabis consumed today is 30 % stronger than 
in the past. This belief, though strongly held, is something of an urban myth. As King in 
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this section notes, the myth has been fuelled by media and politicians, and researchers 
have suggested that the figures come from misinterpretation of the data which, when 
calculated in accurate terms, actually translate to a 1 % increase.
Clearly, there are controversies concerning cannabis potency, and in-depth and careful 
investigation is required in order to explore properly the issue of THC potency. King 
investigates data from seven European countries. When using potency data combined 
with data on resin and herbal cannabis consumption, a weighed mean potency is found. 
Following this strategy, King finds a potency increase only in the Netherlands and he 
thus concludes that no overall upward trend is found except from indoor-cultivated 
Dutch resin, which is thought to make up a small share of the market. But despite 
King’s reassurance that overall cannabis potency has not increased dramatically, there 
is evidence which challenges this view. This is, for instance, pointed out by Leggett and 
Pietschmann in this section, who point towards a possible trend for indoor domestic 
cultivation of sinsemilla to increase in several European countries. Claims have been 
made that this type of cannabis is easily modified and does often imply an increase in 
potency. At present the size of the European domestically produced cannabis market is, 
however, unclear. Additionally, it is unclear to what extent domestic production actually 
implies an increase in cannabis potency.
Clearly, contradictions prevail, and we may conclude that at present it is difficult to 
gain adequate data on the issue of trends in cannabis potency. Forensic data provide 
only a weak basis for evaluating potency trends, largely due to problems associated 
with standardising definitions of cannabis products and sampling issues. Additionally, 
analysis based on drug enforcement seizures may be anomalous in a number of ways, 
including a disproportionate focus on large cultivators and seizures. Finally, it is evident 
that the discussion has been contaminated by scare tactics and ignoring of sound 
evidence. Thus, there is clearly a need to pursue these issues further in order to create 
an improved knowledge base from which the potency issue may be further explored and 
better understood.
In order to facilitate an informed policy debate, there is also a need to explore issues 
indirectly linked to the issue of THC potency, for instance, to investigate adverse short- 
and long-term health effects that might arise from a potential increase in potency. 
Indeed, as pointed out by King, THC potency increase does not necessarily mean that 
there will be an increase in adverse health effects, as an increase in potency may lead 
to an adaptation by the users to smoke less cannabis. In turn this would lead to less 
inhaled smoke in lungs and thus decreased risk of respiratory diseases.
Knowledge of potency as well as the dose consumed by individual users is an important 
and sometimes neglected area in the research literature. As is well accepted in the 
alcohol and tobacco field, the effects of cannabis must be considered in relation to type 
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of cannabis consumed, and pattern of consumption, and hence also THC levels. There 
is little disagreement that there is a difference between drinking a full glass of vodka 
and a full glass of wine and that intense, prolonged use of alcohol is deleterious to both 
physical and psychological well-being. In the case of cannabis, on the other hand, there 
seems to be little effort made to ascertain actual dose rates and hence lifetime intake of 
cannabinoids. Thus, little account is taken of the wide range of concentrations of THC 
and related compounds in smoked cannabis and differences of smoking habits from one 
individual to another. This poses a challenge for future research.
Sharon Rödner Sznitman
Sorad
Börje Olsson
Sorad
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Setting the context
Cannabis has been the subject in recent years of substantial historical study. Overviews 
include Abel (1980), Grinspoon and Bakalar (1993), Mathre (1997), Sloman (1998), 
Matthews (1998, revised 2003), Rätsch (2001), Grotenhermen (2002), Wujastyk (2002), 
Green (2002), Booth (2003), Allegret (2006) and Russo (2007).
This explosion in historical interest is firmly rooted in the present. Reasons for this 
interest include: a wider vogue in historical publishing towards single product histories 
(cod, salt, opium, etc.); advocates of medicinal cannabis research and the hemp industry 
seeking historical legitimacy and lineage; cannabis use among the middle-aged (the 
core audience for history of any kind); cannabis’ emergence as a legislative hot potato; 
lively debate among botanists on the classification of Cannabis sativa (1); not to mention 
the explosion of both encyclopaedic texts and drugs-related historical source documents 
on the Internet. Cannabis has even evolved to have its own portal on Wikipedia.
Rather than retread the all-encompassing historical scope of such studies, this chapter 
provides a focused view of how cannabis aroused interest among pharmacists in 
Europe. It also provides brief reflections on the contemporary revival in research 
into medical applications of cannabis over the past two decades. Analogies can be 
drawn with today’s cannabis debate: for example, European experience of far-flung 
cultures — the past’s Napoleonic soldiers in Egypt, today’s backpackers in Thailand and 
(1) See Watts, G. (2006), ‘Science commentary: cannabis confusions’, in British Medical Journal 332: 
175–176 (available at: www.bmj.com/cgi/reprint/332/7534/175.pdf).
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Morocco; availability of information — the past’s national botanic encyclopaedias and 
pharmacopoeia, today’s cannabis discussion forums and online growguides.
This chapter remains historical in scope. While mentioning recent developments, it does 
not explore in detail current developments in medicinal cannabis. However, a short 
chapter has been added by John Witton, providing a summary of recent developments 
in medicinal cannabis.
Further reading
Histories
Abel, E. L. (1980), Marihuana: the first twelve thousand years, Plenum Press, New York  
www.druglibrary.org/Schaffer/hemp/history/first12000/abel.htm
Allegret, S. (2006), ‘Histoire du chanvre’, in P. Boulloc (ed.), Le Chanvre industriel — production et 
utilisation, Editions France agricole, Paris.
Booth, M. (2003), Cannabis: a history, Doubleday, London.
Green, J. (2002), Cannabis, Pavilion, London.
Grinspoon, L., Bakalar, J. B. (1993), Marihuana, the forbidden medicine, Yale University Press, New 
Haven.
Rätsch, C. (2001), Marijuana medicine: a world tour of the healing and visionary powers of cannabis, 
Healing Arts Press, Rochester.
Russo, E. (2007), ‘History of cannabis and its preparations in saga, science, and sobriquet’, Chemistry 
and Biodiversity, 4: 1614–1646.
Sloman, L. (1998), Reefer madness: a history of marijuana, St. Martin’s Press, New York.
Zuardi, A. (2006), ‘History of cannabis as a medicine: a review’, Revista Brasileira de Psiquiatría, 
28: 153–157.
For primary historical materials, a bibliography of historical mentions of cannabis was compiled in 
1951 in two volumes of the United Nations’ Bulletin on Narcotics (2).
See also the grey literature list in the Appendix to Volume 1 of this monograph (p. 300).
(2) United Nations (1951), Bulletin on narcotic drugs (available at: www.unodc.org/unodc/en/bulletin/
bulletin_1951-01-01_1_page007.html (accessed 11 October 2007)).
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Cannabis as medicine in Europe 
in the 19th century
Manfred Fankhauser
As in the previous centuries, hemp was predominantly used in the 19th century as a 
fibre material. Herbal cannabis played a marginal role as a medicinal plant, although 
its seeds were used medicinally, mostly in the form of pressed oils or hemp milk as 
medicine against gonorrhoea or cystitis. In tandem with prevailing interest in plants, 
products and culture from the Orient, medicinal use of cannabis arrived in Europe from 
the East during the 18th century.
Much has been written on the historical knowledge in Europe of the psychoactive 
properties of hemp prior to the 18th century: among readers of Herodotus’ description 
of Scythian cannabis-incensed burial rites; by alchemists, in particular the herb 
Pantagruelion lauded by author François Rabelais; via knowledge of Islamic medicine 
via al-Andalus, and elsewhere (Bennett et al., 1995; Booth, 2003; Mercuri et al., 2002). 
However, widespread scientific writings on its psychoactive properties came later. For 
example, Gmelin wrote in 1777 of the Eastern use of bhang for stupefying (‘etwas 
Betaeubendes’), mind-clouding (‘Benebelung des Verstandes’) and intoxicating effects 
(Fankhauser, 2002); and in 1786 the Comte d’Angiviller thanked a certain Boulogne 
for his sending of Indian hemp plants with the prophetic words ‘Cette plante sera peut-
être un présent intéressant pour l’Europe’. At the end of the 18th century, the French 
naturalist Sonnerat informed Lamarck’s 1873 Encyclopédique de botanique of Cannabis 
indica (Emboden, 1974) and brought Indian hemp home to France after a journey 
to the Orient. Napoleonic campaigns in Egypt and the Near East introduced colonial 
troops — notably the scientists Silvestre de Sacy, Rouyer and Desgenettes — to hashish 
(Abel, 1980; Booth, 2003).
European interest in this ‘new’, or rather rediscovered, plant grew only hesitantly. The 
first comprehensive description of the medical usefulness of Indian hemp in Europe was 
written in 1830 by the German pharmacist and botanist Friedrich Ludwig Nees von 
Esenbeck. Until that point in time, use of hemp for medical purposes had remained 
at a low level. This situation changed significantly prior to the middle of the 19th 
century. William B. O’Shaughnessy (1809–1889/90), an Irish medical doctor stationed 
in Calcutta, India, published in 1839 a comprehensive study on Indian hemp. Thanks 
mainly to his On the Preparations of the Indian Hemp or Gunjah, Cannabis indica now 
also became recognised within European-school medicine. O’Shaugnessy used various 
hemp compounds in his investigations, partly with great success, against the following 
indications: rheumatism, rabies, cholera, tetanus, convulsions and delirium tremens. 
With hashish he had found a well-suited medicine to give his patients relief, and in the 
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case of cramps, even total disappearance of symptoms. For concluding remarks, he 
wrote: ‘The presented cases are a summary of my experience with cannabis indica, and 
I believe that this medicine is an anticonvulsivum of great value’ (O’Shaughnessy, 1839).
Europe reacted promptly to this new knowledge from India. This is not surprising as until 
then no adequate treatment existed against recognised diseases such as rabies, cholera 
or tetanus. Great hopes were based on O’Shaughnessy’s results. The French were 
the first to engage themselves intensively with the plant. As early as 1840, the French 
medical doctor Louis Aubert-Roche (1809–1874), who resided in Egypt, used hashish 
seemingly successfully against pestilence (Hirsch, 1884–1886). Nearly simultaneously, 
his compatriot and friend, the psychiatrist Jaques Joseph Moreau de Tours (1804–1884), 
began to experiment with hashish. He started out with experimenting upon doves and 
hares, giving them large doses of hashish extracts with their fodder. Then he tested 
hashish on friends, colleagues, patients and himself. He was convinced that hashish was 
the supreme medicament for use in psychiatry. His book, Du Hachich et de l’aliénation 
mentale (1845), caused a great sensation at the time, and is still understood as the 
origin of experimental psychiatry and psychopharmacology (Weber, 1971).
The works of Moreau de Tours had an impact not only in medical circles, but also 
among writers and artists. The poet Théophile Gauthier (1811–1872), for instance, 
received hashish samples from Moreau de Tours. In 1843 he described extensively a 
self-experienced hashish intoxication in the Paris newspaper La Presse under the title 
‘Le Club des Hachichins’. The club of hashish eaters, of which Gauthier was one of 
the founders, had regular meetings in Hôtel Pimodan on the Seine island of St Louis. 
He and Charles Baudelaire (1821–1867) shared a penthouse in the hotel for several 
years. Other prominent club members were Alexandre Dumas (1802–1870) and Honoré 
Daumier (1808–1879) (Moreau, 1904). Further well-known contemporaries such as 
Honoré de Balzac (1799–1850), Gustave Flaubert (1821–1880) and Victor Hugo 
(1802–1885) participated occasionally (Behr, 1982).
Inspired by Moreau de Tours and later by pharmacy professor Eugène Soubeiran 
(1797–1859), the pharmacist Edmond de Courtive published in 1848 his widely noted 
dissertation, Haschish. In addition to chemical analysis, he carried out self-experiments 
with miscellaneous hashish compounds and gave exact descriptions of their physical and 
psychic effects (De Courtive, 1848).
Many medical doctors took advantage of the promising results of the pioneers 
O’Shaughnessy, Aubert-Roche and Moreau de Tours and used these new drugs for 
therapeutic purposes. Initially, primarily doctors from the colonial powers of England 
and France showed interest in the use of compounds made of Indian hemp. The 
necessary commodities or compounds were imported in great quantities to Europe from 
the colonies, especially from India (Smith and Smith, 1847). Hemp was in this period 
sold to Europe primarily in three commercial variations:
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Ganjah•	 : consists solely of the blooming tips of the female, carefully cultivated plant. 
Mostly 24 blooming tips are bundled in a length of approximately 1 m, and 11 cm 
thickness.
Charras•	 : consists of the resin, which is extracted foremost from the blossom, but 
also from leaves and stalks of the female plant. Today, the extracted resin is called 
hashish.
Bhang•	 : extracted from the leafless stalks of the female hemp plant. Bhang was 
predominantly exported to Europe in powder form.
In Europe ganjah was the first to be pharmaceutically exploited. Initially, the fields 
of application known to O’Shaughnessy were adopted. Later on, the therapeutic 
application of hashish was considerably extended. In particular, the English and French 
medics applied this new wonder drug against tetanus (Martius, 1844). Encouraged 
by many positive reports, especially from England, the Bulgarian medic Basilus Beron 
intensively engaged in this problem in a dissertation. His work concludes:
I was so contented that, after having used almost all known antitetanic drugs without result, 
the sick person that had been assigned to me was totally cured after use of the Indian hemp 
(...) wherefore the Indian hemp is strongly recommended against tetanus.
(Beron, 1852)
Homeopathy, founded by Samuel Hahnemann (1755–1843) and rapidly advancing in 
this period, was also quick to include Indian hemp in its medical catalogue. Towards 
the middle of the 19th century, in addition to the illnesses already mentioned, Indian 
hemp was mainly used against neuralgia and other pains, chorea, hysteria, insanity, 
haemorrhage and insomnia. Since prepared products did not yet exist, cannabis extracts 
and tinctures were mostly used.
The real success story of cannabis as a medicine began in the second half of the 
19th century after the publication of Beron’s dissertation in 1852. In the same year, 
Franz von Kobylanski published a dissertation on the effect of cannabis as an oxytocic 
(1852). Four years later, the German Georg Martius wrote his comprehensive work 
Pharmakognostisch-chemische Studien über den Hanf, which attracted much attention. 
Interest was also aroused by the experiments of the Viennese Carl Damian Ritter 
von Schroff (1802–1887). Martius was among the few who did not deem cannabis 
compounds as harmless. He wrote that:
the Indian hemp and all its compounds show great diversity concerning the degree and type 
of effect according to individual differences in healthy as well as in pathological conditions. It 
therefore belongs to the unsafe agents, and the medic should under all circumstances use it 
with great care.
(Von Schorff, 1858)
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At the same time, Ernst Freiherr von Bibra (1806–1878) published his standard work, 
Die narkotischen Genussmittel und der Mensch. Here, he discussed hashish for over 30 
pages. In addition to experiences of others, he describes a self-experiment with hashish. 
His concluding judgement was as follows: ‘Recent experiments and experiences made 
on the medical effect of the hemp plant and its compounds very much point to their 
advantage’ (von Bibra, 1855).
In this period, most European countries, as well as the USA, included Indian hemp 
in their national pharmacopoeia. The monographs Herba Cannabis indicae, Tinctura 
Cannabis indicae and Extractum Cannabis indicae enjoyed increased prominence, 
whereas Semen/Fructus Cannabis and Oleum Cannabis became more and more rare. 
It was first of all France and England, and to a lesser extent the USA, that significantly 
contributed to the definitive breakthrough of the drug into Western medicine.
The study of Indian hemp was even pursued in Germany. A comprehensive work of 
Bernhard Fronmüller, written in 1869, is frequently cited. He had studied the qualities 
of the hemp plant for a long time, and carried out cannabis experiments within the 
framework of ‘clinical studies on the euthanising effect of the narcotic drugs’ with 
exactly 1 000 test patients. These test patients suffered from heavy insomnia due to 
various illnesses. The results of his investigation were positive. Thus, he concluded in 
his work: ‘The Indian hemp is, among the known anaesthetic drugs, the narcosis which 
most perfectly achieves a replacement of natural sleep, without particular repression of 
expulsions, without bad repercussions, without paralyses’ (Fronmüller, 1869).
Well-known medical experts or pharmacologists of the time wrote more-or-less 
comprehensive essays on Cannabis indica. Some of these articles criticise the 
unreliability of hemp compounds. Indeed, the standardisation problem continued to 
be an issue for cannabis compounds until they disappeared. Kobert is one of very few 
who discussed the dangers of long-term consumption: ‘The habitual consumption of 
any effective hemp compound deprives the human being and brings him to a mental 
institution’ (Kobert, 1897).
The period 1880 to 1900 can be considered a peak in the medical use of cannabis. 
The use of hashish compounds had become commonplace in almost all European 
countries and in the USA. Nonetheless, it was still scientists from England, France, 
Germany and the USA who persistently continued cannabis research. It is, therefore, not 
a coincidence that most of the products on the market (‘specialities’) originated in these 
countries. It is first of all through the contribution of the company E. Merck of Darmstadt, 
Germany, that cannabis compounds became more widely used in Europe towards the 
end of the 19th century. One of the preferred source materials in the production of 
cannabis compounds in this period was Cannabinum tannicum Merck. In addition, the 
company Burroughs, Wellcome & Co. in England produced cannabis compounds. In 
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the USA, cannabis compounds were manufactured by Squibb and sons in New York 
(‘Chlorodyne and Corn Collodium’), and, later, Parke-Davis & Co. in Detroit (‘Utroval’ 
and ‘Casadein’) and Eli Lilly (‘Dr Brown’s Sedative Tablets’, ‘Neurosine’ and ‘The One 
Day Cough Cure’). These companies delivered sufficient quantities of high-quality raw 
materials and produced compounds for the market. Probably the most-used hemp 
compound was the sleeping pill Bromidia, of the American company Battle & Co. This 
was a combined drug, that is, in addition to cannabis extract it contained bromine 
potassium, chloral hydrate and henbane. While single compounds dominated during 
the 19th century, combination compounds were preferred in the 20th century. Most 
cannabis drugs were for internal use, but there existed topical compounds, for instance, 
creams or the common clavus tinctures.
In the meantime, France continued its 50-year tradition and honoured medical doctors 
and pharmacists with doctoral degrees based upon works on hashish. In 1891 Georges 
Meurisse (born 1864) published his work Le Haschich, and five years later Le chanvre 
indien by Hastings Burroughs (born 1853) appeared. The latter is strongly based on 
Villard’s work, but also upon his own therapeutic experiments. He summarises: ‘In 
therapeutic doses, the Indian hemp is safe and would deserve to be more frequently 
used’ (Burroughs, 1896).
In Germany, the PhD students H. Zeitler (‘On Cannabis indica’, 1885) and M. Starck 
(‘How to apply the new cannabis compounds’, 1887) first wrote their graduation 
dissertations, before the pharmacist Leib Lapin in 1894 published his dissertation, ‘A 
contribution to the knowledge of Cannabis indica’, under the guidance of the leading 
figures Johan Georg Dragendorff (1836–1898) and Rudolf Kobert (1854–1918). In the 
first part of his work, he gives an overview of ‘common, manufactured and officinal 
hemp compounds’ in use at the time. In the second part he describes the pharmacology 
of ‘cannabindon’, a cannabis derivate first studied by him. In the preamble of his 
investigation, he makes a remark which shows the uncertainty that existed regarding the 
medical safety of Indian hemp:
Had it been so simple to solve the hashish question, it would certainly have been solved by 
one of the numerous previous investigators. I believe that I have contributed to the definitive 
resolution, and this belief gives me the courage to publish the following as a dissertation.
(Lapin, 1894)
A scientific contribution of extraordinary importance within the cannabis research of the 
19th century was the so-called Indian Hemp Report of 1894. This census, carried out by 
Great Britain in its colony India, primarily studied the extraction of drugs from cannabis, 
the trade in these drugs and the implications for the total population. Additionally, the 
study set out to clarify whether prohibition of the compounds might be justified, and an 
expert commission was established for this purpose. Its report impressively shows the 
significance of the stimulant and drug cannabis in India towards the end of the 19th 
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century. The main conclusion of the commission was: ‘Based upon the effects of the 
hemp drugs, the commission does not find it necessary to forbid the growing of hemp, 
nor the production of hemp drugs and their distribution’ (Leonhardt, 1970).
Towards the 20th century, Indian hemp enjoyed an important position in the materia 
medica of Western medicine. Evidence of misuse of cannabis compounds was practically 
non-existent until then. Kunkel writes:
The chronical misuse of cannabis compounds — cannabism — is believed to be widespread in 
Asia and Africa. It results in chronic, heavy disruption of the entire organism, especially mental 
disorder — attacks of raving madness and a subsequent condition of weakness. It is not 
observed in Europe, Indian doctors report however daily frequent cases of this disease.
(Kunkel, 1899)
To sum up, hashish played a significant role as a medicine in Europe and in the USA 
towards the end of the 19th century. The most important applications were against pain, 
especially migraine and dysmenorrhoea, pertussis, asthma and insomnia. Additionally, 
hashish was relatively frequently used as an additive in clavus supplements. Rare 
applications were stomach ache, depressions, diarrhoea, diminished appetite, pruritus, 
haemorrhage, Basedow syndrome and malaria. Cannabis compounds were also used 
in numerous single cases, partly with good results. These were, however, of smaller 
significance.
Typically, doctors who worked intensively with cannabis drugs for years would classify 
them as valuable medicines. Others criticised them, and frequently looked upon them as 
worthless or even dangerous. However, both groups agreed on the unpredictable effect 
of cannabis compounds.
After keen use of cannabis compounds around the turn of the century, they disappeared 
completely in the middle of the 20th century. The main reasons for the disappearance 
of hashish medicaments are medical developments. Even before the 20th century, new, 
specific medicines were introduced for all main applications of cannabis compounds. 
Vaccines were developed for the treatment of infectious diseases (cholera, tetanus, etc.), 
which not only fought the symptoms as cannabis did, but also gave protection against 
infections. Other bacterial illnesses, such as gonorrhoea, that were frequently treated 
with cannabis could somewhat later be treated successfully with chemotherapeutica. 
Cannabis indica received competition as a sleeping and tranquillising drug in the form 
of chemical substances such as chloral hydrate or barbiturate. Contrary to the numerous 
opium drugs, cannabis compounds were also replaced as analgesics by chemical 
substances. In this area, aspirin achieved great importance shortly after its introduction 
in 1899.
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Another reason for the decline of cannabis as medicine was pharmaceutical instability. 
The varying effectiveness of the hashish compounds has often been noted. Very different 
factors, such as origin, age, storage and galenic preparation, affected effectiveness 
of the medicine. Unlike, for instance, alkaloid drugs such as opium, the isolation of 
active ingredients was not successful until the middle of the 20th century. This resulted 
in standardisation problems. There were also legal constraints. The use of cannabis 
compounds became more and more restricted in international and national law. 
Hashish compounds were defined as anaesthetics some time in the 20th century. This 
complicated their use enormously, until finally a general ban made it impossible to 
apply them.
Finally, economic aspects contributed to the decline in use of medical cannabis. Import 
into Europe of high-quality Indian hemp became more and more difficult due to 
constraints in the producing countries (mainly India) and the influences of the two world 
wars. Laws of supply and demand also applied to cannabis, resulting in a massive price 
increase for raw materials (e.g. herba Cannabis indicae) as well as for compounds (e.g. 
extractum Cannabis indicae).
Cannabis as medicine — the contemporary situation
As already mentioned, hemp compounds were still frequently used at the beginning 
of the 20th century, and scientific research on the plant was promoted. However, its 
standing declined rapidly, and towards the middle of the 20th century cannabis as a 
medicine gradually faded into insignificance. Finally, the use of cannabis was prohibited 
worldwide through international agreements.
In particular, use of cannabis as a medicine was made impossible by the Convention on 
Narcotic Drugs of 1961 (see Ballotta et al., this monograph). Only lately have individual 
countries begun to stretch the application of this regime, as in Holland, where since 
September 2003 cannabis can be bought in pharmacies on prescription. In specific 
cases, cannabis can be used as medicine in Canada and in some US states without 
sanctions against the patients. In Canada, the cannabis medicine Sativex as a spray was 
licensed for treatment of neuropathic pain for multiple sclerosis patients in April 2005. 
Until then, only the two cannabinoids, THC and Nabilon, had been legally traded since 
the 1960s (IACM-News, 2005). Other European countries, such as the United Kingdom, 
Spain, and more recently Switzerland and Italy, have for some time undertaken efforts to 
explore possible benefits of cannabis for medical purposes (see Witton, this monograph).
In spite of the ban on cannabis, research on the medical effects of this ancient drug 
plant has not stood still. In many countries, scientific work with cannabis was and is 
allowed. The discovery of ∆9-tetrahydrocannabinols (THCs) in 1964 and the cannabinoid 
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receptors (CBs) in 1988 are important milestones in cannabis research. Four years 
later, the existence of endocannabinoids was proven, that is substances produced by 
the human body that function as agonists to cannabinoid receptors. Presently, the first 
selectively working CB1 receptor antagonist rimonabant is being clinically tested (phase 
III). It seems that this receptor may be used against overweight and metabolic risk 
factors, as well as with tobacco withdrawal (Heinzl, 2005).
Since the cannabinoid system was discovered, agents that make use of the therapeutic 
effects of the cannabinoids have been intensively searched for, thereby avoiding the 
psychotropic side-effects. Just in the years following the discovery and investigation of 
the chemical structure of THCs until 1986, approximately 6 000 scientific studies of the 
chemistry, pharmacology, clinical properties and metabolism of the THCs have been 
published (Mechoulam, 1986). During the last 20 years, research on the hemp plant 
has intensified. It is hardly possible to provide an overview the abundance of data and 
scientific publications. Presently, various clinical studies of the effects of hemp on certain 
illnesses are being undertaken.
A summary of research focal points and possible fields of cannabis application is given 
below. According to Grotenhermen (2004), therapeutic effects of cannabis or segregated 
THC (or dronabinol) may, based on current science, be divided as follows:
 1 Established effect: nausea and vomiting, anorexia and loss of weight.
 2 Relatively well-proven effect: spasms, pain conditions, movement disturbances, asthma, 
glaucoma.
 3 Unproven effect: allergies, itchiness, inflammations and infections, epilepsy, depressions, 
and anxiety disturbances.
 4 Basic research: auto-resistant diseases, cancer, neuroprotection, fever and blood 
pressure disturbances.
As previously mentioned, some of these applications had already been in use for a long 
time based on experience. Interestingly, long-proven indications have more recently 
been scientifically documented. In spite of the ban on cannabis, it is frequently used 
by patients in the form of tea or tinctures and sometimes recommended by medical 
doctors against the law. In practical terms, some multiple sclerosis patients successfully 
use cannabis as an antispastic, and some migraine patients frequently use it as a pain 
reliever.
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Setting the context
The previous chapter looked at the history of medicinal use of cannabis. It is interesting 
to consider that, a century ago, the patent medicine J. Collis Browne’s Chlorodyne 
(a mixture of laudanum, tincture of cannabis, and chloroform) could be purchased 
at chemists and was marketed as ‘the most wonderful and remarkable remedy ever 
discovered’ (1). Yet historical anecdotes about medicinal use of cannabis are gradually 
being displaced by a wealth of international research on cannabinoids and their role 
in therapeutics. This brief chapter — which may be perceived as a postscript to the 
previous one — provides a summary of recent developments in medicinal cannabis.
Researchers in this area are highly productive, and so this chapter is likely to suffer 
from almost instant obsolescence. Nonetheless, the chapter reveals that, at the time 
of writing in late 2007, there are relatively few cannabis-derived medicines that have 
received regulatory approval. Forecasts dating from the early 2000s that cannabinoids 
may become the new blockbuster branch of the pharmaceutical industry seem to 
be premature. Yet a recent market report by Visiongain (2) remains upbeat, valuing 
the global cannabis medicines market at USD 700 million. Besides interest from the 
pharmaceutical industry, there is an increasing body of research on ‘self-medication’ 
using herbal cannabis. The knowledge base is increasing, following relaxation of 
legislation relating to medicinal use of cannabis in some US states and the Netherlands, 
together with grassroots organisations focusing on medicinal use of herbal cannabis in 
Canada and several European countries.
(1) Advertisement for J. Collis Browne’s Chlorodyne, 1891.
(2) www.visiongainintelligence.com/reportDetail.aspx?reportId=1359
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The re-emergence of the 
therapeutic use of cannabis 
products: recent developments 
and future prospects
John Witton
The past two decades have seen renewed and concerted interest in the therapeutic 
potential of cannabis. Tetrahydrocannabinol (THC), the active and most significant 
constituent of cannabis, and other closely related compounds were identified in the 
1960s. However, it was not until the mid-1980s and 1990s that research accelerated, 
when understanding increased of the biology of the body’s endocannabinoid system 
and how cannabis works on the brain. These discoveries opened up possibilities to 
exploit cannabis-based products for medical use. This renewed scientific interest in the 
cannabinoids is evidenced by (i) the increase in the number of research papers on the 
biology of cannabinoids, from 200–300 per year through the 1970s to nearly 6 000 in 
2004, and (ii) the number of cannabinoid drugs under pharmaceutical development, 
rising from 2 in 1995 to 27 in 2004 (Pacher et al., 2006).
The identification of a natural cannabinoid receptor–neuromodulator system in the body 
was the key to pharmacological and therapeutic developments. Receptors are the sites 
of action for brain chemicals, called neurotransmitters, and often the sites of action 
of drugs. Binding of the neurotransmitter or drug to the brain cell receptor causes a 
response in the cell. Two cannabis receptors (termed CB1 and CB2) have been found 
(Pertwee, 1997). CB1 receptors are distributed in discrete areas of the brain, particularly 
concentrated in the hippocampus and cerebral cortex (areas concerned with memory 
and cognition), olfactory areas, basal ganglia and cerebellum (areas concerned with 
motor activity and posture control) and the spinal cord. CB2 receptors are found 
peripherally and are closely linked with cells in the immune system (Kumar et al., 2001). 
With the discovery of cannabis receptors it became possible to develop cannabinoid 
agonists or antagonists — that is, agents that activate or bind but do not activate the 
receptors — that might act as therapeutic tools or help determine the roles of the 
cannabinoid receptors and the body’s own endogenous cannabinoids (British Medical 
Association, 1997). Two major endocannabinoids have been identified and isolated: 
anandamide and 2-arachidonoyl glycerol. This endogenous cannabinoid system is 
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involved in analgesia, cognition, memory, locomotor activity, appetite, vomiting and 
immune control (Kumar et al., 2001).
As the structure–activity relationships of the cannabis receptors and endocannabinoid 
system unfolded, the potential for cannabis-based medicines became clearer. But in a 
review of these developments, a leading neuropharmacologist, Professor Leslie Iversen, 
suggested that pharmaceutical companies faced a range of substantial obstacles in 
developing cannabis-based medications. These obstacles were: development costs would 
be high; only synthetic cannabinoids could be patented rather than the natural product; 
products would be likely to be niche drugs rather than ‘blockbuster’ drugs used to treat 
common health problems; there were already medicines available to treat the problems 
that cannabinoids might be used for; and finally, the vast US marketplace would be 
difficult to enter, with the US having strict regulatory requirements to introduce a drug 
that is derived from or chemically related to a prohibited substance (Iversen, 2003).
Over the last 30 years, widely reported use of illicitly smoked cannabis for self-
medication for a range of illnesses has brought normally law-abiding citizens into 
conflict with their country’s legal system. Surveys have found that the common 
indications for cannabis use include depression, multiple sclerosis, pain, migraine, 
asthma and cancer-related anorexia/cachexia (Schnelle et al., 1999; Gorter et al., 
2005). The ethical dilemmas surrounding this issue were among the factors that led to 
a number of enquiries examining the therapeutic potential of cannabis products. The 
British Medical Association’s 1997 report Therapeutic Uses of Cannabis and the 1998 
report Cannabis: the Scientific and Medical Evidence from a Select Committee of the 
House of Lords both called for the setting up of clinical trials to evaluate the potential 
therapeutic use of cannabinoids. The prestigious US Institute of Medicine published 
its report Medical Use of Marijuana in 1999. Together, these reports established the 
evidence base to support the further examination of cannabis products for medical use. 
Medical and political interest intensified in several European countries and the medical 
use of cannabis was legalised in the Netherlands in 2003 (Grotenhermen and Russo, 
2002; Gorter et al., 2005) and extended for a five-year period in 2007.
Naturally, cannabis products are subject to the same rigorous clinical testing and 
regulatory processes as any other potential medicine. Clinical trials for new medications 
normally follow three phases. In phase I the safety of the drug is established. In phase II 
the efficacy of the drug is established through giving the medication to a small group of 
potential patients who have the condition targeted by the medication. Finally, phase III 
trials use large studies involving hundreds of patients.
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Two synthetic cannabinoid receptor agonists, dronabinol and nabilone, have already 
passed these stringent tests. They have been available and approved for medical use 
since the 1980s. However, neither has been widely prescribed. The effective dose for 
these cannabinoids is close to a dose that causes sedation or intoxication, limiting 
the amount of the drug that can be given to patients (Iversen, 2000). Moreover, their 
therapeutic potential has been superseded by more powerful medications.
Dronabinol is the non-proprietary name for tetrahydrocannabinol. Marinol capsules 
containing dronabinol were approved for use by the US Food and Drug administration 
for nausea and vomiting associated with cancer chemotherapy for patients who had not 
responded to conventional antiemetic medications. Marinol was also approved for use in 
anorexia associated with weight loss in patients with AIDS. Dronabinol is also available 
on prescription in a number of countries outside the USA. Dronabinol is manufactured 
by two German companies, THC Pharm and Delta 9 Pharma, and may be bought 
by pharmacies to produce dronabinol capsules or solutions. The second cannabinoid 
receptor agonist, nabilone, a synthetic derivative of dronabinol, was also approved 
by the FDA in 1986 for use in treatment of nausea and vomiting associated with 
chemotherapy. It is delivered in the form of Cesamet capsules. Nabilone was originally 
developed by Eli Lilly in the USA but was not marketed there, but is available in the UK 
and other European countries.
Two more cannabis-related drugs have become available more recently. The British 
biotech firm GW Pharmaceuticals has developed Sativex, a cannabis plant extract, 
consisting of equal amounts of dronabinol (THC) and cannabidiol, another important 
cannabinoid. Sativex is delivered as an oral spray. Using a spray for delivery provides 
a consistent quality to the medication and enables doctors to set standard dosages. The 
spray technique also avoids the carcinogenic smoke normally associated with cannabis 
use. It also allows for flexible dosing, important when people with MS experience 
variable amounts of pain.
In 2005 Sativex received approval as an adjunctive treatment for the relief of 
symptomatic pain related to muscular sclerosis in Canada through the governmental 
Health Canada’s Notice of Compliance with Conditions policy. This policy is applied to 
products which Health Canada considers as addressing a serious medical condition for 
which there are no currently approved products and where data from clinical trials to 
date appear to be promising. The condition to be satisfied is a need for confirmatory 
phase II study to further verify the clinical benefit of the product. In June 2007 Sativex 
was approved by the Canadian regulatory authority for use in cancer-related pain. More 
recently, GW has reached an agreement with the Japanese pharmaceutical firm Otsuka 
to develop and market Sativex in the USA, where it will be initially trialled for cancer 
pain.
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In Europe, in November 2005 Sativex and the Catalan Health Authority reached 
agreement to supply Sativex to up to 600 patients suffering from multiple sclerosis under 
a compassionate access programme. Initial results from a patient study suggested that 
65 % of the patients had experienced an improvement in quality of life and a decrease 
in pain. In the UK, the Home Office permitted the prescription of Sativex to individual 
patients as an unlicensed medicine. Thus, Sativex can be supplied on a named patient 
basis from the drug’s manufacturing site and dispensed by local pharmacies to patients. 
At the time of writing (end of 2007), Sativex is awaiting approval as a prescription drug 
for multiple sclerosis in Spain, Denmark and the Netherlands.
The second new drug, the cannabinoid receptor antagonist rimonabant, received a 
positive recommendation for approval by the European Medicines Agency in 2006. 
Available in the United Kingdom for the treatment of obesity under the name Acomplia, 
a Cochrane review found rimonabant use with diet and exercise led to modest weight 
loss at one year follow-up in the four studies under review. However the review authors 
suggested caution in interpreting the results of their review because of methodological 
shortcomings in the studies reviewed, high drop-out rates among participants and the 
need for longer term follow-up (Curioni and André, 2007). In the USA, rimonabant 
(planned to be marketed under the name Zimulti) was rejected by the Food and Drug 
Administration in June 2007. The FDA cited concerns on side-effects such as depression, 
anxiety and sleep problems when taking the drug.
Another cannabis-related product under investigation in clinical trials is Cannador, 
containing dronabinol and other cannabinoids. Studies have examined Cannador’s 
value in treating spasticity and other symptoms related to multiple sclerosis and post-
operative pain (Holdcroft et al., 2006; Zajicek et al., 2006). Further trials with Cannador 
have been undertaken at the Institute for Clinical Research in Berlin. There has been 
some interest in investigating the potential of cannabidiol as an antipsychotic (Zuardi et 
al., 2006).
Away from pharmaceutical cannabis-related preparations, the use of its natural form for 
medicinal purposes has also progressed recently. While cannabis remains illegal under 
federal law in the US, 13 states have made available the medical use of cannabis under 
their state laws. The latest to legalise medical use of cannabis is New Mexico, where 
1 742 patients are authorised to possess dried cannabis as a medication. 1 040 are 
licensed to grow their own cannabis and 167 people are licensed to grow cannabis for 
the use of authorised patients. Here the state’s health ministry buys the cannabis from 
these licensed growers and sells it on to the patient.
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In terms of very recent developments, in Finland the Ministry of Social Affairs and 
Health in December 2007 sought to clarify legislation on prescribing cannabis to 
sufferers of chronic pain, based on the implications of a test case involving an individual 
who had obtained special permission from the ministry for using cannabis for pain 
relief. A Canadian pharmaceutical research company called Cannasat Therapeutics 
is developing three candidate medicines, named CAT 210, CAT 310 and CAT 320, 
for which it forecast Phase II testing for the lead candidate, CAT 310, ‘by the end of 
2008’. In late 2007, a Dutch company called Echo Pharmaceuticals, based in Weesp, 
announced funding aimed at developing a cannabis-based pill called Namisol, targeting 
numerous therapeutic applications. The company is partnering with the cannabis grower 
Bedrocan, as well as the companies Farmalyse and Feyecon, to develop a pill.
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Setting the context
To understand cannabis, it is helpful to have a knowledge of the pharmacology of 
the drug. What are the psychoactive effects of the substance, and what physical and 
neurological changes are brought about by the product? What can be said about the 
varying effects of dosage, route of administration, the type of product (herb, resin, oil), 
and the use environment?
Scientific knowledge about the pharmacology of cannabis has seen substantial progress 
in the last three decades. In addition to substantial work in neuroscience, cannabinoid 
research accelerated following the discoveries in the late 1980s of cannabinoid-like 
chemicals produced by the body, known as ‘endocannabinoids’.
As with much science, much of the literature on cannabis is technically challenging, 
especially for those approaching drugs from disciplines such as sociology and political 
science. In addition, there is a glut of information in the scientific journals: a Medline 
search on ‘cannabis pharmacology’ reveals over 3 500 articles, and many more are 
published each month. Meanwhile, users seeking to explore the science of cannabis are 
likely, sooner or later, to encounter disinformation and inaccuracy. User reports are by 
nature subjective, and growshop information is compromised by the incentive to sell. 
Pro-cannabis lobbying information is skewed towards innocuous and euphoric effects 
or favourable comparisons with alcohol. Prohibitionist literature emphasises the risks 
of cannabis smoking without placing sufficient emphasis on the sought-after effects of 
cannabis.
Fortunately, help is at hand for those first approaching the subject. A number of 
initiatives have sought to provide information that is simultaneously accurate and 
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accessible, and valuable publications exist for a variety of audiences (see Further 
reading, below). One of the products of a more didactic approach is the simplified 
summary above by Kumar et al., republished in a number of government monographs 
since its first appearance in 2001 (Table 1). The chapter that follows, by a leading 
authority based at Trinity College Dublin, provides a short summary of what is known 
to date about the pharmacology of cannabis. A glossary is provided to assist non-
specialists.
Table 1: Summary of the effects of cannabinoids
System Effect
Central nervous system (CNS)
Psychological effects Euphoria, dysphoria, anxiety, depersonalisation, 
aggravation of psychotic states
Effects on perception Heightened sensory perception, distortion of space and 
time sense, misperceptions, hallucinations
Sedative effects Generalised CNS depression, drowsiness, sleep, additive 
effect with other CNS depressants
Effects on cognition and psychomotor 
performance
Fragmentation of thoughts, mental clouding, memory 
impairment, global impairment of performance
Effects on motor function Increased motor activity followed by inertia and 
uncoordination, ataxia, dysarthria, tremulousness, 
weakness and muscle twitching
Analgesic effects Similar in efficacy to codeine
Antiemetic effects In acute doses, effect reversed with larger doses or chronic 
use, increased appetite
Tolerance To most behavioural and somatic effects, including the 
‘high’ with chronic use
Dependence, abstinence syndrome Rarely observed but has been produced experimentally 
following prolonged intoxication or administration of 
antagonists
Cardiorespiratory system
Heart rate Increased with acute dosage, decreased with chronic use
Peripheral circulation Vasodilation, conjuctival redness and postural hypotension
Cardiac output Increased output and myocardial oxygen demand
Cerebral blood flow Increased in the short term and decreased with chronic use
Breathing Small doses stimulate, larger doses depress coughing but 
tolerance develops
Airways obstruction Due to chronic smoking
Eye Decreased intraocular pressure
Immune system Impaired activity of bactericidal macrophages in lung and 
spleen
Reproductive system Decreased sperm count and sperm motility in males, 
suppression of ovulation, complex effects on prolactin 
secretion, increased obstetric risks
Source: R. Kumar, W. Chambers, R. Pertwee (2001), ‘Pharmacological actions and therapeutic uses of cannabis and 
cannabinoids’, Anaesthesia 56(11): 1059–1068.
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The pharmacology of cannabis: 
issues for understanding its use
Desmond Corrigan
Abstract
The drug products obtained from the plant Cannabis sativa contain many different 
chemicals. The most active are the phytocannabinoids, such as THC, which exert their 
psychoactive effects by binding to specific receptors within the brain and other parts of 
the body. The existence of a complex endocannabinoid system within humans and other 
animals and the interaction between the phytocannabinoids and this system explains 
many of the rewarding, dependence-producing effects of cannabis drugs as well as 
their influence on movement, coordination, reactions, memory and learning, especially 
since the brain regions implicated in these effects are richest in cannabinoid receptors. 
Cannabinoids are highly fat-soluble and their metabolism and slow excretion from the 
body distinguishes them from other drugs, such as alcohol. The slow elimination of THC 
explains the low intensity of withdrawal symptoms and also why urine tests following 
consumption test positive for cannabinoids for much longer than for most other 
psychoactive drugs (up to two weeks).
Cannabis drugs
The plant Cannabis sativa L. is the source of a number of drug products. While herbal 
cannabis (or marijuana) consists of dried plant parts, the main ingredient in cannabis 
resin (or hashish) is the resin secreted by the glandular hairs found all over the plant 
but mainly around the flowers. In addition to these two kinds of preparation, which 
have been used since time immemorial, hashish oil is extracted by use of a solvent (e.g. 
acetone) and evaporated. In addition, the cannabis plant can be used as a source of 
hemp fibres, as well as hemp seeds and fatty oil.
The flowering tops and leaves of the plant Cannabis sativa secrete a resin containing 
about 60 terpenophenolic compounds which are called cannabinoids, to distinguish 
the plant compounds from the endogenously occurring endocannabinoids found in 
most animals, especially humans. The highest amount of cannabinoids has been 
found in the flowering tops, followed by the leaves, whereas only small amounts are 
found in the stem and roots. While for many years herbal cannabis typically showed a 
lower cannabinoid content than preparations (resin and oil), innovation in cultivation 
techniques, pruning and seed selection have enabled marijuana growers to match or 
exceed the potency of resin (see King, this monograph).
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Glossary
Endocannabinoids Cannabinoids produced by the body, such as anandamide.
Free radical An atom or group of atoms with at least one unpaired electron; in the body 
it is usually an oxygen molecule that has lost an electron and will stabilise 
itself by stealing an electron from a nearby molecule.
Ganglia 
(singular: ganglion)
Tissue mass which provides relay points and connections between different 
neurological structures in the body, such as the central nervous system.
Neurones Nerve cells found in the brain, spinal cord and peripheral nerves. They 
communicate with one another using a complex of chemical and electrical 
signals.
Neurotransmitters Chemicals which are used by neurones to communicate or signal to one 
another. Examples include dopamine and serotonin.
Phagocytosis The ability of certain white blood cells (leucocytes), especially macrophages, 
to scavenge foreign material (especially bacteria) within the body as a first-
line defence against infection.
Pharmacodynamic 
effects
What the drug does to the body, its organs, tissues and cells.
Pharmacokinetics What the body does to the drug, that is, the speed at which it is absorbed 
into the bloodstream, transported to the site of action, metabolised and 
excreted from the body.
Phytochemical A chemical compound containing carbon, hydrogen, oxygen and sometimes 
nitrogen produced by plants. Some are ubiquitous, such as starch. Some 
are pharmacologically active, such as morphine. Some are restricted to just 
one plant species, for example tetrahydrocannabinol in cannabis.
Receptors Drugs act by binding to specific proteins located on the surface of cells. 
Once bound they can elicit a response (agonist effect) by causing an 
electrical impulse to be generated or the release of a signalling chemical 
within the cell. Sometimes drugs can prevent a response from the receptor, 
that is, act as an antagonist.
T lymphocyte A small lymphocyte developed in the thymus; it orchestrates the immune 
system’s response to infected or malignant cells.
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Phytocannabinoids
The main cannabinoid is ∆9–tetrahydrocannabinol (THC), which is recognised as 
the major psychoactive euphoriant responsible for the characteristic intoxication 
(‘high’) which follows the smoking or ingestion of cannabis. High THC doses produce 
hallucinogenic effects. In addition to THC, several less potent metabolites and related 
compounds, such as the also psychoactive ∆8-THC and cannabinol are found in the 
cannabis plant. Another major compound is cannabidiol (CBD), which has antagonistic 
effects to THC because it is a sedative compound. The ratio of THC to CBD in the plant 
is significant in terms of psychoactivity and is genetically determined.
A number of chemotypes exist within cannabis. These are plants which are visually 
and botanically identical but which are chemically dissimilar. One type referred to 
as the fibre- or hemp-type contains predominantly CBD and only trace amounts of 
THC (less than 0.3 % THC according to Commission Regulation (EC no. 327/2002)). 
Conversely, drug-type plants produce predominantly THC with trace quantities of CBD. 
The issue is further complicated by the existence of an intermediate plant which contains 
approximately equal amounts of both THC and CBD. The concentrations of these and 
other cannabinoids vary enormously in practice depending on plant breeding and 
cultivation techniques and on post-harvest handling. The question of the potency of 
cannabis drugs, usually expressed in terms of THC content, is dealt with in the chapter 
by King (this monograph, p. 239). THC is a highly unstable compound, breaking 
down in air and light to a number of inactive molecules, one of which, cannabinol 
(CBN), is commonly found in cannabis products as they age. Other relatively abundant 
cannabinoids include cannabigerol (CBG) and cannabichromene (CBC) but in general 
little is known about the biological activities of these and the remaining less frequently 
occurring molecules.
Most pharmacological research has focused on THC and CBD. However, while THC is 
responsible for many of the effects of cannabis drugs, it is important to bear in mind 
that THC and cannabis are not synonymous for a number of reasons.
Firstly, THC does not exist as such in the plant material but rather it is found as an acid 
(THCA), as is CBD. These acids (THCA and CBDA) decompose slowly during storage to 
the corresponding chemically neutral but pharmacologically potent THC and CBD. This 
conversion is speeded up by the high temperatures involved in smoking and to a lesser 
extent by cooking or baking the drugs. Secondly, the THC/CBD ratio can markedly 
alter the effects of the drugs. Thirdly, some of the non-cannabinoid compounds from 
the plant may modulate the pharmacological effects of the cannabinoids. Terpenoids, 
which are responsible for the characteristic smell of cannabis, have been postulated as 
influencing the effects yet experimental evidence is scarce. Some 1 % by weight of the 
plant is composed of a mixture of 20 flavonoid compounds which are well known as 
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antioxidants and which also scavenge damaging free radicals. Whether the quantities 
which survive the pyrolysis reactions involved in smoking cannabis are sufficient for 
activity is unknown (Musty, 2004).
Pharmacokinetics and metabolism
The dose of THC needed to produce effects in humans ranges from 2 to 22 mg (Adams 
and Martin, 1996). It is estimated that only 1 % of the THC content of a ‘joint’ is found 
in the brain after smoking; hence, only 2–44 µg of THC enters the brain in humans. 
Given the significant variation in cannabinoid content in the crude drugs and also in 
the weights of those crude drugs incorporated into ‘joints’ (Buchanan and O’Connell, 
1998), there is little comparability or standardisation of dosages of THC and the other 
cannabinoids in practice.
THC is rapidly absorbed after inhalation of cannabis smoke and it is detectable in 
plasma within seconds. Between 10 and 50 % of the THC in the drug reaches the 
bloodstream. Losses due to burning account for 30 %, while sidestream smoke, 
incomplete absorption and retention within the cigarette (‘joint’) also produce significant 
losses. Inexperienced and infrequent smokers absorb approximately 10–14 % of the 
available THC whereas regular users absorb double that amount, probably because 
their more efficient smoking technique allows them to hold the smoke longer in their 
lungs. For the other major cannabinoids, the amounts absorbed range from 31 % for 
CBD to 38 % for CBN.
When cannabis is smoked, the effects start within seconds, reach a peak around 20 
minutes and last for two to three hours (Figure 1). In contrast, if the drug is eaten, the 
effects are delayed and last longer, reaching a maximum about 3–4 hours after drug 
ingestion, and lasting for six to eight hours (Grotenhermen, 2003). After smoking, THC 
is detectable in the plasma only seconds after the first puff of a cannabis cigarette, 
with peak plasma level being measured 3–10 minutes after the first puff. This reflects 
the conversion of THC to its metabolites. This metabolism takes place in the liver and 
involves different enzymes, some of which are inhibited by CBD, which can thus affect 
the metabolism of THC. THC is further metabolised to a non-psychoactive molecule, 
which is excreted in urine as its glucuronide, although more than 100 different 
metabolites of THC have been identified (Hawksworth and McArdle, 2004). Only traces 
of the original THC are found in urine.
Because THC is highly fat soluble (lipophilic), plasma levels of THC fall rapidly after 30 
minutes. However, its many metabolites are only slowly eliminated from the body as they 
are stored in fatty tissues. Complete elimination may take up to five weeks. So repeated 
cannabis use leads to an accumulation of cannabinoids in lipid-rich tissues including 
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the brain. THC is slowly released from fatty tissues into the bloodstream. There is, 
however, no simple relationship between the level of THC and its metabolites in blood 
and behavioural effects, such as psychomotor impairment (Agurell et al., 1986). This 
is because there is a delay between the subjective ‘high’ and THC in blood, and there 
are also large variations in individual psychoactive effects experienced at the same THC 
level in blood (see Figure 1).
The endocannabinoid system
THC and other cannabinoids act by binding to specific cannabinoid receptors found 
on the surface membranes of various cells located chiefly in the brain and in the 
immune system. Two receptors have been identified. The first cannabinoid receptor, 
CB1 (Matsuda et al., 1990), is expressed in the brain, in nerve cells, the reproductive 
system, some glandular systems and the microcirculation (Howlett et al., 2002, 2004; 
de Fonseca et al., 2005). The second cannabinoid receptor, CB2, is expressed in the 
peripheral tissues, principally in the immune system (Munro et al., 1993; Felder and 
Glass, 1998; Pertwee, 1999).
The discovery of these receptors — and there may be others in the body — led to the 
identification of a family of ‘endocannabinoids’. These molecules are arachidonic acid 
derivates which have potent actions at the cannabinoid receptors. The discovery of 
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Figure 1: Distribution of THC in the body over time
Source: Nahas (1975), quoted and commented in Ashton (2001).
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cannabinoid receptors and their endogenous ligand, the endocannabinoids, suggested 
the existence of an endogenous cannabinoid system. Subsequent elaboration of the 
biosynthesis, release, transport and degradation of these endocannabinoids within 
the body led to the realisation that they formed part of a new signalling system within 
the body termed the ‘endocannabinoid system’. This has interactions with other 
neurotransmitters including gamma-aminobutyric acid (GABA), the opioid receptors 
and the dopamine system. The endogenous cannabinoid system seems to act as a 
neuromodulatory system, generally inhibiting the release of other neurotransmitters. 
CBD, on the other hand, does not bind to the CB receptors but may exert its sedating, 
hypnotic effects through other cannabinoid receptors which are believed, but not proven, 
to exist.
Cannabinoid receptors control cell differentiation in the developing brain. One of 
their most remarkable features is their high concentration within the brain, with 
densities 10–50 times greater than those of the classical neurotransmitter receptors, for 
example those for dopamine and opioids. CB1 receptors are expressed at particularly 
high densities in the cerebellum, hippocampus and in the basal ganglia (striatum, 
globus pallidum and substantia nigra). The presence of cannabinoid receptors in the 
hippocampus and the cortex suggested their involvement in the learning and memory 
process, whereas cannabinoids appear to mediate effects on motor activity, coordination 
and reactions through receptors in the basal ganglia and cerebellum. CB1 receptors are 
also found in the nucleus accumbens and frontal cortex, which is believed to account for 
the reinforcing effect of cannabinoids. Indeed, the endocannabinoid system controls the 
motivation for appetite stimuli, including food and drugs. Drugs of dependence tend to 
activate dopamine-producing nerve cells in the ventral tegmental area (VTA) and THC 
is no different because it increases dopamine release in the nucleus accumbens and 
prefrontal cortex.
The numerous investigations into the endocannabinoid receptor system and its 
interactions with other neuronal systems have resulted in a large body of scientific 
evidence which indicates that CB1 receptors, especially in the striatum, nucleus 
accumbens and the prefrontal cortex, mediate virtually all of the behavioural and 
neurochemical properties of THC and other cannabinoids. In particular, rewarding 
effects, tolerance and physical dependence have been ascribed to the brain 
endocannabinoid system and its interactions with the opioid, glutamate, GABA and 
especially the dopaminergic systems (Tanda and Goldberg, 2003). Gardner (2002) 
concluded that cannabinoids act on brain reward processes and related behaviours in 
ways that are remarkably similar to other addictive drugs. Studies with CB1 antagonists 
have shown the importance of these receptors in the whole phenomenon of craving. 
Ongoing studies highlight the significance of the endocannabinoid system in alcohol 
dependence, smoking cessation, weight loss, and self-administration of cocaine and 
opioids.
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The CB1 receptor has also been identified in both male and female reproductive 
systems including the ovaries, the uterine endometrium, the testis, sperm, vas deferens 
and urinary bladder. Recent studies reviewed by Park et al. (2004) have demonstrated 
that marijuana, THC and other exogenous cannabinoids exert potent effects on 
the endocannabinoid system in both the gonads and during pregnancy. Current 
understanding indicates that endocannabinoids may be critical for embryo implantation 
and miscarriage.
The CB2 receptor has been detected in the spleen, tonsils and thymus gland, which 
are the major tissues involved in immune cell production. Cannabinoids including 
THC — which activate these receptors (agonists) generally — suppress the functions 
of lymphocytes, natural killer cells, macrophages and mast cells. Roth et al. (2002) 
summarised knowledge concerning CB2 receptors and cells involved in the immune 
system. They suggest a dynamic interaction between the receptors and the immune 
system, particularly leucocytes. Receptor expression is markedly altered in habitual 
cannabis smokers and the pattern of T lymphocyte responses to THC and the resulting 
immunological events may explain epidemiological reports linking cannabis use to 
opportunistic infections, AIDS and respiratory tract cancers. Nevertheless, as Witton 
(this monograph) points out, the evidence is not conclusive. Roth et al. (2002) observe 
that the most convincing evidence of immunosuppression comes from examining 
the antimicrobial activity of alveolar macrophages. Those from herbal cannabis 
smokers exhibit defective phagocytosis, are impaired in their ability to produce key 
immunological chemicals (interleukins, tumour necrosis factor, etc.) and in their ability to 
exhibit effective antibacterial activity when challenged with pathogenic bacteria. Because 
cannabinoid receptors are not found in significant numbers in the brain stem, cannabis 
is not considered to be a drug with fatal overdose risks.
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Chapter 4
Soma, the Wootton Report and 
cannabis law reform in Britain 
during the 1960s and 1970s
Keywords: 1960s – autobiography – the Beatles – cannabis – legislation  
– lobbying – protest movements – social protest – sociology  
– Wootton Report
Setting the context
This chapter provides a first-person account of a significant event in the history of 
cannabis policymaking in Europe: the publication of the UK’s Wootton Report in 1969. 
There was some debate about whether to include this chapter in the monograph. The 
chapter is self-evidently personal in tone. Yet it is also interesting and anecdotal, and we 
believe the monograph benefits from its inclusion with few significant editorial changes. 
However, it should be read for what it is: an oral history, told from an individual’s 
standpoint, with which others might disagree.
Recent literature has tended to play down the level of drug use in the 1960s. Prevalence 
statistics are not available, but cannabis use was likely much lower than today. A recent 
survey suggests that today’s 50-somethings exaggerate their participation in 1960s 
counterculture in order to appear cool to their offspring. Nonetheless, several decades 
on, there is little doubt that the high-profile celebrities of the late 1960s still hold cultural 
resonance in today’s global cannabis culture.
Nostalgia, anachronisms and the Beatles aside, Soma in many ways established the 
prototype for contemporary, often more fragmented, cannabis advocacy groups. It 
was a well-organised, erudite and media-aware pressure group. It had a talent for 
both publicity and linking debate to other contentious issues. Moreover, it was able 
to leverage the polarisation between political liberals and hardliners in the 1960s. 
Similarly, today there is sometimes political capital to be won from taking an extreme 
view, be it for or against cannabis use (see Hall, this monograph). The Soma campaign 
thus remains relevant to contemporary debate on cannabis.
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In recent years, the nature of pro-marijuana activism and lobbying has been subjected 
to some study, amongst others by Calafat et al. (2000), Matthews (2003) and Iversen 
(2004). The key pro and con arguments have been summarised by Scheerer (1993) 
and Wodak et al. (2002). An analysis of recent government reports on cannabis, with 
specific reference to European legislative reforms, is provided by Ballotta et al. later in 
this monograph. Most recently, considerable discussion has focused on the potency of 
1960s and 1970s cannabis vis-à-vis that available today. King explores this issue, and 
suggests that some of the more outlandish claims made of today’s ‘skunk’ should be 
viewed with a critical eye.
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Soma, the Wootton Report and 
cannabis law reform in Britain 
during the 1960s and 1970s
Stephen Abrams
In April 1970 the British government introduced legislation which sharply reduced the 
penalties for simple possession of cannabis. This was done to implement a proposal by 
the Home Office Advisory Committee on Drug Dependence (the ‘Wootton Report’) that 
casual users of cannabis should not face the prospect of imprisonment. This reform, 
under new legislation (The Misuse of Drugs Act 1971) was a step in the direction of 
decriminalisation and marked a limited toleration of cannabis smoking.
Declaration of interest
The author of this chapter was head of the Soma Research Association (Soma (1)), 
which campaigned from 1967 for cannabis law reform. The article therefore expresses 
an insider’s perspective on the reform process. On 24 July 1967 Soma set out its 
proposals for decriminalisation in a full-page advertisement in The Times (Figure 1). 
The issue was debated in Parliament and referred to the Hallucinogens Sub-Committee 
(the so-called ‘Wootton Committee’(2)) of the Advisory Committee. In January 1969, 
the Home Office published the Advisory Committee Report on Cannabis, the so-called 
‘Wootton Report’. The report endorsed the proposals in the advertisement. The Home 
Secretary of the day denounced the report and the advertisement. However, a year later 
he introduced legislation to implement the main proposals of the report. This article 
describes the background to the appearance of the advertisement and describes the 
subsequent reform process up to 1979, when the Home Office advisors proposed the 
‘reclassification’ of cannabis.
A brief history of cannabis convictions in the United 
Kingdom
Cannabis was prohibited in Britain in 1928 under the Dangerous Drugs Act, which 
remained in force during the 1960s. Under the Act, cannabis was classified as a 
(1) Soma was chosen to have associations with the soma of the Rig Vedas, the nectar of the gods and 
the problematic tranquilliser in Aldous Huxley’s novel Brave New World.
(2) The Advisory Committee on Drug Dependence was headed by Sir Edward Wayne, Professor of 
Practice of Medicine at the University of Glasgow. The ‘Wootton’ subcommittee on hallucinogens was 
led by Baroness Wootton of Abinger, a sociologist.
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Figure 1: Advertisement in The Times, 24 July 1967
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narcotic and offences were subject to penalties essentially identical to those for heroin 
and cocaine. The maximum penalties were one year on summary conviction and 10 
years on indictment (3). No distinction was made between possession and supply, 
and most offenders were sent to prison. On the other hand, up to the mid-1960s 
enforcement was lax and directed mainly at black immigrants from the Caribbean. 
The first year in which a minority of offenders (48%) were imprisoned, 1964, was also 
the first year in which white offenders outnumbered black offenders (UK Home Office, 
1968).
During the 1950s there was little evidence of increased use of cannabis in the United 
Kingdom. In 1951 there were 127 convictions and this figure was not exceeded until 
1959, when it rose to 185. A plateau of about 600 convictions was reached in 1962 
and not exceeded until 1966, when a figure of 1 119 was reached. In 1967 convictions 
doubled again to 2 393. That year the total seizures by police and customs amounted 
to 295 kg and 457 plants. For a comparison, 30 years later, in 1997, the year of peak 
enforcement, seizures amounted to about 150 000 kg and 115 000 plants (The Police 
Foundation, 2000), an increase by a factor of 500 and 250 respectively.
1967: a watershed year for cannabis
Witnesses heard by the Wootton subcommittee in December 1967 variously estimated 
the prevalence of cannabis use at between 30 000 and 300 000 persons. Perhaps the 
lower figure corresponds roughly to the number of regular users at the beginning of the 
year. However, there must have been a very dramatic increase in cannabis smoking in 
1967, when the subject was widely and favourably publicised. By the end of the decade, 
a government-funded study indicated that nearly a million people had tried cannabis (4). 
The scale of cannabis use had by then probably reached a level where it was self-
sustaining and could not be moderated by widespread enforcement. The sanction of 
imprisonment was still applied in a quarter of cases heard in 1967, the great majority 
of them for simple possession of small quantities. Seventeen per cent of first offenders 
were imprisoned (UK Home Office, 1968). The possibility of jailing tens, if not hundreds 
of thousands, of people for minor cannabis offences was both unthinkable and quite 
impractical.
In the first half of the 1960s in the United Kingdom, cannabis smoking was a feature 
of the half-world, where it was used by jazz musicians, artists and writers and, 
increasingly, in the universities. In January 1967 an article estimated that 5 % of Oxford 
(3) ‘Summary conviction’ means conviction in a magistrates court. Cases of possession for personal use 
would normally be heard in a magistrate’s court. If the accused elected trial by jury the case would 
be heard in a Crown court and higher penalties would apply.
(4) A survey by Market Advertising and Products Study Ltd (MAPS), commissioned in 1969 by the Home 
Office and the Registrar General’s Office of Population Synthesis and Survey.
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undergraduates smoked pot from time to time (Abrams, 1967). This converted into 
a figure of 500 and was debated in the broadsheet newspapers. At the instigation of 
the Oxford Committee on Student Health, the Vice Chancellor wrote to the then Home 
Secretary Roy Jenkins on 28 February, asking him to commission a national inquiry into 
cannabis and LSD (UK Home Office, 1968). This led to the appointment on 7 April of 
the Hallucinogens Sub-Committee (the so-called ‘Wootton Committee’) of the Advisory 
Committee on Drug Dependence.
Up to the beginning of 1967, cannabis received little publicity and nearly all of this 
was negative. Though prevalence remained low, cannabis use among 1960s celebrities 
and pop stars served to publicise the substance. For example, the arrest of the Scottish 
singer Donovan in mid-1966 was widely reported. Following a denunciation in the mass 
circulation newspaper the News of the World, Mick Jagger and Keith Richards of the 
Rolling Stones were arrested in February 1967 and sent for trial at the end of June for 
minor drugs offences. On 1 June 1967 the Beatles, at the zenith of their creative power 
and influence, released their Sgt. Pepper album, which was saturated with references 
to cannabis and LSD. The last track, ‘A Day in the Life’ (5), was banned from airplay 
on the BBC. The Beatles, and Paul McCartney in particular, were advocates of LSD: 
a serious confrontation was brewing between fashionable alternative society and the 
Establishment.
Soma was looking for a way to put the topic of cannabis law reform on the political 
agenda, and also to influence the terms of the deliberations of the Wootton Committee. 
In particular, the aim was to persuade the subcommittee to report on cannabis alone, 
rather than in conjunction with LSD. This in turn was based on the assumption that 
there was a consensus of informed opinion that cannabis was less harmful than 
stimulants, sedatives and alcohol and confidence that the committee would discover 
this for themselves. The gesture which occurred to me was to take a page of The Times 
newspaper for a paid advertisement in support of the decriminalisation of cannabis. 
The advertisement would draw its force from a number of influential people who would 
put their names to it. Barry Miles (6) mentioned this proposal to Paul McCartney on 2 
June. McCartney immediately realised that the advertisement would have the effect of 
switching the focus from LSD to cannabis and associating the Beatles with prominent 
authorities in a legitimate protest ‘within the system’. Following a meeting between 
McCartney, Miles and myself on 5 June, the Beatles agreed to add their names to the 
(5) The song’s lyrics include the lines ‘Found my way upstairs and had a smoke/Somebody spoke and I 
went into a dream’.
(6) Barry Miles was an author and co-runner of London’s Indica bookshop and gallery, later biographer 
of Allan Ginsberg and Paul McCartney.
Chapter 4
45
advertisement and McCartney guaranteed the funding, finally credited to a Beatles 
advertising account (7).
At the end of June, as the preparation of the advertisement neared completion, Mick 
Jagger and Keith Richards were convicted and sentenced to imprisonment. There was 
a public outcry, including three nights of demonstrations in Fleet Street against the 
newspaper the News of the World, who were accused by Michael Havers, Jagger’s 
counsel, of sending in an agent provocateur. After spending two nights in prison, Jagger 
and Richards were released on bail on 30 June. Jagger had been sentenced to three 
months for possession of amphetamines and Richards was sentenced to a year for the 
‘absolute’ offence that cannabis had been smoked at his home, with or without his 
knowledge (8).
On the following day, 1 July, The Times published a famous leading article with the 
felicitous title, ‘Who breaks a butterfly on a wheel?’. This leader has been much 
misunderstood, not least by its author, William Rees-Mogg, who claims that it ‘helped 
to get Jagger out of prison on a minor drugs charge’ (9). Also, the official history of The 
Times says that the leader was delivered to Jagger in prison by a warder with the advice 
that he would soon be freed on bail (10). As mentioned above, Jagger was freed a day 
before the leader appeared. Many, if not most, accounts of the case, including the most 
recent one in The Times and others in The Guardian, The Independent and on the BBC, 
assert that Jagger was convicted of possession of cannabis (11). Rees-Mogg’s leader 
made it clear that he considered amphetamine to be a ‘soft’ drug and Jagger’s offence 
to be trivial. However, he seemed to regard cannabis as a dangerous narcotic and was 
not, therefore, prepared to question the sentence of a year in prison for Richards. The 
Times got cold feet and postponed the publication of the advertisement, which finally 
appeared on 24 July. In the interim, a Legalise Pot Rally was held in Hyde Park on 16 
July, attended by 10 000 people, marking the colourful advent of ‘flower power’. Most 
national newspapers covered the event with a two-page spread. There were no arrests.
(7) B. Miles, Paul McCartney: many years from now, Secker & Warburg, London, 1997, pp. 386–395; 
S. Abrams, ‘The Wootton Retort’; D. Taylor, It was twenty years ago today, Bantam Press, London, 
1987, pp. 122–127.
(8) T. Hewat (ed.), Rolling Stones file: the trials of Mick Jagger and Keith Richards, Panther Record, 
London, 1967, p. 128.
(9) In a news article, ‘We’ve got to face it, Britain’s gone to pot’ (The Times, 2 July 2001), Lord Rees-
Mogg finally expressed the view that ‘prohibition has not proved to be the answer’.
(10) John Grigg in The Times Magazine, 30 October 1993, p. 39.
(11) Lewis Smith in The Times, 2 August 2005: [Jagger was] convicted of possessing cannabis in 1967 
in a case that became a cause célèbre when first he was jailed for a year and then freed on appeal 
three days later after a leading article in The Times headlined ‘Who breaks a butterfly on a wheel’.
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Paragraph 2 of the Wootton Report reads:
Our first enquiries were proceeding — without publicity — into the pharmacological and 
medical aspects, when other developments gave our study new and increased significance. 
An advertisement in The Times on 24th July, 1967 represented that the long-asserted 
dangers of cannabis were exaggerated and that the related law was socially damaging, if not 
unworkable. This was followed by a wave of debate about these issues in Parliament, the Press 
and elsewhere, and reports of enquiries, e.g. by the National Council for Civil Liberties. This 
publicity made more explicit the nature of some current ‘protest’ about official policy on drugs; 
defined more clearly some of the main issues in our study; and led us to give greater attention 
to the legal aspects of the problem. Government spokesmen made it clear that any future 
development of policy on cannabis would have to take account of the Advisory Committee’s 
Report. Accordingly, we decided to give first priority to presenting our views on cannabis.
The advertisement in The Times (Figure 1) was published by the Soma Research 
Association and signed by 65 people, including the Nobel Laureate Francis Crick, 
novelist Graham Greene, 15 doctors of medicine, one member of the Wootton 
Committee, members of Parliament and the Beatles (12). The advertisement was the 
subject of an adjournment debate in Parliament in the week of its appearance (on 28 
July), when the Minister of State referred the issue to the Wootton Committee (13). The 
Wootton Report was submitted on 1 November 1968 and published in January 1969.
The advertisement in The Times described the existing law as ‘immoral in principle 
and unworkable in practice’ but it stopped short of advocating the legalisation of 
cannabis. Instead, it proposed that users of cannabis should not face the prospect of 
imprisonment. Specifically, the advertisement said that possession of a small amount 
should not be punished by anything more than a relatively small fine of £25. The 
question of supply was ignored. This position has become known as ‘decriminalisation’.
The Advisory Committee Report included many echoes of the advertisement, that:
(…) The long term consumption of cannabis in moderate doses has no harmful effects (…) 
Cannabis is less dangerous than the opiates, amphetamines and barbiturates, and also less 
dangerous than alcohol. (…) An increasing number of people, mainly young, in all classes of 
(12) The Soma Research Association was founded in January 1967, incorporated in 1969 and disbanded 
in 1971. The directors were Dr David Cooper; Francis Crick, FRS; Francis Huxley; Dr R. D. Laing; 
The Rev. Kenneth Leech; Dr Anthony Storr; Professor Norman Zinberg and the present writer. The 
secretary, from 1968, was Don Aitken. Staff included Adam Parker-Rhodes, pharmacologist; Dick 
Pountain, chemist; Derek Blackburn, psychologist; and Sam Hutt and Ian Dunbar, physicians. 
Premises (in London) were at 438 Fulham Road (from 1968) and 4 Camden High Street (from 1969). 
Soma was funded by private donations and subscriptions. The total expenditure did not exceed 
£5 000. This figure does not include the cost of advertisement, which was £1 800.
(13) On 31 July the Court of Appeal quashed Richards’s conviction. This was remarkable because 
Richards had no case to argue. However, the court ignored the fact that the premises offence was 
‘absolute’. Jagger’s conviction was upheld but he was let off with a conditional discharge.
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society are experimenting with this drug, and substantial numbers use it regularly for social 
pleasure. There is no evidence that this activity is causing violent crime, or is producing in 
otherwise normal people conditions of dependence or psychosis requiring medical treatment 
(…) there are indications that (cannabis) may become a functional equivalent of alcohol.
The burden of proof thus passed from the campaigners to the government’s own 
expert advisors; and this was regarded by many as a green light for the consumption 
of cannabis. The Advisory Committee appeared also to accept the principle of 
decriminalisation. The main proposal in the report was that ‘possession of a small 
amount of cannabis should not normally be regarded as a serious crime to be punished 
by imprisonment’. The accompanying letter of submission to the Home Secretary said: 
‘The committee is generally of the view that imprisonment is no longer an appropriate 
punishment for those who are unlawfully in possession of a small amount.’
The Home Secretary of the day, James Callaghan, suggested he would reject the report. 
He told Parliament that on his reading, the committee had been ‘over-influenced’ by the 
‘lobby’ for ‘legalisation’ responsible for ‘that notorious advertisement’, adding, ‘it was 
wrong for the committee to report on one drug in isolation in the way that it did’ (14). 
However, a year later he introduced comprehensive new consolidating legislation that 
had the effect of implementing Wootton’s proposal (15).
Callaghan’s Misuse of Drugs Bill increased the penalties for most drugs offences, 
including trafficking in cannabis. However, this legislation introduced a distinction not 
drawn by Wootton between penalties for use and supply. The penalties for possession 
of cannabis were sharply reduced, by 50 %, to five years on indictment and six months 
on summary conviction. The Wootton Report noted that offences with a maximum 
sentence on summary conviction of six months or less were not normally punished by 
imprisonment, and that such sentences as were passed were suspended as a matter of 
routine. They opted for a maximum sentence on summary conviction of four months.
Callaghan’s legislation perished in the General Election of 1970. However, it was 
soon reintroduced by the incoming Conservative government and became law as 
The Misuse of Drugs Act (1971). When the act received the Royal Assent in 1973, the 
Lord Chancellor, Hailsham, instructed magistrates on sentencing. He said, ‘Set aside 
your prejudice, if you have one, and reserve the sentence of imprisonment for suitably 
flagrant cases of large scale trafficking’ (16).
(14) Hansard, 27 January 1969.
(15) One account suggests James Callaghan got cold feet and tried at the last moment to alter the 
legislation, but he was outvoted in cabinet: entry for 26 February 1970 in A. Howard (ed.) (1979), 
The Crossman Diaries, London.
(16) The Times, 12 October 1973.
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The operation of the new law in its first four years was made the subject of a special 
in-depth statistical analysis by the Advisory Council on the Misuse of Drugs (ACMD), 
prepared in December 1978 and published in 1979 (17). This study showed that the 
law was working as intended and that, with a handful of exceptions, the courts had 
abandoned custodial sentences for cannabis users. During this period, there was a 
further reduction, under the Criminal Justice Act (1977), of 50 % in the maximum 
sentence on summary conviction, to three months’ imprisonment, one month less than 
the maximum proposed by the Wootton Report.
Subsequently, in 1978 the Advisory Council on the Misuse of Drugs (the successor to the 
Advisory Committee) proposed to ‘reclassify’ cannabis, moving it to the weakest of three 
punishment regimes. It took 25 years to implement this recommendation. However, in 
the 1980s the Thatcher government moved sharply in the direction of decriminalisation 
by introducing ‘cautioning’: an offender who was cautioned would escape without a 
fine or a criminal conviction. By the beginning of the 1990s, the majority of minor cases 
were dealt with by means of the caution, so that in 1992, when The Times itself came 
out in support of legalisation, on the 25th anniversary of the Soma advertisement, the 
leader could conclude that the law was ‘all but unenforced’.
In 2000 the question of reclassification was revived in the Report of the Independent 
Police Foundation Inquiry. In response, the Home Secretary sought advice from the 
Advisory Council and from the House of Commons Select Committee on Home Affairs 
(see Ballotta et al., this monograph). The interesting point, perhaps, is that all three 
bodies stressed that the importance of reclassification (which did not directly affect the 
penalty on summary conviction) was that it demonstrated the fact that cannabis is less 
dangerous than amphetamine. With the reclassification of cannabis — where there is a 
‘presumption not to arrest’ reasonably discreet adult users of cannabis — there has thus 
been a complete reversal of the assessment of the relative dangers of these two drugs in 
the 1960s. It is worth adding, perhaps, that Paul McCartney and Mick Jagger were both 
eventually convicted of cannabis offences, for which they received small fines. Today, Sir 
Paul McCartney and Sir Michael Jagger have received knighthoods.
(17) Advisory Council on the Misuse of Drugs (1978) – Report on a review of the classification of controlled 
drugs and of penalties under schedules 2 and 4 of the Misuse of Drugs Act 1971, 15 December 1978. 
This proposal also called for the law to be recast to remove the sanction of imprisonment on statutory 
conviction for possession of cannabis.
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Chapter 5
Cannabis’s role in drawing 
attention to ‘the drugs problem’ 
in Sweden
Keywords: cannabis – jazz musicians – media coverage – moral panic – Sweden
Setting the context
In many aspects of government the ‘Swedish model’ is held up as a paradigm. Sweden 
is often cited as proof that a distributionist welfare state can co-exist with a strong 
market economy. Although Sweden is not immune to social problems, the country’s 
9 million inhabitants are able to boast an impressive record within EU countries on 
many health indicators.
So how does Sweden look in terms of cannabis and illicit drugs? Sweden promotes 
a vision of a ‘drug-free society’ at policy level. It recently appointed a National Drug 
Policy Coordinator to espouse what it terms a ‘restrictive and humane strategy’, and in 
September 2006 its drug policy was singled out for praise from the UNODC in a report 
which concluded that the country’s vision of a drug-free society ‘has not been found to 
be obsolete or misdirected’ (UNODC, 2006).
Cannabis prevalence rose in Sweden in the early 2000s, particularly among youths, 
and was reported as ‘very worrying’ in a Swedish government report (Ramström, 2004). 
Reported last month prevalence among young people rose from 1.3 % in 2000 (16- to 
34-year-olds) to reach 5.3 % in 2004 (18- to 34-year-olds) and dropping to 4.8 % in 
2005 (16- to 34-year-olds) (EMCDDA, 2006). Sweden has also observed a general 
increase in the tested potency of cannabis, and anxiety has been expressed about 
increases in treatment admissions. In 2007, the Swedish Rikskriminalpolisen published a 
report that suggested that the cannabis market is larger than previously thought: 25–30 
tonnes per year, with around 140 cannabis smuggling networks operating. Nonetheless, 
at 2.9 %, cannabis prevalence among young people in Sweden (15- to 24-year-olds) 
remains the third lowest in EMCDDA reporting countries, after Greece and Lithuania.
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This chapter studies cannabis’s cultural role in what sociologists term a moral panic 
about drug use in Sweden. It examines the evolution of drug use from almost a non-
issue to a highly debated cultural construct. Its extracts from contemporary media reports 
with a salacious tone suggest that Europe was no stranger to the much-ridiculed ‘reefer 
madness’ campaigns of 1930s America. 
It is interesting to note how responses to drug use evolved to embrace a moral and 
welfare-related approach as opposed to a medicine- or psychotherapy-based focus. 
While in Sweden the vision of a drug-free society has been able to gain political 
legitimacy, in many other countries more pragmatic approaches have been adopted. 
Today, decades after the reports quoted in this chapter, stories about drug use — 
particularly among youths, celebrities, musicians, criminals and clubbers — still retain a 
hold over the public imagination.
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Cannabis’s role in drawing 
attention to ‘the drugs problem’ 
in Sweden
Börje Olsson
World illicit drug consumption has increased substantially since the beginning of the 
1990s. The annual number of users of all illicit drugs (1) in 2007 was estimated at 
about 200 million people. For cannabis, the corresponding number is 158.8 million, 
compared with 24.9 million for amphetamines, 15.6 million for opiates, 14.3 million for 
cocaine and 8.6 million for ecstasy (UNODC, 2007). 
Even if cannabis is by far the most frequently and widely used drug, the bulk of 
problems related to illicit drug use is linked to other substances, such as heroin and 
cocaine. In this respect, cannabis use is a subordinate issue, but in present and past 
policy controversies cannabis plays, and has played, a central role. Why is this so? This 
chapter focuses on the role of cannabis in the ‘cultural construction’ of the modern drug 
problem in Sweden. It aims to discuss cannabis’s central role, and to provide tentative 
answers.
The modern idea of ‘a drug problem’ developed fairly simultaneously in many Western 
societies in the late 1960s. It was characterised by an increased prevalence in groups 
not previously associated with drug use, and as a particular phenomenon that was 
distinct from previous, medical drug use. While historically cannabis experienced some 
pharmaceutical usage, it largely disappeared from legal medical practice in Western 
Europe before the Second World War (see Fankhauser, this monograph). A number of 
factors contributed to drugs being viewed as a problem: (i) recreational cannabis use as 
an intoxicant among ‘exclusive’ or ‘deviant’ groups as jazz musicians and other artists; 
(ii) claims that cannabis caused crime, mental illness and in severe cases even death; 
and (iii) the fact that synthetic preparations considered more effective than cannabis 
were invented, for example barbiturates and painkillers such as aspirin (Russo, 1998; 
Mack and Joy, 2000; Grotenhermen, 2002). Compared to many other substances 
which today are common on the illicit drug market — for example morphine and other 
opiates — cannabis was fairly easily ruled out from legal medical practice. Yet these 
medicinal substances continued to experience extensive, often highly praised use in 
(1) The number of people who have consumed an illicit drug at least once in the 12 month period 
preceding the assessment.
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regular medicine and as long as the users were seen as patients in need of treatment, 
drug use as a social problem was not an issue (Olsson, 1994; see also Fankhauser, this 
monograph).
Cannabis use played an extraordinarily important role in the process where drug use 
developed into a social problem in modern societies. This might seem odd considering 
its relatively mild effects and limited harms vis-à-vis opiates. As will be discussed, this 
paradox can be explained. In fact, it is doubtful whether our views on drugs and the 
policies developed upon them would have looked the same if cannabis had not existed. 
This general question will be discussed by taking its point of departure at the time of the 
Second World War and in one specific country, Sweden.
Though a prerequisite, the mere existence of drugs is not sufficient to create a drug 
problem. But to understand the roots of the ‘modern’ drug problem in Sweden, it is 
nevertheless a good starting point to turn to the introduction of amphetamines as 
pharmaceutical preparations towards the end of the 1930s. They were introduced 
for medical purposes and, as usual, the new medicament was praised as efficient, 
without side-effects and suitable for a variety of problems, such as narcolepsy, epilepsy, 
depression, psychosis, fatigue, excessive weight and obesity (Goldberg, 1944). 
Amphetamines or similar drugs that stimulate the central nervous system rapidly became 
popular and their use spread to a significant proportion of the Swedish population. It 
has been estimated that in 1942–3 there were about 200 000 users of amphetamines 
in the country, corresponding to 3 % of the adult population (a proportion that exceeds 
today’s amphetamine prevalence by 5 to 10 times). Even if the majority were occasional 
users, nearly 10 000 used them as frequently as between once a week to several times a 
day, and many in the latter group did so in extremely high dosages (Goldberg, 1968). 
Despite this, there were no signs of constructing drug use as a social problem. On the 
contrary, the privilege to formulate drugs as a problem was still solidly contained within 
the medical field. When drug use was perceived as a problem, it was as an individual 
disease suitable for the family doctor to treat (Olsson, 1994).
Multiple Swedish government investigations during the 1950s concluded that drug 
use offered little cause for alarm. Conclusions were drawn that there was appreciable 
prevalence in amphetamine (3%, Goldberg, 1968) and opiate use, although these 
were predominantly used by well-adjusted citizens for medical or therapeutic purposes 
(Medicinalstyrelsen, 1956). Moreover, incidences of opiate addiction could be best 
treated by a family doctor (Olsson, 1994). Although there was some acknowledgement 
of the threat of amphetamines, heroin (Bejerot, 1969) and cannabis, particularly to 
young users, reports on ‘societal risks’ — for example those associated with intravenous 
heroin use — drew predominantly on case studies outside Sweden. Furthermore, 
attempts to link problem drug use to subcultural groups by the Liberal Party MP 
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Rimmerfors were met with scepticism (Rimmerfors, 1954, 1958). In short, drug problems 
were generally perceived as alien to Swedish society. Swedes were using drugs for 
medicinal, not mind-altering, effects.
However, towards the end of the 1950s discussions appeared in which drug use as a 
social problem started to be identified and defined. The reasons behind this had little 
to do with the extensive oral use of amphetamines or morphine among well-integrated 
persons. What the public discourse started to pay attention to were three other 
phenomena: (i) drug use among musicians and artists; (ii) the link between these groups 
and youths; and (iii) a few years later drug addiction among marginalised groups. 
The first two received the most attention in the media. Amphetamines and cannabis 
use among musicians and other artists were perhaps the most frequently highlighted 
in the press. Limited use of morphine was also reported. Half a century after these 
reports and descriptions were published in newspapers, it is evident that one of the 
most distinguishing features in them was a strong tone of moral condemnation. This is 
true not only for drug use and drug users but also for the kind of lifestyle these artists 
represented. The following article illustrates this.
A lot has been written about the historical roots and developments of American jazz music. 
Unfortunately, the historical writing has been blind to the dark sides of jazz music and 
only focused on its charming, exciting and positive aspects (…) but the rush, stress and the 
increased competition between top musicians and, not least, unscrupulous managers have 
provided musicians and artists with an illusory substance that overcomes fatigue, increases the 
performance capacity at the same time as it turns them into slaves under the most dangerous 
vice that exists, drug addiction. (…) Youths talented for the profession as musicians worship 
the American stars as they were gods, and they try to imitate them at any prize. They make 
contacts at frequent guest performances and young Swedes get enthusiastic descriptions of 
how improvisation and other forms of liberation is amplified simply by smoking one joint of 
marihuana.
 (Aftonbladet, 11 April 1954: author’s translation)
The article highlights several aspects of the drug problem that were important in forming 
the general perceptions of drug use/misuse/addiction. In absolute numbers, the groups 
referred to involved only a few persons frequenting certain clubs and bars in the ‘Old 
Town’ of Stockholm, while the much larger group of persons using amphetamines were 
hardly given any attention. The quotation also indicates one of the main reasons why 
anxiety about drugs was soon to escalate, namely the clear link that was established 
between this exclusive group of American musicians and young Swedes. The anxiety 
was further increased through repetitive descriptions in other articles that appeared 
concerning promiscuous young girls and drugs.
It is well known to social workers that the mean age among female prostitutes in Stockholm is 
constantly decreasing. The influx of 16 to 20 year old girls is presently big. It involves teenage 
girls who have a history of being regular frequenters of obscure dance halls where they have 
established contacts with mediocre artists who have provided them with drugs.
(Aftonbladet, 7 November 1954: author’s translation)
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From 1954 onwards, the link between drug use and youth in media becomes more and 
more evident. Also, well-adjusted young people are described in the context of drugs 
and drug use, making it possible for any parent to identify with the narratives presented.
Daily, dozens of teenagers hang out at cafés. It is schoolchildren, often from well-off families, 
who without further ado skip school and homework, who drift about in gangs, who pretend 
they are Bohemians, poets, and drug users. Among the most advanced groups of youth 
in Stockholm, it has come into fashion to smoke hashish or marijuana or to get high on 
Phenedrine and sleeping-pills.
(Arbetaren, 24 February 1954: author’s translation)
Certain important features that have become central to how the Swedish drug problem 
later was conceived and defined were thus already present in 1954. Among the most 
important were the dominant perception of drugs as something alien to Swedish 
culture (2) and drugs as a serious threat to young people. At the same time, less 
attention was paid to the medically initiated use of drugs among somewhat older, 
ordinary citizens, and the fact that amphetamine use was already spreading among 
older criminals was not yet noticed. In other words, the portrayal of cannabis as a threat 
was both pronounced and distinct, but in reality did not yet live up to the legend. Even 
if jazz musicians, certain other groups of artists and a number of young people in their 
circles were given a prominent place in media narratives of drug use, their numbers 
were still very limited and an overwhelming majority of Swedes never had any contacts 
with drug users.
A simultaneous development took place which eventually would develop into the 
factual core issue in the Swedish drug problem: amphetamine use — in particular, 
amphetamines used intravenously — among established criminals. Due to reasons which 
are beyond the scope of this chapter, this unique form of drug use became extremely 
widespread in criminal circles. To some extent this process started already during the 
early 1950s, but it was not until the end of the decade and during the early 1960s 
that this pattern, peculiar to Sweden, really took off. As increased amphetamine use 
among criminals became evident, the controls of these substances also were made more 
stringent. Amongst other developments, by 1960 all amphetamine-like substances were 
included in the national list where narcotic drugs were classified. The legal channels 
to obtain access to these drugs were successively blocked, which led to an increasing 
number of drug crimes as the number of misusers and addicts continued to increase. 
This triggered a series of control measures such as, for instance, the setting up of a 
specific drug prosecutor and a police drug squad, together with a successive sharpening 
of drug legislation. At the same time, the legal consumption of narcotic drugs dropped 
to a fraction of its previous levels (Olsson, 1994).
(2) Drugs as an alien element in Swedish society and culture has later been analysed by Tham (1995).
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To summarise, taken together these three phenomena had a great impact on how 
the definition of the ‘modern’ drug problem developed and which drug policy was to 
be implemented. A crucial factor was that drug use (outside legal medical use) was 
something novel and unknown to Swedish society and culture, and to which frightening 
properties were attributed through references to intravenous heroin addiction in other 
countries. The image of drugs as a serious threat increased significantly due to the links 
made to ordinary youths running the risk to be drawn into the slavery of addiction. 
Also, and in sharp contrast to earlier images of the more familiar and legal medical use 
of drugs, clear links were outlined between drug use at the one hand and criminality 
and marginalisation at the other, as a result of the actual, visible and widespread 
amphetamine use among criminals.
As far as cannabis is concerned, thus far we can draw a tentative conclusion. Seen 
in isolation the actual prevalence of the substance played only a limited role in how 
basic perceptions and definitions of the drug problem originally were formulated in 
Sweden. Cannabis instead played an important role in adding strong moral and legal 
‘spin’ to Swedish drug policy. It was portrayed as strange, unknown, alien, exotic and 
frightening and, in contrast to, for instance, opiates, there was hardly any lingering 
‘normal’ medical use of cannabis after the Second World War. This concept of deviance 
was strengthened by the fact that people had almost solely to rely on illegal channels 
to obtain cannabis. Furthermore, the mind-altering effects of cannabis were unfamiliar 
to the ‘normalised’ intoxication culture in Sweden, that is to get drunk on alcohol. 
Empirical definitions of the substance in the medical field were held back by the absence 
of reporting of negative effects of cannabis in the medical literature. Such a ‘knowledge 
vacuum’ enabled moralists to step in and approach cannabis in alarmist terms. So 
public interest was weighted towards moral, legal and social aspects of cannabis use 
and the threat to young people that cannabis was seen to constitute. This weighting had 
a great impact on the process where not only cannabis, but drugs in general, grew to 
become a disproportionate public problem that required a response at the policy level.
By 1965 the situation around drugs had matured to the extent that all necessary 
prerequisites were at hand for the government to delineate what was to become a 
fundamental aspect of Swedish drug policy. A government commission was appointed 
to conduct the first comprehensive investigation into the drug situation in Sweden. 
The commission worked for four years and published four thick volumes (3) in which, 
apart from the articulation of negative moral perceptions, priority was given to the 
legal and social aspects of drug use. Control, prevention and treatment were from the 
beginning the main pillars in the model which later became one of the most restrictive 
in Europe. It is interesting to note that the legal and social aspects were not only 
dominant in the two first pillars, but also in the third, treatment. In contrast to many 
(3) SOU 1967, 25; SOU 1967, 41; SOU 1969, 52; SOU 1969, 53.
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other countries, the Swedish drug treatment system was built outside the medical sphere 
and to a large extent based on principles that do not constitute medical treatment. 
The overall responsibility for providing drug treatment was placed upon the social 
welfare system and many of the specific treatment methods utilised had strong moral 
and social components. Apart from a small experiment with methadone treatment, all 
treatment activities were drug-free and aimed at total abstinence from drugs. The role 
of medical authorities was limited to handling complications related to drug use and 
to providing detoxification before the patients were transferred to long-term treatment 
provided by the social welfare system, which was preferred to institutional treatment. A 
distinctive feature of Swedish drug treatment was that, at least during its first 15 years, 
drug use was perceived as a symptom of severe social and psychological problems 
and that treatment, therefore, should focus more on what caused the symptom than 
on the symptom itself. Both laymen and non-experts were given an important role in 
treatment, reflected by the very strong influence of treatment institutions run by NGOs 
(Socialstyrelsen, 1973).
A striking example, which serves to illustrate the strong legal, moral and social 
dimensions of drug policy, is the development of an influential form of institutional 
drug treatment model for youths in Sweden, which has become known as the ‘Hassela 
pedagogic’ (named after the village where the first institution was set up in 1969). This 
model — where one of the foundations is ‘medlevarskap’ (living together), meaning that 
clients and staff live together round the clock — put young addicts for a considerable 
period of time in a permanent and stable group of adults to work and study. Such firm 
fostering is a key concept in the model: adolescents are strictly reminded of ‘forgotten 
basics’ such as good friendship, solidarity with the group and respect for work. The 
‘Hassela pedagogic’ goes against the grain of the concept of therapy in the sense that 
treatment is explicitly rejected and the focus is instead on education and fostering pupils 
(the term used instead of clients or patients) into decent, well-integrated and hard-
working citizens (Tilander, 1991). It should also be noted that the majority of young 
addicts in this form of institution are treated compulsorily as a result of a legal decision 
(Bergmark et al., 1989).
This particular form of treatment had a significant impact on treatment models and 
methods for adults when they were designed and it is one of many examples of the 
strong legal, moral and social dimensions of Swedish drug policy. As has been shown, 
this architecture was rapidly constructed once drug use was recognised as a public 
problem and already before the advent of the 1970s, the foundation was laid for a 
policy that has remained unaltered if we consider the basic perceptions of drug use. 
It is true that drug policy became gradually more restrictive over the years and that 
numerous repressive measures were introduced, but this cannot be seen as a redefinition 
of the perceptions, but rather as a quantitative change where more weight was placed 
on the control side of drug policy (Lenke and Olsson, 2002).
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Some of the conclusions, at least tentatively drawn in this chapter, contradict popular 
understandings of how drug use developed in Sweden and how the drug problem was 
formulated. Maybe the most popular belief is that the Swedish drug problem took off 
when different youth cultural trends (hippies, flower power, etc.) spread around the 
world towards the end of the 1960s (see Abrams, this monograph). In these cultures 
drugs, and especially cannabis, played an important role. A closer look at the Swedish 
situation shows that drug use related to these types of youth cultures was hardly a new 
drug epidemic. Certainly, cannabis use among young people became more common 
from about 1965–7, but the prevalence figures which were reached were still modest 
and restricted to limited circles, in particular the major cities. Furthermore, for a vast 
majority of young people drug use was confined to trying cannabis once only or 
experimenting with the substance a few times (SOU, 1969: 53). Prevalence peaked only 
a few years later, after which a rapid decrease occurred (CAN, 2003). Later analysis 
shows that most of those who experimented with drugs in a more serious way, almost 
exclusively cannabis, only did so for a short period of time, after which they returned 
to a ‘normal’ life without drugs (Solarz, 1990). Those making up the group of problem 
drug users in Sweden were recruited through completely different channels, where the 
common denominator was the marginal position which preceded their drug use (Bejerot, 
1965, 1969; Olsson, 1994).
The Swedish hippie era, if it is possible to talk about such an era at all, and the radical 
youth movement around 1968 were important to conceptions of the drug problem. 
However, they added little in terms of originating or redefining ‘the drug problem’. 
The hippie era simply allowed media and other actors to revitalise the public discourse 
on youth and drugs that had already started some 10 years earlier but which, as with 
most discourses, had stagnated. In particular, two dominant aspects of the discourse 
in the mid-1950s were revived around 1968: firstly, the idea of youth oppositionism 
or rebellion, which was attributed to both the youth movements of the mid-1950s and 
those of the end of the 1960s; secondly, the idea of danger, in terms of the grave 
risks that were associated with drug use, with no exception made for cannabis. Since 
cannabis prevalence in the hippie era surpassed by far that in the 1950s, the effect was 
to ‘upscale’ the problem with little change to its key qualitative features. Again, we see 
portrayals of drug addicts as persons without will power who have become slaves to 
a lethal vice compelled to act as chemically driven ‘crime machines’ (Winsløw, 1984). 
Again, we see the factual domestic situation where amphetamine use rapidly spread to 
become an integral part of an established criminal sub-culture. 
In short, the main effect of the ‘drug wave’ towards the end of the 60s in Sweden was 
to revive dormant anxieties of an impending social catastrophe and at the same time 
provide fertile soil for a drug policy with strong moral, legal and social dimensions.
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Setting the context
This chapter examines cannabis use in the 10 Member States which joined the European 
Union in May 2004. It attempts to identify patterns in a cluster, and aims to increase our 
understanding of cultural, social and economic issues which are deeply embedded in 
cannabis use patterns and social responses.
More time will be needed to grasp the full impact of how drug use is affected by such 
a root-and-branch political shift as EU membership — if indeed any generalisations 
can be made in what remain, even after EU membership, very diverse countries. Will 
cannabis use patterns in EU Member States converge or continue to differ? To what 
extent does changing affordability, or the geographical proximity to supply routes, 
affect cannabis consumption? Will new EU members also experience the shift to 
herbal cannabis cultivation, as witnessed in a number of EU countries? Can country 
peculiarities, such as the high prevalence of cannabis in the Czech Republic, be 
easily explained? After EU membership, how does drug use interact with other social, 
economic and health indicators?
This chapter offers some thoughts, impressions and observations on early experiences. 
These experiences invite further validation and consideration as the drugs data for these 
countries mature. Moreover, since this article was written the European Union has further 
grown: two new Member States, Bulgaria and Romania, joined in January 2007. Drug 
use in two candidate countries, Turkey and Croatia, has also begun to be monitored 
directly by the EMCDDA. As the Centre is increasingly sought to comment on drug use 
among its new members and near-neighbours, this chapter emphasises the value of 
expert local insights: the voices behind the statistics.
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Introduction
The 2004 enlargement of the European Union (EU) covered 10 countries of very 
different size, population and culture, spreading from the Baltic to the Mediterranean. 
Considering existing commonalities and differences, three broad groups may be 
distinguished: the Baltic States (Estonia, Latvia and Lithuania); the Central European 
countries (Czech Republic, Hungary, Poland, Slovenia and Slovakia) and the 
Mediterranean islands (Cyprus and Malta). The number of their inhabitants ranges from 
just over 400 000 in Malta to over 38 million in Poland. Altogether, close to 80 million 
people live in the new members of the EU, sometimes referred to as the EU-10.
Significant differences exist in economic development and wealth among the EU-10. 
Gross national product (GNP) per capita adjusted for purchasing power varies from well 
below EUR 8 000 in the Baltic states to over EUR 15 000 in Cyprus, Malta and Slovenia. 
The new EU Member States are also very different in terms of political history. For about 
a half of the last century the Baltic states were part of the Soviet Union, and Poland, 
the Czech Republic and Slovakia, as well as Hungary, belonged to the bloc of socialist 
countries bound militarily and economically to the Soviet Union. Slovenia was part of 
socialist Yugoslavia, while Cyprus and Malta experienced market economies and more 
pluralistic political systems after rejecting the colonial power of the United Kingdom 
about 50 years ago. Eight out of 10 new EU members have been affected, then, by 
root-and-branch social change in the last 20 years.
Introduction of multi-party political systems and reinforcement of the market economy 
have resulted in more personal freedom and economic growth in recent years. On the 
other hand, a sense of everyday security has deteriorated. According to the participants 
of the project, security deteriorated the most, followed by housing security. Cannabis 
has been an illicit drug of choice for relatively large segments of young people in 
Western Europe. After the fall of the Iron Curtain cannabis use has rapidly increased in 
prevalence in Central and Eastern Europe as well, both in terms of physical presence 
and as a symbol of affiliation to the Western youth cultures.
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This chapter is co-authored by individuals from 10 countries. In the first stage of its 
preparation, representatives of each country produced a detailed inventory of available 
cannabis data in standardised format. The inventories served as background material 
that was used extensively during a two-day workshop with the aim to write a first draft 
of the chapter. The participants, divided into three groups which focused respectively 
on epidemiology, social perception and social responses, outlined three sections of 
the chapter which were then elaborated by three individuals: Airi-Alina Allaste (social 
perception), Zsolt Demetrovics (social response) and Danica Klempova (epidemiology). 
Finally, the chapter was combined and edited by Jacek Moskalewicz and Janusz 
Sierosławski. Support and encouragement was offered by Linda Montanari and Sharon 
Rödner Sznitman.
Epidemiology
History of cannabis in the region
Origins and industrial use of cannabis in the new EU Member 
States
Cannabis sativa was thought to be brought to Southern Europe by Scythians in the 
7th century bc. After that it gradually spread to other parts of Europe (Booth, 2004; 
Encyklopédia Slovenska, 1979). During feudalism, it was grown in central Europe, 
including the present territories of the Czech Republic, Hungary, Poland, Slovenia, 
Slovakia and possibly also other new EU Member States (e.g. Cyprus), usually in 
small-scale production by farmers, who processed it to make fabric, ropes and oils. 
The appearance of cheaper materials led to the replacement of hemp and decline of its 
cultivation. After the year 1945 the small-scale production of hemp almost disappeared. 
The industrial cultivation of hemp was, however, still present in some countries in the 
1980s. Main products made from it included fabrics for clothes, ropes, sheets, bags, 
cords for tyres, upholstering materials, oil used to make lacquers and varnishes, soap, 
materials for the food industry, animal foods, medications, materials for the construction 
industry, cellulose, etc. The contents of THC in the hemp grown for industrial purposes 
was low — about 1 %. At the end of the 1980s, growing and cultivation of cannabis 
was entirely stopped or heavily reduced due to stricter controls imposed by international 
conventions.
History of use of cannabis for its psychoactive properties
In Cyprus, cannabis as a psychoactive substance had culturally determined roots: both 
from Turkish culture present on the island, where cannabis resin used to be smoked 
in water pipes, and via Cyprus’s central location in historical Eastern Mediterranean 
cannabis trading routes (Egypt, Greece, Lebanon, Syria, Turkey). In Slovenia, the use of 
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cannabis for its psychoactive and hallucinogenic attributes is also believed to have been 
known to its inhabitants for centuries.
In Malta documented evidence of cannabis dates back to the early 1980s. During this 
time herbal cannabis was grown locally, mainly during the summer months. Between 
1985 and 1990 an increase in trade between other countries resulted in an increase in 
the importation of cannabis oil, which is quite rare today, and Lebanese and Moroccan 
cannabis resin. The latter remains the most common type of imported resin in Malta.
In the Czech Republic, Hungary, Poland, Slovakia and Slovenia anecdotal evidence 
exists about cannabis use during the revolt of the ‘hippie generation’ from the late 
1960s on, although prevalence was rather low. This can partly be explained due to 
low THC content in domestic cannabis and low availability and relatively high prices 
of cannabis sourced abroad. In Slovenia, with its warmer climate, cannabis use was 
supported from home growing during the 1980s. In that period, often referred to by the 
users as a golden age, cannabis supply was based on principles of reciprocity, barter 
and gifts, and not based on a criminal black market (Flaker, 2002).
In Estonia, Latvia and Lithuania, cannabis for psychoactive purposes is anecdotally 
reported to have been brought by soldiers serving their compulsory military service in 
Central Asian republics in the 1970s and 1980s. Herbal cannabis known as ‘anasha’ 
was consumed and brought home to some extent, especially by young soldiers (Kärdi, 
1993: 54–61, 58–63).
However, the history of the use of cannabis for its psychoactive properties in the 10 
new EU Member States is only documented anecdotally, and historical sources in most 
of the countries are scarce. With the exception of Cyprus, and perhaps Malta and 
Slovenia, before the 1990s the psychoactive properties of cannabis went either generally 
unrecognised or its use was very rare.
Contemporary prevalence of cannabis use
European School Project on Alcohol and Drugs
The most consistent data source for country comparison of cannabis use among 
teenagers is probably the European School Project on Alcohol and Drugs (ESPAD, see 
Hibell, this monograph). This survey took place in all of the 10 new EU Member States 
in the years 1995, 1999 and 2003 (Hibell et al., 1997, 2000, 2004).
Figure 1 shows trends in lifetime prevalence of cannabis use among 15- to 16-year-
olds, according to the ESPAD survey in the 10 new EU Member States, while Figure 2 
presents differences between lifetime, last year and last month prevalence, as recorded 
in 2003 (Hibell et al., 2004).
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Figure 1: Lifetime prevalence of cannabis use among 15- to 16-year-olds (ESPAD, 1995, 
1999, 2003)
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The reported lifetime prevalence of cannabis use among 15- to 16-year-old ESPAD 
respondents increased in the years 1995–2003 in all new EU member countries except 
Cyprus, where it remained approximately stable at a relatively low level (2–5 %). The 
increase in the years 1999–2003 was smaller in most countries than in 1995–1999. 
Among the 10 countries, a medium level of lifetime experience with cannabis can be 
found in the Baltic countries (Estonia, Latvia and Lithuania) and in Hungary, Malta and 
Figure 2: Lifetime, last-year and last-month prevalence of cannabis use among 15- to 
16-year-olds (ESPAD, 2003)
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Poland (10–18 %). The highest lifetime cannabis use prevalence is reported in the Czech 
Republic (44 %), Slovakia (27 %) and Slovenia (28 %).
Last year and last month prevalence of cannabis use among 15- and 16-year-olds 
show similar time trends. Last year prevalence is lower than, yet mostly close to, 
lifetime prevalence in this age group. Last month prevalence, as an indicator of regular 
cannabis use, is much lower. In the three countries with the highest prevalence, regular 
use ranges from 18 % in the Czech Republic through 14 % in Slovenia to 10 % in 
Slovakia. The range of the remaining seven countries is narrower and it varies from 2 % 
in Cyprus to 8 % in Poland. As a rule, prevalence of cannabis use during last month 
constitutes about 50 % of the last year prevalence, while last year prevalence is 15–40 % 
lower than lifetime cannabis experience. In effect, the wide gap among countries with 
regard to lifetime use tends to narrow with increasing frequency of use (Figure 3).
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Figure 3: Inter-country variation in lifetime, last-year and last-month prevalence of cannabis 
use among 15- to 16-year-olds (ESPAD, 2003)
The three syringes above show inter-country ranges in lifetime, last year and last month 
prevalence of cannabis use. Each cylinder represents two quartiles of respondents 
spread either side of the median and, finally, a horizontal pusher indicates a median 
value of prevalence among all countries. The declining values of all three indicators 
confirm that the cultural gap in cannabis use tends to close with growing frequency of 
use.
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General population surveys
The general population surveys provide a picture of cannabis use among the young 
population (15–34), which is slightly different from the ESPAD results (see Figures 4 
and 5). In Latvia, general population prevalence is similar to ESPAD survey results. In 
Lithuania, Slovakia and Hungary, the ESPAD results show similar values for lifetime 
prevalence, but indicate higher last year and last month prevalence. In the Czech 
Republic, Estonia, Malta and Poland, cannabis use among 15- to 16-year-olds surveyed 
by ESPAD is markedly higher than in the general population. Cyprus is the only country 
where general population data indicate higher prevalence than ESPAD data. There is a 
sharp contrast between figures for 15- to 16-year-olds — ranging from 1 to 5 % — and 
those for young adults aged 15–34 — ranging from 13 to 25 %. Data from Cyprus also 
show smaller gaps between lifetime experience and last year and last month use.
General population surveys across all 10 countries confirm that cannabis use is not only 
a matter of teenager behaviour, but is also prevalent among young adults up until their 
early 30s. Similarly to ESPAD, general population surveys show that while cannabis has 
been tried by a substantial proportion of young people, regular cannabis use is still only 
represented by small percentages of young adults.
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Figure 4: General population survey results from 2001 or 2002 about the prevalence of 
cannabis use among the young population (15- to 34-year-olds)
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Figure 5: General population survey results from 2003 or 2004 about the prevalence of 
cannabis use among the young population (15- to 34-year-olds)
Differentiation in cannabis use
Gender
Although in all countries cannabis use is higher among males than females, the size of 
the gap between the genders differs. Among 15- to 16-year-olds in 2003 there were 
five males to one female using cannabis in Cyprus, and two males to one female using 
cannabis in Latvia, Lithuania and Poland. The ratio ranged between 1:3 and 1:4 in 
Estonia, Hungary, Malta and Slovakia, and it was very small, at just below parity, in 
the Czech Republic (1:1) and Slovenia (1:1) (Hibell et al., 2004). It is worthwhile noting 
that a trend towards a more narrow gender gap was reported in most of the countries 
between 1995 and 2003.
Urban versus rural areas
All of the countries which explored the difference between rural and urban areas found 
a higher prevalence of cannabis use in the larger cities, for example Estonia, Lithuania, 
Poland or Slovakia (see Figures 6 and 7). In some countries, this difference between 
urban and rural areas is levelling off (e.g. in Poland) while in others (e.g. Slovakia) it 
remains stable.
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Other socio-economic factors
Data from the ESPAD survey in most countries revealed a clear association between 
cannabis use and truancy, sibling substance use and parents not knowing where the 
student spends Saturday night. A slightly weaker, yet still significant, association in most 
countries was living in a non-intact family structure. The association is unclear or non-
existent in the cases of parents’ education and the economic situation of the family in 
which the respondent lives (Hibell et al., 2004).
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Figure 6: Lifetime prevalence of cannabis use (%) by level of urbanisation in Lithuania 
among 15- to 64-year-olds
Figure 7: Lifetime cannabis use (%) among 17- to 18-year-olds in the capital of Poland, 
Warsaw, compared with national data
Source: General population survey 2004.
Source: ESPAD.
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In Estonia, analysis of the available data also revealed higher cannabis use among the 
Russian-speaking part of the population. This discrepancy, which has slowly tended to 
narrow, can be attributed to a number of factors. First of all, Russian-speaking schools 
are mostly located in the cities where drug use is more widespread. Secondly, the 
Russian-speaking population lives in the north-western part of Estonia, which suffers 
from a higher level of social exclusion, including high unemployment and criminality, as 
well as alcohol and drug use (Allaste and Lagerspetz, 2005: 267–285) (Figure 8).
Patterns of cannabis use
Description of the patterns of use
In all new EU Member States, cannabis is found in all forms with various levels of 
THC concentrations: herbal cannabis and cannabis resin, both imported as well as 
grown indoors or outdoors. The general pattern of smoking cannabis herb or cannabis 
resin dominates, with herb dominating in some countries and resin in others. In those 
countries where the traditional consumption mode was the water pipe, this is fading and 
hardly exists among youngsters.
In most countries cannabis use has become more or less normalised among youths. 
This does not mean that all young people use cannabis, but that the drug is fairly 
available and the majority of youths are ‘drug-wise’ and tolerate cannabis use among 
others, even if they themselves do not use the substance (Parker et al., 1998). According 
to qualitative data, cannabis use does not increase the social status of the user, nor 
does it benefit from aggressive marketing. Cannabis has emerged simply as a part 
of the culture of young people, who want to have fun with their friends (Fatyga and 
Sierosławski, 1999).
Figure 8: The difference in lifetime prevalence of cannabis use according to ESPAD surveys 
1995, 1999 and 2003 by working language at school in Estonia
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Polydrug use
Users of cannabis usually have a higher probability to have experienced other drugs, 
in particular stimulants and hallucinogens (e.g. Zimmerman et al., 2005; Milani et al., 
2005; Butler and Montgomery, 2004). This relationship also appears to hold true for 
the new EU Member States. According to secondary analysis of ESPAD data, last year 
prevalence of marijuana use in new EU members highly correlated (P < 0.05) with the 
prevalence of the use of ecstasy and any illicit drug other than marijuana and hashish 
(P= 0.722 and 0.691 respectively).
According to Slovenian qualitative research (Kvaternik, 2004), young people in the age 
group 15–25 (pupils and students) usually engage in more risky behaviour than their 
older peers while using drugs. They consume more drugs (polydrug use) and larger 
quantities in any one occasion. Although being reasonably informed, it seems that in 
practice they do not seriously consider potential health risks.
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Figure 9: Last-year prevalence of other drugs use among last year cannabis users (Poland 
2002, general population, aged 16- to 34-years old)
Users of ‘harder’ drugs are more likely to have used cannabis too. Practically all 
ecstasy users use cannabis to recover from a night of exposure to ecstasy and noise 
(Demetrovics, 2001; Moskalewicz et al., 2004). On the other hand, the majority of 
cannabis consumers do not use other drugs, as documented by the Polish survey data. 
As can be seen from the graph, under one-third of cannabis users combine cannabis 
with other drugs, mostly with stimulants and hallucinogens, while 65 % of them use only 
cannabis. It must be stressed that the vast majority of cannabis users never use opiates 
(Figure 9).
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The role of social networks
According to ESPAD, in all of the 10 countries except Lithuania, the illicit drug first used, 
usually cannabis, is typically obtained from a friend, or shared in a group (ESPAD, 
2003). Polish qualitative research has revealed that the pressure to use cannabis when 
peers are using is not perceived to be strong by young people. They argue that they are 
free not to use when they choose not to (Fatyga and Sierosławski, 1999).
Availability of the drug
Subjective availability
Availability of cannabis can be indirectly inferred from the data on perceived availability, 
police seizures data and also prices of the drug on the street as they indicate economic 
accessibility of drugs if related to incomes.
A few conclusions can be drawn from Figure 10. First, cannabis seems to be fairly easily 
available for a substantial proportion of students in all countries under review — from 
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Figure 10: Perceived availability of cannabis among 15- to 16-year-olds: percentage of 
students who perceive cannabis as ‘very easy’ and ‘fairly easy’ to obtain
Source: ESPAD 1995, 1999, 2003.
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more than 10 % in Cyprus to close to 60 % in the Czech Republic. Second, perceived 
cannabis availability has increased in all countries, and no saturation effect has been 
recorded. In other words, countries that reported high availability already 10 years 
ago tend to see it growing as fast as remaining countries. Third, it is evident that large 
differences still exist among the new EU members. Four groups of countries emerge, 
the first being high availability countries, including the Czech Republic, Slovenia and 
Slovakia, where subjective availability is around 50 % and over. These countries are 
followed by Poland, where the indicator approaches 40 %. Then, remaining countries 
report availability of approximately 20 %. Finally, Cyprus reports the lowest availability, 
where only 12 % of students consider cannabis easily available.
Economic accessibility
For decades, centrally planned economies in Eastern Europe were economically relatively 
self-contained. The economic systems included the non-convertibility of their currencies. 
In effect salaries, although adequate in terms of purchasing power, were extremely 
low when exchanged to any convertible currency, varying between USD 20 and USD 
50 per month. On the one hand, smuggled cannabis was practically unaffordable for 
young people, and, on the other hand, Central and Eastern European markets were of 
little interest for illicit suppliers. The transition to a market economy brought with it the 
convertibility of national currencies and a rapid increase of nominal incomes calculated 
in hard currencies. More than a decade after this transition, prices per gram of cannabis 
in the EU-10 have become relatively stable and are close to prices in the EU-15, ranging 
from EUR 3.5 in Slovenia to EUR 17 in Latvia.
There are substantial variations in prices in relation to purchasing power, too. The 
average monthly income in the Baltic States equates to the value of 30–50 g of cannabis, 
in the Central European countries to 100–150 g. In Cyprus, Malta and Slovenia, where 
the currencies have been convertible for decades, an average monthly income could buy 
200–400 g of marijuana.
Figure 11 shows that herbal cannabis prevalence increases with average purchasing 
power. This is particularly the case for former socialist countries, where national 
currencies became suddenly convertible at the beginning of the 1990s, and where 
purchasing power for imported goods increased manifold almost overnight. The 
outliers of this linear relationship are countries with very high (Czech Republic) or very 
low (Cyprus and Malta) cannabis use. Cyprus and Malta represent relatively affluent 
societies with a longer history of a market economy, where cannabis has been relatively 
affordable for decades. The third outlier — the Czech Republic — has the highest 
prevalence of cannabis use worldwide. Its high position on the plot may partially be 
attributed to its relative wealth. However, all three outliers confirm that socio-cultural 
factors in drug consumption are more important than affordability alone.
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Social representations of cannabis in new EU 
countries
General perception of the drug problem
Officially, the new EU countries do not make distinctions between cannabis and other 
drugs, and the general public supports such grouping of illicit drugs. In most countries, 
the media tends to sensationalise drug use (Paksi, 2000: 70–86). This means that 
overdose cases, seizures and other drug-related crimes are overexposed compared with 
other major social questions. Cannabis, if discussed at all, is primarily mentioned as a 
gateway drug, and the normative idea that smoking cannabis leads to use of harder 
drugs is expressed from time to time in most of the countries. As is common in many 
countries, problem drug users are often stigmatised. A common presentation of drug 
users that is propagated through the media is the image of drug addicts as dirty asocial 
human wrecks with frantic eyes. However, according to public opinion surveys from 
Poland and Estonia, people tend to perceive drug addicts as ill people rather than as 
criminals (Laidmäe and Allaste, 2004: 118–143).
Cannabis leaves per average monthly salary (g)
200 300 400 500
Malta
CyprusLatvia
Estonia
Lithuania
Slovakia
Poland
Hungary
Slovenia
Czech R.
1000
0
5
10
15
20
La
st 
30
 d
ay
s 
pr
ev
al
en
ce
 o
f c
an
na
bi
s 
us
e 
(E
SP
AD
)
Figure 11: Herbal cannabis buying power of an average monthly salary
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Perception of cannabis by the younger generation
Whereas the older generations tend to perceive all drugs as equally dangerous, younger 
generations tend to consider cannabis less harmful than other drugs in all the new EU 
countries. The generation gaps emerge with rapid social and cultural change and ‘the 
young quickly acquire “new strategies of action” for coping with life in unsettled times’ 
(Misztal, 2003: 85). Illicit drugs were introduced to the Baltic market only during the 
last decade, and to the Central European markets only a little earlier. This created a 
situation where the younger generations, who are experimenting with drugs, know more 
about the topic and are also much more tolerant than the older generations.
According to the ESPAD study, social condemnation of experimenting with cannabis 
is decreasing in Central Europe, and the most tolerant attitude towards this issue is 
displayed by school teenagers in the Czech Republic and Poland.
Although cannabis use has become ordinary, especially in the countries of Central 
Europe, it has also sometimes acquired a symbolic meaning of rebellion, at least in 
some youth cultures. Nevertheless, this rebellion is not a total negation of the society’s 
value system, as was evident in the 1960s. Today, young people consider cannabis 
prohibition hypocritical within the context of the growing availability of alcohol. They 
either question the right of the state to impose the ban or demand that liberal economic 
policies applied to legal drugs should be extended to cannabis.
Images of cannabis in the arts and the media
Cannabis is not used extensively in the established visual arts, but the portrayal of 
cannabis with clearly positive connotations can often be seen in graffiti in most of the 
countries. Cannabis symbols are used in souvenirs, T-shirts, earrings, scarves, bracelets, 
cough drops, etc., and images of cannabis leaves can sometimes be found in book 
designs. However, these are niche products that can be bought from alternative shops 
or markets in most of the countries, and are found more commonly only in the Czech 
Republic.
Positive connotations of cannabis are much more often expressed in local popular 
and hip-hop music. In Poland, the vocalist Lora Szafran sings about the society which 
prohibits cannabis use but encourages youngsters to drink alcohol: ‘The society is telling 
you that you better drink and smoke (tobacco) but grass is peace while alcohol — 
madness.’ In the Czech Republic, the columnist of the magazine Reflex, Ji rˇí Doležal, has 
been a strong voice in cannabis advocacy (1).
(1) Seth Fiegerman, Ji rˇí Doležal: ‘Still looking for change’, The Prague Post, 18 April 2007.
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Popular culture stresses the positive features of cannabis in contrast to other drugs: 
‘Weed unites people’, ‘Marihuana heals, other drugs — never use them’. Marijuana is 
strongly associated with rasta culture and hip-hop music, and the respective attitudes 
are openly expressed in the songs. Hip-hop has become a popular part of youth culture, 
and those who claim to belong to the sub-culture often call themselves: ‘The Society of 
Hash and Scun’, ‘League of Blunters’ or ‘bluntoholics’. All of these play on slang for 
cannabis. Cannabis use combined with alcohol seems to have become an integral part 
of their lifestyles, as well as its symbol (Demetrovics, 1998, 2001, 2005; Tossman et al., 
2001).
Social response
Supply reduction
Legislation and policy
Drug legislation in all new EU members has evolved for several decades in an 
unexpected way. Twenty years ago drug legislation was restrictive and repressive in the 
Baltic States, as elsewhere in the Soviet Union. Restrictive laws prevailed in Cyprus and 
Malta, too. However, in Czechoslovakia, Hungary, Poland and Yugoslavia the penal 
sanctions were not that severe and possession of drugs was not penalised at all. In the 
1990s when a number of ‘old’ EU countries tended to liberalise their drug policies, 
countries of Central Europe introduced more repressive legislation, which generally did 
not make any distinction between cannabis and other drugs.
Currently, the new EU countries have stricter drug laws compared with the majority of 
pre-2004 Member States. Nevertheless, in terms of the most repressive legal control 
(prison sentences for drug use), only Cyprus among the 10 new EU Member States 
imposes prison sentences for drug use, vis-à-vis four existing Member States (Greece, 
France, Finland and Sweden). In addition to Cyprus, the Baltic countries deem drug use 
to be an administrative offence.
Possession of small amounts of drugs for personal use is criminalised in all of the new 
EU Member States, although differences exist between legislative penalties and actual 
sentencing practice at the judicial level. Nevertheless, in the Czech Republic, in the case 
of small quantities for personal use, and in the absence of aggravating circumstances, 
the law foresees ‘administrative’ sanctions only (EMCDDA, 2005). In the Baltic States 
(Estonia, Latvia and Lithuania), possession of a small amount of any drug is considered 
a ‘non-criminal offence’. The difference with regard to the Czech Republic is that in 
Estonia, Latvia and Lithuania a ‘non-criminal offence’ may be punished by deprivation 
of liberty for up to 30, 15 and 45 days respectively. In Slovenia, possession for personal 
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use is punished by a monetary fine or 5–30 days of arrest. In the remaining new 
EU Member States any kind of possession for personal use is considered a criminal 
offence, making sentences involving imprisonment possible (EMCDDA, 2005). However, 
possibilities to avoid imprisonment are available in some countries through diversion 
or referrals (entering treatment as an alternative of the legal process or imprisonment 
or suspension of a prison sentence). In other countries the application of the law seems 
to be more lenient than would be possible if the text of the law were taken literally. 
In Hungary, for example, two years of imprisonment is envisaged for possession of a 
small amount of cannabis for personal use only, but until the time of writing no-one has 
been sentenced to such a term of imprisonment. Differentiation between possession for 
personal use and trafficking exists in all 10 countries, while a differentiation between 
small and substantial quantities is defined in a number of ways. In some countries there 
is no exact definition, but the differentiation is based on whether the cannabis was for 
personal use or for dealing (Table 1).
Law enforcement
Among the new members, two groups of countries can be distinguished in terms of law 
enforcement (that is, the extent to which police and other law enforcement agencies 
implement a law). In the first group — Malta and Slovakia — any drug-related crime is 
subject to a high level of police activity, which means that the level of law enforcement 
is the same in the case of personal use as in the case of trafficking. In all other 
countries — with the exception of Estonia, for which data were not available — a more 
Table 2: Absolute number of seizures (all drugs and cannabis alone) and 
number of seizures per 100 000 inhabitants in 2004
Country Number of drug 
seizures (all)
Number of 
cannabis seizures
Number of drug 
seizures (all) 
per 100 000 
inhabitants
Number of 
cannabis 
seizures per 
100 000 
inhabitants
Czech Republic 907 572 8.9 5.6
Estonia (1) 940 270 69.6 20.0
Cyprus n/a n/a n/a n/a
Latvia n/a 316 n/a 13.6
Lithuania 1 552 265 45.0 7.7
Hungary 2 751 1 791 27.2 17.7
Malta 308 113 77.0 28.3
Poland (1) 543 305 1.4 0.8
Slovenia (2) 4 777 3 421 243.2 174.2
Slovakia 1 538 913 28.6 17.0
(1) Data from 2002.
(2) Data from 2003.
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differentiated picture can be identified. In these countries use and possession of a small 
quantity of cannabis for personal use is enforced at a low or medium level, while the 
focus of the police and other agencies is on trafficking or possession of substantial 
quantities of drugs.
Other, more objective data show that the most seizures (both cannabis and other drugs) 
occurred in Slovenia (4 777 seizures for any drugs in 2003; 3 801 in 2004) followed 
by Hungary (2 952 in 2003; 2 751 in 2004), Slovakia (1 532 in 2003; 1 538 in 2004), 
Lithuania (1 029 in 2003; 1 552 in 2004), Estonia (1 060 in 2003) and the Czech 
Republic (979 in 2003; 907 in 2004). When drug seizures are calculated per 100 000 
inhabitants, the highest rate of seizures is found in the smallest countries — Estonia, 
Malta and Slovenia — while the lowest is found in the Czech Republic and Poland. Only 
Hungary diverges from this rule, particularly with regard to cannabis, which has three 
times more seizures than the Czech Republic, yet a comparable number of inhabitants 
(Table 2).
However, there are large differences in what percentage of these numbers are cannabis 
seizures. For example, in Slovenia in the past four years, 70–90 % of all seizures were 
of cannabis. In the Czech Republic, Hungary, Poland and Slovakia this proportion 
varied between 40 and 70 %. Lower shares of cannabis seizures can be found in 
Lithuania (12–17 %), Estonia (26–29 %) and Malta (33–43 %). Figure 12 suggests that 
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Figure 12: Proportion of cannabis seizures among all drug seizures
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the proportion of law enforcement efforts devoted to cannabis is converging in the 10 
countries. In those with the highest ‘cannabis oversight’ (Hungary and Slovenia), the 
cannabis share in their seizures has declined while in the remaining countries this share 
has tended to rise (Figure 12).
Data are available only from Hungary and Malta about the type of cannabis seizures, 
but these two countries are worth comparing as they represent substantially different 
profiles. In Malta the highest percentage of cannabis seizures is registered for cannabis 
resin (70 % to well over 90 %), while in Hungary herbal cannabis represents 93 % of all 
cannabis seizures. This comparison may reflect either a great distinction in consumption 
patterns or a large difference in the focus of control (Figure 13).
A substantial proportion of those who are arrested for petty drug offences — drug 
possession or use but not trafficking — is arrested because of cannabis. The highest 
percentage can be found in Slovenia, where four out of five arrests are related to 
cannabis. In the three other countries where data are available, this share varies from 
30 % to 60 %.
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Demand reduction
Prevention
Prevention campaigns in all 10 countries are dominated by school-based universal 
prevention programmes, and these naturally integrate cannabis-related issues. However, 
programmes do not specifically discuss this drug, and no specific emphasis is placed 
upon cannabis (Paksi and Demetrovics, 2002).
Treatment response
Among the 10 countries, Hungary has the highest prevalence of cannabis users in 
treatment (see Figures 15 and 16), estimated at 45 cannabis clients in treatment per 
100 000 inhabitants (2004). Hungary is followed by Malta (32 per 100 000 in 2003), 
Estonia (15 per 100 000 in 2003) and the Czech Republic (14 per 100 000 in 2004). In 
all remaining countries there are 10 or fewer cannabis clients per 100 000. As is also 
evident in the pre-2004 EU Member States (see Montanari et al., this monograph), all 
of the new EU states have experienced a substantial increase in cannabis admissions 
to treatment in the past 10 years. This increase is, however, proportionately higher in 
Hungary than in the other countries. The reason behind this may be attributed to the 
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proportionately high possibility of referrals (choosing treatment as an alternative to 
the legal process) rather than a greater need for treatment in Hungary. In 2004, for 
example, more than half of the clients entered treatment in the frame of referrals, and 
not on the basis of experiencing physical or mental problems which requires professional 
help.
Slovakia: outpatient treatment services
In relation to the graphs above, it must, however, be noted that the increase in demand 
for treatment is a complicated issue and not fully explained in the literature. Trends 
which indicate an increase in cannabis admissions may reflect: growing numbers of 
problem cannabis users who look for help with their medical problems; an increase in 
specialised services which may attract more clients; and more restrictive legislation and 
enforcement which forces cannabis users to seek an alternative to prosecution in the less 
repressive medical sector (see Simon, this monograph).
Public debate
Political debate
Officially, there is no distinction between soft and hard drugs in any of the new 
Member States. Nevertheless, there are some differences in perception of cannabis at 
the official level. In the Czech Republic, the National Drug Commission has initiated 
amendments in the legislation in order to distinguish between soft and hard drugs. In 
Hungary, the distinction between soft and hard drugs and decriminalisation of cannabis 
use are supported by the representatives of the Hungarian Liberal Party. In Poland, 
representatives of left-wing political parties also favour depenalisation of cannabis. In 
2004, a member of the parliament from the then governing Democratic Left Alliance 
officially issued a statement on the legalisation of drugs, especially cannabis, which 
was widely quoted by the media. Two years ago, the agenda of a local left-wing party 
in Slovakia included decriminalisation of cannabis. By contrast, in the Baltic States and 
Malta, no officials have publicly expressed their support for the decriminalisation of 
cannabis.
The topic of legalisation of cannabis use has received much attention from the public 
in recent years. Much of this discussion has been driven by the liberalisation of drug 
policies and decriminalisation of cannabis in parts of Western Europe. In Estonia this 
Western liberalism is strongly opposed by the authorities. The Minister of Social Affairs 
stated publicly in a newspaper that use of cannabis is illegal and will remain illegal. In 
other countries, particularly in Slovenia, a co-author suggests that politicians may be 
waiting for EU directives or an external initiative in order to deal with this matter.
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To summarise, opposing political forces tend to gain political leverage from the drugs 
question in general, and cannabis in particular. Their motives include generating 
support either among young voters who defend decriminalisation or legalisation, or 
among conservative elements of society who demand more repressive policies. This 
political context is counterproductive to a technical discussion on how to achieve a more 
rational consensus on cannabis policy.
Cannabis activist groups
In Central and Eastern Europe there are active groups advocating drug law reform 
in terms of depenalisation or decriminalisation of cannabis. In Hungary, one of the 
leading professional drug reform organisations is the Hungarian Civil Liberties Union 
(HCLU), which advocates the human rights of other vulnerable populations as well. The 
Hemp Seed Association (Kendermag Egyesület), a local users’ group, actively speaks in 
favour of the legalisation of cannabis. Each year the Hemp Seed Association organises 
a demonstration as part of the Million Marijuana March (an annual, worldwide 
protest campaign for the legalisation of cannabis) in Budapest. It also initiated a civil 
disobedience movement in March 2005. Participants of this movement appeared at the 
National Police Headquarters, blaming themselves for violating drug laws in order to 
raise awareness of the criminalisation of drug users. In the Czech Republic, there are 
also rather professional organisations fighting for the rights of cannabis users, and there 
is also a ‘Cannabis Ombudsman’ whose mission is to help people who have problems 
with the law. In Poland, the Kanaba.info Association is a union of Polish drug users and 
other people alarmed by the present repressive drug policies. In 2003, they participated 
in ENCOD’s ‘Spread the Seeds’ campaign and coordinated a public demonstration 
in Warsaw. In Slovakia, the non-governmental organisation (NGO) ‘Free Choice’ was 
established, as a response to the repressive legislative situation in February 2004. Its 
goal is to ‘invoke discussion about cannabis and its legalisation and demythologise 
the plant that has been used for hundreds of years as food, a cure, for industry or 
pleasure’. In Slovenia, the Konoplja.org project campaigns for cannabis users to be 
given a political voice, together with the depenalisation of cannabis and the introduction 
of alternative sentences or admonitions. Every year, the Million Marijuana March is 
organised in Ljubljana and Maribor, where users can freely smoke cannabis (trafficking 
is forbidden) and point out that changes are necessary. In the Baltic States, Cyprus and 
Malta, activist groups exist, but are more covert and far less active and professional than 
in the above-mentioned countries. In the Baltic States, their main forum is the Internet, 
where they present articles and reports related to cannabis and its effects. There are 
also discussion forums and other information (legislation, pictures, smokers’ stories, 
instructions on how to grow cannabis at home, extracts from legal acts, etc.).
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Discussion
Eight out of the ten new EU Members States have undergone recent transformations 
from a centrally planned economy to a market economy, and from a single-party 
system to a pluralist political system. This shift has ushered in not only positive social 
developments but also a variety of problems which are measurable by ‘objective’ 
statistics and are often magnified in the public perception (Leifman, Edgren Henrichson, 
1999). Drug problems, despite their high media exposure, are considered less important 
compared with other burning social issues such as unemployment, poverty and even 
alcoholism. Nevertheless, a rapid increase in drug use is recorded by relevant statistics 
(Moskalewicz and Swia˛tkiewicz, 2005).
Based on current data it is difficult to fully explore determinates of cannabis use in the 
new EU Member States and, therefore, some of the explanations offered in this chapter 
are hypothetical and need more research. The data do, however, point towards broad 
trends and crucial and intriguing issues, which should be monitored and researched 
more closely.
Cannabis is a widely used illicit drug in the 10 new EU Member States, particularly 
among teenagers and young adults. Its prevalence used to be somewhat lower than in 
the EU-15, but a rising tide of cannabis use in the years 1995–2004 has meant that the 
new EU Member States are reaching approximately the same prevalence rates as the 
rest of Europe (EMCDDA, 2004).
The sudden rise in cannabis use in all the new countries — except for Cyprus and 
Malta — has accompanied root-and-branch social change, which could have increased 
demand for psychoactive substances. Significant influences have been imported from the 
pre-2004 Member States, where cannabis use was more widespread and normalised 
than it used to be in the new Member States before the 1990s. Intensive transmission 
of Western European consumption patterns has affected drug use patterns in general, 
including cannabis. Young men and boys seem to be more open to the new patterns, 
particularly in the more religious societies (Cyprus, Lithuania, Malta, Poland) where 
the gender ratios in prevalence of cannabis use range from 2:1 to 4:1. In other, more 
secular cultures, such as the Czech Republic, this ratio is 1:1. The gender gap tends 
to narrow in practically all countries that have a tradition of female emancipation. As 
in other parts of the world, Westernisation first affects capital cities and larger urban 
centres. This is reflected by the dynamic geographic spread of cannabis in the countries, 
which has spread fast from large cities to smaller towns and then to the countryside.
This Westernisation hypothesis is supported by the fact that new EU countries with the 
highest cannabis prevalence — the Czech Republic, Slovenia and Slovakia, and to 
a lesser extent Hungary and Poland — are also those which are closest to pre-2004 
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Member States. The process of cultural homogenisation of Europe seems to be most 
advanced among younger generations, which are more willing to adopt new cultural 
patterns, including cannabis use. The image of cannabis has a very positive connotation 
in the context of rasta and hip-hop culture, both of which are international youth 
cultures. Cannabis is also popularised by movies, music and souvenirs. The force 
exerted by these influences seems to be higher in Central Europe, especially when 
comparing the Czech Republic with the Baltic States, Cyprus and Malta.
The low prevalence of cannabis use in Cyprus and Malta may also have its roots 
in culture. Unlike in the remaining continental countries, where cannabis has been 
integrated into teenage culture, particularly in large cities, cannabis for young Cypriots 
may be associated with traditional hashish waterpipes smoked by middle-aged and 
elderly men, and therefore have a much less attractive cultural appeal. In Malta, being 
a smaller country where social stigmas may be felt to a greater extent, open views about 
cannabis use may be more restricted.
Increasing cannabis consumption can be explained by its growing availability, which 
is confirmed by subjective opinions collected by the ESPAD study in all countries. The 
availability hypothesis has been backed up by data from international and national 
control agencies that focus on the supply side of the drug market. Nevertheless, our 
study suggests that the availability increase is a phenomenon present in all countries, 
including those where consumption has tended to level off, such as Cyprus, Malta and 
Slovenia. Moreover, it is difficult to explain large gender gaps in cannabis consumption 
recorded in a number of countries, despite its similar availability for boys and girls (see 
Hibell and Andersson, this monograph).
Cannabis prevalence cannot be explained by its affordability. There is no linear 
relationship between the economic situation of the country and its level of cannabis use. 
However, experiences in the new EU members suggest that the income-price elasticity of 
cannabis demand is much higher in those countries whose currencies recently became 
convertible and where incomes expressed in terms of convertible currencies tended to 
grow fast. In more stable economies, cannabis price elasticity is much lower.
Public discussion tends to demonise drugs, to place cannabis on a par with other illicit 
drugs, and generally to portray drug use as something dangerous. Illicit drug use in 
society is also generally stereotyped (Young, 1971: 182), and despite idiosyncrasies 
among the 10 countries, common features include the high social visibility of the drug 
problem and the negative image of drug addicts in general. Since the Eastern European 
countries undergoing transition still suffer from many unsolved social problems, drugs 
have been attributed the role of the ‘good enemy’ (Christie and Bruun, 1986); that 
Chapter 6
91
is, drugs are seen as a straightforward political target, rather than attempts to resolve 
urgent matters such as the problems of disadvantaged groups, inequality in the 
employment market and undeveloped regional policy. However, especially regarding 
cannabis, it is possible to make distinctions between regions. In the Central European 
countries (Czech Republic, Hungary, Poland, Slovenia and Slovakia), cannabis has a 
higher social visibility than in the other countries, where the social perception of drug 
use is focused mainly on problem drug use. Nonetheless, since illicit drug use is a 
relatively new phenomenon in all of these countries, the older generations tend to have 
naive and homogenous views of drugs and drug users. Perhaps reflecting such concerns, 
the majority of new EU countries have recently introduced legislation that is more 
restrictive than under previous regimes.
Rapid political change in 8 out of the 10 new EU member countries and increasing 
integration with the EU has had a serious impact on drug policy. All these countries 
have become more open and more vulnerable to external pressures, particularly from 
the most powerful allies, such as the USA, which has attempted to exert its influence 
through relevant UN agencies and by targeting professionals as well as policymakers 
and politicians. Nordic countries, too, have tended to export their restrictive drug 
policies, especially across the Baltic Sea. On the other hand, pre-2004 EU members 
must also have felt the impact of enlargement in this area. Existing European divisions in 
drug policy may be reinforced by the new Member States, which are more likely to join 
coalitions of more restrictive countries.
The social response to cannabis is overwhelmingly dominated by individually oriented 
approaches, that is, law enforcement and treatment. From incomplete data it can be 
estimated that the number of cannabis users dealt with by law enforcement agencies is 
much higher than those in medical treatment. This results from increasingly repressive 
legislation which applies penalties even for possession of small amounts for personal 
use, which in fact implies penalisation of use. In some countries presence of cannabis 
in body fluids may legally be interpreted as possession. Such legislation implies that 
referrals to medical treatment, where present, are used as much as a social control 
as a psychosocial care method. In most countries cannabis-specific treatment is not 
widely available, and cannabis dependence is accepted as a phenomenon, which is not 
considered as requiring specific treatment centres and methods. Treatment of cannabis 
clients is integrated in general drug treatment settings which focus on opiate-dependent 
individuals. Thus, the growing share of cannabis users in medical treatment probably 
reflects referrals from the criminal justice system rather than impressive advances in 
treatment methods.
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Setting the context
The history of cannabis has been the subject of numerous books in recent years (see 
Fankhauser, this monograph). One of the many historical perspectives that have been 
explored is cannabis’s social, political and legislative history. This chapter provides 
a brief history of controls on cannabis, and analyses a series of recent government 
enquiries that have informed legislative reform, particularly in Europe.
Opinions are divided in this area. Liberalisers and cannabis advocacy groups — the 
key Internet publishers of information on the issue — continue to claim cannabis is a 
recently controlled substance and ‘natural product’, and have espoused a number of 
theories to explain its prohibition (1). Yet the historical picture is more complex. Use 
of cannabis as a psychoactive drug has stirred controversy for centuries. And finding 
the most appropriate control system has interested professionals, politicians and 
governments from the beginning.
Today, international drugs conventions recommend signatories to designate, under 
national legislation, the most stringent control over cannabis. However, some countries 
have used the granted discretion to move away from such recommendations. A cross-
(1) Among others, theories include: diplomatic dealmaking (with Turkey and Egypt) during the 1925 
amendment to the International Opium Convention; timber interests curbing hemp industry growth 
in the USA (particularly involving a marijuana scare campaign by media, controlled by William 
Randolph Hurst); synthetic fibre interests curbing hemp industry growth (in particular Du Pont); 
inter-agency conflict between the FBI and FBN in the USA (with Harry J. Anslinger cast as arch-
prohibitionist); cannabis control as a result of institutionalised racism (stigmatising cannabis as a 
drug of choice of specific racial groups, especially in the USA); and strong international focus on 
stringency by the United Nations (INCB and UNODC).
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reading of governmental enquiries shows that, while cannabis is considered a potentially 
dangerous substance, its dangers, in comparison with other controlled substances, may 
have been overstated and alternative forms of sanctions, such as civil sanctions, fines or 
compulsory health assessments, have been recommended in place of criminal penalties.
European countries’ laws or prosecution policies seem to be broadly in accord with 
these government enquiries. Nonetheless, more liberal positions have attracted some 
concerns, expressed in particular at UN level, on the grounds that leniency on cannabis 
can endanger the overall international effort against drugs. Accordingly, the latest 
developments in some countries seem to tip the balance back towards a new attention 
on restrictive measures.
Further reading
BBC Timeline (2005), ‘The use of cannabis’ 
http://news.bbc.co.uk/2/hi/programmes/panorama/4079668.stm
Böllinger, L., Stöver, H., Fietzek, L. (eds) (2002), Drogenpraxis, Drogenrecht, Drogenpolitik: Ein 
Leitfaden für Drogenbenutzer, Eltern, Drogenberater, Ärzte und Juristen, FHS Frankfurt.
EMCDDA (2001, updated 2006), ELDD: possession of cannabis for personal use, available at http://
eldd.emcdda.europa.eu/index.cfm?nNodeID=5769
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Hall, W., Pacula, R. (2003), Cannabis use and dependence: public health and public policy, 
Cambridge University Press, Cambridge.
Inglis, B. (1975), The forbidden game: a social history of drugs, Hodder and Stoughton, London.
Mills, J. (2003), Cannabis Britannica: empire, trade and prohibition 1800–1928, Oxford University 
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See also the list of governmental reviews (Table 1) in this chapter and the grey literature list in the 
Appendix to Volume 1 of this monograph (p. 300).
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Cannabis control in Europe
Danilo Ballotta, Henri Bergeron and 
Brendan Hughes
Introduction
The use of cannabis as a psychoactive substance has always been a subject of 
controversy. International drugs conventions recommend signatories to designate, 
under national legislation, the most stringent control over cannabis, but some countries 
have used the granted discretion to move away from such recommendations. Indeed, 
finding the most appropriate control system has interested professionals, politicians 
and governments since the beginning. A cross-reading of governmental enquiries 
shows that, while cannabis is considered a potentially dangerous substance, its 
dangers in comparison with other controlled substances might have been overstated, 
and alternative forms of sanctions, such as civil sanctions, fines or compulsory health 
assessments, have been recommended in place of criminal penalties. European 
countries’ laws or prosecution policies seem to be broadly in accord with such enquiries, 
but these positions have attracted some concerns, expressed in particular at UN level, 
on the grounds that such a ‘lenient approach to cannabis’ can endanger the overall 
international effort against drugs. Accordingly, the latest developments in some countries 
seem to tip the balance towards a new attention on cannabis through restrictive 
measures.
Cannabis: a substance under continuous control
Origins of control
Cannabis has been used for a variety of purposes for thousands of years. Yet in Europe, 
consumption remained mostly limited to experimentation by small elites or to those 
having contact with specific countries, in particular North Africa and India (Booth, 2003). 
There is significant evidence to suggest that cannabis has always been a controversial or 
troubled substance, and was placed under some sort of restriction almost as soon as its 
psychoactive effects were discovered.
In 2000 bc in India, religious authorities used cannabis in holy rituals and it is likely 
that only priests had access to it (Booth, 2003). In the Muslim world in medieval times 
there existed an ambivalent attitude towards the use of cannabis (Hamarneh, 1957). 
Hashish, furthermore, had derogatory associations with Sufism and as a precipitator of 
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madness (Booth, 2003). Key critics of cannabis include the theologian Ibn Taymiyyah, 
the judge Ibn Ganim and historian Al Magrii. Much-cited examples of controls include 
the prohibition in 1265 of cannabis in Damascus by King al-Zahir Baybars (Hamarneh, 
1957), and the destruction of cannabis plants and prohibition of cannabis use in 
1378 by the Ottoman emir of Egypt, Soudoun Sheikouni (Rosenthal, 1971; Caballero 
and Bisiou, 2000; Arana and Márquez, 2006). In Europe in 1484 Pope Innocent VIII 
associated the use of hashish with witchcraft in the bull Summis Desiderantes (Booth, 
2003). Such examples, though anecdotal, illustrate that controversy surrounding 
cannabis use is not a new phenomenon.
Some precursors of controls relating to cannabis can be found in Europe’s colonial 
period, though outside the continent itself. Following Napoleon’s invasion of Egypt in 
1798, in 1800 he prohibited his soldiers to smoke or drink the extracts of the plant, 
imposing a penalty of imprisonment of three months, thus implementing perhaps the 
first ‘penal law’ on cannabis. A law in South Africa in the 1870s, that was tightened in 
1887, prohibited the use and possession of dagga (cannabis) by Indian immigrants, 
largely in response to a perception that its use by them was dangerous for white rule 
(Booth, 2003). In India, prohibition of cannabis was mooted in 1838, 1871, 1877 and, 
most famously, rejected following an extensive 3000-page report by the Indian Hemp 
Drugs Commission in 1894. Nonetheless, despite rejections of a blanket ban, various 
Indian cities and states issued quotas, tax regimes or restrictions on cannabis (Booth, 
2003).
While familiarity with cannabis products in the pharmaceutical sphere was widespread 
in the early 20th century (Lewin, 1924; Fankhauser, this monograph), within Western 
Europe there is little evidence of significant cannabis prevalence and criminal 
prosecutions until after the Second World War. Cannabis control is best viewed in the 
context of national and international initiatives in the area of drug control during the 
late 19th and early 20th centuries — in particular, relating to opiates, together with 
increased supervision of pharmaceutical products in general. Controls in Europe focused 
on regulating pharmaceutical use of cannabis. For example, in Germany, the first legal 
act on cannabis was in a Pharmacy Ordinance of 1872 when the sale of Indian hemp 
was limited to pharmacies (this ordinance was still valid in 1920) (see Fankhauser, this 
monograph).
However, in Greece and near-neighbour countries such as Turkey and Egypt, cannabis 
prevalence was higher and attracted strong legal responses. Hashish possession was 
made a capital offence in Egypt in 1868, with a tax on cannabis imposed in 1874, 
although exemptions for non-Egyptians and enforcement issues led to them being 
ineffectual (Booth, 2003). In Turkey a nationwide campaign to confiscate and destroy 
cannabis was begun by the Sultan in 1877, and an import ban imposed in 1879; 
in 1884 cultivation of cannabis became a criminal offence (Abel, 1980). In Greece 
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cultivation, importation, and usage of cannabis was banned in 1890, based on concern 
for hashish use among the poor. Nonetheless, Greece was a significant exporter of 
hashish to Turkey and Egypt into the 1920s (Abel, 1980).
Prior to the First World War, international agreements on narcotic substances increased 
the mechanisms of control on opium and related substances. For opiates, the Opium 
Commission in Shanghai in 1909 contributed to a framework agreement on opium 
control at the First International Opium Conference in the Hague in 1911–1912. 
While the Hague conference concentrated on opium, at this conference Italy lobbied 
for an international ban on cannabis, largely based on hashishism in its protectorates 
Tripolitania and Cyrenaica (obtained from Turkey during a war in 1911). In the USA, a 
number of states also prohibited non-medical use of cannabis: California (1915), Texas 
(1919) and Louisiana (1924). A parallel development was legal restriction on alcohol 
use: a ban in Finland (1919) and the USA (1920), and a rationing system in Sweden 
(from 1914). In Switzerland cannabis was outlawed in 1924.
The key driver of international cannabis prohibition in the early 20th century was an 
amendment to the International Opium Convention (1925), which was extended beyond 
opiates to embrace cannabis. The convention prohibited the export of cannabis resin 
to countries that prohibited its use (Bayer and Ghodse, 1999). The process behind the 
inclusion of cannabis in the convention has been both heavily discussed (e.g. Lowes, 
1966) and roundly criticised (e.g. Kendell, 2003; Holzer, 2004). There is consensus that 
the cannabis subcommittee advising the Second League of Nations Opium Conference 
succumbed to strong Egyptian demands for a ban on cannabis and that delegates were 
certainly given little time to conduct due diligence on materials (Booth, 2003; Kendell, 
2003; Holzer, 2004).
Following the approval of the 1925 International Opium Convention, European 
countries gradually outlawed cannabis use and possession (e.g. the UK’s Dangerous 
Drugs Act, 1928; Germany’s second Opium Law, 1929). Nonetheless, the first 
substantial wave of convictions for cannabis offences did not occur until the 1960s. 
Official crime reports in the 1960s and 1970s did not differentiate cannabis convictions 
from those for other illicit drugs, yet studies suggest that there were very few cases other 
than cannabis. Böllinger suggests that the bulk of the less than thousand ‘narcotics 
cases’ (police registrations) before 1960 in Germany related to the ‘stem of old 
morphinists’ (Böllinger et al., 2002). In Canada the first known seizure of marijuana 
did not occur until 1932, but widespread enforcement is reported much later, with a 
total of 261 convictions for drug offences in 1960 (the majority, however, for heroin 
offences). In the Netherlands, in the first half of the 20th century, no problems or social 
controversy are reported on cannabis, but the opium law was revised in 1953 to include 
cannabis and comply with international treaties. Thus, some authors (e.g. Fischer et al., 
1998) have argued that prohibition was introduced mainly in response to international 
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obligations — in a broader diplomatic context — than to answer to an urgent problem 
at national level between law and enforcement (or necessity of it), as ‘the solution 
without the problem’ (2).
International law
The United Nations Single Convention on Narcotic Drugs (1961) elevated the control on 
narcotic substances and on cannabis to a global level. Under the system introduced in 
1961 (mainly imported from previous treaties), cannabis is to be considered as one of 
the most dangerous existing drugs (3).
This section discusses the texts of the UN Convention. While this approach may appear 
legalistic to the non-specialist reader, a thorough understanding of the legal status of 
cannabis under international law is vital for understanding the ‘room for manoeuvre’(4) 
given to different countries on the issue.
Cannabis, cannabis resin and extracts and tincture of cannabis are listed in Schedule 
I of the 1961 Convention among substances whose properties might give rise to 
dependence and which present a serious risk of abuse, which are subject to all control 
measures envisaged by the Convention (5). Cannabis and cannabis resin are again 
listed in Schedule IV of the 1961 Convention, which comprises 15 substances already 
listed in Schedule I that are considered particularly dangerous by virtue of their harmful 
characteristics, risks of abuse and extremely limited therapeutic value. Among these 
15 substances, we find heroin and cannabis but not cocaine, which is (only) listed in 
Schedule I.
(2) Giffen et al. (1991) affirm that ‘unlike other narcotic drugs brought under federal control up to the 
1920s, marijuana was added to the Schedule I in 1925, before it came to be defined as a social 
problem in Canada. Why this was so remains a mystery’.
(3) Article 2.5(a) of the 1961 Convention introduces the concept of dangerousness for substances 
included in schedule IV.
(4) ‘Room for manoeuvre’ was the title of a report commissioned by the British charity Drugscope, 
with a focus on the UN conventions and potential changes to UK drugs possession laws (Dorn and 
Jamieson, 2000).
(5) There are four schedules under the 1961 Single Convention on Narcotic Drugs: Schedule I — those 
substances which are, inter alia, having, or convertible into substances having a liability to abuse 
comparable to that of cannabis, cannabis resin or cocaine; Schedule II — having addiction-producing 
or addiction-sustaining properties not greater than those of codeine but at least as great as those of 
dextropropoxyphene; Schedule III — preparations which are intended for legitimate medical use, and 
which the WHO considers not liable to abuse and cannot produce ill effects, and the drug therein is 
not readily recoverable; and Schedule IV — substances that are particularly liable to abuse and to 
produce ill effects, and such liability is not offset by substantial therapeutic advantages not possessed 
by substances other than drugs in Schedule IV.
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As specified by the 2001 INCB Annual Report, ‘to be included in Schedule IV, a drug 
has to be considered particularly liable to abuse and to produce ill effects, and such 
liability should not be offset by substantial therapeutic advantages’. In the view of 
the delegations present at the Plenipotentiary Conference that prepared the 1961 
Convention, cannabis certainly presented such characteristics (though cocaine, for 
example, did not). THC, the main psychoactive ingredient of cannabis, is also listed by 
the 1971 Convention on Psychotropic Substances, in the first of four schedules, its use 
being prohibited except for scientific and very limited medical purposes (Article 7a) (6).
This composite classification reflects the concern about the abuse of cannabis and 
the desire of the convention promoters to advise countries to design, under national 
legislation, the most stringent control on cannabis (7). Indeed, this double classification 
(Schedule I plus Schedule IV, 1961 Convention) allows signatory countries to adopt any 
special measures of control regarded as necessary, including prohibition of use, due 
to the ‘particularly dangerous properties’ of the drugs listed in Schedule IV. However, 
a country shall adopt any special measures of control if considered necessary having 
regarded the particularly dangerous properties of drugs in Schedule IV (8). The non-
obligation of this norm, in fact a condition for its implementation, is confirmed by the 
UN Commentary on the 1961 Convention, which restates that a party is ‘obliged to 
apply special measures only if it believes them to be necessary’ (9).
(6) There are four schedules under the 1971 UN Convention on Psychotropic Substances: Schedule I — 
substances whose liability to abuse constitutes an especially serious risk to public health and which 
have a very limited, if any, therapeutic usefulness; Schedule II — substances whose liability to abuse 
constitutes a substantial risk to public health and which have little to moderate therapeutic usefulness; 
Schedule III — substances whose liability to abuse constitutes a substantial risk to public health and 
which have moderate to great therapeutic usefulness; and Schedule IV — substances whose liability 
to abuse constitutes a smaller but still significant risk to public health and which have a therapeutic 
usefulness from little to great.
(7) The UN documents of the years preceding the signatures of the 1961 and 1971 Conventions 
confirm a particular concern towards cannabis. In 1959 countries were requested ‘to increase their 
efforts to suppress the illicit cultivation of cannabis’ (CND Decision 14 December (XIV) April/May 
1959). In 1968 they were recommended to ‘increase their efforts to eradicate the abuse of and 
illicit traffic in cannabis’ or to ‘promote research and advance additional medical and sociological 
information regarding cannabis, and effectively deal with publicity which advocates legalisation or 
tolerance of the non-medical use of cannabis as a harmless drug (Economic and Social Council E/
RES/1968/1291(XLIV), 1520th Plenary Meeting, 23 May 1968, on the abuse of cannabis and the 
continuing need for strict control). An extract from E/RES/1959/730(XXVIII)E 1088th Plenary Meeting, 
30 July 1959, reads as follows: ‘Recalling that the third draft of the Single Convention on Narcotic 
Drugs contains an express provision for the prohibition of the medical use of cannabis drugs except 
in certain systems of indigenous medicine’. An extract from Economic and Social Council Resolution 
IV(XII) on the question of cannabis, April/May 1957, ‘Requests all Governments to abolish, except for 
medical (Ayurvedic, Unani and Tibbi systems) and scientific purposes, the legal consumption of all 
substances having a cannabis base within a reasonable period where it has not been done so far’.
(8) Article 2.5(a), 1961 Convention.
(9) UN Commentary on the 1961 Single Convention (p. 65).
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It seems, therefore, that the 1961 Convention suggests to apply the most stringent 
control system to cannabis, yet leaves countries some flexibility in their interpretation 
of the necessity of such control. According to this classification, use and possession of 
cannabis should not be allowed except for authorised medical or scientific purposes 
(Articles 4c, 33, 36, 1961 Convention). Countries are requested to prevent its misuse 
(Article 28, 1961 Convention) and take all practicable measures for the prevention of its 
abuse (article 38, 1961 Convention). They should also not permit its possession (Article 
33, 1961 Convention) and if they decide to do so, they are entitled to make possession 
of cannabis a punishable offence (Article 36, 1961 Convention), and are mandated to 
make possession for the purpose of trafficking an offence of criminal nature (Article 3, 
paragraph 1(a)(iii), 1988 Convention). Possession for personal consumption may also 
be criminalised (Article 3 paragraph 2, 1988 Convention).
This system of provisions leaves no doubt about the severity requested towards cannabis 
and it is evident that signatory countries cannot allow non-medical use of cannabis, such 
as in a hypothetical legalisation regime, without renouncing the UN Conventions. They 
must set measures to discourage, prevent or — if considered necessary — prohibit and 
punish personal use of cannabis (10).
All this is, however, largely based on the acceptance of the Conventions by the 
signatory countries. This means that countries must judge the opportunity and necessity 
of applying the convention norms. Conventions are, in fact, not self-executing and in 
the transposition of the international dictate into national law, countries are allowed 
discretion, while applying the principle of good faith in interpreting international 
agreements. This is visible throughout in the presence of safeguard clauses in the text 
of the Conventions: subject to constitutional limitations (Article 36.1, 1961 Convention); 
subject to basic concepts of national legal systems (Article 3, paragraph 2, 1988 
Convention); the Parties shall as far as possible (Article 26, paragraph 2, 1961 
Convention); these measures are necessary or desirable (Article 22 and Article 30, 
paragraphs 2 and 4, 1961 Convention). Nevertheless, states should interpret treaties 
in good faith and in the light of their object and purpose, according to Article 31 of the 
1969 Vienna Convention on the Law of Treaties.
A constant quest for evidence
By 1970, 64 states had ratified the Single Convention on Narcotic Drugs and with it the 
control system required for cannabis. Nevertheless, the fact that cannabis was treated 
no differently, even more strictly, than other substances that were perceived to be more 
dangerous provoked uncertainty within governments and parliaments.
(10) An expression that, according to the country considered, might mean use of cannabis or possession 
of small quantities of cannabis for personal use or both.
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There is evidence to suggest that disagreements embraced the question of the 
international classification(s) of cannabis from its beginning. Already, during the 
Plenipotentiary Conference, which drafted the 1961 Convention, controversies arose 
around the question of whether the prohibition of drugs in Schedule IV should be 
mandatory or only recommended. More recently, some authors see the insistence of 
certain countries to place cannabis under the strictest control regime in the convention 
as the main reason for such classification (Canadian Senate Report on Cannabis, 
2002). Others go so far as to use the words ‘arbitrariness’ when addressing cannabis 
classification (Caballero and Bisiou, 2000).
Evidently, the question of the classification of cannabis or of its derivatives is 
controversial and has arisen from time to time (11). In 2003 the WHO Expert 
Committee on Drug Dependence (12), following a Critical Review (13), recommended the 
rescheduling of dronabinol (THC, the main active principle of cannabis), to Schedule 
IV of the 1971 Convention (14). This would mean that the active principle of cannabis 
would be moved from a schedule where substances have very limited, if any, therapeutic 
usefulness and their abuse constitutes an especially serious risk to public health, to a 
schedule where substances have some therapeutic usefulness with a smaller (but still 
significant) risk to public health due to their liability of abuse. If implemented, this would 
probably have important consequences on the overall classification of cannabis and on 
its control requirements worldwide, but no further procedural steps have been taken. 
(11) ARF/WHO Scientific Meeting on Adverse Health and Behavioural Consequences of Cannabis Use, 
WHO and the Addiction Research Foundation of Ontario, 1981; Cannabis: a health perspective 
and research agenda, Division of Mental Health and Prevention of Substance Abuse, World Health 
Organisation, 1997.
(12) The WHO Expert Committee has the task of carrying out medical and scientific evaluations of 
the abuse liability of dependence-producing drugs falling within the terms of the 1961 Single 
Convention on Narcotic Drugs and the 1971 Convention on Psychotropic Substances. It then makes 
recommendations to the United Nations Commission on Narcotic Drugs on the control measures, 
if any, that it considers appropriate. The Expert Committee’s reports are published by WHO in the 
Technical Report Series.
(13) A Critical Review is an assessment process in which the Expert Committee, on the basis of (1) 
a notification from a Party to the 1961 or the 1971 Convention concerning the scheduling of a 
substance; (2) an explicit request from the UN Commission on Narcotic Drugs to review a substance; 
(3) a pre-review of a substance which has resulted in a recommendation for critical review; (4) 
information sent to the attention of the WHO that a substance of especially serious risk to public 
health and society, and of no recognised therapeutic use by any Member State, is clandestinely 
manufactured, with analysis of the substance according to its similarity to known substances and 
effects on the central nervous system, dependence potential, actual abuse and/or evidence of 
likelihood of abuse, therapeutic usefulness, and providing recommendations for scheduling or non-
scheduling.
(14) The WHO Expert Committee report recommend that ‘all stereochemical variants of delta-9-
tetrahydrocannabinol be moved to Schedule IV of the 1971 Convention’, and that this is ‘to avoid 
placing different stereochemical variants of the same substance under different control systems’. 
We have, in fact, to remind that in 1990 the WHO Expert Committee proposed the rescheduling of 
dronabinol, a stereochemical variant of delta-9-tetrahydrocannabinol, to Schedule II of the 1971 
Convention.
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In response to the WHO, the INCB expressed its concern in its 2003 report about this 
possible rescheduling of THC. In March 2006 the WHO Expert Committee on Drug 
Dependence concluded that dronabinol (THC) constitutes a substantial risk to public 
health, but the risk is different from that of cannabis, and it has moderate therapeutic 
usefulness. As a result, it recommended that dronabinol and its stereoisomers should 
be rescheduled from Schedule II to Schedule III of the 1971 Convention (WHO, 2006). 
At the 50th UN Commission on Narcotic Drugs in March 2007, members agreed 
to postpone any decision on dronabinol until more conclusive evidence is available, 
although firm opposition to the rescheduling was expressed by some delegates.
At the level of national authorities, evaluations of cannabis have been carried out on 
a regular cycle. The first ‘official’ enquiries date back to the late 19th and early 20th 
centuries, for example the Indian Hemp Drugs Commission in 1894, the Panama Canal 
Zone Report in 1925 and the La Guardia Report in 1944. The frequency of publication 
of such enquiries, however, picked up from 1969 onwards and has led to a proliferation 
of ‘official’ enquiries in the 1990s and 2000s. Despite their differences in scope, 
methods and conclusions, the recommendations of these, and older enquiries, reveal 
interesting common patterns. Three have been isolated for simplicity: (1) cannabis is not 
a harmless substance; (2) its dangers, in comparison with other controlled substances, 
have been overstated; and (3) civil sanctions, fines, or compulsory health assessments 
should be established in place of criminal penalties for personal use offences (Table 1).
Conclusion of reviews 1: cannabis is not a harmless substance
Cannabis is a substance that poses some kind of threats to health for which certain 
control would be justified. The UK Wootton Report in 1968 affirms that the ‘adverse 
effects that cannabis consumption, even in small amounts, may produce in some people, 
should not be dismissed as insignificant’ (15). These words were echoed more than 30 
years later by the UK Report of the Advisory Committee on Drug Dependence, which 
stated in 2002 that its use ‘unquestionably poses risks both to individual health and 
to society’ (UK Home Office, 2002). This view is also mirrored by other enquiries. For 
example, the inquiry for the Prime Minister of Jamaica in 2001, affirming that ‘it is 
accepted that cannabis is not entirely safe, even where it is still used for traditional 
religious rituals, such as in Jamaica’, and that ‘despite its proven folk medicinal 
qualities, its use can be injurious to health’ (National Commission on Ganja, 2001). The 
general attitude is that cannabis and its derivatives should be maintained as controlled 
drugs (UK House of Lords, 1998), as governments are responsible for restricting the 
availability of harmful substances, in particular to prevent the exposure of young people 
(Canada, 1970; Australia, 1994; New Zealand,1998).
(15) UK Home Office (1969): cover letter to the Wootton Report sent to the Home Secretary by Chairman 
Mr Edward Waine, 1 November 1968. See also Abrams, this monograph.
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Conclusion of reviews 2: the dangers have been overstated
The identification of cannabis as a potentially dangerous psychoactive substance did 
not, however, prevent a substantial number of these enquiries to explore the issue of 
whether current legislation reflected the real dangers posed by cannabis. Already in 
1944, the La Guardia Committee Report on Marihuana concluded that ‘the practice of 
smoking marihuana does not lead to addiction in the medical sense of the word’ and 
that ‘the use of marihuana does not lead to morphine or heroin or cocaine addiction’ 
(Zimmer and Morgan, 1997). In 1968 the Wootton Report stated that ‘the dangers 
of cannabis use as commonly accepted in the past and the risk of progression to 
opiates have been overstated’ and ‘cannabis is less harmful than other substances 
(amphetamines, barbiturates, codeine-like compounds)’. A similar conclusion was 
Table 1: Summary of governmental reviews on cannabis control
Title of report Country Year
Cannabis: Report by the Advisory Committee on Drugs 
Dependence (‘The Wootton Report’)
United Kingdom 1969
Le Dain Report Canada 1970
Baan and Hulsman Commissions The Netherlands 1970, 1971
Report of the Expert Group on the Effects of Cannabis 
Use
United Kingdom, Home 
Office Advisory Council 
on the Misuse of Drugs
1982
Legislative options for cannabis use in Australia, 
Monograph No. 26 
Australia 1994
Inquiry into the Mental Health Effects of Cannabis, 
Report of the Health Committee, AJHR, I.6A 
New Zealand 1998
House of Lords Science and Technology Select 
Committee, Ninth Report, Cannabis: the scientific and 
medical evidence, HL 151 1997–98
United Kingdom 1998
Swiss Federal Commission for Drug Issues, Cannabis 
Report
Switzerland 1999
A Report of the National Commission on Ganja to Rt 
Hon. P. J. Patterson, QC, MP, Prime Minister of Jamaica
Jamaica 2001
The Senate Special Committee on Illegal Drugs, 
Cannabis: our position for a Canadian public policy
Canada 2002
Report by the Advisory Committee on Drug Dependence, 
Home Office, The Classification of Cannabis under the 
Misuse of Drugs Act 1971
United Kingdom 2002
Rapport de la Commission d’enquête du Sénat français 
sur la politique nationale de lutte contre les drogues 
illicites, No. 321
France 2003
Report by the Advisory Council on the Misuse of Drugs, 
Home Office, Further consideration of the classification 
of cannabis under the Misuse of Drugs Act 1971
United Kingdom 2005
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arrived at 34 years later in 2002 when the Advisory Committee on Drug Dependence 
proposed the reclassification of cannabis from Class B to Class C (enforced by law in 
2004 and confirmed in 2005). These views were reiterated by other enquiries, such as 
the Baan Committee in the Netherlands, which affirmed in 1971 that ‘cannabis use does 
not lead directly to other drug use’ (16) or by the US National Commission on Marihuana 
and Drug Abuse, which in 1973 stated that ‘the existing social and legal policy is out 
of proportion to the individual and social harm engendered by the use of the drug 
[cannabis]’ (17). The Canadian Le Dain Commission saw ‘the UN Single Convention of 
1961 as responsible’ for such a situation which ‘might have reinforced the erroneous 
impression that cannabis is to be assimilated to the opiate narcotics’. The same 
commission, however, suggested that the UN Convention did ‘not prevent domestic 
legislation from correcting this impression’ (18).
Conclusion of reviews 3: personal use offences do not require 
criminal sanctions
Endorsing these interpretations, a number of enquiries proposed that criminal sanctions 
should be withdrawn from private use and/or possession for such use, to create instead 
a criminal exemption scheme or to impose fines, to decriminalise personal use or just 
to impose compulsory health assessment. These conclusions were largely based on the 
belief that criminalising the users of small quantities of cannabis could engender far 
more harm than good to the society as a whole (e.g. Jamaica, 2001), and that such 
alternative measures would remove the criminal stigma and the threat of incarceration 
from a widespread behaviour (possession for personal use) which does not warrant 
such treatment (US National Commission on Marihuana and Drug Abuse, 1973). The 
Canadian Senate in 1970 argued that ‘the criminal law should not be used for the 
enforcement of morality without regard to potential for harm’. Three years later, the 
US National Commission on Marihuana and Drug Abuse stated that ‘Relieving the law 
enforcement community of the responsibility for enforcing a law of questionable utility, 
and one which they cannot fully enforce, would allow concentration on drug trafficking 
and crimes against persons and property’. The French Senate in 2003 recommended 
to impose a fine in case of a first offence of drug use (all drugs), and to create an 
obligation for health or social measures. In 2002 the UK Advisory Committee on Drug 
Dependence proposed a reclassification of cannabis in the list of controlled substances. 
The UK government, which endorsed the recommendations to move cannabis from 
(16) In Cohen, P. (1994), The case of the two Dutch drug policy commissions. An exercise in harm 
reduction 1968–1976. Paper presented at the 5th International Conference on the Reduction of Drug 
Related Harm, 7–11 March 1994, Addiction Research Foundation, Toronto. Revised in 1996.
(17) Marihuana: a signal of misunderstanding. The official report of the National Commission on 
Marihuana and Drug Abuse, Raymond P. Shafer, Chairman (1973), 211.
(18) Le Dain, G. et al., Cannabis: report of the Commission of inquiry into the non-medical use of drugs. 
Ottawa: Government of Canada in Report of the Senate Special Committee on Illegal Drugs, 
‘Cannabis: our position for a Canadian public policy’, September 2002, Volume II, 278.
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Class B to Class C, pointed out that reclassification does not mean that cannabis is 
legalised or decriminalised, and that possession for personal use still carries a maximum 
sentence of two years in prison. Yet, following reclassification in the UK, it is unlikely 
that adults caught in possession of cannabis will be arrested, the usual outcome being 
a warning and confiscation of the drug. Nonetheless, some instances may lead to arrest 
and possible caution or prosecution, including repeat offending, smoking in a public 
place, instances where public order is threatened and possession of cannabis in the 
vicinity of premises used by children.
A few enquiries went even further, recommending the regulation of cannabis 
consumption and sale. The Senate Special Committee on Illegal Drugs in Canada 
recommended in 2002 that the government amend the Canadian legislation in order 
to create a criminal exemption scheme that would allow ‘for obtaining licences as well 
as for producing and selling cannabis’. The Senate also asked, as a consequence of 
this legislative modification, for an amnesty to be declared for any person convicted of 
possession of cannabis under current or past legislation (19). Illegal trafficking and export 
would still attract criminal penalties. In Switzerland, in 1999, the Federal Commission 
for Drug Issues recommended the removal of the prohibition of consumption and 
possession of cannabis, and the possibility for cannabis to be purchased lawfully. 
According to the Federal Commission, clear provisions for the protection of the young 
and the prevention of all the potential adverse consequences of legalisation ought to be 
included in the new system. The commission suggested that if the government accepted 
this model, Switzerland should renounce the Single Convention of 1961 given that these 
provisions were not compatible with international drug control agreements. In Australia, 
in 1994, the study undertaken by the government, Legislative options for cannabis use in 
Australia, concluded, more ambiguously, however, that ‘cannabis law reform is required’ 
and that the reform should be one ‘within the broad categories of prohibition with civil 
penalties, partial prohibition and relatively free but regulated availability’.
The value of these inquiries — while in many cases limited in the strict scientific point 
of view — lies in their political significance. The overall picture suggests that cannabis 
consumption potentially poses risks both to individual health and to society, and on this 
basis some sort of legal control seems justified. At the same time, it is acknowledged 
that the dangers of cannabis have in some cases been overstated, that there has been 
a lack of separation between cannabis and other more dangerous substances and that 
its consumption does not necessarily lead to crime or other drug use. Alternative forms 
of criminal sanctions, such as civil sanctions, fines or compulsory health assessments, 
have been suggested. In a few cases, enquiries have included in their suggested options 
the regulation of cannabis consumption and sale, while drawing attention to the political 
impracticability of the option.
(19) Report of the Senate Special Committee on Illegal Drugs, ‘Cannabis: our position for a Canadian 
public policy’, September 2002, Volume III, recommendations nos. 6 and 7, p. 618.
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European Union countries
Classification of cannabis
As far as the classification of cannabis at national level is concerned, the variety of 
laws and procedures within the EU reflect both the severe requirements as suggested by 
the UN Conventions and the ‘room for manoeuvre’ at Member State level. Legislation 
may be organised into a ‘pyramid’: on the bottom tier are those legal systems where 
cannabis is fundamentally considered as different from other drugs; at the top are those 
in which cannabis is treated on a par with all other drugs, but where prosecutorial 
instructions or even judicial discretion in practice apply a distinction between substances, 
usually based on criteria regarding the nature of the substance. Four general groups of 
countries can be identified in which cannabis is classified and controlled differently from 
other drugs, being thus subject to a different prosecutorial approach. These approaches 
are as follows: classification by law; exemption to the law; exception by guidelines; or 
exception due to judicial discretion.
Firstly, in certain countries, lists established in or directly linked to the laws are used 
to determine different legal degrees of severity in control and prosecution of offences. 
Cannabis is included in those lists that do not request the maximum legal response. 
For example, in Cyprus, the Netherlands and the United Kingdom, the respective laws 
classify cannabis in lists where the level of severity demanded in response to offences is 
not as strict as for substances included in other lists. Strikingly, no other substance listed 
in Schedule IV of the 1961 Convention has received this treatment.
Secondly, the law may consider drugs to be equally classified but provide specific 
exemptions for the prosecution of cannabis offences. In countries such as Ireland, 
Belgium and Luxembourg, cannabis is either legally classified amongst those substances 
presenting a serious risk of abuse, no medical value and subject to all control measures, 
or it is included in the general list of controlled substances which do not distinguish 
between such substances based on health risks. However, the national laws or penal 
codes introduce specific distinctions for cannabis possession that can render prosecution 
or sentencing for cannabis more lenient than for other drugs. In Greece, cannabis is 
classified on an equal footing to other drugs but production or cultivation of cannabis 
is legally distinguished from production or cultivation of other drugs for personal 
use. In Spain, classification of drugs is analogous to the UN Schedules, but there is 
a distinct lower penalty range for trafficking in drugs that are not considered as ‘very 
dangerous substances’, and jurisprudence shows this to be interpreted as cannabis. 
Less specifically, in Poland, while cannabis is classified in a way similar to the UN 
Conventions, the laws establish the category of a ‘minor’ drug possession offence, which 
may take into account the substance nature when determining if the offence qualifies as 
‘minor’. In practice, this may be attributed to first time personal use of cannabis.
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A third variant is visible in those countries in which cannabis is legally classified in the 
most stringent lists and the law or penal code does not provide for any exemptions. 
However, prosecutorial guidelines or judicial precedent indicate that a distinction should 
be made based on the nature of the substance when prosecuting. In Denmark a State 
Prosecutor directive and in Germany a Constitutional Court decision request less severe 
measures for possession of cannabis for personal use.
In a separate group of countries (e.g. Czech Republic, Estonia), cannabis is not classified 
differently from other drugs and the law does not differentiate among substances, that 
is, drug offences attract the same penalty regardless of the substances involved. In 
this group there are no prosecutorial guidelines in favour of a less severe approach 
to cannabis. Nonetheless, the nature of the substance is one of the criteria (together 
with the quantity, previous criminal records, and other circumstances) considered by 
prosecutorial or judicial discretion when deciding to reduce the charges or not prosecute 
an offender. Cannabis may be included in this category as a ‘less dangerous’ drug.
The evidence available thus implies that, although international policy suggests that 
cannabis ought to be classified as one of the most dangerous substances to which the 
most severe controls apply, this is not often transposed as such across the different 
European national criminal justice systems. Nevertheless, the different interpretations of 
international conventions can be visible ‘de jure’ or ‘de facto’. They can be managed 
either by legal classification, or by specific mention in the law or penal code, or by 
prosecutorial guidelines, or by the discretionary powers proper to each judicial system. 
The choices between ‘de jure’ or ‘de facto’ options might reflect different political 
attitudes towards cannabis.
Personal use of cannabis (20)
Based on laws passed in parliament, ministerial directives or prosecutorial guidelines, 
a variegated picture emerges of the overall legal attitude towards personal use of 
cannabis. Nonetheless, despite the different legal approaches towards cannabis, a 
common trend can be seen in the development of alternative measures to criminal 
prosecution for cases of use and possession of small quantities of cannabis for personal 
use without aggravating circumstances. Fines, cautions, probation, exemption from 
punishment and counselling are favoured by most European justice systems. The 
EMCDDA maintains a table enabling comparison of legislation regarding cannabis 
offences on its website (21).
(20) ‘Personal use’ here applies to offences for simple use or possession exclusively for personal 
consumption, and where other finalities are excluded (although legal definitions vary, these usually 
involve small quantities and absence of aggravating circumstances).
(21) See eldd.emcdda.europa.eu/index.cfm?nNodeID=5769
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In the European countries considered for this chapter, personal use of cannabis attracts 
administrative sanctions (22) or alternatives to custodial sanctions in 16 countries. 
This suggests that in many European countries considered, personal use of cannabis 
is an offence that attracts sanctions such as fines and deprivation of certain rights, 
for example suspension of driving licence, or other measures such as cautioning, 
discontinuance or suspension of proceedings or, if needed, referral to treatment, but 
does not lead to imprisonment. Indeed, drug policies in many European countries seem 
to concur that criminal action against non-problematic use/possession of cannabis 
should receive the lowest prosecutorial priority (23).
Cannabis legislation: between global consistency 
and national leniency
In recent years cannabis or general drugs laws have been substantially modified in 
a number of European countries. In Portugal, drug use was decriminalised in 2000. 
In Luxembourg in 2001 penalties for cannabis use and possession passed from 
imprisonment to fines. In Belgium in 2003, following a similar approach, legislation 
was introduced that would attract a police registration and fine for the first two cannabis 
use prosecutions, although police registration was annulled by the ruling of the Belgian 
Court of Arbitration in 2004. The United Kingdom reclassified cannabis from a Class B 
to Class C drug in 2004. These are in line with the conclusions of the inquiries described 
above. The cannabis issue has been strongly debated in recent years in France, 
Switzerland, Italy and the Netherlands, fuelled by a number of legislative proposals. 
Some debate has embraced the legal status of cannabis used for therapeutic purposes. 
For example, in the Netherlands a project to supply cannabis to patients was established 
from 2003, with an Office of Medicinal Cannabis strongly regulating supply. However, 
demand has proven lower than expected (1 000–1 500 patients, or around one-tenth of 
predicted demand), although the policy was renewed for a 5-year period in November 
2007.
Modification — or proposed modification of cannabis laws — have often been 
accompanied by heated debate in the media. The political sensitivity of moving away 
from strict control has caused governmental apprehension, and concern has also been 
manifested at the international level. The UN control system has taken a position on 
cannabis in several instances: the INCB has repeatedly raised objections to the way 
some EU countries deal with cannabis offences, in particular where personal use is 
(22) ‘Administrative sanctions’ applies to sanctions not including imprisonment, such as fines or other 
non-criminal measures.
(23) EMCDDA (2002) Prosecution of drug users in Europe, p. 69, and Rand Europe (2003), Cannabis 
policy, implementation and outcome.
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concerned. The Netherlands has often been criticised by the INCB for its ‘coffee shop’ 
policy, and also Luxembourg, Portugal and the United Kingdom have been the object of 
scrutiny for their new laws on cannabis, allegedly because of their non-alignment with 
international drug control treaties (24). This message was again made clear in a chapter 
on ‘the new [high potency] cannabis’ in the UNODC’s 2006 World Drugs Report, which 
stated that ‘It is essential (…) that consensus be regained, and that what is truly a global 
issue is again approached with consistency on a global level. After all, it is for precisely 
this that the multilateral drug control system was designed.’
Such calls for awareness on the presumed cannabis leniency and the danger that such a 
‘soft line’ on cannabis could provoke have not fallen on deaf ears. Without suggesting a 
direct link, some acknowledgement may be detected in the 2004 EU Council Resolution 
on cannabis, and increased scrutiny of cannabis in some EU countries. In Denmark, 
where since the 1970s people caught for possession of cannabis (for personal use) were 
just warned, a new directive of 2004 advises prosecutors that a fine should now be the 
norm. In the Netherlands, the government adopted an action plan to reduce the use 
of cannabis. In Italy, a country where since 1993 cannabis was officially considered to 
be different from other drugs, a 2006 law eliminated this difference on the assumption 
that all drugs are dangerous. In France, in 2005, a new campaign was launched on 
the risks of cannabis for young people after the government turned down the possibility 
of substituting penal sanctions with administrative fines for cannabis consumption, 
adducing that such a modification could have been interpreted as recognition of the 
‘weak dangerousness’ of cannabis and could lead to an increase in consumption (25).
To conclude, there is sufficient evidence to confirm that the legal approach to personal 
use of cannabis is far from homogeneous across the European countries. Nevertheless, 
avoiding imprisonment seems to be the trend for personal use offences, which can be 
applied more or less openly, through the law or through prosecution powers. However, 
there are some efforts to limit this trend. A rise in concern is visible at international 
and national level. An alleged increase of THC content (see King, this monograph) and 
increased demand for treatment with cannabis being the primary drug have contributed 
to this concern. The UN system openly condemns ‘lenient policies’ and recent policy 
shifts in some Member States suggest a renewed attention towards cannabis. Overall, 
it is interesting to note that while drug policies which appeared in the 1990s and early 
2000s suggested a non-criminal approach to personal use of cannabis, more recent 
policies seem to tip the balance back towards more restrictive measures.
(24) See International Narcotics Control Board (INCB) Reports 1999, 2001 and 2002.
(25) Plan gouvernemental de lutte contre les drogues illicites, le tabac et l’alcool 2004–2008. Available at: 
www.drogues.gouv.fr
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Chapter 8
In thinking about cannabis 
policy, what can be learned from 
alcohol and tobacco?
Keywords: alcohol – cannabis – economics – environmental strategy – polydrug 
consumption – prohibition – regulation – taxation – tobacco
Setting the context
Cannabis is just one of many psychoactive substances used in Europe for recreational 
and therapeutic purposes. Research into the topic has never really ignored this real-
life polydrug use. Most joints contain tobacco. A cannabis session often includes the 
consumption of alcoholic drinks. These are givens. Nonetheless, only recently have 
professionals working in the area of cannabis control genuinely begun to look at the 
‘cross-substance’ effects of legislation targeted at other, legal, substances such as 
alcohol and tobacco.
This is not to say that there has been a revolutionary shift towards examining the 
interrelationships of polydrug consumption. The epidemiological regime — which splits 
drug taking along neat substance-specific lines (cannabis, ecstasy, cocaine, etc.) — 
remains in place. Rather, there has been a shift in national drug strategies — at least 
in Europe — to erode the substance-specific approach which traditionally segregated 
activity on licit psychoactive substances from activity on illicit drugs (1). Politically, it is 
no longer taboo to compare legal and illegal substances. The recent advent of smoking 
bans in Europe represents a golden opportunity to measure the knock-on effects on 
consumption of other substances. Moreover, evidence on the effects of decriminalisation 
of cannabis (that is, lower penalties for personal possession) in many European countries 
during the early 2000s is now filtering into the policy literature.
This chapter does not retread the well-worn track of comparative drug harm indexes and 
the relative harms of cannabis and society’s chosen licit drugs. Instead, it examines the 
(1) EMCDDA Annual Report 2006, selected issue: ‘European drug policies: extended beyond illicit 
drugs?’.
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ways in which the market for licit substances has been subject to government control, 
together with brief commentary on the merits of these interventions. The ‘elephant in 
the room’ has been dutifully ignored. There are no ‘what-if’ scenarios on how market 
controls could be transposed to cannabis in a post-legalisation environment. A postscript 
to this chapter provides a range of sources for further reading on the topic of mooted 
cannabis regulation. However, for the time being, any such options would require a 
huge shift in the political balance, which currently appears to be, if anything, more 
tipped in the favour of increased controls on cannabis rather than liberalisation (see 
Ballota et al., this monograph).
Further reading on the regulation of alcohol and 
tobacco
Alcohol
Anderson, P., Baumberg, B. (2006), Alcohol in Europe, Institute of Alcohol Studies, London  
ec.europa.eu/health-eu/news_alcoholineurope_en.htm
Gerritsen, H. (2000), The control of fuddle and flash: a sociological history of the regulation of alcohol 
and opiates, Brill Academic Publishers, Leiden.
Walton, S. (2003), Out of it: a cultural history of intoxication, Random House, New York.
Tobacco
European Commission (2007), Green paper — towards a Europe free from tobacco smoke: policy 
options at EU level, Health & Consumer Protection Directorate-General.
Kopp, P., Fenoglio, P. (2000), ‘Le coût social des drogues licites (alcool et tabac)’, in Observatoire 
Français des Drogues et Toxicomanies 22.
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In thinking about cannabis 
policy, what can be learned from 
alcohol and tobacco?(2)
Robin Room
If caffeine and other such banalised psychoactive substances are left out of 
consideration, almost everywhere in Europe today cannabis is one of the ‘big three’ of 
psychoactive substances, along with alcohol and tobacco. Although the international 
drug control system applies continuing pressure against it, cannabis has taken on a 
semi-legal status in many parts of Europe, at least at the level of the user.
This raises the question, what can be learned from the extensive literatures on alcohol 
and tobacco policy which might be useful in thinking about cannabis policy? The 
question is obviously applicable in a situation where cannabis has a legal or semi-legal 
status. It also has some applicability where cannabis has a clearly illegal status. Total 
prohibition was once fairly common in both the tobacco (Austin, 1978) and alcohol 
fields, in the case of alcohol applying less than a century ago in many parts of Europe 
— Norway, Finland, Iceland, the Russian Empire and then the early Soviet Union. 
Studies of what happened during alcohol prohibition, and also of what happened with 
legalisation, are of interest in thinking about cannabis policy.
Taking into account the alcohol and tobacco experience is particularly important 
because the field of empirical studies of cannabis policy is so little developed. A 
landmark in this field is the sustained effort by MacCoun and Reuter (2001) to assemble 
the evidence on the likely results of illicit drug legalisation in the USA. A byproduct of 
this study, however, was an underlining of how weak the evidence base is in this area. 
A recent review of ‘the contribution of economics to an evidence-based drugs policy’ 
(MacDonald, 2004) found agreement that illicit drug use showed some responsiveness 
to price, but that ‘there is not yet a consensus on the possible range of price elasticities 
for certain drugs’. Evidence on the effects of depenalisation of marijuana still depends 
on a rather small range of studies (Single, 1989; MacCoun and Reuter, 2001; Donnelly 
et al., 2000), in some cases of paradoxical instances where the reach of the criminal law 
actually widened (Single et al., 2000).
(2) This paper draws in part on Room (2005).
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Traditions of studying the impact of alcohol and 
tobacco policies
Alcohol policy impact studies
There is a very substantial literature on the effects of alcohol control policy changes on 
drinking amounts, patterns and problems. Data used in these analyses has primarily 
been of two types: social and health statistics, such as alcohol sales data, police statistics 
and mortality and hospital discharge data; and before-and-after surveys, mostly cross-
sectional but in a few cases longitudinal. Some studies have included control sites, 
and one or two notable studies have included a random assignment to intervention or 
control condition (e.g. Norström and Skog, 2003).
Alcohol policy impact studies have primarily been carried out in a limited range of 
countries, generally excluding both the developing world (Room et al., 2002) and 
Southern European wine cultures. Even between somewhat similar societies, there are 
substantial variations in the research emphasis on particular topics (Room, 2004).
There is an imperfect fit between what those involved in liquor licensing decisions 
may want to know and what is available in the literature on alcohol controls. This gap 
between the content of alcohol control legislation and the research literature has been 
documented in the USA (Wagenaar and Toomey, 2000), but exists also elsewhere — 
particularly in countries where the tradition of alcohol policy impact studies has not 
been strong. The studies are sometimes done because a change was controversial in a 
particular jurisdiction, and funding an evaluation was a way of defusing the controversy. 
Other studies have been opportunistic, where a researcher seizes the chance to do a 
‘natural experiment’ study (‘natural’ here means that the researcher did not have a 
voice in the circumstances of the change, so that the study’s design is often constrained). 
Often studies have made use of available data, such as per-capita consumption data 
or mortality registers. Since research is usually a national government responsibility, its 
topical focus is not necessarily attuned to the concerns of local jurisdictions.
Nevertheless, the growth of the literature evaluating the effects of alcohol controls has 
been a substantial achievement involving a number of national traditions, and lessons 
from it can be applied, with suitable caution, across jurisdictions, and drawn on in 
thinking about cannabis policy. Reviews are now available (e.g. Babor et al., 2003; 
Room et al., 2002) which summarise the findings and implications of the literature. A 
new step forward, as part of the WHO-CHOICE programme (‘Choosing interventions 
which are cost effective’, available at: www3.who.int/whosis/menu.cfm?path=evidenc
e,cea&language=english), has been the estimation of the relative cost-effectiveness of 
different strategies and combinations of strategies to prevent alcohol-related problems 
(Chisholm et al., 2004), in terms of dollars per saved DALY (disability-adjusted life 
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year). Table 1 shows some of the results from these analyses for the ‘Europe-A’ WHO 
subregion, which is roughly coextensive with the European Union. Since evidence was 
lacking for any effectiveness of mass media persuasion of school-based education, these 
strategies were excluded from the analysis as having no apparent cost-effectiveness. In 
terms of cost-effectiveness per DALY saved in developed European countries, then, the 
policies tested ranked as follows (most cost-effective first): taxes (even without counting 
the revenues from taxes); advertising ban; closing times (specifically, Saturday closing for 
off-sales); random traffic breath tests; screening and brief medical advice; and (with no 
cost-effectiveness) mass media persuasion and school education.
Tobacco policy impact studies
There is also a substantial literature of tobacco policy impact studies. As for alcohol, 
there are several synthetic reviews of the literature (e.g. Jha and Chaloupka, 1999; 
Rabin and Sugarman, 2001). Whereas the alcohol policy impact literature aims 
primarily at assessing the impact of specific interventions, the equivalent tobacco 
literature is often aimed at assessing the impact of anti-smoking policy packages as a 
whole (e.g. Siegel and Biener, 1997; Pierce et al., 1998). This partly reflects the reality 
that policy changes in the tobacco area have often involved the simultaneous application 
of multiple strategies. It also reflects the different circumstances of the substances in the 
countries where the main policy impact studies have been done. For alcohol the status 
quo ante has often been a detailed system of controls on availability and on places 
and times of use, with the literature often studying what happens when one or more 
of the controls is removed or relaxed. For tobacco the status quo ante has been very 
little control on availability, and the literature is primarily studying the effect of initiating 
measures such as anti-smoking persuasion campaigns, controls on places of use and 
on age of purchase, and raised prices, which have been increasingly put forward as a 
coordinated package.
Table 1: Comparative cost-effectiveness of alcohol interventions in ‘Europe-A’ 
(Chisholm et al., 2004)
DALYs saved/million 
population
Average cost-effectiveness 
ratio ($/DALY)
Brief medical advice 1 889 2 351
Tax: current + 50 % 1 764 258
Tax: current + 25 % 1 576 289
Tax: current 1 365 333
Advertising ban 459 594
Saturday closing for off-sales 251 1 087
Random traffic breath tests 247 2 467
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Comparing the alcohol policy and tobacco control literatures, one can find clear 
differences in emphasis. Taxes loom even larger as a strategy for tobacco than they 
do for alcohol (see Chaloupka et al., 2001). Although a much greater proportion of 
the total harms from alcohol than from tobacco are to others, the aim of reducing 
harm from ‘second-hand smoke’ has proved politically potent for tobacco control in a 
way that has only been true for drink-driving in alcohol policy. Accordingly, a strong 
emphasis in the tobacco literature has been put on environmental prohibitions — bans 
on smoking at work and in public places — which are already, to a considerable 
degree, taken for granted with respect to alcohol. 
In this connection, Hauge (1999) has argued that the modern emphasis on health 
harm to the drinker has been a policy mistake in the alcohol field. The two policy 
impact literatures have also reached substantially different conclusions about the effects 
of counter-advertising campaigns. This probably primarily reflects the differences in 
the aims and content of the campaigns, as well as differences in the social politics of 
the substances. The anti-smoking campaigns which have proved effective (Pechman 
and Reibling, 2000; Sly et al., 2001, 2002; Wakefield et al., 2003) have often 
involved frontal attacks financed by governmental agencies on the bona fides of the 
tobacco industry. This is an unusual enough occurrence in a capitalist society to have 
impressed teenagers, at least in the short run — although the campaigns have often 
proved politically unsustainable in the longer run (Givel and Glantz, 2000). Also, 
more available in the nicotine field, though underutilised, has been the option of harm 
reduction through changing the mode of use of the psychoactive substance (Shiffman et 
al., 1997).
As for alcohol, the WHO-CHOICE programme has calculated estimated cost-
effectiveness ration for specific interventions, and for combinations of interventions 
(Shibuya et al., 2003). Results for ‘Europe-A’ are shown in Table 2. Again, the cost-
effectiveness calculations exclude the government revenue gained from the tax from 
the calculations. A comparison of the results suggests that somewhat more conservative 
assumptions were used in the alcohol calculations than in the tobacco calculations.
Instead of impact studies: ‘expert knowledge’
As will be apparent from the discussion above, there is great variability in the availability 
of published evidence on the effects of policies governing the availability and use of 
psychoactive substances, both licit and illicit. It should be noted, however, that the lack 
of a formal academic literature does not mean a lack of practical knowledge of the 
effects of policies. As Valverde (2003) has documented for the alcohol control system 
in Ontario, those staffing regulatory systems typically build up a job-based stock of 
knowledge, often mixing ‘facts’ and values, which guide their everyday actions. On 
the other hand, there is ample experience from medicine and other professions with 
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such practice knowledge that its conclusions about effects are often mistaken, when 
subjected to the harsh test of well-designed outcome and impact studies. It would 
be advantageous, with respect to cannabis policy, and for that matter policy on all 
psychoactive substances, to move to an ‘evidence-based’ standard of policymaking. This 
requires a substantial investment in developing the evidence on which the policymaking 
can be based.
Some specific lessons from alcohol and tobacco 
policy research
Does consumption necessarily go up after legalisation?
The answer to this question seems to be, ‘it depends’. The total alcohol consumption 
does not seem to have changed much after the legalisation of alcohol at the end of US 
Prohibition (Gerstein, 1981). But this was in a circumstance of economic depression, and 
with quite stringent alcohol control regimes replacing prohibition in many US states. As 
MacCoun and Reuter (2001 pp. 356–366) conclude, in the US context, depenalisation 
of use seems not to increase cannabis use, but outright legalisation probably would. 
However, the circumstances of legalisation would certainly affect this, and stringent 
regulatory control of cannabis would be likely to hold consumption down (see below).
What regulatory alternatives are there to prohibition?
The history of control of alcohol and other psychoactive substances is full of examples of 
different regulatory regimes, and the effects of some of them have been evaluated. One 
part of such a system is the regulation of the market in the substance, including retail 
sales.
Table 2: Comparative cost-effectiveness of tobacco interventions in ‘Europe-A’ 
(Shibuya et al., 2003)
Total DALYs saved 
(millions/year)
Average cost-
effectiveness ratio 
($/DALY)
Doubling the highest tax 6.9 13
Highest regional tax rate (75 %) 4.8 18
Global average tax rate (44 %) 2.0 44
Enforced bans on smoking in indoor public space 0.8 358
Counter-advertising campaigns 0.7 337
Nicotine replacement 0.7 2 164
Comprehensive advertising ban 0.6 189
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One option for such regulation is a kind of prescription or permit system, issuing licences 
to individuals to purchase cannabis. This could be a system organised with physicians 
and pharmacists as the gatekeepers, like prescription systems for psychoactive 
medications. Such a system, with a mental health screening component, might be 
adopted if there is a major policy concern about cannabis precipitating schizophrenia. 
But it seems more likely that a more bureaucratised system, as for driver’s licences, 
would be adopted. Sweden’s ‘Bratt system’ for alcohol in the decades before 1955 had 
a version of such individualised controls (Frånberg, 1987).
A second option is a rationing system, which allots a maximum purchase amount to the 
purchaser in a particular time period. The Swedish Bratt system included a rationing 
system, and there are also some more recent examples of alcohol rationing (Schechter, 
1986).
A third option is a government monopoly system, where the state monopolises one or 
more levels of the production, distribution and sale of the substance. Such monopoly 
systems presently exist for alcohol in 18 US states and all Canadian provinces (though 
only a few of the states and nine of the provinces have monopoly stores at the retail 
level), as well as in all Nordic countries, except Denmark. There have been state 
monopoly systems for cannabis in India, and monopoly systems for opiates were 
a feature in the Asian territories of the empires of the first half of the 20th century 
(Brook and Wakabayashi, 2000). The medicinal cannabis office set up by the Dutch 
government may be seen as a similar monopoly. There is a recent Canadian proposal 
for government shops to take over the sale of tobacco (Callard et al., 2005), and 
there have also been proposals in Canada and in the US northwest for cannabis to be 
legalised for sale in government alcohol stores.
The fourth option is a licensing system, where private commercial enterprises are 
licensed to sell the product, with the licence conditional on the seller abiding by the 
rules of a regulatory system. Such a system is common for alcoholic beverages, as an 
alternative to a government monopoly. A licensing system is used in the Netherlands to 
regulate the ‘coffee shops’ that allow non-criminalised retail purchase of cannabis (see 
Korf, this monograph). Specific licensing systems for retail tobacco sales have become 
common, for instance, in the USA in recent years (www.healthpolicycoach.org/doc.
asp?id=3147).
Is a rationing system effective?
There is good evidence that rationing systems for alcohol hold down the levels of 
problems from alcohol, whether in terms of violence (Schechter, 1986) or long-term 
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health consequences (Norström, 1987). When the Swedish system of individualised 
rationing was abolished in 1955, for instance, the rate of liver cirrhosis mortality 
jumped by one-third in the following year, reflecting the removal of a constraint on the 
consumption of heavy drinkers (Norström, 1987).
Is a government monopoly system effective?
It has been shown that government monopoly of retail sales can be quite effective in 
holding down retail sales of alcoholic beverages (Her et al., 1999). The effects are partly 
through associated characteristics which have been shown to be effective in holding 
down sales: limitation of the number of sales outlets, and limitation of hours and days 
of sale. Government management of the system also results in more professionalised 
employees, less likely, for instance, to sell to those who are under legal age. And it 
removes the private profit motive, which tends to drive consumption upwards, not only 
in terms of sales promotion but also in terms of political influence from private actors to 
loosen restrictions in availability (Room, 2001).
Do taxes on psychoactive substances affect the amount of 
consumption?
As already indicated in Table 2, the answer to this from both the tobacco and the 
alcohol literature is an emphatic ‘yes’.
Can regulatory policies affect the potency of the psychoactive 
substance used?
The answer to this question is clearly ‘yes’. At least a dozen US states, for instance, ban 
Everclear spirits, a product that is 95 % pure ethanol. The legal availability of lesser-
strength alcoholic beverages (including regular-strength spirits) means that there is no 
substantial black market for Everclear.
Prior to 1915, spirits were the main form of alcohol consumed in all Nordic countries. 
By the 1980s, the main form was beer (wine has now replaced beer in Sweden as the 
most used form in terms of alcohol content). The changeover from spirits to beer was 
accomplished very quickly in Denmark by a swingeing tax on spirits imposed during the 
First World War (Bruun et al., 1975). In other Nordic countries the change was more 
gradual, accomplished partly by differential taxation and partly by making low- and 
middle-strength beer more widely available than other alcoholic beverages.
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Whether a more potent form of the psychoactive substance is more harmful than a 
less potent form is an apparently easy question to answer for alcohol, in the sense that 
most of the harm from drinking alcohol comes from the psychoactive ingredient itself. 
Nevertheless, it can be questioned how much effect the Nordic political effort to channel 
consumption toward beer and wine and away from spirits had on alcohol-related 
problems. The political intent was to moderate drinking customs along with the change 
in beverage, but there is little evidence that this happened. At least in the short run, the 
‘trouble per litre’ of alcohol did not decline when beer was made much more available 
in Finland in 1969, and consumption rose by about 50 % (Mäkelä et al., 1981).
For tobacco, as for cannabis, the issue of whether greater potency is more harmful is 
obviously more complicated, since much of the harm results not from the psychoactive 
ingredient but from what accompanies it, particularly in smoked form (tars, carbon 
monoxide). Thus, low-nicotine, high-tar tobacco cigarettes are likely to cause more 
health harm than high-nicotine cigarettes, since the smoker will get more tar and carbon 
monoxide in the course of reaching the same level of nicotine. Analogously, it should 
not be assumed that a higher THC content will be more harmful.
Interacting with the issue of potency is the issue of mode of ingestion. It is likely that 
there is less risk to health from eating or vapourising marijuana than from smoking 
it. However, for licit as well as illicit psychoactive substances, there is relatively little 
systematic knowledge on the effects in a population of measures designed to favour one 
mode of ingestion over another. Often policies are made on the basis of vague fears 
rather than systematic knowledge. For instance, the Swedish form of snuff, known as 
snus, is banned for sale in the European Union, other than in Sweden, on the grounds 
that it is a health hazard. There are good public health arguments for promoting the 
use of snus as a much less harmful alternative to smoking cigarettes, although these 
arguments are also disputed (Gilljam and Rosaria Galanti, 2003). But at present the 
European legal system considers that it must make decisions on whether snus should 
remain banned on the basis of suppositions.
Snus is much less deadly than smoked tobacco ... [But] one cannot conclude with certainty 
whether offering snus on the market would principally have the effect of encouraging smokers 
to stop smoking (a ‘substitution effect’) or of facilitating, on the contrary, the path towards 
consumption of tobacco (a ‘passage-way effect’) ... The insufficiency of data and the scientific 
uncertainty [is about] the supposed behaviour of the public. The question which poses itself is 
that of knowing if, in these circumstances, the ban on snus can be considered as a protective 
measure efficacious for public health.
(Geelhoed, 2004; translated from French version)
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Can regulatory policies affect the location and circumstances of 
use?
Again, the answer to this is clearly positive. One result of prohibitory policies is to push 
consumption into private or semi-private places. The Dutch coffee shop model of limited 
cannabis availability in designated places may be seen as holding down the public 
nuisance from cannabis smoking (see Korf, this monograph).
Again, however, the issue of which locations of use are more harmful has turned out 
to be complicated in the alcohol field. Drinking in streets and parks is usually seen as 
increasing the nuisance for others (Törronen, 2003), but the perception has varied at 
different times on whether drinking in a tavern or restaurant is more or less harmful than 
drinking at home. On the one hand, control laws in US states at repeal of prohibition 
often forbid sale of ‘liquor by the drink’, since at that time the ‘old-time saloon’ was 
defined as the seat of most alcohol problems. But when ‘liquor by the drink’ was 
finally allowed in North Carolina, no effect on alcohol-related harm statistics could be 
detected (Blose and Holder, 1987). On the other hand, Finnish authorities in the 1970s 
presumed that drinking in a bar or restaurant would be more restrained than drinking 
at home. But in fact, Partanen (1975) found that the empirical results in Helsinki were 
the opposite: ‘people do not drink any more at home than in a restaurant, but they do it 
in a more leisurely manner, which seems to lead to a lower degree of intoxication’. The 
issue of the harm associated with specific circumstances of use should be treated as an 
empirical question rather than a matter of ‘expert knowledge’.
What about the impact of the European single market and of trade 
agreements and disputes?
The prohibition on cannabis sales under the international drug control regime is 
presumably primarily responsible for the fact that there have been so far no challenges 
to any legislation that discriminates, for instance, between cannabis grown in the country 
and imported cannabis. Such challenges have been a regular occurrence for both 
tobacco and alcohol, and both the single market mechanisms of the European Union 
and the trade agreements administered by the World Trade Organisation have created 
substantial difficulties for alcohol and tobacco control regimes (e.g., Room and West, 
1998; Taylor et al., 2000). The new Framework Convention on Tobacco Control may 
help to remedy this situation, but the issue of whether it overrides trade agreements 
is not settled (Room, 2006). It would thus be wise for any move to legalise cannabis, 
however restrictive the regulations, to take into account the need to exempt hazardous 
substances from coverage under trade agreements and disputes.
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Conclusion
Although the literatures have their limits, studies of the impact of tobacco and alcohol 
policies are much more numerous and cover a broader territory than the equivalent 
studies for cannabis. In the absence of formal studies, estimation of the impact of laws 
and policies remains a matter for ‘expert knowledge’, although it is clear from the 
alcohol and tobacco fields, as well as from medical and other research, that expert 
knowledge based only on general principles or practical experience is often wrong. Any 
government that is serious about making laws and policy that have specific intended 
effects needs to build funding into any policy initiative for a scientific evaluation of its 
actual effects, both intended and otherwise.
The alcohol and tobacco research findings suggest some general conclusions about 
the relative strength of different prevention and policy strategies. As with cannabis, it is 
difficult to show lasting effects from public information campaigns and school education 
on tobacco and alcohol. On the other hand, laws which channel rather than forbid 
use — for instance, laws against drink-driving — have been shown to be effective. 
In general, the findings in both the alcohol and the tobacco literatures underline 
the power of regulatory approaches, including taxation, in limiting the harm from 
psychoactive substances. Such regulations are more easily and effectively applied where 
there is a legal market, since in that case there are licensed actors in the market who 
have something to lose by having their licences suspended or taken away. From this 
perspective, the state ties one hand behind its back with a prohibition regime, since its 
ability to control the market is greatly restricted.
On the other hand, it must be acknowledged that Europe has serious health and social 
problems from both tobacco and alcohol. In both areas, the European Union is now 
taking some steps to assist national and local governments in reducing the levels of 
problems. But a clear difficulty in this effort, both at EU and national levels, is the 
entrenched political power of vested economic interests in maintaining the size of the 
alcohol and tobacco markets. Any shift towards regulatory regimes for cannabis would 
be wise to take account of this, and to build into cannabis policies insulation from the 
potential influence of market forces and interests.
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Editorial postscript
This chapter focuses deliberately on experiences with regulating alcohol and tobacco. It 
does not include crystal gazing for regulation of legalised cannabis. In the production of 
the monograph, some reviewers felt that some more information on specific regulatory 
controls on cannabis was required. The chapter, however, remains useful in drawing 
attention to the many ‘unknowns’ faced when regulating psychoactive substances. For 
illicit drugs in general, economic analysis of market size is relatively immature, relies 
on broad assumptions and triangulation of diverse datasets (seizures, prevalence, retail 
prices, arrests, potency, etc.), and usually implies a large margin for error. So significant 
preparatory work would need to be done before regulatory models could be seriously 
considered for cannabis. At this point, it is premature to discuss topics such as product 
certification and licensing, feasibility studies, econometric analysis, market sizing, 
regulatory standards, fiscal forecasting, seasonality, etc. with any degree of certainty. 
While some exploratory work has been done on market sizing in the EU, estimates to 
date remain problematic. In particular, regulation would need to respond to findings 
that home-grown self-supply and informal supply ‘among friends’ make up a substantial 
amount of the market in EU countries (see Legget and Pietschmann, this monograph) 
(Table 3).
In terms of further reading on economic controls of cannabis in a (hypothetical) 
regulated market, the subject has recently experienced a revival in interest. This is true 
both of economic and statistical journals, as well as in the usual drugs and public health 
journals. As a basic introduction, the difficulties of drug market sizing formed the subject 
of a chapter in the UNODC’s World Drug Report 2005 (UNODC, 2005). Specific 
studies on cannabis are generally based on patterns that follow the decriminalisation 
of cannabis use. Specific studies include those in Australia (Clements and Zhao, 2005), 
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British Columbia (Easton, 2004) and Massachusetts (Miron, 2003). In Europe, while a 
regulated cannabis market is frequently a subject of lobbyists’ pamphlets (e.g. Holtzer, 
2004; Atha, 2004), policy-oriented study has either been restricted to domestic market 
profiling (Bramley-Harker, 2001; Pudney, 2004) or has favoured the broad-brush 
analysis of illicit drugs in general (Clark, 2003; Bretteville-Jensen, 2006). A recent study 
in France (Ben Lakhdar, 2007) provides a useful exploration of how the French cannabis 
market is structured, in terms of volume and values. Such quantitative study is rare in 
Europe, yet would contribute greatly to our understanding of the economics of cannabis.
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Setting the context
A European monograph on cannabis would not be complete without a chapter on Dutch 
‘coffee shops’. ‘Coffee shop’ in the Dutch context is a euphemism for cafés where, since 
1976, the sale and consumption of cannabis has been tolerated.
This chapter provides a number of surprising insights on the coffee shop phenomenon, 
from the leading Dutch authority on the subject. The Netherlands has relatively low 
prevalence of cannabis use (see Monshouwer et al., this monograph), despite the 
proximity of retail outlets. The 737 coffee shops (2004) are also found in a small 
number of towns, and their numbers have dwindled as municipalities have sought to 
tighten their licensing. The chapter also describes a number of features of coffee shops: 
the AHOJ-G operating restrictions, under which coffee shops operate; the challenges in 
enforcement of ensuring a limited supply of 500 g on the premises (1); the ‘back door 
problem’ and controlling links with wider trafficking and crime. Indeed, beyond such 
retail outlets, the Netherlands is a wholesale hub in the trafficking of Moroccan cannabis 
resin across northern Europe (see Gamella, this monograph).
Coffee shops are controversial, both within the Netherlands and in the international 
context. This chapter remains focused on the domestic situation in the Netherlands: 
coffee shops and their impact on Dutch drug use patterns. However, coffee shops also 
(1) This problem has become known as ‘the back door’ problem in the Netherlands. A recent case 
in the town of Terneuzen highlights the problem. A police check of the coffee shop Checkpoint in 
June 2007 found over 5 kg of cannabis on the premises and over 90 kg in a nearby warehouse 
(www.hvzeeland.nl/nieuws.php?id=5542).
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Table 1: Dutch coffee shops at a glance
Number 
of coffee 
shops in the 
Netherlands
Coffee shop 
density (in the 
103 localities 
with coffee 
shops present)
Number 
of people 
employed at 
coffee shops
Estimated size 
of domestic 
cannabis 
market
Estimated 
size of non-
domestic 
cannabis 
market
Average 
estimated 
revenue 
per coffee 
shop from 
cannabis 
sales
737 (2004) One coffee 
shop per 
28 715 
inhabitants. 
Highest density: 
Amsterdam 
(one coffee 
shop per 2 969 
inhabitants)
3 400 EUR 211–283 
million (32–43 
tonnes)
EUR 43–88 
million 
(6.6–13.3 
tonnes)
EUR 280 000– 
380 000
Sources: Bieleman et al. (2005), Bieleman and Snippe (2006).
(2) This was one of the broad conclusions of the Cannabis zonder coffee shop report.
play an interesting role in cross-border supply: annual sales volumes to non-Dutch 
buyers are estimated at 6.6 to 13.3 tonnes (Bieleman and Snippe, 2006). Cross-border 
drugs tourism has led to considerable and repeated criticism of the Dutch coffee shop 
policy, particularly among neighbouring countries. A counter argument of note is that 
cannabis prevalence among young people in the Netherlands is lower than many of its 
neighbouring countries, and that most cannabis consumed in these countries will not 
have been purchased at Dutch coffee shops (Table 1).
Perhaps most significantly, Dutch coffee shops play a symbolic role as a paradigm of 
liberal cannabis policies. In addition to their common appearance in academic studies 
of drug policy, they have become associated in popular culture with the liberal attitudes 
of the Netherlands. The coffee shops themselves do little to prevent such notoriety, 
and play a role in cannabis advocacy and the seed distribution businesses operating 
from the Netherlands. So, although in the Netherlands discussions in recent years have 
focused on the inevitability of supply — i.e. underground dealers will supply the demand 
which is currently served by coffee shops (2) — Dutch drug policy is likely to remain a 
controversial subject.
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An open front door: the coffee 
shop phenomenon in the 
Netherlands
Dirk Korf
Introduction
Although cannabis is still an illicit drug in the Netherlands, herbal cannabis and 
cannabis resin are openly sold in so-called ‘coffee shops’. In general, coffee shops are 
café-like places, although some function more as a store where one can buy, but not 
use cannabis. In this paper we first describe the process of decriminalisation of cannabis 
and the evolution of coffee shops in the Netherlands. Then we discuss long-term trends 
in cannabis use in the Netherlands, both among the general population and among 
students at secondary schools, followed by exploring some problems regarding the 
causal relationship between coffee shops and trends in cannabis use in the Netherlands. 
Next, we examine the role of coffee shops relative to other cannabis sellers at retail 
level. Finally, we discuss recent developments regarding the supply of coffee shops.
From underground market to coffee shops
The Netherlands was one of the first countries where cannabis became the object of 
statutory regulation. The import and export of cannabis was introduced into the Opium 
Act in 1928. Possession, manufacture and sale became criminal offences in 1953. 
Statutory decriminalisation of cannabis took place in 1976. De facto decriminalisation, 
however, set in somewhat earlier.
With regard to the cannabis retail market in the Netherlands, four phases can be 
distinguished.
Phase 1
During the first stage, the 1960s and early 1970s, the Dutch cannabis retail market 
was a predominantly underground market. Cannabis was bought and consumed in a 
subcultural environment, which became known as a youth counterculture.
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Phase 2
The second stage was ushered in when Dutch authorities began to tolerate so-called 
‘house dealers’ in youth centres. Experiments with this approach were formalised 
through statutory decriminalisation in the revised Opium Act of 1976. This law 
distinguishes between two types of drugs: on the one hand, hemp products (Schedule 
II drugs), and on the other hand, drugs that represent an ‘unacceptable’ risk (Schedule 
I drugs, such as heroin and cocaine). The law also differentiates on the basis of the 
nature of the offence. For example, drug use is not an offence, possession of up to 30 
grams of cannabis is a petty offence or misdemeanour, while possession of more than 
30 grams is a criminal offence.
Official national Guidelines for Investigation and Prosecution came into force in 1979. 
These guidelines are founded on the expediency principle, a discretionary principle in 
Dutch penal law which allows authorities to refrain from prosecution without first asking 
permission of the courts. Basically, the expediency principle can be applied in two ways. 
The first favours prosecution: prosecution is a default response, but is waived if there 
are good reasons to do so (‘prosecution, unless ...’). This case-directed approach was 
common in the Netherlands until the end of the 1960s.
The second approach applies the expediency principle differently: prosecution takes 
place only if it is expedient and serves the public interest (‘no prosection, unless ...’). 
Society-wide prosecution of cannabis offences was believed not to serve the public 
interest: it would stigmatise many young people and socially isolate them from society. 
According to the 1979 national guidelines, the retail sale of cannabis to consumers 
would be tolerated, provided the house dealer met the so-called AHOJ-G criteria. These 
criteria are:
no overt advertising (•	 affichering);
no hard drugs;•	
no nuisance (•	 overlast);
no underage clientele (•	 jongeren); and
no large quantities (•	 grote hoeveelheden).
Small-scale dealing of cannabis thus remained an offence from a legal viewpoint, but 
under certain conditions would not be prosecuted. It should be acknowledged that this 
legal tolerance was initiated before the Opium Act was revised in 1976, and became 
more visible after 1979 with the entry into force of the national guidelines and AHOJ-G 
criteria. So by the end of the 1970s, the house dealer had become a formidable 
competitor to the street dealer.
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Phase 3
In the third stage, cannabis resin and herbal cannabis were sold predominantly in 
café-like places, which have become known as ‘coffee shops’. Although the government 
never intended this development, through case law it was decided that coffee shops 
were to be tolerated according to the same criteria as house dealers. During the 1980s 
coffee shops captured an increasingly large share of the Dutch retail cannabis market 
(Jansen, 1991).
Phase 4
The fourth stage began in the mid-1990s, when legislative onus was placed on curbing 
the number of coffee shops. Since then, the number of coffee shops has steeply declined 
from about 1 500 to 813 in 2000 and further to 737 in 2004 (Bieleman and Goeree, 
2000; Bieleman et al., 2005). Moreover, in 1996 local communities received the 
opportunity to decide whether or not they would allow coffee shops in their municipality. 
To date, 77 % of the 483 communities have decided not to allow coffee shops at all. 
Consequently, they can close down coffee shops even if they do not violate the AHOJ-G 
criteria. In addition, the minimum age for visitors was increased from 16 to 18 years.
So, coffee shops are not distributed evenly over the country. Over half (52 %) of all 
coffee shops are located in the five largest communities (> 200 000 inhabitants), while 
only 1 % can be found in communities with less than 20 000 inhabitants. Although only 
5 % of the national population lives in Amsterdam, the city is the home of one-third of 
all coffee shops in the country.
Trends in cannabis use
From an analysis of available data on the prevalence of cannabis use between the 
late 1960s and the late 1990s, we concluded that there was little room to doubt that 
cannabis use in the Netherlands spread rapidly around 1970 (Korf et al., 2002). Most 
probably, cannabis use among youths in the Netherlands evolved in two waves, with a 
first peak around 1970, a low during the late 1970s and early 1980s, and a second 
peak in the mid- to late-1990s.
Prior to the Second World War, cannabis use in the Netherlands had hardly been 
heard of, and this did not change much in subsequent years. The 1950s witnessed the 
introduction of cannabis in the Netherlands, when herbal cannabis was used by small 
groups of jazz musicians and other artists who had learned to use it while abroad, as 
well as foreign seamen and Germany-based US military personnel, in particular in 
Amsterdam (Cohen, 1975; de Kort and Korf, 1992).
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In the course of the 1960s, cannabis use in the Netherlands rapidly gained popularity. 
An increasing number of adolescents began smoking it, but not until the end of the 
decade did a cannabis smokers’ subculture emerge. Cannabis spread significantly in 
the wake of the hippie movement, and smoking cannabis at the national monument 
in Dam Square or in the Vondelpark in Amsterdam became a staple of a burgeoning 
international youth sub-culture (Leuw, 1973).
The first indication of the rapid growth in the popularity of cannabis towards the end 
of the 1960s can be found in school surveys. In 1969 as many as 9 % of the students 
in the final form at secondary school reported having used cannabis at least once. Two 
years later this percentage had doubled to 18 %. Yet rates did not continue to rise in 
subsequent years. In 1973, lifetime prevalence was again put at 18 % (see Korf, 1995). 
It was more than a decade before the next national school survey was carried out, in 
1984. This survey yielded a much lower lifetime prevalence of cannabis use (5 %). To a 
considerable degree, however, the lower rate can be explained by inconsistencies in the 
samples. If comparable age groups are examined, the difference between 1973 and 
1984 rates is much smaller: 18 % ever use of cannabis for students with a mean age of 
17.5 years in 1973; 12 % for students 17 years and older in 1984 (Plomp et al., 1990).
Unfortunately, these school surveys did not address nationally representative samples. 
Since 1988 nationally representative surveys have been conducted on the extent to which 
secondary school students aged 12 and older have experience with alcohol, tobacco, 
drugs and gambling. From 1988 to 1996, cannabis rates among students rose, but 
stabilised in the late 1990s, followed by a drop (Monshouwer et al., 2004). (Figure 1).
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Figure 1: Cannabis use among secondary school pupils, aged 12 years (1988–2003)
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General population surveys are another indicator of trends in cannabis use. Between 
1970 and 1991 six national household surveys have been conducted in the Netherlands 
(see Korf, 1995). They reveal a growing percentage of people that report having used 
cannabis at least once in their lives: from 2–3 % in 1970, to 6–10 % during the 1980s 
and to 12 % in 1991. In 1997, a new series of general population studies was initiated, 
using large representative samples of people aged 12 years and over. In addition to 
figures on lifetime use of — amongst others — cannabis, this National Prevalence Study 
also includes data on current use (Abraham et al., 1999). According to the 1997 data, 
the vast majority have never tried cannabis and only one in six respondents have ever 
used cannabis (15.6 %). One in 40 respondents (2.5 %) used cannabis in the month prior 
to the interview (current use). The second National Prevalence Study, conducted in 2001, 
revealed a lifetime prevalence rate of 17 % and 3 % for last month use (Abraham et al., 
2002). A different age group (15–64 years) was studied in the third National Prevalence 
Study (2005/2006). Between 1997 and 2005–2006, trend analysis showed: a decrease 
in last year prevalence in the age group 15–24 years; an increase in lifetime, last year 
and last month prevalence among the age group 25–44 years; and an increase in last 
month prevalence in the age group 45–64 years (Rodenburg et al., 2007).
Cannabis use is not distributed evenly across the Netherlands. Cannabis use is more 
prevalent in urban than in rural areas. Amsterdam tops the list with respect to ever use 
and current use. Such an uneven geographical spread of cannabis use is not only typical 
for the Netherlands, but can also be found in other countries (Partanen and Metso, 
1999). Since 1987, five surveys have been conducted among the general population of 
Amsterdam aged 12 years and over, applying a similar methodology as in the National 
Prevalence Study. Prevalence rates increased (Abraham et al., 2003). To a large extent, 
this increase reflects a generation effect. This generation effect also helps to explain why 
rates for ever use increase much more strongly than those for current use (Figure 2). The 
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Figure 2: Trend in cannabis use, general population, Amsterdam, 12+ years (1987–2001)
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majority of the adult ever users in Amsterdam have stopped using cannabis. While many 
young ever users are currently taking cannabis, few older ones continue to do so. The 
mean age of cannabis use in Amsterdam remained stable at around 20 years. For the 
age cohort of 25–29 years, lifetime use first increased in the 1990s and then stabilised, 
while current use remained quite stable during the period (Figure 3).
Decriminalisation and cannabis use
During the transition from the first to the second phase in Dutch cannabis policy, the 
many underground selling points became consolidated into a more limited number 
of formalised sales outlets that were publicly accessible yet shielded from public view. 
During the third phase, availability increased markedly in numerous coffee shops. More 
recently, availability may have decreased because of the declining number of coffee 
shops. It is striking that the trend in cannabis use among youth in the Netherlands 
parallels our four stages in the availability of cannabis. The number of adolescent 
cannabis users peaked when cannabis was distributed through an underground market 
during the late 1960s and early 1970s, when the drug was available through many 
small-scale retailers (street dealers, in homes and bars). Adolescent use then decreased 
as house dealers superseded the underground market during the 1970s. It increased 
again in the 1980s after coffee shops took over the sale of cannabis. And it stabilised 
or slightly decreased at the end of the 1990s, when the number of coffee shops was 
reduced.
Rising or falling cannabis consumption need not be the unequivocal result of 
decriminalisation or criminalisation. In order to study the possible link between 
decriminalisation and the evolution of Dutch cannabis use, first we need to analyse the 
Year
Ever
Last four weeks
199719941987
C
an
na
bi
s 
us
e 
(%
)
1990
50
40
60
0
20
10
2001
30
Figure 3: Trend in cannabis use, general population, Amsterdam, 25–29 years 
(1987–2001)
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prevailing rates of cannabis use both before and after decriminalisation. Moreover, 
longitudinal trends in cannabis use in the Netherlands can only properly be ascribed to 
decriminalisation when it is made plausible that they are causally related.
In line with MacCoun and Reuter (1997), reasoning by analogy might be helpful in 
getting closer to an understanding of the nature of the link between decriminalisation 
and cannabis prevalence rates in the Netherlands. How do the Dutch trends in the 
cannabis case compare to those in other Western nations? Such a question is not easy 
to answer, mainly because there are few countries where cannabis consumption has 
been consistently and systematically recorded over the years.
The USA has a relatively long tradition of surveys on drug use and the American figures 
consistently appear to be higher than those in the Netherlands (Plomp et al., 1990; 
NDM, 2006). Clearly the USA, as the prototype of a prohibitionist approach towards 
cannabis, reports higher cannabis consumption than the Netherlands, the prototype 
of anti-prohibitionism. Marijuana use among youth in the USA also evolved in waves, 
with a peak during the late 1970s, a decline in the 1980s, a rise in the 1990s and 
then stabilisation. Harrison (1997) concludes that such a wave-like development can 
be understood as a verification of Musto’s more general model on trends in drug use 
(Musto, 1987). In addition, structural factors such as the post-Second World War baby 
boom and drug education (affecting health risk perception) might help to explain the 
development in marijuana use in the USA (Harrison, 1997). Other European countries 
have also reported a wave-like trend in cannabis use (Kraus, 1997). For example, 
cannabis use spread rapidly in (West) Germany toward the end of the 1960s, followed 
by stabilisation and decline in the early 1970s and then an increase in the 1980s 
(Reuband, 1992; Kraus, 1997). The rising use of cannabis in Germany continued in the 
1990s (Kraus and Bauernfeind, 1998; Kraus et al., 1998).
Cannabis use in some other countries with a prohibitionist approach towards cannabis 
— Sweden in particular — is substantially lower than in the Netherlands. Although this 
has been used as supporting evidence that prohibition deters use, the argument does 
not hold when seen in relation to data from other prohibitionist countries, for example, 
the USA, and elsewhere in Europe. From the available data from general population 
surveys in 10 Member States of the EU (which are not absolutely comparable), the 
EMCDDA concluded that the level of cannabis use varies strongly within the EU 
(EMCDDA, Annual Report 2001); from 9.7 % in Finland to 25 % in the UK (England 
and Wales). The Netherlands is placed somewhere in the middle (and this would 
most probably be lower if its level of urbanisation were taken into account). From a 
comparison of data from general population surveys in Germany (Kraus et al., 1998) 
and the UK (Ramsay and Partridge, 1999), we concluded that adolescents and young 
adults in these countries have showed a similar trend to that in the Netherlands: 
increasing cannabis use from the late 1980s onwards (Korf et al., 2002).
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So, trends in cannabis use in the Netherlands appeared to run along similar lines to 
those in other European countries, and Dutch figures on cannabis use between the 
late 1960s and the late 1990s were not out of line with those from countries that did 
not decriminalise cannabis. Over time, prevalence of cannabis use shows a wave-like 
trend in many countries, including the Netherlands. This supports Reuband’s earlier 
conclusion that cannabis use trends evolve relatively independently from drug policy, 
and that countries with a ‘liberal’ cannabis policy do not have higher or lower rates than 
countries with a more repressive policy (Reuband, 1995).
From the data discussed so far, it appears unlikely that decriminalisation of cannabis 
causes an increase in cannabis use. However, before we draw such a final conclusion, 
we need to address three issues. First, we have compared Dutch prevalence data with 
those from countries that did not officially decriminalise cannabis. However, the actual 
enforcement of cannabis offences may be less strict than the law suggests. Second, 
at the level of the ‘dependent variable’, the question is ‘what is the most appropriate 
indicator for cannabis use?’ Third, we must take into account the accessibility of coffee 
shops: as mentioned, there is a minimum age for visiting coffee shops.
How do drug laws relate to the actual enforcement of cannabis offences? The 
Netherlands has separate schedules for cannabis and other illicit drugs. The use of 
cannabis is not illegal, and penalties for trafficking are higher than for possession. 
In this respect, the Dutch drug law is not unique. There are other EU countries with 
differential drug laws (two or more schedules), where cannabis use is not illegal, and 
where the drug law sets higher penalties for trafficking than possession (see Ballotta 
et al., this monograph; Korf, 1995; Leroy, 1992). Most EU countries have penalties 
for cannabis possession, ranging from a fine to incarceration (EMCDDA ELDD, 2001). 
According to Kilmer (2002), in practice most arrests for cannabis possession in EU 
Member States appear to only lead to a fine, while few data are available on the levels 
of these fines and about what happens when they are not paid. So Kilmer examined 
actual cannabis law activities within a number of Western countries, by comparing police 
capacity, enforcement of and punishment for cannabis possession laws. He concluded 
that the probability of cannabis users being arrested for cannabis possession is generally 
between 2 and 3 %. Probability of arrest was fairly similar (2–3 %) in EU countries with 
relatively low cannabis prevalence rates (e.g. Sweden: arrest rate, 2.4 % in 1997) and 
those with higher rates (e.g. United Kingdom: arrest rate, 2.1 % in 1996 and 2.9 % in 
1998). Consequently, formal criminalisation of cannabis possession rarely leads to 
actual criminalisation in practice. So it appears plausible that current cannabis laws in 
EU Member States, as well as other Western countries, have little deterrent effect on 
cannabis use.
It is not uncommon to discuss the effects of decriminalisation of cannabis in the 
Netherlands on the basis of data from school surveys. The analysis by MacCoun and 
An open front door: the coffee shop phenomenon in the Netherlands
148
Reuter (1997) was largely based on data from school surveys, and we included such 
figures in our analysis earlier in this chapter as well. Unfortunately, this is not without 
problems. In 1996 the minimum age for coffee shop visitors was raised from 16 to 18 
years. Consequently, minors are not allowed to buy and use cannabis in coffee shops, 
which means that prevalence rates of cannabis use among youth below the age of 18 
cannot be defined as valid indicators in the analysis of the effects of decriminalisation.
In a secondary analysis of national school survey data from 1992, 1996 and 1999 we 
looked at how the use of cannabis evolved amongst adolescents (Korf et al., 2001). We 
faced two difficulties. First, school populations are constantly changing, partly due to an 
ongoing rise in percentages of ethnic minority students. Second, samples do not always 
precisely reflect school populations. Statistical bias can be corrected to an extent by 
weighting, but that still does not ensure full representativeness. Both the real changes in 
the student population and the sampling errors could potentially damage the reliability 
of the cannabis use statistics. We allowed for this as much as possible by performing 
logistic regression analysis. This enabled us to detect any changes in the use of cannabis 
that were not due to differential background characteristics (gender, ethnicity, school 
type and urbanisation) in the samples. Analysis revealed a break in the previous upward 
trend in current cannabis use among 16–17-year-olds after the raising of the age limit 
for coffee shops in 1996. Cannabis use stabilised between 1996 and 1999. In addition, 
the analysis indicated a shift in supply from coffee shops to other sources. Current 
16–17-year-old cannabis users among the students in 1999 bought their cannabis less 
often in coffee shops (25.7 %) than those from 1996 (45.2 %). Logistic regression led to 
the same conclusion: the 1999 students showed a greater likelihood of buying cannabis 
outside coffee shops (an odds ratio of 0.76).
These figures are a strong indication that the higher age limit at coffee shops has indeed 
resulted in a reduction of cannabis sales to adolescents in coffee shops, in favour of 
more informal supply through friends (from 47.6 % in 1996 to 66.5 % in 1999). These 
figures are somewhat problematic as what has been reported as buying in a coffee 
shop could also mean that the respondents had someone else buy the drug there. 
Nevertheless, the data strongly suggest that raising the minimum age for coffee shops 
had an effect on buying behaviour. According to the 2003 national school survey, 
most current cannabis users among students aged 18 years buy their cannabis also or 
exclusively in coffee shops, substantially more often than younger users (Monshouwer et 
al., 2004). It is tempting to interpret the nationwide stabilisation in adolescent cannabis 
use as a result of raising the age limit. Adolescents are now more likely to obtain 
cannabis from friends and acquaintances instead of from coffee shops. Thus, at the user 
level we see an apparent displacement of the cannabis market (Korf et al., 2001).
In conclusion, trends in the lifetime prevalence of cannabis use in the Netherlands 
developed in parallel to changes in cannabis policy. Alongside the rapid growth in 
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the number of coffee shops, we observed a significant increase in prevalence rates. 
However, this does not automatically support the conclusion that decriminalisation has 
led to an increase in cannabis consumption. First of all, lifetime prevalence is often not 
an adequate indicator since it largely reflects a ‘generation effect’. Current (last month) 
use seems to be a better indicator, although from the perspective of harm reduction it 
might be argued that ‘problem use’ is an even better one. Unfortunately, there is no 
standardised indicator for problematic cannabis use.
Reasoning by analogy through cross-national comparison partly leads to conclusions 
other than MacCoun and Reuter’s (1997). In particular, their conclusion that commercial 
access — through coffee shops — is associated with growth in cannabis use has to be 
questioned. Their study largely focused on data from the USA and Nordic countries 
(Denmark and Norway). Within a Western European context, prevalence rates in 
the Nordic countries are generally rather low, with the exception of Denmark, which 
combines relatively high lifetime figures with low current use. Comparison with other 
EU countries shows striking similarities with Dutch figures on current cannabis use. 
In addition, neighbour countries, as well as the USA, report similar trends in current 
cannabis use over time. Cannabis use in neighbour countries also shows a wave-like 
development, so it seems implausible that the trends in cannabis use in the Netherlands 
were causally related to Dutch cannabis policy. It seems more likely that the parallel 
development of cannabis use with stages in the decriminalisation process in the 
Netherlands was accidental, and that trends in cannabis use were predominantly 
affected by other factors that were not unique to the Netherlands.
Most probably, these factors relate to general youth trends that make cannabis more 
or less fashionable and acceptable. We were able to include more recent figures on 
cannabis than MacCoun and Reuter, and these data show that cannabis use stabilised 
among Dutch youth in the late 1990s. At first glance, this seems to be a result of raising 
the minimum age for access to coffee shops from 16 to 18 years. However, informal 
networks of friends appear to have quickly taken over the role of coffee shops as retail 
suppliers of cannabis. Most probably, the role of such informal networks is similar 
to those in other European countries. This leads to the conclusion that regulating the 
cannabis market through law enforcement has only a marginal, if any, effect on the 
level of cannabis consumption.
The restricted role of coffee shops
As has been mentioned, most communities in the Netherlands do not have coffee 
shops at all, in particular smaller towns and villages. In 2003–2004 we conducted a 
study on the ‘non-tolerated’ sale of cannabis in the Netherlands (Korf et al., 2004). By 
non-tolerated cannabis dealers, we meant the ones outside the officially tolerated coffee 
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shops. The study focused on the retail trade and not on the coffee shop suppliers (the 
back door) or the middle and higher levels of the cannabis market.
The study was conducted in 10 municipalities with more than 40 000 inhabitants, that 
were geographically spread throughout the country and different as regards their size 
and coffee shop density (number of coffee shops per 10 000 residents). Eight of the 
municipalities had one or more coffee shops and the other two did not have any official 
coffee shop at all. Local experts were interviewed in all 10 communities, a survey 
was made among approximately 800 current cannabis users (not recruited in coffee 
shops) in seven communities and an ethnographic field study was conducted in five 
communities.
In all the municipalities we studied, there was a non-tolerated cannabis market at the 
retail level. We distinguished two main categories: fixed and mobile sale points. The 
fixed non-tolerated sales points can be divided into home dealers and under-the-counter 
dealers primarily at clubs or pubs. The mobile non-tolerated sales points can be divided 
into home delivery after cannabis is ordered by telephone (mobile phone dealers) and 
street sales in the street and at spots where people hang out (street dealers). In addition, 
there are home growers, who can be either fixed or mobile dealers.
We found that, whether or not municipalities have coffee shops, the non-tolerated sale 
of cannabis is widespread. At the retail level, the non-tolerated cannabis market was 
very similar in all the municipalities in the study, and the same sales patterns were found 
in virtually all municipalities. In the municipalities with officially tolerated coffee shops, 
an estimate of approximately 70 % of the local cannabis sales went directly through the 
coffee shops. The higher the coffee shop density, the greater their percentage of the 
local sales. In municipalities with no coffee shops or a low coffee shop density, users 
most frequently bought cannabis somewhere else, as well as in a coffee shop.
There are various reasons why non-tolerated cannabis dealers also operate in 
municipalities with coffee shops. The major reasons are the geographic distribution 
of the coffee shops, their opening hours and the minimum age they adhere to. In 
particular, it is the mobile phone dealers and home dealers who take advantage of 
the geographic gaps in the cannabis market and are mainly active in districts where 
coffee shops are rare or non-existent. Additionally, coffee shops are not open 24 hours 
a day and the non-tolerated dealers explicitly take advantage of this by being easy to 
reach customers at times when the coffee shops are closed. For minors, the minimum 
age at coffee shops is an important reason to have cannabis resin or herbal cannabis 
delivered, or to buy it on the street or from a home dealer. In addition, non-tolerated 
dealers can serve as an attractive alternative for coffee shops because users can buy 
larger quantities of cannabis, and sometimes the cannabis is sold more cheaply.
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The ‘back door’ of coffee shops: diverging policy 
options
Originally, most cannabis used in the Netherlands was cannabis resin, and until the 
mid-1980s most cannabis was imported. Due to strong improvement in cultivation 
techniques, domestically grown herbal cannabis became more and more popular. 
In the early 1990s approximately 50 % of the cannabis used in the Netherlands was 
domestically grown (Boekhoorn et al., 1995). In the second half of the 1990s, the 
popularity of domestically cultivated herbal cannabis further increased. According 
to a study among experienced cannabis users by Cohen and Sas (1998), about half 
preferred herbal cannabis, mostly ‘nederwiet’, one-quarter preferred cannabis resin and 
another quarter had no preference. In 2001, from a survey among coffee shop visitors 
in Amsterdam, it was concluded that two-thirds preferred herbal cannabis to cannabis 
resin (Korf et al., 2002).
Today, herbal cannabis is the product sold most often in coffee shops. Mostly this 
is so-called ‘nederwiet’, or home-grown herbal cannabis. In practice, this kind of 
herbal cannabis is grown indoors and only a small proportion is imported herb grown 
outdoors. Most cannabis resin is imported, predominantly from Morocco (see Gamella, 
this monograph) and only a very small proportion of the resin sold in coffee shops stems 
from indoor cultivation in the Netherlands.
The THC content of cannabis as sold in coffee shops in the Netherlands has been 
systematically monitored by the Trimbos Institute since 1999. It might be debated to 
what extent these figures are correct as there is dispute among researchers over what 
is the most appropriate method to measure THC concentrations (King et al., 2005), 
and perhaps the Dutch method generates relatively high concentrations. Nevertheless, 
while consistently applying the same laboratory techniques, the monitoring system is an 
adequate instrument to analyse trends in purity over time. THC concentrations in sold 
‘nederwiet’ more than doubled between 1999–2000 and 2003–2004, from an average 
of 8.6 % to 20.4 %. In 2004–2005 the average concentration dropped to 17.7 %, and 
17.5 % in 2005–2006, which was comparable to 2002–2003. Imported hashish showed 
an increase in THC concentration from 11–12 % in the first two years to 17–18 % in 
2002, and then remained stable. THC concentrations in imported herbal cannabis 
remained quite stable at around 6 % (Pijlman et al., 2005; Niesink et al., 2006).
The supply of coffee shops is commonly known in the Netherlands as ‘the back door’, 
even though in reality both suppliers and customers use the same door to enter the 
coffee shop. While the sale of cannabis to consumers is tolerated in coffee shops, the 
supply remains illegal and is subject to law enforcement. Although a maximum of 
500 grams ‘in stock’ is tolerated, coffee shops can still be prosecuted for sourcing the 
cannabis into their locality. Moreover, cultivation of five plants or more per person is 
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illegal. Police and the judicial authorities have increased their actions against herbal 
cannabis growers. Between 2000 and 2003, the number of cases brought to the public 
prosecutor for cannabis offences increased by more than 40 % (from 4 324 to 6 156). A 
growing number of cannabis plantations have been raided and in both 2005 and 2006 
approximately 6 000 herbal cannabis cultivation sites were dismantled, and about 2.5 
million plants confiscated and destroyed per year (Wouters et al., 2007).
When the Dutch authorities decided to decriminalise cannabis and to tolerate the retail 
sale of cannabis to consumers, they did not, and probably could not, envision that this 
would lead to the coffee shop phenomenon. The strong growth of the number of coffee 
shops — that were never intended to exist — meant that the authorities were confronted 
with a new problem. In order to cap this growth, the national government decided 
to give local communities legal instruments to regulate the number of coffee shops, 
including the option to not allow coffee shops at all. Regarding the supply side of the 
cannabis market, enforcement has focused on large-scale dealers. Interestingly, herbal 
cannabis has taken over from the once-dominant resin. While cannabis resin typically 
was, and still is, imported, herbal cannabis is today mostly domestically cultivated. 
Consequently, a shift in law enforcement can be perceived from controlling import 
to controlling cultivation within the country itself (Decorte and Boekhout van Solinge, 
2006).
While finalising this paper, two options for regulating the supply of coffee shops have 
been debated in the Netherlands. On the one hand, at a national level the Ministry of 
Justice of the previous government was a strong advocate of persistent repression of 
the illegal cultivation of cannabis in the Netherlands. On the other hand, a growing 
number of communities with coffee shops, as well as a majority in the Dutch parliament, 
have pleaded to take a further step towards decriminalisation by regulating the back 
door problem. From their perspective, the fight against international traffickers should 
be continued and intensified, while supply for the national market should become 
less profitable for criminals by allowing the cultivation of herbal cannabis under strict 
conditions for coffee shops only. Just before Christmas 2005, the Ministry of Justice 
gave up its resistance and declared to no longer block an experiment with regulated 
cultivation of herbal cannabis. With the new national government, installed early in 
2007, the future of the supply of coffee shops is an open question.
Recent developments
In 2007, the national guideline that coffee shops are not allowed to sell alcohol has 
finally been implemented in Amsterdam. As a result, most of the approximately 40 
coffee shops in Amsterdam that were also serving alcohol, have decided to stop selling 
cannabis and consequently lost their coffee shop licence.
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Also, there is a trend to be more strict on allowing coffee shops in the proximity of 
schools. The city council of Rotterdam has been the first to decide to close down 
approximately 27 of a total of 62 coffee shops, mostly in the inner city. It is to be 
expected that coffee shop owners will continue to protest in the courts against this 
decision, in particular because the city of Rotterdam has declared that the coffee shops 
to be closed will neither receive any financial compensation, nor be given a licence for a 
coffee shop elsewhere in Rotterdam.
As part of the plans of the national government to ban tobacco smoking from 
restaurants and cafes in 2008, a vivid discussion continues on the question of whether 
coffee shops should become totally smoke-free, be allowed to have a separate smoking 
facility, or will be exempt from the general anti-smoking policy.
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Chapter 10
Cannabis policy: tightening the 
ties in Denmark
Keywords: cannabis – crackdown – enforcement – Christiania – Copenhagen  
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Setting the context
Several chapters in this monograph have touched on the link between cannabis culture 
and social movements of the 1960s and 1970s. One of the remnants of this period is 
the alternative district of Christiania in Copenhagen, Denmark, recently described by 
Time-Life magazine as ‘Europe’s last commune’.
One of the features of Christiania was an open cannabis market known as Pusher Street. 
This chapter describes the events preceding and following the closure of Pusher Street 
in March 2004. The clashes between police and residents described here were more 
recently echoed in a series of incidents in May 2007, which again brought Christiania 
into the international limelight.
So how does Denmark look in terms of cannabis (1)? It has the highest reported lifetime 
prevalence of cannabis in the EU, at 31.3 % of the adult population (EMCDDA, 2005) 
and although recent use is also relatively high, with 20 % of 16- to 24-year-olds reported 
to have used cannabis in the last month (EMCDDA Danish Focal Point, 2004), it is not 
exceptionally high.
This chapter is written from a liberal perspective. Its arguments serve to illustrate the 
resistance law enforcement can face in any attempt to break from established tolerance. 
The chapter documents the considerable efforts made to close down a long-established 
drug market. These efforts were ultimately successful, although the author’s view 
(1) General information and analysis about the Danish drugs situation is compiled each year 
by the EMCDDA’s national focal point in its national report and country situation summary. 
See www.emcdda.europa.eu/index.cfm?nNodeID=435
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suggests that they may have been heavy-handed and not delivered the benefits intended 
in reducing cannabis use.
Others might take a different perspective. It could equally be argued that the authorities 
had demonstrated that public drug dealing was an unacceptable behaviour which would 
not be tolerated and that firm action could be effective. The extent to which longer term 
use of cannabis is influenced by police action is more difficult to assess. This debate 
is still ongoing and will not be resolved here. Nonetheless, enforcement clampdowns 
can be seen as a visible declaration that use of a drug is not socially condoned. Such 
‘denormalisation’ may have an impact in the longer term on the attitudes of young 
people to drug-taking.
Ongoing reporting of cannabis use in Denmark will tell us how current Danish drug 
strategy is affecting cannabis use and drug prevalence in general. This chapter makes 
interesting reading as it details the concerted efforts made to close down Pusher Street. 
Developments in Copenhagen underline the conclusion drawn by Ballotta et al. earlier. 
Although public perception is that attitudes to cannabis are becoming more liberal in 
Europe, there are plenty of examples where a tougher approach is observable.
Further reading
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ties in Denmark
Vibeke Asmussen
General background
Christiania
The self-declared free state of Christiania was set up by activists in 1971. It occupies 
34 hectares of military property in central Copenhagen. In 2004, Christiania had a 
population estimated at between 850 and 1 000 out of a population of over 500 000 in 
central Copenhagen. An eviction ruling from 1976 has never been enforced, enabling 
Christiania to develop over 30 years as a centre for alternative culture, crafts and art. 
As a rare survivor of hippie utopian culture — Time magazine recently called it ‘Europe’s 
last commune’ (2) — it has long played a role as great divider in Danish politics, 
simultaneously lauded by the left and damned by the right. Current developments in the 
late 2000s suggest that the free state’s days may be numbered: negotiations between 
Christiania and the government on its future status have been going on for the past 
three years (Asmussen, 2007).
Pusher Street
Parallel to its free state ideals, Christiania developed a lucrative criminal sideline, 
Pusher Street, which its website calls a ‘multi-million business’(3) for drugs. In 2004, the 
cannabis market included about 40 street stalls, attracting both a domestic clientele and 
cross-border drugs tourists, particularly from Sweden. Clients could openly buy drugs to 
take away, or could smoke ‘in situ’ in the street or in Christiania’s bars and cafés.
Although ‘hard drug’ sales were voluntarily banned from 1980, a 6 May 2003 report 
on Christiania by the Minister of Justice and the Minister of Defence documented links 
with organised crime and biker gangs. It also reported a ‘spillover’ effect of hard drugs 
being sold on the periphery of Christiania, if not actually within it (4) (EMCDDA Reitox 
Danish Focal Point Report, 2004). Regular police drugs seizures — not to mention the 
contested estimate of 20 kg per day, discussed below — suggest a high revenue business 
(2) Christopher Thompson, ‘Europe’s last commune braces for battle’, Time magazine, 23 July 2007. 
Available at: www.time.com/time/world/article/0,8599,1637000,00.html
(3) www.christiania.org, accessed February 2007.
(4) On 24 April 2005 a shootout among cannabis gangs left one dead and three injured.
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with efficient logistics, where daily deliveries were made to the point-of-sale. Moreover, 
experience with arrests of dealers over two decades revealed Pusher Street’s resilience to 
controls: points-of-sale were restaffed and replenished within hours of police action. The 
May 2003 report concluded that extraordinarily high police resources, most likely for a 
sustained duration, were needed.
While for many years Pusher Street was effectively a no-go area for uniformed police 
patrol routines, surveillance and arrests in the area intensified throughout the early 
2000s as the Ministry of Justice and the Copenhagen Metropolitan Police Force sought 
to ‘normalise’ conditions for drug dealers in line with the rest of the city (EMCDDA 
Danish Focal Point, 2004). Increased policing of Christiania was accompanied by the 
nationwide tightening in 2004 of legislative controls over cannabis in Denmark, aimed 
at curbing both dealing and personal possession of cannabis (EMCDDA ELDD, 2006).
The culmination of police actions in Pusher Street was the March 2004 operation to 
‘close’ the market and arrest its dealers. This chapter describes the nature of the police 
action in March 2004, together with the judicial process and convictions that followed 
it, as reported in the Danish press (5). It also discusses the political background to the 
government’s official policy on drugs, launched in 2003, The Fight against Drugs.
Danish drug policy 2001–2005: legal tightening
In the course of the 2000s, Denmark has experienced a tightening in drug policy — and 
cannabis policy in particular — from a liberal to a relatively repressive regime.
2001’s Law Prohibiting Visitors to Designated Places (popularly called ‘the Hash-
Club Law’) was proposed as a response to a moral panic about youths frequenting 
underground ‘hash clubs’ (6) (Asmussen and Moesby-Johansen, 2004). The new law 
enabled police to clamp down on hash clubs, and has since been reinterpreted in 2005 
to make it even easier to close down hash clubs. The number of offences that the police 
needed in order to close a hash club was reduced from 10–15 to 3–5.
2004’s Law on Euphoria-inducing Substances was revised to criminalise possession 
of cannabis. While possession of less than 10 grams of cannabis was not prosecuted 
(5) Descriptions of the arrests, trials and sentences are based on a corpus of newspaper articles published 
between March 2004 and July 2005 in three Danish newspapers: Jyllands-Posten, Berlingske Tidende 
and Politiken. A second source of information — a description of the sentences handed out — is 
taken from the Copenhagen City Court’s website (www.domstol.dk/). For a detailed description of 
the closure of Pusher Street, see Asmussen, 2007.
(6) Hash clubs are illicit speakeasies at private addresses where cannabis can be bought. The hash club 
law states that an apartment’s inhabitant can be forbidden to receive visitors if he or she is known 
‘to practice a systematically illegal business which can disturb and endanger his neighbours’.
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before the revision, it is now punished with the minimum of a fine. It is thus illegal 
to possess any amount of drugs, cannabis included, in Denmark. At the same time, 
another part of the Law on Euphoria-inducing Substances was revised. Penalties were 
increased from a fine to a prison term ‘if drug dealing is performed with children and 
young people under the age of 18 years’ at discos, clubs or music festivals.
Also in 2004, prison sentences for drug crimes were raised during revisions to The 
Prison Law. The maximum prison sentences for drug crimes were raised from 6 to 10 
years, for serious drug crimes (trafficking and dealing) from 10 to 16 years, with even 
sentences of up to 24 years for particularly serious drug crimes (Storgaard, 2005).
The swing towards repression is not an entirely new phenomenon (7). Storgaard (2005) 
argues that drugs policy — about different control policies for users versus dealers, ‘soft’ 
drugs versus ‘hard’ drugs, etc. — has been a permanent parliamentary battlefield in 
Denmark over the last 30 years, with the liberal-conservative and the centre-left wing, 
headed by the Social Democratic Party, in opposing camps (Storgaard, 2005). The 
centre-left’s position dominated Danish drug policy until 2001. For example, from 1969 
to 2004 possession of up to 10 grams of cannabis for personal use was not prosecuted, 
and onus was placed on combating hard drugs and organised crime, with a blind eye 
being turned towards small-scale cannabis sales (Grytnes, 2003).
Since the liberal-conservative government came into power in 2001, its self-styled 
‘zero-tolerance’ policy has been to tighten the legal control of drug crimes and to raise 
the penalties for drug offences, while also increasing access to treatment, particularly 
in prisons. Moreover, its action plan, The Fight against Drugs, explicitly removes the 
distinction between seller and buyer, stating that the drug policy targets both supply and 
demand side, drug dealers and drug users (Danish Government, 2003). The action plan 
also prioritises actions that protect youths from drug misuse.
Party political divides should also be placed in the context of growing responsiveness 
to media ‘hot button’ issues, with drugs suffering both negative connotations on one 
hand and a stranglehold on headlines on the other (Christie and Bruun, 1985). Thus, 
the first new legal instrument, the Hash Club Law, was as much the work of the former 
social democratic government as of the new liberal-conservative government. Moreover, 
at the same time that laws were tightened, liberalising proposals by the centre-left 
opposition — respectively to decriminalise cannabis on almost the same terms as the 
Netherlands, to implement safe injection rooms, and to implement heroin trials — were 
all overturned, suggesting a general hostile climate towards liberalisation.
(7) On the Danish drug policy combating hard drugs in the 1990s and the effects it had on hard drug 
users see, for example Frantszen (2003) and Laursen and Jepsen (2002).
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So what does this legal tightening mean in practice? First, the former differentiation 
between users and dealers, ‘soft’ drugs and ‘hard’ drugs is no longer the heart of 
Danish drug policy. Use of any drug is perceived as drug misuse, and in particular, 
use of cannabis is now criminalised. This effectively brings the appreciable numbers of 
cannabis consumers in Denmark within reach of prosecution (EMCDDA Danish Focal 
Point, 2005; Storgaard, 2005).
Another aspect of these changes is the concern for young people. On the one hand, 
adolescent drug users have been criminalised by the legislation covering possession of 
cannabis for personal use. On the other hand, they are protected by the revision of drug 
dealing to young people and the closure of illicit dealing premises under the Hash Club 
Law (Asmussen and Moesby-Johansen, 2004).
Finally, sentences for drug crimes have been raised and can be compared to sentences 
for manslaughter and homicide. The former focus in Danish drug policy on organised 
crime is now also widened and includes ‘zero tolerance’ towards all kinds of dealers. 
It is this last change which provided the leverage to police to tackle the long-standing 
quandary of Pusher Street.
The Pusher Street raid: 50 cannabis dealers and security guards 
arrested
The date 16 March 2004 represents a milestone in Danish drug policy. At 5 am police 
action to close down Pusher Street began. Bulldozers and several hundred armed police 
officers entered Christiania and removed the small wooden, zinc-roofed stalls where 
cannabis was sold (Asmussen, 2007). Simultaneously, over 50 cannabis dealers and 
security guards were arrested in different locations in Copenhagen and remanded in 
custody. Major police actions had occurred in Christiania before, as Laursen (1996) 
and the EMCDDA Danish Focal Point (2005) point out, but this was the first time that 
a police action was planned so thoroughly with the aim to actually close down Pusher 
Street. This was also the first time so many dealers (and security guards) were arrested 
simultaneously.
Surveillance of Pusher Street was carried out by police between October 2003 
and March 2004, involving videotaping of Pusher Street and the tapping of radio 
communication and phone calls. Tapped phone calls and radio communications were 
especially important in enabling the police to charge people for being members of, 
or employed by, a private security force that warned the dealers and customers about 
police activity. This security force was dubbed Christiania’s Intelligence Service by the 
police, and it represented a key argument for the police, the judges, and prosecutors 
in categorising Pusher Street as ‘well organised’. The police claimed the security force 
was regimented into six posts in different parts of Christiania from where guards could 
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warn dealers if the police were approaching. Police argued that the guards worked in 
shifts from these posts and communicated via radio and cell phones, substantiating 
claims with both tapped phone calls and radio communications between the guards 
and with a duty roster found in one of the managers’ houses. The duty roster consisted 
of initials of the guards, their phone numbers and a list of day and evening shifts. The 
police also worked as undercover agents, buying cannabis at the stalls in Pusher Street. 
Swedish and Norwegian policemen were used together with the Danish police. Using 
undercover police as a method of investigation is exceptional in Danish police work 
and requires court permission. With the videotapes and the undercover police work the 
police systematically registered the dealers that operated from the different stalls. It was 
on the basis of the videotapes and the undercover police work that the police estimated 
that about 3.6 tonnes of cannabis was sold in Pusher Street during the six months of 
surveillance. The amount was, however, disputed by the defence lawyers as well as by 
the defendants, and the judges later found these calculations too uncertain.
The pre-trial detention
The dealers and security guards arrested on 16 March were remanded in custody in 
solitary confinement by the City Court of Copenhagen. The pre-trial detention was 
prolonged multiple times on the grounds that the police needed time to investigate and 
prepare the trials. A few were released after two months, but about 40 of the defendants 
spent three months in solitary confinement, the legal upper limit for solitary confinement 
in Denmark. At the same time, the pre-trial procedures were held behind closed doors 
on account of police investigations. In July several of the dealers were discharged, but 
during the summer and autumn of 2004 the City Court continued to prolong pre-trial 
detention, three to four weeks at a time, with the security guards in particular having 
their custody prolonged. Five months after 16 March, 36 defendants were still in 
custody. On several occasions when a defendant was discharged by the City Court the 
prosecutor immediately appealed to the High Court, who on all occasions decided to 
confirm the prolonged pre-trial detentions. The defence attorneys protested each time 
the City Court prolonged the pre-trial detentions, and called into question the closed 
doors at the pre-trial procedures.
Since the court meetings were held behind closed doors the detailed arguments behind 
the prolongations were kept secret from the public. The only reason given was that the 
defendants could jeopardise the police investigations as well as the presumed risk that 
the defendants would take up their criminal activities again, that is, dealing cannabis, 
and this risk was considered especially high since they were ‘well organised’.
In the beginning of September one of the defence lawyers received permission from 
the Danish Board of Appeal Permission to try one of the cases with the long pre-trial 
detentions in the Supreme Court. In late November the Supreme Court confirmed 
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the decision made by the High Court that the defendants should continue to be in 
custody. The reason given was, again, that the cannabis sale had been extensive and 
well organised, which was reason enough to keep them in custody. Therefore, in late 
November 2004, 36 of the initial 50 defendants were still in custody. They had at 
that time been in custody for almost nine months. Media reports mentioned two of the 
defendants in custody that were affected by illness. One suffered from claustrophobia, 
the other had gained 23 kg, and as a consequence suffered repeatedly from thrombosis 
in his legs. These cases were reported in the news because their defence lawyer 
complained about the defendants being in custody while suffering different forms 
of illnesses. The City Court in Copenhagen discharged the two defendants, but the 
prosecutor appealed to the High Court. Here, one was discharged, the other one who 
suffered from claustrophobia was moved to a larger cell and maintained in custody.
The charges
The defendants were charged as dealers or as security guards. The dealers were 
charged with extensive cannabis dealing from stalls in Pusher Street and for having sold 
between 25 and 150 kg of cannabis in the period the police held Pusher Street under 
surveillance. The amount that each individual dealer was charged with was based on 
calculations made from the surveillance and the undercover police work. The dealers 
were ‘and could only be’ charged for the amount of cannabis they had sold themselves, 
that is, for specific dealing. Thirty of the defendants were charged as dealers, and some 
were facing up to three-and-a-half years of imprisonment.
The security guards did not sell cannabis themselves but secured that all the dealers 
could run their business, and were therefore charged for complicity. The police 
calculated that 20 kg of cannabis was sold every day in Pusher Street and multiplied this 
by the days the police monitored Pusher Street, resulting in total sales of several tonnes 
of cannabis. Since the guards worked on a structured duty roster in day and evening 
shifts, they could be charged collectively, and thus faced up to four years’ imprisonment.
This was the first time in Denmark that persons were charged collectively for drug 
crimes. The police claimed that the security force during the preceding years had 
developed from individual persons warning cannabis dealers with whistles if the police 
were in the neighbourhood, to a structured force with duty rosters, managers organising 
the shifts, and payment by the dealers, thus making guarding a lucrative business. The 
defendants themselves, however, described themselves as a kind of ‘buffer’ between the 
police and the dealers in Christiania, ensuring that any trouble accompanying police 
presence in Christiania did not escalate. They also claimed that they ensured hard 
drugs or biker gang members did not appear in Christiania. This was highlighted by 
the defence lawyers, who also denied the existence of a formal Christiania Intelligence 
Service.
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The trials and sentences
At the end of August 2004 the first trial began. Two dealers — a stallkeeper and a 
helper — were charged with having sold 114 and 30 kg of cannabis respectively. 
However, the sentences that the two dealers received in December only convicted them 
for selling 25 and 10 kg of cannabis respectively, with accompanying prison sentences of 
one-and-a-half years and one year. The method of calculation that the police had used 
was accepted by the judges, but only in part: they accepted what was to be seen on 
the videotapes and the testimonies from the undercover policemen, but in general the 
means of calculating what was sold from the stalls in the whole period was deemed too 
uncertain. After this first trial, 10 of the defendants that were charged with having sold 
less than 40 kg of cannabis were released from custody by the City Court on the account 
that the sentence would no longer be equivalent with the pre-trial detention.
Throughout December 2004 and January 2005 the rest of the dealers were convicted. 
However, it was not until the end of May 2005 that the last trial ended. The dealers were 
all convicted for having sold less cannabis than they were charged with. They received 
sentences of between 30 days and 2 years and 6 months. In total, the convicted dealers 
got 35 years of imprisonment. Only one defendant was found not guilty.
The joint trial against the security guards began in May 2005. Seventeen persons 
were charged for being security guards in the Christiania Intelligence Service and 
three were charged for being managers of the service. The latter organised the shifts, 
supervised the security guards and collected money from the cannabis dealers. All the 
defendants pleaded not guilty to the charges. Based on tapped phone calls and radio 
communication between the guards and the three managers, the City Court found 
all guards, but only two of the three managers guilty. The two managers received a 
two-and-a-half years prison sentence each. The security guards got a sentence between 
one and two-and-a-half years, depending on how long they had been employed in the 
security force. In total, the 19 defendants received 34 years of imprisonment.
Concluding remarks
This report of the arrested dealers and security guards illustrates how the Danish 
government’s ‘zero-tolerance’ drugs policy is implemented in practice. The closure of 
Pusher Street was clearly a ‘show of strength’, as seen in the Ministry of Justice and 
Ministry of Defence report submitted in 2003, detailed planning by police, the use of 
undercover agents, the simultaneous arrest of so many dealers and security guards, the 
involvement of detectives from Norway and Sweden, etc. Also unusual was the use of the 
upper level of solitary confinement (three months), as well as of extremely long pre-trial 
detentions (up to 10 months) for what in effect was retail street dealing rather than 
wholesale trafficking of drugs.
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In terms of police success, the convictions could be viewed as a mixed bag. Many 
of the dealer defendants were discharged after sentence for time served in pre-trial 
custody, with none being convicted of selling the full volume of cannabis claimed by 
police. Conversely, the collective charging of the security guards resulted in all but 
one being found guilty as charged. This latter result highlights the extension of Danish 
drug legislation beyond dealers towards those aiding and abetting drug sales, and the 
lowering of the threshold for what is considered ‘organised’ and ‘well organised’ drug 
crime.
One can question the rationale behind the sudden departure from the ‘blind eye’ that 
was turned to cannabis dealing for about 30 years in Pusher Street. Nothing indicates 
that cannabis dealing had changed or increased in years preceding before the closure 
of Pusher Street. Moreover, when denying the existence of the Christiania Intelligence 
Service the defence lawyers pointed to the self-regulation within Christiania with 
regard to hard drugs, even the cooperation of individuals as mediators during any 
confrontations between police and dealers. The clampdown must therefore be viewed 
as a political and ‘moral’ change in attitude rather than a change in cannabis dealing 
practice.
The most important question is, what effect did closing Pusher Street have? Not much, 
it seems. Cannabis dealing is still carried out in Christiania, according to the police 
as well as personal observation. However, cannabis dealing no longer occurs in 
public from small stalls in Pusher Street, but more discreetly from person to person. In 
Copenhagen in general there is also just as much cannabis circulating, both according 
to the police and the Municipality of Copenhagen. However, the market has dispersed 
into many different and new areas, with some anxiety that cannabis is now even more 
easily available to young people (Asmussen, 2007).
So, the recent change in Danish drug policy seems to follow what scholars on drug 
policy like Kilmer (2002) and Korf (2002) in general argue: drug policy, whether 
repressive or liberal, does not influence either a decrease or an increase of cannabis 
use. The closure of Pusher Street is more an example of how a government pursues a 
‘zero tolerance’ policy rather than a serious attempt to solve drug problems. Seen in the 
context of the gradual dismantling of the Christiania commune, it can also be viewed as 
a moral rejection of laissez-faire.
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Chapter 11
Cannabis: a harm reduction 
perspective
Keywords: cannabis – education – harm reduction – information – vaporisers
Setting the context
‘Harm reduction’ means many things to many people. A useful and concise definition 
is provided by the UN’s Glossary of Terms on Demand Reduction (1), which mentions 
‘policies or programmes that focus on reducing the harm resulting from the use of 
alcohol or other drugs, both to the individual and larger community (...) without 
necessarily requiring abstinence’. The definition clarifies that harm reduction may 
‘precede subsequent efforts to achieve total abstinence’ and ‘is neutral regarding the 
wisdom or morality of continued drug use and should not be synonymous with moves to 
legalize, decriminalize or promote drug use’.
With regard to cannabis, harm reduction is more difficult to define than, say, 
programmes to reduce needle injuries, hepatitis and HIV transmission among 
heroin users. One problem is that harm reduction for cannabis is often a bottom-up 
phenomenon that is delivered via unofficial rather than governmental or central sources, 
for example, cannabis magazines, websites and headshops. Harm reduction is also 
transferred via word of mouth. Long before a user comes into contact with a drugs 
professional, information will be delivered by dealers, fellow cannabis users, peers and 
siblings.
Among the more formal harm reduction programmes, there is considerable overlap 
across harm reduction, prevention and early treatment interventions. For example, 
low threshold interventions such as drugs helplines, the Jellinek self-screening test 
and French cannabisetconduite.fr campaign (see Burkhart, and Beck and Legleye, 
(1) UNDCCP (2000), Demand reduction: a glossary of terms, UNODCCP, Vienna. Available at: 
www.unodc.org/pdf/report_2000-11-30_1.pdf
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this monograph) could be loosely defined as harm reduction initiatives. Although the 
nature of harm reduction programmes varies greatly across the EU, many programmes 
borrow from the fields of alcohol and tobacco. Actions include advice on safer modes 
of administration (e.g. on the use of vaporisers, on rolling safer joints, on less risky 
modes of inhaling); skills to prevent confrontation with those who disapprove of use; 
encouraging users to moderate their use; discouraging mixing cannabis with other 
drugs; drug driving prevention and controls; reducing third-party exposure to second-
hand smoke; education about spotting signs of problematic use; and self-screening for 
problematic use.
First and foremost, harm reduction centres on helping users to make informed 
decisions with information that is understandable, accurate and non-judgemental. 
For example, a recent initiative, the Evidence-based Electronic Library for Drugs and 
Addiction (EELDA) (2), attempts to filter the huge body of scientific literature on cannabis, 
cocaine and ecstasy into a more accessible format using relatively simple language. It 
includes discussion of the risks of cannabis use as it relates to medical conditions (while 
pregnant, if epileptic, if suffering from liver, lung or heart problems) and to specific use 
settings (at work, when driving).
This chapter focuses on specific work on harm reduction at the HIT project in the United 
Kingdom. Its discussion of the need to communicate effectively, to empathise with 
cannabis users and to understand the motivations for using cannabis will be relevant to 
drugs practitioners everywhere.
Further reading
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cannabis and THC’, Journal of Cannabis Therapeutics 1 (3).
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O’Hare, P., Newcombe, R., Matthews, A., Buning, E., Drucker, E. (eds) (1992) The reduction of 
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Cannabis: a harm reduction 
perspective
Andrew Bennett
Harm reduction forms a part of many European countries’ response to licit and illicit 
drug use: drinkers are advised to consume alcohol at safe levels; heroin users receive 
substitute drugs such as methadone; and drug injectors are encouraged to use clean 
injecting equipment.
Defining harm reduction
There is not a generally accepted definition of harm reduction. Historically, the main 
stimulus to the development of harm reduction policies and programmes was the 
identification of the role of injecting drug use and the sharing of needles and syringes 
in the transmission of HIV (Hunt, 2003). This led to the introduction of a range of 
practical initiatives such as needle and exchange schemes, low threshold services and 
programmes offering safer injecting advice. Thus, harm reduction strategies were seen 
as concerned with providing services to drug users at the individual level intending 
to reduce risk or rates of harm (e.g. needle exchange), while also aiming to reduce 
harm to others, e.g. preventing HIV among the wider community; and reducing public 
nuisance connected to drug taking.
Harm reduction definitions often do not describe whose harm should take priority: the 
user, the family or the wider community, and what type of harm it refers to — health, 
social, economic. Harm reduction also posits that individuals are able to make rational 
decisions about their behaviour. Once informed about the risks associated with drug use 
and how to avoid them, drug users are expected to be able to act on this information 
(Rhodes, 2002). While some commentators have seen abstinence as an ideal goal, most 
harm reduction strategies do not require abstinence.
Swift et al. (2004) provide practical criteria for assessing whether a policy or programme 
practises harm reduction that encompasses some of the above key points. Their central 
defining characteristic of harm reduction is the reduction of harm as a primary goal 
rather than the reduction of use per se. It must include strategies for those that continue 
to use as well as those aimed at reduction of use or abstinence. There should also be 
some attempt to evaluate whether these strategies will result in a net reduction in drug-
related harm.
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While harm reduction is often associated with schemes to reduce the harms of opioid 
use, strategies have also addressed other substances, in particular tobacco and alcohol. 
These include alcohol campaigns promoting sensible drinking and discouraging drink 
driving, training bar staff and door staff in avoiding incidents of drunkenness, and 
public space smoking bans to reduce people’s exposure to second-hand smoke. While 
experience and practical measures are still limited, harm reduction may also have a role 
to play in helping with cannabis-related problems.
Health-related harm reduction and cannabis
Information, education and communication
Citizens in the EU will have varying degrees of access to a range of materials and media 
designed to impart knowledge about cannabis. However, drug related information, 
education and communication is an area of practice that is widespread yet seriously 
under-researched. In his review of harm reduction research, Hunt concludes that the 
existing evidence says very little about what sort of approaches work; for whom; to what 
extent; and whether they are cost-effective (Hunt, 2003).
In the United Kingdom, a small number of government-funded but independent 
organisations, such as DrugScope, HIT and Lifeline, produce and distribute booklets, 
leaflets and posters; host websites; and run multi-component campaigns that focus 
specifically on cannabis or include cannabis amongst other drug communications. 
Schools have a mandatory responsibility to educate young people about drugs, 
including cannabis. While guidance exists regarding school-based education and 
drug communication, the nature and extent of both activities can vary enormously. 
Increasingly, much health information is disseminated through non-official channels. 
Cannabis users, activists, ‘headshops’ and seed suppliers inform and educate about 
cannabis. Increasingly, websites and other multimedia publications offer information on 
the health effects of cannabis (3).
Information, education and communication approaches are not necessarily strategies of 
harm reduction.
Producing information materials that aim to reduce harm rather than prevent use per 
se is challenging, especially when the target audience is young people. Politicians, 
the media, parents and others can easily misconstrue a resource as condoning or 
(3) While web resources on cannabis vary greatly, some sites offer strong harm reduction materials, 
for example www.seedsman.com/en/health/cannabis-and-health and http://en.eelda.org/index.
aspx?o=5809
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encouraging drug use. Below is an extract from HIT’s The Stuff on Cannabis booklet, 
which is aimed at young people aged 14 and above. The objective of the booklet 
(in its entirety and not just the extract) is to provide accurate, acceptable and useful 
information about cannabis for young people. The goal of the resource is to reduce 
harm.
To avoid the dangers of cannabis:
Don’t use it. But if people do use cannabis the advice is ...
Don’t take too much or use too often. Don’t smoke every day.
Be aware that some types are very strong and could make you feel bad.
Remember it is still illegal and you could get into trouble with the law.
Don’t smoke it with tobacco.
Avoid using it when you feel really down. It will probably make you feel worse.
Don’t operate machinery or drive whilst stoned.
Avoid sexual situations you may later regret. If you have sex, use condoms.
Don’t take other drugs at the same time, particularly alcohol. Mixing drugs can be dangerous.
If you are trying to cut down or stop, avoid people using it and places where they go.
© 2005 HIT UK Ltd
Consumption methods and techniques
The potential long-term harmful consequences of cannabis use are strongly related 
with the consumption method, that is respiratory risks associated with smoking the drug 
without, or simultaneously with, tobacco. A UK House of Lords Cannabis Report (1998) 
proposed the following hierarchy of risk:
Smoking a cannabis and tobacco joint is the most risky way of using the drug because the tars 
and toxins (plus the cigarette paper) is inhaled. Smoking a cannabis only joint enables the user 
to avoid inhaling tobacco. If cannabis is smoked in a pipe, no papers are burnt and inhaled 
and a proportion of tars and toxins may remain in the pipe. Water pipes or bongs may have 
advantages since the smoke will be inhaled at a cooler temperature and some tars may 
remain suspended in the water. Vaporisers are designed to heat cannabis to a point where the 
THC will be released without the plant combusting. Finally, the respiratory risks of cannabis 
smoking would be completely eliminated if users adopted oral methods of use.
Although research shows that cannabis may be a risk factor for the development of 
respiratory-related diseases (see Witton, this monograph), cannabis smoking is not 
thought to have a major public health impact on respiratory risks, including cancer, 
because most cannabis users stop their use in their 20s, few smoke more than a few 
joints in each session and the number of people who use in a chronic way is currently 
relatively small (Hall and MacPhee, 2002).
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Nonetheless, recent information of the comparative pulmonary risks of cannabis 
smoking vis-à-vis cannabis smoking has improved, and suggests that cannabis has 
a similar effect on airflow obstruction to the lungs of two-and-a-half to five cigarettes 
(Aldington et al., 2007). Moreover, the low overall impact of cannabis smoking assumes 
that existing low-intensity patterns of use, together with a tendency for users to quit 
in their 20s, will continue. If more people smoked cannabis more frequently and for 
longer periods of their lives, the public health impact associated with respiratory-related 
diseases would be greater. It is also important to consider that cannabis consumption 
affects public health in other ways, for example its contribution to mental health 
problems and the consequences to users of a criminal conviction.
A number of cannabis resources provide information about specific techniques and tips 
that may reduce potential harm linked to airflow obstruction and inhalation of toxins. 
The rationale for such advice by necessity is often based on ‘common sense’ rather than 
research evidence. Below is an extract from HIT’s cannabis booklet, which is aimed at 
cannabis users aged 16 and above.
You should:
Avoid holding the smoke in your lungs – you won’t get any more stoned and this just makes 
more tar and other dangerous chemicals stick to your lungs.
Avoid inhaling too deeply – sucking on a bong or buckets may cool the smoke, but it forces it 
deeper into your lungs, so you breathe in more tar.
Clean weed properly – the bulk of THC is in the sticky tops and flowers, so you should take 
out the stem, leaves and other bits.
Avoid using a cigarette filter for a roach – filters may reduce the amount of THC you smoke. 
As a result you inhale more deeply which may increase the amount of tar you breathe. Avoid 
using anything printed (printers’ ink gives off dangerous fumes when heated). A piece of plain 
card, loosely rolled up for a roach, allows the smoke to flow easily.
Avoid using too many papers — three-skinners are big enough and you will inhale less burnt 
paper.
Avoid using plastic bottles, rubber hoses, PVC, aluminium or foil to smoke cannabis — these 
all give off toxic fumes when hot (you run fewer health risks with a pipe made from glass, steal 
or brass.
Clean bongs and pipes properly after use – germs can hang around long enough to infect you 
and your friends.
Warning: Just because you like to get high, it doesn’t mean everyone does. Show some respect 
and don’t smoke around others, particularly children, who may be affected by you sparking 
up.
© 1999–2005 HIT UK Ltd
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Assessing the evidence that one mode of consumption is safer than 
another
In theory, the risk of damage to the respiratory system could be reduced if users 
adopted consumption methods and techniques that reduced the inhalation of cannabis 
(and tobacco) and related tars and toxins. The evidence for proposing that one mode of 
consumption is safer than another is, however, limited.
Laboratory studies suggested vaporisers provided the safest delivery of cannabis when 
compared with unfiltered and filtered joints and waterpipes (Gieringer, 1996; 2001). 
Vaporisers heat cannabis to temperatures between 180°C and 200°C and above, 
enabling the release of THC and other cannabinoids as a fine mist while reducing 
the toxic byproducts of smoked cannabis. While vaporisers are becoming increasingly 
available for cannabis smokers, a need for a safe delivery mode for therapeutic 
cannabis products have also prompted interest in this technology.
Perhaps surprisingly, the unfiltered joint ‘performed better’ than the waterpipes, that is, 
the ratio of THC to tar was less in an unfiltered joint compared with the waterpipes. The 
performance of the filtered joint was similar to the waterpipe, that is, the filter reduces 
the amount of THC, thus leading to the user inhaling more vigorously, resulting in 
increasing the amount of tars. The two vaporisers performed better than the unfiltered 
joint. A follow-up study by Gieringer (2001) confirmed that vaporisers offer the best 
prospects for reducing the harm from cannabis smoke. However, the researchers stress 
caution with these findings. They point out that the findings in the laboratory may not be 
reflected in humans, for example, the potency of cannabis used may be different than 
street cannabis.
Further research has been done on vaporisers as a delivery method. A laboratory study 
found that a vaporisation device provided an efficient and reproducible mode of delivery 
of THC (Hazekamp et al., 2006). A further pilot human laboratory study comparing a 
vaporiser to smoked cannabis found that the vaporiser was as effective as delivering 
THC but with little or no increase in carbon monoxide levels, a marker for toxins that 
may be generated by smoking (Abrams et al., 2007). Further suggestive evidence for 
the value of vaporisers emerged from a large Internet survey, which found that the 
use of vaporisers was associated with fewer respiratory symptoms than other modes of 
delivery used by respondents, although the self-selecting nature of the sample and the 
self-report basis of the data limits the generalisability of the study’s findings (Earleywine 
and Barnwell, 2007).
This may have important health implications if, as is reported in Australia, users believe 
waterpipes are ‘safer’ because the water cools the smoke and dissolves some tar 
(Hall and Solowij, 1998). The study raised concerns about waterpipes not necessarily 
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protecting users from dangerous tars since they filter out more psychoactive THC than 
they do tars, thereby requiring users to smoke more to get the desired effect. The 
research raises doubts about the likelihood of an improved high by using waterpipes 
because some of the THC is lost in the water. However, as Gieringer (1996) and Iversen 
(2000) recognise, this ‘loss’ may be compensated by simply using more cannabis and 
holding the fumes in the lungs for longer periods.
Some studies also highlight the possibility that increased cannabis potency may have 
a potentially protective effect, since the concentration of tars relative to THC will be 
reduced. If this is the case, it would suggest a contradictory perspective to that which is 
most commonly highlighted in scientific and popular debate regarding increased THC 
potency, namely that potency increase causes increased adverse health effects (Hall and 
Swift, 2000; see also King, this monograph).
Will cannabis users adopt safer ways of administration?
The consumption modes significantly associated with respiratory risks — cannabis and 
tobacco joint or cannabis joint — are the most frequently used in Europe. Conversely, 
only a minority of cannabis users choose to vaporise or swallow the drug as their main 
method of use, even though they offer a means to avoid respiratory risks. Hence, it is 
important to pose the question: will users adopt safer ways of administration?
Smoking is an effective way of delivering drugs to the brain and the rapid delivery of 
the drug to the brain by smoking seems to be an important factor in determining the 
subjective experience of the ‘high’ (Iversen, 2000). The effects are felt almost instantly 
and it is relatively easy to control or titrate the dose, for example if the cannabis is 
stronger than anticipated, the user will know this within a matter of seconds. By contrast, 
taking cannabis by the mouth is less reliable in delivering a consistent dose of the drug. 
Most of the drug when swallowed will be processed in the liver before general circulation 
takes it to the brain. The peak levels of the drug, and thus the ‘high’, will occur 1–4 
hours after taking the drug (Stafford, 1992; see also Corrigan, this monograph).
However, the behaviours and consequences of cannabis consumption are not just 
determined by the drug and its method of use. Individual beliefs, expectations and 
reasons for using, as well as the social environment in which it is used, are also 
important. Surprisingly, there is a limited amount of research that explores the social 
context, use preferences and roles of cannabis use. Research that did explore the 
functions and pathways of young adult drug takers in Salford in the United Kingdom 
illustrates that different modes of cannabis consumption produce different effects.
I don’t really take buckets (4) cos they don’t really agree with me, the rush is too fast. It hits me 
too quick. I like to get it gradually. I’ll have a bong cos it don’t hit you as fast. Spliffs are just 
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brilliant because you get everything out of it, you get all the feeling. Buckets you don’t cos it 
just hits you and then it’s gone. Bongs hit you slow but it don’t last long.
20-year-old unemployed female, as quoted in Henderson (1995).
In a Mixmag (2002) (5) article a ‘willing guinea pig examines the merits of spliffs, bongs 
and cakes’. In response to the question ‘how long till you’re battered?’ the guinea pig 
answers ‘two minutes’ (spliff), ‘little under a minute’ (bong) and ‘two hours’ (cake). In 
response to the question, ‘how long do you feel caned for?’ the subject answers ‘two 
hours’ (spliff), ‘no idea ... in the morning I realise it had lasted six hours’ (bong) and 
‘fucking ages. I’m useless for eight hours’ (cakes).
Bell et al.’s (1998) research focuses on the role of friendship groups as a means of 
initial contact with cannabis, and learning about its use in the context of transitions to 
adulthood. He argues that understanding the social context of cannabis use involves 
examining their explanations for cannabis use, the methods of use, the physical location 
and the time they take it, and the social group it occurs within. Examples are provided of 
young people experimenting with a range of methods of using cannabis, and different 
ways of getting a ‘hit’, sometimes with unintended consequences, as one interviewee 
explains:
I was cookin’ it and that, yeah, an’ I didnae get to ma bed til aboot 4 am, ken and I didnae 
feel quite right ken, I woke up in the morning and I was still the same.(6)
Research conducted by Bennett (2002) explored the reasons why people use cannabis 
in the way they do and discussed the public health implications of the findings. It was 
concluded that a range of factors negate against the adoption of safer consumption 
methods. Cannabis, when inhaled in the form of a joint or spliff, is controllable in 
terms of the severity and length of the effect when compared with using bongs and 
vaporisers or eating the drug. Preparing and sharing joints is routine and a social 
activity. Alternative methods of smoking, including bongs and vaporisers, involve using 
other paraphernalia that may be inconvenient to use and expensive to buy. Further 
research that examines the different nuances and complexities of cannabis use, including 
consumption methods and techniques, is needed.
(4) ‘Buckets’ is a way of smoking cannabis in the UK. Usually, the cannabis smoke is captured in a plastic 
bottle with the bottom cut off. The plastic bottle is then pushed down into water (often in a bucket), 
thus causing the cannabis smoke to be released very quickly through the top of the bottle in relatively 
large amounts. The smoke is then inhaled.
(5) Mixmag is a UK dance magazine. The phrase ‘how long till you’re battered?’ means, how long 
before you feel the effect of the cannabis; and ‘how long do you feel caned for?’ means, how long 
do the effects last.
(6) The extract is in the local dialect. The word ‘cookin’ refers to preparing cannabis in food; and ‘ken’ 
should read ‘know what I mean’.
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Cannabis and tobacco: double trouble?
It has been estimated that 70 % of cannabis users in the United Kingdom smoke with 
tobacco (Atha and Blandchard, 1997). Two qualitative studies in Scotland with 15- to 
19-year-olds have identified three links between cannabis and tobacco (Amos et al., 
2004) (7). These are:
Cannabis is linked to starting tobacco consumption — ‘I hadn’t smoked at all, but •	
... I got into that (hash) and then that made me get addicted to tobacco.’
Cannabis can reinforce tobacco consumption — ‘if you’ve no’ got any hash, you •	
just smoke your fags.’
Cannabis can make giving-up tobacco more difficult – ‘I’ve tried to stop smoking •	
but ... you cannae go without a fag ... you need it for your hash.’
Recognising the cannabis-tobacco link, Health Scotland published a booklet for young 
people titled Fags ‘n’ Hash: the essential guide to cutting down the risks of using tobacco 
and cannabis. In some parts of the United Kingdom, the National Health Service 
tobacco smoking cessation services are incorporating cannabis within their interventions 
with adults. Faced with the difficulties in promoting safer cannabis use, secondary 
prevention and treatment approaches aimed at controlling, cutting down or stopping 
consumption could also be seen as a plausible harm reduction technique.
A number of countries have recently developed and implemented interventions designed 
to enable heavy, frequent users to reduce or stop their cannabis use. In the UK the 
government in 2004 launched the Know Cannabis campaign to enable users to cut 
down or stop their cannabis consumption. The multi-component campaign included 
leaflets, posters, A Guide to Cutting Down or Stopping Cannabis and a self-help 
website (8). In the Netherlands a self-help website has been in existence for a number 
of years (9). These interventions use cognitive behavioural approaches, and include: 
assessment of the benefits and costs of cannabis; planning and preparing for change; 
setting targets; identifying high-risk situations; dealing with withdrawal; and relapse 
prevention.
The above types of secondary prevention or treatment approaches should form a part 
of a comprehensive approach to reducing cannabis-related harm. Harm reduction 
establishes a hierarchy of goals, with the more immediate and realistic ones to be 
achieved as first steps toward reduced risks or, if appropriate, abstinence. Cannabis 
users need to be aware and have the option of accessing a range of appropriate 
interventions.
(7) ‘Hash’ is cannabis and ‘fags’ are cigarettes.
(8) See www.knowcannabis.org.uk
(9) See www.jellinek.nl/zelfhulp/cannabis
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Conclusion
Cannabis is the most widely used drug in Europe and many users seemingly enjoy their 
use of the drug without it leading to any significant negative social or health effects. 
However, it is not a harm-free drug. Heavy, frequent use is associated with increased 
susceptibility to respiratory disorders, dependency, precipitation or exacerbation of 
mental health problems in vulnerable people, and cognitive impairment. Some young 
people, especially those that use heavily and frequently, may be particularly vulnerable 
to mental health problems. Furthermore, a criminal record as a consequence of 
cannabis can also cause problems.
Harm reduction frameworks provide a useful way to appraise and respond to cannabis-
related problems. However, there is a lack of information about the design and delivery 
of harm reduction interventions, and a greater lack of evidence of successful application. 
Many EU countries are beginning to recognise the healthcare needs of cannabis users. 
There is a need for the development of accessible interventions for cannabis-related 
problems including accurate, credible and targeted information; and secondary 
prevention for young people and adults who want to cut down or stop their cannabis 
consumption.
Unfortunately, the most common method of using cannabis — smoking — is also the 
most risky mode of administration. While some cannabis consumption methods and 
techniques, such as vaporiser use, may protect health to an extent, the evidence base is 
limited. Social, cultural and economic obstacles, and preferences by users themselves 
indicate that such modes of administration may not be widely adopted.
Cannabis and harm reduction has been considered in various ways in this chapter. 
Critical to the success of any intervention is the need to recognise that many people 
experience cannabis as enjoyable and trouble free, whilst accepting that some people 
require help to reduce or stop. Another vital aspect is to realise that non-official sources 
of information — cannabis-using peers, advocacy groups, headshops and websites — 
often play a role in educating cannabis users, and there is a need to engage such actors 
in delivering accurate harm reduction messages.
Thanks to Mark Bellis, Annemarie Carr, Neil Hunt, Simon Lenton and John Witton.
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Setting the context
Sizing markets for illicit products is always difficult. The most basic challenge is that the 
standard yardsticks common for legal markets cannot be used. Analysis and forecasts 
are simply not available for illicit goods, and economists working on the issue are faced 
with a lack of standard sources such as investor reports, tax declarations and fiscal 
yields, obligatory bourse filings, performance indicators, customs duties, wholesale and 
retail reports and the trade press.
So drug market analysts must instead make do with a piecemeal substitute, triangulating 
information obtained from various channels: enforcement (police reports, crime 
statistics, customs seizures data), healthcare (drugs epidemiology, treatment indicators) 
and a more nebulous literature base produced by drugs workers and charities, think 
tanks, academics and policymakers, and journalists. While in some cases, statistics are 
produced on a standard, usually annual cycle (United Nations Office on Drugs and 
Crime (UNODC), EMCDDA, World Customs Organisation, Interpol), more often than 
not analysis is ad hoc and restricted in scope, for example national, regional or single-
theme studies.
UNODC is the primary provider of research into the machinations of the global illicit 
drugs market. In this chapter, UNODC authors reveal that, for cannabis, estimating 
supply is even more difficult than for other drugs, such as heroin and cocaine. For 
example, while satellite data have recently been used to estimate areas of cultivation in 
a report on Morocco, there is strong variation in crop yields and the cost of expanding 
such scrutiny on a global level is prohibitive. Another difficulty is that supply is moving 
closer to the consumer. As indoor cultivation, self-supply and locally grown herbal 
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cannabis become more common, the likelihood of seizures providing a complete picture 
of the market decreases. Beyond this, there is also considerable variation in how herbal 
cannabis and cannabis resin seizures are reported, a fact further impacted by the 
relatively low standardisation of information on the product itself (e.g. resin or herb, 
potency and estimated dose consumed by users).
Nonetheless, this chapter points out that indicators suggest that worldwide cannabis 
cultivation increased throughout the 1990s until 2004, in keeping with growing 
demand, both at the global level and in Europe. Only in 2005 was a reduction 
reported. For herbal cannabis, North America remains the largest market and is largely 
self-contained. For cannabis resin, Europe remains the largest consumer market, 
predominantly supplied by Morocco (see also Gamella and Jiménez Rodrigo, this 
monograph), even though Morocco’s importance as a source country for cannabis is 
declining. Despite some progress made in recent years, there can be no doubt that 
more research and better official record-keeping are required to provide more precise 
estimates on the total amount of cannabis grown and consumed globally. And while 
work is taking place — some European countries are modelling consumption patterns 
for intensive cannabis use (EMCDDA, 2007) — this chapter offers practical suggestions 
for improving our knowledge of the market.
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Global cannabis cultivation and 
trafficking
Ted Leggett and Thomas Pietschmann
Abstract
Though cannabis is, by far, the most widely used illegal drug worldwide, consumed by 
some 3.8 % of the population aged 15–64 in 2005–2006, little scientific information 
is available on the actual extent of its cultivation and its yields. Information collected 
by UNODC indicates that it is produced in (at least) 172 countries across the globe. 
UNODC’s best estimates, based on Member States’ estimates and some indirect 
measurement techniques, suggest that some 42 000 tonnes of cannabis herb and 6 600 
tonnes of cannabis resin were produced at the global level in 2005, slightly down from 
the peak in 2004, though still significantly more than in the early 1990s. This pattern is 
in line with global cannabis herb and resin seizures and global cannabis consumption 
estimates. The largest cannabis herb seizures have been reported from North America 
(Mexico, followed by the USA), followed by Africa and South America. The largest 
cannabis resin seizures have been reported from Western Europe (notably Spain), 
followed by countries of South-West Asia (Pakistan, Iran and Afghanistan) and North 
Africa (Morocco). Production of cannabis resin in Morocco, the world’s largest cannabis 
resin producer and main supplier of it to Europe, has been declining since 2004, while 
production in Afghanistan is increasing. The chapter also makes a number of proposals 
on key areas where more research is needed.
Strong increases in global cannabis cultivation have been reported over the last four 
decades, largely related to rising demand in North America, Europe and Australia. 
Increased production occurred first in the traditional cannabis-producing countries and, 
more recently, in the developed countries that provide the most lucrative consumer 
base. Only in 2005 were the first signs of a decline in global cannabis production seen, 
following years of continuous increases in the 1990s and in the early 2000s.
It remains difficult to establish how much cannabis is produced globally. Unlike other 
drug crops, cannabis is a plant that can be grown in virtually every inhabited region 
of the world, and can be cultivated with little maintenance in small plots, or even 
indoors. UNODC regularly collects, mainly using its Annual Reports Questionnaire 
(ARQ), estimates from UN Member States on the areas under cannabis cultivation 
and estimated yields. But reliability of these figures is significantly lower than the 
corresponding estimates for heroin or cocaine, which are typically made using satellite 
photos and scientific yield assessments.
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Heroin and cocaine production estimates are facilitated by the fact that production of 
opium and of coca leaf is nowadays geographically concentrated in just a few areas. 
A global assessment of cannabis cultivation, in contrast, would have to be truly global, 
and would be both extremely difficult and expensive. An idea of the costs involved can 
be derived from UNODC’s work in this area. UNODC has conducted studies of the 
extent of cannabis cultivation in Central Asia in the late 1990s and, in collaboration 
with the government of Morocco, of the primary cannabis-producing areas of that 
country in 2003, 2004 and 2005. The latter studies employed the use of remote 
sensing technology as well as ground survey data. Conducting such comprehensive 
surveys in countries the size of Morocco would probably cost between USD 200 000 
and USD 300 000 per country. While Morocco actually covers a large part of the survey 
costs, many other countries would not be in a position to do so, which would leave the 
costs with the international community.
Even if the precise number of hectares dedicated to cannabis cultivation worldwide 
could be determined with the help of remote sensing technology, estimates of crop 
yields would still be a challenge. Although cannabis can be grown in most countries, its 
productivity is directly linked to growing conditions, and cannabis is a highly adaptable 
plant. Depending on the cultivar and the environment in which it grows, cannabis can 
vary in appearance from a small weed to a substantial bush to a five-metre tree (Clarke, 
1981).
Yield estimates provided by Member States to UNODC ranged from as low as 5 kg per 
hectare for wild cannabis to 17 500 kg per hectare for countries that reported a high 
proportion of hydroponically grown cannabis. The median cannabis yield was 730 kg 
per hectare, and the unweighted average yield was 2 070 kg per hectare (UNODC, 
2007). Moreover, cannabis can be ‘adulterated’ considerably by the inclusion of inert 
(or relatively inert) plant material. All of this makes coming up with an estimate of yield 
per plant or per unit area (square metre or hectare) a difficult exercise. Yield estimates 
must also take into consideration whether the plants in question were intended to be 
used for cannabis herb or resin production. Cannabis can be consumed with little 
processing after harvesting. As a result, users can feasibly cultivate their own supply, and 
production is highly decentralised. While substantial international trafficking of cannabis 
does occur, it is unclear what share of the total market this comprises. It appears that 
many countries can satisfy much of domestic demand with locally produced cannabis 
(see Korf, this monograph), and this trend appears to be growing in many important 
markets.
The matter is complicated further by the fact that cannabis comprises two distinct drug 
products, cannabis herb and cannabis resin. Over the period 2000–2005, 82 % of 
the cannabis end-product seizures concerned cannabis herb and 18 % cannabis resin 
(UNODC, ARQ). Herbal cannabis comes in various grades, including a product made 
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up of only the unfertilised buds of the female plant, known as sinsemilla. There are also 
various grades of hashish, based on amount of impurities contained in the final product. 
In addition, it is possible to produce ‘cannabis oil’, although this form of the drug is not 
widespread: 0.02 % of global seizures of cannabis end-products over the 2000–2005 
period, and only 0.01 % in 2005.
While herbal cannabis is consumed throughout the world, the largest market for 
cannabis herb is in North America, where 63 % of global seizures occurred in 2005, 
followed by Africa (18 % in 2005). Europe accounted for just 2 % of global cannabis herb 
seizures in 2005, down from 4 % in 2000 (UNODC, ARQ). Changes in law enforcement 
priorities among some European countries may also have played a role here.
Western Europe is the largest market for cannabis resin, responsible for more than 
70 % of global seizures in 2005. UNODC estimates that around 70 % of this hashish 
was produced in Morocco in 2006, down from some 80 % in previous years (UNODC, 
2007). In 2003, France reported that 82 % of the cannabis resin found on its market in 
2002 originated in Morocco. Similar estimates were made for Belgium (80 %), Sweden 
(85 %), and the Czech Republic (70 %). Spain, Italy, Denmark, Finland and Ireland 
reported that almost all of the cannabis resin originated in Morocco (UNODC, 2006). By 
2005–2006, most European countries reported a decline of the importance of Moroccan 
cannabis resin. Based on individual drug seizure data provided by the World Customs 
Organisation (WCO) to UNODC cannabis from Morocco accounted for, in weight terms, 
74 % of total cannabis resin seizures made in Western Europe in 2006, down from 82 % 
in 2004. In terms of number of seizure cases, the proportion of Moroccan cannabis fell 
to 67 % by 2006, according to WCO data. All of this reflects an underlying decline of 
cannabis resin production in Morocco in recent years.
While UNODC relies primarily on official government figures for its global estimates, 
these estimates are not available for all cannabis-producing countries in the world. 
Only a few countries have scientifically valid estimates based on remote sensing 
technology or based on ground surveys. Most countries provide estimates based on 
some extrapolations from their cannabis eradication activities. Where official figures for 
cannabis herb production are not available, UNODC bases its estimates on demand 
data, also taking police intelligence into account. Law enforcement information is 
often available with regard to a country’s position as a cannabis production, transit or 
export country. For countries that are neither importing nor exporting countries, it can 
be assumed that domestic demand is covered by domestic production. For cannabis 
importing countries, there are usually rough estimates available on the share of 
imported cannabis. Similarly, for cannabis exporting countries there are rough estimates 
available on the proportion of cannabis produced for local production and for export. 
Based on such information and estimates on the size of the local cannabis market, likely 
orders of magnitude of domestic cannabis production can be established.
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This approach, of course, is not without difficulties. Survey data on cannabis use are 
also not available for all countries. In such cases, the sub-regional prevalence rates 
are used as a proxy. Even where available, many important questions may remain 
unanswered, particularly with regard to the quantities of cannabis consumed per user. 
Where these figures are available, the reliability of such consumption estimates can still 
be questioned. Even for experienced users, estimating total consumption can be difficult: 
cannabis is often smoked communally, with many consuming less than a whole ‘unit’ in 
a single session of use. Use levels also vary based on drug availability and potency.
Despite these difficulties, available data show some general trend patterns. Most 
available indicators suggest that cannabis production, after having fallen in the late 
1980s (mainly due to large-scale eradications in Latin America), rose again in the 
1990s and continued rising in the new millennium until 2004 before falling back 
in 2005. Similarly, the volumes of cannabis seized by customs and the police have 
been increasing from the early 1990s until 2004 at the global level before declining 
strongly in 2005. Drug use surveys also show that global demand increased until 2004 
before declining in 2005. An estimated 159 million people, or 3.8 % of the population 
age 15–64, used cannabis at least once in the 12 months prior to the survey(s) in 
2005–2006, down from 162 million people in 2004. This figure for 2005–2006 
is, however, still some 10 % higher than for the late 1990s (144 million people in 
1997–1998) (UNODC, 2007). Despite the decline in 2005, consumption estimates and 
expert opinions solicited from UN Member States suggest that cannabis use has been 
growing faster than the use of cocaine or opiates over the last decade (UNODC, 2007).
To keep up with growing demand, either more land area would have been needed 
for the crop, or technological innovation would have been required to make cannabis 
production more efficient. Both factors seem to have played a role in increasing 
supply over the last decade. In fact, in addition to some expansion in the area under 
cultivation, great strides have been made in improving cannabis plot productivity, 
particularly indoors in developed countries.
Cannabis herb production
As argued above, the unique properties of the cannabis plant have led to its widespread 
and diffuse cultivation. Over the 1995–2005 period, 82 countries provided UNODC 
with cannabis production estimates. For comparison, only 46 countries provided 
estimates for opium-poppy cultivation, and only five provided estimates for coca-leaf 
production (DELTA, 2007). But the fact that a country did not provide an estimate does 
not mean that no cultivation exists, as some countries simply lack the capacity to come 
up with estimates. However, there are also some other ways of identifying cannabis-
producing countries.
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UN Member States — as part of the ARQ — are asked to identify the source(s) of the 
cannabis consumed in their countries. While this anecdotal evidence is basically opinion 
data, it is often based on considerable experience in the field, and its value should not 
be underestimated. On this basis, 134 producer countries could be identified as likely 
cannabis producers (UNODC, 2007). A third list of producer countries can be generated 
by singling out those that report the seizure of whole cannabis plants. It is extremely 
inefficient to transport whole plants internationally, as only certain parts are useable as 
a drug. Thus, when a whole plant is seized, it is very likely that it was locally produced. 
Seizures of whole cannabis plants were reported in 146 countries during the 1995–2005 
period. Combining these three lists results in the identification of 172 countries and 
territories where cannabis is produced, out of 197 countries reporting (87 %) (UNODC, 
2007).
Of course, evidence of some cultivation does not mean the practice is large in scale. 
Many of these 172 countries seem to produce primarily to satisfy local demand, but 
there are a number of countries that produce for mass export.
For example, Paraguay produces much of the cannabis consumed in its neighbouring 
countries, and European production hubs include Albania and the Netherlands. Other 
significant exporters include:
in Africa: Nigeria, South Africa, Malawi, Lesotho and Swaziland;•	
in the Americas: Mexico, Canada, Jamaica and Columbia;•	
in Central Asia: Kazakhstan and Kyrgyzstan;•	
in the Middle East: Egypt and Lebanon;•	
in South Asia: India; and•	
in South-East Asia: Cambodia, Thailand and the Philippines.•	
Quantifying this production is another matter. As discussed above, estimating the 
volume of global cannabis production is extremely difficult. The 2004 World Drug Report 
(WDR) provided an estimate of about 32 000 tonnes of cannabis herb production at the 
global level for 2001–2002. The 2005 WDR estimated global cannabis herb production 
to have amounted to 42 100 tonnes in 2003. Since the methods used in arriving at 
these two calculations were not identical, this should not be interpreted as a dramatic 
increase in just two years. Excluding demand-based production estimates, introduced for 
the first time in the 2005 WDR, the global estimate would have still increased to around 
35 000 tonnes for 2004. Applying the revised methodology, as developed for the 2005 
WDR, the 2006 WDR saw a further increase from 42 100 to 45 000 tonnes in 2004. The 
upward trend, however, did not continue for the subsequent year. Without any further 
change in methodology, the 2007 WDR saw a decline to 42 000 tonnes in 2005 — the 
first decline in several years — mainly due to declines reported from North America and 
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Africa, while production continued to rise in many other parts of the world. Despite this 
decline, production is still higher than a decade ago (Figure 1).
There are also other indications suggesting that global cannabis production has been 
increasing over the last decade before falling in 2005. Estimates of the number of 
cannabis consumers globally (based on survey data) and information on the quantities 
of cannabis seized globally by law enforcement have shown increases until 2004 and a 
decline in 2005. Where prevalence data and seizure data are available, such as in the 
USA, a strong correlation between the two datasets was identified in the past, suggesting 
that cannabis seizure statistics, in general, do reflect consumption trends rather well. The 
same is true, if looked at from a global perspective, for cultivation and production trends 
(UNODCCP, 1999) (Figure 2).
In terms of distribution, estimates made available to the UNODC suggest that the 
Americas account for some 47 % of global cannabis herb production. About half of this, 
or close to 10 000 tonnes, is produced in North America. The second-largest producer 
is Africa, accounting for some 25 % of global production. Asian countries account for 
about 22 % of global cannabis production. Most of the cannabis in Asia is produced in 
South-West Asia and the Middle East. Production in Europe, estimated at less than 2 300 
tonnes, accounts for 5 % of global cannabis herb production.
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Figure 1: Estimates of global cannabis herb production
Sources: UNODC annual reports questionnaire data, other government reports and UNODC estimates.
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As mentioned above, all of these must be considered as tentative estimates. For 
instance, for the USA, one of the best studied countries in the world, estimates based on 
cannabis eradication data ranged from 5 600 tonnes to 16 700 tonnes (Drug Availability 
Steering Committee, 2002) in 2000/2001 while demand-based estimates suggested 
production figures of around 1 000 tonnes (ONDCP, 2000). Eradication-based 
production estimates for 2006 ranged from 5 650 to 9 420 tonnes, with a mid-range 
estimate of some 7 530 tonnes. Estimates of net production (after eradication) ranged 
from 2 830 to 6 590 tonnes with a mid-range estimate of 4 710 tonnes for the USA in 
2006 (US Department of Justice, 2007) (Figure 3).
There has been some debate as to whether potency has increased in recent decades. 
This debate is complicated by the fact that comparable potency data are available for 
only a small number of countries throughout the world. A review of the potency evidence 
in Europe was undertaken by EMCDDA in 2004 (see King, this monograph). It remained 
sceptical about overall increases in Europe. Unfortunately, this analysis conflated herbal 
and resin markets.
In fact, the potency of cannabis resin — which is mainly imported into Europe from 
Morocco — seems to have remained stable. However, there is strong evidence that 
herbal cannabis, which appears to be growing in popularity in a number of European 
countries, is becoming more potent, largely due to the increasing availability of indoor-
produced sinsemilla, a trend seen both in Europe and in other developed countries. 
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Figure 2: Global cannabis herb seizures
Source: UNODC annual reports questionnaire data.
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For example, Dutch sinsemilla, which accounts for the bulk of the cannabis market in 
the Netherlands, doubled in potency in just five years, from about 9 % in 1999/2000 
to about 18 % in 2004–2005 (Niesink et al., 2005). In Germany, the European country 
with the largest sample base, no distinction is made between sinsemilla and commercial 
cannabis. Despite this, aggregate herbal potency has doubled in less than a decade. In 
1996, samples averaged about 5 %, rising to about 11 % in 2004. (Bundeskriminalamt, 
2005). In the United Kingdom, sinsemilla potency doubled between 1995 and 2002, 
from about 6 to about 12 % (King et al., 2004). In the other two countries for which 
comparable data are available, the USA and Canada, cannabis potency is also 
increasing (Second Technical Conference on Drug Control Research, 2004). In the USA, 
the Cannabis Potency Monitoring Project found an increase in the average potency of 
cannabis from less than 2 % in 1980 to around 4 % in the late 1980s, around 5 % in 
the late 1990s and 8.5 % in 2006 (1). This total included an average sinsemilla potency 
of over 14 % in each year since 2002, up from 8 % in the mid-1980s (University of 
Mississippi, 2007) (Figure 4).
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Figure 3: Distribution of cannabis herb production, 2005 (42 000 tonnes)
(1) The proportions were calculated based on 59 369 cannabis herb samples, 1 225 cannabis resin 
samples and 443 cannabis oil samples analysed by forensic laboratories in the USA over the 
1975–2006 period. Two-thirds of the 2006 samples were obtained from law enforcement seizures 
and purchases, and the remaining were from domestic eradications. The law enforcement seizures 
were obtained from 45 different states across the USA (University of Mississippi, 2007).
Source: UNODC annual reports questionnaire data, other government reports and UNODC estimates.
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Increases in potency may be also linked to a growing share of the herbal cannabis 
market in developed countries being produced domestically, with a declining share 
being the relatively low-potency product traditionally imported from developing 
countries. In the United Kingdom, it is estimated that as much as half the cannabis 
consumed is domestically grown, and this share has been on the increase in recent 
years (Hough et al., 2003). In Iceland, ‘domestically cultivated marijuana has become 
increasingly competitive with imported marijuana, and current estimates indicate it 
makes up anywhere from 10 to 50 percent of the total cannabis market’ (INCB, 2005). 
Again, this trend appears to be occurring in a number of other developed countries as 
well. In 1986, it was estimated that one-sixth of cannabis consumed in the USA was 
produced within the country (President’s Commission on Organized Crime, 1986), 
whereas more recent estimates are closer to a third (Williamson, 2005), and it would 
appear that this trend is continuing (National Drug Intelligence Center, 2005 and 2007). 
In Canada in 1985, only 10 % of the cannabis consumed was produced domestically 
(Stamler et al., 1985), but by 2002 it was estimated that ‘well over half’ was Canadian 
grown (RCMP, 2002).
In most developed countries, an increase in the share of domestic production means 
an increase in the share of indoor production, and thus an increase in sinsemilla in the 
Figure 4: USA — average cannabis potency, 1980–2006
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Source: University of Mississippi, 2007.
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market (2). Unfortunately, time-series data on the share of the herbal cannabis market 
commanded by sinsemilla in Europe are scant. In discussing the results of their surveys 
of regular cannabis users, Atha et al. concluded that ‘skunk’ (sinsemilla) was the only 
type of herbal cannabis to improve its market share in the United Kingdom between 
1994 and 1997, up just under 10 % (Atha, 2002). Sinsemilla is now said to comprise 
about half of the United Kingdom and Irish herbal markets (King et al., 2004). Outside 
Europe, the share of eradicated cannabis cultivation operations that are located indoors 
in the USA has increased in recent years, from 2 % indoor in 1985 (DEA, 2005) to 
more than 6 % in 2005 (National Drug Intelligence Center, 2006). According to the US 
National Drug Threat Assessment 2005, the prevalence of sinsemilla is continuing to 
grow in the USA (National Drug Threat Intelligence Center, 2005). In Canada between 
1997 and 2000, some 78 % of cannabis production operations detected in British 
Columbia, which produced over 40 % of the detected cultivation operations in Canada, 
were indoors. The number of detected indoor operations tripled during the same time 
period (Plecas et al., 2002). On a national level, a slightly lower share of all operations 
detected were indoors (RCMP, 2002). In New Zealand, the number of national survey 
respondents who had ever used ‘skunk’ increased from 10 % in 1998 to 14 % in 2001 
(Wilkins et al., 2002). After many years of winning market share from both imports and 
a remarkable outdoor industry, hydroponic production is now also the most commonly 
detected method of cultivating cannabis in Australia (Australian Crime Commission, 
2004, reconfirmed in Australian Crime Commission, 2007).
Cultivation for personal use is also a significant source of supply in many areas, and 
in many developed countries this is likely to mean indoor cultivation. In the United 
Kingdom, one study found that 63 % of a sample of regular users reported having 
grown the drug at some point in their lives, growing an average of 24 plants. The 
authors estimated that 30 % of the cannabis used by regular users in the UK was home-
grown in 1997 (Atha et al., 1999). In Spain, legal constraints on carrying — but not 
consuming — cannabis have led to an increase in production for personal consumption 
since 1992 (Gamella and Jimenez Rodrigo, 2004). Cultivation for personal use is also 
common outside Europe, in Oceania, for example. In New Zealand, a household survey 
found that 10 % of all current users grew at least some of their own supply (Wilkins et 
al., 2002). The share of people cultivating for personal use is much higher among those 
who use the drug frequently. A survey of regular users in Australia found that two-thirds 
of respondents grew some cannabis for their own use, and nearly half grew all or most 
of the cannabis they used (Reilly et al., 1998).
(2) The terminology in this area can be confusing. While it is possible to produce seeded cannabis 
indoors, most indoor operations of any scale produce sinsemilla, and as do nearly all hydroponic 
operations. And while there is extensive outdoors production inside consumer countries like the USA, 
in many developed countries there is a substantial overlap between domestically produced cannabis 
and indoor-produced cannabis, due to poor climate and the presence of law enforcement, as well 
as a desire to enhance yield and potency through available technology. The term ‘skunk’ is also used 
for high potency strains of cannabis in parts of Europe and Oceania, a reference to an early ‘Indica/
Sativa’ cultivar that forms the basis of many modern breeds.
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Cannabis resin production
Global cannabis resin production estimates are derived from estimates of hashish 
production in key producing countries, seizure information and intelligence information 
about the importance of various markets. Another approach has been to estimate 
cannabis resin production backwards from estimated cannabis herb production, 
applying the global distribution of cannabis resin to cannabis herb seizures. The two 
approaches give a range of the likely cannabis resin production from 3 800 to 9 500 
tonnes for 2005, and a mid-point estimate of around 6 600 tonnes. Previous year’s 
estimates, based on the same methodology, resulted in a range from 4 200 to 10 700 
tonnes with a mid-point estimate of some 7 500 tonnes. These results reflect falling 
cannabis resin production in the world’s largest hashish producing country, Morocco. 
The declines in Morocco were, however, partially offset by rising levels of cannabis resin 
production in other parts of the world, notably Afghanistan. As a side-product of the 
annual village surveys undertaken as part of UNODC’s Afghanistan Opium Survey, data 
on the area of cannabis cultivation are also collected. These surveys found that the area 
under cannabis (resin) cultivation in Afghanistan rose from some 30 000 hectares in 
2004 to 50 000 hectares in 2005–2006 and 70 000 hectares in 2007 (UNODC, 2007, 
and UNODC, Afghanistan 2007) (Figure 5).
Attempts to break down global cannabis resin production in 2002–2003 suggested that 
more than 40 % of the global cannabis resin supply is being produced in northern Africa 
and more than a quarter in the Near East and Middle East. These two regions thus 
Figure 5: Global cannabis resin production
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Sources: UNODC estimates based on UNODC and government of Morocco cannabis surveys 2003, 
2004 and 2005 and UNODC annual reports questionnaire data.
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accounted for more than two-thirds of global cannabis resin production. Central Asia 
and South Asia accounted for less than 10 % each; South-East Europe for some 5 % and 
the Caribbean for some 3 % of global production (UNODC, 2005).
When UN Member States were asked about the source of cannabis resin in their 
countries, Morocco was also the most often cited country (27 % of all mentions over the 
period 2003–2005 period), followed by Pakistan and Afghanistan. Other important 
source countries identified are Nepal and India, the Commonwealth of Independent 
States (CIS) countries, notably Kazakhstan and Kyrgyzstan, the Netherlands and Albania 
in Europe, Jamaica and Paraguay in Latin America, as well as the Lebanon and Egypt in 
the Near East. If compared with a similar exercise done previously, data suggest that the 
importance of Morocco is declining: 31 % of all mentions over the 1999–2003 period 
versus 20 % in 2005 (UNODC, 2007) (Figure 6).
Morocco remains, nonetheless, the world’s most significant cannabis resin exporter. 
In recent years, about 80 % of cannabis resin seized in Western Europe originated in 
Morocco. By 2005–2006, it is estimated that this proportion declined to around 70 %. 
Since resin is the primary form of cannabis consumed in most of Europe, an analysis of 
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Figure 6: Main source countries of cannabis resin, 2003–2005 (based on information from 
61 countries)
Note: the percentages reflect the number of times a country was identified — by other countries — as a 
major source country for cannabis resin, expressed as a proportion of all such mentions. Source: 
UNODC annual reports questionnaire data, other government reports and UNODC estimates.
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cannabis production for the European market must focus on Morocco (see Gamella and 
Jiménez Rodrigo, this monograph).
UNODC and the government of Morocco conducted comprehensive cannabis resin 
surveys of the country in 2003, 2004 and 2005. The resulting estimates are based on 
the analysis of satellite photos (SPOT 5 and IKONOS) (3) covering the whole of the Rif 
area of northern Morocco, and subsequent ground truthing. The 2003 survey placed 
total resin production at about 3 070 tonnes, cultivated on 134 000 hectares of land in 
the Rif region (equivalent to 10 % of the total land or 27 % of the agricultural area in 
the five provinces (4) investigated) by some 96 600 families, providing income for some 
800 000 people in the region. This was significantly higher than the previously estimated 
80 000–85 000 hectares for the late 1990s by the EU (US Department of State, 2000) or 
the 44 500 hectares estimated by the Moroccan authorities in 1995 (5).
The 2004 survey showed a 10 % decline in the land dedicated to cannabis cultivation 
(120 500 hectares) compared with a year earlier, with production falling to 2 760 tonnes 
(UNODC, 2004) (6). This decline was mainly due to lower levels of cannabis cultivation 
in the provinces of Taounate (–43 %) and Al Hoceima (–54 %), an indirect consequence 
of the earthquake in early 2004, which led to increased ‘interest’ and assistance by the 
authorities. Most cannabis was produced in the province of Chefchaouen (50 % in 2003, 
62 % in 2004) (Figure 7).
The 2005 survey showed a further strong decline (–40 %) in the area dedicated to 
cannabis cultivation in Morocco to 72 500 hectares. Cannabis resin production declined 
to 1 066 tonnes. The area under cultivation was, thus, also lower than the levels in 
the late 1990s. Declines were reported from most provinces, including Chefchaouen 
(–46 %). The largest areas under cannabis cultivation continued to be in the province of 
Chefchaouen (56 % of total), followed by Taounate (17 %) and Al Hoceima (16 %).
The overall area dedicated to cannabis cultivation in Morocco in 2005 was less than 
the area found in a previous UNODC cannabis survey in Kazakhstan (330 000 hectares 
in 1998–1999; though most of this was ‘wild cannabis’) (UNODCCP, 1999) and less 
than opium-poppy cultivation in Afghanistan in 2005 (104 000 hectares) but more than 
opium-poppy cultivation in Myanmar (32 800 hectares) or Laos (1 800 hectares). It was 
(3) The survey was based on the analysis of 16 SPOT5 (multi-spectral, 10 m resolution) and 13 IKONOS 
(panchromatic, 1 m resolution). 
(4) The five provinces were Al Hoceima, Chefchaouen, Larache, Taunate and Tétouan.
(5) It should be noted, though, that all cultivation estimates prior to 2003 have not fulfilled strict scientific 
criteria and must thus be treated with caution.
(6) Some of the decline appears to have been a consequence of an earthquake, resulting in increased 
attention being given by the national authorities and the international community to the region 
concerned.
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also less than the area under coca cultivation in Colombia (860 000 hectares), but 
more than the area under coca cultivation in Peru (48 200 hectares) or Bolivia (25 400 
hectares) in 2005 (UNODC, 2007).
The yield estimates for 2004 were based on a scientific study, conducted on 30 plots 
across the five provinces. The yield on rain-fed land was found to amount to 750 kg/ha; 
the yield on irrigated land was, on average, 1 270 kg/ha in 2004. The rain-fed area 
amounted to 106 100 hectares; the irrigated area was 14 500 hectares. The overall yield 
of herbal material amounted, thus, to 813 kg/ha. Total production of cannabis material 
was estimated at 98 000 tonnes. Out of this cannabis material the farmers produced 
1 019 tonnes of first-quality resin, 921 tonnes of second-quality resin and 823 tonnes 
of third-quality resin, that is, in total some 2 760 tonnes of cannabis resin. This was 
equivalent to 2.8 % of all cannabis material (UNODC Morocco, 2007).
A subsequent yield survey, conducted in 2005, based on data from 87 plots across 
the cannabis producing provinces, found overall lower results. While average 
cannabis production on irrigated land increased to 1 821 kg/ha, due to an increasing 
concentration of cannabis production in more fertile areas of the Rif region, cannabis 
production on non-irrigated land declined, due to a drought, to just 459 kg/ha. Given 
the distribution between irrigated and non-irrigated land in the Rif area (14 750 hectares 
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Figure 7: Area under cannabis cultivation in Morocco, 1986–2005
Sources: UNODC, Maroc — Enquête sur le cannabis 2005, January 2007; UNODC, Maroc — Enquête 
sur le cannabis 2004, May 2005; UNODC annual reports questionnaire data; United 
States Department of State, Bureau for International Narcotics and Law Enforcement Affairs, 
International narcotics control strategy report, March 2000.
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irrigated; 57 728 hectares non-irrigated), the overall average yield amounted to 735 
kg/ha, yielding 53 300 tonnes of raw cannabis. The conversion ratio from dried raw 
material to cannabis resin — based on the analysis from 87 plots — fell to 2 kg of 
cannabis resin per 100 kg of cannabis raw material in 2005, down from 2.8 kg in 
2004. Total cannabis resin production thus amounted to 1 066 tonnes in 2005, down 
from 2 760 tonnes a year earlier (UNODC Morocco, 2007).
In parallel to the decline in production, cannabis farm gate prices doubled, from 25 Dh/
kg in 2004 to 50 Dh/kg in 2005 (i.e. from EUR 2.3/kg to EUR 4.5/kg); cannabis resin 
farm gate prices almost tripled, from 1 400 Dh/kg in 2004 to 4 000 Dh/kg in 2005 (i.e. 
from EUR 127/kg to EUR 363/kg) (UNODC Morocco, 2007). No such price changes 
were, however, reported from European countries in 2005 (UNODC Morocco, 2007).
The income for the farmers from the production of cannabis resin was around EUR 260 
million in 2004, equivalent to 0.7 % of GDP. In 2005, high prices led to an increase 
to EUR 325 million. The amount of money earned with this Moroccan cannabis resin 
in Western Europe (deducting seizures made in Morocco and in Western Europe) was 
estimated at around EUR 10.8 billion in 2004. As cannabis resin prices were not 
reported to have increased significantly in European countries in 2005, the value of the 
smaller amounts of cannabis exported from Morocco and sold on European markets is 
estimated to have declined to some EUR 4.6 billion in 2005 (UNODC Morocco, 2007).
The analysis of the THC content, done by the Laboratoire de Recherches et d’Analyses 
Techniques et Scientifiques, MARATES, based on samples from the 30 plots in 2004, 
revealed that the dry cannabis leaf had, on average, a THC content of 1.2 %; the dried 
flowering tops had a THC content of on average 2.7 % (confidence interval 2.1–3.4 %) 
and the cannabis resin had on average a THC content of 8.3 % (confidence interval 
7.1–9.4 %) with a THC content of the samples analysed from 5.5 to 11.3 % (UNODC 
Morocco, 2005).
Trafficking
Survey data from a number of countries suggest that much of the cannabis consumed 
is not ‘trafficked’ in the traditional sense of the word, but rather grown on a small scale 
and distributed within social networks. As discussed above, cultivation for personal use 
is widespread in many countries. In the United Kingdom, Atha et al. note that ‘most 
home grown (cannabis) is not sold’ and they estimate that 30 % of the cannabis used 
by regular users in the UK was home-grown in 1997 (Atha et al., 1999). If this is 
correct, a significant share of the cannabis used in the UK at that time was produced 
and distributed free within the country. A second study concurs, ‘domestic production is 
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on the increase and as much as half of the cannabis consumed in England and Wales 
may be grown here. Some cultivation is on a commercial basis, but much is on a small 
scale, for personal use or use by friends’ (Hough et al., 2003). As this second study 
suggests, what these small growers do not use or give away, they often sell within their 
social circle. According to survey data from the United States National Survey on Drug 
Use and Health, most (78 %) of those who say they bought the drug in the last year say 
they bought it from ‘a friend’. Similar figures were found in an international comparative 
study of cannabis users in Bremen (80 %) and San Francisco (95 %) (Borchers-Tempel 
and Kolte, 2002) (7). The 2006 National Survey on Drug Use and Health revealed that 
53 % of the persons who used cannabis in the last year at least once, obtained it most 
recently for free (i.e. they shared someone else’s cannabis); 42.8 % bought it; 1.19 % 
traded something for it; and 0.9 % grew it themselves (SAMHSA, 2007). Distribution 
along social lines thus undercuts many of the negative effects associated with drug 
markets dominated by organised crime, but it also facilitates access to the cannabis 
market.
In terms of volume, cannabis remains the most extensively trafficked drug worldwide. 
Expressed in drug units (doses), 70 % of all drug units seized in 2003 concerned 
(7) This study also included users in Amsterdam, most of whom bought their cannabis from a coffee 
shop.
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Figure 8: Global cannabis seizures, 1985–2005
Source: UNODC, annual reports questionnaire data/DELTA.
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cannabis (DELTA, 2005). By 2005, this proportion declined, however, to 59 %, followed 
by cocaine (24 %), opiates (12 %) and amphetamines (4 %) (UNODC, 2007). In contrast 
to other drugs, most of the cannabis-related trafficking arrests — in most countries — 
are accounted for by nationals of the respective country (DELTA, 2007).
Cannabis end-product seizures showed a small downward trend in the late 1980s, 
strong increases in the 1990s and in the first years of the new millennium, but declined 
by 31 % in 2005 to around the levels reported in 2002. Cannabis herb seizures 
amounted to 4 644 tonnes, cannabis resin to 1 302 tonnes and cannabis oil to 0.7 
tonnes in 2005. Cannabis herb seizures thus accounted for 78 % of all cannabis end-
product seizures in 2005. In addition, 32 million cannabis plants and more than 600 
tonnes of cannabis plant material were seized worldwide in 2005. This corresponded to 
a decline of close to 70 % compared with 2003 (DELTA, 2007) (Figure 8).
Following years of increase in the 1980s, the 1990s and the first years of the new 
millennium, cannabis seizures declined by 18 % in Europe in 2005. While cannabis 
herb is the predominant type of cannabis product found globally, cannabis resin is 
the predominant form of cannabis seized in Europe, accounting for almost 90 % of all 
cannabis end-product seizures in 2005. Most of these seizures have been made by the 
Spanish authorities (Figure 9).
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Figure 9: Cannabis seizures in Europe, 1985–2005
Source: UNODC, annual reports questionnaire data/DELTA.
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The global market for cannabis herb in 2003 was estimated at production level to 
amount to some EUR 8 billion, at the wholesale level to some EUR 28 billion and at the 
retail level to some EUR 107 billion. The global market for cannabis resin was estimated 
at the production level to amount to some EUR 0.6 billion, at the wholesale level to 
some EUR 10 billion and at the retail level to some EUR 27 billion in 2003. In value 
terms, the cannabis market accounted for 44 % of the global drug market (EUR 304 
billion) while in terms of the number of drug users (161 million) about 80 % of all drug 
users (200 million) were estimated to consume cannabis (UNODC, 2005). Though no 
new estimates are available, one could assume that the global cannabis market in 2005 
was of similar magnitude.
Trafficking in cannabis herb
More cannabis herb is seized, in a wider range of locations, than any other drug in 
the world. Out of 182 countries and territories reporting seizures to UNODC over the 
2003–2005 period, 165 reported seizures of cannabis herb, more than for heroin (150), 
cocaine (150), cannabis resin (119), amphetamines (96) or ecstasy (97). Cannabis herb 
seizures declined, however, by 35 % in 2005 to the levels reported in 2000, but were still 
92 % higher than in 1990 (DELTA, 2007) (Figure 10).
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Figure 10: Cannabis herb seizures — regional breakdown, 1985–2005
Source: UNODC, annual reports questionnaire data/DELTA.
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In 2005, 63 % of global cannabis herb seizures occurred in North America, followed 
by Africa (18 %) and South America (‘non-NAFTA’) (11 %). The remainder took place in 
Asia (5 %), Europe (2 %) and the Oceania region (0.1 %). This distribution of seizures, 
with most cannabis herb seizures being reported from North America followed by Africa 
and South America, has been consistent for most years since 1994. The proportion of 
seizures made in North America rose from 32 % in 1990 to 63 % in 2005 reflecting 
stronger efforts to fight cannabis trafficking, while the proportion of seizures made in 
South America declined over the same period from 46 % to 11 % as cannabis production 
increasingly shifted to North America, where cannabis with a higher THC content is 
being produced. The proportion of seizures made in Africa increased from 16 % of 
global cannabis herb seizures in 1990 to a peak of 41 % in 2004 (DELTA, 2007), in 
line with reports of ever larger areas under cannabis cultivation. In 2005, however, 
the proportion fell back to 18 % as eradication efforts were intensified in a number of 
countries. This decline in cannabis herb production may not be sustainable, however 
(UNODC, 2007).
The world’s largest cannabis herb seizures in 2005 were made by the law enforcement 
agencies of Mexico (1 781 tonnes or 38 % of the total), followed by those of the USA 
(1 112 tonnes, or 24 % of the total). These two countries have led the world in cannabis 
seizures since 1994 (except for the year 2000, when the USA ranked fifth). The next 
largest seizures in 2005 were reported by South Africa (6 % of total), followed by 
Brazil, Tanzania, India, Colombia and Nigeria (3 % each). The largest seizures among 
European countries were shown by the Russian Federation (rank 15), followed by the UK 
(rank 18) (DELTA, 2007).
The share of Europe in global cannabis herb seizures increased from 1 % in 1985 
to 13 % in 1994 as consumption increased, before falling gradually back to 2 % of 
global seizures by 2005. In 2005, cannabis herb seizures declined in Europe by 40 % 
compared with a year earlier, thus exceeding the global decline in that year (–35 %). 
Declines were also reported from Africa, North America and the Oceania region, while 
seizures increased in Asia and in South America (DELTA, 2007). The decline of cannabis 
herb seizures in Europe seems to reflect primarily changes in law enforcement priorities 
in a number of European countries. In addition, the decline may have been due to a 
decline in cannabis herb imports into Europe, as supply is increasingly shifting towards 
domestic sources. The fall in seizures does not appear to be due to any significant 
decline in consumption. Lifetime usage among 15- to 16-year-olds in Europe increased 
by more than 80 % between 1995 and 2003 (UNODC, 2005) and cannabis use also 
increased among the general population over the last decade. In recent years, cannabis 
use seems to have reached a plateau in several European countries and started falling 
in others. However, these declines have been far less important than the reported 
declines in seizures (UNODC, 2007).
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Trafficking in cannabis resin
Global cannabis resin seizures declined in 2005 by 11 % compared with a year earlier, 
dropping to 1 302 tonnes, below the levels reported in 2003. Resin seizures declined 
at a rate above average in Europe (–15 %), reflecting falling levels of cannabis resin 
production in Morocco (DELTA, 2007).
Out of global cannabis resin seizures, Europe accounted for 922 tonnes, of which 916 
tonnes (70 % of the total) was seized in West and Central Europe, 18 % in the Near and 
Middle East/South-West Asia and 8 % in North Africa. The largest seizures worldwide 
were reported by Spain (670 tonnes, or 51 % of the total), followed by Pakistan (94 
tonnes, or 7 %), Morocco (92 tonnes, or 7 %). Significant amounts were also seized by 
the authorities in Iran (69 tonnes, or 5 %) and Afghanistan (42 tonnes, or 3 %) (DELTA, 
2007). The largest seizures in Europe, after Spain, were reported by France (6 % of total 
in 2005), the UK (5 %), Portugal (2 %) and Italy (2 %) (Figure 11).
The main destination of cannabis resin is West and Central Europe. About 70 % of the 
cannabis resin destined for the West and Central European market in 2005–2006 is 
estimated to have originated in Morocco, down from around 80 % a few years earlier 
(UNODC, 2007). Much of the cannabis resin transits Spain and the Netherlands before 
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Figure 11: Cannabis resin seizures — regional breakdown, 1985–2005
Source: UNODC, annual reports questionnaire data/DELTA.
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being shipped to other countries (see Gamella and Jiménez Rodrigo, this monograph). 
Most of the remainder of the resin supply originates in Afghanistan/Pakistan (e.g. 59 % 
in Greece, 30 % in Turkey, 30 % in the Czech Republic, 14 % in Belgium, less than 10 % 
in France and Italy), in Central Asia (mostly for the Russian Federation, other CIS states 
and some of the Baltic countries) or from within Europe (mainly Albania, supplying the 
markets of various Balkan countries and Greece) (DELTA, 2007).
The second-largest destination of cannabis resin is the Near and Middle East/South-West 
Asia region. This region is mainly supplied from cannabis resin produced in Afghanistan 
and Pakistan and, to a lesser degree, from cannabis resin originating in Lebanon. Some 
of the cannabis resin from Afghanistan/Pakistan is also being shipped to Canada and to 
countries in Eastern Africa.
North Africa makes up the third-largest market and is predominantly supplied by 
cannabis resin produced in Morocco. The importance of other markets is limited. Nepal 
is a source country for cannabis resin exports to India and to some other countries and 
Jamaica is a source country for cannabis resin exports to some other countries in the 
Americas.
More research required
Generating sound estimates of global cannabis production levels is likely to remain a 
slippery subject for many years to come, but there are several areas where data could 
be improved greatly:
There is a need for more scientific surveys on the areas under cannabis cultivation. •	
These should help to identify the areas under ‘wild cannabis’ and the areas where 
cannabis is cultivated, on irrigated and on rain-fed land. This may be expensive, 
but remote sensing technology is becoming more readily available and is being 
used in other areas of agriculture. Using a sampling approach, a growing number 
of countries should be in a position to undertake such surveys if control of cannabis 
cultivation is deemed a priority. Where satellite imagery is not available, UNODC 
has developed methods to identify illicit crops by means of a sampling approach 
and helicopter over-flights, as well as through ground surveys. The ‘know-how’ for 
such surveys is readily available in UNODC to be shared with Member States. The 
situation is more difficult when it comes to indoor cultivation which, in general, 
cannot be identified through the analysis of satellite photos or helicopter over-
flights. Nonetheless, more reliable estimates on the extent of outdoor cultivation of 
cannabis could form the basis for reasonably good estimates on the likely extent of 
such indoor cultivation activities, in combination with eradication data and forensic 
analyses of cannabis seizures.
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There is also a need for scientific yield data across a wide typology of cultivars and •	
cultivation styles. Feral or semi-cultivated strains found in Kazakhstan are likely to 
differ greatly in productivity when compared with intensively grown cannabis in 
Morocco, or informal plots in South Africa, or indoor operations in Canada. These 
figures will remain imprecise, but at the very least, a plausible range of values 
needs to be compiled.
Distinction between the various cannabis products is essential: a standardised •	
definition of sinsemilla would be useful to differentiate this drug from other herbal 
cannabis.
The quality of reported seizure data should be analysed. One possible source of •	
the discontinuity between supply- and demand-based production estimates could 
be inflated seizure data, based on either inaccurate plant-to-product conversion 
rates or the inclusion of bulk plant material not suitable for sale. Finally, there is 
a general danger of double counting once various law enforcement bodies are 
involved.
There remains a need to analyse, on a systematic basis, the THC content of •	
cannabis found on the market, and its development over time. Standards to 
undertake such analyses in an internationally comparable way would need to be 
developed. Forensic analysis could also help to identify the sources of the cannabis.
It would also be useful to have studies made of the distinction between the drug as •	
sold and the drug as used. Herbal cannabis users, including sinsemilla users, clean 
their product before consumption. This could help to explain some of the significant 
differences between supply and demand-side estimates.
On the demand side, more data are required on cannabis consumption (amounts 
consumed per cannabis user). While some data exist on the number of days of use 
amongst annual users, the data on volumes consumed remain dubious. Scientific 
study needs to be made of the standard dose for inexperienced users and the rate and 
extent to which tolerance develops. In addition to this, empirical observation of actual 
use patterns needs to be made across a wide range of cultural contexts. User surveys 
would benefit if they were to distinguish between herbal cannabis and cannabis resin 
consumption.
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Chapter 13
Monitoring cannabis availability 
in Europe: issues, trends and 
challenges
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Setting the context
In most of Europe, few would argue that cannabis is difficult to obtain for those who 
seek to use it. Nonetheless, when looking at issues of supply and demand, sellers 
and buyers, products and distribution, there are numerous pieces of the picture which 
need to be assembled to gain an insight into how policymakers may tackle the drug’s 
distribution. This chapter looks at the broader concept of availability of cannabis, a 
concept that goes beyond market analysis and embraces further issues such as price and 
the perceived ease of purchasing a drug.
Cannabis is the most frequently used illicit drug in the EU. Some commentators 
have suggested that the drug has become more readily available, yet the concept of 
availability is one that is both difficult to define and to measure. Nonetheless, it is 
possible to look at a number of indirect indicators that, when taken together, allow for 
the construction of a more general picture of cannabis availability in Europe.
In this chapter, data on drug seizures, prices, potencies and perceived availability 
among the general public are used to explore overall trends in the availability of 
cannabis products in Europe between 1998 and 2003. Analysis is presented for EU 
Member States and Norway.
Data analysis at this level is always challenging and a range of methodological issues 
and data limitations means that conclusions must be drawn with caution. In particular, 
the amount of missing data on some measures presents a serious problem for analysis. 
Despite these difficulties some clear trends do seem evident in some of the indicators. 
However, when taken together no coherent picture emerges, with some datasets 
supporting the assumption that cannabis availability has been increasing whilst other 
information suggests a more stable situation.
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Further reading
Cyclical sources of data on drug supply
EMCDDA, Annual reports and Statistical bulletin, European Monitoring Centre for Drugs and Drug 
Addiction, Lisbon (published annually in November).
UNODC, World drugs reports and Interactive seizure reports, United Nations Office on Drugs and 
Crime, Vienna.
World Customs Organisation, Customs and drugs reports (published annually in June).
General reading
Gouvis Roman, C., Ahn-Redding, Simon, R. (2007), Illicit drug policies, trafficking, and use the world 
over, Lexington Books, Lanham.
UNODC (1987), Recommended Methods for Testing Cannabis, United Nations Office on Drugs and 
Crime, Vienna.
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Monitoring cannabis availability 
in Europe: issues, trends and 
challenges
Chloé Carpentier, Meredith Meacham and Paul 
Griffiths
Towards a conceptual framework for exploring 
drug availability — approaches and data sources
The availability of illicit drugs is an important concept for drug policy, and reducing 
availability can be found as an explicit policy objective at both European and national 
levels (1).
Rationale
Policy interest in drug availability can be broadly characterised as focusing on two 
topics. The first topic is the relationship between availability and demand and rests 
upon an implicit assumption that changes in the availability of drugs will be associated 
in some way with levels of use. At EU level this has resulted in a fairly pragmatic 
monitoring strategy of collecting and analysing information that may allow changes over 
time in drug availability to be charted. Currently, as described below, EMCDDA activities 
in this area focus on improving the reliability and comparability of data sources to allow 
better monitoring of trends in availability at street level for the more prominent groups 
of drugs.
The second topic of interest is to understand what factors can have an impact on the 
availability of different drugs, in order to inform the development of interventions with 
the aim of addressing these factors. Answering this sort of question goes beyond simply 
monitoring and requires more complicated research or statistical modelling exercises.
(1) Drug availability appeared in the EU political debate in the mid- to late-1990s. One of the four initial 
aims of the UK 10-year (1998–2008) Drugs Strategy, ‘Tackling drugs to build a better Britain’ (UK 
Government, 1998), was ‘to stifle the availability of illegal drugs on our streets’. It was soon followed 
by a similar target (Target 4) at the EU level in the EU Drug Strategy 2000–2004 (European Council, 
1999), ‘to reduce substantially over five years the availability of illicit drugs’, while the EU Action 
Plan 2000–2004 (European Council, 2000) emphasised a monitoring approach of this issue in its 
call for the development of ‘indicators of availability of illicit drugs (including at street level) and drug 
seizures’ to be supported by the EMCDDA and Europol.
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Defining ‘availability’
From an operational perspective it is clear that defining availability is not simple: the 
word has been interpreted differently in different contexts. In a general sense, availability 
might be treated as synonymous with ‘access’, and in the drugs field the concept has 
sometimes been simply associated with ‘drug supply data’. For example, one report 
from the USA on cocaine availability produced various estimates based on a model 
derived principally from production and interdiction data (ONDCP, 2002).
Data from demand-side indicators have also been used to estimate drug availability, 
most simply in questionnaires that ask respondents to rate, in some way, the availability 
of drugs in their locality. Additionally, data on drug consumption or offers of drugs have 
also been used as indirect indicators. Currently, the developing consensus supports 
a conceptual framework for assessing drug availability that includes both supply and 
demand elements, though these elements have been made operational in a variety of 
ways and no common approach currently prevails.
Nonetheless, it does appear reasonable to consider drug availability as consisting of a 
synthesis of the following elements:
the amount of illicit drugs physically on the market (drugs produced and trafficked •	
but not seized — drug supply to the market);
the structure of drug flows and distribution (retail outlets, dealers, drug scenes); and•	
the relationships between drug users/non-drug users and this distribution structure •	
(access).
A further valuable analytical distinction is between global availability and street level 
availability. In the context of the EU, global availability might be defined as drug 
availability at the upper/wholesale level of the market, or at the trafficker’s level, as 
a result of the interaction between drug supply and drug control strategies at that 
level of the market. Street level availability might be defined as drug availability at the 
retail level of the market, or at the user’s level, as a result of the interaction of global 
availability, distribution processes and strategies, drug control strategies at retail market 
level and access of various groups of users/non-users to different illicit products. Except 
for data relating to seizures, a common link between global and street level availability, 
this paper will focus on the street level of availability.
Current indicators
The current EMCDDA approach has been to develop a set of indicators of drug 
availability, with particular focus on street level availability. As drug availability is an 
ill-defined concept, a multi-indicator approach has been adopted with the objective 
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of bringing together these different data sources into a more general measure of 
availability. Information is provided annually through the Reitox network of national 
focal points and covers areas including: drug prices at retail level, contents of drugs and 
potency, drug seizures and the perceived availability of drugs at street level.
Clearly, none of these information sources produce a simple or unproblematic reflection 
of the availability of drugs in Europe and any analysis must be made with caution. 
The corroboration of contextual and qualitative information is particularly important 
if erroneous inferences are to be avoided. Drug seizures, for example, are influenced 
by the level and efficiency of law enforcement activity (which vary both between and 
within countries over time) as well as the availability of drugs in a particular market. 
Despite this problem, seizure data do appear to be useful in looking at trafficking routes 
(UNODC, 2005) and in many cases it seems fair to make the assumption that drug 
seizures in a given country are at least somewhat correlated to the amount of drugs 
imported or smuggled into that country. It has even been assumed in international 
discourse that drug seizures represent a relatively stable proportion of the drug supply 
(often assumed to be about 10 %) and could therefore be considered as an indicator 
of drug availability on the national market. In the case of cannabis, seizures of plants 
have also been taken as an indicator of the extent of domestic cannabis cultivation or 
cultivation in neighbouring countries (Pietschmann, this monograph).
Similarly, both price and the potency of illicit drugs may have an impact on the 
perceived availability of illicit drugs and reflect important supply-side factors that affect 
access. This relationship is often not a simple one, but both price and potency can be 
considered as indirect indicators of drug availability. Drug prices may vary according to 
many factors including the level of the market or volume at which they are traded. Prices 
are also likely to reflect the basic laws of supply and demand. In this respect, lower 
prices would in theory seem to indicate a higher availability (or a greater supply), or, 
although it is perhaps less likely, reduced demand.
For a number of methodological and practical reasons, interpreting data on potency 
is a complicated task — and these difficulties are particularly apparent for cannabis 
(see below). However, this information is collected in some EU countries principally as 
a legal requirement for criminal prosecutions, but also, in some cases, as part of drug 
monitoring activities. Although establishing a direct link between potency and availability 
is difficult, changes in the overall potency of drugs, especially when prices are moving in 
an opposing direction, can be regarded as a useful indirect indicator of availability — 
albeit one to be interpreted carefully.
Finally, school and adult surveys sometimes include questions on the perceived 
availability of drugs in the communities from which the respondents are drawn. Although 
important methodological questions exist, such as the influence on such perceptions of 
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different kinds of exposure to drug use and the overall reliability of perceptions reported 
in drug surveys, this kind of data can also provide indirect yet complementary data on 
drug availability.
What do the available data tell us about cannabis 
availability in Europe?
Due to methodological issues and a simple absence of complete and detailed time-
series data, limitations are imposed on any attempt to answer this question. Despite 
this setback, it is possible to some extent to construct a general picture of the different 
indicators of cannabis availability in Europe. Taking the year 2003 as an example, 
below we describe the information available and explore to what extent a coherent 
picture of trends in cannabis availability can be established.
Seizures
The EMCDDA dataset on drug seizures dates back to 1985, and the data records 
both seizures and quantities of drugs seized. Data availability has varied as countries 
have improved their reporting capacity, but considerable work remains to be done on 
improving the comparability of measures used. These data relate to all seizures made 
over the course of a year by all law enforcement agencies (police, customs, national 
guard, etc.). Although generally rare, double-counting may occur within the data 
presented by some countries.
The implications of looking at quantities seized or numbers of seizures can be different. 
A major proportion of the number of overall seizures usually comprises small seizures 
made at the retail or street level of the market. Quantities seized may fluctuate from 
one year to another due to a few exceptionally large seizures of drugs made further up 
the distribution chain. For this reason the number of seizures is sometimes considered 
a better indicator of trends — although a count of the number of seizures is sometimes 
less available. A further complication for cannabis arises because of the different types 
of cannabis available in Europe. Only since 1995 has it been possible to begin to make 
a distinction between different types of cannabis products — that is, plants, herb and 
resin — and some countries are not able to do this. Therefore, the corresponding time 
series are sometimes incomplete, making the analysis of EU trends more difficult (2).
(2) Caution is required on the reporting of herbal and plant seizures, as practices might vary by country, 
possibly leading to the incorrect categorisation of one type of substance into either herbal or plant 
seizures.
Chapter 13
221
Seizures of cannabis plants
Cannabis grown within the EU is beginning to represent a significant part of the market. 
Data on seizures of cannabis plants from EU reporting countries and Norway in 2003 
amounted to 8 600 (3) seizures of about 1.6 million plants and 8.9 tonnes of the same 
material. The highest numbers of seizures were reported by the United Kingdom, 
followed by Hungary and Finland (4), while the largest quantities were recovered in the 
Netherlands, followed by Italy, Poland and the United Kingdom.
Not all countries can provide data for the period 1998–2003 but based upon the 
information available a decline was evident in the number of seizures of plants reported 
until 2001, followed by a subsequent increase. Since 1998, overall quantities seized 
have been increasing with peaks in 2000 and 2001, mainly due to exceptionally large 
seizures made by Italy in these years (1.3 and 3.2 million plants, respectively).
Seizures of cannabis resin
About 200 000 seizures (5) and 1 025 tonnes of cannabis resin seized were reported in 
the EU and Norway in 2003, with Spain accounting for the biggest share by far, both 
in terms of numbers and quantities seized, and reflecting the importance of the Iberian 
peninsula as an importation route for Moroccan-produced cannabis entering Europe 
(see Gamella et al., this monograph). France and the United Kingdom, which represent 
relatively large markets for cannabis, also stand out as countries seizing significant 
quantities of the drug. Both in terms of numbers and quantities, overall cannabis resin 
seizures increased during the period 1998–2003. However, in 2003, the number of 
seizures declined while quantities increased highly due to large amounts recovered in 
Spain.
Seizures of herbal cannabis
In the EU herbal cannabis is less commonly seized than resin — illustrated by the fact 
that in 2003 the total amount of herbal cannabis seized was 79 tonnes, or less than 
10 % of the amount of resin seized, with the United Kingdom recovering the largest 
quantities every year, followed by Italy. Numbers of seizures of herbal cannabis have 
been increasing overall since 1998, though they remained stable in 2003, as opposed 
to figures for quantities seized, which have been declining for most years.
(3) Reported by 17 countries (data not available for Denmark, France, Italy, Cyprus, Latvia, the 
Netherlands, Poland, Slovenia and Sweden).
(4) However, data on the number of seizures made were not available for countries seizing the largest 
quantities — Italy and the Netherlands.
(5) Reported by 19 countries (data not available for Denmark, France, Italy, Cyprus, Latvia, the 
Netherlands and Slovenia).
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In analysing seizure data a useful distinction can be made between police and customs 
seizures, based on the assumption that police seizures may better reflect retail level 
activity and that customs seizures are at a wholesale level and may include drugs in 
transit to third countries. Since 1995, data collection at the European level have included 
a request for a breakdown by seizing entity. This dataset requires further development 
as not all countries are currently able to provide this information nor is it possible at 
present for some countries to make a distinction between different cannabis products. 
Therefore, due to missing data, totals will represent an underestimate of the true 
situation.
Despite these limitations, data show that from 1998 to 2003 there was a general 
increase in the number of police seizures of cannabis (all material included) whilst the 
number of reported customs seizures remained relatively stable. Quantities of cannabis 
seized by both police and customs authorities increased during this period at about 
the same rate. For both seizing entities Spain was responsible for a major share of 
the quantity of drugs recovered. A gross calculation of the average sizes of cannabis 
seizures (6) over the period 1998–2003 shows that police seizures are usually smaller 
than customs ones, with size ratios up to 1:100 in Spain and the United Kingdom.
Retail prices
Data on retail prices of cannabis products come from a range of different sources, the 
comparability of which is often unclear. These sources include test purchases, interviews 
with arrested dealers/consumers, police intelligence and surveys of drug users. 
Sampling strategies used for calculating price estimates also vary considerably and in 
some countries the representativeness of these data is questionable. The EMCDDA is 
working with national experts to improve the comparability of data and methodological 
approaches of collecting price data at the street or retail levels. Although caution is 
required when drawing any firm conclusions from the currently available dataset, it is 
possible to obtain a general picture of overall trends.
Because prices vary by product type, efforts have been made to distinguish between 
different types of cannabis. The main breakdown by product type is made between 
herbal cannabis and cannabis resin. Whenever possible, a further distinction is made 
between different types of herbal cannabis, as the herbal cannabis market often contains 
a number of distinct products. In particular, high potency types of cannabis, such as 
some forms of domestically produced product, attract a premium price. However, it has 
only recently become possible to make this sort of distinction, and further analysis is 
hampered by a lack of data on the dynamics of the European cannabis market.
(6) Dividing quantities seized by numbers of seizures.
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Prices in 2003
Data for 2003 on the price of resin and herbal cannabis are available from 24 and 
21 European countries respectively. The ranges reported for minimum and maximum 
prices of cannabis resin and herb are relatively narrow compared with potency data 
(see below). Although considerable variation is seen between the cheapest and most 
expensive countries, considerable overlap also exists between many countries with 
respect to average prices reported. The average price of resin varied from EUR 1.4/g 
in Spain to EUR 21.5 in Norway, with about half of all countries reporting average 
prices in the range of EUR 5–11. Most countries reported a lower price for herbal 
cannabis than resin, again with a considerable range of EUR 1.1/g in Spain to EUR 12 
in Latvia, and most countries reporting average prices between EUR 5 and 8 per g. The 
importance of looking at sub-types of herbal cannabis was illustrated by the Netherlands 
and the United Kingdom, where analysts were able to provide a separate estimate for 
home-produced cannabis, the price of which was higher — on average EUR 6/g in the 
Netherlands and EUR 8.2/g in the United Kingdom.
Because cannabis prices may be higher in countries where other goods are more 
expensive or there is a higher standard of living, in order to attempt to explain 
differences in cannabis prices between countries, it is possible to look at correlations 
between a country’s average prices of cannabis products and the country’s demographic 
and socio-economic situation in the same year, as represented by two indices — the 
human development index (HDI) (7) and gross domestic product per capita in purchasing 
power parity (GDP per capita in PPS) (8). Analyses show that there is no clear correlation 
between such indicators and cannabis prices (by product) when considering all the 
reporting countries together. However, further distinction between groups of countries 
suggests that prices of both resin and herbal cannabis are positively correlated to both 
the HDI and GDP (per capita in PPS) in the countries from the EU-15 (9). In the new EU 
Member States, there is either a negative or non-existent correlation between prices of 
both cannabis products and the HDI and GDP (per capita in PPS). However, it should be 
noted that the negative correlations found in this group of countries were stronger for 
herbal cannabis than for resin (10).
(7) The Human Development Index is a composite index measuring the average achievements in a 
country in three basic dimensions of human development: a long and healthy life (measured by 
life expectancy at birth); knowledge (measured by the adult literacy rate and the combined gross 
enrolment ratio for primary, secondary and tertiary schools); and a decent standard of living 
(measured by GDP per capita in purchasing power parity (PPP) US dollars) (UNDP, 2005).
(8) Taking as a basis EU-25 = 100 (source: http://epp.eurostat.ec.europa.eu).
(9) The correlation coefficients in the EU-15 in 2003 were: 0.66 between resin price and HDI; 0.46 
between resin price and GDP (per capita in PPS (purchasing power standard)); 0.54 between herbal 
cannabis prices (type unspecified or imported) and HDI; and 0.59 between herbal cannabis prices 
(type unspecified or imported) and GDP (per capita in PPS).
(10) The correlation coefficients in the new Member States in 2003 were: –0.16 between resin price and 
HDI; –0.05 between resin price and GDP (per capita in PPS); –0.50 between herbal cannabis prices 
(type unspecified or imported) and HDI; and –0.34 between herbal cannabis prices (type unspecified 
or imported) and GDP (per capita in PPS).
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Though this analysis is tentative, it does suggest some relationship between cannabis 
prices and national demographic and socio-economic situations in the older EU Member 
States, where cannabis markets are relatively long established. The picture is less 
clear for the new Member States, where there are not only questions of data quality 
but also the possibility that markets in these countries are subject to strong change. 
Other indicators have suggested that cannabis use is increasing, though often from low 
initial levels, and that these cannabis markets should be considered relatively ‘young’ 
and far less established. Routes of cannabis trafficking might also explain some of the 
differences observed between EU countries in the retail level price of cannabis products 
— particularly by noting the proximity of Morocco for producing cannabis resin and the 
increasing importance of Albania for producing herbal cannabis. Countries that are 
closer to these producing regions are likely to experience lower transport costs during 
trafficking and, therefore, lower prices.
Long-term price trends
An analysis of long-term trends in prices is hampered by the fact that although a few 
countries have been reporting data on cannabis products since the mid-1990s or earlier, 
it takes several years for the dataset to grow sufficiently large enough to explore trends 
at a European level. It should also be noted that data from the new EU Member States 
have only been available since 2002. The EU mean (arithmetic mean) of average prices 
of cannabis resin (corrected for inflation (11)) in reporting countries slowly decreased 
in the period 1996–2003 (see Figure 1). A more detailed analysis of such prices in 
countries that have been reporting for four years or more shows that overall trends for 
1999–2003 (12) were either stable or declining in all countries, with the exception of 
France and Luxembourg, where a modest increase was noted.
Changes in the average prices of herbal cannabis are less clear than those of 
cannabis resin. Indeed, Figure 2 does not show a clear overall EU trend of such 
prices in reporting countries, except for a fall in 2003 in a majority of countries. Over 
1996–2003, however, the EU mean (13) of reported prices increased overall, with a 
peak in 2001 and a fall since then (14). In most of the countries reporting for at least 
four years, herbal cannabis prices have remained stable or have decreased (15), while 
an upward trend was reported by the Czech Republic, Latvia, Luxembourg and Portugal. 
The average price of locally produced herbal cannabis has been declining in recent 
years in both of the countries that are able to report on the price of these products 
separately (Netherlands, United Kingdom).
(11) Taking 1996 as a base year for the value of money in all countries.
(12) Taking 1999 as a base year for the value of money in all countries.
(13) Arithmetic mean.
(14) Taking 1996 as a base year for the value of money in all countries.
(15) Taking 1999 as a base year for the value of money in all countries.
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Figure 1: Average retail price of cannabis resin (EUR/g) — adjusted to inflation — in the EU 
Member States and Norway, 1996–2003
Notes: Prices are adjusted for inflation, taking 1996 (for all countries) as a base year. Belgium (1996, 
1997, 1999, 2000, 2003); Czech Republic (1998–2003); Germany (2002); Latvia (2001–2003); 
Norway (2002–2003); Poland (2002–2003); Slovakia (2002–2003); Slovenia (1996–2003): 
figures reported as averages are actually middle points between minimum and maximum prices. 
The Netherlands: 1999 data refer to 1999/2000; 2000 data refer to 2000/2001; 2001 data refer 
to 2001/2002; 2002 data refer to 2002/2003; 2003 data refer to 2003/2004. Spain: the price 
reported as average refers to quantities sold by gram. Hungary: the figure reported as average is 
actually the modal, or ‘typical’ price. Source: Reitox national focal points.
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Figure 2: Average retail price of herbal cannabis (EUR/g) — adjusted to inflation — in the 
EU Member States and Norway, 1996–2003
Notes: LP refers to ‘nederwiet’, usually locally produced cannabis herb. Prices were adjusted to inflation, 
taking 1996 (for all countries) as a base year. Hungary: the figure reported as average is actually 
the modal, or ‘typical’ price. The Netherlands: 1999 data refer to 1999/2000; 2000 data refer 
to 2000/2001; 2001 data refer to 2001/2002; 2002 data refer to 2002/2003; 2003 data refer 
to 2003/2004. United Kingdom: figures submitted as ‘nederwiet’ refer to ‘skunk’. Belgium (1996, 
1997, 1999, 2000, 2003); Czech Republic (1998–2003); Germany (2002); Latvia (2001–2003); 
Poland (2002–2003); Slovakia (2003); Slovenia (1996–2003): figures reported as averages are 
actually middle points between minimum and maximum prices. Source: Reitox national focal 
points.
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Time trends of the average price of both resin and herbal cannabis have also been 
reported by 15 EU Member States (16). Comparisons between prices of both products (17) 
show that over the period 1996–2003, the average price of resin was overall higher 
than that of herbal cannabis in all but two of the reporting countries, although this 
difference was not often strongly pronounced. Additionally, trends in the average price 
of both products by country are similar in all the reporting countries, except France, 
which reported an overall fall in herbal cannabis prices and an increase in average 
resin prices. Lastly, reported data show a possible convergence between average prices 
of cannabis resin and herb in many countries.
Potency
The potency of cannabis products is a topic considered in detail elsewhere in this 
monograph and so will only be briefly considered here. Potency of cannabis is usually 
defined as the tetrahydrocannabinol (THC) content by percentage. Both practical 
and methodological difficulties mean that data on cannabis potency must be viewed 
with some caution. For example, the number of samples analysed varies greatly 
between countries (from four to over 3 000 samples in the 2003 data submitted to the 
EMCDDA) and, thus, the representation of samples in a given user population may be 
questionable. Furthermore, there are analytical difficulties in the precise and accurate 
determination of the potency of cannabis products (EMCDDA, 2004) and considerable 
variations in both the practice of taking samples from cannabis cultivation sites for 
analysis and that of sampling parts of the material to be analysed (ENFSI, 2005). All of 
these reasons mean that there is a need to improve and standardise approaches in this 
area if the reliable monitoring of cannabis potency is to be achieved. As stated above, 
it is important to distinguish between different types of cannabis (resin and herbal 
cannabis) — especially when considering potency. Theoretically, a further distinction 
should be made whenever possible between imported herbal cannabis and home-
produced herbal cannabis, although in practice very few countries can systematically 
report data separately. For all types of cannabis the assessment of trends over time are 
hampered by a lack of historical data, with only a couple of countries reporting before 
1999.
(16) Belgium, Czech Republic, Germany, Ireland, Spain, France, Cyprus, Latvia, Lithuania, Luxembourg, 
Netherlands, Portugal, Slovenia, Sweden, United Kingdom.
(17) In each country, we have taken the first year of the series of data available (from 1996 onwards) as 
a basis for the value of money.
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Cannabis resin potency
Compared with prices, cannabis potency is reported by fewer countries but still shows 
considerable variation. Average potencies of cannabis resin in 2003 varied between 
less than 1 % and nearly 25 %, with a majority of countries reporting average potencies 
between 7 % and 15 %. The range of values upon which average potencies are 
calculated was very wide in some countries — raising questions about how meaningful 
the reported average values are for describing the cannabis market. An extreme 
example is in Slovakia, where there is a difference of 53 percentage points between 
the lowest and the highest potencies found. Out of the 16 countries reporting data 
on resin potency in 2003, eight report minimum values under 1 % while seven report 
maximum values over 25 % (three of which report maximum values of 40 % or over). 
Given that much of the cannabis resin consumed in Europe is produced in North 
Africa under similar conditions, these differences are difficult to explain (see Gamella, 
this monograph). Data available show an overall (moderate) increase in the average 
potency of cannabis resin since 1999, although there has been a decline in 2002 in a 
majority of reporting countries.
Herbal cannabis potency
The average reported potency of herbal cannabis in 2003 was generally lower than 
that of resin in all countries, with the exception of the United Kingdom. Reported values 
ranged from less than 1 % to nearly 14 %, with half of the countries (18) reporting 
estimates of between 4 % and 9 %. Locally produced herbal cannabis is now available 
in most EU countries, and when produced under intensive conditions it can be of high 
potency. Only the Netherlands was able to provide a separate estimate in 2003 for this 
type of product (20.3 % THC on average). It is hard to observe any overall clear trend 
for the EU in the potency of herbal cannabis in general over the last five years (see 
Figure 3). At a national level some countries reported a modest increase. Elsewhere, a 
relatively stable situation can be observed. Overall, the mean value (19) of the reported 
averages of herbal cannabis shows little variation over the period 1999–2003 (20). The 
reported potencies of locally produced herbal cannabis where these data are available 
show an increase in the Netherlands, and a relatively stable situation in the Czech 
Republic. In both countries the estimated potency of home-produced herbal cannabis 
exceeded that of cannabis resin from 2002.
(18) Seven out of a total of 14 countries reporting data on the average potency of herbal cannabis in 
2003.
(19) Arithmetic mean.
(20) It is actually slightly decreasing over 1999–2003, but variations in the mean can be explained by the 
fact that the number of countries reporting data has varied over the period, thus affecting the number 
of countries upon which the mean is calculated; indeed five countries reported data on the average 
potency of herbal cannabis of type unspecified or imported for 1999 and 14 for 2003. Indeed, the 
calculated means of the data from the nine countries reporting over 2001–2003 and of those from 
the seven countries reporting over 2000–2003 are both slightly increasing.
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Figure 3: Average potency of herbal cannabis, measured as percentage of THC content, in 
the EU Member States and Norway, 1996–2003
Notes: LP refers to ‘nederwiet’, usually locally produced cannabis herb. Czech Republic: figures reported 
as average are actually middle points between minimum and maximum potencies. Figures 
reported as ‘nederwiet’ refer to more potent cannabis herb, such as sinsemilla or ‘skunk’ (locally 
produced as well as imported). Figures reported as ‘other herb’ refer to cannabis herb of type 
other than ‘nederwiet’. Germany: figures reported as average are actually the median. The 
Netherlands: 1999 data refer to 1999/2000; 2000 data refer to 2000/2001; 2001 data refer to 
2001/2002; 2002 data refer to 2002/2003; 2003 data refer to 2003/2004. Portugal: data are 
based on users’ reports until 2001 and since 2002 on users/traffickers and traffickers’ reports. 
Portugal LP: although these are resin samples, given the high THC % found, it is suspected that 
they might be locally produced herbal cannabis. Source: Reitox national focal points.
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Similar trends in resin and herbal cannabis potency?
Data available from 12 countries allow a time trend comparison of the average potency 
of both resin and herbal cannabis. Although resin potency was estimated as higher in 
2003, this was not necessarily the case in previous years: only two countries reported 
resin as having a consistently higher potency than herbal cannabis. Overall trends 
are difficult to define. Data available show similar trends in resin and herbal cannabis 
potencies in France (customs data) (21), the Netherlands and Slovakia. In France both 
resin and herbal potencies showed a moderate increase from 1997–2002 and then a 
decrease in 2003. In the Netherlands and Slovakia, average potencies of all cannabis 
products have been increasing (1999–2003 in the Netherlands, 2001–2003 in 
Slovakia), although the increase for resin (and locally produced herb in the Netherlands) 
was much steeper. In the United Kingdom too, overall trends in the potency of resin 
and herb in the period 1998–2003 are similar, although the potency of resin increased 
steadily while the potency of herbal cannabis fluctuated greatly within the general 
upward trend. Austria (2001–2003) and Italy (1999–2003) (22) reported the opposite 
trend in resin and herbal cannabis potencies. In Austria, resin potency decreased 
from 2001 to 2002 then increased in 2003, while the potency of herbal cannabis 
increased and then decreased. In Italy, cannabis resin potency increased until 2002 then 
decreased, while the potency of herbal cannabis decreased then increased. Although 
these reports must be checked against data for future years, trends reported in 2003 
suggest a convergence between potencies of cannabis resin and herbal cannabis in 
some countries — Belgium, Italy, Latvia and the United Kingdom (23).
Perceived availability
In addition to market information, the availability of drugs has been a part of questions 
posed in surveys of both general and school populations. Surveys allow researchers to 
get information on the perception of availability and behaviours of the population in 
terms of reported use or non-use of illicit substances. Availability questions have been 
used in a number of surveys in Europe, though with no standardisation of approach. 
Thus, differences in formats, variables and answering modalities make comparisons 
and analysis difficult at the EU level. The EMCDDA is currently working with Member 
States to develop a new module on drug availability in the existing European Model 
Questionnaire (EMCDDA, 2002) for population surveys. Recently, guidelines have 
(21) This is also the case in France for the data from the police, but this source reports only data for 2002 
and 2003, which limits the analysis of time trends.
(22) As well as in Latvia and Norway, but these countries report only data for 2002 and 2003, which limits 
the analysis of time trends.
(23) In Germany, too, a convergence was reported, but only in 2001 and 2002 since 2003 data were 
not available.
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been developed to include questions on exposure (offers or propositions of drugs 
and opportunities to use drugs), perceived availability (subjective assessment of drug 
availability based on current individual circumstances) and access to drugs (how, where 
and from whom to get drugs in individuals’ current situations).
Currently, the only cross-European source able to provide standardised data on 
perceived availability is the ESPAD (2005) school survey series (European School Survey 
Project on Alcohol and Other Drugs) (see Hibell, this monograph). This is a repeated 
survey carried out among 15–16-year-old students in 26 to 35 European countries in 
1995, 1999 and 2003. The survey allows a comparison to be made on the perceived 
availability of cannabis across the EU Member States and Norway for the age group 
sampled. Results for 2003 show that getting ‘hashish or marijuana’ was reported to be 
‘fairly easy’ or ‘very easy’ by 40–60 % of the students in the Czech Republic, Denmark, 
Ireland, France, Italy, Slovenia, Slovakia and the United Kingdom; by 25–40 % in 
Poland, Portugal and Norway; and by 10–25 % in Estonia, Greece, Cyprus, Latvia, 
Lithuania, Hungary, Malta and Sweden. The percentage of those finding it fairly or very 
easy to get cannabis has been increasing overall since 1995 in the Czech Republic, 
Estonia, Italy, Lithuania, Hungary, Poland, Slovenia and Slovakia, and at a more 
moderate rate in Cyprus, Denmark, France (24), Latvia, Malta, Portugal, Finland, the 
United Kingdom and Norway, while the reported ease of getting cannabis decreases in 
Ireland, Greece (25) and Sweden.
These differences broadly reflect patterns found in consumption data in the EU Member 
States and Norway between aggregated data on perceived availability of cannabis and 
lifetime prevalence of cannabis use in this population — demonstrated by a strong 
linear correlation for the years 1995 (r = 0.91), 1999 (r = 0.81) and 2003 (r = 0.90). 
There is also a relatively strong correlation between changes in perceived availability of 
cannabis and changes in lifetime prevalence of cannabis use, between 1995 and 1999 
(r = 0.83) and between 1999 and 2003 (r = 0.62).
Discussion
Clearly, many methodological challenges exist regarding the interpretation of data on 
seizures in general (26), the analysis of data on price and potency, and understanding 
data on perceived availability in general and school populations. One of them, not 
(24) Based on 1999–2003 only.
(25) Based on 1999–2003 only.
(26) It is now widely acknowledged that, across countries, drug seizures do not represent the same 
proportion of the amount of drugs being smuggled into or circulating in a given country, especially 
as this may vary according to trafficking routes and location of production areas. We have assumed 
for this analysis that there is a somewhat positive relationship between cannabis seizures and its 
availability on the national market.
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Table 1: Comparative analysis of national cannabis trends (seizures, prices, potency, 
perceived availability) during the period 1998–2003  
Country Seizures Qty police Nb customs Qty customs Price Potency Perceived availability
Nb plant Qty plant Nb resin Qty resin Nb herbal Qty herbal Nb police Resin herbal Resin herbal 95–03 99–03
Belgium (+) + + (+) (+) + – =/– + + H
Czech Republic (+) (=) (=) (+) (+) + + + – + – (+ rec) (+ H) = LP =/+ +
Denmark (+) + –
Germany – – – + =(– rec) – =/+ =/+ – +
Estonia + + + = – + (+) (=) + +
Ireland = – – + + + + – – – =/– –/= =/+
Greece (=) (+/=) + (–/=) – (–) – = =/+ –
Spain (+) + (+/=) + (+) + + + + + = =
France (–) (–/=) k 
(=/+) p
(+) + (+) + – + + – +C (+P) = H/Cu 
(+/= H/Po)
+
Italy = = – +/= – + (–) H + =/+
Cyprus + (–) = – (–) (–) +/= +
Latvia = + (–) (+) H +
Lithuania (+) (+) + – (+) (+) (=) (+) – = + +
Luxembourg – +/= + + + + + – + + + +
Hungary (+) (+) (+) + (+) H
Malta (=) (+) + (+) (–) H + +
Netherlands + = – = = H
= LP
+ + IMP
+ LP
Austria + + – + + –(+ rec) (–)
Poland + + + + + + + + + (=) + +
Portugal + (+) = + + + = + + + +/= +/= + =/+ H
(– LP)
+ +
Slovenia (=) (+) (=) = (+/=) + (–) (=) – – + +
Slovakia + + = = + – (+) (–) (–/=) (=) + (+) H + +
Finland + + + =/+ + + – + (–/=) =(/+) (–) (–) H + =/–
Sweden (=) (=) + =/+ + + + + + – – – –/= –
United 
Kingdom
= –(+ rec) – –(+ rec) + + – + – –(+ rec) – – = + H +/= +
Norway + + = + +/= + = (–) H
Notes
Nb, number of seizures; Qty, quantity seized; PAV, perceived availability (‘fairly easy’ and ‘very easy’ to get cannabis).
Prices adjusted to inflation (taking as a basis the initial year of the series for each country).
+, increasing; –, decreasing; =, stable; +/=, slightly increasing; –/=, slightly decreasing; =/+, rather stable, although very 
slightly increasing; =/–, rather stable, although very slightly decreasing.
rec, recent change in the trend; LP, locally produced herbal cannabis; IMP, imported herbal cannabis; H, herbal cannabis of 
type unspecified; k, quantities in kg; p, quantities in number of plants.
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Table 1: Comparative analysis of national cannabis trends (seizures, prices, potency, 
perceived availability) during the period 1998–2003  
Country Seizures Qty police Nb customs Qty customs Price Potency Perceived availability
Nb plant Qty plant Nb resin Qty resin Nb herbal Qty herbal Nb police Resin herbal Resin herbal 95–03 99–03
Belgium (+) + + (+) (+) + – =/– + + H
Czech Republic (+) (=) (=) (+) (+) + + + – + – (+ rec) (+ H) = LP =/+ +
Denmark (+) + –
Germany – – – + =(– rec) – =/+ =/+ – +
Estonia + + + = – + (+) (=) + +
Ireland = – – + + + + – – – =/– –/= =/+
Greece (=) (+/=) + (–/=) – (–) – = =/+ –
Spain (+) + (+/=) + (+) + + + + + = =
France (–) (–/=) k 
(=/+) p
(+) + (+) + – + + – +C (+P) = H/Cu 
(+/= H/Po)
+
Italy = = – +/= – + (–) H + =/+
Cyprus + (–) = – (–) (–) +/= +
Latvia = + (–) (+) H +
Lithuania (+) (+) + – (+) (+) (=) (+) – = + +
Luxembourg – +/= + + + + + – + + + +
Hungary (+) (+) (+) + (+) H
Malta (=) (+) + (+) (–) H + +
Netherlands + = – = = H
= LP
+ + IMP
+ LP
Austria + + – + + –(+ rec) (–)
Poland + + + + + + + + + (=) + +
Portugal + (+) = + + + = + + + +/= +/= + =/+ H
(– LP)
+ +
Slovenia (=) (+) (=) = (+/=) + (–) (=) – – + +
Slovakia + + = = + – (+) (–) (–/=) (=) + (+) H + +
Finland + + + =/+ + + – + (–/=) =(/+) (–) (–) H + =/–
Sweden (=) (=) + =/+ + + + + + – – – –/= –
United 
Kingdom
= –(+ rec) – –(+ rec) + + – + – –(+ rec) – – = + H +/= +
Norway + + = + +/= + = (–) H
For potencies in France: Cu, customs data; Po, police data.
Between brackets (. . .): to be taken with great caution as series might be too incomplete (only two years available or two last 
years missing), numbers might be too small or there might be a dramatic change in the last year.
Blank: no (trend) data available, or high fluctuations showing no clear trend.
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yet mentioned, is that available data may indicate changes in different parts of the 
population. Indeed, changes in the perceived availability in one group of young people 
(which uses only a small proportion of all the cannabis consumed) may indicate 
something else than, for example, changes in seizures or potency. Yet, if analytical 
difficulties are put aside for a moment, a simple comparative analysis of the national 
trends in each of the indicators over 1998–2003 (27) can be constructed. This can be 
seen in Table 1 (pp. 232–233), which summarises the trends per indicator and per 
cannabis product that available data show.
Existing data point towards increasing availability of cannabis products in four countries. 
In Belgium, there seems to be a clear trend towards the increasing availability of both 
resin and herbal cannabis, based on an upward trend in seizure and potency data and 
a downward trend in cannabis prices. In the United Kingdom too, the availability of 
both products seems to be on the increase, although this is comparatively less clear-
cut as seizure and perceived availability data experienced shifts in trends. Data from 
France point towards an increasing availability of herbal cannabis, while it is less clear 
that this is also true for resin. In the Netherlands, the availability of locally produced 
herbal cannabis seems to be on the increase, while that of resin and (imported) 
herbal cannabis might be said to have remained comparatively stable, or have slightly 
increased, during this period.
In other countries the picture is less clear, or there is simply insufficient information 
available to judge. In Italy, Lithuania and Slovakia data point to a possible increase in 
the availability of resin, while in Spain, Portugal and Slovenia data seem to indicate an 
increase in the availability of both resin and herbal cannabis. In Ireland it is not clear 
whether data point to an increasing availability of both herb and resin (especially at 
retail level as quantities seized by customs are decreasing) or to a stable trend. And 
in Poland there is a possible increase in availability of cannabis in general (data do 
not allow for more specificity). It should be noted, however, that data may point to 
decreasing availability in Greece at the retail level, in particular for herbal cannabis, 
and in Germany, with respect to resin.
Conclusion
It is not our intention here to suggest that this simple analysis can be anything but 
exploratory. However, it is helpful in illustrating the difficulties in producing an 
operational research and analysis framework for the concept of availability, especially 
for a drug like cannabis. The first of these difficulties is the simple observation that 
(27) However, trends in perceived availability in school surveys have been included for both 1995–2003 
and 1999–2003, as considering only the latter trend means calculating a trend between only two 
measures, which is quite limited.
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availability is a very difficult concept to separate out from that of prevalence. Trying to 
decide this from available indicators risks asking chicken-or-egg type questions. For 
example, perceived availability can be seen as closely associated with levels of use, 
as can some seizure data. That said, there may still be a use for a general concept of 
availability that is not simply reducible to an indirect reflection of prevalence. Clearly, 
both conceptual and modelling work is required here if a more robust and useful 
conceptual framework for thinking about drug availability is to emerge.
A second general observation regards the need to improve both the availability and 
quality of data sources. In all the data sources discussed above, some progress has been 
made in moving towards common approaches, definitions and reporting standards. But 
in comparison to other areas of monitoring much remains to be done and at present 
any attempt at identifying trends is severely limited by the available time-series data. 
This is a particular problem for cannabis because there are particular methodological 
and practical problems to overcome in some of the areas of data collection, such as 
assessing potency or the amount of plant material seized. Additionally, at least three, 
and possibly more, major product types exist and trends in availability vary by each 
type and may be different in different countries. Trends in the availability of herbal 
imported cannabis, cannabis resin and cannabis grown with the EU may all be different 
and yet at the same time are all important in understanding the overall availability of 
the drug. Currently, data sources are simply not sufficiently developed to elaborate this 
complexity adequately. In conclusion, if cannabis has, as many believe, become a more 
available drug in Europe, it is difficult to show it convincingly using the available data. 
If the concept of availability is to remain a key target for drug policy then investment is 
required in improving the availability of data necessary to measure changes in this area, 
as is conceptual work to better understand and define the concept of availability itself.
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Setting the context
Perhaps spurred by rises in treatment admissions and increased knowledge about the 
health-related harms of cannabis, much has been claimed in the past few years about a 
change in the potency of cannabis.
There are patterns in recent media coverage of cannabis potency. High-potency herbal 
cannabis is often contrasted with a purported milder substance smoked in the 1960s 
and 1970s. European languages use evocative words to label high-strength, indoor-
grown cannabis —‘skunk’, ‘nederwiet’, ‘summum’. There is a tendency for coverage 
of high-potency cannabis to share newspaper pages with extreme cases of cannabis-
related psychosis, schizophrenia, treatment admissions or violent crime. Occasionally, 
high-potency herbal cannabis is linked to discussion of genetically modified crops, 
subverting identification of cannabis as a ‘natural’ drug.
There are historical precedents to such alarmism about cannabis potency. Higher 
strength has been attributed in the past to variants in cannabis products, notably Thai 
sticks in the 1970s. Authors often refer to an infamous response at a murder trial in 
1938 in Newark, New Jersey: when the pharmacologist James Munch was asked about 
what happened when he himself had tried cannabis, he replied ‘After two puffs on a 
marijuana cigarette, I was turned into a bat’. Such quotes reveal the difficulties we face 
when trying to discuss cannabis potency from an objective perspective.
This chapter, based broadly on the findings of a longer Insights publication produced by 
the EMCDDA in 2004, is refreshingly scientific and reassuring in tone. It suggests that 
overall recorded cannabis potency has not increased dramatically in Europe in recent 
years.
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This is not to say that cannabis potency is a non-issue, but rather that the data in this 
area are incomplete and far from conclusive. This chapter should be read with the 
caveat that potency data were — and remain — very limited and that some forms of 
cannabis now grown in Europe show relatively high potency. More research would be 
welcome, for example, on how exposure to high potency cannabis affects different user 
populations, particularly young people and vulnerable groups. In terms of long-term 
trends, very little is known about the strength of the cannabis smoked in the 1960s 
and 1970s. And what is striking is that there is considerable variation in the potency 
of cannabis recorded in Europe. While press coverage tends to concentrate on the 
strongest THC concentrations rather than average potency, what is constant is the wide 
range in recorded potency, with only moderate variation in average potency for all 
cannabis consumed.
One complicating factor is that there has been a recent shift in consumption away from 
imported cannabis resin to indoor-grown herbal cannabis. While few question that 
high potency herbal cannabis is increasingly available, particularly in northern Europe, 
there is a need to track the precise nature of this shift in the market from resin to herb. 
Are people receiving higher THC doses today than before? Are they smoking fewer 
joints per session? How are they consuming alcohol and tobacco in combination with 
high-potency cannabis? Are they smoking joints on more, or fewer days each month? 
How does a resin joint smoked in the early 2000s compare with a herbal joint smoked 
today? Can we profile typical consumers of high-potency cannabis, and are they more 
at risk of problems? Is the shift to herb affected by the drop in supply of Moroccan resin 
to Europe?
Potency is thus far more complex than the basic task of measuring seized samples 
of cannabis. More research in particular is needed on titration (the potency–dose 
relationship) and whether high-potency cannabis is necessarily linked to patterns of 
problematic use (see Beck and Legleye, Volume 2 of this monograph). While a recent 
study in the Netherlands provided some findings that high-potency cannabis sourced 
from Dutch coffee shops can lead to a higher THC concentration in the blood, it also 
suggested that a core risk group exists (young males aged 18–45, smoking cannabis 
regularly) which will ‘get as high as possible in one session’ (Mensinga et al., 2006). 
Such insights help policymakers to make joined-up decisions that go beyond issues of 
strength alone, addressing risky use patterns and behaviour over time.
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Abstract
The ∆9-tetrahydrocannabinol (THC) content (potency) of herbal cannabis and cannabis 
resin imported into Europe has remained stable for many years at around 2–8 %. Yet 
cannabis produced locally by intensive, indoor cultivation (sinsemilla) typically has 
twice as much THC. In some Western European countries, where cannabis resin is the 
most commonly consumed product and herbal cannabis continues to be imported, 
the weighted average potency is largely unaffected by these modern developments. 
However, elsewhere not only is herbal cannabis the dominant product, but that market 
is largely supplied by sinsemilla. Few countries in Europe have THC measurements 
stretching back more than five years, and the data are somewhat compromised by 
analytical difficulties, sampling strategies and the varying nature of cannabis and 
cannabis resin. Also lacking is any evidence to show that users of high-potency cannabis 
have higher blood THC levels. The widely publicised claims that cannabis is now 10 
or more times more potent than it was 10 or 20 years ago are not supported by the 
evidence from Europe.
Introduction
The potency of cannabis is defined as the concentration (%) of ∆ 9-tetrahydrocannabinol 
(THC), the major active principal of the cannabis plant. As a broad guide, cannabis and 
cannabis resin typically contain 2–8 % THC. However, as will be discussed later, certain 
products may contain appreciably more. Cannabis grown for fibre production (hemp) 
will normally contain less than 0.3 % THC. Although references will sometimes be found 
in the literature to ‘cannabis purity’, this term is ambiguous and could refer to whether 
or not the material has been adulterated. For example, in the publication Global Illicit 
Drug Trends (UNODC, 2003), ‘purity levels’ of herbal cannabis and cannabis resin are 
either clustered around 1 to 10 %, where they probably reflect the THC content, or they 
are much higher, typically above 50 %, suggesting some other measure of purity.
The chemical structure of THC is shown in Figure 1(a). It is one of a large number of 
related substances known as cannabinoids. Other major constituents of cannabis and 
cannabis resin are cannabinol (CBN; Figure 1(b)) and cannabidiol (CBD; Figure 1(c)). 
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It has been suggested that CBD can act as an antagonist of THC (Smith, 2005). This 
would be of some concern if, as THC levels increased, the CBD concentration stayed 
constant. However, as far as can be determined from the limited published analytical 
data, there is a positive correlation between the THC and CBD levels (King et al., 
2005a). Cannabis resin has higher relative levels of CBD than herbal cannabis, but the 
pharmacological significance of this is unclear.
A large fraction of the THC may be in the form of ∆9-tetrahydrocannabinolic acid 
(THCA). When cannabis is smoked, THCA is converted to THC, although other 
substances are also formed (Hazekamp, personal communication, 2004). The active 
isomer ∆8-THC is found in much smaller amounts. The highest levels of THC occur in the 
resinous material produced by glandular trichromes, mostly situated around the flowers 
of the female plant. Fertilisation and consequent seed production cause a reduction in 
the level of THC. Much lower amounts are present in the leaves and in male plants, 
while the stalk and clean seeds contain almost no THC.
Atmospheric exposure of THC causes oxidation to cannabinol (CBN; Figure 1(b)) and 
other substances. In cannabis resin, Martone and Della Casa (1990) showed that, even 
when stored in the dark, the half life of THC was often less than one year, and in some 
cases THC had disappeared almost completely within two years. In a block of resin, this 
could lead to variations in the THC concentration between the outside and the inside. 
The rate of THC decomposition in cannabis at room temperature was estimated as 
H3C
H3C O
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CH3
C5H11
H3C
H3C O
OH
(a)
CH3
C5H11
H3C
H2C HO
OH
(c)
CH3
C5H11
Figure 1: The structures of three major cannabinoids (THC, CBN and CBD) 
Notes: (a) ∆9-tetrahydrocannabinol (THC); (b) cannabinol (CBN); (c) cannabidiol (CBD).
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17 % per annum by Ross and ElSohly (1997–1998). Since CBN is almost entirely absent 
from fresh cannabis, these authors suggest that the ratio CBN/THC could serve as a 
measure of the age of a sample. The relevance of this to questions of potency can be 
understood when it is realised that some imported products may have been harvested 
or manufactured many months before consumption or analysis. By contrast, local 
production will lead to a fresher product containing more THC.
During the past few years, some concern has been expressed that the potency of 
cannabis could be much greater than it was. It has been suggested that the THC 
concentration may have increased so much that the illicit drug now bears little 
resemblance to the cannabis that was used only 30 years ago. A widely publicised 
example of this is the statement by the so-called ‘drug czar’ in the USA (Walters, 
2002), published in the Washington Post, that ‘parents are often unaware that today’s 
marijuana is different from that of a generation ago, with potency levels 10 to 20 times 
stronger than the marijuana with which they were familiar’. In a similar vein, Henry 
(2004) commented on the apparent increase in association between cannabis and 
deaths recorded as accidents and suicides. He is quoted as saying, ‘until the early 
1990s, there was less than one per cent tetrahydrocannabinol in most cannabis. Now 
the most potent form, skunk, contains up to 30 per cent’. Most cannabis is smoked, 
and according to Ashton (House of Lords, 1998), ‘a typical “joint” today may contain 
60–150 milligrams or more of THC’.
Meanwhile, in some European countries the numbers of those entering specialised drug 
treatment centres, who are reported as having cannabis-related problems, have been 
rising (EMCDDA, 2004) and it has been suggested that high-potency cannabis may be 
a factor in this trend. High dose cannabis may also be a consideration in evaluating the 
impact of cannabis on the development of mental health problems such as psychosis, 
depression and schizophrenia (see, for example, Arseneault et al., 2004).
However, the potency question is not new. Nearly 20 years ago, Cohen (1986) noted 
that ‘material ten or more times potent than the product smoked ten years ago is being 
used, and the intoxicated state is more intense and lasts longer’. But Mikuriya and 
Aldrich (1988) pointed out that the cultivation of sinsemilla and its superiority to other 
forms of cannabis was well known to the British government in India in the 19th century. 
So what is the evidence that the potency of cannabis has increased in recent decades?
Changes in cannabis potency in Europe
The THC content of cannabis products is routinely determined in many European and 
other countries. Analyses are usually carried out in forensic science laboratories on 
behalf of law enforcement agencies, in some cases to provide evidence of cultivation/
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production. Some information on cannabis potency since 1998 can be found in the 
EMCDDA’s national reports (Standard Table 14). However, these data are rather limited, 
and no clear trends can be detected. In a recent study (King et al., 2004), much more 
data were collected, although information on potency trends over five years or more 
was only available from five countries and a number of methodological problems and 
information gaps existed. The participants in that survey were asked, by means of a 
questionnaire, to provide annual mean values of THC percentage in cannabis products, 
together with information on sample sizes, sampling strategies, method of analysis, 
the relative consumption of different cannabis products and other information. Despite 
the limitations, a fairly clear pattern emerged from the survey. Firstly, the potencies of 
resin and herbal cannabis that have been imported into Europe have shown little or 
no change, at least over the past 10 years or so. This is hardly surprising since these 
products have been made by traditional methods that have probably remained the same 
for generations (see Gamella and Jímenez, this monograph). A brief summary of those 
findings and a discussion of the implications has been provided by King et al. (2005b). 
Figure 2 shows the potency of cannabis resin over the period 1997–2003 in the original 
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Figure 2: Mean potencies of cannabis resin in seven European countries
Notes: UK, United Kingdom; NL, Netherlands; D, Germany; CZ, Czech Republic; P, Portugal; A, Austria; 
F, France.
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six countries reported by King et al. (2004) together with data subsequently received 
from France (OFDT, 2005).
The rapid rise in potency in the Netherlands after 1999 can be explained by the 
local production of cannabis resin. This material, known as nederhasj, is not only 
uncommon in the Netherlands, but is almost unknown elsewhere. When the data from 
the Netherlands are excluded from Figure 2, no overall trend is apparent in the overall 
mean potency. In the United Kingdom, THC measurements date back 30 years, and the 
annual mean potencies of cannabis resin as shown in Figure 2 are, if anything, slightly 
lower than those in the period 1975–1989 (Baker et al., 1980, 1981, 1982; Pitts et al., 
1990; Gough, 1991). Cannabis (hash) oil is uncommon in Europe, but its THC content 
has also shown no clear trend over many years (Baker et al., 1982; Gough, 1991; 
King, 2001).
What has changed throughout Europe and elsewhere is the appearance, from the early 
1990s, of herbal cannabis grown from selected seeds by intensive indoor methods. 
This material, best described as domestically produced ‘sinsemilla’ (from the Spanish, 
‘without seeds’), is also known as ‘skunk’, ‘buds’, ‘tops’ or ‘nederwiet’. Its hydroponic 
cultivation, with artificial control of ‘daylight’ length, propagation of female cuttings and 
prevention of fertilisation, certainly does produce cannabis with a greater potency; on 
average, it may be twice as high as imported herbal cannabis. Further information on 
the production of sinsemilla can be found in the reviews by Szendrei (1997–1998) and 
Bone and Waldron (1997–1998).
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Figure 3: Mean potencies of two types of herbal cannabis examined in the United 
Kingdom
Note: The total sample sizes were: sinsemilla = 938; imported herbal = 117. Source: Forensic Science 
Service.
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The THC content of herbal cannabis in the United Kingdom is shown in Figure 3. 
However, it must be recognised that it is not always possible for a forensic scientist 
to distinguish the two forms of herbal cannabis. To a large extent, the definition of 
material as sinsemilla must rely on other circumstances, such as the characteristics of 
the plantation or ‘grow room’. This information may not always be provided by law 
enforcement agencies and hence some confounding of the two forms may occur. This 
is illustrated in Figure 3 where the rise in the potency of imported herbal cannabis 
after 1998 could be an artefact. A similar, albeit modest, rise in the potency of herbal 
cannabis was also found in Germany (see Figure 4) although no distinction was 
made between traditional (i.e. imported) herbal cannabis and material produced by 
hydroponic methods. A small rise in the potency of herbal cannabis was reported by the 
Czech Republic, but no information was available on the sampling strategy or sample 
sizes. Further evidence that sinsemilla has a higher potency than imported cannabis 
can be seen in data produced by the Netherlands (Figure 5). Potency data for herbal 
cannabis in France are shown in Figure 6, and represent the overall annual mean 
values for both police and customs seizures (OFDT, 2005). No distinction was made 
between traditional imported herbal cannabis and sinsemilla, but in each year the mean 
potency of material examined by the police was close to the mean potency of customs 
cases. Furthermore, for both herbal cannabis and resin in France, there was little 
difference in the THC content, according to whether the samples had been seized by law 
enforcement agencies or the samples had been collected from users (Bello et al., 2005). 
As with the other countries for which trend data were supplied (Austria and Portugal), 
little evidence was found for an increase in the potency of imported herbal cannabis.
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Figure 4: Mean potencies of all herbal cannabis in Germany
Note: Figures against each point represent the number of measurements.
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The most recent data from the Netherlands (Pijlman et al., 2005) show that the THC 
content of cannabis products has increased even further than illustrated in Figure 5. 
However, these data need to be interpreted with caution since the Netherlands is 
anomalous for several reasons. Firstly, in all other countries in the EU the available 
THC data derive from the analysis of law enforcement seizures. In the Netherlands, 
the material examined has been purchased in coffee shops: establishments that are 
permitted to sell small amounts of cannabis (see Korf, this monograph). The samples 
purchased were generally of better quality material and may not have been necessarily 
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Figure 5: Mean potencies of two types of herbal cannabis in the Netherlands
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Note: Figures against each point represent the number of measurements
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Figure 7: Frequency distributions of THC in herbal cannabis examined in the United 
Kingdom
representative of all cannabis products consumed. This may explain the finding that 
the cannabis resin purchased for analysis also had a much higher THC content than 
is seen elsewhere in Europe. Secondly, as noted elsewhere in this report, the relative 
consumption and origins of cannabis products available in the Netherlands is quite 
different to other countries.
There is little doubt that, on average, sinsemilla has a higher potency than imported 
herbal cannabis, but it is also clear that the two potency distributions overlap, as shown 
in Figure 7. Some samples of imported cannabis are, and always have been, of high 
potency. The increased THC content of herbal cannabis produced by indoor methods is 
a consequence of a number of influences. These include: genetic factors (selected seed 
varieties and cultivation of female plants); environmental factors (cultivation technique, 
‘pruning’ during harvesting, prevention of fertilisation and seed formation); and 
freshness (production sites are close to the consumer and storage degradation of THC is 
thereby reduced).
More recent data from the UK for 1999 to 2005 (Figure 8) show that the THC content of 
sinsemilla may have increased further, probably as a result of continual improvements 
in technique. Figure 8 also shows, for comparison, the frequency distribution of THC in 
cannabis resin. Whereas the shape of the distribution of THC in sinsemilla is reasonably 
symmetrical, the distributions of both imported herbal cannabis and cannabis resin are 
strongly skewed, with the most common values occurring at the lowest end of the scale.
The increases that have occurred with time in the potency of some types of cannabis 
must be put into the context of the relative consumption of the various products in 
Source: Forensic Science Service, 1996 to 1998.
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different countries. Table 1 sets out estimates of the relative proportion of each cannabis 
product on the domestic market in recent years. These estimates are shown for those 
countries where data were either available in the published literature, were supplied 
directly in response to a questionnaire in the EMCDDA study (King et al., 2004) or were 
derived indirectly from the relative number of samples examined in each case.
Using both potency data and a knowledge of the relative consumption of different 
products as shown in Table 1, it is possible to derive the weighted mean potency, that 
Table 1: Relative consumption (%) of cannabis products in European countries 
since 1999
Country Imported cannabis Cannabis resin Sinsemilla Domestic resin
Belgium 80 (1) 20 (2) – –
Czech Republic 90 (1) 10 (2) – –
Germany 40 (1) 60 (2) – –
Estonia 85 (1) 15 (2) – –
Ireland 5 90 5 –
Netherlands 3 29 67 1
Austria 70 (1) 30 (2) – –
Portugal 10 (1) 90 (2) – –
United Kingdom 15 70 15 –
(1) All herbal, imported or not.
(2) All resin, imported or not.
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Figure 8: Frequency distributions of THC in cannabis resin and sinsemilla examined in the 
United Kingdom
Source: Forensic Alliance, 1999–2005.
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is, the effective THC concentration as would be perceived by the average user. Figure 9 
shows the effective potency averaged over all cannabis products in several European 
countries.
Except for the Netherlands, where it is a dominant product, the limited market share 
experienced by sinsemilla in other countries suggests that, other aspects of behaviour 
being constant, users have not been exposed to significantly larger amounts of THC. 
Although not shown graphically here, UK data for the earlier period 1975 to 1989 
indicate that the effective potency in the UK has been around 6 % for the past 30 years. 
In Ireland, where resin is also the main product, the effective potency in 2000 was closer 
to 4 %.
If the effective potency of cannabis had shown an appreciable rise over the past 10 to 
20 years then it might be assumed that users would need to consume less cannabis on 
a weight basis. However, the content of reefer cigarettes (also known as joints or spliffs) 
examined in the UK over the past 20 years has been remarkably constant (Figure 10). 
Thus, the typical reefer contains 150–200 milligrams of cannabis or cannabis resin, 
equivalent to around 10 mg of THC (Humphreys and Joyce, 1982; Bal and Griffin, 
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Areas for improvement in analysis and 
interpretation
If a more accurate picture of potency trends is to be obtained then a number of areas 
require attention. Apart from a purely quantitative need to obtain more data, these 
improvements include the following.
Nomenclature of cannabis products
A particular need is the use of an agreed scheme for describing and naming imported 
herbal cannabis and sinsemilla. At present, a wide variety of terms are in use by 
authors, including ‘seeded cannabis’, ‘skunk’, ‘tops’, ‘buds’ and ‘nederwiet’. Even 
the term ‘imported’, usually implying a source such as the Caribbean, Africa or Asia, 
may not be ideal since, in some cases, sinsemilla may be imported from elsewhere in 
Europe. As noted earlier, confusion may still occur if the growing conditions of the plant 
material are uncertain, since visual examination of isolated plant material is not always 
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Figure 10: Mean herbal cannabis and cannabis resin content of reefer cigarettes examined 
in the United Kingdom over a 20-year period
Note: The sample size in each case is shown. Source: Forensic Science Service.
2001). Similar results were found in Ireland (Buchanan and O’Connell, 1998). The 
assertion by Ashton (House of Lords, 1998) that ‘a typical “joint” today may contain 
60–150 mg or more of THC’, suggests a potency of over 50 %.
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conclusive. Yet, the alternative possibilities for classification (THC content, size of seizure, 
type of cultivation, such as indoor or outdoor or level of sophistication) also seem 
unsuitable.
Relative consumption of cannabis products
In most countries, estimates of the relative consumption of different cannabis products 
are based largely on seizure data. Such data have limits and may not directly reflect the 
relative market share of different cannabis products or availability as experienced by 
drug users. One way forward would be to complement statistics from drug seizures with 
data from user surveys carried out at the retail level. This might also include information 
from seed suppliers and shops selling growing equipment/paraphernalia.
Proxy measures of potency
Few countries have published data on the herbal cannabis or cannabis resin content of 
reefers. This information would be useful as a proxy measure for potency as well as a 
means of tracking methods of consumption (i.e. use with or without tobacco). In Europe, 
information is collected routinely by the EMCDDA on drug prices at retail level. However, 
the quality and comparability of this information needs to be reviewed and standard 
methods for collection and reporting developed. Data from the Netherlands suggest a 
close relationship between potency and price (Trimbos Institute, 2002).
Extent of domestic production
It is important to have a better understanding of the extent of domestic cannabis 
production, the different types of production methods used, as well as the use of 
domestically produced cannabis products compared with imported products and how 
this varies within Europe and over time. Furthermore, home-produced cannabis may not 
always benefit from hydroponics or other sophisticated growing techniques.
Data presentation
When compiling data, many laboratories calculate simple mean values (often called 
averages: the sum of all values divided by the number of values). In a few cases, 
weighted means may be calculated. These take account of the fact that not all samples 
may be of equal size. Few authors consider whether the distribution of potency is 
normally distributed or if other measures of central tendency such as the median or 
mode would be better. Ideally, data collections should always indicate details about the 
sampling strategy, sample size, the mean, and where possible more detailed descriptive 
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statistical information (e.g. mode and median values, standard deviation and treatment 
of outliers).
Sampling
Sampling is probably the most important variable relating to the measured potency 
of cannabis. Cannabis, and to a lesser extent cannabis resin, is an extremely 
inhomogeneous material. As noted earlier, the THC content of different parts of 
the plant shows considerable variation. As well as the flowering tops of the female 
plant, where most of the THC is located, a sample may contain varying amounts of 
stalk, seeds and leaves, none of which contains much active drug. If potency is to be 
compared between different laboratories, or even within the same laboratory at different 
times, then a standard method of sample preparation is required.
Laboratory analysis
Assuming that the THC in cannabis and cannabis resin can be solvent-extracted with 
total, or at least a known, efficiency, then most laboratories use gas chromatography, 
often with flame-ionisation detection (Raharjo and Verpoorte, 2004) to determine 
THC concentration. This has the merit that the naturally occurring precursor (THCA) 
is decarboxylated to THC, just as occurs during smoking. Cannabinoids can also be 
determined by high-performance liquid chromatography, a method suited to profiling 
(‘chemical fingerprinting’) and the separate measurement of THCA. To measure the total 
THC content by HPLC, the sample must be heat treated before analysis (Lehmann and 
Brenneisen, 1995; Rustichelli et al., 1998; Kanter et al., 1979).
The major issue to arise in the analysis of THC concerns the accuracy (closeness to the 
‘true’ value) of the measurement process. Poortman van der Meer and Huizer (1999) 
claimed that in a series of proficiency tests, using standard solutions of THC, and 
organised in 1997 for 30–40 European laboratories, the relative standard deviation was 
about 29 %, whereas cocaine and amphetamine gave less than 5 % and 8 % respectively. 
This means that around one-third of results for THC were either more than 29 % above 
or more than 29 % below the mean value. It is clear that even worse precision could be 
expected if the measurement error caused by the sampling and extraction process were 
to be included.
As a reference standard, THC is usually only available from chemical suppliers in the 
form of an ethanolic solution and may be labelled, for example, as ‘approximately 
95 %’. Not only could confusion arise if analysts assume the concentration to be 100 %, 
but Poortman van der Meer and Huizer (1999), using the response of a flame-ionisation 
detector, found that one sample of a commercial THC solution had only 90 % of the 
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concentration of a different commercial solution. These authors recommended that THC 
quantification should be based on cannabinol or cannabidiol as the internal standard 
and a correction made for the expected detector response from the effective carbon 
number of the respective substances. They claimed that this method had been used 
in Germany for the past 10 years. It was also the method used by Maguire (2001) to 
study the cannabinoid content of (mostly fibre-type) cannabis in Ireland. However, as 
far as could be determined in the EMCDDA study (King et al., 2004), other European 
laboratories continue to prepare standard dilutions of stock THC solution to construct 
calibration curves.
To a large extent, and excluding the special situation of locally produced Dutch 
nederhasj, the cannabis resin consumed in Europe in recent years has originated mostly 
from North Africa, with smaller amounts coming from South-West Asia. Since resin is 
rarely adulterated, it could be argued that, in any given year, all laboratories have been 
measuring broadly similar material. Despite the variation of THC content in cannabis 
products discussed above, if those laboratories had made sufficient measurements, 
then the mean potency of cannabis resin in any year should be found to be similar 
for all countries. Inspection of Figure 2 shows that not only is there no time trend, but 
there is considerable variation in the reported THC levels, both against time in any one 
country and between countries at any one time. It is not obvious why there should be 
consistently less THC in cannabis resin in Portugal compared with cannabis resin in, for 
example, the Czech Republic or France. This finding raises questions about the accuracy 
of measurement of THC in different laboratories. In other words, if all analysts had used 
the same THC reference standard for instrumental calibration, then these differences 
might not have occurred.
Pharmacology
In Europe, cannabis is normally smoked often in a mixture with tobacco in a reefer 
cigarette, but some is smoked in a water pipe (a bong). By contrast, in the USA where 
little resin is consumed, cannabis is usually smoked alone. Furthermore, the sources of 
cannabis and cannabis resin consumed in North America are not the same as those in 
Europe. Nearly all studies on the smoking of cannabis and its relation to potency have 
been carried out in North America, and it is clear that this research may not translate 
well into the European situation. Thus Matthias et al. (1997) found some evidence that 
those who smoke more potent cannabis are less exposed to noxious smoke components 
than those who use less potent forms. But in Europe, or at least in Ireland and the 
United Kingdom, where a reefer cigarette typically contains only 150–200 milligrams 
of cannabis (Buchanan and O’Connell, 1998; Bal and Griffin, 2001; Humphreys and 
Joyce, 1982), much of the tar, carbon monoxide and other combustion products will 
derive from the concomitant tobacco.
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The concerns that have been expressed about a possible rise in cannabis potency 
often assume that users will necessarily consume more THC, but the evidence for this 
is equivocal. If the potency of cannabis products has shown a marked increase, then it 
might be expected that the typical user would need to consume less on a weight basis to 
achieve the desired effect. Given a choice, users preferred cigarettes with a higher THC 
content (Chait and Burke, 1994; Kelly et al., 1997). Ashton (1998) also argued that 
users would not titrate the dose of THC from cannabis in contrast to tobacco smokers. 
However, Heishman et al. (1989) found that those smoking cigarettes with a higher THC 
content tended to have a lower inhalation rate than control subjects. Yet little research 
has been conducted, particularly in Europe, to answer a crucial question: do those 
smoking high potency cannabis have higher blood levels of THC?
However, even if the strength of some forms of cannabis has increased, and even 
assuming that, as a consequence, users do have higher blood levels of THC, then 
it cannot be concluded that this will translate into a greater harm to the individual. 
Experience with alcohol suggests that the health consequences are not simply related 
to the alcohol concentration of what is consumed, but rather it is the total quantity of 
alcohol consumed that is important. As Hall et al. (2001) note, age of onset of use and 
frequency of use are likely to be more influential than changes in potency in determining 
consumption levels.
Medicinal cannabis
In any discussion about the health impact of high-potency cannabis, mention 
should also be made of cannabis used for medicinal purposes (see also Witton, this 
monograph). In the Netherlands, herbal cannabis is available as a prescription medicine 
(Office of Medicinal Cannabis, 2004). It is indicated for multiple sclerosis, certain types 
of pain and other neurological conditions. Patients are advised to consume the cannabis 
by means of a hot water infusion. However, Hazekamp (personal communication, 2004) 
has found that, even in boiling water, the conversion of THCA to THC can take some 
hours and other byproducts are formed. Remarkably, one of the forms of this medicinal 
product, known as ‘cannabis flos’, has a nominal THC content of 18 % and is locally 
produced by the same intensive indoor methods that are used for illicit cultivation. 
Not only is high-potency cannabis considered suitable as a medicinal product, but 
an assessment carried out by the Dutch Coordination Centre for the Assessment and 
Monitoring of New Drugs concluded that (illicit) higher-potency cannabis products 
did not pose any additional risk than those present for cannabis products as a whole, 
either to the individual, to society, to public order or criminality (W. Best, personal 
communication, 2004).
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Conclusion
The potency, that is, the THC concentration, of herbal cannabis produced by intensive 
indoor cultivation can average over 10 %, compared with an average of 5 % for both 
imported cannabis resin and cannabis grown by traditional methods. For all cannabis 
products there is a wide variation about average values and some users will inevitably 
have been exposed in almost random fashion to higher than normal THC levels in 
their careers. The evidence from Europe does not support the widespread claims that 
cannabis potency is now 10 or more times greater than it was in earlier periods. 
Although not part of this present review, experience from outside Europe (King et al., 
2004) comes to a similar conclusion.
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Chapter 15
Multinational export–import 
ventures: Moroccan hashish into 
Europe through Spain
Keywords: cannabis – cannabis resin – crime networks – criminology – Morocco 
– socio-economic analysis – trafficking
Setting the context
In recent decades, Morocco has emerged as the world’s largest producer and exporter 
of cannabis resin, or hashish. The Moroccan cannabis resin market is substantial: the 
country supplies over 70 % of the cannabis resin consumed in Europe, and half of 
global production (EMCDDA, 2006). Within Morocco itself, hashish is one of the key 
agricultural products of the provinces containing the Rif mountain range in northern 
Morocco, and an estimated 760 000 peasant farmers (2.5 % of the population) obtain 
their livelihoods from hashish. By 2003, Morocco’s cannabis resin production had 
reached 3 070 tonnes, with a retail market value estimated at over EUR 12 billion 
by the UNODC. Since then, cultivation has decreased substantially, due both to 
crop eradication efforts, political pressure placed on the Moroccan government and 
the damage wrought by a major drought in 2005. The most recent UN figures put 
production at around 1 070 tonnes, resulting in a retail market estimate of EUR 4.6 
billion.
The full picture of hashish trafficking is more complex. It is estimated that only about 
a tenth of the retail earnings are likely to end up in the pockets of Moroccan farmers, 
wholesalers and traffickers. The majority of profits are made lower down the supply 
chain once the resin has entered the EU. Most Moroccan hashish is exported through the 
Iberian peninsula, particularly Spain, a country that is today the crucial transit zone for 
Moroccan hashish sold in the European market. From Spain, cannabis resin is bounced 
through a complex network that unites producers, traffickers, dealers and consumers.
This chapter examines the export–import system of cannabis resin between Morocco and 
the EU through Spain. It combines a review of the literature on the Moroccan production 
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of hashish and a preliminary analysis of over 2 000 press reports using an event history 
analysis approach (Franzosi, 1995; Olzak, 1992). The result is data on 1 370 groups of 
importers and dealers apprehended during a 27-year period, and a first sketch of the 
structure of the multinational smuggling industry. The result is a typology of networks 
and groups who deal with hashish at different levels of a distribution pyramid, profiled 
according to the size of ‘project’ they manage. The chapter thus clarifies the importance 
of networks and hierarchies in illegal enterprises, the type of complex and impermanent 
structure that has received considerable attention in EU criminology literature (see Dorn 
et al., 2005).
A number of enforcement questions arise from this chapter. Given the strong decrease 
in Moroccan cannabis resin production, is supply moving elsewhere? A number of 
countries in northern Europe are reporting increasing use and domestic cultivation of 
cannabis herb (see Carpentier, this monograph), with an indirect effect on the potency 
of cannabis consumed (see King, this monograph). Recent press reports also suggest 
that Sub-Saharan Africa is stepping into a gap in the market: seizures of resin are 
increasing along the Saharan route via the North African coast, and countries such as 
Algeria, Libya, Niger and Mali have reported overall increases in seizures. However, 
given the fluctuation that characterises such seizure statistics, it is difficult to draw clear 
conclusions. Another question is whether Moroccan cannabis resin trafficking networks 
are diversifying into cocaine trafficking. This is a concern expressed by the Spanish and 
French authorities, together with Europol with some concern about cocaine seizures on 
the Cádiz coast, a traditional hashish route. Reported seizures of cocaine in Morocco 
have fluctuated greatly since 2000, peaking at 15.8 tonnes in 2002, yet with a wide 
range starting at 0.9 tonnes in 2000 to just over 4 tonnes in 2004 (UNODC, 2006).
Further reading
Dorn, N., Levi, M., King, L. (2005), Literature review on upper level drug trafficking, UK Home Office 
Online Report 22/05, London.
Europol (2005), European Union situation report on drug production and drug trafficking 2003–2004, 
Europol, The Hague.
UNODC (2007), ‘Invisible empire or invisible hand? Organized crime and transnational drug 
trafficking’, Chapter 2 in World Drugs Report 2007, United Nations Office on Drugs and Crime 
Control, Vienna.
UNODC and Kingdom of Morocco (2007), Enquête sur le cannabis 2005, United Nations Office on 
Drugs and Crime, Vienna.
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Multinational export–import 
ventures: Moroccan hashish into 
Europe through Spain (1)
Juan Francisco Gamella and Maria Luisa Jiménez 
Rodrigo
Introduction
The production of cannabis is a global phenomenon; 134 countries have been 
identified as source countries of this substance (UNODC, 2007). Two regions, however, 
concentrate the largest markets for cannabis products, and the largest accumulation of 
revenues: North America, where two-thirds of all cannabis products are sold, mainly 
in the form of marijuana, and Europe, the largest importer and consumer of resin or 
hashish (for more detail on the world cannabis market, see Legget and Pietschmann, 
this monograph).
(1) We want to thank Alicia Rodríguez Marcos for her help in collecting news clips, and Alexandra 
Bruehl, Aryelle Goins and Isabel Velez for their suggestions and corrections to previous versions of 
this paper.
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While the production of herbal cannabis is widely dispersed around the planet, including 
a growing number of European home-growers, the production of resin is centred in 
a few countries such as Morocco, Pakistan, Afghanistan, Lebanon and Nepal. Among 
them, Morocco has become the world’s largest producer and exporter, supplying over 
70 % of resin consumed in Europe (EMCDDA, 2007). Although statistics vary widely, 
in recent years Morocco’s hashish production has declined from 3 070 tonnes in 2003 
to 1 070 tonnes in 2005 (UNODC, 2007). Average retail prices for cannabis resin is 
reported in Europe at between EUR 2.30 and EUR 11.40 per gram, while cannabis 
resin seizures for 2003 in Spain and Portugal were reported at 809 tonnes, or just 
over a quarter of Moroccan production (EMCDDA, 2006). The UNODC’s estimate of 
the annual international market for Moroccan cannabis resin has seen a decline from 
EUR 10.8 billion in 2004 to EUR 4.6 billion in 2005.
Most Morocco-produced hashish is exported through Spain, a country that is today the 
crucial transit zone for Moroccan hashish sold on the European market (Figure 1). In 
2003, out of the 757 tonnes of Moroccan resin seized in the EU, 727 tonnes (over 90 %) 
were seized in Spanish territory or jurisdictional waters (UNODC, 2005). This binational 
industry has exploded in the last three decades from a traditional base of rural growers 
in the Ketama region, whose products were distributed from the late 1960s by hippie 
entrepreneurs. In the last decade, smuggling networks have begun to move faster and 
further, and to establish international connections with traffickers of other drugs, for 
instance with large cocaine exporters from South America, who are increasingly using 
the routes opened by the distribution of Moroccan hashish.
The 14 km of the Strait of Gibraltar, and the frontier around the Spanish enclaves of 
Ceuta and Melilla, make up one of the deepest socio-economic and cultural divides on 
the planet (2). Disparities in wealth, income, demographic structure, educational and 
labour opportunities are huge and stimulate a licit and illicit movement of persons that 
in many ways parallels the movements of drugs, money and manufactured products. 
This is a crucial frontier for the EU and its policies concerning development, immigration 
and drug control.
This chapter examines the export–import system of cannabis resin between Morocco 
and the EU through Spain. First, we will review what is known about the extent, location 
and organisation of cultivation and manufacture in northern Morocco. We will then 
explore the structure of the import industry using Spanish data. We will consider the 
type of organisations and networks that participate in this trade, their structure, and the 
tasks their members perform in their transactions. We will also examine the profile of 
(2) In 2004 the GNI per capita of Spain was 14 times that of Morocco; the GNI per capita of France 
was 20 times that of Morocco. By comparison, the US GNI per capita was six times that of Mexico, 
its southern neighbour (World Bank).
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workers and entrepreneurs in these groups, and the changes that seem to have occurred 
in recent decades. We will also present some observations about the permanence of 
the smuggling networks and organisations, their strategies to avoid detection, and the 
pricing tendencies in this market. This information may help to clarify the importance of 
networks and hierarchies in illegal enterprises (Morselli, 2001; Natarajan and Belanger, 
1998; Ruggiero and South, 1995; Reuter and Haaga, 1989; Adler, 1985; Reuter, 
1984), and the nature of the cannabis industry.
Data sources
We use a combination of primary and secondary data sources, including prior studies 
and reports published by international agencies, data from our ethnographic fieldwork 
in drug trading environments and our ongoing research and analysis of seizure cases 
published in the Spanish press from 1976 to 2003. In this period, thousands of illegal 
deals were prevented. The press reports on these failed transactions provide important 
insights on the structure of hashish distribution and the character of drug trafficking 
organisations. We have applied to this topic the methodology of event analysis as it has 
been developed by historians in their study of collective actions along a wide time span 
(see Franzosi, 1995; Olzak, 1992; Tilly et al., 1975).
Production and manufacture in Morocco
In the past 20 years, cannabis cultivation has spread in all directions from the traditional 
areas in the central Rif, where it has been present since the 15th century (OGD, 1996). 
However, recent crop eradication efforts, together with the effects of a drought in 
2005 have led to a strong decline in cultivation from 2004 until 2006. From the early 
1980s to the 2000s, the area devoted to cannabis seemed to have multiplied by 20, 
and doubled every three to five years. There is considerable agreement in the literature 
about this rising trend in the various estimations available, notwithstanding their 
disparities (see Labrousse and Romero, 2001). This constant growth occurred despite the 
well-publicised campaigns by the Moroccan government in the 1990s to eradicate drug 
trafficking (Ketterer, 2001).
Recently the UNODC has undertaken detailed surveys of cannabis cultivation with the 
cooperation of the Moroccan government (UNODC, 2004, 2005, 2006). These surveys 
provide the most accurate data on the extent, characteristics and value of cannabis 
production in the country today. Table 1 summarises their results.
Most kif, as cannabis is locally known, is grown in four northern provinces along the Rif 
mountain chain. One province alone, Chefchaouen, accounts for 56 % of cultivation, 
followed by Taounate (17 %), Al Hoceima (16 %) and Tetouan (11 %). A further province, 
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Larache, reported no significant cannabis cultivation following a crop eradication 
programme in the summer of 2005. In Chefchaouen a quarter of arable land was 
planted with cannabis in 2005, while in other provinces this share was between 3 % and 
10 %. Cannabis was grown in three out of four duars (villages), mostly in smallholdings. 
Nearly 90 000 families grew kif, obtaining about half their income from cannabis (Dh 
38 900 or EUR 3 600). About 760 000 peasants live from this illicit crop (UNODC, 2005) 
and other estimations are even larger (3). Kif has become a pillar of the economy.
A hectare planted with kif produces 2–8 tonnes of raw plant (2.3 tonnes on average) 
depending on soil conditions, irrigation, use of fertilisers, etc. The estimated resin 
production for 2005 was 1 066 tonnes. Productivity varies from year to year, often 
drastically. This is typical of dry farming conditions in the Mediterranean basin, due to 
great oscillations in rainfall. Part of the crop is locally consumed, mostly in the form of 
low-grade marijuana, which has been traditionally smoked in the region since the 16th 
century (OGD, 1996). Nevertheless, most of the production is exported to European 
markets in the form of resin or hashish. Programmes for substituting cannabis with 
alternative crops have failed so far, although significant progress was made from 
2004 until the time of publication in 2008. Kif is 12 to 46 times more profitable than 
traditional cereal crops, such as wheat and barley (Labrousse and Romero, 2001). In 
fact, some of the best plots, previously devoted to food crops, are now used to grow 
cannabis, and forest land has been cleared to plant kif.
Manufacturing: from kif to hashish
Farmers sell both raw cannabis plants, and powder (sandouk). According to UNODC, 
35.4 kg of raw cannabis are needed to make 1 kg of hashish. Extracting resin powder 
from plant material increases profits by about 13 % (4) (UNODC, 2005). Pascual Moreno 
offered different estimations. According to his fieldwork, extracting the resin dust from kif 
would increase profits by up to 66 % (5). However, the risks of being denounced to the 
police also increase (Labrousse and Romero, 2001). Thus, it seems that two out of three 
farmers sell raw plants to manufacturers and middlemen.
(3) Pascual Moreno, an agronomist, director of an EU substitution program in the Rif, has worked for 25 
years in the region. He estimated that over 200 000 smallholders cultivated cannabis in the Rif in the 
early 2000s, covering a total area of around 250 000 hectares and affecting from 1 to 1.5 million 
people (cited in Labrousse and Romero, 2001).
(4) The difference in price is from Dh 3 500 for 100 kg of raw cannabis to about Dh 3 950 for the 2.82 kg 
of resin obtained from them.
(5) According to Pascual Moreno, 100 kg of kif will get the farmer 5 200 Dh. The 3.5 kg of hashish that 
can be obtained from the 100 kg, Dh 8 750, a further profit of Dh 3 500 (Labrousse and Romero, 
2001).
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Hash oil is more concentrated and valuable than hashish itself, and is also easier 
to conceal and to transport. 10 kg of hashish is needed to produce 1 kg of oil. The 
techniques for hash oil production were introduced to Morocco in the 1960s following 
Lebanese and Pakistani methods, in what is claimed to be a dual initiative of both 
foreign and Ketami traffickers to address export demand and to increase the value of 
their products (Labrousse and Romero, 2001).
Farm prices and export prices
Cannabis offers a good source of income for small farmers in an underdeveloped 
region, even though the farmer only receives a small part of the retail price of hashish. 
According to UN data for 2003, farmers sell 1 kg of resin for Dh 1 400, or about 
EUR 130. In Spain, the same kilogram could be sold for EUR 2 725 at wholesale prices 
(UNODC, 2007) or around EUR 4 400 at retail prices (EMCDDA, 2006).
Export prices in Morocco vary considerably, depending on quality, amount purchased, 
place of acquisition, etc. If bought directly from the farmers, a gram of best quality 
hashish (sputnik, doble cero) could reach a price of EUR 0.45 to EUR 0.75 (6). Second- 
or third-rate hashish will get a third of that (Labrousse and Romero, 2001). In our 
own research we have found prices as low as EUR  0.10 per gram, or EUR 100 per kg 
for larger quantities. A common price of second-rate hashish would be EUR 0.50 per 
gram for those who smuggle up to 1 kg. In one field trip to Chefchaouen in 2001, for 
instance, we knew of three Spaniards who bought 500 g of second quality hashish at Dh 
8.5, about EUR 0.60, per gram. They felt cheated, because the sample they were shown 
in advance was of much better quality. However, they retailed most of the batch in Spain 
at about EUR 4.00 per gram, which paid for the costs of their trip, together with a small 
profit.
Comparing different sources, including our fieldwork, we estimate that export prices 
oscillate between EUR 0.10 and EUR 1.00 per gram of hashish. The total country 
earnings of the Moroccan hashish industry includes farmers’ revenues, exporters’ profits 
and remittances from Moroccan traders and dealers abroad. If about 2 200 tonnes of 
Moroccan hashish were successfully exported in 2003, earnings could be estimated in 
the range of EUR 1 billion to EUR 1.5 billion. In any case, earnings are multiplied by 
a factor of 8 to 10 when sold in Europe. Compared with the price paid by consumers, 
at about EUR 5.4 per gram of resin, the total turnover of the market for Moroccan 
cannabis could be estimated at EUR 12 billion. Yet most of this is generated in European 
markets and is invested in Europe.
(6) In 2001 we noted that in a café in Chefchaouen, a 10 g egg of good quality hashish retailed at 
around EUR 1.50 for foreign customers.
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The commodity chain of hashish: private and public actors
Smallholders in the Rif economy grow cannabis plants both in rain-fed and irrigated 
plots. They often hire labourers in summer months, mostly in August, to harvest the 
plant. Once harvested and dried, plant material is sold to middlemen who extract the 
sticky dust, especially from the tops of the female plants, press it into balls or blocks 
of hashish and often adulterate it. Intermediaries then stockpile large amounts of the 
product in central locations such as Tangier, Tetouan, Al Hoceima and Asilah and 
have the resin sent to Ceuta and Melilla or across the Strait of Gibraltar to Spain. From 
Spanish locations, the product is then distributed to all European countries directly, or 
to the Netherlands, which serves as a secondary distribution centre for northern Europe 
(Korf and Verbraeck, 1993; De Kort and Korf, 1992).
A pyramid-like structure may be at work, with middlemen buying kif or sandouk from 
peasants and producing blocks of hashish of different qualities, stockpiling them, and 
transporting them to storehouses (Labrousse and Romero, 2001).
Cannabis fields are visible from the roads, and there is no attempt to hide them. Every 
summer, busloads of workers arrive to work in the kif harvest and thousands of tonnes 
of plant product are moved, apparently within reach of police officers. Bribery may be 
widespread, and a local joke tells of traffickers who count distances by the number of 
bribes they have to pay (Labrousse and Romero, 2001; Ketterer, 2001).
Some cannabis resin networks use a legal business as a façade and have no difficulty 
recruiting from the young and unemployed in what is a poor region. Among the higher 
echelons, there is evidence that the hashish trade has become industrialised. The 
Observatoire Géopolitique des Drogues (OGD) notes that hashish exporters are involved 
in large Moroccan firms in agribusiness, fishing, transportation, and import–export 
operations. There is some speculation that this would mean a shift away from the 
Tangier cartels and toward the Casablanca cartels, which are more acceptable to the 
government because they do not contest state power in the same way (Ketterer, 2001).
Export practices serve to link expatriate Moroccans in different European countries 
with drug distributors in the target country. Drug money has changed the consumption 
patterns of the region. Ketterer recently described the scene:
Driving east from Tangier along the Mediterranean coast, the signs of drug power are 
obvious: heavily guarded villas with strangely stylised pagodas, frequent roadblocks with police 
looking for the next payoff and an endless supply of young men going about their workdays in 
the drug business.
(2001)
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Corruption of public officials is part of the operating routine of illegal businesses (Reuter, 
1984). In the case of the Moroccan cannabis resin trade, it is difficult to avoid the 
conclusion that involvement or interested acquiescence of law enforcement officials must 
be widespread, considering the level of cultivation, storage and export in place. Some 
scandals have revealed the involvement of powerful actors in the Moroccan political 
scene. For instance, in November 1995, data from a secret report of the OGD appeared 
in the French newspaper Le Monde, alleging public sector corruption had reached the 
highest political levels, including the royal entourage (7). The Moroccan government 
sued the newspaper. A backlash against the drug trade produced several notorious 
arrests and trials in the following months and years. These revealed the connections that 
operated in the hashish trade between public officials and entrepreneurs.
Two major drug traders had become leaders of networks in the north and had become 
a threat to state power. One of them, Yakhaoufi, was arrested in late 1995. His 
subsequent trial revealed a sophisticated and massive organisation with international 
scope. His own organisation transported hashish out of the central Rif, stockpiled it in 
Tetouan, shipped it to Spain by sea, then delivered it to wholesalers in Amsterdam. In 
addition to bank accounts in Morocco, Spain, Gibraltar and Canada, along with a yacht 
and 15 cars, Yakhloufi boasted of personal, commercial and political ties to the Castro 
regime in Cuba. These ties facilitated contacts with the Colombian cocaine cartels, which 
craved Morocco’s easily penetrable borders as distribution points into Europe. Yakhloufi 
was sentenced to 10 years in jail and died of an apparent heart attack in 1998. ‘He 
was too dangerous — he knew too much,’ said one Tangier street dealer of Yakhloufi’s 
death (Ketterer, 2001).
A second major figure in the cannabis resin trade in Morocco was H’midou Dib. He 
retains folk hero status in northern Morocco. A former fisherman, he constructed his 
own port in Sidi Kankouch on the coast north of Tangier, which was an embarkation 
point for a steady stream of speedboats. Dib constructed an enormous network of 
loyal foot soldiers and villagers eager to protect him. He supplied jobs, built mosques, 
delivered social services and kept the despised authorities at bay. Dib was also involved 
in complex real estate transactions in Tangier, money laundering operations and other 
elements of organised crime.
The Dib trial revealed other links between drug traffickers and government officials, 
including two advisors to former governors in the Tangier province, three civilian police 
colonels, the military police colonel in charge of coastal surveillance and three former 
chiefs of the Tangier urban judiciary and national security police services. Some of these 
officials were fired, arrested and tried, but it is clear that the cleansing campaign of the 
mid-1990s did little to curb the growth of the drug trade or its ties to official Morocco 
(Ketterer, 2001).
(7) See www.ifex.org/en/content/view/full/60123 for further details.
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Sociopolitical and ecological consequences
The cannabis industry has had powerful effects on the society of northern Morocco, the 
ecology of the region and its political relationships with the rest of the country. Cannabis 
plots have expanded so fast and so far into hillsides that they are causing soil erosion 
and the destruction of old forests (Bowcott, 2003; Labrousse and Romero, 2001). 
Moreover, they compete with the best land for traditional food products and now the 
region is dependent on food imports. On the other hand, the Rif has traditionally been 
an impoverished region, discriminated against in investment and infrastructure and 
driven by resentment towards the central government and the accumulation of wealth 
and power in the hands of a few. In the years after independence, people in the region 
revolted and were subjugated by military intervention that caused thousands of deaths 
(OGD, 1996).
Today, the economy of northern Morocco depends heavily on the kif trade and is 
becoming a society of smugglers, both of people and commodities into Europe, and 
manufactured goods into Morocco, with multiple links with Costa del Sol real estate 
business, Gibraltar offshore banks, and Ceuta and Melilla smuggling organisations. 
Furthermore, the drug trade affects the crime situation in the country. Some networks 
of drug traffickers are very often involved in other drug-related crimes and activities. 
Moreover, there are certain crime prevention-related phenomena inherent to the country 
and its traditions, namely child labour, some involvement of underage recruitment in 
liberation movements (mostly in the Western Sahara region), trafficking of human beings 
and smuggling of migrants (UNODC, 2003).
A young, growing and often restless population looks to the other side of the 
Mediterranean for jobs, money and a better future. As Ketterer (2001) observed, 
northern Morocco represents a challenge for the Moroccan state. The region has a 
potent mix of discontent, drugs, organised political opposition and religion. Morocco’s 
drug barons have steadily become a serious crime problem and security threat, and 
also major players in the domestic political system. Moreover, there is a growing 
evidence that violent Islamist cells have become involved in the hashish trade both in 
Morocco and in Spain. Tragically, several major terrorists acts have been funded with 
hashish money (Wilkinson, 2003). The two most important so far are the bombing in 
Casablanca in May 2003, which left 32 people dead; and the train bombings in Madrid 
in March 2004, that killed 192 people and injured over a thousand (8).
(8) See, among others, ‘La masacre financiada por el narcotráfico’ [The massacre funded by drug 
trafficking], El Mundo, 15 April 2004.
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The other side of the Strait: smuggling kif into 
Europe
Hundreds of tonnes of hashish are smuggled into Europe every year from the Rif. This is 
a multifaceted export–import industry which enriches thousands of people. Balls, blocks 
and packages of hashish and hashish oil are carried to Europe by speedboat, fishing 
boat, cargo ships, cars, vans, trucks, small aircraft, and individuals who carry the drug 
in their bags, their clothes or their bodies (9). Hashish is hidden beneath vegetables, fish, 
wood and any other commodities crossing the Strait. Lately, Moroccan hashish and Latin 
American cocaine have been smuggled together, and South American networks are 
using West African connections with bases in Morocco to smuggle cocaine into Europe.
In Spain most hashish is seized at sea or in coastal areas, including docks, harbours, 
beaches and local roads. The most common route of entry crosses the provinces 
of Cádiz and Malaga, bordering the Strait of Gibraltar. However, more and more 
quantities have been seized as far away as Catalonia in the east, and Galicia on the 
north-west Atlantic coast, as drug smugglers use both faster and larger boats. One of 
the reasons for this displacement of smuggling routes may be the stricter control of the 
Strait trying to curb illegal immigration.
The constant growth of the hashish trade
If enforcement agencies’ data on seizures are an indicator of this trade, and not of 
police resources or priorities, the evolution of cannabis seizures in Spain shows the 
substantial growth of this drug industry in the last 15 years. Spain has recorded a 
continuous rise in cannabis resin seizures since 1980, reaching over half a million 
kg a year by the 2000s (Figure 2). Spain alone seizes more hashish than the other 
26 countries of the European Union (plus Norway) together. The increase might 
partly reflect the increase or improvement of police resources. However, the rise 
in confiscations in Spain parallels the spread of cannabis crops in the Rif, with the 
moderate tail-off reported for 2005 reflecting the reduction in cultivation reported 
since 2004. It is thus plausible that the increase in confiscations in Spain is mostly due 
to growth in the hashish trade. By comparison, seizures in Morocco have fluctuated 
throughout the last decade (Table 2).
(9) The World Customs Organisation splits cannabis resin seizures as follows: vessel, 56 %; vehicle, 
42 %; air, 1 %; mail, 0.1 % (Pierre Bertrand, WCO RILO unit, meeting at the EMCDDA, 29 November 
2004).
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Demand/supply: prices in Spain and Europe
Retail prices for cannabis resin vary greatly within and between European countries 
(see Carpentier, this monograph), with average prices reported in Europe at between 
EUR 2.30 (Portugal) and EUR 12.50 per gram (Norway) (EMCDDA, 2006). Average 
prices of cannabis resin, corrected for inflation, fell over the period 1999–2004 in 
EMCDDA reporting countries except in Germany and Spain, where prices remained 
stable, and Luxembourg, where a slight increase occurred (EMCDDA, 2006). In Spain 
prices tend to increase as one moves north. In Seville or Granada, for instance, in 
2003 retail prices of hashish ranged from EUR 2 to EUR 5 per gram, while in Bilbao 
or Barcelona they commonly ranged from EUR 3.5 to EUR 7. The quality of Moroccan 
hashish seems to oscillate considerably, although its potency has remained in a 
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Figure 2: Seizures of cannabis resin in Spain (kg), 1981–2005
Table 2: Seizures of cannabis in Morocco (kg), 1995–2005
1995 1996 1997 1998 1999 2000
Herb 35 808 38 521 27 956 37 161 46 136 83 720
Resin 110 245 64 769 71 887 55 520 54 755 143 946
Total 146 053 103 290 99 843 92 681 100 891 227 666
2001 2002 2003 2004 2005
Herb 68 169 88 529 69 058 318 610 115 000
Resin 61 356 66 394 96 306 86 800 92 423
Total 129 525 154 923 165 364 405 410 207 423
Source: UNODC, 2007.
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range of 5–14 %, with little sign that it has increased in the last decade (see King, 
this monograph). If export prices range from EUR 0.15 to EUR 0.60, retail prices 
provide a margin of 16–80 times cost. This is an important price differential, and the 
main incentive for the international trade, but does not seem larger than other drug 
businesses (see Moore, 1977; Reuter, 1985; Reuter and Kleinman, 1986; Wagstaff, 
1989; Reuter et al., 1990).
Event analysis from a sample of newspaper articles
We have applied to this topic an event analysis methodology developed by historians for 
the study of collective actions such as strikes and social protests across a wide time span 
(see Olzak, 1989; Franzosi, 1995). In this methodology, events are commonly defined 
as non-routine, collective, and public acts. The first step in this method is to establish 
formal rules for coding information on collective events using records from archives, 
newspapers, historical documents, and police and magistrate records. This allows 
information on different aspects of a particular type of collective action to be measured 
and compared across social systems or across time periods, as data are collected in 
commensurate dimensions (Olzak, 1989).
Historians have observed that newspapers provide the most complete account of 
events for the widest sample of geographical or temporal units (Tilly et al., 1975) and, 
despite the limitations of the newspapers as a source of socio-historical data, they 
often constitute the only available source of information. ‘Exclusion of newspaper data 
would prevent research in fields where no alternative data are available’ (Franzosi, 
1987). This is especially apt in the case at hand. However, as Franzosi has noted, ‘the 
validity of newspaper information is questionable: newspapers differ widely in their 
reporting practices and news coverage’. ‘The values, routines, and conventions of 
news organisations constrain the amount and nature of coverage devoted to any story’ 
(Kielbowicz and Scherer, 1986). Nevertheless, in using mass media reports, the type of 
bias more likely to occur ‘consists more of silence and emphasis rather than outright 
false information’ (Franzosi, 1987). In the study of illegal enterprises it is evident ‘that no 
data source is without error, including officially collected statistics’, but ‘in the absence 
of systematic and comparative validation, there is no a priori reason to believe that data 
collected from newspaper would be less valid than other commonly used sources’.
The sample of events
We have reviewed over 2 000 news reports from the newspaper El País, concerning 
cannabis seizures from May 1976 to December 2003. They describe 1 370 failed 
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schemes or projects of smugglers or distributors. On average, these events represent 
40.2 % of all cannabis seized during this period in Spain, with a considerable variation 
from year to year (standard deviation: 21.7). In total, our sample includes reports 
of about one out of every three groups detained in Spain for hashish trafficking in 
this 27-year period. We chose El País for the quality and consistency of its reporting 
concerning social issues, and because it is the only newspaper that is edited throughout 
Spain with local editions in all major regions, and, more importantly, because it has 
indexed all of its issues published since its first edition in May 1976. We have attempted 
to check the selected cases found in El País against other news and police reports of 
the same events. Our analysis is still ongoing, and the results we present here are 
provisional and tentative.
The organisation of smuggling and distribution of hash into Spain
We can draw some preliminary conclusions from our sample of events. In Table 3 we 
present the number of episodes described in our sample by the amount of cannabis 
seized. In most cases the substance confiscated was hashish, although some herbal 
cannabis was also seized, in particular during the 1970s and in the last decade.
When examining the 1 370 operations we found that over 800 regional distributors 
and importers were involved. Almost all of those arrested with over 500 kg of hashish 
were smugglers or large-scale distributors. It is important to note that some of the 
Table 3: Number of seizures by amount seized, news events sample from El 
País (1976–2003) (n = 1 370)
Amount (kg) n % % accumulated
1 or less 86 6.3 6.3
2–9 76 5.5 11.8
10–49 156 11.4 23.2
50–99 94 6.9 30.1
100–499 331 24.2 54.2
500–999 197 14.4 68.6
1 000–4 999 363 26.5 95.1
5 000–9 999 37 2.7 97.8
10 000 or more 30 2.2 100.0
Total 1 370 100.0 100.0
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Nationalities of smugglers and traders
We were able to identify the nationality of people arrested in 757 cases. Over a third 
of all groups (38 %) were formed by Spaniards working with Spaniards (Table 4). 
Moroccans working with people of their nationality formed the second most frequent 
type (19 %), and groups of nationals from other European countries formed the third 
most common type. When people from different nationalities cooperated within range 
of Spanish police, the most frequent combination was that of Spanish and Moroccan 
nationals (8 % of all groups arrested). Spaniards working with other Europeans was 
also a common type of association, representing 5.5 % of all episodes in our sample 
(Table 5).
We observed a correlation between the size of the haul seized and the nationality of the 
members of the distribution groups. Furthermore, nationality was linked to the dominant 
task of the organisation. Almost all retailing is done by Spaniards working alone or 
in small groups of same-country nationals. Moroccan immigrants were commonly 
Table 4: Number of seizures larger than 1 000 kg by period, total news events 
from El País, Spain, 1976–2003 (n = 1 370)
Years n % % accumulated
1976–1979 5 1.2 1.2
1980–1984 10 2.3 3.5
1985–1989 27 6.3 9.8
1990–1994 120 27.9 37.7
1995–1999 122 28.4 66.0
2000–2003 146 34.0 100.0
Total 430 100.0
groups or individuals caught with smaller amounts, even those arrested with less than 
1 kg, were also smugglers. Large import operations of 1 000 kg or more became more 
frequent from 1990 onwards (Table 4). This is coherent with the growth of total seizures 
that surpassed 100 tonnes in 1990 and 1991. In the 2000s, the level of operations 
seems to have increased even more. We have found data on 430 groups that imported 
between 1 and 36 tonnes. On average, 3.4 tonnes were seized in these operations, 
although there is great variation in this sample (standard deviation: 4.5). On average, 
7.4 people were arrested by project or police raid (mean: 4.5). The size of these groups 
varied a great deal (standard deviation: 10.6). In one case, 97 people were arrested in 
several European countries in a connection with a wide transnational ring of smugglers, 
distributors and money launderers; in some cases only one person was arrested, for 
instance, the driver of the truck.
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found in small smuggling and wholesale operations involving less than 100 kg. French, 
British, Dutch and other Europeans were also important in smuggling these quantities, 
and sometimes they transported cannabis from Morocco. Often, however, for these 
quantities the traffickers sourced the cannabis from Spain before shipping it to France, 
the UK and the Netherlands. In large-scale smuggling, the role of foreigners tends to 
be proportional to the size of the cargo. Besides Spaniards, French, Dutch and British 
nationals were commonly involved in smuggling between 1 and 5 tonnes of resin. In the 
largest, multi-tonne schemes, the groups tended to be more complex and international, 
and some of the combinations are not reflected in Table 4. For instance, South 
Americans appeared to be progressively associated with Spaniards and Moroccans in 
smuggling operations of over 5 tonnes.
We were able to collect information on the nationality of members of 224 groups of 
importers dealing with one or more tonnes of cannabis resin. Most of these groups were 
composed of non-Spanish Europeans (40 %), followed by groups in which Spaniards 
cooperated with other Europeans (30 %). It is important to note that the data cover 
only people who were arrested in Spain and do not provide information on all the 
members of transnational drug-dealing organisations. Thus, it underestimates the level 
of international cooperation in cannabis trafficking to Europe.
Hashish trafficking and gender
In 280 cases the sex of traffickers was specified, and about 19 % were women. Women 
were especially active in the lower ranges of the hashish trade. Thus, in the groups 
dealing with 1 kg or less, a third were women working alone or in association with 
men. In the range of over 1 kg to 50 kg, 29 % of all arrestees were women, often 
dealing in same-sex teams. In the higher echelons of the trade, however — defined 
as those involving 500 kg or more — less than 5 % of arrestees were women, and they 
always worked in groups led by men. Mixed gender teams were present in all levels of 
the trade; 11 % of all groups were of mixed gender. We found two culturally defined 
feminine roles culturally sanctioned in the hashish trade — one was sanctioned by 
the derogatory labels of ‘culeras’ and ‘vagineras’, or mules who conceal the drug in 
their rectums (‘culo’, ‘ass’) and vaginas. The other involved middle-aged women with 
grown-up sons and daughters leading family networks in unstructured families and 
destitute neighbourhoods. Evidently, this is a male-dominated market and women often 
experience processes of exclusion and exploitation.
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Types of organisations and networks
We have found a variety of organisations and networks involved in smuggling and 
distributing cannabis resin into Europe via Spain. They vary in structure, strategy and 
main tasks. Case examples of the schemes and groups included in the newspaper 
corpus serve to illustrate key aspects of smuggling networks, such as their size, tactics, 
roles, tasks and permanence in the trade. These are crucial elements in the organisation 
of illegal enterprise (Haller, 1990; Dorn et al., 1992).
The smallest unit of smuggling and distribution
The smallest unit of smuggling and distribution is formed by individuals or by small 
groups of two or three people who carried the drug in their bags, clothes or within their 
stomachs, rectums or vaginas. They do not need much investment or organisation, and 
can repeat their schemes several times every month, or not at all. They are ‘freelancers’, 
in the typology proposed by Natarajan and Belanger (1998).
In the early 1980s, trips to the Spanish enclaves of Ceuta and Melilla in northern Africa 
or to Tangier or Tetouan to import small amounts of hashish, often within one’s own 
body, became a sort of rite of passage for many novices of the Spanish drug wave. 
In slang, the adventure was known as ‘bajar al moro’. A theatrical comedy and the 
subsequent film of this title were commercial successes. The film, somehow, reinforced 
the gendered hierarchies of the trade, as the protagonist had to lose her virginity to be 
able to make such a trip to a ‘Moorish’ country. What follows are several examples of 
this level of trafficking.
Case 1 A 60-year-old ‘mule’
In May 1985, a 60-year-old woman went to the emergency room at the hospital in 
Ciudad Real, a city in central Spain. She could not defecate the 96 10-g ‘eggs’ of 
hashish she had swallowed in Morocco. She had to undergo several surgical procedures 
to extract what had become a large pulp of hashish. She was later indicted for drug 
trafficking (El País, 1 May 1985). This case reflects the not infrequent involvement of 
older women in the hashish trade. They may transport drugs in order to pay for their 
family’s needs, sometimes with the help of male members of the family.
Case 2 Three Frenchmen who loved oil
Three young Frenchmen bought 80 g of hash oil in Tetouan. They sealed it in packages 
made with condoms, swallowed them, and crossed into Spain through Algeciras. In 
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Madrid, one of them felt very sick and his colleagues took him to the hospital. The 
police were called (El País, 10 April 1980).
Case 3 An individual multikilo importer
In September 1989, a 28-year-old Moroccan was arrested in Almeria’s harbour when 
getting off the Melilla ferry. He was carrying two suitcases with 45 kg of cannabis resin. 
He was on his way to Cordoba. Police estimated that the drugs were worth 9 million 
pesetas, or about EUR 1.20 per gram wholesale (El País, 12 September 1989).
Case 4 Small-scale smuggling from Spain into France
In November 1992, four women were arrested in Madrid’s Chamartín train station when 
they were boarding the Bordeaux train with 32 kg of hashish in their bags. It seems that 
they were related. Two of them were Spanish, a 54-year-old woman and her 26-year-
old daughter, and the other two were French nationals, a 26- and 19-year-old. They 
were travelling with two babies. They had arrived two days before, exchanged a large 
amount of French currency in the station bank, took a taxi to Madrid Airport, and flew to 
Malaga. Upon their return, their bags were searched by suspicious police officers. They 
had made similar trips in June and September of the same year (El País, 26 November 
1992).
This appears to be a case of small-scale smuggling from Spain to France. It is possible 
that these women were wholesalers or retailers in France. There was some continuity 
in their projects, and they may be an example of a family business, in the typology 
proposed by Natarajan and Belanger (1998).
Smugglers for multiregional distribution
The second type or level of drug trade organisation includes networks that smuggle 
hundreds of kilograms using boats, trucks, or even small aircraft. Often they work 
together with importers or regional distributors in other European countries, and 
maintain, at least for a period, some continuity in their operations.
Case 5 By air: importation and regional distribution
In February 2000, Spanish police forces were suspicious of wholesalers in four provinces 
that followed similar routines. They were able to trace a common contact in Seville, 
and learned of an incoming shipment arriving at a makeshift airfield in the Cadiz 
countryside. There they seized 639 kg of ‘pollen’ or high-quality resin, and five high-end 
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cars. A light aircraft made the three-hour round trips from a small airport in Seville to 
Morocco and back, with an intermediate landing in countryside locations. Seven people 
were arrested at the landing grounds. The financier and an aide were arrested on their 
return from Morocco. In the financier’s home the police found 40 million pesetas in 
cash (about EUR 240 000). All arrestees seemed mature, knowledgeable and careful. 
Their average age was 38. Police found that they had been conducting regular flights to 
Morocco, often at night, for several months.
This appears to be a case of importers linked to regional distributors and wholesalers, 
with a clear hierarchy and division of tasks based on resources, contacts and expertise. 
They seemed to work exclusively in Spanish regional distribution covering a large area. 
They exhibited some permanence and repeated the same modus operandi over several 
months.
Large-scale importers for an international market
A higher level of operations is reached when tonnes of hashish are smuggled into Spain 
and sent to other European countries for wider distribution.
Case 6 Middle-tier distribution network: smuggling to the wider 
Europe
In March 1977, the British yacht Cynosure was seized in Palma de Mallorca’s harbour. 
In the yacht’s stores the Spanish police found over 2000 kg of hash in sealed packages. 
Two French sailors were arrested on the spot. The captain and owner, a prominent 
businessman from the Balearic hotel trade, fled but was arrested in Amsterdam some 
weeks later and extradited. The cargo had been transferred to the yacht from a fishing 
boat in Betoya’s Bay in northern Morocco. The two French sailors had been hired in 
Ibiza to sail the yacht from Morocco to Southern France. Near Mallorca the engines 
failed, and in their search for help they provoked police suspicion. There was evidence 
of previous trips by the Cynosure from Moroccan ports to Southern France, with stops in 
the Costa del Sol, Costa Brava and Mallorca. Here we see a small organisation, linking 
Morocco and France, with a minimal hierarchy and distribution of work, and some 
recurrence in their operations.
The industrial level
The higher level of the cannabis resin export–import industry is composed of groups that 
deal with dozens of tonnes at a time in industrial scale operations.
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Case 7 Large-scale smuggling: an electric train in a cave
The sophistication of the higher echelons of the cannabis resin import industry was 
revealed in July 1988 when police discovered one of the largest stashes of hashish 
on record in a cove near the Costa Brava resort of Lloret de Mar in north-east Spain. 
Smugglers had constructed a 50-metre tunnel through a mountain that connected the 
beach to a cabin in a field via a small train. In the tunnel, police found 15 tonnes of 
cannabis resin. Another 2 tonnes were found in a farm nearby. Air conditioners and 
humidifiers maintained the hashish’s quality, and refrigerated trucks took the product 
to markets in France, Britain and West Germany. Six people were arrested, all in their 
40s and 50s. A Corsican and a Spaniard were the leaders of the group. The Spaniard 
had already been prosecuted in 1981 when found with 2.5 tonnes of hashish. Police 
claimed that ‘The Corsican’, as the second leader was known, was considered the chief 
of a ring of international smugglers (El País, 26 July 1988). He was a French citizen 
who owned several restaurants on the Costa Brava. One of these restaurants had been 
attacked with a bomb three years before. His arrest was world news, and he was related 
to the Corsican Mafia (see Time article, ‘Smugglers On Ice’, 8 August 1988). In 1992, 
when the trial took place, it became evident that the group had been operating for some 
time, and probably was responsible for the smuggling of hundreds of tonnes of hashish 
(El País, 16 July 1992). ‘The Corsican’ was arrested again in June 1997 in relation to 
another haul of 6 tonnes of hash seized near Barcelona. Six people were arrested. He 
had, at the time, been out of jail for less than a year (El País, 24 June 1997).
This is an example of a section of an international network, armed and well organised, 
with credit and capacity to invest in infrastructure and the trafficking of tonnes of 
cannabis resin in every operation. These traffickers had been in the business for over 15 
years, although it seems that much of this time they were inactive.
Case 8 A freight cargo with fish meal
Early in 1996, customs officers in Marín, a small harbour in the Galician coast of north-
western Spain unloaded thousands of 10-kg hashish packages hidden beneath fish meal 
in the storerooms of the Volga One, a 49-metre cargo ship registered in Panama that 
had arrived that day. Three months before, the same ship, with a different name, had 
unloaded a legal cargo of 260 tonnes of tuna fish. This time, 36 tonnes of Moroccan 
hashish were hidden beneath a cargo of 90 tonnes of fish meal. The ship picked up its 
cargo in Asilah, a small harbour in the Atlantic coast south of Tangier. Most of the eight 
crew members were Russians. This was the largest seizure of hashish on record, and 
11 people were charged. A highly indebted businessman from the Canary Islands, with 
experience in food imports, appeared to be the financier and the contact with Dutch 
and Moroccan distributors. A Galician entrepreneur linked to tobacco smuggling and 
cocaine importers seemed to have organised the shipment and local storage. A trade 
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union leader and a prison officer were also charged. The ‘Canario’ entrepreneur had 
USD 2.5 million in cash, mostly in Dutch currency, when apprehended.
Here, we see a coalition of entrepreneurs working together on a large project. 
Individuals from at least four countries were playing roles according to their expertise 
and capacity: financiers and buyers of the drug, organisers, wholesalers, ship crews, 
transporters and Dutch importers. The network they had developed, however, seemed 
transitory, project-oriented, and non-hierarchical.
In this simplified overview, we have shown the emergent lines of a pyramid that 
includes various actors performing different tasks in association or competition. Our 
sample reveals only failed schemes, and of those, only the portion operating in Spain. 
Obviously, the limitations of our sample are considerable. Further work is necessary to 
document networks operating in other countries at both ends of the commodity and the 
financial chains followed by hashish and the money that pays for it. Thus, much work 
remains to be done in Morocco, Gibraltar, Costa del Sol and in the receiving European 
countries.
Violence in the hashish market
Violence in the hashish market seems to be much less frequent and serious than in 
the cocaine and heroin markets, although perhaps in both cases its effects tend to be 
exaggerated. As Reuter observed, ‘there are many limitations on the use of violence as 
a tool for competition, that only in very narrowly defined circumstances can violence be 
used to suppress competition’ (Reuter, 1984). We found violent acts in three realms of 
the hashish trade: in connection with large networks in which some associates abandon 
their duties; in retailing, where some dealers (in Spanish: ‘camellos’) and clients fight 
over prices, money, thefts, etc., and when traffickers react violently against enforcement 
officers. Here we present some examples.
In June 1990, a suspected hashish dealer was arrested in Madrid when he knifed a 
client in a central square notorious for the drug scene (El País, 27 June 1993). In the 
Costa del Sol there have been some cases of murders related to hashish trafficking, 
apparently related to unpaid debts (see El País, 20 January 1993). In 1996, a ‘mule’ 
who did not deliver the drug he was given in Morocco to bring to Spain inside his body 
was kidnapped (El País, 6 June 1996). There was also the case of an international 
criminal network that poisoned two importers who had apparently sold adulterated 
hashish. Following this incident, one of the dealers attacked became a police informant 
(El País, 10 May 1994). In another case, a group was using 15-year-olds to smuggle 
hashish within their bodies from Ceuta, and used intimidation and violence to coerce the 
minors (El País, 11 October 1995).
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In our sample, episodes involving violent acts are few and far between, and the 
atmosphere in the hashish trade does not seem as threatening or violent as that of the 
cocaine industry. Violence and intimidation may be a means to solve disputes in the 
hashish market, and to enforce contracts and obligations. But, at least on the European 
side in Spain, there is little sign that it is used to maintaining monopoly or oligopoly 
conditions, which would prevent people from entering this trade.
Concluding comments
The market for hashish in Europe has grown substantially in the last three decades 
and has stimulated the spread of an illicit plantation and manufacturing economy on 
the other side of the Mediterranean. Today, 22.5 million Europeans are reported to 
have consumed cannabis in the last year (see Vicente, this monograph). Two major 
products dominate the European market: a relatively standardised cannabis resin, 
and domestically or Dutch-grown herbal cannabis. Most of Europe’s cannabis resin 
originates in Morocco and is imported through Spain, and then often taken to the 
Netherlands to be distributed in northern countries (UNODC, 2007).
Cannabis-related policies are contentious issues in international relations. European 
countries have often been accused of leniency regarding cannabis use and possession, 
as occurred in the meeting of the United Nations Commission on Narcotic Drugs 
(UNCND) held in May 2002. The growing links and transfers of people, commodities 
and ideas from both sides of the Mediterranean have facilitated the explosion in 
the production of hashish. The multiple transactions and displacements to and from 
Morocco facilitate the smuggling of hashish.
The rapid growth of cannabis resin production in Morocco is a dramatic phenomenon. 
Cannabis resin is the most successful Moroccan export of the last quarter of a century. 
For northern Morocco it has been a mixed blessing. In the short term, it may be helping 
to alleviate some social and political tensions, providing a source of foreign currency 
in a region in which underprivileged, forgotten and resentful citizens are pitted against 
their government. However, it is also increasing corruption, raising local prices, and 
cutting incentives for local production of legal crops and other goods. Long term, 
the drug trade could produce nastier effects if it leads to an increase in the local 
consumption of hashish and other drugs, or if the European demand for cannabis 
diminishes and the Rif turns to other crops, for instance opium poppies. Growing links 
between hashish and cocaine traders may prove ominous.
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The structure of drug export–import organisations
From our limited review of importers and distributors arrested in Spain, we will venture 
some observations concerning the types of organisations and networks involved in the 
trade.
First, the hashish trade, like most illegal markets, is a service industry and ‘the bulk of 
total cost of getting the final good to the consumer is not production but compensation 
to those involved in the distribution of the drug from production point to the final 
consumer’ (Reuter, 1984). Technologically, the hashish industry is very simple. There 
is little transnational cooperation in the manufacturing of the product, and chemical 
precursors are not needed. The hashish industry is mostly a storage and transport 
industry. Some initial investment is necessary for seeds and fertilisers, and to buy raw 
material from farmers. As in other drug industries, ‘capital in this business consists 
almost entirely of an inventory which is turned over very rapidly and the “goodwill” built 
up by knowing good suppliers and customers’ (Reuter and Haaga, 1989). Thus, the cost 
curve of cannabis resin distribution is likely to be determined by human factors (Reuter, 
1984).
Second, although our data are partial and preliminary, they echo the findings of authors 
who have been analysing drug dealing networks or organisations from a relational or 
industrial organisation perspective. For instance, Reuter and Haaga explored careers 
and organisations in the upper levels of the cocaine and herbal cannabis markets, and 
found that successful operations did not require ‘a large or enduring organisation’. 
More or less formal organisations may exist, but are not indispensable for ‘operational 
or financial success’. Relationships between partners ‘were more like networks than like 
hierarchical organisations’ (Reuter and Haaga, 1989). Therefore, the relational aspects 
of the drug industry may play a crucial role in its structure, although few studies have 
focused on this topic. Morselli (2001) has recently reviewed the operational methods 
of a long-term distributor of hashish, and found that he never worked within an 
organisation but was able to operate via his own strong and weak links within a very 
wide social network.
As we have shown, the major groups working in smuggling hashish present a 
hierarchical division of roles and tasks, but this structure seems to be transitory and 
informal. As Reuter and Haaga noted, asymmetries of information ‘would preclude 
formal organisation’ (Reuter and Haaga, 1989). Participants often work as independent 
specialists or salesmen, hired for one project, more like freelancers or specialists. Thus, 
Morselli concludes that ‘informal cooperation rather than formal organisation’ is a more 
suitable notion to describe the links of those participating in drug importing (Morselli, 
2001).
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In sum, hashish smuggling and distributing firms tend to be informal, changing 
and decentralised, more cooperative than corporative. As Zaitch (2002) has found 
concerning cocaine import groups in the Netherlands, hashish trading organisations 
are more flexible than the notion of a ‘cartel’ suggests. Some are individual enterprises. 
Others adopt the form of temporary partnerships between two or three persons who 
collaborate in a single project. Individuals who function as brokers play a central role 
in bringing about these coalitions for specific transactions or projects (Zaitch, 2002; 
Morselli, 2001; Korf and Verbraeck, 1993). Larger operating groups rarely involve 
more than nine persons, and the division of labour is not rigid or compartmentalised 
along vertical lines, and despite the importance of kinship ties and the frequent use of 
relatives, few of these enterprises are ‘family businesses’ (Zaitch, 2002).
Our results indicate that the organisations in this trade seemed more cooperative 
than hierarchical, and were based on network modes of resource allocation where 
transactions occur neither through discrete exchanges nor by administrative fiat, but 
through networks of individuals engaged in reciprocal, preferential, mutually supportive 
actions (Morselli, 2001). It is probable that the structure of drug organisations is 
somehow different in Europe and Morocco, for a number of reasons. One area of 
difference stems from the varying roles of the state institutions and officials on both sides 
of the Strait. Furthermore, the need to grow, harvest, collect, manufacture and store the 
product on a yearly basis may promote more stable transactions and, perhaps, networks 
and organisations in Morocco. However, we know very little direct information about 
groups based primarily in Morocco.
Competition and disorganised crime
The hashish trade seems relatively open and competitive, although competition seems 
greater at the lower echelons of the market. There is no evidence of smuggling cartels or 
oligopolies operating in the Spanish side of the trade, and even the existence of large, 
stable organisations is doubtful. This is more difficult to ascertain for the Moroccan side.
We know that some entrepreneurs have been able to remain involved in the cannabis 
trade for decades, but for long periods of their careers they were inactive for their own 
reasons, or because they suffered arrests, trials and incarceration. In any case, most 
entrepreneurs seem to work ‘without having the organizing force and support of a 
reputed and resource-yielding criminal organisation’ (Morselli, 2001). Instead, they may 
rely on legal enterprise for a more permanent business structure and stable contractual 
relationships for some of their associates.
In some cases, one small group, even a single individual, runs the whole pyramid, 
buying from Moroccan farmers, smuggling it into a European country and retailing 
the drug to consumers. But larger operations reveal considerable complexity and 
Chapter 15
287
coordination of people in Morocco, Spain and other European countries buying, storing 
and transporting the product through several frontiers and selling it to wholesalers and 
smaller distributors.
There are competing views of how drug markets are organised. Most studies 
assume that organised crime plays a major role in structuring these markets through 
organisations that are hierarchical, relatively permanent and bureaucratic. Some authors 
posit the existence of ‘corporations’ in the drug trade. In parallel, there are explanations 
in which ‘violence is typically regarded as the principal regulator of competition’ 
(Morselli, 2001). This model does not seem to apply to our data. It appears that hashish 
dealers face few barriers to entry in the low and middle levels of the market, and also 
in the higher levels if they have the right contacts and funds. A successful operation 
does not require the creation of a large or enduring organisation, and it is possible to 
function as a high-level dealer without recourse to violence (Reuter and Haaga, 1989). 
Moreover, violence and intimidation do not have as much of a presence in the European 
hashish trade as in the cocaine business. There are cases concerning kidnappings and 
killings in our sample, but they are rare and usually connected with rip-offs, fights at the 
retail level or reactions against enforcement officers.
Regarding the origin of the agents of this market, Moroccan hashish importers both 
compete and cooperate with native Spanish and other European importers, and to a 
lesser extent with traffickers of other nationalities, which is similar to what Zaitch (2002) 
has recently found concerning Colombian importers in the Netherlands. All traffickers 
experience conditions that both promote and limit their opportunities. While some 
Moroccans may have privileged access to hashish supply, local entrepreneurs tend to 
have better access to human resources and infrastructure in their countries.
Prices, standardisation of products and economies of scale
Price data are a potentially important research tool for understanding the workings of 
drug markets and the effects of law enforcement (Caulkins and Reuter, 1998), but its 
collection has not been a priority in Europe. Thus, we lack historical data on such a 
crucial variable, which makes it difficult to understand the evolution of drug markets. 
With regard to cannabis resin and other cannabis products, European evidence shows 
a clear decrease in real prices, at least from 1989 to 2004, a period in which there 
has been a clear increase in demand of cannabis products. This appears to have also 
happened in other European countries, such as the UK. It seems that international 
groups which operate in a European common market for cannabis have developed 
economies of scale, with declining costs per unit of output, and this has resulted in a 
decrease of prices, the standardisation of supply, and a reduction in the diversity of the 
final product both in quality, origin and type of derivative.
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Chapter 16
An analysis of the significance 
of supply and market factors for 
variations in European cannabis 
use
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Setting the context
The chapter by Carpentier et al. (this monograph) discussed the broad concept of 
‘availability’ as applied to the cannabis market in Europe. The chapters by Ballotta 
et al., Korf and Asmussen also suggest that governments across Europe are placing 
emphasis upon the stronger enforcement of the supply of cannabis. Despite this, our 
understanding of the cannabis market remains limited, as does our understanding of 
how variations in supply-side factors may influence demand. This short chapter provides 
a postscript to the previous chapter by Gamella and Jiménez Rodrigo on Moroccan 
cannabis resin, by describing an innovative approach to modelling the cannabis resin 
market. It analyses some recent initiatives that may increase our knowledge of supply-
side factors, and discusses some differences between the markets for cannabis and those 
for other illicit drugs, in particular heroin and cocaine.
While correlations can be identified, there remains considerable work to be done in 
the area of mapping availability. It may prove useful to identify whether there are any 
regional correlations between prevalence and resin seizures, and to determine any 
cross-border patterns that are linked to supply lines.
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An analysis of the significance 
of supply and market factors for 
variations in European cannabis 
use
Leif Lenke
Introduction
Various studies have noted that national cannabis policies, be they liberal or repressive, 
do not show a constant impact on demand (Reuband, 1998; Korf, 2002). It is therefore 
important to explore other factors that may contribute to the different patterns of 
cannabis use we find in Europe today. This chapter takes as its basis a co-authored 
study of heroin supply factors and market conditions, on which the author worked for 
the Council of Europe (Lenke and Olsson, 1998).
Developing a supply model for illicit psychoactive substances
The analysis for the Council of Europe study was based on a number of assumptions. 
These include:
the geographical distribution of seizures is not random;•	
some correlation exists between heroin consumption and distribution;•	
the accumulation of large amounts of heroin at distribution points is generally •	
avoided;
the seizure of large consignments of narcotics is given priority, irrespective of the •	
type of drug policy pursued; and
a positive correlation would be expected over the longer term between quantities •	
seized and quantities distributed.
The study suggested that it was possible to show a strong positive correlation for western 
Europe whereby increases in the amount of heroin seizures in a given country tended to 
be followed by an immediate increase in consumption, as measured by some indirect 
indicators, including fatal overdoses. Moreover, this model allowed conclusions to be 
drawn about the impact on these indicators of changes in the supply situation.
The development of a seizures-based model for analysing cannabis markets may not be 
as straightforward as that for heroin. The cannabis market is much broader than that 
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for heroin, and the profile of consumers more mixed. Further to this, important changes 
may be occurring in the nature of the European cannabis market. The long-term 
domination in many countries of Moroccan-produced resin trafficked through Spain is 
now called into question by data suggesting increases in home-grown or domestically 
cultivated herbal cannabis. This trend is likely to have shortened the distance between 
product source and consumer, and the extent to which cannabis is trafficked across 
borders. Nonetheless, cannabis resin still accounts for the bulk of the cannabis that is 
seized in Europe (Pietschmann and Legget, this monograph) and the analysis presented 
here focuses solely on resin and is therefore partial by definition.
In the Council of Europe heroin case study it was possible to show that the supply of 
heroin was a central factor for understanding consumption patterns. For example, 
proximity of different countries to the Balkan route was important: countries along the 
route had particularly serious heroin problems, while those at a greater distance, for 
example the Scandinavian countries, had been to some extent shielded. As cannabis 
resin consumed in Europe is largely produced in North Africa and imported via the 
Iberian peninsula, it is possible to explore the extent to which geographical proximity to 
resin trafficking routes is reflected in cannabis consumption indicators.
If the quantity of cannabis seized in proportion to the population size is analysed, it is 
possible to identify differences between countries, with those countries in Europe that 
have close contacts with Morocco tending to report larger seizures. For this purpose, 
‘close contact’ refers not only to geographical proximity, but also social proximity 
resulting from colonialism and migration. This has been referred to in the American 
literature as ‘pipelines’, with reference to the Colombian involvement in the American 
cocaine market (Reuter and Kleiman, 1986). For the purposes of this exploratory 
analysis, each country has been allocated an ‘exposure score’, which was found to 
have a strong positive correlation (approaching r = 0.90) with the population-adjusted 
seizure total. Spain was excluded from the analysis as it was an extreme outlier due to its 
atypically high values for both seizures and cannabis consumption.
Important differences exist between the organisation of the cannabis market and that of 
other drugs. Among these is the involvement of a large number of actors, lack of clear 
hierarchy, and relative ease in which new operations can be established (see Gamella 
and Jiménez Rodrigo, this monograph). Profits can be substantial and relatively low 
investment is required to establish new operations. This low degree of organisation 
and the absence of a monopoly may manifest itself in relatively low and stable prices 
found for cannabis resin (see Carpentier et al., this monograph). However, again a 
geographical effect is apparent: prices reported in Norway and Iceland are over four 
times higher than those found in Spain and Portugal, for example.
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Another important difference in the structural organisation of the cannabis market, as 
opposed to some other drug types, is that its operations tend to be European based, 
often involving nationals from or with good contacts in the target market. This means 
that trafficking networks have ‘natural’ contacts with the local distribution networks. This 
has often been a problem for the distributors on the heroin market where ‘outsiders’ 
can face difficulties in selling consignments of drugs directly on the local markets, and 
success is dependent on having reliable contacts with networks in both the production or 
trans-shipment country and the country of consumption.
How does drug supply impact on the consumption 
of cannabis?
In order to explore the question of how drug supply impacts on consumption an 
indicator of the extent of current or recent cannabis use is required. Methods to access 
the size and nature of the cannabis market are described elsewhere in this monograph 
(Vicente et al.). For the purposes of the exploratory analysis presented here, a good 
proxy measure, even if it is somewhat partial, is provided by the ESPAD data set (see 
Hibell et al., this monograph). The advantage of ESPAD is that it is conducted in a 
systematic fashion and guarantees anonymity to the participants and thus the level of 
comparability can be regarded as relatively high. The disadvantage is that the data is 
only available for 15–16 year-old students and patterns of use in the broader population 
may differ. However, as changes in deviant behaviour tend to manifest themselves 
earlier among the youngest age groups (Carlsson, 1972) this group may provide a 
useful window on changes in overall consumption patterns.
The result is that a clear — although not particularly strong — positive statistical 
correlation exists between last-month prevalence from the ESPAD studies and seizures. 
For 16 west European countries, the strength of the correlation lies at r = 0.56 
(F = 6.02). Given the uncertainties involved in the measure of supply in particular (i.e. 
quantities seized), this can be interpreted as providing support for the hypothesis on the 
significance of supply for cannabis consumption.
The correlation between the supply of cannabis and ‘recent use’ is relatively strong 
among students; in countries with high prevalence, the quantities of cannabis seized are 
also high. Spain has again been excluded from the analysis as an extreme outlier. It 
is not as easy to comment on the correlation between quantities seized and recent use 
over time. This is due in large part to the absence of robust and comparable time series 
in which contrasts can be made. However, a general impression that emerges from the 
data that are available does suggest a relationship between seizures and consumption. 
It can be noted that the most substantial increases in cannabis use appear to have 
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occurred during the first half of the 1990s (UNODC, 2004). This was also the period 
that saw the greatest increases in the production of cannabis in Morocco and also the 
greatest increases in the quantities seized in Spain (Gamella and Jiménez Rodrigo, this 
monograph).
Concluding remarks
To summarise, the correlations reported here support the conclusion that a relationship 
exists between indicators of cannabis supply and the extent of cannabis use in western 
Europe. This factor has relevance for the discussion on the significance of drug policy 
choices in influencing the extent and trends in cannabis use over time. As such, the 
analysis offered here, although preliminary, supports the conclusions made by Reuband 
(1998) and Korf (2002) that the ‘level of repression’ found in different national cannabis 
policies does not appear to be a consistent central factor for explaining the variations 
found in the epidemiological data on cannabis consumption patterns.
That said, in the context of a discussion on the factors that do determine national 
variations in levels of cannabis use, it is not helpful to simply shift the point of focus 
from drug policy to drug supply. Clearly other factors are also likely to be important. 
The structure of the correlations provides little if any support for the contention that 
cannabis use is determined by demand at the macro level, however.
One factor that is often presented as an explanation of variations in cannabis use is 
that the drug is associated with specific cultural patterns, and in particular with specific 
patterns of youth subculture. These subcultural patterns arguably then determine the 
patterns of demand and consumption. Testing a hypothesis of this kind is difficult, 
although some types of drug consumption, at some periods of time, do appear to be 
closely linked with particular subcultural groups, for example ecstasy (MDMA) was 
associated with the emergence of rave culture in Europe. Linking today’s widespread 
patterns of cannabis use to any specific subcultural group would appear, however, more 
problematic. A more reasonable interpretation of the relationships is that the supply of, 
and access to, drugs contributes to and intensifies the establishment of consumption 
behaviours. Such a relationship is exemplified by, for example, the drinking cultures 
described in the field of alcohol research, which are also, at least in part, determined by 
supply-side factors.
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Index
The index below covers both volumes of this monograph. Volume number is denoted by the principal 
number in the index entry, e.g. ‘absorption’ can be found on p. 33 of Volume 1.
A
absorption 1.33
abuse 2.33–4
Acomplia see rimonabant
action plan on drugs see European Union
activist groups 1.88
adolescents 2.3–26, 2.79–95, 2.332
correlates of consumption 2.74–7
screening tests 2.39–40
treatment 2.209
see also ESPAD; students
advertising 2.224
Advisory Committee on Drug Dependence 1.44, 
1.46
advocacy 2.97–110
affordability 1.76–7
see also economic accessibility
age 2.287
agonists 1.19
AHOJ-G criteria 1.141
see also environmental strategies
ALAC 2.53
alcohol 2.79, 2.330–1
health effects 2.151
prevalence 2.85–6
see also harm indices
alcohol policy 1.122–3
alternatives to prohibition 1.125–6
consumption after legalisation 1.125
and potency 1.127–8
rationing system 1.126–7
Alcohol Use Disorders Identification Test 
(AUDIT) 2.36
Algeria 1.262
amotivational syndrome see psychological effects
amphetamines 1.54, 1.56, 1.74, 2.63, 2.79
prevalence 2.85–6
Amsterdam 1.138, 1.142, 1.143–5, 1.151, 
1.152, 1.204, 2.39
anandamide 1.19
anasha 1.67
antagonists 1.19
anthropology 2.97–110
antiemetic use 2.165
anxiety 2.133–4
see also mental health
2-arachidonoyl glycerol 1.19
Austria 1.232–3
consumption of cannabis products 1.250
potency of cannabis 1.245, 1.251
availability 1.75–6, 2.64
current indicators 1.218–20
definition of 1.218
Europe 1.215–36
global 1.218
perceived 1.230–1, 1.232–3, 2.72
street-level 1.218
see also supply
awareness 2.63–4
B
back door problem (coffee shops) 1.151–2
Baltic States 1.65, 1.68, 1.76, 1.78, 1.79, 
1.87–8, 1.90, 1.91
Balzac, Honoré de 1.6
Baudelaire, Charles 1.6
Beatles, the 1.44
Becker, Howard S. 2.109
Bedrocan 1.23
Index
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behaviour 2.97–110
behavioural effects 2.189–90
Belgium 1.232–3
consumption of cannabis products 1.250
Maat in de Shit programme 2.222
see also Flanders
Beron, Basilus 1.7
bhang 1.7
Bibra, Ernst Freiherr von 1.8
bongs see waterpipes
botanic classification 1.32
box-score reviews 2.205–7
Bromidia 1.9
buckets 1.178–9
bupropion 2.212
Burroughs, William 2.115
C
CAGE test 2.36, 2.39, 2.43, 2.48
Callaghan, James 1.47
Canada 1.22
CANDIS 2.212
cannabichromene 1.32
cannabidiol 1.32, 1.243
cannabigerol 1.32
cannabindon 1.9
cannabinoids 1.17–24
detection of 2.189
effects of 1.28
pharmacology 1.17–24, 1.27–37
cannabinol 1.243
Cannabinum tannicum Merck 1.8
Cannabis: the Scientific and Medical 
Evidence 1.20
cannabis
as medicine 1.3–14
psychoactive properties 1.5, 1.66–7
Cannabis Abuse Screening Test (CAST) 2.40, 
2.43, 2.53
cannabis clubs 1.23
cannabis flos 1.256
Cannabis indica 1.8
cannabism 1.10
cannabis oil 1.191
trafficking 1.279–80
cannabis plants
seizures 1.221
see also herbal cannabis
Cannabis Problems Questionnaire 2.40
cannabis resin 1.5, 1.30, 1.73, 1.84, 1.100
commodity chain 1.269–70
export 1.272–84
growth of trade 1.272–3
lifetime experience 2.66–7, 2.71
potency 1.228, 1.230
prices 1.225
production 1.199–203, 1.264
production/manufacture 1.265–71
seizures 1.221
sources of 1.200
trafficking 1.208–9, 1.278
see also Morocco
Cannabis sativa L. 1.30
Cannabis Use Disorders Identification Test 
(CUDIT) 2.38, 2.43, 2.47
Cannador 1.22
carcinogenicity 2.121–4
childhood cancers 2.123–4
respiratory cancer 2.121–3
CARED study 2.310
CB1 see receptors
CB2 see receptors
Cesamet capsules 1.21
charras 1.7
chemical structure 1.243
childhood cancers 2.123–4
Christchurch Health and Development 
Study 2.130–1
Christiania 1.157, 1.159
charges 1.164
Intelligence Service 1.162–3
pre-trial detention 1.163–4
Pusher Street 1.157, 1.159–60, 1.162–3
trials and sentences 1.165
classification 1.105, 1.110–11
clubbers see recreational settings
cocaine 1.74, 2.79
prevalence 2.85–6
Cocaine Craving Questionnaire 2.41
Cochrane Collaboration 2.251
coffee shops 1.113, 1.129, 1.137–58
back door problem 1.151–2
policy options 1.151–2
restricted role of 1.149–51
collision risk 2.177–88
communication 1.174–5
comorbidity 2.115–40
competition 1.286–7
Composite International Diagnostic Interview 
(CIDI) 2.36
concealed use 2.101–2
means of concealment 2.102–3
consumption 1.250
after legalisation 1.125
correlates in adolescents 2.74–7
and perceived availability 2.72–4
relative 1.253
and risk perception 2.74
consumption techniques see mode of 
administration
Index
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contingency management 2.210–11
continuation (conversion) rate 2.16–17
controls see legislation
controlling use 2.103
Convention on Narcotic Drugs (1961) 1.11
convictions 1.41, 1.43
Copenhagen 1.157–72
Council of Europe 1.293–5
Courtive, Edmond de, Haschish 1.6
crack 1.74
crackdown 1.157–72
crime
disorganised 1.286–7
smuggling see trafficking
see also legislation
Criminal Justice Act (1977) 1.48
criminal justice system 2.232–3
culpability index 2.184
cultivation see production
culture of silence 2.104
current use 2.7, 2.11–12, 2.14, 2.15, 2.29
measurement of 2.7–8
medicinal 1.11–12, 1.17–24
Cyprus 1.232–3
availability 1.75
drug seizures 1.82, 1.83
herbal cannabis buying power 1.77
legislation 1.80
lifetime prevalence 1.66, 1.68, 1.71
Czech Republic 1.232–3
availability 1.75
consumption of cannabis products 1.250
drug seizures 1.82, 1.83
herbal cannabis buying power 1.77
legislation 1.80
lifetime prevalence 1.67, 1.68, 1.70
potency of cannabis 1.245, 1.251
D
Dangerous Drugs Act (1928) 1.41
data presentation 1.253–4
Daumier, Honoré 1.6
debut drugs 2.69–70
see also gateway theory, initiation
decriminalisation 1.97–117
and cannabis use 1.145–9
demand 1.273–4
demand reduction 1.85–7
Denmark 1.157–72, 1.232–3
Hash-Club Law 1.160
legislation 1.160–6
depenalisation 1.87, 1.88, 1.121, 1.125
dependence 2.16, 2.33, 2.37, 2.126–7, 2.150
physiological 2.34
psychological 2.34
depression 2.133–4
Deutsche Hauptstelle für Suchtfragen 
(Germany) 1.307
deviance 2.97–110
Diagnostic Interview for Genetic Studies 
(DIGS) 2.38
Dib, H’midou 1.270
discos and bars 2.65
distribution 1.275–6
middle-tier network 1.281
multiregional 1.280
smallest unit 1.279
divalproex 2.212
domestic production 1.253
Donovan 1.44
dopamine 1.31, 1.35
dopaminergic system 1.35
Dragendorff, Johan Georg 1.9
driving 2.173–98
assessment of behavioural effects 2.189–90
collision risk 2.177–88
effects on performance 2.175–7
dronabinol 1.20–1, 1.105, 1.106
drug policy 2.157–71
drug recognition experts 2.189
DrugScope 1.174
drug use progression 2.329–30
DSM-IV 2.33, 2.35, 2.37, 2.45–6
Dumas, Alexandre 1.6
Dunedin Multidisciplinary Health and 
Development Study 2.129–30
Dutch drug policy see Netherlands
Dutch National School Survey 2.79–95
dysphoria 1.28, 2.119
dysthymic disorder 2.316, 2.317
E
Early Developmental Stages of Psychopathology 
(EDSP) study 2.131
early intervention 2.279–95
early onset use 2.70
economic accessibility 1.76–7
economics 1.119–35
economies of scale 1.287
ecstasy 1.74, 2.63, 2.79
prevalence 2.85–6
polydrug use with cannabis 2.85–6
EDDRA database 2.234
education 1.174–5, 2.219–21
Egypt, legislation 1.100–1
EMCDDA 1.53, 1.111, 1.187, 2.3–26, 2.32, 
2.144
EDDRA database 2.234
PERK project 2.225, 2.227
Index
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endocannabinoids 1.19, 1.27, 1.30, 1.31, 
1.34–6
environmental prevention strategies 1.119–35, 
2.220, 2.223–4
see also alcohol, tobacco
epidemiology 1.66–77, 2.3–26, 2.59–77, 
2.79–95
ESPAD 1.67–9, 1.231, 1.294, 2.23, 2.59–77
Estonia 1.232–3
availability 1.75
consumption of cannabis products 1.250
drug seizures 1.82, 1.83
herbal cannabis buying power 1.77
legislation 1.80
lifetime prevalence 1.67, 1.68, 1.71, 1.73
Europe
availability of cannabis 1.215–36
cannabis use 2.19–21
importing 1.272–84
legislation 1.97–117
medicinal use of cannabis 1.3–14
potency of cannabis 1.239–62
recent trends 2.21–4
supply and market factors 1.291–7
treatment demand 2.261–76
see also individual countries
European Union 1.110–12, 2.3–26
classification 1.110–11
new Member States 1.63–93
personal use 1.111–12
event analysis 1.274
Evidence-based Electronic Library for Drugs and 
Addiction 1.172
experimentation 2.7
expert knowledge 1.124–5, 2.349–53
export prices 1.268
exports see imports/exports
exposure score 1.294
Extractum Cannabis indicae 1.8
F
family approaches to prevention 2.230, 2.333–4
farm prices 1.268
Finland 1.232–3, 2.97–110
First International Opium Conference 1.101
Flanders 1.304
see also Belgium
Flaubert, Gustave 1.6
flower power 1.45
France 1.8, 1.9, 1.232–3
potency of cannabis 1.245, 1.248
free radicals 1.31
Fronmüller, Bernhard 1.8
G
ganglia 1.31
ganjah 1.7
see also herbal cannabis
gateway theory 1.77, 2.60, 2.92, 2.93, 2.223, 
2.329–31, 2.335
Gauthier, Théophile 1.6
gender 1.71, 2.287
and cannabis use 2.18–19, 2.69
and prevention programmes 2.228
and trafficking 1.278
generation effect 1.149, 2.22
genetic factors 2.338
Germany 1.8, 1.22, 1.232–3
consumption of cannabis products 1.250
Deutsche Hauptstelle für Suchtfragen 1.308
legislation 1.100
potency of cannabis 1.245, 1.247, 1.251
Quit the Shit programme 2.222
treatment demand 2.305–23
glaucoma 1.12
global availability 1.218
government monopoly system 1.126
effectiveness of 1.127
see also environmental prevention strategies
Greece 1.232–3
legislation 1.100–1
grey literature 12.300–10
GW Pharmaceuticals 1.21
H
Hachichins, Club des 1.6
Hahnemann, Samuel 1.7
hallucinogens 2.79
harmful use 2.33
harm indices see classification
harm potential 2.147–52
harm reduction 1.171–83
definition of 1.173–4
health-related 1.174–80
harm risk 2.146–7
Hash-Club Law 1.160, 1.161
hashish see cannabis resin
Hassela pedagogic 1.58
health benefits 2.164–5
health effects 1.106–7, 2.115–40, 2.157–71
acute 2.118–20, 2.160–1
carcinogenicity 2.121–4
cardiovascular 2.119
causal inferences 2.159–60, 2.162–3
chronic 2.120–1, 2.161–2
dependence 2.16, 2.33, 2.37, 2.126–7
immune system 2.120
improved assessments 2.166–7
Index
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mood 2.119–20
premature mortality 2.125–6
prenatal cannabis exposure 2.124–5
reproductive system 2.124
respiratory system 2.120
see also public health impact
health impact assessment 2.143
hemp 1.5, 1.6–7, 1.8
Hemp Seed Association 1.88
Herba Cannabis indicae 1.8
herbal cannabis 1.73, 1.76–7, 1.84
lifetime experience 2.66–7, 2.71
potency 1.228, 1.229, 1.230
prices 1.226
production 1.192–8
seizures 1.221–2
THC in 1.249
trafficking 1.206–7
heroin 2.79
health effects 2.151
prevalence 2.85–6
supply model 1.294
hippie era 1.45, 1.59, 1.67, 1.159
history 1.3–14, 1.99–100
new EU Member States 1.66
HIT 1.174
homeopathy 1.7
house dealers 1.141
Hugo, Victor 1.6
Hungarian Civil Liberties Union 1.88
Hungary 1.232–3
availability 1.75
drug seizures 1.82, 1.83, 1.84
herbal cannabis buying power 1.77
legislation 1.81
lifetime prevalence 1.67, 1.68, 1.70, 1.71
I
ICD-10 2.37, 2.313–14
immune effects 2.120
imports/exports 1.272–84
large-scale 1.281
see also trafficking
India 1.99–100
Indian hemp see hemp
Indian Hemp Report (1894) 1.9
indicated prevention 2.220, 2.235
information 1.174–5
inhalants 2.79
initiation (age of first use) 2.267–8, 2.331–2
intensive use 2.14–17, 2.34
continuation rates 2.16–17
current 2.14
daily 2.14–16
dependence/problematic use 2.16
international law 1.102–4
intoxication 2.148
Ireland 1.232–3
consumption of cannabis products 1.250
ISD-10 2.33
Italy 1.22, 1.232–3
Iversen, Leslie 1.20
J
Jagger, Mick 1.44, 1.45, 1.48
jazz scene 1.43, 1.44, 1.53, 1.55, 1.142–3
Jellinek Clinic (the Netherlands) 2.39
Jellinek self-screening test 1.171, 2.39
see also, Know Cannabis test 
Joseph Rowntree Foundation 1.302, 1.309
K
key indicators 2.24, 2.34
kif 1.265, 1.267
trafficking into Europe 1.272–84
see also cannabis resin, Morocco
Know Cannabis test 2.48–51
Kobert, Rudolf 1.9
L
laboratory analysis 1.254–5
Lapin, Leib 1.9
last month prevalence 1.51, 1.67–70, 1.144, 
1.295, 2.68–9
last year prevalence 1.69, 1.74, 1.144, 2.68–9
Latvia 1.232–3
availability 1.75
drug seizures 1.82, 1.83
herbal cannabis buying power 1.77
legislation 1.80
lifetime prevalance 1.67, 1.68, 1.71
laws see legislation
law enforcement 1.82–5, 1.147
Denmark 1.157–72
law reform 1.109
legalisation 1.47
legislation 1.39–49, 1.63–93
consistency of 1.112–13
Denmark 1.160–6
driving 2.190–1
Europe 1.97–117
origins of 1.99–102
licensing 1.126
Lifeline 1.174
lifestyle 2.288–9
lifetime prevalence 1.67–9, 1.73, 2.9, 2.66–7
lifetime use 2.8
liposolubility 1.33
Index
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Lithuania 1.232–3
availability 1.75
drug seizures 1.82, 1.83
herbal cannabis buying power 1.77
legislation 1.80
lifetime prevalence 1.67, 1.68, 1.71, 1.72
lobbying 1.39–49
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Introduction
Smoked, eaten, imbibed — or just talked about — it seems the world has a strong 
appetite for cannabis. An estimated one in five European adults have tried it. Thirteen 
million Europeans have consumed it in the past month. Nearly 50 000 tonnes of 
cannabis herb or resin is produced for consumption each year. Little wonder, then, that 
cannabis has become a controversial cultural and commercial phenomenon. Today, 
cannabis has a unique ability to divide opinion among policymakers, scientists, law 
enforcers, drugs professionals and consumers.
This EMCDDA cannabis monograph addresses one basic question. How can I find 
quality information on cannabis, amid all the bias and opinion? During the editing of 
this monograph it soon became clear that the EMCDDA was entering an area crowded 
with general guides, even competing cannabis monographs. This is where the idea of 
a cannabis ‘reader’ emerged. Our audience — researchers, parliamentarians, drugs 
professionals, students, European citizens — is currently faced with an overload of 
professional publications. Added to this is the daily flood of information on the Internet, 
often crusading in nature, and sometimes misleading. This threatens to obscure the 
genuine progress made in cannabis research during the past two decades.
The EMCDDA cannabis reader underlines the point that cannabis is not just a static, 
unchanging plant, but a dynamic product that is subject to gradual evolution in potency, 
prevalence, cultivation, legislative and public health concerns. In this monograph, 
leading experts provide short, sharp insights on a range of cannabis topics while 
offering advice on further reading for each topic. Brief editorial notes provide concise 
introductions to each topic, occasionally drawing attention to political sensitivities and 
the need for a ‘critical eye’. So this cannabis reader has a value both as a shortcut to 
researchers entering the area and a synthesis for experts.
You will find a wide range of views expressed in the chapters in this monograph, not 
all of them in agreement. The arguments, tone and conclusion of each chapter is the 
responsibility of the author alone, and is not necessarily endorsed or supported by the 
EMCDDA. This reflects the wider discourse on cannabis where different positions and 
perspectives often lead to different conclusions being drawn from the same evidence. 
We believe each chapter represents a useful contribution to the overall debate, even if 
their individual perspectives differ.
Introduction
x
Two volumes, multiple audiences: policymakers, 
enforcers, researchers, professionals
The monograph is divided into two volumes, each comprising three sections. There are 
a number of reasons for the two-volume approach. While complementary, each has a 
slightly different audience. The first volume centres on political, legislative, commercial 
and social developments relating to cannabis. Its core audience thus comprises 
policymakers, sociologists, historians, journalists and those involved in enforcement. 
The second volume is very much centred on drugs professionals working in the fields of 
treatment, prevention and healthcare.
Volume 1
Cannabis in the past•	
Policies, legislation and control strategies•	
Supply and production issues•	
Volume 2
Epidemiology•	
Health effects of cannabis use•	
Prevention and treatment•	
Changing perspectives: from global issues to local 
experiences
What unites both volumes is an attempt to fuse general chapters with specific case 
studies. Within each section, you will encounter a progression from a ‘top level’ to a 
‘close-up’ view of the subject. So each section begins with chapters providing a general 
introduction to a single cannabis issue, often of an encyclopaedic nature, together with a 
summary of the current state of scientific research. The monograph then ‘zooms in’ with 
a case study about a specific aspect of cannabis.
In Volume 2 ...
In Volume 2 we can read general overviews of impact of cannabis use on health, from 
an individual perspective (the Witton chapter) and public health perspective (the Hall 
and Room chapters); descriptions of current European patterns of cannabis use, from 
a general population perspective (EMCDDA analysis) and in terms of adolescent use 
(results from the ESPAD surveys and from Dutch schools); and descriptions of treatment 
demand for cannabis use disorders in Europe. Case study articles look at the way 
cannabis users perceive their use in Finland, the specific effects of cannabis use on 
driving and the rise in cannabis treatment demand in Germany.


xii i
Foreword
The first volume of the EMCDDA’s cannabis reader reviewed the history of the drug 
and its social impact, and also explored legislative issues. In this second volume, the 
focus moves to describing contemporary patterns of use, reviewing what is known about 
the potential health effects of the drug and highlighting how Europe is responding to 
cannabis use in terms of prevention and treatment.
The cannabis reader would not have been possible without the input of many European 
and international experts and the EMCDDA is indebted to all the scientists and 
researchers who have contributed original papers to this publication. We would also 
especially acknowledge the excellent work carried out by the Centre for Social Research 
on Alcohol and Drugs (SoRAD) in Sweden, which was the main contractor on this 
project. We also thank the reviewers from the EMCDDA’s Scientific Committee, and John 
Witton and Wendy Swift, independent scientific editors.
Epidemiology, and the need to focus on ‘at-risk’ 
populations
The epidemiology of illicit drug use has seen marked improvements in the last two 
decades, with standard indicators having been set up and more reliable surveying 
methods introduced in many European countries. However, while surveys now allow us 
to chart the changing prevalence of cannabis use, they currently remain a weak vehicle 
for identifying those who may be using the drug intensively or experiencing problems. 
Measuring problematic cannabis use at the population level is methodologically 
challenging, but progress is being made.
This volume includes a chapter on screening instruments for identifying cannabis use 
problems, together with a Dutch schools study, which explores how cannabis use can be 
part of a broader pattern of polydrug consumption.
Cannabis consumption in the European population, particularly among adolescents and 
young adults, has been increasing since the 1960s. The most recent EMCDDA figures 
estimate that 13 million of the nearly 500 million Europeans in the EU Member States 
have consumed cannabis in the past month. Yet despite its being the most commonly 
consumed drug, cannabis use is far from ‘standard behaviour’. The number of people 
who have not smoked cannabis in Europe in the last month is clearly far higher than 
the number of those who have, by a factor of around 40 to 1. Cannabis is a drug 
associated with the young. Yet even in high-prevalence countries, among those aged 
between 15 and 34 years, at most only one in five are estimated to have used cannabis 
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in the past month. And a more typical representative estimate across Europe is that only 
one in eight young people have smoked cannabis in the last month, whilst in the lower 
prevalence countries such as Greece, Bulgaria and Sweden, as few as 1 in 20 young 
people report last-month use of the drug.
Moreover, much cannabis use can be described as experimental behaviour which does 
not result in regular consumption patterns becoming established. Some surveys have 
sought to identify intensive use, defined as ‘daily’ or ‘near-daily’ use. Among the EU 
Member States for which data are available, the proportion of last-month cannabis users 
reporting daily or near-daily use ranges from 1 in 20 (Latvia) to 1 in 3 (Spain). Other 
reporting countries state that around one-quarter to one-fifth of last-month cannabis 
users report ‘daily or near-daily use’. While data are insufficient to indicate an accurate 
estimate of intensive cannabis users across Europe, a rough figure would place the 
number of daily or near-daily cannabis users in Europe at around 3 million.
Most last-month cannabis users are young, with males generally more likely to have 
used cannabis in the last month. Data from the ESPAD series of school surveys provides 
us with an interesting window on consumption patterns among 15–16 year olds. Among 
this group, young males are generally more likely to have used cannabis on a frequent 
basis (defined as having used cannabis on 40 or more occasions). Reported frequent 
use by male students is twice, three times or even, in one country, four times higher than 
among female students.
Even among those who establish regular cannabis use patterns in their youth, many will 
stop using the drug as they grow older. Cannabis prevalence rates tend to peak among 
younger adults (aged 15–24 years), suggesting that the majority of cannabis users quit 
as they get older and assume more responsibilities. However, whilst most cannabis users 
will have stopped consuming the substance by their mid- to late 30s, there is some 
evidence to suggest that more people are now continuing to smoke the drug into middle 
age. If this is true, it could have important implications for assessing the likely longer-
term public health impact of cannabis consumption.
More positively, recent studies suggest that in many high-prevalence countries, cannabis 
use is now showing signs of a stabilisation, or even a moderate decrease. Interestingly, 
this finding may be particularly evident in younger age cohorts. Nonetheless, cannabis 
use in Europe remains at a historically high level, and it remains unclear if we are 
seeing any stabilisation or fall in the numbers of those using the drug intensively and 
chronically — a group who are likely to be at particular risk of experiencing adverse 
consequences.
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Cannabis and health
Historically, the cannabis health debate has often appeared poorly grounded in science 
with the possible adverse health effects of use being either trivialised or exaggerated. 
In this volume, a number of commentaries address cannabis and health issues. This is 
an area of emerging science where the evidence base is developing rapidly. A clear 
message emerges from this discourse: when discussing the health impact of cannabis 
use, it is vital to understand that different consumption patterns are likely to be 
associated with different risk profiles, and that risks may vary according to individual 
susceptibilities.
Cannabis has been associated with a number of adverse physical and psychological 
health effects, especially if used regularly. Recently, considerable concern has been 
expressed regarding cannabis’s relationship with mental health problems, including 
a possible association with schizophrenia. Studies on the physical effects of cannabis 
use have also appeared regularly in the research literature. Amongst others, they have 
examined cannabis and respiratory problems, potential genetic vulnerabilities linked to 
cannabis-related problems, the effects of cannabinoids on the body’s endocannabinoid 
system and cannabis’s potential to impair driving skills.
A chapter in this volume by John Witton summarises the predominant recent studies of 
cannabis’s adverse health effects. An appendix also offers a guide to help students to 
navigate the research base, with advice on how to approach the many claims made 
for and against cannabis use with a critical eye. Witton’s chapter argues that, although 
cannabis use has been linked to psychological problems, and an association clearly 
exists between cannabis use and some forms of mental illness, determining with certainty 
a direct causal relationship still remains a more difficult question.
Although few people today regard cannabis as a harm-free substance, there is debate 
as to the relative public health impact of the substance, particularly in comparison with 
tobacco, alcohol and other illicit drugs. This volume of the monograph includes analysis 
by Wayne Hall and Robin Room of the global burden of cannabis use disorders in 
comparison with other drugs. While cannabis appears to have lower intrinsic risks than 
drugs such as heroin and other opiates — for example in terms of overdose risk, degree 
of intoxication and risk of dependence — cannabis use is far more widespread than the 
use of other illicit drugs, and so relatively low risks at the individual level can still result 
in a significant problem for public health at the population level. 
Beyond the direct risk that cannabis use may pose to health, a number of broader public 
health issues exist. Among these are the secondary health risks posed by the drug, for 
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example the extent to which the drug is associated with road traffic accidents. Some 
work has been done in this area, particularly with respect to cannabis use and driving. 
This topic is reviewed here in a chapter that suggests that a minority of cannabis users 
drive under the influence of cannabis, with an adverse effect on road safety.
Although reports of drug treatment attendance by cannabis users have been growing, 
it is difficult to interpret what this means regarding the extent to which users experience 
difficulties. There are a number of reasons for this, including the fact that this data 
reflects both direct referrals from criminal justice and other agencies, as well as 
individuals spontaneously seeking help. Additionally, treatment services specifically 
targeted to cannabis users are still relatively rare in Europe. This may be beginning to 
change, but it is still worth noting that few evaluation studies of the efficacy of different 
cannabis treatment approaches have been carried out. More research is necessary to 
identify the best practices in this area. At the current time, no ‘gold standard’ exists 
for treating cannabis-related disorders, although structured psychosocial interventions 
appear to offer some promise in this area.
Prevention: a shift towards standard programmes and 
measuring effectiveness
In the field of prevention, considerable progress has been made in identifying factors 
which may influence cannabis use (age of initiation, peer influence, risk perception) 
and organisation of prevention intervention (universal, selective, indicated prevention). 
A number of countries have standardised prevention practice in schools by introducing 
manuals, although there is considerable variation in prevention programmes across 
Europe. Some evaluation of outcomes of specific prevention projects (e.g. EU-Dap) 
has showed that prevention, according to the predefined objectives, can contribute to 
a decrease in cannabis use. However, little is still known about the cost-effectiveness 
of interventions in this area. Moreover, the evidence base for some specific types of 
intervention, in particular mass media campaigns, remains weak.
The cannabis reader . . . one more addition to a growing 
evidence base
Drawing the various strands of cannabis in Europe together, this monograph 
demonstrates that cannabis is a complex subject, in which we see considerable changes 
over time. The dynamic nature of this topic is evident not just in developments in the 
way the drug is used but also in attitudes, legislation and societal responses. Our 
understanding of this complex phenomenon is, however, growing and new material of 
all types is becoming ever more available.
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There may be cause for muted optimism. Prevention practice is increasingly responding 
to the evidence base for what works. In terms of science, the workings of the 
endocannabinoid system are gradually being unravelled, with developments in the 
medicinal use of cannabis encouraging research scientists to identify the neurological 
and biological mechanisms that have a bearing on behaviour. In terms of mental health, 
there is increased understanding of the risk factors that accompany cannabis-associated 
psychological problems. Perhaps the most positive development is that, increasingly, 
drug policy in Europe reflects the evidence base drawn from the fields of epidemiology 
and drug treatment. This evidence base is growing ever stronger, with surveys, medical 
studies and statistical data all contributing to a sharper, more multidirectional focus on 
the subject.
The growing volume of new data in this area will naturally need regular review and 
synthesis. If anything is certain in this field, it is that this will not be the last monograph 
to published on cannabis in Europe, nor should it be considered as ‘the final word’ 
on this topic. However, it is clear that, in 2008, our understanding of cannabis use in 
Europe and its probable implications has improved substantially. Cannabis, a substance 
used in Europe for millennia, still remains worthy of our attention, concern and 
vigilance.
Paul Griffiths
Head of Epidemiology, crime and markets unit, EMCDDA
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Part I: Epidemiology
 1 Prevalence, patterns and trends of cannabis use among adults in Europe 
Julian Vicente, Deborah Olszewski and João Matias
 2 Measuring cannabis-related problems and dependence at the population level 
François Beck and Stéphane Legleye
 3 Patterns of cannabis use among students in Europe 
Björn Hibell and Barbro Andersson
 4 Cannabis in the context of polydrug use: results from the Dutch National School 
Survey 
Karin Monshouwer, Filip Smit and Jacqueline Verdurmen
 5 Cannabis users and their relation to Finnish society 
Taru Kekoni
Historically, the focus for much work in the area of drug epidemiology has been 
treatment demand data. However, in recent years we have increasingly seen the parallel 
development of survey data sets, relating both to the general population and selected 
population groups. This shift in focus has important implications for our understanding 
of patterns of cannabis use, particularly as in the past the drug has been less associated 
with problematic patterns of use, while most cannabis users will never come into 
contact with drug treatment services. In Europe, the EMCDDA has helped coordinate, 
standardise and collate national drug surveys since it was set up in 1993. Important 
supranational surveys such as the European School Survey Project on Alcohol and 
Other Drugs (ESPAD) also offer insight into drug use among adolescents. Monitoring 
cannabis use trends across countries and over time is now possible in Europe, although 
methodological differences still exist between countries which mean that data in this area 
require appropriate technical scrutiny.
The EMCDDA’s key indicator on drug use in the general population is represented in 
this volume in Chapter 1, by Vicente, Olszewski and Matias. The chapter describes 
cannabis use in the adult population, and the state of play in data collection on 
cannabis use today. Picking up on one of the conclusions of the EMCDDA chapter — the 
need for increased knowledge of frequent and intensive patterns of use — the next 
chapter, by Beck and Legleye, from the French focal point OFDT, provides an overview 
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of instruments that have been developed to screen populations for intensive cannabis 
use. These screening instruments vary in length, nature and content, yet some consensus 
is forming about common ways to measure the incidence of cannabis use disorders, and 
to identify at-risk populations.
The section proceeds to look at cannabis use among adolescents. Björn Hibell of the 
ESPAD survey describes cannabis use trends in the school student population, focusing 
on ESPAD’s methodology and its measures of a common age group (15–16 year olds) 
across Europe. Cannabis use among adolescents is also examined in the following 
chapter by Monshouwer, who uses data from Dutch school surveys. In particular, this 
chapter looks at the issue of polydrug use and how cannabis fits alongside alcohol, 
tobacco and other drug use.
While statistics can tell us much about drug use, there are stories behind numbers and 
percentages that can provide an additional perspective on this issue. This section ends 
with a chapter from Finland that uses a qualitative, interview-based approach. Kekoni 
describes how cannabis users view the substances in terms of their lives, lifestyles and 
political outlooks. While the chapter makes no claim to be representative of Finnish 
cannabis users as a whole, it does serve to underline the fact that cannabis use has a 
social dimension and that the meanings, rationales and experience of cannabis users in 
different Member States are likely to be important for informing our understating of why 
consumption patterns differ.
Part II: Health effects of cannabis use 
 6 Cannabis use and physical and mental health 
John Witton
 7 The public health significance of cannabis in the spectrum of psychoactive substances 
Robin Room
 8 Assessing the population health impact of cannabis use 
Wayne Hall
 9 Cannabis use and driving: implications for public health and transport policy 
Robert E. Mann, Gina Stoduto, Scott Macdonald and Bruna Brands
Overview of Volume 2
xxi
Considerable research effort has been, and continues to be, devoted to the investigation 
of adverse health effects of cannabis use. Although the current state of research does 
not provide a clearcut understanding of the issues, some conclusions are beginning 
to emerge from the current evidence base. This section begins with a chapter by John 
Witton, summarising what we know about the health effects of cannabis today. He 
highlights that the issue of the extent of comorbidity of substance-specific and non-
substance-specific disorders is crucial when discussing cannabis use, and especially 
frequent and harmful use.
The topic of health effects to the individual naturally has a bearing on the health 
of entire populations. The chapter by Room looks at the issue of the public health 
‘footprint’ of cannabis. It provides some insight into the significance of cannabis-related 
health issues in comparison with tobacco, alcohol and other illicit drugs such as heroin. 
Room takes on the controversial task of comparing cannabis with other substances, 
legal as well as illegal. In so doing he provides the reader with a sense of perspective, 
from which the relative adverse health and social effects of cannabis may be better 
understood.
In the following chapter, Hall notes that one problem in the debate concerning health 
effects of cannabis use has been an ‘inflationary–deflationary dialectic’, in which a 
demand for unreasonably high standards of proof is often made by both sides of the 
debate. There are those who argue that there are few or no adverse health effects 
of cannabis use, and there are those who argue that effects are serious and grave. 
Hall discusses the problems that arise from conducting research on cannabis use and 
potential social and health outcomes, and proposes some guidelines for improved 
research in the future.
Beyond somatic and psychological effects of cannabis, there are other health 
consequences of cannabis use as it relates to behaviour. One of the areas of cannabis’s 
effect on behaviour that has received strong attention is driving under the influence 
of cannabis (DUIC). Mann et al. discuss the specific issue of cannabis and driving. 
The authors have reviewed the scientific literature concerning the effects of cannabis 
on psychomotor skills, as well as the evidence of the combined effect of alcohol and 
cannabis on driving skills. They also address the issue of how society might be able to 
detect and protect itself from cannabis-impaired drivers. As drug-driving tests are being 
introduced in many European countries, the chapter looks at how countries have sought 
to quantify the impact of cannabis on road safety.
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Part III: Prevention and treatment
 10 Treating cannabis use disorders: perspectives and best practices 
Anders Bergmark
 11 Cannabis prevention in the EU 
Gregor Burkhart
 12 Moving towards evidence-based practice: school-based prevention of substance use 
in the USA 
Zili Sloboda
 13 Cannabis users in drug treatment in Europe: an analysis from treatment demand 
data 
Linda Montanari, Colin Taylor and Paul Griffiths
 14 Cannabis treatment in Europe: a survey of services 
Sharon Rödner Sznitman
 15 Has treatment demand for cannabis-related disorders increased in Germany?  
Roland Simon and Ludwig Kraus
 16 Risk factors for cannabis use 
Niall Coggans
Cannabis prevention and treatment are areas filled with complexity and contradictions. 
The issue of what constitutes effective treatment remains relatively open in comparison to 
many other types of drug, and considerable debate exists on whether prevention efforts 
are effective in this area. Nonetheless, in recent decades a large number of interventions 
have been developed in Western countries in order to prevent and treat the use of 
cannabis and other drugs, and the knowledge base in this area is steadily growing.
This section begins with an introduction to cannabis treatment. As the first chapter by 
Bergmark shows, there is considerable research regarding evidence-based cannabis 
treatment, yet this does not necessarily mean that the data provide adequate information 
as to which approach is the most appropriate and effective. For instance, studies do 
not allow us to determine guidelines for type, duration or intensity of treatment. We 
also do not know if it is the treatment as such which provides the effect, as it might 
be the decision to come to treatment in itself that determines the outcome. From this 
perspective, as Bergmark points out, it is clear that, despite an expanded pool of 
treatment effect research, the literature does not necessarily provide clearcut answers 
and guidelines on the issue of best practice in cannabis treatment.
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Chapter 11, by Burkhart, provides an overview of prevention relating to cannabis in 
Europe, categorised according to the typology of universal, selective and indicated 
prevention. A number of EU Member States have begun to standardise universal 
school prevention programmes, yet have also placed emphasis on selective prevention 
linked to risk factor research. Nonetheless, the knowledge base on prevention is based 
strongly around research in the USA. The third chapter in this section, by Zili Sloboda, 
an American prevention expert and former Director of the Division of Epidemiology 
and Prevention Research of the National Institute on Drug Abuse (NIDA), provides an 
overview of school prevention programmes in the USA, together with some explanation 
of their rationale.
The section then looks at the issue of the treatment of cannabis use disorders. In recent 
years, there has been an apparent increase in demand for treatment related to cannabis 
use. Montanari et al. of the EMCDDA provide an analysis of cannabis treatment demand 
in Europe, based on data from the EMCDDA treatment demand indicator. The data 
used are gathered for the purpose of cross-national comparisons, and thereby provide a 
fruitful starting point for analysing the current situation in Europe. A chapter by Rödner 
Sznitman then provides an analysis of fresh data gathered in order to reach a better 
understanding of the current treatment system available to cannabis cases in Europe 
today. This overview provides relatively up-to-date information about the treatment 
facilities that see cannabis cases in Europe and what kind of treatment is offered, as 
well as information about client characteristics. A more in-depth analysis of treatment 
demand follows in the chapter by Simon and Kraus. This chapter focuses solely on 
Germany, and analyses what may lie behind the increase in treatment demand related 
to cannabis use in Germany.
The final chapter looks at risk factors relating to cannabis use. Coggans summarises 
the literature on the subject of risk factors for cannabis use, and discusses how these 
might be used to help us target populations at risk. Risk factors are, naturally, important 
aspects of both prevention and treatment. The chapter thus provides a useful resource 
for practitioners to understand the needs of their clients, and to target interventions 
accordingly.
Peter Thomas
EMCDDA
Sharon Rödner Sznitman
Sorad

Epidemiology
Prevalence, patterns and trends of cannabis use among adults in Europe
2
PART I
3Chapter 1
Prevalence, patterns and trends 
of cannabis use among adults in 
Europe
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Setting the context
A total of 71 million European adults (22 %) have tried cannabis: 23 million European 
adults (7 %) have used it in the last year while 13–14 million European adults (4 %) have 
used the drug in the last 30 days. A crude estimate suggests that 3 million European 
adults (around 1 %) are ‘daily’ or ‘almost daily’ cannabis users.
Such headline figures provide neat, newspaper-friendly estimates of the number of 
cannabis users in Europe. Yet it is important to differentiate between the numbers. There 
is a vast difference between those who admit having tried cannabis and those whose use 
appears to be intensive. Beyond this basic distinction there are myriad other variations: 
growth and decay in perceived risk of use; intensity and setting of use; generational or 
demographic acceptance and disapproval; country-by-country and region-by-region 
variation; and ethnicity and gender differences. In short, while cannabis use may be 
perceived as common in one subgroup, it might be considered outright deviance in 
another.
Reliable statistics are crucial for defining evidence-based drugs policy. For example, 
knowing that there is a large difference in lifetime use between 15- to 16-year-olds and 
17- to 18-year-olds (1) demonstrates that much experimentation with the drug clusters in 
the late teens. Targeted prevention should, thus, take into account the fact that late-teen 
initiation is commonplace. Moreover, early indications that use is growing among forty-
somethings should be monitored. Middle-age concerns, such as careers, parenthood, 
rent and mortgages, have traditionally counteracted regular drug use — is something 
changing today?
 (1) http://stats06.emcdda.europa.eu/en/elements/eyefig01a-en.html
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Information on cannabis use in Europe has improved substantially in recent years, and 
is subject to a standard reporting cycle. Each year, for over a decade, the EMCDDA has 
published analysis and information on the prevalence of cannabis and other illicit drugs 
in its Annual report (2) (currently covering 29 countries). Since 2004, the Annual report 
has also included a companion publication, the Statistical bulletin (3), that provides 
further information on the underlying data, information sources and methodology. On a 
less strict yet still frequent cycle — dependent upon implementation of the questionnaire 
— the ESPAD (4) school survey (37 countries) provides a key transnational source for 
cannabis use patterns among adolescents. Beyond Europe, the standard transnational 
source for epidemiological data on cannabis is the United Nations Office on Drugs and 
Crime (UNODC)’s annual World drugs report. In addition to this, at a domestic level, 
many countries publish prevalence surveys in the context of focused national surveys 
on drugs (e.g. Australia’s National drug strategy household survey and the SAMHSA 
National survey on drug use and health in the USA).
In addition to these statistical publications, the EMCDDA’s National reports (5) include 
discursive analysis of cannabis trends in different European countries. Grey literature 
(governmental, NGO, think tank) publications on cannabis typically appear several times 
per year (see the Appendix to Volume 1 of this monograph). Such publications play an 
important qualitative role, providing explanations for trends and nuanced information at 
regional level (6).
There remains work to be done. With the EU growing — the recent entry of Bulgaria 
and Romania having brought the total number of EU citizens close to 500 million — the 
scope for generalisation is getting smaller. One of the challenges of adding complexity 
to any sample is that the lists of exceptions grows. There are also possibilities for mining 
the rich seams of data in the grey literature and ad hoc surveys. As the reporting cycle 
matures to cover not simply years but decades of data, longitudinal analysis will become 
possible. For example, it is perhaps premature to speak about generational shifts in 
cannabis use in 2007.
 (2) http://annualreport.emcdda.europa.eu
 (3) http://stats07.emcdda.europa.eu
 (4) www.espad.org/
 (5) www.emcdda.europa.eu/index.cfm?nNodeID=435
 (6) See also EMCDDA (2000), Understanding and responding to drug use: the role of qualitative 
research, EMCDDA Monograph Series 4, European Monitoring Centre for Drugs and Drug 
Addiction, Lisbon.
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Cannabis epidemiology: key websites
Bibliography of European nationwide drug surveys: Table GPS-0 
www.emcdda.europa.eu/stats07/gpstab00/
EMCDDA Annual report 
http://annualreport.emcdda.europa.eu
EMCDDA Handbook for surveys about drug use among the general population 
http://www.emcdda.europa.eu/?nnodeid=1380
UNODC World drug report 
www.unodc.org/unodc/world_drug_report.html
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Prevalence, patterns and trends 
of cannabis use among adults in 
Europe
Julian Vicente, Deborah Olszewski and João Matias
This chapter presents an overview of prevalence and trends in cannabis use in Europe, 
based on survey data reported annually to the EMCDDA. This source of information on 
cannabis use in Europe has improved substantially in recent years. Not only have most 
countries now conducted national surveys on drug use, but most have also adopted a 
common set of core items for measuring this behaviour. Methodological differences 
still exist in the way some surveys are conducted. Nonetheless, overall this information 
source can now be considered a relatively robust one for commenting on trends and 
levels of cannabis consumption in Europe.
Cannabis is by far the illegal substance most frequently used in Europe. It is estimated 
that roughly 71 million people have tried the substance in Europe (about 22 % of adult 
population of 15–64 years), although recent use (last 12 months) or current use (last 30 
days) is clearly lower. A rough estimation for Europe indicates 23 million recent users 
(about 7 % of adults) and 13–14 million current users (about 4 % of adults), although 
with marked differences between countries.
Levels of cannabis use are highest among young adults, and this is particularly true 
when more recent or current use is considered. For example, at the European level, on 
average among those aged 15–34, last year and last month prevalence is estimated to 
be 13 % and 7 % respectively. Use is generally discontinued in later adult life, although 
it is possible that in future years we will see an increased use of the drug among older 
people as there is some evidence to suggest that regular use of the drug is becoming 
more common. Despite increasing concerns about intensive cannabis use, very limited 
information is available in Europe on the extent of this problem. A rough estimate made 
by EMCDDA in 2004 suggested that probably around 1 % of European adults may be 
daily cannabis users, and among young adults (15–34 years) estimates range roughly 
between 1 and 3.5 %.
Use of cannabis, as with other illegal drugs, is more common among males, and 
this is particularly true for measures of more recent or current use. There are marked 
differences between countries in gender differences, although among young people 
and school children these differences tend to be smaller. Of the Europeans that have 
ever tried cannabis, it is estimated that only 18 % have used it also in the last 30 days 
Chapter 1
7
(current use), although a higher 32 % have used it during the last 12 months (recent 
use).
Cannabis use has increased substantially in most EU countries during the 1990s, in 
particular among young people. In the new Member States that have more recently 
joined the European Union, increases have also been generally notable since the 
mid-1990s. The picture may be beginning to change, however. Although increases are 
still continuing to some extent, in recent data they are generally less marked and some 
countries now report a stabilisation or even a decrease in levels of use in the most recent 
data available.
Introduction
The increasing levels of cannabis use observed during the last 10 years in most of 
Europe clearly requires close monitoring as this drug continues to generate considerable 
public and policy interest. While there is recent evidence that cannabis use may be 
decreasing in some high-prevalence countries, such as the United Kingdom and Spain, it 
remains an important topic. Monitoring patterns of cannabis use, especially the intensive 
and sustained use of the drug, has also become more important as concerns have 
grown about the possible longer-term health and social consequences of use. Overall, 
in Europe the information available on the use of this drug varies considerably and 
there is generally an absence of data on more intensive patterns of use — which may 
be most important for considering the implications of cannabis use for public health 
(see Beck and Legleye, this monograph). A comprehensive review of the European data 
can therefore provide a more robust platform for facilitating a debate on cannabis 
and identifying information needs. This chapter offers a basic descriptive overview of 
cannabis prevalence in the different EU countries. In addition, crude European averages 
have been computed for basic patterns of cannabis use: lifetime experience, last year 
prevalence, last month prevalence and, with more difficulties, more intensive forms of 
use such as daily use. The method to estimate these European figures has been relatively 
simple (weighted averages) and results should be taken as a first but informative 
approximation, which will require improvement in the future as further data become 
available.
Measuring cannabis use in the population
Cannabis use in the general population can be measured through representative surveys 
among adults and school children, which provide estimations of the proportion of the 
population having used drugs during standard timeframes: any use in the lifetime (also 
sometimes referred to as ‘experimentation’), any use in the previous 12 months (also 
sometimes referred to as ‘recent use’) and any use in the previous 30 days (also referred 
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to as ‘current use’). Although response and non-reporting biases can have an impact on 
any survey exercise, population surveys — if well conducted — are generally considered 
to produce reasonable estimations of cannabis use. This is particularly true of cannabis 
use: compared with other drugs, cannabis smoking is a relatively less stigmatised 
behaviour, and it is also more common than use of other drugs.
‘Lifetime use’ as a measure has limited value in describing current levels of drug use, 
although it may be useful for exploring broader questions, for example, the difference 
between users and non-users in attitudes and perceptions, or charting cannabis over 
time to analyse ‘use careers’. Use in the previous 12 months and the previous 30 days 
give better indicators of actual drug use. The latter can be used to indicate regularity of 
use, although clearly this is an imperfect measure in this respect.
Information presented here is based on national surveys among adults (7), but the reader 
should note that school surveys are addressed in detail elsewhere in this monograph. 
Analysis is presented here that is predominantly based on surveys conducted by EU 
Member States, between 2003 and 2006 (8). The results of these surveys are reported 
annually by Member States to the EMCDDA through a standardised form. Detailed 
information on those datasets included here can be found in the EMCDDA annual 
reports and the accompanying Statistical Bulletin.
The EMCDDA has developed guidelines for surveys that include a set of common core 
items (‘European Model Questionnaire’ (EMQ)) (9). These questions are now used in 
most adult surveys conducted in the EU Member States. Although, overall, the quality, 
reliability and comparability of European survey data have improved considerably, 
some methodological differences still exist between countries in they way surveys are 
conducted. This means that caution is still required in interpreting differences, especially 
where they are small.
In this chapter we will restrict our attention to the issue of prevalence. However, it 
is worth noting that survey work in Europe is increasingly addressing a wider set of 
questions in this area. Among these are: the identification of risk and protective factors 
for initiation of cannabis use or for progression to more intensive forms of use (see 
Coggans, this monograph); and the assessment of levels of problems and dependence 
found with different patterns of use. Readers interested in these issues are directed to 
recent reviews by Hall et al. (2001), INSERM (2001), Rodin Foundation (2002) and 
Simon (2004).
 (7) The term ‘adults’ is used in this paper to refer to the group of 16–64 years of age. Most surveys 
target this population, although the reporting may address other specific subgroups selected by 
age.
 (8) Malta 2001, Portugal 2001 — new survey conducted in 2007 — and Poland 2002.
 (9) See EMCDDA (2002), Handbook for surveys about drug use among the general population: 
www.emcdda.eu.int/?nnodeid=1380
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Prevalence of cannabis use in Europe
Lifetime prevalence (ever use)
Cannabis is by far the most commonly used illegal substance in Europe (10). Recent 
surveys indicate that between 2 and 37 % of adults (15–64 years) have tried the 
substance at least once. The lowest lifetime prevalence estimates were found in Romania 
(1.7 %), Malta (3.5 %) and Bulgaria (4.4 %) and the highest in the United Kingdom 
(29.8 %), France (30.6 %) and Denmark (36.5 %). In most countries (12 of the 26 
countries from which information was available) lifetime prevalence was estimated to be 
between 10 and 25 % of the adult population.
A crude estimation, computed as an average from national prevalence data and 
weighted to reflect population size, suggests that over 70 million adults (15–64 years) 
have tried cannabis in Europe as a whole, representing about 22 % of the adult 
population. Perhaps unsurprisingly, cannabis use is concentrated among young adults 
(15–34 years), who consistently report higher rates of lifetime use than the population 
average. Between 3 and 49.5 % of young Europeans report having tried the drug, with 
the lowest prevalence estimates found in Romania, Malta and Bulgaria and the highest 
in Denmark (49.5 %), France (43.6 %) and the United Kingdom (41.5 %). In general, 
the prevalence levels are found to be greatest among young people aged 15–24 years, 
with most countries reporting that somewhere in the range of 20–40 % of this age group 
have tried the drug at least once.
Last 12 months prevalence (‘last year’, recent use)
Overall in the EU, an estimated one-third (32 %) of people who have ever tried cannabis 
have also used it in the last 12 months. Put another way, around two-thirds of those 
who have ever used cannabis have not done so in the last year. Interestingly, among 
those who have used cannabis in the last year, about 60 % have also done so in the last 
month, suggesting some regularity of use.
Depending on the country surveyed, between 1 and 11.2 % of adults report having used 
cannabis in the last 12 months, with Malta, Bulgaria and Greece presenting the lowest 
prevalence estimates and Italy (11.2 %), Spain (11.2 %), the Czech Republic (9.3 %) and 
the United Kingdom (8.7 %) the highest. Most countries (13 out of 25) reported figures in 
the range of 4–9 %.
 (10) Estimates for the EU presented in this paper relate to the European Member States and Norway, 
which participates in EMCDDA activities by special agreement.
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A crude estimate would suggest that over 23 million adults, around 7 %, have used 
cannabis in the last 12 months in the European Union as a whole. Most of those who 
had used the drug in the previous 12 months were young, with 18 of the 23 million 
estimated users falling into the age range of 15–34 years. In other words, about 13 % 
of all those aged 15–34 had used the drug, a rate nearly five times higher than that 
found among those aged 35–64 years, among whom, at the European level, last year 
prevalence is estimated to be about 2.5 %.
European averages are naturally most influenced by patterns of use in the countries with 
larger populations. They can therefore obscure heterogeneity at the Member State level. 
Depending on the country surveyed, between 2 and 20 % of young adults (15–34 years) 
report having used cannabis, with the lowest figures found in Malta, Greece, Cyprus and 
Bulgaria, and the highest in Spain (20.3 %), the Czech Republic (19.3 %), France (16.7 %) 
and Italy (16.5 %). Overall, 11 countries reported prevalence estimates for this age 
group in the range of 7–15 %.
If attention is restricted to young adults, last year prevalence rates rise considerably. 
Among Europeans aged 15–24 years, estimates of use in the last year range from 4 
to 28 %, with most countries falling between 10 and 25 %. This means that, depending 
on the country, somewhere between 1 in 10 and 1 in 4 young Europeans have used 
cannabis in the previous year, with the figure rising to nearly one out of every two males 
between 15 and 24 in some countries (Figure 1).
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Figure 1: Recent use (last 12 months) of cannabis among young adults (15–34 years old) 
and very young adults (15–24 years old) in EU Member States
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Last 30 days prevalence (current use)
In recent European surveys, current use (last month prevalence) was reported somewhere 
between 0.5 and 8.7 % of all adults. The highest figures were found in Spain (8.7 %), 
Italy (5.8 %) and the United Kingdom (5.2 %) and the lowest in Malta, Sweden and 
Lithuania. Thirteen out of 26 countries for which information was available reported 
figures in the range 2–6 %. These data can be used to produce an EU population 
estimate that around 13.5 million adults (aged 15–64 years) have used cannabis in 
the last 30 days, representing nearly 4 % of all adults. This figure should be considered 
as a minimum estimate. The majority of those who had used in the last month were 
young, with about 10 million out of the total 13.5 million falling in the 16–34 years 
age group, suggesting that around 7 % of young adult Europeans can be considered 
current cannabis users. These figures vary considerably depending on the country, from 
less than 2 % (1.5 %) to over 15 %, with the highest figures in Spain (15.5 %) and France 
(9.8 %). Sixteen out of 25 countries for which information was available reported figures 
in the range of 3–10 %. By restricting the analysis to an even younger age group (15–24 
years), even higher levels of last month use were generally reported. For this age cohort, 
last month prevalence varied between 1.2 and 18.6 %, with most countries typically 
falling in a range of between 5 and 10 %.
‘Use in the last 30 days’ can be taken as an indicator of ‘current use’ and will include 
people who use cannabis regularly, although clearly not all will fall into this category. 
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Figure 2: Current use (last 30 days) of cannabis among all adults (15–64 years old), 
among young adults (15–34 years old) and among 15- to 24-year-olds, in the EU 
Member States
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It is also unclear what proportion of those reporting use in the last month will be 
consuming the drug on a daily or near-daily basis. A clue is provided by a recent 
estimate conducted by the EMCDDA, based on more detailed analysis of data available 
from seven countries. In this exercise, it was found that between 19 and 33 % of those 
reporting use in the last 30 days were daily or near-daily users (EMCDDA, 2004a) 
(Figure 2). As those using cannabis on a regular and intensive basis are an important 
group for developing a better understanding of the public health impact of cannabis 
consumption, improving the information available on this kind of consumption pattern 
is, therefore, an important task for the future (see Beck and Legleye, this monograph).
Comparing figures from Europe and other parts of the 
world
When considering cannabis consumption in Europe, one question that often arises is 
how it compares with patterns of use elsewhere. Cannabis consumption is estimated to 
be common in both parts of Africa and Asia, but data to allow meaningful comparisons 
with European patterns are not available. A contrasting point of reference can be found 
in data from the USA, Canada and Australia, all of which have undertaken surveys of 
cannabis use that are broadly similar to European studies. In 2005, the US national 
household survey on drugs (11) reported that 40.1 % of adults (12 years and older) 
reported lifetime use of cannabis. This can be compared with an EU average of about 
22 %. Even taking into account the slightly different age range covered, the US figure 
is clearly higher than the European average, although some European countries come 
close. For example, both Denmark and the United Kingdom report lifetime prevalence 
estimates slightly in excess of 30 %.
To some extent, differences in lifetime prevalence between America and Europe can 
be seen to reflect a historically earlier — that is, generational — experience with 
widespread drug use. This is illustrated by looking at last year prevalence estimates, 
which are more similar, at 10.4 % and 7 % respectively, with a number of European 
countries (Italy, Spain and the Czech Republic) reporting similar figures that approach 
the higher US estimate. Further points of comparison are provided by Canadian 
data (2004) (12), with lifetime adult prevalence (defined as 15 years and above) being 
estimated at 44.5 % and last year prevalence at 14.1 %, higher than the figures for 
 (11) Source: SAMHSA, Office of Applied Studies, National Survey on Drug use and Health, 2005 — see 
www.samhsa.gov and http://oas.samhsa.gov/nhsda.htm#NHSDAinfo. Note that the age range 
for ‘all adults’ in the US survey (‘12 years and over’) is wider than the age standard range for 
European surveys (15–64), implying that these will present relatively higher figures.
 (12) Source: Adlaf, E.M., Begin, P. and Sawka, E. (eds) (2005), Canadian Addiction Survey (CAS): A 
national survey of Canadians’ use of alcohol and other drugs — prevalence of use and related 
harms, detailed report. Canadian Centre on Substance Abuse, Ottawa. Note that the age range 
for ‘all adults’ in the Canadian survey (‘15 years and over’) is wider than the age standard range 
for European surveys. See Note 4.
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both Europe and the USA. Similarly, Australian data (2004) (13) suggest that one-third 
(33.6 %, or 5.5 million people) of adults (defined as 14 years and older) have ever used 
cannabis; 11.3 % have used cannabis in the last year; and 6.7 % are estimated to have 
used the drug in the last 30 days.
A similar picture is found when prevalence rates among younger adults are compared 
(Figure 3). In Europe, lifetime prevalence is overall around 30 % for the 15–34 years age 
group. This can be compared with estimates of nearly half (49.1 %) of 16- to 34-year-
olds in the USA, and a similar figure of 48 % for Australians, although the available 
age breakdown is slightly wider in Australia (14–39 years). In Canada, the estimate 
for lifetime prevalence among young adults (aged 15–34) is higher still, at 58.6 %. For 
these same age groups, last year prevalence estimates report some divergence: Europe 
at 13 %, the USA at 21.6 %, Australia at 20 % and Canada at 28.1 %. Again, it should 
be noted that at national level some of the higher-prevalence European countries — the 
Czech Republic, France, Spain and the United Kingdom — reported estimates that were 
broadly similar to those found in the USA, Australia and Canada.
 (13) Source: Australian Institute of Health and Welfare, 2005. 2004 National drug strategy household 
survey: detailed findings. AIHW cat. no. PHE 66. Canberra: AIHW (Drug Statistics Series No. 16). 
Note that the age range for ‘all adults’ in the Australian survey (‘14 years and over’) is wider 
than the age standard range for European surveys.
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Figure 3: Lifetime prevalence and previous 12-month prevalence of cannabis use among 
young adults, in the EU Member States, in the EU as an average and in third 
countries (USA, Canada, Australia)
Prevalence, patterns and trends of cannabis use among adults in Europe
14
Prevalence of more intensive forms of cannabis use
There is an increasing concern about prevalence of intensive cannabis use and its 
potential health consequences (14). Unfortunately, very little information is available 
that might allow some assessment of either levels or trends in this pattern of cannabis 
use. Where information sources do exist, they are usually difficult to compare across 
studies. Even the concepts in this area lack standardisation, with different researchers 
using terms such as ‘regular’, ‘repeated’ or ‘intensive’ use with differing operational 
definitions. Some population surveys have started to include scales to assess 
‘problematic use’ or ‘dependence/abuse’, although this work remains very much in its 
infancy, and harmonisation at the European level is needed (see Beck and Legleye, this 
monograph).
Last 30 days use
Given the lack of alternatives, last 30 days cannabis prevalence (current use) could 
be used as a very rough proxy indicator for estimating regularity of use. However, it 
should be stressed that this indicator does not imply problematic use or dependence. 
Information about prevalence of last 30 days use is presented in Figure 4. However, 
it should be noted that trends over time in this pattern of use are difficult to assess at 
the European level. Very few countries have data series with more than two measured 
points, and no clear picture emerges from the data that are available: in many countries 
no marked changes are observed. In the United Kingdom, a decreasing trend has been 
observed since 2004, whereas increases of different magnitude are reported in Spain, 
Belgium, Italy and Finland.
Daily use of cannabis
‘Daily use’ or ‘almost daily use’ (use on 20 days or more during the previous 30 days) 
may be considered a better indicator of ‘intensive use’ of cannabis and is included as 
a topic in a number of different studies and the EMQ. Although it is in need of update, 
the EMCDDA included an analysis on the available data in this area for the 2004 
EMCDDA Annual report (EMCDDA, 2004a). Eight countries (15) provided data, and, with 
the exception of Latvia, where the figure was lower (4 %), approximately one-quarter 
(19–33 %) of those who had used cannabis in the last 30 days were reported to be daily 
or near-daily users (Figure 5). In terms of overall prevalence rates, daily use estimates 
 (14) For further discussion of the public health effects of cannabis, see chapters by Hall and Room, this 
monograph, and also dedicated publications by Hall et al. (2001), INSERM (2001), the Rodin 
Foundation (2002) and Simon (2004).
 (15) France, Greece, Ireland, Italy, Latvia, the Netherlands, Portugal and Spain. Finland decided not 
to report due to the small number of last month users in their survey. See more details in 2004 
Annual report (http://ar2004.emcdda.europa.eu).
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Spain (2001;
15–64 n = 14 113;
15–34 n = 6 915)
Greece (1998;
15–64 n = 3 398;
15–34 n = 2 014)
France (2000;
15–64 n = 11 317;
15–34 n = 4 749)
Ireland (2002/03;
15–64 n = 4 925;
15–34 n = n.a.)
Latvia (2003;
15–64 n = 4 534;
15–34 n = n.a.)
Netherlands (2000/01;
15–64 n = 14 045;
15–34 n = 6 687)
Italy (2001;
15–64 n = 6 032;
15–34 n = 3 689)
Portugal (2001;
15–64 n = 14 184;
15–34 n = 6 406)
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Figure 5: Prevalence of ‘daily or almost daily’ use of cannabis (≥ 20 days in the last 30 days) 
in different EU Member States
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ranged between 0.5 % and 2.3 % of all adults (15–64 years) and between 0.9 % and 
3.7 % of young adults (15–34 years). Extrapolation of these data would give a rough 
estimation that there may be around 3 million daily cannabis users in the EU, or about 
1 % of the adult population.
Almost all daily users concentrate in the age range 15–34 years, and the vast majority 
are male. At present, it is difficult to assess trends in daily use, as information reported 
here was based on an ad hoc data collection exercise. However, this exercise is currently 
being repeated. Moreover, the data currently available are simply a behavioural 
measure of drug use. No supplementary information is available that allows informed 
comment on the extent to which daily users are likely to be experiencing problems or 
dependence. It would, nonetheless, be reasonable to assume that daily use would be 
associated with both. A study conducted in 1992 in the USA (Kandel and Davis, 1992) 
reported that one in three daily users met DSM-III criteria for dependence. The extent to 
which this estimate is likely to be valid for patterns of cannabis use in Europe today is 
unclear.
Estimations of cannabis dependence or problematic use
Frequency of use is relatively easy to measure in questionnaires, although additional 
information on dependence or problems would add insight into the implications and 
correlates of substance use. Despite the difficulties, it can be argued that surveys have 
the potential to better estimate cannabis use disorders. At present, there is limited 
information on prevalence of cannabis dependence or problematic use in Europe. A 
recent review of surveys carried out in European countries from 1990 until 2002 found 
that 0.3–2.9 % of adults met the criteria for ‘drug dependence’ (including all illicit drugs) 
in the previous 12 months, and in addition similar or higher numbers were classified as 
using the drug in a manner that could be defined as ‘abuse/harmful use’. The highest 
estimates were found among young people aged 18–25 years (Rehm et al., 2005).
Figures from the US survey may provide a useful point of reference, although they 
cannot be assumed to translate directly to the European situation. In the 2003 National 
Survey on Drug Use and Health (SAMHSA, 2004a) 1.8 % of people aged 12 or over 
fulfilled DSM-IV criteria for cannabis dependence or abuse during the previous year, or 
around 4.2 million Americans. The proportion among 18- to 25-year-olds was higher, 
at 5.9 %. Data from this survey suggested that 16.6 % of those who had used cannabis 
in the last year met the criteria for either dependence or abuse of the substance.
Patterns of use: continuation rates of cannabis use
In general, cannabis use tends to be occasional or discontinued some time after its 
initiation in adolescence or during a user’s early 20s. Thus, prevalence rates become 
Chapter 1
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lower with increasing age, in particular for measures of last year or last month use. 
‘Continuation rates’ can be considered as the proportion of people that, having used 
a drug for a longer period of time (e.g. during their lifetime), have also used it in a 
more recent period (e.g. during the last 12 months or last 30 days). As a European 
average, only 18 % of those that have ever tried cannabis have used it also in the last 
30 days (Figure 6). National figures range from 10 % or less in Denmark, Lithuania, 
Romania and Sweden to over 20 % in Belgium, the Czech Republic, Spain, Italy, Cyprus 
and Portugal. In addition, on average in Europe, about one-third of those who have 
ever used the substance have used it in the last 12 months. It is worth noting that, in 
most countries a relatively high proportion, averaging almost 60 %, of those who have 
used cannabis in the last 12 months have also done so in the last 30 days, suggesting 
a certain regularity of use, although not necessarily frequent or intensive use. However, 
there is a wide variation between countries (30–78 %).
Continuation rates are relatively stable in those few EU countries where this rate can be 
computed over a number of years. A similar finding is observed in the USA. This may 
suggest that there is not an intensification of use patterns among most users, although 
this may not apply to the more intensive or problematic forms of use. Furthermore, this 
statement must be made with the caveat that the overall European dataset in which this 
question can be explored is limited.
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Figure 6: Continuation rates of cannabis use — European Union average, Germany, Spain 
and the United Kingdom, and the USA
Note: LMP, last month prevalence; LTP, lifetime prevalence; LYP, last year prevalence.
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Gender differences in cannabis use
In Europe, most young people who have tried an illicit drug have used cannabis, and 
males are generally more likely to have done so than females. Adult and school survey 
data suggest that there has been only limited convergence in cannabis use between 
males and females, and increases in cannabis use have tended to occur largely in 
parallel. Some patterns are, nonetheless, detectable. For example, female and male use 
tends to become more equal as prevalence of cannabis use increases, and this gender 
gap is generally wider for use of other illegal drugs and for recent or frequent patterns 
of drug use.
Male to female ratios (16) tend to be consistently higher among surveys of adults than 
among school students. Among students aged 15–16 years, lifetime experience of 
cannabis is slightly higher among males in all but three countries (Ireland, Finland and 
Norway). School student male/female differences are fairly consistent and small across 
most countries in the European Union, ranging from equal ratios in Ireland, Finland 
and Norway to 1.8 in Portugal. However, among adults (aged 15–64 years) gender 
differences for lifetime experience of cannabis use reveal a greater gender gap and 
more variation across countries than among school students: male to female ratios 
range from 1.25 in Finland to 4.0 in Estonia.
The gender gap also becomes wider if one progresses from lifetime use through recent 
(last 12 months) to current use (last 30 days) (Figure 7). Recent use (last year prevalence) 
male–female ratios range from 1.5 in Finland to 4.3 in Hungary. In the case of current 
use, male–female ratios are even larger, ranging from 1.8 in Norway to 5.9 in Portugal. 
Among school students, gender ratio differences are considerably greater for ‘frequent 
use’ of cannabis (defined as ‘used 40+ times during a lifetime’) than for lifetime 
prevalence or last year prevalence. Nonetheless, some caution is needed in interpreting 
results for current or frequent use because of the relatively small numbers involved. In 
European Union countries with relatively high prevalence rates, the difference between 
male and female adults tends to be less marked than in countries with low prevalence 
rates. Sweden, Norway and Finland are exceptions, as prevalence is relatively low and 
male/female differences are minimal.
From 1995 to 2003, although increases generally occurred in parallel among both 
male and female school students, the trend in countries with relative high prevalence 
has generally been towards equality between males and females. Among adults, there is 
 (16) Differences between males and females are presented here as ratios of prevalence of use among 
males over prevalence of use among females. Ratios higher than 1 indicate more males than 
females; for example, a ratio of 2 indicates twice as many males as females (diagrams are 
drawn with logarithmic scaling).
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little evidence of gender convergence in countries with trend data. It is not clear to what 
extent male predominance at low prevalence levels is determined by persistent cultural 
factors that make males disproportionately prone to illicit drug experimentation and to 
what extent it arises from the fact that in many of these countries drug use is a relatively 
recent historical phenomenon, developing first within the male population. The gender 
ratios for school students aged 15–16 years reporting that they had drunk five or more 
drinks in one session during the past 30 days and for lifetime prevalence of cannabis 
use are broadly similar among different countries (a log scale correlation of 0.46). This 
may suggest a common association of drug use with an outgoing lifestyle related to 
gender or age.
Evolution of cannabis use in Europe — long-term and 
recent trends
Only a few European countries have a series of drug surveys that allow long-term 
trends to be identified with any precision. Most countries do not have a set of historical 
data that can reasonably be considered to represent a time series in any strict sense, 
although sporadic surveys are sometimes available that give some indication of the 
historical situation. Moreover, even in those countries where data are the strongest, it 
is only possible to extend the observational window with any confidence to the early or 
mid-1990s.
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Initial expansion of cannabis use in European countries
In the USA the widespread expansion of cannabis use began in the first half of the 
1960s (Kandel et al., 2001). It is generally considered that this cannabis use began 
to spread to parts of Europe at this time as part of a growing counterculture (see 
Olsson and Abrams chapters, this monograph). Where it had become established, the 
popularity of the drug continued to grow through the 1970s and 1980s. However, both 
within and between countries there was considerable heterogeneity in levels of use, and 
the drug was probably more clearly linked with particular subgroups than it is today.
Some indication of patterns of use over time can be gained by looking at the dates 
given for when a cross-section of cannabis users report their first use of the drug. An 
analysis on initiation of cannabis use (age of first use) found, for example, that cannabis 
use expanded markedly in Spain during the 1970s, in the former West Germany during 
the 1980s and in Greece during the 1990s. In addition, it was observed that the more 
recent young generations had reported higher levels of cannabis experience than any 
previous generation in these countries (Kraus and Agustin, 2002). Surveys conducted 
between 2000 and 2003 indicate significant levels of lifetime experience (12–24 %) 
among the 45- to 54-year-olds in Denmark, France, Germany, the Netherlands, Spain 
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(Figure 8), Sweden and the United Kingdom, suggesting that the number of cannabis 
users was probably not trivial in these countries 25–30 years ago.
Recent trends in European countries (1990s to present)
Different types of surveys (national or local household surveys, conscript and school 
surveys) have shown that cannabis use increased markedly during the 1990s in almost 
all EU countries, particularly among young people (Hibell et al., 2004; EMCDDA, 
2005a) (Figure 9). In most European countries, cannabis use has continued to increase 
until recent years, although different paces of growth have been observed between 
countries. Nonetheless, it is worth noting that several countries are reporting a recent 
stabilisation in levels of use in different settings (EMCDDA, 2005a).
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Figure 9: Trends in recent use of cannabis (last 12 months) among young adults (15–34 
years old)
Prevalence, patterns and trends of cannabis use among adults in Europe
22
Differences by countries
In the United Kingdom (England and Wales) (17), which since the early 1990s has 
reported among the highest figures in Europe, cannabis use among young adults 
(16–34 years) remained stable from the mid-1990s until 2003 (19–20 %) and then fell 
between 2003 and 2006 (20–16.3 %). It is worth noting that levels of reported use fell 
more in a time comparison of the age group 16–24 years, while continuing to increase 
among 25- to 34-year-old males (from 9.4 % in 1994 to 14.8 % in 2003–2004), 
although a slight decrease is seen here in the most recent data (12 % in 2005–2006). 
These UK data suggest a ‘generational effect’ in which those who started using the drug 
10 or 15 years ago may be more likely to be continuing to use the drug into adulthood, 
and that the popularity of cannabis may be waning slightly among younger age cohorts 
(Figure 10).
 (17) In this section the information for the United Kingdom is based on British Crime Survey data (for 
England and Wales). The first BCS (E&W) for which information on drugs is available at the 
EMCDDA is from 1994.
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Figure 10: Trends in recent use of cannabis (last 12 months) by age group in the United 
Kingdom, illustrating a possible ‘generational effect’
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Prevalence figures among young adults in France, Spain and Italy have reached 
the levels of the United Kingdom in recent years (2002 or 2003), after a markedly 
increasing trend for several years. However, some stabilisation is also becoming 
apparent in these countries. France reported a decrease in 2005, and Spain a clear 
moderation in the increasing rate in the more recent data (2006). Figures from the 
Czech Republic (2002) were similar to those from these high-prevalence countries, 
although more recent information (2004) suggests stabilisation or a slight decrease in 
prevalence levels.
It is worth noting that, in contrast to the United Kingdom, increases in France and Spain 
among 15- to 24-year-olds have continued until very recently, with a decrease in France 
only in its most recent survey. Among 25- to 34-year-olds, a marked increase has been 
observed in Spain since 1999, with only a slight decrease in 2006. It is, thus, likely that 
trends among younger people anticipate trends in the broader population, and should 
therefore be monitored with particular attention.
Denmark and Germany also reported increases in cannabis use until recent years 
(reaching 12–15 % of last 12 months use among young adults), although not reaching 
the levels of the high-prevalence countries above. The most recent information for these 
countries indicates stabilisation or small decreases. In the Netherlands, prevalence 
figures have remained stable, at around 10 %, in the period 1998–2005.
Finland and Sweden have presented comparatively low prevalence estimates of cannabis 
use since the early 1990s. Although some increases have been observed, their figures 
remain low compared with other countries, without apparent signs of likely convergence 
with high-prevalence countries. The increase observed in Sweden between 2000 (1.3 %) 
and 2004 (5.3 %) may be related to methodological changes. Prevalence estimates for 
Sweden in the 2004, 2005 and 2006 surveys suggest a stable situation.
Among new Member States, the available information, mainly from school surveys within 
the ESPAD project (Hibell et al., 2004; EMCDDA, 2004a), suggests that there has been 
a substantial increase in cannabis use in recent years, in particular since the mid-1990s. 
Consecutive surveys among adults in Estonia (1998, 4 %; 2003, 10 %) and Hungary 
(2001, 5.4 %; 2003, 7.7 %) have also revealed increases of cannabis use among young 
adults.
It can be noticed in several new Member States that last 12 months prevalence among 
15- to 24-year-olds is in the same range as other EU countries. By contrast, prevalence 
estimates drop considerably among the immediately older age groups (25–34 or 
35–44 years), suggesting a generational effect that could be related to lifestyle changes 
occurring during political and social changes that took place in these countries during 
the 1990s, and that were possibly adopted initially by the younger generations (see 
Moskalewicz et al., this monograph).
Prevalence, patterns and trends of cannabis use among adults in Europe
24
Finally, from different sources (adult surveys, youth or conscripts surveys and school 
surveys, etc.) it can be noted that a number of countries are now reporting recent 
stabilisation or even a decrease in levels of cannabis use. In some cases, different 
surveys may signal opposite trends in a country, possibly due to the different age 
ranges or social milieu covered. Among countries reporting stabilisations are the Czech 
Republic, Denmark, Germany, France, the Netherlands, Finland, the United Kingdom 
and Norway. These findings may indicate that the overall increase in cannabis use 
observed during the 1990s and early 2000s may be starting to stabilise, at least in some 
countries, and in particular among younger people.
The present situation and future information needs
Information on prevalence of cannabis use and patterns has increased substantially 
in recent years in the European Union. Most European Union countries are now 
conducting harmonised school surveys at regular intervals within the ESPAD project, 
although sample sizes are sometimes relatively small. Almost all EU countries have 
conducted general population surveys on drugs, with overall strong compatibility with 
the EMQ. However, clear limitations still do exist on information at EU level. There are 
still differences in methodology (e.g. data collection, sampling). Only very few countries 
have a series of repeated surveys with consistent methodology. Harmonisation beyond 
the basic items of the EMQ is often limited, including questions that would allow better 
assessment of more intensive forms of use.
Added value is accrued from surveys if they are repeated over time using comparable 
methods. It is, therefore, important to consolidate national series of household surveys 
to generate robust time series. This would greatly increase the analytical value of the 
data and permit more complex and detailed analyses. There is a need to educate 
policymakers and those commissioning surveys that this is, by necessity, a long-term 
investment, with the value of information progressively increasing as survey series 
become longer.
Data from population surveys form one of the EMCDDA key indicators and there is a 
political commitment to implementing the indicators in the current EU action plan on 
drugs. However, although almost all European countries have made progress in this 
area, there is a clear need to stimulate more regular data collection exercises and a 
greater adoption of common standards of good practice.
As concern increases about the possible public health implications of cannabis use, it 
is imperative to improve existing methods and capacity to assess intensive patterns of 
use, and to analyse their correlates, and potential health and social consequences. This 
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approach may also need to be extended to embrace other substances (e.g. stimulants, 
psychoactive medicines, problematic and combined use of alcohol with drugs).
Finally, survey data need to be complemented with longitudinal and more focused 
studies to describe the specific behaviour of vulnerable subgroups, or to explore 
important temporal issues, such as drug use initiation and cessation rates. In particular, 
qualitative studies of users can contribute valuable information that can illuminate the 
drier statistics. These help to understand the associations found within the statistics, by 
placing them in the context of an understanding of the individual user’s experiences, 
rationale and motivation.
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Setting the context
While there is evidence of stabilisation or slight decline in use in some high-prevalence 
countries, cannabis use has, on the whole, increased in most European countries over 
the last 15 years, especially among adolescents and young adults.
Despite strong public health interest, the commonly used indicators of cannabis use — 
lifetime and last year prevalence — aim to assess not problematic use but broader use 
patterns. Indicators of current use — last month prevalence and frequency of use in the 
past month — provide indirect indications of the extent of more intensive forms of use 
and problematic use of drugs. Yet frequent use of cannabis does not necessarily imply 
that users will experience problems, so a more detailed picture is required. As Europe 
becomes increasingly sensitive to the health risks of cannabis use, particularly among 
high-prevalence populations, distinguishing between various kinds of use is vital to 
ensure that interventions are targeted to those most at risk.
Nearly all EU countries now collect information on how many days cannabis has 
been used in the month prior to interview. However, standardisation remains far 
from complete: some collect number of days, others number of times smoked or less 
well-defined measures. The EMCDDA, in collaboration with several national experts, 
is currently developing the methodological and conceptual framework necessary for 
monitoring ‘intensive forms of drug use’ to better identify those experiencing problems. 
Several projects to test psychometric instruments are under way in Germany, France, 
the Netherlands, Poland, Portugal, the United Kingdom and, most recently, Spain 
(EMCDDA, 2007).
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This chapter, written by experts based at the OFDT (the National focal point for 
France), presents the main concepts for diagnosing harmful cannabis use, abuse and 
dependence as well as tolerance and withdrawal symptoms from cannabis. It also 
touches on wider difficulties in abstaining and controlling use, together with other factors 
linked to problematic use (family disapproval, financial impacts, etc.). The authors have 
collected the existing screening tests for cannabis-related disorders. They review the 
screening processes and comment on their reliability. They then present and discuss 
the main available cannabis tests and how they may be used in general population 
surveys. While they suggest that even if the concepts and tools are somewhat arbitrary 
and vary according to cultural background, such screening instruments remain useful in 
increasing research into cannabis-related disorders.
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Measuring cannabis-related 
problems and dependence at the 
population level
François Beck and Stéphane Legleye
Introduction
Although common perceptions of the ‘harmlessness’ of cannabis have often been 
countered in recent years, the fact remains that a majority of cannabis users do not 
encounter any clinical or social problems. So epidemiologists have sought ways to 
distinguish — among the many people who report lifetime, last year or last month 
cannabis use — the profiles of cannabis users who suffer from a cannabis use disorder 
or who manifest patterns of cannabis use that may require a timely intervention.
The definition of an acceptable level of cannabis use, i.e. the establishment of a 
threshold beyond which the use becomes problematic, is beset with ethical issues. 
First, cannabis is an illegal drug and so establishing use guidelines may be perceived 
as condoning its use (see Bennett, this monograph). Second, as with legal drugs such 
as alcohol or tobacco, problematic use can emerge from what some groups — peers, 
specific generations and subcultures — might perceive as moderate or normative 
consumption. Indeed, in the light of increasing treatment demand for cannabis 
(Montanari, 2004; Simon and Kraus, this monograph), there is considerable demand to 
operationalise concepts of dependence into measurable criteria, and to inform people of 
cannabis-related health risks.
Problematic use can be defined as use leading to negative consequences on a social 
or health level, both for the individual user and for the larger community. From this 
definition of problematic use, various other concepts can be defined, such as misuse, 
abuse and dependence, together with difficulties faced in abstaining or controlling use. 
Harms are either directly linked to the substance itself, for example loss of concentration 
in the short term or lung damage in the long term (see Witton, this monograph, Vol. 
2), or are secondarily harms linked to polydrug use (principally, alcohol and tobacco) 
or risky behaviour (drug driving, binge patterns). Such risk situations should ideally 
be detected early by practitioners. By identifying problems early, drugs workers have 
a window of opportunity to minimise cannabis-induced problems, for instance by 
referring users to treatment or by taking actions aimed at preventing intensive use and 
dependence.
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Monitoring of cannabis use has been improved since the beginning of the 1990s, partly 
due to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), which 
has developed a European model questionnaire for general population surveys (Bless 
et al., 1997). Nonetheless, most studies dealing with abuse, problematic use, harmful 
use or dependence reflect a lack of standardised screening tools (1). And more study is 
needed on the links between various types of use, socio-demographic characteristics and 
socio-medical factors.
The literature provides evidence that brief rating scales are well suited for screening 
purposes, and that instruments with direct questions appear to perform better than 
scales with more subtle questions (Rost et al., 1993; Svanum and McGrew, 1995). 
Yet, there remain many different screening instruments used to measure cannabis use 
disorders (2). This heterogeneity reflects the diverse goals of researchers and practitioners 
(which types of uses are to be screened and in which contexts), and of the means they 
choose to reach them (which types of questions, how many items and what kind of 
questionnaires). Although there are a number of definitions of cannabis use disorders, 
those which operationalise specific types of drug use are relatively vague. Furthermore, 
the way such definitions are translated into questions in screening tools can be very 
different. This is partly because identifying potentially harmful drug uses is complex and 
partly because in most countries attempts to distinguish problematic cannabis use from 
other types of cannabis use are new.
In this chapter we first clarify the different concepts for defining general substance use 
disorders and how these are applied to cannabis. Second, we describe the various 
screening instruments which attempt to measure cannabis use disorders, their differences 
and similarities. Finally, we discuss the various problems with existing screening tools 
and propose a possible step forward in order to better screen cannabis-related disorders 
in the future.
Concepts and their adaptation
The basics of screening potential problematic drug use are (i) establishing criteria 
to define problem use and (ii) developing questions that can be used to diagnose 
whether a respondent meets these criteria. Screening typically takes the form of a 
clinical interview between a patient and practitioner. Nonetheless, difficulties can 
 (1) The majority of these tests are conceived for all the psychoactive substances then adapted to 
cannabis; the others were specifically conceived for this product.
 (2) Recent European screening can be summarised as follows: Germany: Severity of Dependence 
Scale (SDS); France: Cannabis Abuse Screening Test (CAST); the Netherlands: CIDI modified 
plus additional ad hoc scale; Poland: Problematic Use of Marijuana (PUM); Portugal: Diagnostic 
and Statistical Manual of Mental Disorders, 4th edition (DSM-IV scale); Spain: Estudes study, 
combining CAST, SDS and the abuse subscale of the DSM-IV.
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be encountered by the researchers, practitioners and respondents. This section does 
not focus on cannabis use or particular screening tests. Instead, it deals with three 
questions which should precede screening: ‘what is problematic use of drugs?’, ‘how 
is problematic use best screened?’ and ‘will the screening process give us relevant and 
reliable information?’.
Concepts
The concepts of drug use disorders have a history. Until the middle of the 20th century 
the clinical study of drug addiction was characterised by many different theoretical 
approaches. Theory shifted to practical definition within a number of international 
standardised grids describing the disorders associated with drug use. Since this period, 
criteria have been modified alongside evolution in research and in interpretations of 
dependence. The term ‘dependence’ was borrowed from psychopharmacology, where 
it referred to tolerance and withdrawal, and was used more generally to replace the 
term addiction by a WHO Expert Committee in 1964. Edwards et al. (1981) introduced 
cognitive and behavioural signs and symptoms to the concept, and dependence became 
both behavioural and physical. Thanks to Goodman (1990), behavioural criteria gained 
more importance and the concept of dependence could be used to describe addictions 
without a drug, for example addiction to gambling. Dependence might also include a 
physical dependence characterised by pharmacological criteria (Kaminer, 1994; Bailly, 
1997, 1998).
Today, the most widely accepted definitions of use disorders are harmful use, abuse 
and dependence. These are defined by a list of criteria. Harmful use and dependence 
are defined in the International Classification of Diseases (ICD-10), Section F10–F19 (3), 
of the World Health Organisation, a concept developed from a European perspective, 
whereas the American Psychiatric Association’s Diagnosis and Statistical Manual of 
Mental Disorders (DSM-IV) (4) defines abuse and dependence — a concept developed 
from a US perspective.
Abuse under DSM-IV and harmful use under ICD-10 can be regarded as immediate 
damaging use for the individual, and are parts of a continuum that ranges from 
abstinence to dependence. Abuse may involve legal problems resulting from use, for 
example arrests for substance-related problems, and risky behaviours, such as use 
in physically hazardous situations, which are not included in the definition of harmful 
use. Yet, despite their differences, both take into account problems linked to the wider 
environment of the user, such as reproaches from the family circle or personal or social 
 (3) www.who.int/classifications/apps/icd/icd10online
 (4) www.dsmivtr.org. DSM-IV is currently in the process of being updated to a new manual, DSM-V.
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difficulties associated with use. Still, neither definition allows us to classify cases in terms 
of staggered stages of increasing gravity, and concepts of dependence stricto sensu 
require further definition.
Two other components make up the definition of dependence according to DSM-IV: 
physiological and psychological dependence. Physiological dependence comprises 
tolerance and withdrawal. Tolerance is defined by the need for increased amounts of 
the substance to achieve the original effects of the substance, or a markedly diminished 
effect with continued use of the same amount of the substance (criterion 1). The 
withdrawal symptom (used in criterion 2) is described as a maladaptive behavioural 
change that occurs when the substance concentration declines in an individual who 
has maintained prolonged heavy use of the substance (APA, 1994). Psychological 
dependence includes compulsive use (criteria 3, 4, 7), intensity of use (criterion 5) and 
consequences of use (criterion 6). These concepts may be found in most of the existing 
drug screening tests, whether specific to cannabis or not.
In Europe, some definitions of substance use problems are not based on ICD-10 
or DSM-IV concepts, but are purely pragmatic. One is the EMCDDA’s definition of 
problematic drug use as injection or regular use of opiates, cocaine, crack and/or 
amphetamines. The EMCDDA uses its definition of problematic use as one of its key 
indicators, and the definition is helpful in establishing a link with its key indicators on 
drug-related infectious diseases and drug-related deaths and mortality.
Work is still ongoing in Europe in defining problematic use of cannabis. One approach 
used in general population surveys is to assess problematic use by measuring ‘intensive 
use’, which can be defined through indicators of intensity or frequency of use (Simon, 
2004). This notion is based on the idea that the use is problematic above a certain 
excess threshold. This makes sense, but its definition is arbitrary and not based on 
medical criteria. Furthermore, many studies have shown that a statistical link between 
problems and use appears even at very low levels of use (Ramström, 2003), although 
this link must be cautiously interpreted as it varies with other variables such as gender, 
age, socio-economic context and the illegal status of the drug. Nonetheless, intensive 
use is useful in identifying those who are more at risk of developing problems linked to 
cannabis use.
Such criteria of problematic drug use play a practical role in diagnosis, alerting 
practitioners to problem patterns and enabling immediate diagnosis of harms. 
Nonetheless, difficulties remain in shifting from abstraction to action, i.e. to develop 
practical screening instruments for cannabis use disorders:
Definitions of substance use disorders do not easily translate into screening tool •	
questions.
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Problems related to consumption are not purely somatic, but embrace other aspects •	
of the user’s environment — associated risks, medical, educational, social and legal 
problems.
A survey given at a specific time may not be able to gauge the risk of a user, for •	
example mid- or long-term problems that have not yet transpired.
From concepts to screening tests
Screening consists of comparing substance disorder criteria — that is, the concept 
defining harmful use — against the actual pattern of use. This process can provide 
a variety of insights on the side of both the practitioner and patient or respondent, 
which are open to diverse interpretation. Thus, it is crucial to design a questionnaire 
that adequately reflects the criteria defining problematic use, and which ensures 
that responses are accurate, valid and actionable. There are basic delivery issues 
too: the context of use and population sample (adults, children, at school, at clinics, 
etc.) determines how questions are worded, how many questions are asked, how 
questionnaires can ‘fork’ to provide further details, and so on.
Harmful use criteria can differ from one population to another. Harrison et al. (1998) 
showed, for example, that DSM-IV does not completely fit adolescents. Within DSM-IV, 
criteria applicable to adolescents are often absent for concepts such as withdrawal, 
tolerance or giving up other activities providing pleasure and interest. Thus, it has 
been argued that DSM-IV concepts, when applied without adaptation to adolescents, 
do not deliver the prognostic value they have for adults (Bukstein and Kaminer, 1994). 
According to many researchers, current tools made for the screening of adults only 
deliver a late screening of youth-specific problems. So, it has become common for 
research teams working on adolescents to try to develop their own tools (Inserm, 2001).
Validation and quality measures
Measuring the quality of a screening test is not easy. As stated, a test must be theory 
based and should correctly screen users according to a harmful use concept. This 
concept must be clarified through a reference test, i.e. a ‘dry-run’ test that may or may 
not offer the kind of responses one obtains during actual use of the test. Thus, validation 
of the screening test needs to be iterative, based on comparing actual responses with the 
reference test, and tweaking the screening test accordingly. This process can be split into 
two basic tasks: first, comparing the screening test with the reference test; and, second, 
assessing the quality of the screening test (and its reference test) in a clinical situation 
in which a practitioner’s diagnosis can be compared with the result of the test. While it 
is not our aim to summarise best practices in survey validity here, validity can be tested 
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in a number of ways: completeness (Have all questions been answered? In the right 
sequence?); respondent base (Has the test been adequately prepared? Have sufficient 
respondents been used to test the practicality of the test? Have respondents answered 
sincerely and have interviewers correctly recorded responses?); and logic (Does the test 
reflect the harmful use concept? Can conclusions be generalised across the respondent 
base? And are other plausible explanations ruled out?). While preparation does not 
guarantee the ideal screening instrument, it is possible to avoid common pitfalls and to 
‘build in’ validation into clinical interviews or in general population surveys.
Existing screening tests for cannabis use disorders
Standardised early screening instruments have been used for tobacco (Fagerström and 
Schneider, 1989) and alcohol (Daeppen, 2004) for a long time. These tools are used as 
an aid in informing a diagnosis in a clinical situation, and also as an epidemiological 
tool in general population surveys among adults or adolescents in order to measure the 
levels of the different patterns of use. For alcohol, the most common instruments are the 
Alcohol Use Disorders Identification Test (AUDIT) (Saunders et al., 1993) and the CAGE 
test (Cut down, Annoyed, Guilty, Eye-opener test) (Ewing, 1984).
For other drugs, a large number of tests exist. Most have been developed for use with all 
drugs but can be adapted to a specific drug. For example, the Severity of Dependence 
Scale (SDS), was conceived for heroin and opiates (Gossop et al., 1995), and then 
adapted for cocaine and amphetamines, and recently for cannabis (Swift et al., 1998; 
Kraus et al., 2005). A literature review on screening tests and on their validation, 
describing the great diversity of what is available, has been conducted in France (Beck 
and Legleye, 2007a).
For cannabis, available screening tests are relatively recent and rarely used in general 
population surveys. In the 1990s, assessment instruments such as the Composite 
International Diagnostic Interview (CIDI) and the Schedules for Clinical Assessment in 
Neuropsychiatry (SCAN) have been used in several general population surveys, but 
their ability to measure cannabis dependence and cannabis abuse remains a matter for 
discussion (Compton et al., 1996). One difficulty is that contexts and motivation for use 
vary greatly among heavy cannabis users. Heavy use can develop both through solitary 
use, for example to manage stress or enable sleep, and in social settings, for example at 
recreational events or among peers. The same respondent can report both recreational 
use and harmful effects due to use.
A good example of adaptation of the concept of dependence into a set of questions 
can be found in aggregated data from three waves (1991 to 1993) of the US National 
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Household Survey on Drug Abuse (NHSDA) (5), with 87 915 respondents aged 12 
and over (Kandel et al., 1997). For this survey, a measure of cannabis dependence 
was developed, inspired by DSM IV (see Appendix A). The test asked questions about 
tolerance, withdrawal, loss of control, how much time spent on using cannabis, negative 
consequences for daily life, and continued use despite knowing that cannabis causes 
significant problems.
Among adolescents, problems associated with physical cannabis dependence appear 
to be rare (Beck et al., 2004), although they are reported in some studies (Dennis et 
al., 2002; Martin et al., 2005). Adolescents reporting problems seem to suffer more 
from psychological dependence, exacerbated by the fact that cannabis is almost always 
mixed with tobacco. Adolescents also appear more likely to experience risky situations, 
concentration and motivation difficulties or problems in their relationships with their 
family and friends (Obradovic, 2006). However, many of these factors might derive from 
the fact that cannabis is an illegal substance.
As dependence is considered to be the last and most harmful stage of use, screening in 
general population surveys rarely aims to detect dependence and its symptoms, although 
there are some exceptions (e.g. the OPCS Surveys of Psychiatric Morbidity in the 1980s 
and 1990s in the United Kingdom; the ESA survey in Germany; the Australian National 
Drug Strategy Household Survey). Some questions related to dependence criteria may 
be included in some tests, for example the screening carried out by the Alcohol Advisory 
Council of New Zealand (ALAC, see Appendix A). However, other tools could be used 
for this purpose, such as SDS or MINI Cannabis, or the instrument developed by Kandel 
et al. (1997), with questions from the NHSDA.
There have been several recent attempts to develop a scale measuring problematic 
cannabis use. These screening instruments intend to measure problems related to 
cannabis use in various areas:
 (i) consumption per se;
 (ii) physical dependence (withdrawal and tolerance);
 (iii) psychological dependence;
 (iv) social harm from use (legal difficulties, harm to relationships, work role harm, etc.); 
and
 (v) health harm due to use (memory loss, physical ailments, casualties, etc.).
Many of these are familiar. DSM-IV and ICD-10 include the second and third of these 
dimensions in their definition of dependence. ICD-10 includes item (v) as harmful 
use. DSM-IV includes criteria from items (iv) and (v) as abuse. Some diagnostic 
 (5) NHSDA is a household survey conducted by the federal government’s Substance Abuse and 
Mental Health Services Administration (SAMHSA).
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instruments also include these criteria, although they sometimes also include other 
harms, for example guilt or deviance from a standard context of use. Some items, like 
the reproaches of relatives, may enter many categories, such as social harm, health 
problems or dependence. Solitary smoking may indicate either dependence or social 
harm.
Screening scales used among adults
Although they seem to underestimate heroin, cocaine or amphetamine use disorders, 
general population surveys can be used to give a relevant estimate of cannabis use 
disorders (Rhem et al., 2005). The 2003 Epidemiological Survey on Substance Abuse 
(ESA) in Germany employed the Severity of Dependence Scale (SDS), as proposed by 
Gossop et al. (1995), to measure cannabis dependence (see Appendix A). This general 
population survey (self-administered questionnaires) was carried out with a sample of 
8 061 adults aged 18–59 years. The SDS was used to identify subjects who showed signs 
of cannabis dependence. A score of three or more points was taken as a cut-off point 
for cannabis-related problems. Overall, 1.1 % of the sample exceeded the threshold of 
three or more points on the SDS and were characterised as cannabis dependent (Kraus 
et al., 2005). The scale consisted of five items, with each scored on a four-point scale 
(0–3). The greater the score, the higher the degree of psychological dependence. The 
total score is obtained through the addition of the five-item ratings. The scale explores 
strictly psychological dependence and no other areas of harm.
A team from New Zealand used the Cannabis Use Disorders Identification Test 
(CUDIT, see Appendix) screening instrument (Adamson and Sellman, 2003), derived 
by modifying the AUDIT test for alcohol (Saunders et al., 1993). This 11-question scale 
aims to screen for cannabis abuse or dependence. It was used in a clinical sample 
of alcohol-dependent adults who reported some cannabis use over the preceding six 
months (n = 53). The scale was compared with the self-reported frequency of cannabis 
use in the preceding six months. The scale explores the nature of consumption per 
se, including intensity of use and compulsive use, physical dependence, psychological 
dependence, social harm from use, health harm due to use, and also guilt and 
reproaches or blame from relatives. Several queried items could be classified as linked 
to more than one harm, for example cannabis consumption in the morning.
According to the authors, on the basis of the Diagnostic Interview for Genetic Studies 
(DIGS) providing a DSM-IV diagnosis (Nurnberger et al., 1994), the CUDIT test was 
better than a frequency measure (at least 80 days using cannabis), achieved positive 
predictive power of 84.6 % and sensitivity of 73.3 % at a cut-off of 8, compared with 
positive predictive power of 81.8 % and sensitivity of 60.0 % for the frequency measure. 
Such results indicate the viability of the CUDIT measure for identifying cannabis use 
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disorder in risk populations, and its use for the general population should be assessed. 
However, one general problem of this scale is that the reference period (6 months) 
would need to be adapted to European standards (last month, or last year use), defined 
by EMCDDA.
On several French prevention websites, a cannabis-specific adaptation of the CAGE 
(Cut down, Annoyed, Guilty, Eye-opener) alcohol screening test has been tried to enable 
self-evaluation of problematic cannabis use. CAGE explores four areas of harms: 
psychological dependence, social harm, guilt and physical dependence. Two positive 
answers out of a possible four is interpreted as indicating problematic cannabis use 
(Midanik et al., 1998). The test has never been validated in its cannabis version. It 
should, however, be noted that the alcohol version has been criticised by Bisson et al. 
(1999). Moreover, CAGE is not recommended as a brief alcohol screening test among 
adolescents, as it appears to perform less well than AUDIT or CRAFFT (Knight et al., 
2003).
Some surveys focus only on one or two areas of harm; for example, a survey carried out 
in Ontario (Ferris et al., 1994) explored only health and social harm (see Appendix A). 
Alternative scales are sometimes created for self-assessment of cannabis use and its 
impact, such as the one developed by the Jellinek clinic in Amsterdam (Kerssemakers, 
2000) (6). The Know cannabis test has 16 questions, and can be filled out on a website. 
The result is accompanied by recommendations for the cannabis user. The scale 
explores multiple consequences of cannabis consumption per se, including spending 
money and compulsive use, polydrug use, motivations for use, dependence, social harm, 
guilt, health consequences and reproaches and blame from relatives. Again, some items 
may explore more than one area of harm.
Screening scales used in the youth population
Several recent studies have explored the feasibility of measuring adolescent cannabis 
use disorders in the general population. In Poland, a study in progress aims to assess 
the accuracy of a test focused on problematic herbal cannabis use in an adolescent 
population (Okulicz-Kozaryn and Sieroslawski, 2005). In France, Chabrol et al. (2000) 
conducted a study on abuse and dependence, according to the DSM-IV criteria, in 
a school survey. They used the MINI cannabis screening test, derived from the Mini 
Neuropsychiatry International Interview (Lecrubier et al., 1997; Sheehan et al., 1997; 
see Appendix A). The MINI tests for cannabis dependence as well as for cannabis abuse.
 (6) The Jellinek test can be taken at www.knowcannabis.org.uk and www.jellinek.nl/zelfhulp/
cannabis
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In France, the Cannabis Abuse Screening Test (CAST) (see Appendix) was constructed to 
be used in general population surveys. It was used in a sample of 20 000 adolescents 
in the ESCAPAD survey (Beck and Legleye, 2003). CAST explores consumption per se, 
deviance from a common standard of use, health and social harm, and reproaches from 
relatives and dependence. It aims to determine two kinds of populations: adolescents 
with no problem and adolescents who need a diagnosis on their cannabis use (Karila 
et al., 2004). Clinical validation of CAST is in progress in a partnership between the 
French monitoring centre for drug and drug addiction (OFDT) and two specialised 
centres for cannabis use prevention and treatment.
CAST is used both in general population surveys and in cannabis consultation to screen 
problematic cannabis users and to refer them to the appropriate service. Thresholds 
enable practitioners to normalise the interview with the person in consultation and 
to gauge whether the cannabis use pattern is potentially problematic. Two positive 
answers highlight the need for the person to be careful about use. Three or more 
positive answers indicates that the use may be problematic and the person should be 
offered a specialised consultation to obtain help to diminish or stop use, thereby alerting 
clinicians that a deeper assessment is warranted. Other tests are also in the process of 
clinical validation in this study, such as the French versions of the CRAFFT and of the 
ALAC tests used as self-administered evaluation instruments. The ALAC questionnaire 
(see Appendix A) for the self-evaluation of cannabis use is recommended by the Alcohol 
Advisory Council of New Zealand (1996). Two positive answers indicate a moderate 
risk of abuse, and three positive answers indicate a strong risk of abuse. The ALAC 
questionnaire has not yet been validated, but it aims to assess the harms of reproaches, 
health problems, dependence and social problems. It appears to be problematic 
compared with the other tests, as several of the questions do not mention drugs at all.
Longer screening tests
Other scales, which query a greater number of harms, have been used among specific 
populations. For example, the Cannabis Problems Questionnaire (CPQ) was very 
recently modelled (Copeland et al., 2005; Martin et al., 2006) on the 46 items of the 
Alcohol Problems Questionnaire (APQ; Williams and Drummond, 1994). The study was 
conducted among 72 adolescents smoking at least 15 days per month. It left the final 
CPQ as a 22-binary-item scale, which seems to be an efficient and reliable measure of 
cannabis-related problems for use with populations of current cannabis users, offering 
more than 80 % sensitivity and specificity, according to DSM IV criteria.
Heishman et al. (2001) have developed and validated the Marijuana Craving 
Questionnaire (MCQ), a 47-item multidimensional questionnaire on marijuana craving, 
based on the model of the Questionnaire on Smoking Urges (Tiffany and Drobes, 
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1991) and the Cocaine Craving Questionnaire (Tiffany et al., 1993). In their study, 
current marijuana smokers (n = 217) not seeking treatment completed forms assessing 
demographics, drug use history, marijuana quit attempts and current mood. The 
findings suggested that four specific constructs characterise craving for marijuana: 
compulsivity — an inability to control marijuana use; emotionality — use of marijuana 
in anticipation of relief from withdrawal or negative mood; expectancy — anticipation 
of positive outcomes from smoking marijuana; and purposefulness — intention and 
planning to use marijuana for positive outcomes. Heishman et al. (2001) found that the 
MCQ is a valid and reliable instrument for assessing marijuana craving in individuals 
not seeking drug abuse treatment, and that marijuana craving can be measured in the 
absence of withdrawal symptoms.
The Marijuana Effect Expectancy Questionnaire (MEEQ) assesses motivation to use 
marijuana (Schafer and Brown, 1991). It has 70 yes/no format items with agree/
disagree instructions similar to those of the Alcohol Expectancy Questionnaire (AEQ). 
Subjects are asked to respond according to their own beliefs and whether they have 
actually used marijuana. Although MEEQ is not designed for general clinical screening, 
it contains items with potential for screening. It has been tested in a psychometric 
evaluation on 279 adolescents from a clinical and community sample (Aarons et al., 
2001) and on 149 males from a clinical sample (Galen and Henderson, 1999).
The Marijuana Screening Inventory (MSI-X) is a 39-binary-item scale. Thirty-one of the 
items are used to calculate a simple score to classify into one of the four following 
categories: no problem; normal or experimental marijuana use; potentially problematic 
marijuana use; and problematic marijuana use. The study was conducted on a sample 
of 420 military reservists (a convenience sample). The MSI-X was found to be promising, 
especially for rapid diagnosis assessment, but a clinical validation is yet to be conducted 
(Dale, 2003).
These instruments seem, at a first glance, to be too long to apply as part of a general 
population survey. The application of such instruments requires more time than available 
in most cases in population surveys, and sometimes skilled interviewers, too. They have 
only been tested in clinical populations, which might not be sufficient to assess their 
applicability in the general population.
Discussion
This chapter presents the main tools aiming to screen different kinds of cannabis use 
and problems resulting from it. It is not an exhaustive presentation of the published 
literature, yet it provides concise discussion of the concepts and tests developed so far.
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There is evidence that cannabis use sometimes leads to problems, and these problems 
are now a major concern in the field of public health. As a consequence, many surveys 
try to evaluate the proportion of cannabis users who suffer problems resulting from 
cannabis use or the proportion of dependent users. The largest recent surveys were 
conducted in the USA and Australia. Estimations vary and depend on the instruments 
used. In Australia, the National Survey of Mental Health and Well-being conducted 
a study in 1997 among a representative sample of 10 600 people of the Australian 
population aged 18 and over, and used DSM-IV and ICD-10 diagnoses. Swift et al. 
(2001) found that 1.5 % (DSM-IV) or 1.7 % (ICD-10) of this population was cannabis 
dependent, with marked differences in symptom prevalence. The proportions among 
cannabis users during the last 12 months were 21 % (DSM-IV) and 22 % for ICD-10. In 
the USA, according to a recent NHSDA survey (SAMHSA, 2002), 2 % of people aged 
12 and over fulfilled DSM-IV criteria for cannabis dependence or abuse during the last 
12 months. The proportion among those aged 18–25 years was 6 %. According to this 
survey, 17 % of last year cannabis users fulfilled criteria for cannabis dependence or 
abuse.
The concepts and definitions used in the DSM and in the ICD are controversial, and not 
all studies support the idea that cannabis smokers develop dependence as well as abuse 
(see also Witton, this monograph, Vol. 2). In a study by Hollister (1986), for instance, 
cannabis was given to subjects for a certain period of time in order to study the effects 
of interruption of the supply. The first attempts failed, but this may be due to amounts of 
cannabis, which were too small, and a period of supply, which was too short, for ethical 
reasons. Many authors do, however, confirm that dependence can occur with long-term 
use: patients who receive significant doses over a long period of time develop symptoms 
such as occasional perspiration, slight nausea, anxiety and sleeplessness (Compton et 
al., 1990; Jones, 1996; Crowley et al., 1998; Haney et al., 1999a,b; Vandrey et al., 
2005). Despite this general agreement, Jones (1996) emphasises that frequency of 
dosing and dose interval are more important than daily dose for producing a cannabis 
withdrawal syndrome. Typical patterns of cannabis use appear to be non-optimal 
conditions to get an obvious withdrawal syndrome, though less obvious symptoms may 
be relevant when treating cannabis-dependent patients. Smith (2002) points out that 
these symptoms are not specific for cannabis (they can be observed with tobacco) and 
vary with the psychological profile of the individual. Coffey et al. (2002), argue that 
tolerance might be useless in clinical assessment of cannabis dependence.
The list of criteria used for psychological dependence for all drugs in the DSM-IV 
definition of dependence appears non-exhaustive. In addition, some of these criteria 
have been criticised for not seeming relevant for certain researchers (Soellner, 2002). 
For example, criterion 7, dealing with the continuation of use despite the recognition of 
its contributing role to some psychic or physical problems, ignores the eventuality that 
the user might have no intention of stopping use and, on the contrary, might rationally 
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choose to continue to use it because it provides greater benefits. This possibility has not 
been investigated. Indeed, the challenge of adapting a generic mental health standard, 
such as DSM-IV, to use of a specific drug is illustrated in the discrepancy between DSM-
IV’s definition of dependence for all drugs and the criteria it proposes for cannabis.
Problems with conceptualising harmful use and thresholds are compounded by the 
difficulties of developing the screening tools themselves. Measures such as MINI use 
items from the ‘problem domain’ and refer to them as criteria of dependence. It also 
seems problematic to define dependence by its consequences, for example criterion 6 
in the DSM-IV. As the definition of dependence is so strictly delimited in DSM, a link 
between dependence and its potential consequences cannot be proven (Soellner, 2002). 
‘Drift’ in the use of items from the problem domain can also be criticised as these items 
do not measure whether users intend to quit. Intention to quit is crucial, as research 
shows that cannabis users argue that they would and could quit if cannabis consumption 
led to suffering (Swift et al., 1998), and cannabis use is not necessarily viewed as a 
problem by dependent users.
Other variables are also problematic. Some of the dependence criteria, such as 
spending a great deal of time around the substance, might be confounded by the 
illegality of the drug (this is a problem for MINI and ICD-10, for instance). In CUDIT and 
CAGE there is a question about feelings of guilt after using cannabis, which could also 
be confounded by the illegality of the drug. Thus, most screening measures combine 
the dimensions of psychological dependence and harm. This is true of CUDIT, MINI 
and CAST, and thus it is not clear what they are screening for: dependence? Or abuse? 
These are concepts that DSM-IV makes a serious attempt to separate, and combining 
the two areas is problematic for an illicit substance: many of the problems have resulted 
from the fact that cannabis is illegal.
In general, analysis of diagnostic tools, such as DSM-III, DSM-IV and ICD, used as 
severity scales for drug dependence shows that diagnostic algorithms greatly influence 
the results (Langenbucher et al., 1995). A comparison between DSM-III R and DSM-IV 
emphasises the influence of the evolution of the diagnostic criteria on the screening 
results (Mikulich et al., 2001). These problems question the very nature of the concepts 
of addiction: what should be measured, why and how?
An examination of concepts used in American and European definitions of the stages of 
drug use disorders reveals some cultural differences. For example, the definition of drug 
abuse, according to the American DSM-IV, contains moral criteria and characteristics, 
either in the concepts themselves or in the wording of the concepts, whereas the 
European definition of harmful use, according to the ICD-10, seems more pragmatic. 
Law transgression or failing in social roles are included in DSM-IV’s definition of abuse, 
in addition to using despite knowledge that damage results from use. Use in hazardous 
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situations, such as driving, may be seen as risky behaviour that increases risk of being 
injured or of causing injury, yet an accident may never occur. In DSM-IV’s definition of 
dependence, criterion 7 presupposes that use itself is bad, even if it brings a benefit and 
contributes to the psychological balance of the user, who might have made a rational 
decision to continue using. In a sense, the user under DSM-IV is presupposed to have a 
social duty and responsibility: he or she must conform to social and legal norms. Users’ 
knowledge of the law and their psychological reaction both contribute to the definition 
of abuse. Such moral rationale seems less present in ICD-10’s definition of harmful use, 
although these concepts should perhaps be examined when defining drug-related harm.
Conclusion
Measuring the proportion of problematic or dependent cannabis users from among the 
wider cannabis user base is complex. It presents far more challenges than measuring 
prevalence by lifetime or last month cannabis use in general population surveys. Faced 
with an increase in cannabis use, policymakers may choose to add some tools to 
general population surveys or the monitoring instruments used by addiction treatment 
centres.
Today, a great number of concepts and tools exist to monitor problematic cannabis 
use, and they vary in terms of both quality and robust scientific validation. Nonetheless, 
these instruments do offer valuable insights into use patterns. Implementing a common 
screening tool, even if not validated, can deliver important information to inform the 
fields of prevention and treatment. Policymakers should be prepared for some criticism 
based on the lack of consensus surrounding dependence and abuse, but screening at 
least delivers a base of knowledge that can be used by specialists in defining public 
policy.
There is clearly a need to develop screening tools that are more reliable in measuring 
adverse effects of cannabis use than those presently in use. Some existing instruments, 
such as CIDI and CAST, go some way to providing a standard, practical tool, and can 
provide a basis for further work. In Europe, screening projects for cannabis are under 
way in Germany, France, the Netherlands, Poland, Portugal, the United Kingdom and, 
most recently, Spain (EMCDDA, 2007). It is hoped that such initiatives will help to 
develop a reliable and comparable indicator of problematic cannabis use in the general 
population.
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A: Measuring cannabis dependence based on DSM IV (Kandel et 
al., 1997) (the numbers refer to DSM items, the following sentences 
to the corresponding question in the NHSDA)
 1 Tolerance: during the past 12 months, for which drugs have you needed larger amounts 
to get the same effect; that is, for which drugs could you no longer get high on the 
same amount you used to?
 2 Withdrawal: for which drugs have you had withdrawal symptoms; that is, you felt sick 
because you stopped or cut down on your use of them during the past 12 months?
 3 Greater use than intended: which drugs have you felt that you needed or were 
dependent on in the past 12 months?
 4 Unsuccessful efforts to cut down or control: during the past 12 months, for which drugs 
have you consciously tried to cut down on your use? During the past 12 months, for 
which drugs have you been unable to cut down on your use, even though you tried?
 5 Great deal of time spent in using: have you used three joints or more nearly daily (three 
times or more a week) in the past 30 days; or 2 oz or more (86 joints or more or 43 g 
or more) in the past 30 days; or traded service for cannabis?
 6 Reduction in social, occupational or recreational activities: as a result of drug use, at 
any time in your life, did you, in the past 12 months, get less work done than usual 
at school or on the job?
 7 Continued using cannabis despite knowing it caused significant problems: as a result of 
drug use at any time in your life, did you in the past 12 months … (become depressed; 
have arguments/fights with family and friends; feel completely alone and isolated; 
A DSM-IV dependence adapted in National Household Survey on 
Drug Abuse
Kandel et al. (1997)
B SDS (Severity Dependence Scale) Gossop et al. (1995)
C CUDIT (Cannabis Use Disorders Identification Test) Adamson and Sellman (2003)
D CAGE-cannabis Midanik et al. (1998)
E Ontario alcohol and other drug opinion survey Ferris et al. (1994)
F Know cannabis test Kerssemakers (2000)
G MINI-cannabis Lecrubier et al. (1997), 
Sheehan et al. (1997)
H CAST (Cannabis Abuse Screening Test) Beck and Legleye (2003)
I ALAC (Alcohol Advisory Council of New Zealand) ALAC (1996)
J CPQ (Cannabis Problem Questionnaire) Copeland et al. (2005)
K MCQ (Marijuana Craving Questionnaire) Heishman et al. (2001)
L MEEQ (Marijuana Effect Expectancy Questionnaire) Schafer and Brown (1991)
M MSI-X (Marijuana Screening Inventory) Dale (2003)
Appendix A: List of tests and references
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feel very nervous and anxious; find it difficult to think clearly; have health problems; 
feel irritable and upset; feel suspicious and distrustful of people; find it harder to 
handle your problems; have to get emergency medical help; have someone suggest 
you seek treatment)?.
B: SDS (Gossop et al., 1995)
In the past year:
 A Did you think your use of cannabis was out of control?
 B Did the prospect of missing cannabis or not chasing make you anxious or worried?
 C Did you worry about your use of cannabis?
 D Did you wish you could stop?
 E How difficult did you find it to stop, or go without cannabis?
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1 How often do you use cannabis? Never Monthly
or less
2–4 
times a 
month
2–3 
times a 
week
4 times a 
week or 
more
0 1 2 3 4
2 How many hours were you ‘stoned’ on 
a typical day when you had been using 
cannabis?
1 or 2 3 or 4 5 or 6 7 to 9 10 or more
0 1 2 3 4
3 How often were you ‘stoned’ for six or 
more occasions?
Never Less than
monthly
Monthly Weekly Daily or 
almost daily
0 1 2 3 4
4 How often during the past six months did 
you find that you were not able to stop 
using cannabis once you had started?
0 1 2 3 4
5 How often during the past six months did 
you fail to do what was normally expected 
from you because of using cannabis?
0 1 2 3 4
6 How often during the past six months 
have you needed to use cannabis in the 
morning to get yourself going after a 
heavy session of using cannabis?
0 1 2 3 4
7 How often during the past six months did 
you have a feeling of guilt or remorse 
after using cannabis?
0 1 2 3 4
8 How often in the past six months have 
you had a problem with your memory or 
concentration after using cannabis?
0 1 2 3 4
9 Have you or someone else been injured as 
a result of your use of cannabis over the 
past six months?
No Yes
0 4
10 Has a relative, friend or doctor, or other 
health worker been concerned about your 
use of cannabis or suggested that you 
should cut down over the past six months?
No Yes
0 4
C: The Cannabis Use Disorders Identification Test (CUDIT) 
(Adamson and Sellman, 2003)
 A Have you used any cannabis over the past 6 months?  Yes No
If yes:
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D: CAGE (Cut down, Annoyed, Guilty, Eye-opener) questionnaire 
for cannabis smoking (Midanik et al., 1998)
 1 Have you ever tried to, or felt the need to, Cut down on your smoking?
 2 Do you ever get Annoyed when people tell you to quit smoking?
 3 Do you ever feel Guilty about smoking?
 4 Do you ever smoke within half an hour of waking up (Eye-opener)?
E: Ontario alcohol and other drug opinion survey
Was there ever (and in the last 12 months) a time that you felt your use of marijuana 
had a harmful effect on your:
 A friendship or social life?
 B physical health?
 C home life or marriage?
 D work, studies or employment opportunities?
 E financial position?
F: Know cannabis test
Source: Kerssemakers (2000). Also available at www.knowcannabis.org.uk/ and www.
jellinek.nl/zelfhulp/cannabis/
 1 How often do you smoke cannabis?
 1 a few times a year (0)
 2 once or twice a month (0)
 3 once or twice a week (1)
 4 almost every day (2)
 2 How much money do you spend on cannabis in an average week? (Base your answer 
on what you pay, or should have to pay, as a consumer.)
 1 3 euros or less (0)
 2 3 to 9 euros (1)
 3 10 to 25 euros (2)
 4 more than 25 euros (2)
 3 How often are you stoned?
 1 more than half of the day (2)
 2 a few hours every day (2)
 3 a few times a week (1)
 4 a few times a month (0)
 5 once a month or less (0)
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 4 When you smoke cannabis, how often do you light up a second joint or pipe to get extra 
stoned?
 1 never (0)
 2 sometimes (0)
 3 regularly (1)
 4 almost always (2)
 5 Do you ever smoke cannabis in combination with other drugs or alcohol?
 1 yes, often (2)
 2 yes, sometimes (1)
 3 no, never (0)
 6 When do you usually smoke cannabis? (More than one answer possible.)
 1 morning (1)
 2 afternoon (1)
 3 evening (1)
 4 night (1)
 7 What are (three of) the most important reasons why you use marijuana and/or hash?
 1 it’s more fun than drinking alcohol (0)
 2 to relieve boredom (1)
 3 to feel good (0)
 4 I’m just accustomed to taking it/it’s part of the game (1)
 5 it’s nice to smoke with friends (0)
 6 to relieve feelings of depression (1)
 7 to help me relax, like before going to sleep (0)
 8 to perform or concentrate better (1)
 9 I forget my problems for a while (2)
 10 to change the effects of other substances (drugs or alcohol) (1)
 11 I don’t know (0)
 8 When you smoke cannabis, what people do you usually smoke with?
 1 always with friends (0)
 2 usually with friends, but sometimes alone (0)
 3 usually alone, and sometimes with friends (1)
 4 always alone (2)
 9 Could you stop smoking marijuana or hash whenever you want?
 1 no, I couldn’t (2)
 2 maybe, but it would take me a lot of trouble (1)
 3 probably, but not without some trouble (0)
 4 sure, I would have no trouble at all (0)
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 10 How often have you thought to yourself in the past year, ‘I should cut down or 
stop’?
 1 never (0)
 2 a few times (0)
 3 once a month (1)
 4 once a week (2)
 5 almost every day (2)
 11 In the past year, how often has your use of cannabis affected your performance in 
your work or studies?
 1 never (0)
 2 a few times (0)
 3 once a month (1)
 4 once a week (2)
 5 almost every day (2)
 12 Do you sometimes put things off or procrastinate because you are stoned?
 1 no, never (0)
 2 yes, sometimes (0)
 3 yes, regularly (1)
 4 yes, almost always (2)
 13 Have you ever felt extremely frustrated because you couldn’t smoke cannabis when 
you wanted to?
 1 no, never (0)
 2 yes, sometimes (0)
 3 yes, quite often (1)
 4 yes, almost always (2)
 14 How often in the past year have you felt worried about your use of cannabis?
 1 never (0)
 2 a few times during the year (0)
 3 a few times a month (1)
 4 a few times a week (2)
 5 every day (2)
 15 Do you ever have trouble remembering what you said or did?
 1 no, never (0)
 2 yes, sometimes (0)
 3 yes, quite often (1)
 4 yes, almost all the time (2)
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 16 Has a friend or acquaintance of yours who also smokes cannabis ever told you that 
you really need to cut down on marijuana or hash?
 1 yes, sometimes (0)
 2 yes, regularly (1)
 3 no (0)
 4 no, because they don’t know I smoke it (2)
Score ranges:
0–5: No added risk, although taking drugs always carries risks.
6–15: Definite risk. You’re taking too many chances. Try to reduce the risks of your 
drug use.
16–36:  Serious risk. Your drug use is getting out of hand.
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G: MINI cannabis (Sheehan et al., 1997)
Considering your use of cannabis in the past 12 months:
A Have you found that you needed to use more cannabis to get the same 
effect that you did when you first started taking it?
Yes No
B When you reduced or stopped using cannabis, did you have withdrawal 
symptoms (aches, shaking, fever, weakness, diarrhoea, nausea, sweating, 
heart pounding, difficulty sleeping, or feeling agitated, anxious, irritable, 
or depressed)? Did you use any drug(s) to keep yourself from getting sick 
(withdrawal symptoms) or so that you would feel better?
Yes No
C Have you often found that when you used cannabis you ended up taking 
more than you thought you would?
Yes No
D Have you tried to reduce or stop taking cannabis but failed? Yes No
E On the days that you used cannabis, did you spend substantial time (> 2 
hours), obtaining, using or in recovering from the drug, or thinking about 
the drug?
Yes No
F Did you spend less time working, enjoying hobbies, or being with family or 
friends because of your cannabis use?
Yes No
G Have you continued to use cannabis, even though it caused you health or 
mental problems? Yes No
Considering your use of cannabis in the past 12 months:
H Have you been intoxicated, high, or hungover from cannabis more than 
once, when you had other responsibilities at school, at work, or at home? 
Did this cause any problem?
Yes No
I Have you been high or intoxicated from cannabis more than once in any 
situation where you were physically at risk (for example, driving a car, 
riding a motorbike, using machinery, boating, etc.)?
Yes No
J Did you have legal problems more than once because of your drug use, 
for example, an arrest or disorderly conduct?
Yes No
K Did you continue to use cannabis, even though it caused problems with 
your family or other people?
Yes No
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H: Cannabis abuse screening test (CAST) (Beck and Legleye, 2003)
During the last 12 months:
No Yes
1 Have you ever smoked cannabis before midday? 0 1
2 Have you ever smoked cannabis when you were alone? 0 1
3 Have you ever had memory problems when you smoke cannabis? 0 1
4 Have friends or members of your family ever told you that you ought 
to reduce your cannabis use?
0 1
5 Have you ever tried to reduce or stop your cannabis use without 
succeeding?
0 1
6 Have you ever had problems because of your use of cannabis 
(argument, fight, accident, bad result at school, etc.)? Which: 
………………………………………………………
0 1
I: ALAC (ALAC, 1996)
1 Have people close to you complained about your cannabis use? 1  Yes 2  No
2 Do you have problems with short-term memory? 1  Yes 2  No
3 Have you experienced ‘paranoid’ episodes following cannabis use? 1  Yes 2  No
4 Do you consider it difficult to go through a day without a ‘joint’? 1  Yes 2  No
5 Do you lack the energy to get things done in the way you used to? 1  Yes 2  No
6 Do you ever worry about the effects of your cannabis use? 1  Yes 2  No
7 Do you have more difficulty in understanding new information? 
(difficulty in studying)
1  Yes 2  No
8 Have you ever unsuccessfully attempted to cut down or stop your 
cannabis use?
1  Yes 2  No
9 Do you like to get ‘stoned’ in the morning? 1  Yes 2  No
10 Are you spending more and more time ‘stoned’? 1  Yes 2  No
11 Do you experience cravings, headaches, irritability or difficulty in 
concentration when you cut down or cease cannabis use?
1  Yes 2  No
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Setting the context
Cannabis is the most used illicit drug among adolescents in Europe. The European 
School Survey Project on Alcohol and Other Drugs (ESPAD) is the key transnational 
instrument for comparing adolescent cannabis consumption in Europe. This chapter 
provides a summary of recent ESPAD findings on cannabis.
Use of alcohol, illegal drugs and other substances among young people is of great 
concern in all countries. Acute consequences can be harmful for the individual and 
negatively affect the development and future well-being of an adolescent. Another 
concern is that the heavier the use in adolescence, the larger the risk an individual may 
encounter substance-related problems in the future (1).
The literature is plentiful on suggested associations between early-onset drug 
consumption and wider psychosocial problems, both in late adolescence and in later 
adulthood (2). However, cannabis is usually placed in a wider psychosocial context of risk 
factors, and direct causal links are not attributed to the drug. Still, studies among youth 
detention centres and school drop-outs, for example, highlight associations between 
delinquent behaviour and high prevalence of intensive drug or alcohol consumption (3). 
 (1) For a wider discussion of risk factors and cannabis use, see Coggans, this monograph.
 (2) A review of psychosocial correlates with ESPAD data (Bulgaria, Croatia, Greece, Romania, 
Slovenia and United Kingdom) was recently carried out (Kokkevi et al., 2007).
 (3) A study in Spain by the Centro de Estudios sobre Promoción de la Salud (CEPS, 2004) of a sample 
of youths at protection and reform centres found approximately one-third reported weekly 
cannabis use. Two Dutch studies (Korf et al., 2005; Vreugdenhil, 2003) also reported high 
prevalence of cannabis use among youths in detention centres (see Dutch National Focal Point, 
Netherlands National report, 2006).
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Moving from deviant patterns to normative behaviour, studies have suggested 
correlations between cannabis use and impaired educational performance, and (less 
strongly) occupational performance, interpersonal relationships, mental health issues 
and suicide (4).
There is also a strong economic argument for building strong epidemiological data 
to inform cannabis prevention activities (5). With school drug prevention budgets in 
the larger Member States running to tens of millions of euros, it is not surprising that 
debate in the area is lively. Points of contention include: the ‘gateway’ or ‘stepping 
stone’ theory (cannabis use as a risk factor for use of ‘harder’ drugs) (6); effects on 
adolescent neurological development (including some genetic predisposition debate); 
means to evaluate the efficacy of programmes (7); polydrug patterns in adolescents, in 
particular correlations to alcohol, tobacco and inhalant misuse; the dangers of episodic 
or ‘binge’ patterns; the role to be played by prevention actors (peers, teachers, family, 
drugs workers, police); and delivery of drug prevention in the context of general health 
programmes (smoking, alcohol, sex education, obesity, healthy lifestyles) (8).
Beyond the enormous volume and varied quality of school prevention and harm 
reduction materials (websites, brochures, films, cartoons, posters), a number of recent 
European publications have sought to distil the research literature into practical 
publications. Resources include practical guidelines for teachers and parents (9), 
screening instruments (10) and grey literature (see Appendix). On the internet, the Drugs 
 (4) A useful synthesis is given by Hall and Pacula (2003); see further reading list. Key studies include: 
Lynskey and Hall (2000); Macleod et al. (2004); the ESTUDES project (Spain, 2004); and Silva 
and de Deus (2005).
 (5) For a wider discussion of prevention in Europe, see Burkhart, this monograph.
 (6) For a concise analysis of the gateway theory, see ‘What is the current evidence for cannabis 
as a gateway drug?’ in the 2006 Australian publication Evidence-based answers to cannabis 
questions: a review of the literature (Copeland et al., 2006). Longer analysis can be found in 
Chapter 10 of Cannabis use and dependence (Hall and Pacula, 2003).
 (7) The EU-Dap study (Austria, Belgium, Germany, Greece, Italy, Spain, Sweden) has reported on 
evaluation mechanisms for school-based drug prevention programs (Faggiano et al., 2005) — 
see www.eudap.net. A strong introduction to the principles of school drug prevention evaluation 
is the Australian government’s Principles for school drug education (2004) and its series of eight 
monographs, Innovation and good practice in drug education (2003).
 (8) A long-running study in the area of general health concerns is the WHO’s Health behaviour in 
school-aged children. See www.hbsc.org/
 (9) Publications include: Unplugged, a teaching manual produced in the context of the EU-Dap 
project (www.eudap.net); in Germany, Schule und Cannabis (BZgA, 2004) and materials for the 
Bekifft in der Schule project (SuchtPräventionsZentrum Hamburg, 2004); in Switzerland, Ecoles 
et cannabis (OFSP, 2004); in France, Repérage précoce de l’usage nocif de Cannabis (INPES, 
2006); in the United Kingdom, School drug policy: a review process (Blueprint, UK Home Office, 
2004) and Advice for teachers on delivering drug education (Drug Education Forum, 2004). A 
Rowntree Foundation study of cannabis supply routes to adolescents is scheduled for 2008 (see 
www.jrf.org.uk/knowledge/wip/record.asp?ID=804400).
 (10) For a discussion of screening instruments, see Beck and Legleye, this monograph.
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Education Forum’s newsblog (11) has evolved into a strong channel for practitioner 
information and debate in the area. Cross-border cooperation training (study visits, staff 
exchange) in school drug programmes is likely to benefit from funding under a current 
European Commission programme on drugs prevention and information (12).
Further reading
Drugs in Focus No. 5: Drug prevention in EU schools (EMCDDA, 2002) — includes a short reading 
list.
Drugs in Focus No. 10: Drug use amongst vulnerable young people (EMCDDA, 2004) — includes a 
short reading list.
EMCDDA website on school-based universal prevention 
www.emcdda.europa.eu/index.cfm?nnodeid=1578
ESPAD website 
www.espad.org/
Hall, W., Pacula, R. (2003), ‘Adolescent psychosocial outcomes’, Chapter 11 in Cannabis Use and 
Dependence: Public Health and Public Policy, Cambridge University Press.
McBride, N. (2005), ‘The evidence base for School Drug Education Interventions’, in Stockwell, T., 
Gruenewald, P. J., Toumbourou, J. W., Loxley, W. (eds), Preventing harmful substance use: the 
evidence base for policy and practice, John Wiley and Sons, Chichester, 101–112.
Soole, D. W., Mazerolle, L., Rombouts, S. (2005), Monograph No. 07: School based drug prevention: 
a systematic review of the effectiveness on illicit drug use, DPMP Monograph Series, Fitzroy: 
Turning Point Alcohol and Drug Centre.
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Korf, D. J., Benschop, A., Rots, G. (2005), ‘Geweld, alcohol en drugs bij jeugdige gedetineerden en 
school drop-outs’, Tijdschrift voor Criminologie 47(3): 239–254.
Vreugdenhil, C., Van den Brink, W., Wouters, L. F., Doreleijers, T. A. (2003), ‘Substance use, 
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Debate on policy and prevention for young people requires accurate data. This is the 
rationale that drives the European School Survey Project on Alcohol and Other Drugs 
(ESPAD) (13). ESPAD collects comparable data on alcohol, tobacco and drug use among 
students aged 15–16 years in European countries. It also monitors trends in alcohol 
and drug habits among students in Europe and compares trends between countries and 
groups of countries.
ESPAD began in the early 1990s. So far, data have been collected three times in 
an increasing number of countries (14). The first survey was done in 1995 with 26 
participating countries, the second in 1999 with 30 countries and the third in 2003 with 
35 countries. More than 100 000 students answered the ESPAD questionnaire in 2003. 
The surveys were carried out on nationally representative samples of school classes (15). 
However, there were three exceptions from this. One is Germany, in which the study was 
limited to 6 out of 18 Bundesländer. In Turkey, data were collected in six large cities, 
and in Russia the survey was carried out only in Moscow. In addition to the 35 countries 
that participated in the 2003 data collection, the report also included data from Spain 
(collected in 2002) and the USA (Hibell et al., 2003).
Awareness of cannabis: a well-known drug
Of all illicit drugs, marijuana and hashish (16) are the best known by students aged 
15–16. This is true for nearly all countries and among boys as well as girls: gender 
differences for cannabis awareness are small. Looking at the averages of all the 35 
ESPAD countries in the 2003 data collection, 92 % of students admitted that they had 
heard of marijuana and hashish. Equally well known are cocaine and heroin (91 % 
each). Next in terms of awareness are ecstasy (83 %) and amphetamines (66 %). In 
some countries nearly all students have heard about marijuana or hashish. This is the 
 (13) The ESPAD website is at www.espad.org
 (14) ‘Country’ here refers to a political entity, but not necessarily a national state. Such subnational 
entities as the Faroe Islands and the Isle of Man are included.
 (15) A full description of survey methodology is available on the ESPAD website at  
www.espad.org/method.asp.
 (16) ‘Marijuana and hashish’ is used together with ‘cannabis’ in this chapter as ‘marijuana and 
hashish’ are the terms used in the ESPAD questionnaire. Elsewhere in the monograph, ‘herbal 
cannabis’ and ‘cannabis resin’ are the preferred terms.
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case among 95 % or more of the students in 11 ESPAD countries. The highest figures 
(98–99 %) are found in the Czech Republic, France and Slovakia. The lowest proportion 
of students who have heard of cannabis products is found in Turkey (six cities), where 
68 % of the students reported that they were aware of cannabis. In all other countries, 
81 % or more of the students reported that they had heard of cannabis.
Availability: the most available illicit drug
To measure the perceived availability of different substances the ESPAD students were 
asked the following question: ‘How difficult do you think it would be for you to get 
each of the following?’. For each of the listed substances the response categories were: 
‘impossible’, ‘very difficult’, ‘fairly difficult’, ‘fairly easy’, ‘very easy’ and ‘don’t know’. 
Besides beer, wine and spirits, the highest proportion of students answering ‘very easy’ 
and ‘fairly easy’ is for inhalants (41 %, in ESPAD 2003).
However, if one looks only at illegal drugs, cannabis is the drug that is perceived 
as most available. On average, this was the case for a little more than one-third of 
the students in the ESPAD countries (35 %). Other substances perceived to be readily 
available are tranquillisers and sedatives (21 %), followed by ecstasy (17 %). The 
perceived availability differs widely between countries; from 7 % in Turkey (six cities) to 
60 % in Ireland. In seven countries a majority of the students answered that marijuana or 
hashish is ‘very easy’ or ‘fairly easy’ to obtain. These include the Czech Republic, Ireland 
and the United Kingdom (58–60 %), as well as Denmark, the Isle of Man, Slovenia and 
Switzerland (51–55 %). Hence, countries with high perceived availability of cannabis 
are spread throughout Europe. However, more of them are found in the north-west, 
including all the countries of the British Isles.
A high perceived availability is also found in the two non-ESPAD countries from which 
some data are available in the ESPAD report. In Spain 67 % of the students reported that 
marijuana or hashish was ‘very easy’ or ‘fairly easy’ to get, and in the USA the figure 
was even slightly higher (74 %). Turkey (six cities) showed particularly low perceived 
availability (at 7 %), and other countries reporting low perceived availability were Cyprus, 
Romania and Ukraine, at 10–13 %.
Supply channels: mainly available in discos and bars
ESPAD students were asked where they thought that they could easily buy marijuana or 
hashish if they wanted it. The proportion of students reporting places of purchase varies 
considerably between countries. In some countries many students do not know where 
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to buy cannabis. The highest figures in this respect are found in Turkey (six cities) and 
Ukraine (80–83 %), followed by Romania and Russia (69–73 %). ‘Disco, bar, etc.’ is 
the option selected by most students. The ESPAD average was 27 % in 2003, followed 
by ‘street, park, etc.’ (23 %) and ‘home of a dealer’ (21 %). In 20 countries the option 
‘discos, bar, etc.’ was recognised as the easiest place to buy cannabis. ‘Streets and 
parks’ was the most popular option in seven countries and ‘home of a dealer’ in six.
When looking at individual countries, the highest figure for ‘discos and bars’ was 
found in the Czech Republic, where 55 % gave this answer. Other countries with high 
figures (40–46 %) include Belgium, Denmark, Germany (six Bundesländer), Austria and 
Slovakia. ‘Streets and parks’ was reported mainly from Italy (45 %), followed by Belgium, 
Ireland, Norway, Slovenia and Switzerland (35–38 %). The highest figures for ‘home 
of a dealer’ were found in France, Italy and the United Kingdom (39–43 %). However, 
the highest single figure is found in the Netherlands, where 60 % of the students 
answered ‘coffee shops’ (17). This category was included only in the Dutch and Belgian 
questionnaires. In Belgium it was mentioned by a far smaller number of students than in 
the Netherlands (29 %).
The availability of drugs in schools is a sensitive issue (18). However, on average, 
‘schools’ was the least reported option for purchasing cannabis. Nonetheless, 16 % 
of ESPAD students reported availability at school. The variation between the countries 
with the smallest and highest figure is large. Among Italian students, as many as 43 % 
reported that cannabis products could easily be bought in schools. Other countries with 
high figures include Belgium, the Czech Republic, France and Ireland, where 30–36 % 
gave this answer. Countries in which only 3 % of the students reported that cannabis was 
easily available in schools include the Faroe Islands, Greenland, Turkey (six cities) and 
the Ukraine. Responses about places where marijuana and hashish can easily be bought 
are similar for both boys and girls. The most striking gender difference in the ESPAD 
averages is that more girls (30 %) than boys (24 %) answered that they can buy cannabis 
products at a disco or a bar. Among the boys there is no difference in the averages for 
the two alternatives ‘disco, bar, etc.’ (24 %) and ‘street, park, etc.’ (25 %).
 (17) ‘Coffee shop’ in this context refers to the category of shops in the Netherlands where cannabis is 
openly available to those aged 18 and above (see Korf, this monograph).
 (18) With regard to legislative approaches to cannabis possession, a number of countries include 
references to cannabis use which places minors at risk. See the ELDD map of European legislation 
on cannabis possession at: http://eldd.emcdda.europa.eu/index.cfm?nnodeid=5769
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Lifetime prevalence: the most widely used illicit drug, yet 
large differences between countries
Cannabis is the most commonly used of all the illicit drugs (19) (Figure 1). In 2003 the 
ESPAD average for lifetime cannabis prevalence was 21 %. However, the proportion of 
students who have tried cannabis varies from 3 to 44 % between countries.
 (19) Far behind cannabis comes ecstasy, which was mentioned on average by 3 % of students. The 
highest prevalence rate for any drug other than cannabis in any single country is 8 %: 8 % of 
Czech students reported use of ecstasy as well as of magic mushrooms.
Boys Girls
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Czech Republic (44)
Romania (3)
Turkey (6 cities) (4)
Cyprus (4)
Greece (6)
Sweden (7)
Norway (9)
Faroe Islands (9)
Malta (10)
Finland (11)
Lithuania (13)
Iceland (13)
Portugal (15)
Latvia (16)
Hungary (16)
Poland (18)
Ukraine (21)
Bulgaria (21)
Austria (21)
Russia (Moscow) (22)
Croatia (22)
Estonia (23)
Denmark (23)
Slovakia (27)
Italy (27)
Greenland (27)
Germany (6 Bundesl.) (27 )
Netherlands (28)
Slovenia (28)
Belgium (32)
USA (36)
Spain (36)
United Kingdom (38)
France (38)
Isle of Man (39)
Ireland (39)
Switzerland (40)
50403020100
Figure 1: Lifetime experience of marijuana or hashish. Percentages among boys and girls, 
2003
Note: Values within brackets refer to all students. Germany and Turkey — limited geographical coverage. 
Spain and USA — limited comparability.
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Students in the Czech Republic reported the highest cannabis use, at 44 %, yet high 
prevalence rates were also reported from Switzerland (40 %), Ireland and the Isle of Man 
(39 % each), France and the United Kingdom (38 % each). Other countries where more 
than a quarter of students have used cannabis include Belgium (32 %), the Netherlands 
and Slovenia (28 % each), Germany (six Bundesländer), Greenland, Italy and Slovakia 
(27 % each). The lowest levels of cannabis use are reported from Romania (3 %), Cyprus, 
Turkey (six cities) (4 % each), Greece (6 %) and Sweden (7 %). Low prevalence rates are 
also found in the Faroe Islands, Norway (9 % each) and Finland (10 %). Data from the 
non-ESPAD countries Spain and the USA reveal that 36 % of students in both countries 
had ever used cannabis (Figure 2).
0–7%
8–14%
15–25%
26–35%
36–45%
Data uncertain
or not available
Non-participating
country
Figure 2: Lifetime experience of marijuana or hashish. Percentages among all students, 
2003
Note: Germany and Turkey — limited geographical coverage. Spain and USA — limited comparability.
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Recent use of cannabis (last year and last month 
prevalence) — between 2 and 36 %
In adult populations regular drug use can be measured in different ways. One of these 
is last month prevalence (drug use in the last 30 days). In many cases this indicates not 
only recent use but also more regular consumption. However, for a 15- or 16-year-old 
student, last month prevalence may very well be identical with first use. A better way of 
defining regular use is to ask young people to declare frequency information for last 
year (use in the last 12 months) and last month prevalence. For example, to measure 
whether a student has used cannabis ‘10 times or more during the last 12 months’ and 
‘three times or more during the last 30 days’ (20).
In the current absence of explicit frequency-of-use data, one way to build a picture of 
recent use is to compare the figures for last year prevalence with those for last month 
prevalence.
As mentioned earlier, an average of 21 % of ESPAD students reported ever-in-lifetime 
use of cannabis. By comparison, 16 % of ESPAD students reported last year prevalence 
and 9 % last month prevalence. For other drugs, the highest figure for any other drug 
was 2 % for the last year prevalence for ecstasy and 1 % for last month prevalence of 
amphetamines, ecstasy and magic mushrooms. Thus, there is a broad overlap between 
average ever-in-lifetime use (21 %) and last year prevalence (16 %).
The Czech Republic reported the highest last year prevalence (36 %), while other high-
prevalence countries include the Isle of Man (34 %), France, Ireland, Switzerland and 
the United Kingdom (31 % each). Countries where very few students have used cannabis 
during the last 12 months are to a large extent the same that reported low lifetime 
prevalence rates. Thus, the smallest number of students reporting this behaviour are 
found in Romania (2 %), Cyprus, Turkey (six cities) (3 % each), the Faroe Islands (4 %), 
Greece and Sweden (5 % each). In the non-ESPAD country, Spain, 32 % of the students 
had used cannabis during the last 12 months. The corresponding value for the USA is 
28 %.
Not unexpectedly, the high- and low-prevalence countries with regard to last month 
prevalence are about the same as for last year prevalence. Countries with the highest 
last month prevalence include France (22 %), the Isle of Man (21 %), Switzerland, the 
United Kingdom (20 % each) and the Czech Republic (19 %). Other countries with 
relatively high rates are Belgium, Ireland (17 % each) and Italy (15 %). In some countries, 
however, very few report last month prevalence. The six countries with the lowest figures 
 (20) This information is available in the ESPAD national datasets, but at the time of writing it was not 
available for comparative analysis.
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are the Faroe Islands, Romania, Sweden (1 % each), Cyprus, Greece and Turkey (six 
cities) (2 % each). In Spain and the USA last month prevalence rates are 23 % and 17 % 
respectively.
Gender differences?
There is a clear gender gap in cannabis prevalence (21), with boys generally more likely 
to have tried cannabis, or to have recently used cannabis, than girls.
For lifetime prevalence, with one exception (Ireland), in no country are there more girls 
than boys who have tried cannabis. Boys are in the majority in about two-thirds of the 
ESPAD countries (see Figure 1). However, in some countries there are no strong gender 
differences. Few differences in gender can be seen in the British Isles and among the 
Nordic countries, including the Faroe Islands, Finland, Greenland, Iceland, Ireland, 
the Isle of Man, Norway and Sweden. Greece is also an exceptional southern country, 
reporting near-equal lifetime prevalence for girls and boys. In the Czech Republic, 
Denmark, Estonia, Ireland, Latvia, Poland, Slovakia and Norway the gender gap has 
narrowed in successive surveys. It may also be noted that countries with near-equal 
prevalence between genders relate to both high- and low-prevalence countries.
More boys (19 %) than girls (14 %) on average report last year use of cannabis. 
This pattern applies to the majority of reporting countries, and applies to both 
high-prevalence countries (e.g. Czech Republic, France, the United Kingdom) and 
low-prevalence countries (e.g. Cyprus and Turkey). The largest gender gap in last year 
prevalence is found in the Ukraine, with 18 % for boys and 6 % for girls. Large gender 
divides in last year prevalence are also reported by Belgium (32 % boys, 22 % girls) and 
Slovakia (24 % boys, 14 % girls).
For last month prevalence, on average 11 % of boys and 7 % of girls reported cannabis 
use in the last 30 days. The pattern is reflected in nearly half of the countries. There is 
no real geographical pattern in the gender distribution.
The typical debut drug
Cannabis is the illegal substance most commonly reported as a debut drug among both 
boys and girls. On average, 18 % of all ESPAD students report that cannabis was the 
first illegal substance they have tried, corresponding to about 80 % of all students who 
 (21) Gender issues in drug use were explored in the EMCDDA selected issue, A gender perspective 
on drug use and responding to drug problems (EMCDDA, 2006), available at: http://issues06.
emcdda.europa.eu/en/page013-en.html
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have tried any illicit drug. Cannabis is the leading debut illegal drug in all but three 
ESPAD countries. Second to cannabis, but with much lower figures, are tranquillisers or 
sedatives, reported by 2 % of all students, about 9 % of students who report having tried 
any illicit drug.
Early onset
If one excludes inhalants, which are not defined as an illicit drug, cannabis is the most 
common drug that is used at an early age. Of all ESPAD students, 4 % report that they 
were 13 years or younger when they tried cannabis for the first time (‘early onset’) (22). 
The figures for early onset vary between countries, from 0 % in Romania to 13 % in the 
United Kingdom. Examples of other countries with high early onset figures include the 
Isle of Man (12 %) and Switzerland (11 %). These figures are similar to those reported in 
the USA (10 %). Very small gender differences appear when it comes to early onset. In 
the very few cases where a gender gap exists, figures are slightly higher for boys. The 
largest gender difference is found in Belgium, where 10 % of boys and 5 % of girls report 
trying cannabis at age 13 or younger.
Increased use in many countries
Between the first ESPAD data collection in 1995 and the second in 1999, a majority 
of countries reported an increase in lifetime cannabis prevalence. Many countries also 
showed continuing increases between 1999 and 2003.
Of the ESPAD countries that participated in 1995, 21 provided comparable data 
from the second data collection. Two-thirds of these countries reported higher lifetime 
cannabis prevalence in 1999. These countries were spread geographically across 
Europe and include countries with high lifetime prevalence (e.g. the Czech Republic, 
with 35 % in 1999) and low lifetime prevalence (e.g. Finland, with 10 %, and Hungary, 
with 11 % in 1999). Three countries reported a decline in lifetime cannabis prevalence 
between 1999 and 1995. Two of these were the top countries in both 1995 and 1999: 
the United Kingdom (35 % in 1999) and Ireland (32 % in 1999). The third country was a 
low prevalence country: the Faroe Islands (7 % in 1999).
Six countries reported minor decreases in lifetime prevalence between 1999 and 2003: 
Denmark (23 % = –1 %), Greece (6 % = –3 %), Sweden (7 % = –1 %), Norway (9 % = –3 %), 
Iceland (13 % = –2 %) and Latvia (16 % = –1 %) (Figure 3). In a majority of the countries 
that participated in both surveys (18 out of 28) the figures were about the same in the 
two data collections. However, lifetime prevalence increased in absolute percentage 
 (22) For further discussion of early initiation into cannabis use in Europe, see Kokkevi et al. (2006).
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points by over 4 % in 10 countries: Czech Republic (44 % = +9 %), Ireland (39 % = +7 %), 
France (38 % = +4%), Slovakia (27 % = +8 %), Estonia (23 % = +10 %), Croatia 
(22 % = +8 %), Bulgaria (21 % = +9%), Poland (18 % = +4 %), Portugal (15 % = +6 %), 
Hungary (16 % = + 16 %).
Of the 21 countries that have comparable data from all three data collections, six show 
an increased trend through all three data collections. These are Croatia, Czech Republic, 
Estonia, Hungary, Poland and Slovakia: all Eastern European countries. In 1995 some 
of these countries were among those with lowest prevalence (e.g. Hungary with 4 % 
and Estonia with 7 %). In 2003 one of these was at the top of all participating countries 
(Czech Republic with 44 %), three others are in the upper half and two are around the 
middle (Hungary with 16 % and Poland with 18 %) (23). The number of countries which 
showed an increase in prevalence between 1999 and 2003 are about the same both for 
last year prevalence (nine countries) and for lifetime prevalence (10 countries). However, 
relatively few countries reported an increase in last month prevalence (three countries). 
In nearly all countries the trends over time have been about the same among boys and 
girls.
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Figure 3: Changes between 1999 and 2003 in lifetime prevalence of marijuana or 
hashish
Note: Countries above the line have increased prevalence rates, and countries below have decreased. All 
students.
 (23) For a more detailed analysis of cannabis in these countries, see Moskalewicz et al., this 
monograph.
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Increased perceived availability in many countries
Perceived availability of cannabis (24) increased strongly compared with other substances 
from 1999 to 2003, from an average of 29–35 %. Changes in perceived availability 
are also very similar for boys and girls. The number of countries in which perceived 
availability increased for other drugs is much smaller, and averages were about the 
same in 2003 as in 1999.
Increases in cannabis perceived availability were reported in nearly half of the countries 
with available information (13 out of 28). These countries were broadly concentrated in 
the eastern parts of Europe (10 out of these 13 countries). Increases were reported in 
countries with low as well as high perceived availability; for example, Romania (11 %) 
and the Czech Republic (58 %). Only three countries — Denmark (52 %), Greece (20 %) 
and Norway (26 %) — reported lower perceived availability of cannabis in 2003 than in 
1999.
In seven countries perceived availability of cannabis increased in all three data 
collections from 1995 to 2003 (Croatia, the Czech Republic, Estonia, Lithuania, Poland, 
Slovakia and Slovenia). All are Eastern European countries, and five of them are among 
the six countries in which the lifetime prevalence increased in 1995, 1999 and 2003 
(Croatia, the Czech Republic, Estonia, Poland, Slovakia).
Consumption and perceived availability — strongly 
correlated
ESPAD uses, to some extent, the same questions that are used in the Monitoring the 
Future (25) studies in the USA, where they have a long series for grade 12 students 
(17–18 years old), dating back to the 1970s (Johnston et al., 2005). In the USA, it is 
evident that there have been changes in cannabis use over time. However, during the 
whole period the perceived availability seems to have remained relatively stable among 
12th graders.
Information about students in grade 10 (15–16 years old), i.e. students of about the 
same age as the ESPAD target group, is available in the US studies only from 1991. The 
use of marijuana increased in this group between 1991 and 1997, then levelled off, 
before decreasing from 2001 onwards. For the whole period the availability trend has 
followed the use trend very closely.
 (24) Defined as the share of students reporting that marijuana or hashish were ‘very easy’ or ‘fairly 
easy’ to obtain.
 (25) The website of the Monitoring the Future Study is www.monitoringthefuture.org/
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As mentioned in the previous section, in five out of the six ESPAD countries in which 
the lifetime prevalence for cannabis increased consistently in 1995, 1999 and 2003, 
perceived availability also increased. This indicates that there is a strong relationship 
in the ESPAD countries between changes in the level of consumption in a country and 
changes in the perceived availability of cannabis. This relationship is found in 2003 
when one compares the proportion of students in different ESPAD countries who have 
ever used cannabis and the proportion of all students who perceive marijuana and 
hashish ‘very easy’ or ‘fairly easy’ to obtain (Figure 4). It is obvious that there is a strong 
positive relationship between lifetime prevalence of cannabis and perceived availability 
(rxy = 0.85, rrank = 0.85).
These results indicate that use of cannabis and perceived availability are highly 
correlated among 15- to 16-year-old students in Europe, as well as in the USA. 
However, this is not the case among 17- to 18-year-old American students. Possible 
explanations for this could include age (12th graders are about two years older than 
the ESPAD target group), degree of availability (in 2003, 87 % among the 12th graders, 
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Figure 4: Correlation between lifetime use of cannabis (Canlife) and the proportion 
of students answering that cannabis is very/fairly easy to obtain (Verfaireas) 
(rxy = 0.85, rrank = 0.85)
Source: ESPAD data from 2003.
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74 % among 10th graders, compared with 35 % on average among the ESPAD students, 
with a range from 7 to 60 %); the degree of stability of perceived availability (this has 
changed among the 15- to 16-year-old students, while it has been stable among 
American 12th graders). A conclusion from this is that changes in the availability of 
cannabis are linked to changes in consumption among 15- to 16-year-old students, 
even though any direct causal link needs to take into account other psychosocial factors.
Consumption and risk perception — strongly correlated
The Monitoring the Future study in the USA has found a strong relationship between 
changes in the perceived risk of cannabis use and changes in consumption levels. This 
has been interpreted as reflecting a causal connection (Johnston et al., 2005). With 
only three data collections within ESPAD, a similar analysis of the possible influences 
of changes over time is difficult. However, a comparison between the countries in the 
2003 data collection shows a very strong relationship between the risk perception of 
cannabis and consumption level. The correlation at the country level between the lifetime 
prevalence rates of cannabis use and the proportion of students who indicated that 
there is a ‘great risk’ related to using it once or twice was strongly negative (rxy = –0.76, 
rrank = –0.79). This indicates that at the country level there is a strong negative 
relationship between risk perception and consumption levels, i.e. the lower the risk 
perception, the higher the consumption levels.
Correlates of adolescent cannabis use
The research literature offers numerous studies of psychosocial factors that correlate with 
adolescent cannabis use (26). However, findings are mixed or inconsistent, and focus on 
a single country or restricted group of countries, with different methodological aspects 
influencing the results. Moreover, such statistical associations are far from deterministic: 
there is hardly any correlate of adolescent substance use that has not been found to be 
non-significant in some study.
As ESPAD data collections in the different countries are carried out in a standardised 
way, the ESPAD project includes data that may be more suitable for cross-cultural 
comparison. One of the chapters in the latest ESPAD report includes correlates at the 
individual level from nearly all ESPAD countries (Hibell et al., 2004: 194–199). The 
summary below provides an overview of correlates for cannabis. Some caveats are 
 (26) A review of psychosocial correlates with ESPAD data from Bulgaria, Croatia, Greece, Romania, 
Slovenia and United Kingdom was recently carried out (Kokkevi et al., 2007). Another recent 
study analysed correlates of adolescent cannabis use and consumer expenditure (PCE), 
unemployment and peer factors in 31 countries (ter Bogt et al., 2006).
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required, however. ESPAD is based on a clustered not random sample (samples of 
classes, with classes as the sampling unit), which complicates statistical calculations. 
Yet, for pragmatic reasons standard t-tests have been used in this section, based on the 
understanding that these tests of statistical significance are likely to overestimate any 
correlates: the results must be interpreted as offering useful general guidelines only.
The lifetime use of cannabis was correlated with parents’ education (27) (father’s and 
mother’s education separately), family structure (single parents and one parent together 
with a step-parent) (28), economic situation (how well-off the students thought their family 
is compared with other families), perceived parental control (the students’ opinions 
concerning the extent to which their parents know where they spend Saturday nights), 
truancy (the number of days of school skipped during the last 30 days) and siblings’ use 
of cannabis (Table 1).
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Chapter 4
Cannabis in the context of 
polydrug use: results from the 
Dutch National School Survey
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Setting the context
Polydrug consumption, the consumption of more than one drug, is one of the great 
confounders of our knowledge of drug use. A vast array of psychoactive substances, 
both legal and illegal, are consumed in Europe today: alcohol, tobacco, prescription 
drugs, ecstasy, inhalants, cocaine, amphetamines, heroin, hallucinogens, not to mention 
the long list of synthetic substances monitored by the EMCDDA’s early warning system 
(GBL, TMA, 4-MTA, MDBD, etc.). This wide range of substances means that, in practice, 
drug use can come in many forms.
Despite the puzzle it represents, examination of polydrug consumption is rewarding, 
providing valuable insights into the context of drug use and complementary risk patterns. 
People who consume psychoactive substances commonly do not restrict themselves 
to a single drug (i.e. cocaine or heroin alone). Nonetheless, there are pairings and 
combinations that often go hand in hand. This is particularly the case with cannabis, 
which is very often combined with tobacco, and is commonly consumed together with 
alcohol, and, less commonly, other illicit substances. In terms of drug use among 
young people, studies looking at contexts such as schools, youth detention centres and 
recreational nightlife settings have sharpened our insight into polydrug use.
This chapter outlines two of the key concepts in defining polydrug use: ‘concurrent use’, 
i.e. use of multiple substances within a defined time period, and ‘simultaneous use’, i.e. 
use of multiple substances on the same occasion. It also looks at means of ‘clustering’, a 
technique that helps us to identify common pairings or clusters of drugs used in a given 
population, and to build a typology of different groups of drug users. Such typologies 
are useful in enabling practitioners, teachers and parents to identify ‘at-risk’ groups.
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School surveys provide a useful opportunity for examining drug use across the 
population. This chapter looks in particular at school students aged 12–16 years in the 
Netherlands. This age group encompasses younger students than in the most exhaustive 
European school survey, ESPAD, which surveys students aged 15–16 years (see Hibell, 
this monograph). Using a younger sample for drugs surveys is interesting. Teenagers 
are at a stage in life when many will encounter drugs for the first time, with some of 
them beginning to drink alcohol or smoke in their early teens. And, as with many other 
aspects of life, experiences at school, even if they do not determine or accurately predict 
later behaviour, strongly influence drug-using behaviour in adult life.
So, while this chapter provides a national case study of polydrug consumption within a 
restricted sample, its insights will have wider relevance. They are particularly valuable 
for those attempting to decipher the many complexities of polydrug use, with a view to 
informing intervention.
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polydrug use: results from the 
Dutch National School Survey
Karin Monshouwer, Filip Smit and Jacqueline 
Verdurmen
Summary
A survey was conducted to describe the position of cannabis in the wider context of 
polydrug use among secondary school juniors (aged 12–16 years) in the Netherlands. 
Data were derived from the 1999 sample of the Dutch National School Survey 
on Substance Use. Studied substances were alcohol, tobacco, cannabis, ecstasy, 
amphetamines, opiates and cocaine. Among the total student population, 56.7 % use 
one or more substances, of whom 41.8 % are polydrug users in that they used more 
than one substance during the previous four weeks. Projected to a Dutch student 
population of 1 million, 237 000 are polydrug users, of whom 142 000 use only alcohol 
and tobacco, 65 000 combine alcohol or tobacco with cannabis, and 20 000 combine 
alcohol, tobacco or cannabis with at least one hard drug such as ecstasy, cocaine, 
amphetamines or heroin. The risk of polydrug use increases with age. Prevalence rates 
were highest among ethnic Dutch students, very low among Moroccan students and 
high at the lower educational levels. By comparison with girls, boys had a specific risk of 
becoming the type of polydrug user using soft or hard drugs. The position of cannabis 
use in the context of polydrug use is an ambiguous one. On the one hand, cannabis use 
is more strongly associated with drinking and smoking than with the use of hard drugs. 
On the other hand, among cannabis users, higher prevalence rates of hard drug use 
can be observed than is the case among drinkers and smokers.
Introduction
Although it has been well established that cannabis and other substance use often 
co-occur, relatively few studies have focused on polydrug use and its relation to 
cannabis use. In the Netherlands, for example, reliable epidemiological figures about 
polydrug use are rare (NDM, 2001).
Yet polydrug use is important: using combinations of drugs can have often unpredictable 
risks through additive and synergetic effects (Earlywine and Newcomb, 1997; Leccese 
et al., 2000). Studies have shown that the combined use of substances increases the 
likelihood of both physical and psychological damage (Feigelman et al., 1998). For 
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example, Stronski et al. (2000) found that cannabis users who were also using other 
illicit drugs were at higher risk for risk-related behaviour (for example, antisocial 
behaviour and accidents) than those who were not using other drugs in addition to 
cannabis. Furthermore, in 2003 in the Netherlands, 40 % of the newly registered 
individuals in addiction care had a problem with more than one addictive substance 
other than tobacco use (IVV, 2001). Of all clients reporting a cannabis use disorder 
as their primary problem, 38 % also had a secondary substance use problem, most 
commonly alcohol (reported at 18 % of all primary cannabis clients).
However, the number of people in treatment does not provide a strong picture of 
polydrug use in the general population. With regard to polydrug use, secondary school 
students form a group that warrants special interest. Most substance use is initiated 
in adolescence and students can easily be targeted with preventive interventions. In 
addition, this group can be regarded as a new generation, in which the contours of 
what lies ahead, in an epidemiological sense, start to appear. After all, polydrug use 
during the teenage years is a significant predictor of polydrug use in adult life (Galaif 
and Newcomb, 1999; Jessor, 1987).
For these reasons, in our study, we sought answers to the following:
What polydrug use patterns can be discerned among secondary school students, •	
and where does cannabis fit in?
What types of user groups can be defined among students, and how many students •	
can be found in each of these user groups?
What are the corresponding social and demographic risk profiles?•	
This chapter is based on the work of Smit et al. (2002a), which appeared in Drugs, 
Education, Prevention and Policy (DEPP). The editorial board of DEPP kindly gave 
permission to make use of the original work.
Method
Sample, data collection and response
Data were used from the fifth wave of the National School Survey on Substance Use, 
conducted in 1999 (De Zwart et al., 2000). The school survey methodology has been 
fully described elsewhere (Smit et al., 2002b). In short, a questionnaire was administered 
in classes, which included questions on substance use during the previous four weeks. 
The non-response rate was low: on average, 4.8 % of students in each class were not 
reached due to illness, truancy or other reasons, and only 0.07 % of the students refused 
participation. Analysis was limited to secondary school students between the age of 12 
and 16 years, an age at which school attendance is compulsory (n = 6 236). In this way, 
Chapter 4
83
insight was gained into a broad group of students attending all different school types 
and we avoid overrepresentation of students older than 16, who mostly attend school 
types of a higher, pre-university level.
Polydrug use
In the literature, two forms of polydrug use are distinguished: concurrent and 
simultaneous polydrug use. Concurrent polydrug use is the use of at least two 
substances in the same time period, for instance the previous four weeks. A specific 
form of concurrent polydrug use is simultaneous polydrug use, in which a user combines 
two or more substances on the same occasion (see Earlywine and Newcomb, 1997; 
Collins et al., 1998). In this study, polydrug use was operationalised as the use of 
two or more substances by one person in the four weeks preceding the study, i.e. 
‘concurrent polydrug use’. According to this definition, polydrug users can also be 
people who use several substances on the same occasion and who therefore may be 
called ‘simultaneous polydrug users’. In this study we included the following substances: 
alcohol, tobacco, cannabis, ecstasy, amphetamines, heroin and cocaine.
Demographics
The following demographic characteristics were included: gender, age, level of 
urbanisation, school type (first class secondary school, lower vocational, lower general, 
higher general and pre-university education) and ethnicity. The five levels of urbanisation 
used by the central bureau of statistics in the Netherlands (Statistics Netherlands) were 
collapsed into two categories: the index category ‘very urbanised’, i.e. more than 
2 500 addresses per km2, and a reference category, ‘all other urbanisation levels’. This 
division was made because in a number of studies (e.g. Monshouwer et al., 2003) we 
concluded that ‘very urbanised’ living environments are significantly associated with 
substance use, and the same association has also been found by others (Abraham et al., 
1999). Ethnicity was divided into six categories: Dutch (reference category), Caribbean, 
Surinamese, Moroccan, Turkish and others. Following the rules of Statistics Netherlands, 
a person was regarded, for example, as Surinamese if he or she was born in Surinam, 
or if at least one of the parents was born in Surinam. With the aid of these demographic 
variables, the recognition of the group with an increased risk of polydrug use can be 
enhanced. This information can be useful for targeting preventative interventions.
Analysis
In order to assess the representativeness of the sample, we compared the multivariate 
distribution over the variables of school type, school year and level of urbanisation in the 
sample with the corresponding distribution in the Dutch student population, as described 
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by Statistics Netherlands. The small differences between sample and population were 
corrected by weighting, after which the distribution in the sample was exactly the same 
as in the population.
It is of note that we obtained a cluster sample, as all students from the same class 
were drawn as a single group. This method is not without consequences. Students 
from the same class share several characteristics, such as having the same teacher, or 
being exposed to the same educational system. This results in dependence between the 
observations and this, in turn, can influence the standard errors, confidence intervals 
and P-values. Therefore, robust variance-related statistics were obtained, using the first-
order Tailor-series linearisation method.
A number of substance use variables suffered from non-response to items. The item 
non-response rate was highest for alcohol, at 6.1 %, followed by cannabis, at 2.2 %. 
For the remaining substances, item non-response was less than 1 %. The missing values 
were imputed with the help of a regression model, using the demographic variables 
as predictors. Under the regression model, the most likely values were calculated 
and used to replace the missing values. Tables 1, 2 and 3 include only percentages. 
In Table 4 odds ratios (ORs) are presented, obtained by multiple logistic regression 
analysis. The interdependence between the use of the various substances was studied 
with ‘homogeneity analysis through alternating least squares’ (HOMALS; cf. Van de 
Geer, 1993; Van der Heijden et al., 1999). HOMALS is a multivariate scaling technique, 
similar to factor analysis, but applicable to nominal variables. HOMALS can be used for 
finding homogeneous clusters of substance users who resemble each other (see Figure 
1). In this chapter only, the statistics after imputation, weighing and correction for cluster 
effects are presented.
For the HOMALS analysis SPSS version 8.0 was used (SPSS Inc., 1988). For all other 
analyses, Stata version 6.0 was used (StataCorp, 1997).
Results
Demographic characteristics
Of the total student population, 76.2 % were Dutch, 1.3 % Caribbean, 4.7 % Surinamese, 
4.1 % Moroccan, 2.8 % Turkish and the remaining 10.9 % were of another, mainly 
European or Asian, origin. The average age was 14 years (range 12–16 years). Of the 
students, 30.3 % attended the first year of secondary school, 25.3 % lower vocational, 
19.6 % lower general, 12.8 % higher general and 12.1 % pre-university education. A 
minority (15.1 %) of the students lived in densely urbanised areas.
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Prevalence of substance use
Table 1 shows the four-week prevalence rates of use of the different substances, by 
gender. The prevalence rates were highest for the use of alcohol and tobacco, followed 
immediately by the use of cannabis. The prevalence rates of the use of hard drugs were 
relatively low. Cocaine ranked at a similar level to ecstasy and amphetamines. Heroin 
occupied the last place.
Table 2 shows the top 10 of the most frequently occurring patterns of use, divided 
according to non-use, mono- and polydrug use. Of the 12- to 16-year-olds, 43.3 % 
had used no substance during the previous four weeks, 28.2 % had used only alcohol 
and 14.7 % had combined alcohol with tobacco. In fourth position was the combination 
Table 1: Four-week prevalences (%) of the separate substances by gender
Substances Girls Boys Total
Alcohol 45.8 54.1 49.8
Tobacco 26.6 25.2 25.9
Cannabis 5.9 10.0 7.9
Ecstasy 0.6 1.8 1.2
Cocaine 0.4 1.7 1.1
Amphetamines 0.6 1.2 0.9
Heroin 0.2 0.4 0.3
Table 2: Top 10 of four-week prevalences (%) of no use, mono- and polyuse 
by gender
Substances Girls Boys Total
Nothing 48.0 41.5 43.3
Only alcohol 24.8 31.2 28.2
Alcohol, tobacco 15.3 12.9 14.7
Alcohol, tobacco, cannabis 4.0 6.0 5.4
Only tobacco 5.9 3.4 4.8
Alcohol, cannabis 0.5 1.4 1.0
Tobacco, cannabis 0.2 0.6 0.5
Alcohol, tobacco, cannabis, other 0.3 0.5 0.4
Alcohol, tobacco, cannabis, cocaine 0.1 0.3 0.2
Alcohol, tobacco, cannabis, amphetamine 0.2 0.2 0.2
Total 99.2 97.7 98.5
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of alcohol, tobacco and cannabis, with a prevalence of 5.4 %, followed by the group 
of students using only tobacco (4.8 %). All other patterns of substance use showed 
prevalence rates of 1 % or less. We counted 46 patterns of use, but the top 10 
accounted for 98 % of the students and, consequently, gives an accurate picture. Of the 
students who had used at least one substance during the previous month (56.7 % of 
students), 41.8 % were polydrug users.
Pairwise associations between substances
Table 3 shows how the use of one substance increased the likelihood of the use of 
another substance. For instance, the use of any other substance was about double 
for alcohol users compared with the general population. Among tobacco users, the 
likelihood of cannabis use was three times higher than among the general population. 
To use another example, cocaine use had a low prevalence among the general 
population. However, among cannabis users, the prevalence of cocaine use was almost 
10 times higher, and among ecstasy users the prevalence was 43 times higher. Heroin 
use appeared to coincide mainly with the use of amphetamines and cocaine.
Clusters
Table 3 shows the associations between pairs of substances. However, we also wanted 
to know whether clusters of three or more substances could be found. These clusters are 
depicted in Figure 1.
A homogeneity analysis (HOMALS) solution of substance use results in a graph in 
which the distances between the substances illustrates how drug use clusters. The line in 
Figure 1 runs from non-use, via alcohol, tobacco and cannabis use to ecstasy, cocaine 
and amphetamines use, and finally reaches heroin. It shows that non-use and the use 
of alcohol and tobacco are located close together. This mutual proximity points to a 
relationship which may be interpreted as the level of social acceptance of non-use 
and the use of alcohol and tobacco. The associations between alcohol, tobacco and 
cannabis use can then be regarded as a second cluster. Noticeably, a third cluster, in 
which ecstasy, cocaine and amphetamines were found close together, was located at 
some distance from the first two clusters. These ‘harder’ substances appear to be mainly 
used in recreational settings, and are, therefore, otherwise known as ‘party drugs’. 
Heroin was located the furthest from the ‘normal’ use of alcohol and tobacco.
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Typology of polydrug users
The previous analyses showed, in different ways, that a number of clusters of substances 
can be found. Closer inspection of Table 3 reveals a hierarchy which resembles Russian 
dolls, each enclosing the other: a heroin user almost certainly uses one or more of 
the party drugs, while a user of party drugs is more than likely to use alcohol, tobacco 
and cannabis. Taking these patterns into account, we tried to construe a hierarchical 
typology of polydrug users. In so doing, we strove to place in a concise typology as 
many polydrug users as possible. We came up with three types of polydrug users:
Type A: students who combined only alcohol and tobacco and used no other •	
substances. We called this type the ‘ordinary’ polydrug users.
Type B: students who used cannabis in addition to alcohol or tobacco, but did not •	
use hard drugs. We called this type ‘soft’ polydrug users. It should be mentioned 
here that, under Dutch law, cannabis is recognised as a ‘soft drug’ as opposed to 
a ‘hard drug’ such as ecstasy, amphetamines, cocaine or heroin, hence, our use of 
the phrase ‘soft polydrug user’.
Type C: students who used one or more hard drugs (ecstasy, cocaine, •	
amphetamines, heroin) in addition to alcohol, tobacco or cannabis. We called this 
type of user a ‘hard’ polydrug user.
Type A represented 59.9 % of polydrug users, type B 27.4 % and type C 8.6 %. In all, 
95.9 % of polydrug users were described by this typology. The remaining 4.1 % must be 
classified as ‘atypical’, since they used two or more hard drugs, without combining them 
with alcohol, tobacco or cannabis. Extrapolating our findings to 1 million students in the 
Nothing
alc
tob
can
xtc
coc
amph
her
Figure 1: Clusters of three or more substances
Note: Alc, alcohol; amph, amphetamines; can, cannabis; coc, cocaine; her, heroin; tob, tobacco; 
xtc, ecstasy.
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All pupils
n = 1 000 000
Users
n = 567 000
(56.7%)
Non-users
n = 433 000
(43.3%)
Mono
n = 333 000
(58.2%)
Poly
n = 237 000
(41.8%)
Ordinary
n = 142 000
(59.9%)
Soft
n = 65 000
(27.4%)
Hard
n = 20 000
(8.6%)
Rest
n = 10 000
(4.1%)
Figure 2: Classification of adolescent drug use and prevalence rates (per 1 million)
population, we would expect to find 142 000 ‘ordinary’, 65 000 ‘soft’ polydrug users, 
20 000 ‘hard’ polydrug users and 10 000 ‘atypical polydrug users’ (Figure 2).
Risk profiles per type
Table 4 shows the associations between the demographic characteristics and the three 
types of polydrug users. The group that did not use any of the substances during the 
four weeks before the study was used as the reference group. A measure for association 
is the odds ratio (OR). An OR < 1 implies that the presence of a demographic 
characteristic is associated with a lower risk being the type of polydrug user concerned. 
A demographic characteristic with an OR > 1 implies a higher risk. All ORs were 
corrected for the influence of the other variables in Table 4.
Age was related to every group type. As the age of the student increased, the risk 
of belonging to one of the three types of polydrug users also increased. The risk of 
becoming an ‘ordinary’ polydrug user increased by a factor of 2.17 for every additional 
year. For ‘soft’ and ‘hard’ polydrug use, these factors are 3.09 and 2.58, respectively. 
Age, therefore, was a general and not a specific risk factor.
There was no statistically significant difference between boys and girls in the risk of 
becoming an ‘ordinary’ polydrug user. However, boys had a greater risk of becoming 
a type B or type C. As gender was a differentiating factor, it could be regarded as a 
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Table 4: Demographic risk profile of polydrug users compared with abstainers
Type A (alcohol and 
tobacco only)
Type B (alcohol 
or tobacco and 
cannabis)
Type C (soft drug 
and hard drug)
Risk factor ORa Significance OR Significance OR Significance
Age (years) 2.17 *** 3.09 *** 2.58 ***
Gender (ref = girls) 0.96 1.80 ** 2.51 **
Urbanisationb 0.62 * 0.69 0.63
School type (reference = lower vocational education)
First-class secondary 
school
0.61 * 0.76 0.44 *
Lower general 0.91 1.29 0.53
Higher general 0.73 0.69 0.50 *
Pre-university 0.47 ** 0.42 * 0.20 *
Ethnicity (reference = Dutch)
Caribbean 0.72 0.79 0.30
Surinamese 0.38 *** 0.81 0.75
Moroccan 0.03 *** 0.11 *** 0.06 **
Turkish 0.14 *** 0.20 * 0.58
Other 0.53 ** 0.84 1.40
Notes
aOR, corrected odds ratio.
bindex = very densely urbanised (versus the rest).
*P < 0.05, **P < 0.01, ***P < 0.001.
specific risk factor for ‘soft’ and ‘hard’ polydrug use. Living in a highly urbanised area 
coincided with a smaller risk of becoming an ‘ordinary’ polydrug user. Students who 
attended lower vocational education had the highest risk of polydrug use, and especially 
of ‘hard’ polydrug use. Students who attended pre-university education had the lowest 
risk of polydrug use. Students in higher general education had a significantly lower risk 
of becoming a type C. Students in the first year of secondary school had a significantly 
lower risk of belonging to types A and B.
Compared with different ethnic groups, autochthonous Dutch had a larger risk of 
belonging to any type of polydrug users. Moroccans, in particular, had a very low 
risk of becoming a polydrug user. This also applied, but to a lesser extent, to students 
of Turkish origin and, as far as the A-type was concerned, to Surinamese students 
and students from other ethnic origins. Students from the Caribbean did not differ 
significantly from the Dutch.
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Discussion
Main findings
With this study we wanted to answer three questions concerning polydrug use among 
secondary school students: Which combinations occur most frequently and where 
does cannabis fit in? What are the numbers of students per user type? What are the 
corresponding risk profiles? We are now able to answer these questions as follows.
Looking at all the students (abstainers included), almost a quarter (23.7 %) were 
polydrug users. Thus, among a student population of 1 million students in the age range 
12–16 years, approximately 237 000 would be polydrug users. Among students who 
reported using one or more substances (abstainers excluded), almost one-half (41.8 %) 
were polydrug users. We were able to classify nearly all of these polydrug users using a 
simple typology. ‘Ordinary’ polydrug use (only alcohol and tobacco), which extrapolates 
to 142 000 students per million, was by far the most common type. This was followed at 
some distance by a group of 65 000 students who might be classified as ‘soft’ polydrug 
users (alcohol or tobacco combined with cannabis). ‘Hard’ polydrug use (alcohol, 
tobacco or cannabis combined with a hard drug) is relatively rare, extrapolating to 
20 000 students.
Thus, the position of cannabis use in the context of polydrug use is an ambiguous 
one. On the one hand, cannabis use is more strongly associated with drinking and 
smoking than with the use of hard drugs. On the other hand, cannabis users show 
higher prevalence rates of hard drug use than is the case among drinkers and smokers. 
In other words, cannabis use occupies the ‘middle ground’ between alcohol/tobacco 
and ‘hard drug’ use. The risk of belonging to a ‘soft’ or ‘hard’ type of polydrug user 
increases with age, is largest for ethnically Dutch students, is very low among Moroccans 
and limited among Turkish and Surinamese students, and seemed to be concentrated 
mostly in the lower educational school types. Compared with girls, boys have a specific 
risk of becoming a ‘soft’ or ‘hard’ polydrug user; however, the risk of becoming an 
‘ordinary’ polydrug user is equal for both sexes.
Limitations of this study
Before we discuss the implications of our findings, we want to address the limitations 
of our study. Firstly, our data come from a cross-sectional study. Therefore, we cannot 
make causal inferences. However, the associations found can be helpful in identifying 
groups at risk. Secondly, the data were based on self-reports. Consequently, recall 
errors could have occurred (Engels et al., 1997). However, we expect these errors to 
play only a minor role, because the questionnaire was concerned with recent behaviour, 
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i.e. during the last four weeks. This idea finds empirical support elsewhere (O’Malley 
et al., 1983; Johnston and O’Malley, 1985). Systematic errors (bias) in self-reports are 
another concern. It is conceivable that not all students disclosed the true rates of their 
drug use and some under- or over-reporting cannot be ruled out.
Thirdly, in this study polydrug use was measured as the use of two or more substances 
in the four weeks preceding the study. It is possible that this type of polydrug use is less 
harmful and therefore of less importance than simultaneous polydrug use, when a user 
combines two or more substances on the same occasion (see Earlywine and Newcomb, 
1997; Collins et al., 1998). However, regarding these effects, the distinction between the 
forms of polydrug use is not unequivocal, because metabolites of a substance can still 
be present in the body when another substance is used several days later. Moreover, the 
study of Collins et al. (1998) showed that, among people who used several substances 
during the previous year, 76 % used these substances simultaneously.
Finally, because we have only looked into substance use during the preceding four 
weeks, it is unknown whether it concerned occasional (i.e. experimental) use or a 
longer history of substance use. In addition, this study does not provide information on 
the frequency and the amounts that were used. For example, while we have proposed 
that a ‘hard’ polydrug group of users exists, we cannot determine whether this group 
represents problematic behaviour as we have no additional information on the length 
and frequency of the use and the amounts used.
Implications for future research
Taking into account the findings and limitations of this study, we want to present the 
following considerations. First, Table 3 and Figure 1 suggest an ‘axis of use’, with 
alcohol on one side being the most commonly used substance, followed by tobacco, 
cannabis, ecstasy, cocaine and amphetamines, and ending with heroin. A Norwegian 
study (Pedersen and Skrondal, 1999) found an almost identical sequence, although they 
did not include cocaine. Similar sequences are also found in longitudinal studies (cf. 
Bailey, 1992; Kandel et al., 1992).
Since cannabis is usually smoked, it is suggested that cigarette smoking might act as a 
‘gateway’ to cannabis use (Kandel et al., 1992). However, although there seems to be 
a natural sequence in the use of the various substances, it is not clear whether there is a 
direct causal influence. For example, Lynskey et al. (1998) concluded from their results 
that correlations between tobacco, alcohol and cannabis use during adolescence are 
largely or wholly non-causal and arise because the risk factors and life pathways that 
encourage the use of one substance also encourage the use of other substances.
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Furthermore, there are also indications for a reverse influence. Amos et al. (2004) 
found that, among those who wanted to quit smoking, cannabis use reinforced cigarette 
smoking (see also Coggans, this monograph). While smoking and alcohol use often 
precede cannabis use, most drug users use cannabis first before progressing to other 
drugs. Findings from a 21-year longitudinal study of a New Zealand birth cohort 
seem to support the view that cannabis may act as a gateway, encouraging the use 
of hard drugs. However, the authors state that they cannot rule out the possibility that 
the association is non-causal and reflects uncontrolled confounding factors (Fergusson 
and Horwood, 2000). The mere existence of a sequence does not imply a causal role. 
More important is the question of how many people follow this route, and how far they 
venture on that route. Considering our data, we are inclined to conclude that, as far as 
a ‘route’ exists, it does not imply that everybody takes that route, or follows it to its full 
‘extent’.
Our cross-sectional snapshot study identifies some groups that were more inclined to 
venture a long way on this route. These were mainly ethnically Dutch boys in the lower 
secondary school types. Explaining why this is so, although an intriguing subject, lies 
beyond the scope of this study. Again, it must be emphasised that in this ‘snapshot’ 
study, the observed sequence cannot be read as a deterministic longitudinal pathway of 
individual drug use careers.
Second, the HOMALS analysis reveals an interesting finding: use of cannabis was 
relatively far removed from the use of hard drugs. Likewise, ‘hard’ polydrug use was 
less prevalent than either ‘soft’ or ‘ordinary’ polydrug use. This might be, in part, a 
reflection of the Dutch policy on drug use, in which the markets for soft and hard drugs 
are separated as much as possible, in order to prevent people who buy cannabis getting 
into contact with hard drugs and criminality (Verdurmen and Van Laar, 2005). However, 
how the licit/illicit divide affects the prevalence rates cannot be deduced from our data.
Third, this study shows that drug use should, to a very large extent, be equated with 
polydrug use, especially as far as alcohol, tobacco and cannabis are concerned. Until 
now, information regarding polydrug use was lacking in the Netherlands and it is fairly 
rare elsewhere. This information gap forms an obstacle for adequate policymaking.
Finally, the polydrug use patterns discerned in this study could be leveraged in future 
research:
Can the typology found in this study be replicated?•	
What are the prevalence rates per user type, and do these rates differ across •	
countries?
Is each user type associated with a distinct risk profile, enabling high-risk groups to •	
be recognised and targeted?
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In longitudinal studies, can we determine whether young people progress toward •	
the use of harder drugs by moving from one user type to another?
What kind of qualitative research will help us shed light on the main drivers (or •	
motives) that influence how a student moves from one user type to another?
Bibliography
Abraham, M. D., Cohen, P. D. A., Van Til, R.-J., De Winter, M. A. L. (1999), Licit and illicit drug use 
in the Netherlands, 1997, CEDRO, Amsterdam.
Amos, A, Wiltshire, S., Bostock, Y., Haw, S., McNeill, A. (2004), ‘ “You can’t go without a fag … 
you need it for your hash” — a qualitative exploration of smoking, cannabis and young people’, 
Addiction 99: 77–81.
Bailey, S. L. (1992), ‘Adolescents and multisubstance use patterns: the role of heavy alcohol and 
cigarette use’, American Journal of Public Health 82(9): 1220–1224.
Collins, R. L., Ellickson, P. L., Bell, R. M. (1998), ‘Simultaneous polydrug use among teens: prevalence 
and predictor’, Journal of Substance Abuse 10: 233–253.
Earleywine, M., Newcomb, M. D. (1997), ‘Concurrent versus simultaneous polydrug use: prevalence, 
correlates, discriminant validity, and prospective effects on health outcome’, Experimental and 
Clinical Psychopharmacology 5(4): 353–364.
Engels, R., Knibbe, R. A., Drop, M. J., de Haan, Y. (1997), ‘Homogeneity of cigarette smoking within 
peer groups: influence or selection?’, Health Education Behaviour 24: 801–811.
EMCDDA (2001), Annual report 2001, European Monitoring Centre for Drugs and Drug Addiction, 
Lisbon.
Feigelman, W., Gorman, B. S., Lee, J. A. (1998), ‘Binge drinkers, illicit drug users, and polydrug 
users: an epidemiological study of American collegians’, Journal of Alcohol and Drug Education 
44(1): 47–69.
Fergusson, D., Horwood, L. (2000), ‘Does cannabis use encourage other forms of illicit drug use?’, 
Addiction 95: 505–520.
Galaif, E. R., Newcomb, M. D. (1999), ‘Predictors of polydrug use among four ethnic groups: a 
12-year longitudinal study’, Addictive Behaviors 24(5): 607–631.
van de Geer, J. (1993), Multivariate analysis of categorical data: theory, Sage, Newbury Park.
van der Heijden, P., Gilula, Z., van der Ark, L. (1999), ‘An extended study into the relationships 
between correspondence analysis and latent class analysis’, 147–186 in M. Sobel and M. Becker 
(eds), Sociological Methodology, Blackwell, Cambridge.
IVV (2001), Kerncijfers Verslavingszorg 2000, Landelijke Alcohol en Drugs Informatie Systeem (LADIS) 
[Core data on addiction treatment 2000, National Alcohol and Drugs Information System], 
Stichting Informatie Voorziening Verslavingszorg (IVV), Houten.
Jessor, R. (1987), ‘Problem-behavior theory, psychological development and adolescent problem 
drinking’, British Journal of Addiction 82: 331–342.
Johnston, L. D., O’Malley, P. (1985), ‘Issues of validity and population coverage in student surveys of 
drug use’, in Rouse, B., Casual, N., Richard, L. (eds), Self-report methods of estimating drug use: 
meeting current challenges to validity, NIDA Research Monograph 57, US Government Printing 
Office, Washington DC, 31–54.
Kandel, D. B., Yamaguchi, K., Chen, K. (1992), ‘Stages of progression in drug involvement from 
adolescence to adulthood: further evidence for the Gateway theory’, Journal of Studies on Alcohol 
53: 447–457.
Korf, D., Nabbe, T., Benschop, A. (2001), Antenne 2000. Trends in alcohol, tabak, drugs en gokken 
bij jonge Amsterdammers [Trends in alcohol, tobacco, drugs and gambling among the Amsterdam 
youth population], Rozenberg Publishers, Amsterdam.
Chapter 4
95
Leccese, A., Pennings, E., De Wolf, F. (2000), Combined use of alcohol and psychotropic drugs. A 
review of the literature, Academic Hospital Leiden (AZL), Leiden.
Lynskey, M., Fergusson, D., Horwood, L. (1998), ‘The origins of the correlations between tobacco, 
alcohol and cannabis use during adolescence’, Journal of Child Psychology and Psychiatry 39: 
995–1005.
Martin, C., Clifford, P., Clapper, R. (1992), ‘Patterns and predictors of simultaneous and concurrent 
use of alcohol, tobacco, marijuana, and hallucinogens in first-year college students’, Journal of 
Substance Abuse 4: 319–326.
Measham, F., Aldridge, J., Parker, H. (2002), Dancing on drugs: risk, health and hedonism in the 
British club scene, Free Association Books, London.
Monshouwer, K., Smit, F., De Zwart, W., Spruit, I., Van Ameijden, E. (2003), ‘Progress from a first 
drink to first intoxication: age of onset, time-windows and risk factors in a Dutch national sample 
of secondary school students’, Journal of Substance Use 8: 155–163.
NDM (2001), Nationale drug monitor: jaarbericht 2001 [National drugs monitor: annual report 
2001], Trimbos-instituut, Bureau Nationale Drug Monitor, Utrecht.
O’Malley, P., Bachman, J., Hohnston, L. (1983), ‘Reliability and consistency in self-reports of drug 
use’, International Journal of Addiction 18: 805–824.
Parker, H., Aldridge, J., Measham, F. (1998), Illegal leisure: the normalization of adolescent 
recreational drug use, Routledge, London.
Pedersen, W., Skrondal, A. (1999), ‘Ecstasy and new patterns of drug use: a normal population 
study’, Addiction 94: 1695–1706.
Smit, F., Monshouwer, K., Verdurmen, J. (2002a), ‘Polydrug use among secondary school students: 
combinations, prevalences and risk-profiles’, Drugs: Education, Prevention and Policy 9: 
355–365.
Smit, F., Zwart, W. de, Spruit, I., Monshouwer, K., Ameijden, E. van. (2002b), ‘Monitoring substance 
use in adolescents: school- or household survey?’, Drugs: Education, Prevention and Policy 9: 
267–274.
SPSS Inc. (1988), Statistical software for the social sciences, SPSS, Chicago.
StataCorp (1997), Stata release 6.0, College Station, Stata Press.
Stronski, S., Ireland, M., Michaud, P., Narring, F., Resnick, M. (2000), ‘Protective correlates of stages 
in adolescent substance use: a Swiss national study’, Journal of Adolescent Health 26: 420–427.
Taylor, S., Chermack, S. (1993), ‘Alcohol, drugs and human physical aggression’, Journal of Studies 
on Alcohol and Drugs (Suppl. 11): 78–88.
Verdurmen, J., Van Laar, M. (2005), Factsheet drugsbeleid [Factsheet Drug policy], Trimbos Institute, 
Utrecht.
Vermaas, P. (1999), ‘Drugs en geweld: polygebruikers zijn onvoorspelbaar agressief’ [Drugs and 
violence: polydrug users are unpredictably aggressive], Algemeen politieblad 10: 3.
Zwart, W. de, Monshouwer, K., Smit, F. (2000), Jeugd en riskant gedrag: kerngegevens 1999. Roken, 
drinken, drugsgebruik en gokken onder scholieren vanaf tien jaar [Adolescents and high-risk 
behaviour: core data 1999. Smoking, drinking, drug abuse and gambling among schoolchildren 
from the age of 10], Trimbos Institute, Utrecht.

97
Chapter 5
Cannabis users and their relation 
to Finnish society
Keywords: advocacy – anthropology – behaviour – cannabis – deviance – 
Finland – sociology – subcultures
Setting the context
The great societal themes — power, status, wealth, religion, tolerance, class, 
mainstream culture, subcultures, generational divides, crime, respect for the law — all 
have a bearing on drug use and the way it is perceived. In Europe, in a similar way to 
consumption patterns, societal acceptance of cannabis use and perceptions of its users 
varies greatly across the continent.
As if to demonstrate the complexity of cannabis’s role in society, the languages 
of Europe have spawned entire vocabularies to describe cannabis, its users, its 
paraphernalia and its cultural symbolism. Cannabis has many street names in all 
European languages. In English, dictionaries of cannabis slang run to several hundred 
terms. When crossing linguistic borders from Lisbon to Helsinki, a cannabis cigarette will 
be variously named a ‘charro’, ‘porro’, ‘pétard’, ‘joint’ or ‘pind’. It may be associated 
with all kinds of youth tribes and subgroups, from surfers and skaters, through okupas 
and pasotas, casseurs, hoodies, clubbers and kiffers, new bohemians and bobos, to 
rastas, hip-hoppers, and — perhaps the core archetype — hippies. Yet cannabis will 
also be consumed by people who would consider themselves entirely mainstream, and 
not affiliated to any particular sociological groups.
In this chapter, we take an anthropological look at cannabis. Based on structured 
interviews with cannabis users, the author examines social attitudes to cannabis use 
in Finland. Subcategories of cannabis users are defined, and the author looks at 
reasons why people smoke cannabis and the meanings they attach to the substance. In 
including this case study in a European monograph, the EMCDDA does not suggest that 
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observations in the Finnish context will translate wholeheartedly to a wider Europe in 
which diversity, not homogeneity, is the norm.
Nonetheless, readers are likely to recognise many of the experiences, thoughts and 
ideas expressed by the interviewees. Numerous concepts bubble up to the surface: 
escapism, group affiliation and individuality, clandestine activity, fear of exclusion from 
employment, confrontation, rebellion and rejection, taboo-breaking, societal withdrawal 
and engagement. There are also interesting insights common to all societal subgroups: 
visible signals of affiliation to the group and adapting behaviour to fit when in a 
mainstream environment.
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Cannabis users and their relation 
to Finnish society
Taru Kekoni
Abstract
This article examines the relationship of Finnish cannabis users to society. A total of 35 
cannabis users were interviewed for the study. The narrative modes that were identified, 
which interviewees employ to describe their relationship to Finnish society, included 
‘concealed use’, ‘open activism’ and ‘social withdrawal’.
In the narrative of ‘concealed use’ the cannabis user wishes to appear as an upholder 
of traditional values and conventional lifestyles, even though there is a hidden, ‘deviant’ 
behaviour in the background. The most significant denominators of the relationship 
to society are controls and mechanisms related to concealment. In the narrative of 
‘open activism’ the relationship to society is constructed on the basis of an openly 
alternative lifestyle connected to cannabis use and the associated activism. In the ‘social 
withdrawal’ narrative, the user’s relationship to society is characterised by experiences of 
being offended or excluded because of his or her cannabis use. Withdrawal may also be 
a personal choice to stay outside the constraints of social activity.
Background to cannabis use in Finland
Cannabis is the most frequently used illegal narcotic substance in Finland, though 
cannabis prevalence is low compared with the European average. According to 
information for 2004, lifetime prevalence in the age group 15–64 years was 12.9 %, 
last year prevalence 2.9 % and last month prevalence 1.6 %. Judging by these figures, 
the maximum number of ‘regular cannabis users’ in Finland could be estimated at 
about 40 000. The majority of cannabis users are below 29 years of age, and two-thirds 
are male. As regards socio-economic status and marital status, cannabis use is most 
prevalent among students and unmarried or co-habiting persons, reflecting the young 
age of the majority of users. In terms of geography, cannabis use is clearly concentrated 
in the capital region around Helsinki and elsewhere in southern Finland. Overall, 
prevalence of use and experimentation with cannabis increased by about 50 % from the 
mid-1990s to the 2000s, although in recent years the level of experimentation reported 
among school students has declined. Increases in regular use are estimated to have 
levelled off at the beginning of the 2000s (Hakkarainen and Metso, 2003). Cannabis 
use, home growing, possession, buying, importing and distribution are all criminalised 
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under Finnish law. The consequence of being caught using cannabis is most often a 
fine, although incarceration of up to 10 years is a possible penalty for cannabis-related 
crimes.
Seppälä and Mikkola (2004) consider that the cultural meaning of cannabis use in 
Finland is distributed along at least two distinct axes. On the one hand, cannabis does 
not possess a single homogeneous ‘world of meaning’, but different circles associate 
it with widely divergent ‘meanings’. In addition to its symbolic value, cannabis has 
emerged as a kind of ‘universal drug’, with its use defined not only by different 
meanings related to subcultures, but also by loose and flexible mainstream meanings. 
On the other hand, cannabis use itself is associated with an abundance of tangible 
cultural products and paraphernalia, which is manifested, for example, by various 
implements for its use, by cannabis varieties and by historical and cultural stories linked 
to cannabis.
In their study of cannabis use from the viewpoint of research into social identity, 
Hammersley et al. (2001) note that cannabis users are connected to the surrounding 
society and the mainstream population in many ways. Nevertheless, their use of 
cannabis also requires the ability to manage an illegal activity carrying negative 
sanctions, including potential exclusion from arenas of social activity. This is equivalent 
to managing a hidden ‘disability’ (Goffman, 1963) or hidden deviancy (Becker, 1963) 
(cf. Young, 1999). There is a requirement that cannabis use is hidden from one set of 
people but revealed to another, to the right people under the right social circumstances. 
The social identity of the user is, in fact, shaped depending on the situation (Hammersley 
et al., 2001), and is a continuously evolving, dynamic characteristic.
Analysis and description of the data
This chapter examines the relationship of Finnish cannabis users to society, and the 
conditions under which the relationship is constructed. The users’ ‘relationship to society’ 
is defined as the individual’s experience of his or her own social status and the means 
by which this status is constructed and maintained in relationship to the mainstream 
population and social constraints. The questions posed were:
In relation to personal cannabis use, how did the user perceive his or her •	
relationship to the structures of surrounding society and the mainstream population?
What meanings, behaviours and coping mechanisms do the cannabis users •	
associate with their relationship to society?
The analysis combines the methodological approaches of grounded theory and 
narrative research. It aims to identify the narrative modes which cannabis users employ 
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in interviews to describe their relationship to Finnish society to the researcher. These 
narrative modes have been structured into concepts that have been categorised into 
‘concealed use’, ‘open activism’ and ‘social withdrawal’. In the analysis of the data, it is 
considered possible to move between realistic and constructionist discourse (cf. Glassner 
and Loughlin, 1987: 34–35). The data reveal something of what actually happens but, 
at the same time, information is generated precisely in the research situation and for it 
(cf. Pösö 2004: 35–36).
A total of 35 cannabis users were interviewed for the study. Since the focus of interest 
was the ideological thinking and social activity related to cannabis use in more general 
terms, data collection was initiated by submitting an interview request to the electronic 
mailing list of the Finnish Cannabis Association. Leaflets containing a description of 
the study and the researcher’s contact data were also distributed during the Million 
Marijuana March in Tampere in the spring of 2003. The way in which data were 
collected has a clear effect on the selection of interviewees. The data were considerably 
affected by the recruitment of persons who use cannabis exclusively, or as their main 
drug. Because of this, the extensive group who use cannabis in addition to other drugs 
has been almost completely excluded from the data. On the other hand, it seems 
obvious that the data do not include people who deny using cannabis, people who use 
it only very occasionally and people who express very little (or no) ideological ‘choice’ in 
using cannabis.
The majority of the interviewees were men (23). The average age of the interviewees was 
32 years, ranging from 19 to 56 years. The interviewees mainly lived in or near large 
cities in south and south-west Finland, but a few came from further north and smaller 
localities. All the interviewees contacted the researcher voluntarily.
‘Concealed use’ as the relationship to society
‘Concealed use’ is defined as the type of cannabis use and the associated relationship 
to society in which efforts are made to conceal use of cannabis from organisations and 
persons who might have a negative impact on the user’s social status if they learned 
about its use. Among the interviewees who described their relationship to society within 
a ‘concealed use’ narrative, nine were students in secondary or tertiary education, six 
were gainfully employed and one was unemployed at the time of interview. Among 
the total of 12 women in this study, 10 were placed in this category. The average age 
of the group members was 29.5 years, ranging from 19 to 47 years. The youngest 
interviewees belonged to this group. Two of the interviewees were married, seven were 
co-habiting and six were single, of whom one was divorced and one lived with his 
parents.
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In terms of gender and employment, the figures for this group differ significantly 
from the statistical data available on Finnish cannabis users (see Hakkarainen and 
Metso, 2003). The narrative of ‘concealed use’ appears understandable in the light 
of the socio-economic situation of those who described their relationship to society 
within this narrative. In one way or another, being revealed as a cannabis user could 
endanger the relatively stable social status these interviewees had achieved, or could 
lead to unfortunate consequences for the family situation or other social relationships. 
‘Concealed use’ has clear links with the ‘hidden deviancy’ behaviour described by 
Becker (1963). The person’s behaviour deviates in some aspects from social rules and 
norms, and the behaviour is concealed from the mainstream population (Oinonen, 
2002).
The general motives mentioned for ‘concealed use’ are the fear of losing one’s job or 
study opportunity or, in general, the fear of being stigmatised if cannabis use becomes 
known to the employer or a teacher. The fear in itself is not groundless, for several 
interviewees had actually lost their jobs after being revealed as cannabis users. On 
the other hand, a significant cause for fear is that a projected course of study or work 
career would founder due to cannabis use if a narcotics crime were to be listed on 
the user’s criminal record. In Finland, an extract of criminal records is required of 
persons applying for jobs with minor children, and one of the categories relevant to this 
occupation is crimes related to narcotics.
Another important motive for concealed use is the fear of being caught by the 
authorities. Besides an entry in their criminal records, the interviewees fear a house 
search or surveillance by the police. Interviewees with families also fear the intervention 
of the social services in family life if the parents are found to be using cannabis. The 
fear of being caught is most acutely linked to the buying of cannabis, which often brings 
the users in contact with ‘actual’ drug criminals. In fact, after becoming parents many 
interviewees have purposefully distanced themselves from criminal circles. Users do not 
necessarily want to give up cannabis because of their children, though all interviewed 
mothers did report that they had given it up during pregnancy and breast-feeding, and 
the solution adopted may be to grow cannabis either at home or at a friend’s home.
Means of concealment
Cannabis users describe various ways in which concealment is practised and their 
relationship to society maintained. ‘Not telling’ as a means of concealment means that 
the use is hidden from most of one’s acquaintances and only revealed to one’s most 
intimate circle, who are themselves often users or otherwise approve of cannabis use. 
‘Not telling’ is the easiest solution if one wants to avoid guilt-inducing or condemnatory 
reactions from third parties. Not telling is also relatively easy. Cannabis use is not a 
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general topic of conversation. On the contrary, several interviewees report that a kind of 
‘culture of silence’ prevails both within families and in public.
‘Controlling use’ is another important means of concealment vis-à-vis the mainstream 
population. At the same time, it is a qualitative or quantitative check on the habit. 
Means of control may be related to the place and time of use, as well as to the mode 
and intensity of use. In most cases, use is reported to take place at home or in another 
private space, alone or with certain friends. Users also report that the time of use is 
significant in terms of how ‘deviant’ they consider their behaviour to be. Users mostly 
say that use is generally accepted in the evening, which is when the interviewees mostly 
reported using cannabis. Controlling use in order to be courteous and well mannered 
are also described. For instance, it is not considered appropriate to use cannabis in 
children’s play areas, in non-smoking areas, or in situations where others may feel 
offended or confused because of it. These controls of use are described as ‘gentlemen’s 
agreements’, whose purpose is not to reveal one’s use to others, and also not to weaken 
the reputation of cannabis use in general any further.
‘Not telling’ may be experienced as an awkward solution, if one feels compelled to 
hide a part of one’s life that is important for one’s identity. In addition to relaxation or 
enjoyment, cannabis use may contain other meanings, which may be religious, ritual or 
otherwise strongly linked to one’s world view (see, for example, Booth, 2003). In spite of 
this, it may be necessary to hide one’s use to safeguard one’s social status, and this may 
actually be experienced as the biggest problem related to cannabis use. For this reason, 
affiliation to cannabis culture may be indicated by various symbolic signals. Dreadlocks, 
or an exceptionally relaxed style of dress, may indicate membership to those who are 
able to read these symbolic messages. Cannabis use may also be referred to by using 
terms which outsiders may not understand in the context or by employing gestures which 
only another user can understand.
It has been noted within cultural criminology research (Ferrel, 2003) that deviant and 
criminal subcultures are becoming fragmented in a world of symbolic communication. 
Symbolic communication for cannabis users may partly depend on the desire to 
experience a community and belonging with other cannabis users, but also on practical 
needs and the usefulness of revealing oneself or another person as a user. The 
usefulness may be linked, for instance, to a desire to extend the established circle of 
users, perhaps with the interest of finding new channels of acquiring cannabis.
‘Open activism’
Instead of concealment, the relationship to society of a cannabis user may also be 
based on ‘open activism’. This denotes a relationship with the mainstream population 
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and social domains in which there is no attempt to hide cannabis use. Rather, there is 
a desire to bring the matter out into the open, as a topic of debate in both private and 
public spheres. In the ‘open activism’ narrative, the most important aspect of cannabis 
use in relation to social status is considered to be the desire to break the so-called 
‘culture of silence’ surrounding cannabis use. In this context, the interviews also often 
refer to the taboo aspect of cannabis. The aim of ‘open activists’ is to bring cannabis, 
as a topic, from the marginal to the mainstream arenas. On the other hand, in the open 
activism narrative, openness is also manifested as the personal choice of individuals. 
Since the matter is strongly linked to the user’s way of life, he or she does not want to 
keep it a secret, but rather shows honestly in all situations his or her personal attitude 
towards it.
Among the cannabis users interviewed, 13 were ‘open activists’. They were all male. 
The average age of the group was 32.5 years, ranging from 21 to 56 years. Nine of 
the interviewees were employed at the time of the interview, two were unemployed, one 
was a secondary school student and one in civilian service (in lieu of conscripted military 
service). Eight of the interviewees were unmarried, two married, two co-habiting, and 
one was divorced. Their educational level varied from comprehensive school to university 
degrees, as in other groups. However, in this group the proportion of interviewees with 
university degrees was slightly higher than in the others: four out of the total of eight 
university graduates belonged to this group (three belonged to the ‘concealed use 
group’ and one to the ‘withdrawal from society’ group).
The desire to act as an active proponent of cannabis may be rooted in events in the 
person’s biography, or may be a lifestyle choice. Some activists reported that they were 
motivated by events in their early childhood. For example, someone with alcoholic 
parents may view society’s relatively permissive attitudes about alcohol and sharply 
condemnatory attitudes about cannabis as contradictory. This may lead to active defence 
of cannabis. Similarly, someone who has once been strongly labelled as a cannabis user 
and faced the consequences may be encouraged to become an open activist. Someone 
who has already served a prison sentence may feel that loss of social status is already 
complete, and that it is therefore relatively easy to become an activist.
By contrast, younger activists did not necessarily report alienating experiences related 
to cannabis use. For them, activism may be only one way of working towards a better 
and more liberated society. In this narrative, cannabis activism is viewed not so much 
as a discrete movement but more as a part of a ‘culture of resistance’ or a general 
lifestyle that attempts to call into question current values and to create a new, individual 
value base. It might include criticism of consumer behaviour and the global or national 
economy. Similarly, the unpleasant effects of continued concealment of cannabis use 
and the fact that cannabis has become increasingly important for one’s lifestyle may 
have the result that even a younger user becomes an activist. In this narrative, even 
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being caught by the police may appear as positive, as was noted by an interviewee 
when describing this situation: ‘So I also thanked the police and said, like, “hey, this is 
great, now you know about me so I needn’t try to hide anything!” ’
In the ‘open activism’ narrative, the relationship to society was described from the 
viewpoint of personal ideology and lifestyle more markedly than with the preceding 
group. For activists, personally defending cannabis as a positive substance, a medication 
and the raw material of various industries is so important that they are ready to 
jeopardise their own social status.
Means of open activism
As might be expected, open activists are more likely to be active members of a cannabis 
advocacy organisation than those belonging to the two other groups. For them, activity 
in organisations serves as a means of making their cannabis-related thinking and 
lifestyle more visible and also more acceptable in different social spheres. At the same 
time, it serves their needs for a community and for sharing experiences with like-minded 
people. Although the use of cannabis is not regarded personally as wrong or as a 
criminal activity, the culture constructed around it is constrained by the fact that cannabis 
use is nonetheless illegal.
Activist organisations strive to spread their message chiefly by means of information 
provided on their internet pages and through the discussion groups they maintain. 
Among activists, online media are regarded as very useful channels for disseminating 
information and promoting more favourable attitudes. By contrast, the Million Marijuana 
March introduced in 2001 in Finland is regarded as a slightly more dubious way of 
spreading the message of legalising cannabis. Some of the activists do not take part in 
the march, for they believe that it attracts stigma for both the participants and cannabis 
users in general. Finland’s longest-established association, the Finnish Cannabis 
Association (FCA), active since 1991, has been most assiduous among the cannabis 
organisations in attempting to establish dialogue with members of parliament and 
political decision-makers. The means used by FCA for this include position papers and 
press releases drafted as a result of membership and/or board meetings, which are 
distributed as widely as possible, including to members of parliament and other political 
actors. FCA was also consulted when Finland’s first national drug strategy was drawn up 
in 1997.
Cannabis activists are also prepared to discuss the topic in the arenas of their 
‘opponents’ or the mainstream population, and in a manner approved by these 
opponents. In the open activism narrative, an important enabler of discussion with the 
mainstream population is the way in which the discussion is conducted. This involves 
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such concepts as ‘adjustment to censorship’ and ‘orientation to the media’. These 
imply that it is important to present their message in a form that is not too aggressive 
towards general social attitudes to cannabis and does not directly offend anyone, not 
even those who oppose cannabis most strongly. The activists report that they achieve 
this by ‘disguising’ the message so that, for example, an item in the press may not even 
mention the word cannabis, but the attitudes involved are visible in the text in other 
ways. Another point stressed by interviewees was that the story needs to match the 
format of the particular media outlet to which it is offered.
The most infrequent means of activism in the interview data is the attempt to exert 
influence in mainstream arenas. In the data this primarily means activity in party or 
municipal politics, and defending cannabis together with other personal values in this 
context. One of the interviewees describes involvement in party politics as a means of 
open activism and as a personal cause:
It’s like, they [cannabis use and becoming aware of its social status] have had a fairly strong 
impact on my, let’s say, awakening, on becoming a conscious human being instead of a 
sleepwalker, so to speak. So I read the papers more carefully, looked for ways to make an 
impact, I even joined the party and went to the party convention. Incidentally, I even gave a 
speech at the convention. There are people there, too, who support legalisation, and, well, 
my three minutes were that, it was a reply to another speech, in which I mentioned that in my 
personal opinion people who can’t distinguish say, marijuana from coke, then I think a person 
like that is incapable of taking decisions at all in this matter. Meaning, get informed, you guys, 
get informed.
Withdrawal from society
The third narrative mode is one in which cannabis users describe their relationship to 
society within the narrative of withdrawal from arenas of social activity. ‘Withdrawal’ 
may be explained as a personal choice, which is resorted to in order to avoid conflict 
with the authorities, or more generally, with condemnatory attitudes. On the other hand, 
withdrawal may also include strong elements of exclusion, whether economically from 
working life, socially from the mainstream population or judicially from the spheres 
of ‘decent citizens’. In this case, withdrawal may be understood as social exclusion as 
defined by Young (1999). The withdrawal narrative may also be linked by a strong 
feeling of being mistreated by society, which is linked either to judicial conflicts or more 
generally to a feeling of losing one’s ‘human rights’ and being shunned because of 
one’s lifestyle.
Six cannabis users described their relationship to society within the social withdrawal 
narrative. Two of them were female, and the average age of the group was 36 years, 
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with actual ages varying from 26 to 50 years. Thus, those classified as belonging to this 
group were slightly older than those in the other groups. At the time of interview, one of 
the interviewees was employed, four were unemployed and one was on parental leave. 
Four group members had completed comprehensive school, one had a secondary-level 
qualification and one an almost complete university degree. The group included one 
co-habiting couple, one married person with minor children, one divorced and two 
unmarried single persons. An interesting distinguishing factor in the demographic data 
of the social withdrawal group is that they reported having started using cannabis 
considerably earlier than the other groups. The most commonly reported starting age in 
the interview data was around 20 years, but in this group the most general starting age 
was 13–15 years. The average age in Finland for starting the use of cannabis is about 
16–18 years (Hakkarainen and Metso, 2003).
The interviewees within the ‘social withdrawal’ narrative reported problems with 
intoxicant use more frequently than interviewees in the other groups. They reported 
earlier problematic use of other illegal drugs, medications or alcohol, which had then 
been dropped as cannabis became the drug they chiefly used. One of the interviewees 
did not report earlier problematic use of other substances, but did report continuing 
experimental use of other illegal drugs. In this narrative, more clearly than in the other 
groups, interviewees suggested that earlier use of cannabis and also current cannabis 
use was linked, to some degree, to problems or addiction. The problems could be 
associated with social relationships and with the necessity of withdrawing from them, 
conflicts with the judiciary, family problems, health problems or difficulties in finding 
work. Many reported several of these problems. On the other hand, the interviewees 
could also have experienced addiction as a neutral or even a pleasant experience.
Within the ‘social withdrawal’ narrative, use was almost invariably justified from the 
viewpoint of maintaining mental balance and/or of mental health problems, mostly 
depression. The interviewees felt that cannabis use helped to ‘smooth the edges’ of an 
otherwise bumpy life or to ‘heal traumas’ created during one’s life. Several interviewees 
reported having used mood medication earlier for the same problems, but had felt that 
it was of no help or that it had caused severe addiction or other problems.
Two people within the ‘social withdrawal’ narrative reported that a significant factor for 
their habit was its medicinal impact on physical illnesses which had not been alleviated 
by any other medicine. Physical symptoms of varying severity (such as headache, 
flu, asthma, menstrual cramps, migraine, nausea, indigestion) were also reported as 
the cause of use in the other groups, but the social withdrawal narrative includes the 
interviewees who reported using cannabis primarily for medicinal reasons.
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Withdrawal as a relationship to society
For these interviewees, social withdrawal primarily meant being excluded from society 
in one way or another and an experience of being labelled as criminal or otherwise 
unfit for society. Three people within this narrative talked about recent experiences of 
being caught by the police or customs. They had been charged with growing cannabis 
at home, driving under the influence of cannabis and with a crime related to the sale of 
cannabis products. A house search by the police and the subsequent sentence appears 
as one example of experienced social exclusion. A cannabis user recently sentenced for 
the sale of seeds describes the experience as one entailing severe exclusion, which also 
has unfortunate future consequences:
But now I’ve actually lost everything, in that I lost all the money I had and it’s really difficult 
getting a job in Finland now that I’ve a record of drug crimes. And all the liquids that they 
found, fertilisers and spices, they were sent to the drug laboratory, and they took my photos, 
my employment certificates and all possible documents. They took my bank statements, my 
mobile phone and just everything … And apparently they figured that I’m some drug Mafia 
man or something. And they just walked into my flat on the grounds that they wanted to see if 
I had any weapons and so on …
This extract imparts a strong feeling of an experience of stigmatisation, apparent in 
such terms as ‘drug Mafia man’ used by the interviewee to describe himself through 
the eyes of the authorities. Becker (1963) noted that deviancy does not consist of the 
behaviour itself, but of the stigmatisation as deviant of a behaviour, as a result of the 
rules and norms of the mainstream population. Thus, a deviant person is a person 
labelled as such. According to Becker, stigmatisation is a two-directional process. With 
stigmatisation of the deviant, changes occur in the identity of the person and he or she 
also begins to feel excluded from society on the level of his or her identity.
More frequently than the other two, the ‘social withdrawal’ narrative describes the 
user’s intimate circle as consisting mainly of other users. The circle may also include 
users of stronger drugs than cannabis or persons with links to the sale of cannabis and 
other criminal activity. This could naturally be caused simply by the fact that friends 
and acquaintances are generally selected from among people who uphold the same 
values and have the same hobbies. On the other hand, the mainstream population and 
old friends may also shut out a cannabis user if, for example, he or she is labelled as 
criminal or otherwise deviant. Clearly, more often than the other two, the narrative of 
social withdrawal is linked to unemployment.
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Conclusions
Finnish cannabis users’ relationship to society has been categorised into the narratives 
of ‘concealed use’, ‘open activism’ and ‘social withdrawal’. The interviewees suggested 
that in Finland users of illegal drugs are often portrayed in black and white terms and 
assumed to exist outside domains of social activity, at the margin of society, where 
distinctive modes and motives of action are constructed for them. Cannabis use is not 
portrayed differently from use of other illegal substances. On the other hand, cannabis 
use in the present day may be seen as involving a diverse group of people — especially 
in the framework of relaxation or recreational use — and it is not necessarily regarded 
as having any impact on the conditions of a person’s relationship to society.
A positive outcome of this study is to reach a set of cannabis users who have been 
invisible in Finnish drug research before. Reaching and researching hidden populations 
is one important role of qualitative drug research (Rhodes, 2000). To my knowledge, 
the relationship of cannabis users and cannabis use to society has previously not 
been researched or called into question in Finland or in any other European country. 
According to Rhodes (2000), both the nature of knowledge itself and the process by 
which it is acquired shape the lived experience and perceived meaning of drug use. Two 
key tenets of qualitative research are to describe the social meanings participants attach 
to drug use experiences and the social processes by which such meanings are created, 
reinforced and reproduced (Moore, 1993; Rhodes, 1995; Agar, 1997). An examination 
of Finnish cannabis users’ relationship to society reveals how cannabis use is lived and 
interpreted through social interactions.
I have shed some light on the motives, means and ideologies attached to cannabis use 
in Finland. The study reveals the mechanisms and controls that are employed to make 
cannabis use possible in a social situation, an activity that carries a risk of relatively 
strict control policy and judicial sanctions. It also brings to light different ways of viewing 
society and the divergent positions in which people live. In addition, it reveals different 
meanings and contents in the internal culture of cannabis use, which may not be easily 
visible to the mainstream population and therefore unidentified by them.
When studying the use of drugs, one should bear in mind the thesis presented by 
Howard S. Becker (1970), concerning research on deviancy, according to which it is not 
the researcher’s task to be involved in the value debate concerning the research topic, 
but simply to study deviancy as behaviour that is condemned by some and approved 
by others. The study of internal meanings of the culture of use and its relationship to 
society is one way of understanding cannabis users’ way of regarding drug use and its 
meanings.
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Setting the context
In 1956, the novelist William Burroughs wrote about cannabis that ‘the effects of this 
drug have been frequently and luridly described’. He mentioned such effects as ‘acute 
sensitivity to impressions’, ‘disturbance of space–time perception’ and an increase in 
appetite. Yet he also warned that cannabis was ‘a sensitizer’ and that its effects are ‘not 
always pleasant’: ‘depression becomes despair, anxiety panic’ (1).
So what, 50 years later, can be said about the health effects of cannabis use and 
cannabis smoking in particular? Cannabis use has been associated with a range 
of adverse health effects, and new studies regularly appear that are extending our 
knowledge of the possible adverse health consequences of cannabis use.
From a review of this growing literature, John Witton argues in this chapter that it still 
remains difficult to make conclusive statements about the health effects of cannabis. 
Despite the wealth of available information, there still remains a shortage of robust 
research from well-designed studies. Moreover, a number of basic hurdles exist that 
make it difficult to disentangle the effects of cannabis from other drug use and other 
confounding factors. These methodological problems are compounded by the difficulties 
of ascertaining dose–response relationships.
Nonetheless, some health problems can be identified. Links between chronic cannabis 
use and respiratory disease, carcinogenesis and adverse child development after 
 (1) Burroughs, W. (1956), ‘Letter from a master addict to dangerous drugs’, British Journal of 
Addiction 53(2).
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maternal cannabis use have been identified. There has also been a recent increase in 
research interest examining the association between cannabis use and psychosis and 
depression. This brief chapter summarises the many hundreds of studies into the health 
effects of cannabis. It is important to note, however, that new research is emerging in 
this area at such a pace that any review is likely to become quickly out of date. 
So while this chapter represents a snapshot of current knowledge — a recent Spanish 
monograph (Ramos Atance et al., 2007) covers the subject of cannabis and mental 
health in further detail — it is likely that the knowledge base on the health effects of 
cannabis will develop further over the coming years, and any conclusion drawn based 
on the current evidence must be regarded as tentative.
Further reading
Advisory Council on the Misuse of Drugs (2008), Cannabis: classification and public health, Home 
Office, London.
Copeland, J. (2006), ‘Cannabis use, depression and public health’, Addiction 101: 1380.
Corrigan, D. (this monograph, Volume 1), ‘The pharmacology of cannabis: issues for understanding 
its use’.
EMCDDA (2007), Drugs profiles: cannabis 
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Inserm (2001), Cannabis: Quels effets sur le comportement et la santé?, Les éditions Inserm, Paris.
Kalant, H., Corrigal, W., Hall, W., Smart, R. (eds) (1999), The health effects of cannabis. Addiction 
Research Foundation, Toronto.
Ramos Atance, J. (ed.) (2007), Aspectos psiquiátricos del consumo del cannabis, Sociedad Española de 
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Cannabis use and physical and 
mental health
John Witton
Introduction
The health effects of cannabis have been the subject of a number of scientific reviews 
by national and international bodies since the seminal Indian Hemp Commission of 
1893–4. Yet, over a century later, the health effects of cannabis are still regularly 
debated. Uncertainty about these effects seems to contribute to confused scientific, public 
and political arguments. This is perhaps a surprising situation, given that there is now no 
shortage of recent authoritative reviews to draw upon to help weigh up the evidence (Joy 
et al., 1999; Kalant et al., 1999; Inserm, 2001; Hall and Pacula, 2003; UK Advisory 
Council on the Misuse of Drugs, 2002; Kalant, 2004; Iversen, 2005). So what makes it 
so difficult to arrive at a consensus view about the health effects of cannabis?
In his chapter in this monograph, Wayne Hall outlines the factors that prevent us from 
arriving at the same kind of consensus view of cannabis as we have for alcohol and 
tobacco. In particular, there is a paucity of good quality studies of cannabis and health 
effects or long-term studies that enable a careful assessment of the possible causal role 
of cannabis in the development of a range of health concerns (Macleod et al., 2004).
Analysts seeking to make conclusive statements on the health aspects of cannabis are 
faced with three major hurdles. The first is the absence of a standardised product. 
Cannabis cigarettes — ‘joints’ — can contain varying doses of the main psychoactive 
constituent of cannabis, tetrahydrocannabinol (THC), and many of the studies under 
review can only provide approximate indicators of the amount of THC consumed. As 
cannabis is an illicit product, how can we assume, with confidence, that the joint smoked 
by one consumer is comparable with the next joint, and the next consumer? These issues 
are further confounded by differences in how the substance is consumed, embracing 
such aspects as joint construction, other modes of administration (water pipe, vaporiser), 
intensity of use and frequency of use (2).
 (2) For a discussion of screening for intensive use, see Beck and Legleye, this monograph. More work 
is needed on the nature of THC dosage among regular cannabis users and polyconsumption 
patterns, in particular the simultaneous use of other substances together with cannabis. 
Nonetheless, some studies on intensive use patterns have been published with European 
relevance. In the United Kingdom, Atha and Blanchard (1997, 1998) have estimated THC 
exposure among regular UK users; in Spain, some attempt has been made to divide regular 
users into ‘pure’ users who use cannabis alone and ‘polyconsumers’ who use cannabis and other 
illicit drugs (Calafat et al., 2000); in the Netherlands, a recent study examines intensive use of 
high potency cannabis (Mensinga et al., 2006).
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The second hurdle is that cannabis is often consumed with other substances. It is most 
commonly mixed with tobacco in a joint, and frequently used concurrently with other 
substances, especially alcohol. Thus, the question arises: ‘how can we disentangle the 
effects of each substance on the cannabis smoker?’.
A third hurdle is that cannabis use is more common among adolescents and young 
adults — generally, a physically healthy population — who often give up consuming 
cannabis before their mid-30s. This, combined with the paucity of long-term studies of 
cannabis users into middle and old age, means that the precise role played by cannabis 
in health problems later in life is difficult to determine.
Together, these three hurdles have meant that, although there has been a recent surge 
in cannabis research adding to the large number of extant studies, it is premature to 
pronounce conclusively on a range of long-term health concerns surrounding cannabis 
use.
The research evidence presented in this brief review has been identified according to 
the standard criteria for causal inference. These criteria imply that evidence should 
demonstrate that there is a relationship between cannabis use and a health outcome 
using an accepted type of research design. Thus, studies should have ‘built-in’ 
trustworthiness and show that:
through statistical testing, the relationship is unlikely to be due to chance;•	
drug use precedes the adverse effect; and•	
that the evidence eliminates as far as possible the likelihood that the relationship •	
is due to some other variable that is related to both cannabis use and the adverse 
health effect.
So this brief review presents the best currently available evidence, together with 
comments on any shortcomings of this evidence in the light of the above criteria.
Acute effects of cannabis
The reported effects of acute cannabis use are a sense of euphoria and relaxation, 
perceptual distortions, time distortion and the intensification of sensory experiences such 
as listening to music. Cannabis use in social settings can lead to increased talkativeness 
and infectious laughter followed by states of introspection and dreaminess. The user 
typically has a feeling of greater emotional and physical sensitivity that can include 
greater interpersonal empathy. Short-term memory and attention are also impaired 
(Joy et al., 1999; Hall and Pacula, 2003). Acute subjective effects have been found to 
be significantly increased according to dose of THC in laboratory studies (Hart et al., 
2001).
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Cannabis use can increase the heart rate by 20–100 % above baseline. This increase is 
greatest in the first 10–20 minutes after use then decreases rapidly thereafter. The rate 
of decrease depends on whether smoked or oral cannabis is used, lasting 3 hours in the 
former and 5 hours in the latter (Joy et al., 1999). Blood pressure is increased while the 
person is sitting and decreased while standing. The change from sitting to standing can 
cause faintness and dizziness due to the change in blood pressure. These cardiovascular 
effects are of negligible clinical significance because most cannabis users are young and 
healthy and develop tolerance to these effects (Joy et al., 1999; Sidney, 2002).
However, these changes may present serious problems for older users, particularly 
individuals with pre-existing heart disease (Joy et al., 1999; Sidney, 2002). Cases of 
acute cardiovascular death in which THC was present in post-mortem blood samples, 
indicating recent cannabis use, have been reported (Bachs and Morland, 2001). 
An interview-based study of 3 882 patients (1 258 women) with recent myocardial 
infarctions found that the cannabis smokers in the group were 4.8 times more likely to 
experience a myocardial infarction 1 hour after smoking than during periods of non-
use. The small number of 124 cannabis smokers in the study were also more likely to 
be male, overweight and cigarette smokers, and cannabis was a rare trigger of acute 
myocardial infarctions in this study group (Mittleman et al., 2001). A longitudinal study 
of risk factors for coronary artery disease in a group of young adults aged 18–30 did 
not find an association between cannabis use and cardiovascular risk factors such as 
elevated cholesterol levels and blood pressure or high body mass index (Rodondi et al., 
2006). There have been a small number of case reports of strokes following cannabis 
use, but further research is needed to determine the relationship of cannabis use to 
cerebrovascular disease (Moussouttas, 2004).
Acute mood effects
Adverse mood effects can occur, particularly in inexperienced users, after large doses 
of cannabis. Anxiety and paranoia are the most common of these effects, which also 
include depersonalisation, panic, dysphoria (unpleasant mood), depression, delusions, 
illusions and hallucinations. These effects normally disappear a few hours after cessation 
of use and are responsive to reassurance and a supportive environment (Adams and 
Martin, 1996; Joy et al., 1999).
Acute toxicity
The acute toxicity of cannabis is very low and there is no overdose risk from cannabis. 
While there have been occasional reports of human deaths suspected of being related to 
cannabis use, these have not been confirmed by appropriate analytic techniques (Tewari 
and Sharma, 1980; Hall and Pacula, 2003).
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Chronic effects of cannabis
Immune system
While cannabis smoking has been found to impair the function of lung macrophages, 
which provide a defence against inhaled pathogens, there is no conclusive evidence that 
cannabis impairs immune function to any significant extent (Roth et al., 2004; Kraft and 
Kress, 2004). The few studies that have suggested that cannabis has an adverse effect 
on the immune system have not been replicated. Two prospective studies of HIV-positive 
men have shown that cannabis use is not associated with progression to AIDS (Kaslow et 
al., 1989; Hollister, 1992; Joy et al., 1999).
Respiratory system
Cannabis smoke contains many of the same components as tobacco smoke, while 
having a higher proportion of particulate matter and some carcinogens (Tashkin, 1999). 
As much as four times the amount of tar can be deposited on the lungs of cannabis 
smokers as cigarette smokers if a cigarette of comparable weight is smoked. This 
difference is probably the result of differences in administration. Cannabis smokers 
usually develop a larger puff volume, inhale more deeply and hold their breath several 
times longer than tobacco smokers (Wu et al., 1988; Joy et al., 1999).
Chronic cannabis smoking effects are similar to those of tobacco smoking. Regular 
heavy use of cannabis can produce chronic inflammatory changes in the respiratory 
tract, resulting in increased symptoms of chronic bronchitis such as coughing, shortness 
of breath, production of sputum and wheezing (Tashkin et al., 2002). As many cannabis 
smokers also smoke tobacco, analysis of data from a prospective study of almost 
1000 young adults in the Dunedin, New Zealand, birth cohort study (see below) took 
this possible confounding factor into account in assessing the effects of cannabis and 
tobacco on lung function. After correcting for the contribution of tobacco smoking, 
symptoms of bronchitis were 61–144 % more frequent in in dependent cannabis smokers 
than in non-smokers (Taylor et al., 2000).
The epidemiological literature on the effect of cannabis on chronic obstructive 
pulmonary disease (COPD) is inconclusive. In a prospective study involving 990 
individuals aged under 40, ‘non-tobacco’ smoking had a larger effect on respiratory 
function than tobacco smoking, an effect that was maintained in a follow-up of the 
sample (Bloom et al., 1987; Sherrill et al., 1991). In contrast, a longitudinal study 
following groups of cannabis-only smokers, cannabis and tobacco smokers, tobacco-
only smokers and a control group found no significant change in lung function in the 
smoking groups after initial assessments (Tashkin et al., 1987; Tashkin et al., 1997). 
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Lung function was also examined in the Dunedin birth cohort during the follow-ups at 
ages 18, 21 and 26. While a correlation was found between the amount of cannabis 
smoking in this period and a decrease in expiratory flow rate, an indicator of COPD, 
this correlation became of statistically marginal significance only once the subjects’ 
tobacco use was taken into consideration in the statistical analysis (Taylor et al., 2002). 
A recent exploratory study with a convenience sample of 339 participants, mainly 
recruited via the media, found a dose-related impairment of the large airway function, 
resulting in an obstruction of air flow and causing increased pressure on the lungs, with 
more adverse effects reported at higher doses (Aldington et al., 2007).
Carcinogenicity
Respiratory cancer
There is no conclusive evidence that cannabis causes cancer in humans, including those 
cancers associated with tobacco use. However, cellular, genetic and human studies 
suggest that cannabis smoke may be an important risk factor for the development of 
respiratory cancer. Laboratory studies have found little evidence that THC can cause 
mutations in bodily cells that may lead to cancer (Hall and MacPhee, 2002). While 
reviews of laboratory studies have shown that cannabis smoke can produce mutations 
and cancerous changes, these laboratory studies have typically used doses of the drug 
larger than those used by humans on a regular basis and indicate the possibility rather 
than the probability of such changes occurring in humans who smoke cannabis (Kalant, 
2004). Biopsy samples taken from a group of crack, cannabis and tobacco smokers 
found evidence of biochemical and gene alterations — indicators of precancerous 
change (Barsky et al., 1998). These changes occurred in more of the biopsy samples 
taken from the smokers, whether the drugs were smoked alone or in combination, than 
those from the non-smokers.
There is not yet any evidence from controlled studies showing a higher rate of 
respiratory cancers among chronic cannabis smokers. However, there is evidence of an 
additive effect of cannabis and tobacco smoking on histopathological abnormalities in 
lung tissue, similar abnormalities to those that precede lung cancer in tobacco smokers 
(Joy et al., 1999; Tashkin et al., 2002; Hall and Pacula, 2003). However, several factors 
militate against cannabis smokers developing lung cancer. Patterns of cannabis use 
differ to those of cigarette smoking. Cannabis use tends to be time-limited, with most 
smokers stopping in their early to-mid-20s. Those who do continue their cannabis use 
tend to smoke 1–3 cannabis cigarettes a day, compared with 10–30 tobacco cigarettes 
by tobacco smokers. Finally, there are far fewer cannabis smokers than tobacco smokers 
(Hall and MacPhee, 2002).
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There have been case reports of cancers in the aerodigestive tract of young adults with 
a history of heavy cannabis use. These findings are significant because these kinds of 
cancers are rarely found in the adults under the age of 60, even among those who 
smoke tobacco and drink alcohol. This suggests that cannabis smoking may potentiate 
the effects of other risk factors, such as tobacco smoking, and is a more important risk 
factor than tobacco and alcohol use in the early development of respiratory cancers 
(Sridhar et al., 1994; Joy et al., 1999).
Epidemiological studies have provided conflicting evidence for the likelihood of cannabis 
smokers developing cancers. A cohort of 64 855 members of the Kaiser–Permanente 
Medical Care Program in California were recruited to a prospective study over a 6-year 
period. They were asked about their cannabis use on entry into the study and data 
on cancer incidence among the group were collected from a cancer registry and the 
California mortality data system (Sidney et al., 1997). The study did not find an excess 
of cancers among those who used cannabis at the entry to the study or who were current 
smokers compared with those who did not use cannabis when the study started. While 
there was a small but significant risk of developing cancer of the prostate in men and 
cancer of the cervix in women, there was no evidence of a risk of developing tobacco-
related cancers. However, with only 22 % of the people in the study being current 
cannabis smokers, the numbers were small and most were also followed up to an 
average age of 43, too young to find evidence of excess cancers among the cannabis 
smokers.
A second prospective study at the same centre, this time following 133 811 members 
over a period of up to 21 years, found that those who smoked cannabis at least once 
a month had an increased risk of developing malignant primary adult-onset gliomas, 
tumours most commonly developed in the brain and spinal cord. However, other 
important risk factors, such as ionising radiation, were not considered in this study (Efirt 
et al., 2004).
Another epidemiological study retrospectively followed the medical histories of 173 cases 
of head and neck cancers (upper aerodigestive tract) matched with 176 blood donors 
at the same hospital without a history of cancer who were matched by age, sex, race, 
education and alcohol and tobacco use (Zhang et al., 1999). Cancer risk was 2.6 times 
higher in the cannabis smokers than among the non-smokers, and three times higher 
in those who were 55 or younger. There was an increase in cancer risk according to 
increasing frequency and duration of cannabis use. While this study added more weight 
to the suspicion that cannabis smoke may be linked to cancer, it had a number of 
methodological limitations, including the small numbers involved in the study and the 
possible role of other factors not taken into account in the study.
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Two other studies failed to find an association between cannabis use and oral cancers 
(Llewellyn et al., 2004; Rosenblatt et al., 2004). The first, a case–control study of young 
adults, had only 10 % heavy cannabis smokers in its sample of 116 patients. The study 
by Rosenblatt et al. was a large community-based case–control study with 407 patients 
and 615 controls aged 18–65. The study found no relation between the risk of oral 
cancer and ever in lifetime cannabis use or increasing duration and average frequency 
of use. The authors suggested that the discrepancy between their findings and those 
of Zhang et al. arose from the low frequency of cannabis use in the control subjects in 
Zhang’s study, while the frequency of cannabis use in the control subjects in their study 
matched that predicted from population surveys of adults in the USA. However, the study 
had relatively low participation and may have missed cases who had used cannabis.
A recent study attempting to address the methodological deficiencies of the earlier 
studies used a population-based case–control design, with 1 209 cancer patients aged 
between 18 and 59 identified by the Los Angeles County Cancer Surveillance Program, 
matched to cases on age, gender and neighbourhood. Interview data were collected 
on lifetime histories of alcohol, tobacco and illicit drug use, socio-demographic factors, 
diet, family history of cancer and occupational exposures. Cumulative cannabis use 
was measured in joint-years, where 1 joint-year equalled 365 joints. Preliminary 
analysis of the data did not find a positive association between cannabis use and lung 
and aerodigestive tract cancers, with a positive association absent with the long-term 
heavy smokers as well (Morgenstern et al., 2005). Another recently reported study 
examined cannabis use in 611 people who had developed lung cancer and 601 people 
who had developed cancer of the head or neck, matching them on age, gender and 
neighbourhood with 1 040 people without cancer. Heavy cannabis smokers in this study 
had smoked more than 22 000 joints, while moderately heavy smokers had smoked 
between 11 000 and 22 000 joints. Neither group were at increased risk of developing 
cancer and were not at increased risk compared with those in the study who smoked less 
cannabis or none at all (Tashkin et al., 2006).
Childhood cancers
Three studies exploring the risk of cancer in childhood have found evidence of a link 
with maternal cannabis use during pregnancy. The most notable of these studies 
found an association between maternal cannabis use and acute non-lymphoblastic 
leukaemia (ANLL). This case–control study was designed to assess the impact of 
the parents’ environmental exposure to petrochemicals, pesticides and radiation on 
childhood cancer, with maternal cannabis use recorded as one of the factors included 
in the analysis. The results showed that mothers of children with the cancers were 11 
times more likely to have smoked cannabis than the comparison group. When the 
rate of cannabis use was adjusted among the control group to bring it up to the level 
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of other studies of childhood cancer, the risk of cancer was still three times greater 
(Robinson et al., 1989). In the other two case–control studies, again investigating a 
range of factors that may have had an impact on childhood cancers, an increased risk 
of rhabdomyosarcoma and astrocytomas was found in children born to mothers who 
smoked cannabis during their pregnancy (Kuitjen et al., 1992; Grufferman et al., 1993). 
However, there is no evidence for an increase in incidence of these cancers over the 
period 1979–95, which would be expected if maternal cannabis use was a cause of 
these cancers (Hall and MacPhee, 2002).
Reproductive system
THC has been found to inhibit reproductive function in the few human studies reported, 
although these studies have yielded inconsistent evidence. On the basis of research on 
animals, it has been argued that cannabis would probably decrease fertility for both 
men and women in the short term (Joy et al., 1999). It has been suggested that the 
possible effects of cannabis use on spermatogenesis and testosterone may be most 
significant for those males whose fertility is already impaired, for example those with a 
low sperm count (Hall and Pacula, 2003).
The results of research studies on the effects of prenatal cannabis use and birth outcome 
have been small and inconsistent. Some studies have suggested that cannabis smoking 
in pregnancy may reduce birth weight. Controlled studies, including a recently reported 
study analysing the records of live births in New South Wales hospitals over a 5-year 
period, found that this relation remained after controlling for any confounding variables, 
although this relation has not always been found in other studies (Zuckerman et al., 
1989; Joy et al., 1999; Burns et al., 2006). The effects of cannabis smoking where an 
association has been found are small compared with tobacco (Fried et al., 1998). There 
is some evidence that gestation is shorter, especially for adolescent mothers (Cornelius 
et al., 1995; English et al., 1997; Burns et al., 2006). The relative contributions of 
smoking and THC are not known from the evidence available. Large, well-controlled 
epidemiological studies have found no evidence that cannabis causes birth defects 
(Zuckerman et al., 1989).
Maternal cannabis use and infant development
A review of the consequences of prenatal cannabis exposure found that, while prenatal 
exposure did not have an impact on global IQ, it did appear to have an impact on 
aspects of executive function, and, in particular, attentional behaviour and visual 
analysis/hypothesis testing beyond the infant stage. However, the reviewers draw 
attention to the limited literature, the small sample sizes and the quasi-experimental 
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nature of the studies reviewed and urged caution when interpreting the results of their 
review (Fried and Smith, 2001).
There are two major ongoing longitudinal studies examining prenatal exposure and 
subsequent effects on growth, cognitive development and behaviour. The first is the 
Ottawa Prospective Prenatal Study (OPPS), under way since 1978. The sample in this 
study consists of low-risk, white and predominantly middle-class families. The second 
study, the Maternal Health Practices and Child Development Study (MHPCD), began in 
1982. The study sample is high-risk, with low socioeconomic status and just over half 
are African American (Goldschmidt et al., 2000).
The OPPS found that there was a developmental delay after birth in the infant’s visual 
system with an increased rate of tremors and startle among the children of cannabis 
users. These effects had disappeared after 1 month and there were no detectable effects 
on standardised ability tests at 6 months and 12 months (Fried and Smith, 2001). The 
cohort has now been followed up to age 13–16 years. Effects were found on memory at 
age 4, attention at age 6 and visual integration and attention and visual-related aspects 
of executive function in 9- to 12-year-olds. There was no difference between children 
who were and were not prenatally exposed to cannabis on global IQ scores but there 
were differences in tasks that required visual memory, analysis and integration at age 
13–16 (Fried et al., 2003).
A recent study from the Pittsburgh MHPCD examined the effects of prenatal cannabis 
and alcohol exposure on academic achievement at age 10. In contrast to the OPPS, 
which found no effects of prenatal exposure to cannabis on school performance, use of 
cannabis in the first trimester was associated with poorer performance on reading and 
spelling tests and a lower performance evaluation by the children’s teachers. Analysis 
suggested these effects were mediated by the effect of first-trimester use of cannabis on 
the children’s anxiety and depression symptoms. Cannabis use in the second trimester 
was significantly associated with underachievement in school performance. While a 
range of factors, including socioeconomic, home environment and maternal prenatal 
and current drug use, were taken into account in the study, other important factors such 
as motivation and parental involvement in the child’s education did not feature in the 
statistical analysis (Goldschmidt et al., 2004).
Premature mortality
The two prospective studies on mortality amongst cannabis smokers are inconclusive. 
The Swedish study of conscripts showed an increased risk of premature death among 
those who smoked cannabis 50 or more times before the age of 18. Violence and 
accidental death were the main causes of death. This association disappeared after 
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alcohol and other drug use amongst this group were taken into account in the statistical 
analysis (Andreasson and Allebeck, 1990).
In an American study, regular cannabis use had a small association with premature 
mortality, which was entirely explained by the increased deaths from AIDS in men in 
the study. However, only men up to an average age of 43 were included in this study. 
With cigarette smoking and alcohol only modestly associated with premature mortality, 
it is too early to conclude from this study that cannabis use does not increase premature 
mortality (Sidney et al., 1997).
Cannabis and dependence
The US classification of psychiatric disorders, the Diagnostic and Statistical Manual of 
Mental Disorders (DSM), lists seven criteria for assessing substance dependence. These 
criteria are:
tolerance;•	
withdrawal;•	
the substance is often taken in larger amounts or over a longer period than was •	
intended;
there is a persistent desire or unsuccessful attempts to stop or cut down use;•	
a great deal of time is spent trying to obtain or use the substance;•	
important social, occupational or recreational activities are given up or reduced •	
because of substance use; and
use is continued despite knowledge that the substance is causing or exacerbating •	
physical or psychological problems.
A diagnosis of substance dependence is given if at least three of these symptoms are 
experienced in the same 12-month period (American Psychiatric Association, 1994).
Human and animal studies have found that tolerance to many of the physiological and 
behavioural effects of cannabis develops after repeated exposure to the drug (Adams 
and Martin, 1996; Joy et al., 1999). A laboratory study in which oral THC was given to 
human subjects over a 30-day period found a decline in the acute cardiovascular and 
psychological effects of THC (Jones and Benowitz, 1976). In another laboratory study, 
tolerance to the subjective effects of cannabis developed after oral administration of a 
small amount of THC for several days, with greater tolerance developing with increased 
amounts of THC (Jones, 1983).
Laboratory studies, while using a range of experimental approaches, have identified 
a number of adverse symptoms associated with withdrawal from cannabis. The most 
common symptoms include restlessness and nervousness, irritability, loss of appetite and 
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sleep disturbance. However, the extent to which the pattern of cannabis use contributes 
to the severity of withdrawal symptoms is undetermined. Most of the laboratory studies 
have involved heavy daily users as their subjects and the extent to which withdrawal may 
affect light or non-daily users is unclear (Budney and Hughes, 2006).
Using standardised diagnostic criteria for dependence such as DSM, epidemiological 
studies have estimated the extent of cannabis dependence in the general population. For 
example, the US Epidemiologic Catchment Study (ECA) estimated that 4.4 % of the US 
adult population had either abused cannabis or were dependent on it at some point in 
their life (Robins and Regier, 1991). Seventeen per cent of those in the ECA study who 
used cannabis more than five times had met DSM-III criteria for dependence at some 
point in their lives (Anthony and Helzer, 1991). Studies of long-term cannabis users in 
Australia found a substantial proportion of them were dependent. In a study of 200 
young Sydney adults who had used cannabis at least weekly for 11 years, 77 % met the 
DSM-III criteria for dependence in the past year and 40 % were classified as severely 
dependent (Swift et al., 1998).
National drug treatment systems have recorded an increase in the number of people 
seeking treatment for cannabis problems including dependence (see Montanari et al., 
this monograph). However, several studies have found that most regular cannabis users 
discontinue their use of cannabis by their mid-20s. For example, a longitudinal study 
of US school students found that less than 15 % of them were using cannabis daily by 
the age of 28–29 (Kandel and Davies, 1992). While studies of cannabis users who 
are unable to discontinue their use with assistance found that they were experiencing 
impaired functioning and a reduction in the quality of their lives, for the most part those 
with cannabis dependence seem to be able to remit their cannabis use without treatment 
(Budney and Moore, 2002; Hall and Pacula, 2003).
Cannabis and psychosis
There is evidence that large doses of THC can produce an acute psychosis marked 
by confusion, amnesia, delusions, hallucinations, anxiety, agitation and hypomanic 
symptoms. Nonetheless, such high THC doses are rare among cannabis smokers, 
given that they are likely to stop smoking if they experience undesired effects. Cases do 
exist, however, of high doses following ingestion of cannabis (cannabis cookies, space 
cake), where the user has less immediate control over THC titration. Such reactions may 
also occur after heavy cannabis use, or in some instances, after acute cannabis use by 
sensitive/vulnerable individuals. These effects abate rapidly after discontinuing cannabis 
use. There is little evidence that cannabis alone produces a psychosis that persists after 
the period of intoxication in non-vulnerable cannabis users (Joy et al., 1999; Hall and 
Degenhardt, 2000).
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Cannabis has been found to have an adverse effect on the clinical course of 
schizophrenia. In a Dutch prospective study which assessed patients each month over 
a year, the 24 people in the cannabis-using group had significantly earlier psychotic 
relapses than the non-cannabis-using group, an effect that was dose-related (Linszen et 
al., 1994). Similar findings emerged in a 3-year follow-up community study of psychotic 
and non-psychotic patients also in the Netherlands. The cannabis users at the beginning 
of the 3-year study were more likely to have psychotic symptoms and particularly severe 
ones at follow-up. Those who were diagnosed as psychotic at the beginning of the study 
had more adverse effects from cannabis use than those who were not psychotic at the 
start of the study (van Os et al., 2002). In a study that followed up 81 patients in acute 
psychiatric wards weekly for 6 months, a higher frequency of cannabis use led to more 
psychotic relapses in the patients, after controlling for other established factors leading 
to relapse in the statistical analysis (Hides et al., 2006). In contrast, a follow-up study 
of alcohol- and cannabis-using patients in a psychiatric outpatient continuing care 
programme in Canada found that symptoms of schizophrenia-spectrum disorders were 
reduced at 12 months (Margolese et al., 2006).
Findings from national surveys in the USA, Australia and the Netherlands have 
found higher rates of cannabis use in patients with schizophrenia than the general 
population. For example, the US National Epidemiological Catchment Area study 
(Robins and Regier, 1991) indicated that 50 % of those identified with schizophrenia 
also had a diagnosis of substance use disorder (abuse or dependence), compared 
with 17 % of the general population (Regier et al., 1990). People who used cannabis 
on a daily basis were 2.4 times more likely to report psychotic experiences than non-
daily cannabis users, after controlling for a variety of confounding variables such as 
socio-demographic factors, social role and psychiatric conditions (Tien and Anthony, 
1990). A study of cannabis use and psychotic symptoms at age 18 in a cohort of 3 500 
Greek adolescents found positive associations between frequency of cannabis use and 
psychotic experiences after controlling for other drug use and depressive symptoms in 
the statistical analysis, with a stronger association for those who started their cannabis 
use before age 15. However, the rates of cannabis use in the study group was low, with 
6 % reporting lifetime cannabis use and 0.9 % reporting daily or near-daily use (Stefanis 
et al., 2004).
Four main views on the nature of this association have been proposed. Firstly, the 
link may be due to socio-demographic, economic or genetic factors common to both 
substance use and schizophrenia. Secondly, the self-medication hypothesis suggests 
that patients with schizophrenia may be using cannabis and other drugs as a form of 
self-treatment for their condition. Thirdly, some suggest that cannabis causes psychosis. 
Finally, the vulnerability hypothesis proposes that the use of cannabis can increase the 
risk of schizophrenia among people with a predisposition to the illness.
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A number of carefully designed prospective studies have helped to assess the value of 
these hypotheses. These studies have been used to chart the development of a number 
of psychosocial and behavioural topics, and cannabis is just one issue the datasets 
have allowed to be explored. The findings from these studies have been summarised 
in a number of reviews (Arseneault et al., 2004; Smit et al., 2004; Degenhardt and 
Hall, 2006) and two meta-analyses and one systematic review (Henquet et al., 2005a; 
Semple et al., 2005; Moore et al., 2007).
The Swedish conscript study
A 15-year prospective study of cannabis use and schizophrenia in 50 465 Swedish 
military conscripts was the first study to report a potential link between cannabis use 
and later schizophrenia. The study recruited conscripts who were 18–20 years old in 
1969–70. Conscripts who were hospitalised for schizophrenia or psychosis and could 
be linked to their military medical records were identified. Through this linkage, the 
relationship between cannabis use and the onset of schizophrenia might be established.
The relative risk for a diagnosis of schizophrenia was 1.3 times higher for those who 
had used cannabis 1–10 times, three times higher for those who had used cannabis 
1–50 times and six times higher for heavy users of cannabis (defined as use on more 
than 50 occasions) than among those who had not used cannabis. However, over half 
of the heavy users had had a diagnosis of a psychiatric condition other than psychosis 
at conscription and when the analysis took this factor into account the relative risk fell to 
2.3 (Andreasson et al., 1987; Allebeck, 1991).
A follow-up of the conscripts reported in 2002. Again, heavy cannabis users were found 
to be 6.7 times more likely than non-users to be at risk of a diagnosis of schizophrenia 
after 27 years. The risk held when the analysis was carried out on a subsample of 
conscripts who had used cannabis only. While not an exhaustive array, when other 
possible confounding factors such as psychiatric diagnosis at conscription, IQ, growing 
up in a city and cigarette smoking were taken into account the risk, though reduced, still 
remained, with heavy cannabis users having a threefold relative risk of a diagnosis of 
schizophrenia (Zammit et al., 2002).
The Dunedin Multidisciplinary Health and Development Study
The Dunedin Study from New Zealand has followed a birth cohort of 1 037 people from 
the general population born in 1972–3. At age 11 they were examined to identify any 
self-reported psychotic symptoms before cannabis use may have begun. At 15 and 18 
they were examined for self-reported cannabis use, enabling the investigation of the 
age of onset in relation to later outcomes. At age 26 the subjects were interviewed to 
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see if they met the criteria of schizophreniform disorder according to DSM-IV diagnostic 
criteria. A diagnosis of schizophreniform disorder enabled the elimination of psychotic 
symptoms resulting from being under the influence of alcohol or drugs. Ninety-six per 
cent of the birth cohort had remained in the study at this point.
Those who used cannabis at ages 15 and 18 had higher rates of psychotic symptoms 
at age 26 than non-users, a relationship that remained after the analysis controlled 
for psychotic symptoms predating cannabis use. Those who started using cannabis 
by the age of 15 showed a fourfold increase in the likelihood of a diagnosis of 
schizophreniform disorder by the age of 26. The analysis also showed that cannabis use 
by age 15 did not predict depression at age 26, suggesting the outcome was specific 
to the cannabis use. The study reported that 10.3 % of the 15-year-olds using cannabis 
received a diagnosis of schizophreniform disorder by the age of 26, compared with 3 % 
of the controls. The number of 15-year-olds smoking cannabis in the study was small, 
however (Arseneault et al., 2002).
The Christchurch Health and Development Study
Another New Zealand Study followed a birth cohort of 1 265 people born in 
Christchurch urban region, with annual measurements up to the age of 16. Additional 
measurements were taken at age 18, including whether the individuals had a DSM 
diagnosis of cannabis dependence and whether psychotic symptoms were identified. 
This examination was repeated at ages 21 and 25. Researchers were able to draw on 
a sample of 1 055 participants for whom information on cannabis use and psychotic 
symptoms were available at ages 18, 21 and 25, when 1 011 people remained in the 
study. Psychosis symptomatology was measured with psychosis items selected from of the 
symptom checklist as representative of the psychotic symptoms. This study addressed two 
main questions about the relationship between cannabis and psychosis in its analysis. 
It attempted to control for residual confounding in its analysis and examine whether 
reverse causality may be in play, with an increased susceptibility to use cannabis 
resulting from the individual’s psychological state. A wide range of confounding factors 
were controlled for in the analysis, including family socioeconomic status, family 
functioning, child abuse including physical punishment, educational achievement and 
psychotic symptoms at the previous assessment. Analysis also took into account non-
observed fixed sources of confounding (Fergusson et al., 2003, 2005).
The results showed that young people using cannabis daily had rates of psychotic 
symptoms that were between 2.3 and 3.3 times higher than those of non-users. After 
adjusting the analysis to take into account the confounding factors, this relationship 
persisted with daily users 1.6–1.8 times more likely to be experiencing rates of psychosis 
than non-cannabis users. While the study could not control for all possible confounding 
factors and the diagnostic tools used in the study may not have found all the aspects 
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of psychosis, the research shows that increasing use of cannabis was associated 
with increases in the risks of psychotic symptoms, and that the increases in psychotic 
symptoms were not associated with increased rates of cannabis use, casting doubt on 
the self-medication hypothesis (Fergusson et al., 2005).
The Netherlands Mental Health Survey and Incidence Study 
(NEMESIS)
This study followed 7 076 adults aged 18–65 years randomly selected from the Dutch 
general population, who were examined in 1996, 1997 and 1999. A total of 4 848 
people were still in the study at the 1999 follow-up, 4 045 of whom were considered as 
the ‘at-risk’ set. The attrition of participants was covered in the analysis of findings from 
the study. At the 3-year point those who used cannabis at baseline were three times 
more likely to show psychotic symptoms than non-users. This relationship persisted after 
controlling for a range of factors in the analysis, such as ethnic group, marital status, 
educational level and urbanicity. The study also found a dose–response relationship, 
with the highest risk of psychotic symptoms amongst those who used cannabis more 
frequently at the beginning of the study. Lifetime history of cannabis at baseline was 
a stronger predictor of later psychosis than cannabis use at follow-up, suggesting that 
the relationship between cannabis use and psychosis is not simply one resulting from a 
short-term psychotic episode (van Os et al., 2002).
The early developmental stages of psychopathology (EDSP) study
The EDSP study examined the prevalence, incidence, risk factors and 4-year course of 
mental disorders in a random representative sample of adolescents and young adults 
aged 14–24 in Munich. The baseline survey with 3 021 participants was conducted in 
1995, with follow-up data for 2 437 participants in 1999. After adjusting for a range 
of factors in the analysis, cannabis use at baseline moderately increased the risk of 
psychotic symptoms at follow-up. The effect of cannabis was stronger for those with 
any predisposition for psychosis at baseline than those without, with a dose–response 
relation with increasing frequency of use. Predisposition to psychosis did not predict 
cannabis use at follow-up in the analysis, suggesting that the cannabis was not used as 
self-medication in this group (Henquet et al., 2005b).
What is the relationship between cannabis and 
psychosis?
While these various studies used a range of methodologies, measurements of cannabis 
use and psychosis and, in the cases of the Dunedin and NEMESIS studies, were marked 
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by small sample sizes, there was some consistency in the risk of developing psychosis 
after cannabis use across all the populations studied. The Moore et al. meta-analysis 
concluded that those who had ever used cannabis were 40 % more likely to experience 
a psychotic outcome than non-users and regular cannabis use increased the chances of 
developing later schizophrenia or schizophrenia-like psychotic illness by approximately 
two- to threefold (Arseneault et al., 2004; Henquet et al., 2005a; Semple et al. 2005; 
Moore et al., 2007). In the Dunedin study, those who started their cannabis use by age 
15 had a higher risk of developing schizophreniform disorder by age 26 than those 
who started at age 18, suggesting that early cannabis use may provide higher risk 
of psychosis outcomes (Arseneault et al., 2002). The analysis from the Christchurch 
population study has gone the furthest in terms of controlling for a wide range of 
possible confounding demographic, social and individual factors in their analysis, 
suggesting that the association between cannabis use and psychosis in the study 
population is unlikely to be due to confounding factors (Fergusson et al., 2005). The 
analysis also suggested that the direction of causality was from cannabis to psychosis.
With the Christchurch and other studies eliminating the self-medication hypothesis, 
the studies also eliminated the idea that other drugs may be involved and found that 
cannabis makes its own unique contribution to the development of later schizophrenia or 
psychotic symptoms.
The significance of the relationship between cannabis and 
schizophrenia to public health
However, the increased rates of cannabis use in the last 30 years have not been 
accompanied by a corresponding increase in the rates of psychosis in the population 
(Degenhardt et al., 2003a). The studies reviewed here suggest that cannabis is a 
modest statistical risk factor, with studies calculating that 6–8 % of schizophrenia could 
be prevented if cannabis use was removed from the general population of adolescents 
and young adults (Arseneault et al., 2004; Henquet et al., 2005b). The vast majority of 
young cannabis smokers do not develop psychosis, and this supports the hypothesis that 
a small minority of users may be vulnerable to the effects of cannabis and time of onset 
to psychotic illness. The vulnerability hypothesis has received some support from a study 
that explored substance use and psychotic experiences in daily life. The acute effects 
of cannabis were stronger among participants with high vulnerability for psychosis 
(experiencing at least one bizarre psychotic symptom or at least two non-bizarre 
symptoms over the first month). Those vulnerable participants reported increased levels 
of perceived hostility and unusual perceptions, and also decreased levels of pleasure 
associated with the experience of using cannabis (Verdoux et al., 2003). That cannabis 
is a risk factor for earlier onset is further supported by a study examining first-episode 
psychosis in the Netherlands, which found that cannabis users in the group presented 
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to treatment earlier than non-users, with a median age difference of 7.5 years (Veen 
et al., 2004). Adding further weight to the strength of the vulnerability hypothesis is a 
recent study that examined a gene–environment interaction in the Dunedin population, 
finding that a gene called COMT moderated the influence of adolescent cannabis use 
on developing adult psychosis in the Dunedin population, a finding also reported in an 
experimental setting (Caspi et al., 2005; Henquet et al., 2006). However, this interaction 
was reported only in a small subgroup of participants in each study and awaits further 
replication.
Cannabis and depression and anxiety
There have been a number of case reports of panic reactions after cannabis use. In a 
survey of 1 000 young adults in New Zealand, acute anxiety and panic was the most 
common psychiatric problem reported by cannabis smokers in the study (Thomas, 
1996). Lifetime cannabis dependence, measured using DSM criteria, was significantly 
related to an increased risk of panic attacks in a large statewide randomly sampled 
household survey conducted in the USA (Zvolensky et al., 2006). National population 
studies have found evidence for a link between cannabis use and depression. A study 
of a nationally representative sample of 7 000 adults aged 15–45 in the USA found a 
small increased risk of depression among the current users of cannabis (Chen et al., 
2002). Another study of a nationally representative sample of 40- to 50-year-olds in 
the USA found a small increased risk, but one that was associated with earlier onset of 
cannabis use rather than current use (Green and Ritter, 2000). A national population 
study in Australia found that cannabis users were between two and three times more 
likely to meet criteria for a mood disorder than non-users. Prevalence of mood disorders 
increased from 6 % in non-users to 14 % of those who met criteria for cannabis 
dependence (Degenhardt et al., 2001).
A meta-analysis of cohort studies found a modest but significant association between 
early onset heavy use of cannabis and later depression but no evidence that depression 
increased the probability of later use of cannabis (Degenhardt et al., 2003b). For 
example, a follow-up study of participants with no depressive symptoms at the beginning 
of the Epidemiologic Catchment Area study found that those with a diagnosis of 
cannabis abuse at baseline were four times more likely than those without a cannabis 
abuse diagnosis to have depressive synmptoms at follow-up (Bovasso, 2001). In a 
longitudinal study of a representative sample of 1 601 secondary school students in the 
Australian state of Victoria, weekly or more frequent use led to a doubling of the risk 
for later anxiety or depression by the age of 20, while female daily users had a fivefold 
increase in later depression and anxiety (Patton et al., 2002). Depression and anxiety in 
the students did not predict later cannabis use in the analysis, suggesting that cannabis 
was not used for self-medication. However, findings from the smaller New Zealand 
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Dunedin sample indicated that those in the sample using cannabis by age 15 did not 
have a significantly higher risk of later depression by the age of 26 than non-users 
did, although the sample size may have prevented the identification of a relationship 
in the statistical analysis (Arseneault et al., 2002). In a follow-up study of the New 
Zealand Christchurch sample, the analysis controlled for a range of confounding factors 
that might explain the association between cannabis and a range of psychosocial 
outcomes including depression and suicide attempts. The link between cannabis and 
these outcomes and heavy (at least weekly) cannabis use still persisted, suggesting that 
cannabis was contributing directly to these outcomes (Fergusson et al., 2002). A recent 
analysis of data from the ongoing National Longitudinal Survey of Youth of 1979 with a 
large cohort of 12 686 men and women born between 1957 and 1964 did not find that 
past-year cannabis use predicted later development of depression (Harder et al., 2006). 
However, the study group may have been too old and restricted in age range for the 
relatively low level of their cannabis use to result in significant symptoms of depression 
(Copeland, 2006). Overall, a recent meta-analysis has concluded that the majority of 
studies of cannabis and affective mental health problems have not adequately addressed 
the issue of reverse causation, and the evidence for a link is not strong (Moore et al., 
2007).
Impact of increased potency of cannabis
High-THC cannabis is reported to have become increasingly available, although the 
published evidence for this is scant (Hall and Swift, 2000; King et al., 2005). This 
may reflect an increased market for more potent cannabis amongst regular users and 
improved methods of growing high-potency cannabis. The health implications of this 
development are unclear. Those who use these high-potency products may increase their 
risks of developing respiratory disease or experiencing psychotic symptoms (Hall and 
Pacula, 2003). However, regular users may be able to titrate their dose and decrease 
the risks of respiratory disease, and naive users who experience adverse effects may be 
deterred from further cannabis use (Hall and Pacula, 2003). As yet, there is insufficient 
evidence to inform a conclusive view of the risks to health posed by high-potency 
cannabis (King et al., 2005).
Conclusion
Most cannabis users cease smoking cannabis by their late 20s or early 30s and the 
vast majority do not experience any adverse effects from their use. A minority continue 
their use into middle age, and such long-term heavy users have reported a range of 
negative health effects (Reilly et al., 1998; Gruber et al., 2003). However, the causal 
role of cannabis in the development of negative physical and mental health problems 
for some users remains uncertain and in need of further investigation. Recent research 
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has provided more information on the involvement of cannabis in the development 
of psychiatric disorders such as depression and psychosis in vulnerable people, or 
bronchial problems resulting from cannabis smoke. But more research work is needed to 
address the precise role of cannabis in health-related problems and the broad research 
agenda for cannabis remains much the same as 30 years ago.
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Chapter 7
The public health significance 
of cannabis in the spectrum of 
psychoactive substances
Keywords: cannabis – DALY – economics – health – mental health – public 
health
Setting the context
There has been a growth in interest in measuring and quantifying the public health 
impact of specific health issues, from influenza outbreaks, through obesity, tobacco 
smoking and heart disease, to behavioural items such as sports and workplace injuries 
and risks associated with mobile phones. The discipline is increasingly termed ‘health 
impact assessment’ (HIA), with an international conference on HIA in its eighth year in 
2007.
Illicit and licit drugs, in particular alcohol and tobacco, are no exception to this euro- 
and dollar-counting trend. Increasingly, public health economists are joining forces with 
epidemiologists and treatment professionals to estimate or quantify the impact of drug 
use — social, economic or, more specifically, in terms of healthcare service and resource 
allocation. Specifically for cannabis, however, methodologies to gauge the global public 
health impact of cannabis use are yet to emerge, although studies have examined areas 
such as the treatment of cannabis use disorders, prevention costs, secondary health risks 
such as driving under the influence of cannabis (see Mann et al., this monograph) and 
indirect costs (truancy, workplace absenteeism or sick leave, etc.).
As this chapter demonstrates, measuring the global impact of cannabis use represents 
serious methodological challenges, even when compared with other areas of drug 
policy. There are confounding issues that arise from consumption of cannabis together 
with alcohol and tobacco. And whereas other illicit drugs with better understood health 
risks offer more clear-cut features to measure — in terms of toxicology and effects 
on physical health — cannabis health effects are more amorphous and offer fewer 
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opportunities for benchmarking harms (see Witton, this monograph). For example, 
studies of the impact of needle exchange, or prison-based harm reduction projects are 
able to record changes in drug-related deaths, HIV or hepatitis transmission. Similarly, 
studies of the impact of smoking bans might measure air quality in bars and clubs, or 
look at improvements across the general population with regards to smoking-related 
problems (respiratory problems, heart disease and lung cancer). While some measures 
can be made of the prevalence of treatment demand, population-level screening for 
problems related to cannabis use is underdeveloped. Furthermore, cannabis treatment 
takes many shapes and forms (an overview is provided by Rödner Sznitman, this 
monograph), making estimations of ‘average cost of treatment’ difficult. 
Any further precision into the public health costs specifically for cannabis in Europe is 
likely to draw strongly on the expertise of the EMCDDA’s Reitox national focal points, 
and on their scrutiny of treatment demand and treatment costs in particular. Yet this 
task is far from easy. Estimates were recently made for the EMCDDA on ‘health and 
social care expenditure’ for all illicit drugs in Europe (Reitox national reports, 2007; 
EMCDDA Annual Report, 2007). The exercise showed high variability in reporting: a 
figure for total drug-related public expenditure in the EU on illicit drugs ranged from 
EUR 13 billion to EUR 36 billion. Tangible expenditure on illicit drugs — treatment, 
prevention, enforcement, epidemiology — is subject to a wide range of labels, and is 
typically distributed across a range of actors: ministerial budgets, NGOs, private and 
public health insurance, police, customs, etc. In Europe, these actors differ not just within 
each country in Europe, but also on a federal or provincial level. There are further issues 
of country size, currency conversion, differing levels of cannabis prevalence, varying 
patterns of co-consumption (alcohol, tobacco, other illicit drugs) and divergence in the 
relative cost of healthcare provision and policing across the EU. So, estimating the full 
impact of cannabis on health with an accountant’s accuracy is a distant prospect, even 
at the level of single Member States.
Nonetheless, the UNODC has begun exploration into the area, and has proposed using 
treatment demand rates as one of the means to ‘weigh’ the dangers of illicit drugs. It 
estimated in 2005 that 78 per 1 000 users of opiates undergo treatment, higher than 
for cocaine (66 per 1 000 users), amphetamines (16) or cannabis (7) (UNODC, 2005). 
Work by the European Brain Council, while looking at wider mental health problems, 
has also improved understanding of the global public health ‘footprint’ of brain 
disorders.
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The public health significance 
of cannabis in the spectrum of 
psychoactive substances
Robin Room
The public health significance of psychoactive substances: 
the risk of harm
Cannabis is one among a whole spectrum of psychoactive substances used by humans. 
They are used not only for their psychoactive properties, but also in various other 
practical functions, depending on the substance — for example, as a medicine, a food, 
a thirst-quencher, a solvent. Apart from their physical effects, strong values (both positive 
and negative) are attached to psychoactive substances — in different circumstances, they 
may serve as a sacrament, as a taboo object, as a symbol of fellowship, as a symbol of 
stigmatisation (Room, 2005a).
Along with the positive effects and symbolic values of psychoactive substances, to a 
greater or lesser extent the substances also carry the risk of harm, particularly to the 
user but also sometimes to those around the user. The public health significance of 
psychoactive substances lies in these potential and actual harms. Establishing the harms 
is a prerequisite for deciding on effective public health responses.
It is a commonplace in the literature that the harms associated with psychoactive 
substances are multidimensional, and that they are greatly affected by the mode and 
context of use. A recent British publication on Dangerousness of Drugs, for instance, 
rates different psychoactive substances in terms of nine different domains of harm, and 
also in terms of seven domains of factors (such as route of administration or context of 
use) that can increase or reduce the dangers. Best et al. (2003) make ‘no attempt … 
to rank order the target substances, even within each of the domains specified. This is 
because the dangers are not uni-dimensional nor do they generally occur in isolation’. 
They continue: ‘Drugs are not, of themselves, dangerous, with the risk residing in the 
interaction between the substance, the individual, the method of consumption and the 
context of use’ (Best et al., 2003).
The dangers are indeed multidimensional and greatly affected by mode and context 
of use. But still, in a public health policy context it is worthwhile to consider the risk 
of different psychoactive substances in an overall frame. The present international 
drug control regime, and national drug control regimes operating in accordance 
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with it, generally classify drugs into a set of classes according to ‘the harm they may 
cause’ (Advisory Council on the Misuse of Drugs, 2002). Any effort to arrive at an 
improved classification or ranking must start from the rankings implied by the existing 
classifications.
However, there is presently no clear agreement on how to arrive at an improved and 
scientifically defensible ranking of dangerousness or of the degree of social and public 
health problems from different substances (in various use-forms).
Comparing present levels of social and health harm
One relevant policy consideration, obviously, is the present level of harm in a given 
society, or on a global basis. Comparisons are most available here between tobacco 
(considering primarily cigarettes), alcohol and all illicit drugs taken together. For 
instance, according to the World Health Organisation’s estimates for the Global Burden 
of Disease in 2000, tobacco accounts for 4.1 % of the total burden in disability-adjusted 
life-years globally, alcohol for 4.0 %, and illicit drugs for 0.8 %. For developed societies 
such as the United Kingdom, the corresponding figures are 12.2 %, 9.2 % and 1.8 % 
(Ezzati et al., 2002). Another mode of comparative estimation of harm is in terms of 
the economic costs to a society from use of different psychoactive substances. While 
the assumption behind such estimations are subject to substantial criticism (e.g. NIAAA, 
1994: 253–259), they do have the advantage of including some of the social as well as 
the health costs. A representative set of estimates in this mode is for Canada for 1992: 
CAD 9.6 billion for tobacco, CAD 7.5 billion for alcohol, and CAD 1.4 billion for illicit 
drugs (Single et al., 1998). In general, the costs for illicit drugs are dominated by the 
criminal justice costs, primarily of policing the illicit market and punishment for illicit 
dealing or use.
In a new cost-of-illness analysis for Canada, cannabis, despite being by far the most 
commonly used illegal drug, accounted for a relatively small part of the estimated 
health burden from illicit drugs: 6.4 % of the overall healthcare costs due to illegal drugs 
and 2.3 % of the years of life lost due to mortality from illegal drugs (calculated from 
analyses prepared for Rehm et al., forthcoming).
Comparing the potential for harm
The most obvious objection to basing policy decisions on such estimates is that the 
present levels of social and health harm are not necessarily the same as what the levels 
of harm would be if policies changed. The question this leaves, however, is: what is, 
then, the appropriate basis for judging between psychoactive substances in terms of 
their adverse effects? Presumably, the answer to this question should be in terms of 
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realistic scenarios of the substance’s potential for harm — its dangerousness — in cases 
of heavy use. In a research team of which I was a member (Hall et al., 1999), we took 
the approach to this of comparing the importance (probability and severity) of effects 
resulting from heavy use of the different substances in their most harmful commonly 
used form – in the case of cannabis, use by smoking. A more nuanced approach, from 
a public health perspective, would pay attention to likely rates of such heavy use in a 
whole population with ready and cheap availability. Rates of dependence or heavy use 
among users in current circumstances may give some indication in this direction, but for 
illicit substances they obviously fall short of the full test with ready and cheap availability. 
At this stage in Europe, cannabis is an in-between case; it could be argued that in the 
Netherlands cannabis use might not rise much from present levels with full legalisation 
(cf. MacCoun and Reuter, 2001).
Comparison on dimensions of danger: overdose
One important dimension of dangerousness or harm is the likelihood of an overdose 
from the substance. This dimension is obviously of special significance not only for 
overdoses among recreational and heavy users, but also in more general terms of 
poison control — for example, labelling and child-proofing containers of the substance. 
The first column of figures in Table 1 shows partial results of a recent review of the 
literature by Gable (2004). The ‘safety ratio’ shown is the ratio between ‘the usual 
effective dose for nonmedical purposes’ and the usual lethal dose, for the mode 
of administration specified. Gable comments, concerning the wider range of drugs 
considered in his review, that ‘the range of safety ratios is so wide that the data appear 
to have the attributes of an ordinal scale’. In such a scale, cannabis would be in the 
lowest-risk group, those substances with a ratio of 100 or above.
Comparison on dimensions of danger: degree of intoxication
Another dimension of dangerousness is the level of intoxication produced by the 
substance, which ‘increases the personal and social damage a substance may do’ (Hilts, 
1994). Obviously, the level of intoxication produced by taking a substance is highly 
influenced by the dose taken, and the set and setting of the consumption. A glass of 
alcohol with dinner will not result in intoxication, while on the other hand, traditional 
ways of using tobacco among some indigenous South Americans routinely resulted 
in intoxication to the point that the smoker passed out (Robicsek, 1978). But despite 
these caveats, there are inherent differences in the propensity of different psychoactive 
substances to intoxicate. The second column of Table 1 shows rankings made by Jack 
Henningfield and Neal Benowitz on this (Hilts, 1994). Cannabis was ranked as more 
intoxicating than tobacco, but less so than alcohol, cocaine and heroin.
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Comparison on dimensions of danger: dependence
The dependence potential or addictiveness of a substance plays rather little part in 
the formal criteria for scheduling of substances under the international conventions 
(Room, 2005b). Nevertheless, there is no doubt that the popular imagery of addiction 
and addictiveness plays a part in setting the policy stage; in countries like the USA, 
arguments about the addictiveness of nicotine, for instance, have been secondary only 
to arguments about second-hand smoking in moving the political process of tobacco 
control forward. Accordingly, ratings are also available of the dependence potential or 
addictiveness of different substances. For instance, Henningfield and Benowitz (Hilts, 
1994) give comparative ratings of the different substances on withdrawal, tolerance, 
reinforcement and dependence (‘how difficult it is for the user to quit, the relapse 
rate’, etc.). The recent report of the UK Prime Minister’s Strategy Unit (2005) offers a 
rating on ‘potential addictiveness’, and a French committee chaired by Bernard Roques 
(1999) offers a rating on ‘psychic dependence’ (see last three columns of Table 1). The 
UNODC proposed a ‘harm/risk factor’ for drugs for use in creating an Illicit Drugs Index 
(UNODC, 2005), using treatment demand data as a measure of harmfulness. Though 
there is some disagreement in the rankings for other drugs, each of these rankings 
places cannabis at the lowest level for the substances in the table (the Strategy Unit 
shows a lower ranking for LSD).
Comparisons on dimensions of danger: more global ratings
The Roques committee also took a more global approach to the issues of 
dangerousness. Table 2 shows the Roques committee’s rankings on ‘Toxicité générale’ 
(general toxicity) and ‘Dangerosité sociale’ (social dangerousness). In the usage of 
the Roques report, ‘toxicity’ includes long-term health effects such as cancer and liver 
disease, and infections and other consequences of mode of use, as well as the acute 
effects represented by the safety ratio. The concept of ‘social dangerousness’ focuses on 
Table 2: Ratings on global dimensions of ‘dangerousness’ (Roques, 1999)
General toxicity Social dangerousness
Cannabis Very weak Weak
Benzodiazepines (valium) Very weak Weak (except when driving)
MDMA/ecstasy Possibly very strong Weak (?)
Stimulants Strong Weak (possible exceptions)
Tobacco Very strong None
Alcohol Strong Strong
Cocaine Strong Very strong
Heroin Strong (except therapeutic use of opiates) Very strong
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Table 3: A summary of adverse effects on health for heavy users of the most 
harmful common form of each of four drugs (according to Hall et al., 1999)
Cannabis Tobacco Heroin Alcohol
Traffic and other accidents * * **
Violence and suicide **
Overdose death ** *
HIV and liver infections ** *
Liver cirrhosis **
Heart disease ** *
Respiratory diseases * **
Cancers * ** *
Mental illness * **
Dependence/addiction ** ** ** **
Lasting effects on the fetus * * * **
**Important effect, *less common or less well-established effect.
‘states of comportment which can generate very aggressive and uncontrolled conduct 
… induced by the product or varied disorders (fights, robberies, crimes …) in order to 
obtain it and risks for the user or others, for example in the case of driving a vehicle’ 
(Roques, 1999: 296; original in French). It will be seen that the Roques ratings on 
‘general toxicity’ are compatible with the safety ratios reported by Gable (2004), and 
that the ‘social dangerousness’ ratings are compatible with the ratings by Henningfield 
and Benowitz on intoxicating effect (Hilts, 1994). Cannabis is ranked ‘weak’ on ‘general 
toxicity’, and ‘very weak’ on ‘social dangerousness’.
Hall et al. (1999) took another approach to a global rating of adverse effects of 
psychoactive substances, comparing four classes of substances in terms of whether there 
was ‘important effect’ or a ‘less common or less well-established effect’ on each of 
11 dimensions (Table 3). According to these rankings, alcohol clearly has the greatest 
potential for harm; among the four substances, cannabis has the lowest number of 
asterisks.
Nutt et al. (2007) used another global method, identifying three main factors that 
together determine the harm associated with different drugs: (i) the physical harm 
to the individual user caused by the drug; (ii) the tendency of the drug to induce 
dependence; and (iii) the effect of drug use on families, communities and society. 
Within these categories, they recognised three components to create a nine-category 
‘matrix of harm’. Physical harms were split into ‘acute’, ‘chronic’ and ‘intravenous’ 
harm. Dependence was split into ‘intensity of pleasure’, ‘psychological dependence’ 
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and ‘physical dependence’. Social harms were split into ‘intoxication’, ‘other social 
harms’ and ‘healthcare costs’. Expert panels gave scores, from 0 to 3, for each category 
of harm for 20 different drugs. Cannabis was rated at 11th most harmful out of 20 
substances: heroin and cocaine were rated the most harmful, while both alcohol and 
tobacco were rated more harmful than cannabis, with khat, alkyl nitrates and ecstasy 
rated as least harmful.
Accounts have appeared in Swedish newspapers of a recent ranking of drugs 
according to their dangerousness, circulated by the Swedish authority for prosecutions 
(Åklagarmyndigheten) to all Swedish prosecutors. Heroin was listed as the most 
dangerous drug, with others in descending order: ecstasy, amphetamines, cannabis, 
khat (TT, 2005).
In summary, on every comparison of dangerousness we have considered, cannabis is at 
or near the bottom in comparison with other psychoactive substances.
The implications of the comparative findings
The ratings above, and the literature considered elsewhere in this volume, do not 
by any means exonerate cannabis as a public health concern. In recent years, as 
noted elsewhere in this volume, there has been some strengthening of the evidence 
that cannabis may play a part in precipitating or worsening psychosis. The evidence 
on the adverse effects of driving under the influence of cannabis has also somewhat 
strengthened (see Mann et al. in this volume). In my view, the asterisks in Table 3 
already accommodate these findings, in terms of relative ratings and public health 
significance. But, whichever way one looks at it, the findings emphasise that, as with 
most psychoactive substances, use of cannabis can be harmful for some users and in 
some circumstances.
Comparing degrees of dangerousness is a fraught topic. General comparisons of 
this type have often faced substantial opposition in the course of publication. The 
material from the Prime Minister’s Strategy Unit was only released on 1 July 2005, 2 
years after compilation, in partial compliance with a Freedom of Information request 
(Travis, 2005). The report by Hall et al. (1999) was eventually published after a media 
storm (Anonymous, 1998) over its omission from the report for which it was originally 
commissioned (WHO, 1997). The Roques report also caused considerable controversy 
when it appeared. As a French review noted, there were complaints not only about 
including alcohol among ‘drugs’, but also that the group of experts ‘banalized the 
danger of cannabis by putting in evidence the weak physical and psychic dependence 
from this product, compared with those of tobacco and alcohol’ (Jauffret-Roustide, 
2004: 17–18; original in French).
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The news reports of the Swedish prosecutors’ ranking noted that ‘few Swedish politicians 
admit that certain kinds of drugs are less dangerous than others’. One quoted expert 
noted the ranking was just ‘from a legal perspective’, and another that ‘one must 
differentiate between public debate and jurisprudence’. In this perspective, distinctions 
on dangerousness should remain hidden knowledge: ‘if one talks about drugs to youth 
one has to keep to what is important for them’ (TT, 2005). To the question of which 
are the most dangerous drugs, the Swedish police website answers: ‘According to the 
National Police Board’s decision, there is no reason to discuss the dangerousness of 
different drugs. Preparations classed as narcotics are forbidden or require prescription; 
hence they are dangerous or harmful to misuse’ (Rikspolisstyrelsen, 2005).
There is an enormous commitment by many involved in the international control system 
and equivalent national systems to keeping the status quo, with the outer defensive line 
often set around cannabis. But, in a broad public health perspective on psychoactive 
substances and their potential for harm, it is clear that, on the one hand, tobacco and 
alcohol are greatly underregulated in current international drug control and regulatory 
systems, while on the other hand, the restrictions on cannabis are too harsh.
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Chapter 8
Assessing the population health 
impact of cannabis use
Keywords: cannabis – drug policy – economics – health – mental health – 
public health
Setting the context
There is a tendency in discussions of responses to cannabis use to rely on faulty logic. 
From the perspective of drugs professionals, these might manifest themselves in terms 
of a mild prejudice: ‘study finds that mass media prevention campaign had boomerang 
effect’ becomes ‘mass media preventions do not work’. Or perhaps ‘higher prevalence 
of schizophrenia among cannabis users’ becomes ‘there is a causal link between 
schizophrenia and cannabis use’.
In a stronger form, the media may encourage the inference of unrelated behaviours 
in relation to cannabis. Issues of cannabis potency, mental health and crime often 
share headlines. We may cite examples noted in the EMCDDA’s press corpus during 
production of this monograph: ‘Deranged cannabis smoker obsessed with Satanism 
stabbed country vicar to death’ (1); ‘Son twisted by “skunk” knifed father 23 times’ (2). 
Public and political debate on cannabis users can sometimes be drowned out by the 
noise generated by such salacious headlines.
This chapter — written by Wayne Hall, one of the world’s most published experts 
on cannabis use — advocates a sceptical eye with regard to claims made for the 
public health impact of cannabis. Developing the theme of public health impact 
studies discussed by Robin Room in the previous chapter, this chapter looks at the 
difficulties involved in assessing the global effect of cannabis use on the health of entire 
populations.
 (1) London Evening Standard, 17 October 2007.
 (2) Daily Mail, 23 July 2007.
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On a practical level, the chapter provides a checklist to help researchers to question any 
assumptions or to avoid causal inferences (3). From an epidemiological point of view, 
the data on the precise impacts of chronic cannabis use are weak, especially compared 
with what we know about alcohol and tobacco. Furthermore, assessing the impact of 
cannabis problems is difficult and beset with ethical problems, not least because of the 
illicit status of the drug and a tendency for it to be discussed in conjunction with, or 
compared with, other illicit drugs that carry higher toxicological risks.
The chapter also mentions an ‘inflationary–deflationary dialectic’, in which cannabis 
problems have been both demonised by moralists and belittled by pro-cannabis 
organisations. Decoupling cannabis from political discussions is necessary in order 
to quantify the harms of cannabis, and to place them against a neutral background 
where they are compared with other health issues. The chapter also suggests that 
the temptation to focus on adverse health effects needs to be balanced with potential 
positive effects of cannabis use. This argument is often applied to defend moderate 
alcohol use vis-à-vis the harms of binge drinking or alcoholism. While efforts to quantify 
the public health harms of illicit drug use are currently only in an embryonic stage, 
research into any ‘balancing’ public health benefits is extremely rare.
Further reading
Hall, W., Pacula, R. (2003), Cannabis use and dependence: public health and public policy, 
Cambridge University Press, Cambridge.
MacCoun, R., Reuter, P. (2001), Drug war heresies: learning from other vices, times and places, 
Cambridge University Press, Cambridge.
Mackay, C. (1852), Memoirs of extraordinary popular delusions and the madness of crowds, Office 
of the National Illustrated Library, London.
See also the grey literature list in the Appendix to Volume 1 of this monograph.
 (3) See also the comments on meta-reviews by Bergmark, this monograph.
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Assessing the population health 
impact of cannabis use
Wayne Hall
There are major technical challenges in assessing the impact that cannabis use has on 
the health of users and public health (Hall, 1999). These include difficulties in deciding 
whether cannabis use is a contributory cause of the adverse health and psychological 
effects attributed to its use and in quantifying the magnitude of these adverse health 
effects. These technical challenges are amplified by the difficulties in separating the 
political debate about the legal status of cannabis use from appraisals of its health 
effects.
Making causal inferences
Before a claim can be accepted that cannabis causes an adverse health outcome there 
must be evidence that there is an association between cannabis use and the health 
outcome; the association is not due to chance; cannabis use preceded this outcome; and 
we can make a case for the implausibility of alternative, non-causal explanations of the 
association (Tukey and Brillinger, 1984; Hall, 1987; Strom, 2000).
Evidence of association: reasonable evidence of an association between cannabis •	
use and a health outcome (e.g. schizophrenia) is provided by finding a relationship 
between cannabis use and the outcome in case–control, cross-sectional, cohort or 
experimental studies.
Excluding chance: evidence that chance is an unlikely explanation of the relationship •	
is provided by constructing a confidence interval around the sample value of a 
measure of association. We infer that an association exists if the confidence interval 
does not include the null value (i.e. the value consistent with no relationship). The 
width of the confidence interval provides an indication of the degree of uncertainty 
surrounding the inference, while its upper limit indicates how large an association 
may have gone undetected (Altman and Gardner, 2000).
Ascertaining temporal order: if cannabis use is the cause of an effect, then there •	
should be good evidence that cannabis use precedes it. The strongest evidence that 
cannabis use precedes certain health effects is provided by either a cohort study or 
an experiment. In the former the researcher observes that cannabis use precedes 
the health effect while in the latter the experimenter ensures by design that it does 
so.
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Deciding between alternative explanations: the hardest criterion to satisfy is that of •	
excluding the possibility that the relationship between cannabis use and the health 
outcome is due to an unmeasured variable that causes both cannabis use and the 
adverse health outcome. In surveys of high-school-aged adolescents, for example, 
cannabis users typically perform more poorly at school than non-cannabis users 
(Hawkins et al., 1992). This may be because cannabis use is a cause of poor school 
performance but an equally plausible hypothesis is that learning difficulties cause 
both poor school performance and cannabis use (Lynskey and Hall, 2000).
Experimental evidence provides the ‘gold standard’ for ruling out these common causal 
explanations (Fisher, 1947; Cook and Campbell, 1979; Shadish et al., 2002). Randomly 
assigning adolescents to use cannabis or not, for example, would ensure that cannabis 
users and non-users were equivalent before using cannabis. Hence, any subsequent 
differences in educational performance could be attributed to cannabis use rather 
than to pre-existing differences in ability. When studying anything except acute and 
innocuous health effects, random assignment of individuals to use cannabis or not is 
impossible for ethical and practical reasons. It would be unethical, for example, to force 
some adolescents to use cannabis, and impracticable, even if ethical, to prevent those 
assigned not to use the drug from doing so.
Experimentation using laboratory animals is one way of getting around the impossibility 
of human experimentation. But suitable experimental animal models are not available 
for many of the putative adverse psychosocial effects of cannabis use such as psychosis, 
school performance and personal adjustment. In addition, there are problems in 
extrapolating results across species, different routes of administration (e.g. oral and 
parenteral in animals versus smoked in humans), and the very high doses that are 
typically used in animal studies.
When a suitable animal model does not exist, and randomisation of human subjects 
is impractical or unethical, statistical methods must be used to adjust for the effects of 
pre-existing differences in risk between cannabis users and non-users. If the relationship 
persists after statistical adjustment, the confidence is increased that the relationship 
is not attributable to the variables for which statistical adjustment has been made 
(MacLeod et al., 2004). This type of control has been used, for example, in longitudinal 
studies of adolescent cannabis use and psychosis (e.g. Caspi et al., 2005; Fergusson et 
al., 2005; Henquet et al., 2005).
Acute health effects
The acute health effects of any drug are easier to appraise than the chronic effects: the 
temporal order is clear; drug use and the effects occur closely together in time; and 
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if the effects are not dangerous, they can be reliably reproduced by giving the drug 
under controlled conditions. All this is true of the most common psychoactive effects 
of cannabis (e.g. euphoria, relaxation, sociability) and some of the more commonly 
reported adverse acute effects such as anxiety, panic and depression (Hall and Pacula, 
2003).
It is more difficult to decide upon the causal contribution that cannabis use makes to 
relatively rare, acute adverse experiences such as flashbacks and psychotic symptoms. 
It is difficult to decide whether these are rare events that are coincidental with cannabis 
use, the effects of other drugs which are often taken together with cannabis, rare 
consequences of cannabis use that only occur at doses that are much higher than those 
used recreationally, cannabis effects that require unusual forms of personal vulnerability 
or the results of interactions between cannabis and other drugs.
Chronic health effects
Causal inferences about the long-term effects of chronic cannabis use become more 
difficult the longer the interval between use and the adverse effects. It takes time 
for adverse effects to develop and usually it takes even longer for a connection to 
be suspected between the two. This is largely because the longer the time interval 
between cannabis use and the health consequence, the more numerous the alternative 
explanations of the association that need to be excluded.
We often have to trade off rigour and relevance in evidence on the effects of chronic 
cannabis use. The most rigorous evidence is provided by laboratory investigations using 
experimental animals, but its relevance to human use is often uncertain. Epidemiological 
studies are manifestly more relevant in assessing human health effects, but they are 
usually less rigorous in assessing exposure to cannabis and in excluding alternative 
explanations of the associations. The consequence is increased uncertainty about 
the interpretation of epidemiological studies that affects interpretations of the causal 
significance of associations (‘positive’ studies) as well as studies that fail to find such 
relationships (‘negative’ studies).
A common interpretative problem with positive findings is that cannabis use is correlated 
with alcohol, tobacco and other illicit drug use that also adversely affect health. 
Generally, the heavier the cannabis use, the more likely that the person also uses these 
other psychoactive drugs (Newcomb and Bentler, 1989; Kandel and Yamaguchi, 1993). 
This can produce spurious associations between cannabis use and health outcomes, 
which makes it difficult to confidently attribute any adverse health effects to cannabis. 
This has been the case, for example, in interpreting the evidence on the role of cannabis 
use in motor vehicle accidents (Hall and Pacula, 2003; Mann et al., this monograph).
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When studies fail to find adverse health effects of chronic cannabis use, for example 
immunological effects, it may be unclear whether this means that THC has few, if any, 
immunological effects in humans, or that our research has not had the sensitivity to 
detect its effects. The answer to this question depends upon the likely magnitude of any 
adverse effects, their relationship to dose, frequency and duration of use, and the ability 
of studies with small sample sizes to detect them (Hall and Einfeld, 1990).
An overall appraisal of causal hypotheses
Causal inferences are often made in the light of a research literature by judging the 
extent to which standard criteria such as those outlined by Hill (1977) are met. These 
criteria are not sufficient for establishing that an association is a token of a causal 
relationship since it is possible for the criteria to be met and yet to be mistaken in 
making a causal inference. In general, however, the more of the criteria that are met, 
the more likely it is that the association is a token of a causal relationship.
Strength of association: relationships that are stronger indicate that if cannabis is used 
there is a high likelihood that the health effect will also occur. Stronger relationships are 
generally more deserving of trust than weaker ones because the latter are more easily 
explained by measurement or sampling biases.
Consistency of relationship: relationships which are consistently observed by different 
investigators, studying different populations, using varied measures and research 
designs, are generally more credible than relationships which are not. This is because 
a relationship that persists despite differences in sampling and research methods is less 
likely to be explained by sampling, measurement or other biases.
Specificity is a desirable but not a necessary condition. It exists when cannabis use is 
strongly associated with the outcome, and the health outcome is rare in the absence 
of cannabis use. Specificity is desirable in that if it exists we can be more confident 
that there is a relatively simple and direct causal relationship but its absence does not 
exclude the possibility of a more complex causal relationship (e.g. in which the effect is 
conditional on the presence of other factors).
Biological gradient refers to the existence of a dose–response relationship between 
cannabis use and the health outcome: the more heavily cannabis has been used, 
the greater the likelihood of the health outcome. Satisfaction of this criterion is also 
desirable but not necessary since there may be other patterns of relationship between 
exposure and disease, for example a threshold effect, an ‘all or none’ effect or a 
curvilinear relationship.
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Biological plausibility refers to the consistency of the relationship with other biological 
knowledge. If we can think of no conceivable mechanism whereby cannabis can 
produce such an effect, then we may have grounds for scepticism. But in the face of 
compelling evidence of association from well-controlled studies, implausibility may be 
a signal that existing theories are wrong or that we need to develop new theories that 
explain previously unknown phenomena.
Coherence means that the relationship coheres with, or makes sense of, other 
information about the natural history and biology of the disease. This, too, is desirable 
but not necessary: it is desirable that we have independent information that we can trust 
but its absence is not fatal, since the other information with which it is inconsistent may 
be in error.
Assessing the magnitude of risk
The standard epidemiological measures of risk magnitude are relative risk and 
population attributable risk. The relative risk is the increase in the odds of experiencing 
an adverse health outcome among those who use cannabis compared with those who 
do not. It may be quantified as a relationship between the frequency and duration of 
cannabis use and the risk of experiencing an adverse health outcome. The population 
attributable risk represents that proportion of cases with an adverse outcome that can be 
attributed to cannabis use, if it is causal.
The two measures of risk have different uses and implications. Relative risk is most 
relevant to individuals attempting to estimate the increase in their risk of experiencing 
an adverse outcome if they use a drug. Attributable risk is of most relevance to a 
societal appraisal of the harms of drug use. The importance of the two measures of risk 
magnitude depends upon the prevalence of drug use and the base rate of the adverse 
outcome. An exposure with a low relative risk may have a low personal significance but 
a large public health impact if a large proportion of the population is exposed (e.g. 
cigarette smoking and heart disease). Conversely, an exposure with a high relative risk 
may have little public health importance because very few people are exposed to it, but 
it may have major significance for those individuals who are exposed.
Another way of assessing the health risk posed by cannabis use is to compare its health 
risks with those of other widely used recreational drugs such as alcohol, tobacco, 
cocaine and heroin (Hall et al., 1999). Such comparisons minimise double standards 
in the appraisal of the health effects of cannabis use by using a common standard for 
comparison. The comparison, however, is more difficult than it seems at first, even in the 
case of the more widely used and best-studied drugs, alcohol and tobacco. Comparison 
is even more difficult in the case of less commonly used illicit drugs like cocaine, heroin, 
ecstasy and amphetamine.
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First, we know much more about the risks of acute and chronic tobacco and alcohol use 
than we do about the risks of cannabis use. The legal drugs have been consumed by 
substantial proportions of the population over centuries and there have been more than 
50 years of scientific studies of the health consequences of their use (see English et al., 
1995). Cannabis, by contrast, has been much less widely used in Western society, for 
a shorter period, and primarily by healthy young adults who have usually discontinued 
their use in their mid- to late 20s (Hall and Pacula, 2003).
Second, the prevalence of regular use of cannabis is much lower than that of alcohol 
and tobacco. In principle, this problem could be addressed by estimating what the 
health effects of cannabis use would be if its prevalence approached that of alcohol and 
tobacco. Although conceptually simple, in the absence of good data on the quantitative 
risks of cannabis use a large number of contestable assumptions have to be made in 
order to make such estimates.
We cannot simply estimate what the health risks of cannabis use would be if it were 
as commonly used as alcohol and tobacco by multiplying its estimated risks on current 
patterns of use by the number of potential users in the population. This calculation 
assumes that the risks are the same regardless of who uses cannabis, or the legal 
regime under which it is used. These may be unreasonable assumptions because (i) 
the variability among the characteristics of cannabis users or the diversity of ‘types’ 
of people who use cannabis when its prevalence of use is low might increase under a 
regime of legal use and (ii) if cannabis use were legal it would be possible to reduce 
some of the respiratory risks of cannabis smoking by encouraging cannabis users to 
ingest or vaporise rather than to smoke the drug. It would also be easier if cannabis use 
was legal to give users advice on how to reduce other risks, for example by not driving a 
car for several hours after using the drug, and restricting the frequency of use to weekly 
or less often.
Are there any benefits of cannabis use?
The benefits of cannabis use are rarely discussed in cannabis policy debates. The 
exception is its possible use to treat symptoms of chronic illnesses that are unresponsive 
to current medical treatment (Hall and Pacula, 2003). The key role played by health 
effects in the policy debate has meant that there has been very little research on the 
benefits of recreational cannabis use. If, as economists argue, adults are the best judges 
of their own interests, then the fact that a substantial proportion of adults in developed 
societies use cannabis for recreational purposes is prima facie evidence that some 
cannabis users benefit from its use (Hall and Pacula, 2003). There is an absence of 
evidence for more specific benefits of cannabis use, although a number of such effects 
have been suggested.
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One possible benefit is that moderate cannabis use may improve mental health, as 
recent evidence suggests may be true for moderate use of alcohol (Rodgers et al., 
2000). In the case of cannabis, epidemiological studies to date have typically found 
that the heavier the cannabis use is, the poorer the user’s mental health (see Hall and 
Pacula, 2003, Chapter 13) but more and much better controlled research is needed 
(MacLeod et al., 2004).
The evidence is also limited and mixed on a second possible benefit of cannabis 
use, namely, that of substituting for the use of arguably more harmful drugs like 
alcohol, cocaine and heroin. The epidemiology of alcohol and cannabis use suggest 
a complementary relationship in that heavy consumers of alcohol are more likely to 
be heavy cannabis users and vice versa, particularly among young people (see Hall 
and Pacula, 2003, Chapter 13). The evidence among adults is more mixed, with race, 
ethnicity and country of origin influencing the findings. The evidence on the relationship 
between cannabis and other illicit drugs is controversial (Hall and Pacula, 2003). Both 
questions deserve to be better investigated.
There is better evidence for the therapeutic uses of cannabis. There is reasonable 
evidence for the therapeutic use of THC as an antiemetic agent in the treatment of 
nausea and vomiting caused by cancer chemotherapy. More effective antiemetic agents 
are now available, so it remains to be seen how widely the cannabinoids will be used for 
this purpose. There is also reasonable evidence for the efficacy of THC in the treatment 
of AIDS-related wasting. There is evidence that cannabinoids may have analgesic and 
antispasmodic properties that warrant further research into their effectiveness (Hall and 
Degenhardt, 2003).
The social and political context of appraisal
Appraisals of the hazards of most drug use are affected by the societal approval or 
disapproval of the drug (Room, 1984). Those who approve of using the drug tend to 
engage in ‘problem deflation’ by minimising the adverse health and social effects of 
its use. Those who disapprove tend to engage in ‘problem inflation’ by uncritically 
accepting any evidence of harm.
An inflationary–deflationary dialectic has affected appraisals of the health effects of 
cannabis use. Politically conservative opponents of cannabis use, for example, justify 
its continued prohibition by citing personal and social harms of its use (e.g. Nahas and 
Latour, 1992). When the evidence is uncertain, they resolve the uncertainty by assuming 
that cannabis use is unsafe until proven safe. Complementary behaviour is shown by 
those proponents of decriminalisation who discount evidence of harm and resolve 
uncertainties about the ill-effects of cannabis use by demanding evidence that is difficult 
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to provide, arguing that until uncertainty is resolved individuals should be allowed to 
choose whether or not they use the drug.
Problem deflationists typically discount the adverse effects of their preferred drugs by 
denying that there is a causal connection between drug use and particular adverse 
health effects. A popular way of discounting evidence of adverse health effects of drug 
use is to set such a high standard of proof that we can never ‘know’ whether it causes 
the effect. The standard of proof reflects the degree of confidence we require in a 
causal connection between drug use and harm. In courts of law, the standard of proof 
demanded depends upon the seriousness of the offence and the consequences of a 
conviction. The standard is ‘beyond reasonable doubt’ in criminal cases that may lead 
to imprisonment if convicted while the ‘balance of probabilities’ is acceptable in civil 
cases where the penalties are fines. Sceptics often demand something close to ‘beyond 
reasonable doubt’.
The standard legal method for resolving a dispute in the face of uncertainty is to create 
a default outcome by placing a burden of proof upon one or the other side in the case. 
The arguer who bears the burden of proof loses the case if they fail to discharge their 
burden. The accused in a murder trial, for example, is presumed to be innocent until 
proven guilty because it is the prosecution’s burden to make a case for guilt beyond 
reasonable doubt; failure to do so means that the defendant has to be acquitted.
In the debate about the legal status of cannabis, the question of who bears the burden 
of proof is controversial (see Rescher, 1977, Chapter 12). If the burden of proof falls on 
those who claim that the drug is safe, uncertainty will be resolved by assuming that it 
is unsafe until proven otherwise; conversely, if the burden falls on those who claim that 
the drug is unsafe, then it will be assumed to be safe until proven otherwise. Proponents 
of continued prohibition of cannabis use appeal to established practice (Whately, 1963 
[1846]), arguing that since the drug is illegal the burden of proof falls on those who 
want to legalise it to demonstrate its safety. Proponents of legalisation often argue 
that there was no evidence that cannabis was harmful when its use was criminalised. 
Some argue that, in any case, the burden of proof falls upon those who wish to use the 
criminal law to prevent adults from choosing to use a drug (e.g. Husak, 1992).
Improving assessments of the health effects of cannabis
The following proposals aim to improve assessments of the health risks of cannabis by 
ensuring that ignorance is disclosed, making it easier to identify what we need to know 
in order to reduce it, and making it less likely that empirical issues will be confused with 
moral ones and vice versa.
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Avoid treating cannabis as a special case
According to some, cannabis is a ‘mind-expanding’, ‘consciousness-raising’ drug, which 
is especially benign in its effects on health. To its opponents, cannabis is a ‘deceptively 
dangerous’ drug in which the absence of acute toxic effects disguises its insidious 
adverse effects on users and society (Nahas and Latour, 1992). We should instead 
adopt the same approach to evaluating the health effects of cannabis use that are used 
in appraising the health effects of alcohol, tobacco and other illicit drugs.
Burden of proof should be responsive to evidence
Any inquiry into the health effects of cannabis should begin with the assumption derived 
from pharmacology and toxicology that it may harm the health of some users when used 
at some dose, frequency or duration of use, or some methods of administration (Fehr 
and Kalant, 1983). Given that cannabis is an intoxicant like alcohol, and a drug that is 
usually smoked like tobacco, there are additional reasons to expect that cannabis will 
share at least some of the acute and chronic health effects of these two drugs.
This expectation does not mean that we assume that cannabis use is unsafe until proven 
safe. Rather, it means that the burden of proof will be responsive to the state of the 
evidence and it may vary for different health effects. If there is a prima facie case for 
cannabis causing a specific harm, then evidence of safety should be required. A prima 
facie case could comprise either direct evidence that cannabis has ill effects in humans 
(e.g. from a case–control study), or a compelling argument for such an effect, for 
example the fact that the constituents of cannabis and tobacco smoke are similar, and 
that tobacco smoking causes respiratory cancers, makes it likely that heavy cannabis 
smoking is also a contributory cause of these cancers (Hall and MacPhee, 2002).
Use a reasonable standard of proof
If we require proof beyond reasonable doubt that there are adverse health effects of 
cannabis, then very few conclusions will be drawn about its health effects, and very little 
advice can be given on how to reduce these risks. Reasonable inferences and sensible, 
if fallible, health advice can be given if evidential criteria are used to draw conclusions 
about the probable adverse health effects of cannabis in the same way as we do about 
any other drug. This standard may be taken to be satisfied by the consensus of informed 
scientific opinion that sufficient evidence has been provided to infer a causal connection 
between cannabis use and a health outcome. A consensus is indicated by the views 
expressed in authoritative reviews in peer reviewed journals and consensus conferences 
of experts (e.g. Institute of Medicine, 1982; Fehr and Kalant, 1983; WHO Programme 
on Substance Abuse, 1997).
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Apply standards consistently
There will continue to be disagreements about standards of proof, burden of proof and 
what kinds of evidence count, but whatever evidential standards are used should be 
applied even-handedly. The best protection against the use of double standards in their 
application is for those conducting appraisals of the health effects of cannabis to be as 
explicit as possible about the evidential standards that they have used, and as even-
handed as possible in their application.
Separate the legal and health issues
We would improve our appraisal of the health effects of cannabis if we clearly separated 
it from the legal issue. The two issues are connected since the adverse health effects of 
cannabis use are one of the justifications offered for treating cannabis use as a criminal 
offence. Consequently, if there were no adverse health effects of cannabis use, a 
different justification would need to be found for its continued prohibition.
Even if there are adverse health effects of cannabis, the connection between the adverse 
health effects of cannabis and its legal status is not as simple as has been assumed. 
If adverse health effects were a sufficient warrant for the legal prohibition of cannabis 
use then logic would demand that alcohol and tobacco use should also be prohibited. 
Our failure to prohibit alcohol and tobacco use indicates that socially important values 
other than personal or public health are at stake. These include individual autonomy 
and personal liberty, and the economic and social costs of trying to prevent a substantial 
proportion of the adult population from doing something that they want to do. These 
values must be weighed against public health, and a balance produced as the outcome 
of a political process that is informed by a fair appraisal of the health risks of cannabis 
use (Hall and Pacula, 2003).
The failure to separate the health and legal issues means that the appraisers’ views 
about the legal status of cannabis often prejudice their appraisals of its health effects. 
A clear distinction between the two issues is the best way of ensuring a fair and useful 
discussion of both.
Conclusions
Causal inferences about the adverse health effects of cannabis are complicated by a 
dearth of good studies of relationships between cannabis use and health outcomes; 
uncertainty in some cases about which came first, the cannabis use or the health 
effect; difficulties in excluding plausible alternative explanations of associations that 
have been observed in the absence of experimental studies; and, in the case of null 
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findings, uncertainty as to whether they provide reasonable evidence of the absence 
of effects, or only an absence of evidence. An estimation of the magnitude of the 
health risks of cannabis is handicapped by the absence of epidemiological studies that 
provide quantitative estimates of the risks in representative samples of users. Attempts 
to compare the public health significance of cannabis use with that of more widely used 
drugs like alcohol and tobacco are complicated by the greater comparative ignorance of 
the adverse health effects of cannabis use, and by the marked difference in their current 
prevalence of use. More attention needs to be given to evaluating evidence for and 
against benefits claimed for cannabis use.
A fair appraisal of the health effects of cannabis has been hampered by a deflationary–
inflationary dialectic between opponents and proponents of cannabis use. Problem 
deflation has been assisted by demands for unreasonably high standards of proof, and 
the disagreement about who bears the burden of proof has prevented a resolution of 
uncertainty about these health effects.
Our appraisals of the health effects of cannabis would be improved if we: stopped 
treating cannabis use as a special case; distinguished clearly between health and legal 
issues; varied the burden of proof depending upon the state of the evidence about 
adverse health effects; used a reasonable standard of proof; and above all else, applied 
evidential standards consistently and even-handedly.
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Chapter 9
Cannabis use and driving: 
implications for public health and 
transport policy
Keywords: cannabis – driving – DUIC – road safety – roadside testing
Setting the context
While cannabis has been a topic of research interest for many years, it has only 
been recently that the issue of cannabis and road safety has been the subject of a 
substantial amount of public and government interest. In Europe, the subject has 
received considerable attention in recent years. An EMCDDA literature review on the 
effects of drug use on driving, originally published in 1999, was updated in 2007, 
while a selected issue on drugs and driving formed part of the 2007 Annual report. At 
the European Member State level, numerous initiatives have been carried out on drugs 
and driving, including specific interventions to reduce driving under the influence of 
cannabis. For example, in France a major research and prevention campaign (1) was 
launched in 2006, while a supporting study estimated that cannabis accounted for an 
additional 230 annual road deaths in France, with a significant proportion of these 
deaths affecting young people under 25 (French national report, 2005). A survey into 
drug use in recreational settings in the Czech Republic (n = 1 010) found that 56 % of 
respondents reported driving under the influence, a higher rate than for alcohol (41°%) 
(Czech Republic national report, 2005).
From a law enforcement perspective, a number of European countries have tightened 
drug driving laws in the past decade, for example to stipulate mandatory toxicological 
tests in the case of fatal accidents or to enable roadside drug testing. Furthermore, 
increased traffic controls for drug driving have been tested, although approaches vary 
— controls typically take the form of behavioural ‘sobriety’ tests and/or device-based 
‘quick’ screening (typically, saliva testing), which are later validated with urine and/or 
blood analyses (EMCDDA, 2007). Yet, the ‘operationalisation’ of penalties in a similar 
 (1) See www.cannabisetconduite.fr for information on the campaign, together with supporting 
studies.
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way to the blood alcohol concentration (BAC) limits commonly used for drink driving is 
not as commonplace in Europe for cannabis as in the USA (Grotenhermen et al., 2005). 
Exceptions exist, however: Belgium and Luxembourg, for example, use a threshold of 
2 ng THC/mL blood (Belgian national report, 2006; Luxembourg Ministry of Transport, 
2007). Some states in the USA also provide blood THC concentrations to guide judicial 
practice.
Thus, driving under the influence of cannabis (DUIC) has become an increasingly 
important issue from a public policy and road safety perspective. Available evidence 
suggests that while the prevalence of DUIC in the general population is relatively 
low (Walsh and Mann, 1999), it is substantially higher in important subgroups of the 
population, in particular young, male drivers (Lenne et al., 2004). Among users of 
cannabis, and in particular those who seek treatment for cannabis problems, 50 % 
or more may report DUIC at least once in the previous year (Albery et al., 1999; 
Macdonald et al., 2004a). As well, among young drivers in North America at least, the 
prevalence of DUIC is similar to or higher than the prevalence of driving after drinking 
(Adlaf et al., 2003; Asbridge et al., 2005).
While no data on trends in DUIC over time are available, if cannabis use increases in 
the population DUIC, it is likely that DUIC will increase as well. Thus, there is a clear 
need to assess the evidence on the impact of cannabis use on collision risk, in order 
to provide an evidence-based perspective to discussions of the magnitude of the DUIC 
problem and the need for legislative or programme action. The principal objective of 
this chapter is to examine critically the findings connecting cannabis and traffic crashes, 
and a second objective is to consider the problems in developing methods to assess 
cannabis impairment for legal purposes.
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Cannabis use and driving: 
implications for public health and 
transport policy
Robert E. Mann, Gina Stoduto, Scott Macdonald and 
Bruna Brands
Impairment: effects of cannabis on performance
A substantial amount of information has accumulated on the effects of cannabis on 
human performance. Of particular interest here are those studies most relevant to the 
possible effects of the drug on driving behaviour. According to Maes et al. (1999), 
research measures can be grouped in the following categories: attention tests (simple 
and divided attention); vigilance tests (ability to sustain attention); auditory and visual 
tests (visual acuity, accommodation to darkness/light); reaction time (simple and choice 
reaction time); cognitive tests (e.g. digit/symbol substitution test, Stroop word/colour test, 
letter cancellation test); memory tests; mental arithmetic; flicker fusion test; visual–motor 
coordination tests; body sway; physiological measurements (EEG, eye movements, 
pulse, blood pressure); and self-awareness measures. Additionally, studies may involve 
simulated or actual driving tasks.
Several comprehensive reviews of this literature have emerged, and the results appear 
to be very consistent. A consistent conclusion is that the acute effect of moderate or 
higher doses (2) of cannabis impairs the skills related to safe driving and injury risk. 
Moskowitz (1985) concluded that marijuana use impairs driver performance under a 
variety of experimental conditions. Berghaus and Guo (1995) conducted a meta-analysis 
of 60 studies and concluded that marijuana causes impairment of every performance 
area connected with safe driving of a vehicle, such as tracking, psychomotor skills, 
reaction time, visual functions, and attention. Of these performance criteria, the 
most deterioration from marijuana use was found for measures of attention (e.g. the 
continuous performance task), tracking (e.g. the pursuit rotor task) and psychomotor 
skills (e.g. simple reaction time) (Coambs and McAndrews, 1994; Berghaus and Guo, 
1995). Similar conclusions have been reached by other reviews (Hollister, 1981; Maes 
et al., 1999; Smiley, 1999; Ashton, 2001; O’Kane et al., 2002; Ramaekers et al., 
2004; Lenne et al., 2004). Some authors have postulated that the various cognitive 
impairments mentioned previously are related to duration of drug use (Hall and Solowij, 
1998). Johns (2001) notes that cannabis use can occasionally result in short-term 
 (2) See Corrigan, this monograph, for a discussion of dosage and the pharmacology and 
pharmacodynamics of cannabis.
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psychiatric distress and even psychotic states, and that cannabis may provoke relapse 
and aggravate existing symptoms in people with major mental illnesses such as 
schizophrenia. In addition, potential withdrawal effects of heavy, long-term cannabis 
use, such as restlessness, insomnia, and anxiety, could also influence injury risk (Ashton, 
2001).
Smiley (1999) concluded that marijuana impairs skills and ability. She speculated that 
drivers are aware of this impairment, which may prompt them to slow down and drive 
more cautiously, suggesting that experienced cannabis users can compensate for the 
deleterious effects of cannabis on driving skills. This compensation for the effects of 
the drug is a form of tolerance to its effects. Tolerance is defined as a reduction in 
response to a particular dose of a drug with repeated administration, or the requirement 
that larger amounts are needed to obtain the same drug effect (Kalant et al., 1971). 
Tolerance to cannabis over repeated administrations is observed in animal studies with 
cannabis (Ashton, 2001), but little systematic research on cannabis tolerance in humans 
is available. When considering the extent to which tolerance to cannabis might influence 
drivers, it is useful to consider possible parallels between tolerance to cannabis and 
tolerance to alcohol. Tolerance is observed for both drugs, and substantial research 
has addressed the issue of alcohol tolerance in humans (e.g. Vogel-Sprott, 1992). The 
impairing effect of alcohol on psychomotor tasks is readily observed. However, under 
conditions where reinforcement is provided for non-impaired performance, tolerance will 
develop over a series of drinking sessions (Mann and Vogel-Sprott, 1981; Beirness and 
Vogel-Sprott, 1984), and the extent of tolerance development is related to awareness of 
impairment and efforts to compensate (Mann et al., 1983). Nevertheless, impairment 
returns when reinforcement contingencies are withdrawn (Mann and Vogel-Sprott, 1981; 
Zack and Vogel-Sprott, 1993). This return of impairment indicates that even tolerant or 
experienced users will display impairment of psychomotor performance. Thus, the same 
process that Smiley (1999) suggested may alleviate performance deficits in experienced 
cannabis users has been extensively studied with human subjects in laboratory research 
with alcohol. These studies indicate that even in those who learn to compensate for a 
drug’s impairing effects, substantial impairment in performance can still be observed 
under conditions of general task performance (i.e. when no contingencies are present to 
maintain compensated performance).
Other researchers have investigated the effects of cannabis combined with alcohol on 
laboratory performance measures. These studies have been stimulated in part by the 
apparent frequency with which both drugs are used together (Cimbura et al., 1990; 
Jonah, 1990; Stoduto et al., 1993; Walsh and Mann, 1999). In general, these studies 
typically, but not always, reveal that the effects of cannabis plus alcohol are greater 
than the effects of cannabis alone (Liguori et al., 2002; Chait and Perry, 1994). The 
research suggests that the effects of combining cannabis with alcohol on skills necessary 
for safe driving such as visual search and road tracking are either additive, in which 
the effects of both drugs together are roughly equivalent to adding the effects of the 
Chapter 9
177
two together, or multiplicative, in which the effects of the two drugs together are greater 
than the effects of the two individually (e.g. Robbe, 1998; Laemers and Ramaekers, 
2001). In reviewing this literature, O’Kane et al. (2002) observed that alcohol’s effects 
are strongest on integrative tasks while the effects of cannabis are strongest on tasks 
requiring attention and psychomotor skills.
Epidemiological studies on collision risk associated with 
cannabis use
Epidemiological studies are necessary to assess the impact of cannabis use on collision 
risk. In the past two decades, several studies have been published on the involvement 
of cannabis in collisions. In this review of the literature, conclusions from three types 
of studies will be drawn: (i) descriptive and analytical epidemiological studies on the 
prevalence of cannabis use through drug testing in injured drivers; (ii) studies of collision 
risk of clinical samples of cannabis users; and (iii) studies of collision risk among 
general populations of drivers. The purpose of this section is to review the available 
empirical research in order to assess the risks that cannabis may pose for traffic 
collisions. This assessment of risk is central to our understanding of the role of cannabis 
in traffic safety.
Studies using drug tests of injured drivers to detect cannabis 
metabolites
Studies that obtained drug tests of urine, blood or saliva from injured drivers are 
included in this section. Also included are studies of special populations where drug tests 
were taken of drivers suspected of driving under the influence or of reckless driving. A 
large number of descriptive studies have been conducted where the blood or urine of 
injured drivers has been analysed for the presence of cannabis metabolites. Thirty-two 
studies were found. The research methodologies and results in terms of the proportion 
testing positive for cannabis metabolites are described in Table 1.
There have been many epidemiological studies that have reported drug tests of fatally 
and non-fatally injured drivers. The percentage of fatally injured drivers testing positive 
for cannabis ranged from 1.4 to 27.5 % (mean = 10.7 %); while for non-fatally injured 
drivers the percentage ranged from 5 to 15.7 % (mean = 11.5 %) (Macdonald et al., 
2003). The prevalence rates for cannabis are highest for the special driver populations, 
that is, those suspected of drug or alcohol impairment or reckless driving. The 
percentage of impaired or reckless drivers testing positive for cannabis ranged from 7.4 
to 65.9 % (mean = 34.6 %).
Although many studies have been conducted on the prevalence of positive drug tests 
among injured drivers, few studies incorporated control groups so that assessments 
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Table 1: Summary of study results on the percentage of injured drivers  
testing positive for cannabis (continued)
  
 
Reference Jurisdiction Consent 
required
% positive 
cannabis
Comparison group Study group Comments
Brookoff et al. 
(1994)
Memphis, Tennessee, 
USA
No 33 % No 150 drivers stopped for reckless driving 12 % positive for both cocaine and cannabis. 18.7 % 
positive for alcohol (0.03–0.21 mg/dL)
Budd et al. 
(1989)
Los Angeles, California, 
USA
No 19.6 % 
(preliminary), 
18.5 % (follow-up)
No Preliminary study: 102 fatally injured drivers. 
Follow-up study: 492 fatally injured drivers
18.6 % positive for alcohol + cocaine/cannabis/
both (preliminary). 16.2 % positive for alcohol + 
cocaine/cannabis/both (follow-up)
Christopherson 
et al. (1990)
Norway No 31.5 % No 3 159 drivers suspected of driving under the 
influence of alcohol and drugs
One or more drugs present in 67 %
Cimbura et al. 
(1990)
Ontario, Canada No 10.9 % — 
drivers; 7.6 % — 
pedestrians
No 1 169 fatally injured drivers, 225 fatally injured 
pedestrians (aged 14 or over)
9.2 % positive for cannabis + alcohol (drivers). 
5.8 % positive for cannabis + alcohol (pedestrians)
Crouch et al. 
(1993)
Salt Lake City, Utah, USA No 13 % No 168 fatally injured truck drivers Impairment due to cannabis use in all cases where 
THC level exceeded 1.0 ng/mL 2.3 % positive 
cannabis + alcohol. 20 % of accidents positive for 
drugs had driver fatigue
Drummer 
(1995)
Melbourne, Australia No 11 % Yes; drivers not 
responsible
1 045 fatally injured drivers, 1990–93 Responsibility analysis conducted. No statistical 
significance for cannabis
Drummer et al. 
(2003)
Australian states: 
Victoria, New South 
Wales and Western 
Australia
No 13.5 % fatally 
injured drivers
No 3 398 fatally injured drivers, 1990–99 11.8 % positive for car drivers; 22.2 % positive for 
motorcycle drivers; 6.5 % positive for truck drivers; 
15.9 % positive for single vehicle crash; 11.1 % 
positive for multiple vehicle crash; 10.9 % positive 
for 1990–93; 13.5 % positive for 1994–6; 15.6 % 
positive for 1997–9
Dussault et al. 
(2002)
Quebec, Canada No for fatal 
drivers; yes 
for controls
19.5 % for fatal 
drivers; 6.7 % for 
controls
Yes 354 fatally injured drivers; 11 952 roadside 
controls
Fatalities were significantly associated with positive 
tests for cannabis in the case–control study. 
No significant relationship was found for the 
responsibility analysis. Selection bias due to the 
49.6 % response rate of providing a urine sample 
for the control group could have inflated the odds 
ratios
Everest and 
Tunbridge 
(1990)
England and Wales No 2.6 % No 1 273 fatalities (drivers, passengers, motorcycle 
drivers, pedestrians)
8.3 % of those positive for drugs were also positive 
for alcohol (> 0.08 mg/100 mL)
Fortenberry et 
al. (1986)
Alabama, USA No 11 % — 
drivers; 5 % — 
passengers; 1 % 
— pedestrians
No 510 fatally injured drivers, passengers, and 
pedestrians with urine samples
8.8 % positive for both cannabis + alcohol
Holmgren et al. 
(2005)
Sweden No 33 cases positive 
for THC
No 855 fatally injured drivers
Kintz et al. 
(2000)
Strasbourg, France No 9.6 % No 198 injured drivers (car, motorcycle, truck, 
bicycle) aged 13–57
Laumon et al. 
(2005)
France No At-fault drivers 
— 8.8 %; control 
drivers — 2.8 %
Yes; 3 006 not-at-fault 
fatally injured drivers
6 766 at-fault fatally injured drivers Cannabis increased fatal collision risk in a dose-
related manner after controlling for alcohol, age, 
type of vehicle and time of crash
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Table 1: Summary of study results on the percentage of injured drivers  
testing positive for cannabis (continued)
  
 
Reference Jurisdiction Consent 
required
% positive 
cannabis
Comparison group Study group Comments
Brookoff et al. 
(1994)
Memphis, Tennessee, 
USA
No 33 % No 150 drivers stopped for reckless driving 12 % positive for both cocaine and cannabis. 18.7 % 
positive for alcohol (0.03–0.21 mg/dL)
Budd et al. 
(1989)
Los Angeles, California, 
USA
No 19.6 % 
(preliminary), 
18.5 % (follow-up)
No Preliminary study: 102 fatally injured drivers. 
Follow-up study: 492 fatally injured drivers
18.6 % positive for alcohol + cocaine/cannabis/
both (preliminary). 16.2 % positive for alcohol + 
cocaine/cannabis/both (follow-up)
Christopherson 
et al. (1990)
Norway No 31.5 % No 3 159 drivers suspected of driving under the 
influence of alcohol and drugs
One or more drugs present in 67 %
Cimbura et al. 
(1990)
Ontario, Canada No 10.9 % — 
drivers; 7.6 % — 
pedestrians
No 1 169 fatally injured drivers, 225 fatally injured 
pedestrians (aged 14 or over)
9.2 % positive for cannabis + alcohol (drivers). 
5.8 % positive for cannabis + alcohol (pedestrians)
Crouch et al. 
(1993)
Salt Lake City, Utah, USA No 13 % No 168 fatally injured truck drivers Impairment due to cannabis use in all cases where 
THC level exceeded 1.0 ng/mL 2.3 % positive 
cannabis + alcohol. 20 % of accidents positive for 
drugs had driver fatigue
Drummer 
(1995)
Melbourne, Australia No 11 % Yes; drivers not 
responsible
1 045 fatally injured drivers, 1990–93 Responsibility analysis conducted. No statistical 
significance for cannabis
Drummer et al. 
(2003)
Australian states: 
Victoria, New South 
Wales and Western 
Australia
No 13.5 % fatally 
injured drivers
No 3 398 fatally injured drivers, 1990–99 11.8 % positive for car drivers; 22.2 % positive for 
motorcycle drivers; 6.5 % positive for truck drivers; 
15.9 % positive for single vehicle crash; 11.1 % 
positive for multiple vehicle crash; 10.9 % positive 
for 1990–93; 13.5 % positive for 1994–6; 15.6 % 
positive for 1997–9
Dussault et al. 
(2002)
Quebec, Canada No for fatal 
drivers; yes 
for controls
19.5 % for fatal 
drivers; 6.7 % for 
controls
Yes 354 fatally injured drivers; 11 952 roadside 
controls
Fatalities were significantly associated with positive 
tests for cannabis in the case–control study. 
No significant relationship was found for the 
responsibility analysis. Selection bias due to the 
49.6 % response rate of providing a urine sample 
for the control group could have inflated the odds 
ratios
Everest and 
Tunbridge 
(1990)
England and Wales No 2.6 % No 1 273 fatalities (drivers, passengers, motorcycle 
drivers, pedestrians)
8.3 % of those positive for drugs were also positive 
for alcohol (> 0.08 mg/100 mL)
Fortenberry et 
al. (1986)
Alabama, USA No 11 % — 
drivers; 5 % — 
passengers; 1 % 
— pedestrians
No 510 fatally injured drivers, passengers, and 
pedestrians with urine samples
8.8 % positive for both cannabis + alcohol
Holmgren et al. 
(2005)
Sweden No 33 cases positive 
for THC
No 855 fatally injured drivers
Kintz et al. 
(2000)
Strasbourg, France No 9.6 % No 198 injured drivers (car, motorcycle, truck, 
bicycle) aged 13–57
Laumon et al. 
(2005)
France No At-fault drivers 
— 8.8 %; control 
drivers — 2.8 %
Yes; 3 006 not-at-fault 
fatally injured drivers
6 766 at-fault fatally injured drivers Cannabis increased fatal collision risk in a dose-
related manner after controlling for alcohol, age, 
type of vehicle and time of crash
Cannabis use and driving: implications for public health and transport policy
180
Table 1: Summary of study results on the percentage of injured drivers  
testing positive for cannabis (continued)
  
 
Reference Jurisdiction Consent 
required
% positive 
cannabis
Comparison group Study group Comments
Logan and 
Schwilke (1996)
Washington State, USA No 11 % No 347 fatally injured drivers 10 % positive for alcohol + drugs; 15 % positive for 
drugs alone; 63 % of cannabis users positive for 
alcohol
Longo et al. 
(2000a,b)
Australia No 10.8 % Yes; non-culpable 
drivers
2 500 injured drivers admitted to an ER 7.1 % tested positive for cannabis-only. Blood tests 
taken — most drivers who tested positive for THC 
acid, the inactive metabolite
McBay (1986) Los Angeles, California, 
USA
No 13.4 % No 2 610 fatally injured drivers 2.8 % of drivers were positive for cannabis without 
any other drug; 28 % positive for drugs + alcohol
McLean et al. 
(1987)
Tasmania, Australia No 6 % of total 
sample
Yes; 387 blood 
donors
194 road users (42 fatally injured, 37 accident 
survivors, 115 breath-tested drivers/riders)
8 % of those positive for alcohol (> 0.5 g/L) had also 
used cannabis. Non-significant differences in drug 
use between groups
Marquet et al. 
(1998)
France No drivers — 13.9 %; 
patients — 7.6 %
Yes; 278 non-injured 
patients, aged 18–35
296 injured drivers, aged 18–35 Prevalence of cannabis among female drivers 
was significantly higher than for female patients 
(P < 0.05)
Mason and 
McBay (1984)
North Carolina, USA No 7.8 % No 600 fatally injured drivers 11 % positive for alcohol + drugs; 2.8 % positive for 
drugs alone
Mercer and 
Jeffery (1995)
British Columbia, 
Canada
No 13 % No 227 fatally injured drivers 11 % positive for alcohol + drugs
Movig et al. 
(2004)
The Netherlands Yes 12 % hospitalised 
drivers; 6 % 
controls
Yes; 816 roadside 
survey controls
110 injured drivers admitted to hospital Urine/blood test determined drug positivity. 39 % of 
injured drivers had urine test versus 85 % of controls 
had urine test. Effect of cannabis on risk of injury 
accident not significant
Mura et al. 
(2003)
France 10 % of drivers, 
5 % of controls
Yes; 900 controls 
admitted to 
emergency room of six 
hospitals
900 injured (non-fatal) drivers 10 % injured drivers positive for THC, 5 % of controls 
positive for THC. Among under-27-year-olds, 
cannabis increased collision risk significantly
Orsay et al. 
(1994)
Chicago, Illinois, USA No 7.4 % of total 
sample
Yes; 300 non-
impaired, injured 
drivers
285 alcohol or drug-impaired, injured 
motorists and motorcyclists
Impaired drivers had higher injury severity scores 
than control drivers (P < 0.001). Impaired drivers 
more frequently involved in collisions, cited for 
moving violations; found to be at fault
Peel and Jeffrey 
(1990)
Canada No 20 % of impaired 
drivers
No 492 cases: 94 injured; 172 impaired and 226 
fatally injured drivers
Of 53 impaired drivers, 4 % positive for cannabis
Poklis et al. 
(1987)
St Louis, Missouri, USA No 47 % No 137 drug positive DUI drivers, Jan. 1983 to 
May 1986
32 different drugs detected
del Rio and 
Alvarez (2000)
Northern Spain No 1.4 % No 285 fatally injured drivers Of all positive for drugs, 19.6 % were also positive 
for alcohol
Risser et al. 
(1998)
Vienna, Austria Yes 47 % of 19 
samples in 1993; 
72 % of 99 
samples in 1996
No 205 reckless drivers from 1993 to 1996, aged 
17–24 years. 199 car drivers; six motorcycle 
drivers
Increase in cannabis use increased significantly over 
time (P < 0.05)
Seymour and 
Oliver (1999)
Strathclyde, Scotland No 39 % of impaired 
drivers
Yes; 151 fatally 
injured drivers
752 drivers suspected of being impaired Drugs were present in 19 % of fatally injured drivers; 
polydrug use was prevalent; alcohol detected in 
33 %
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Table 1: Summary of study results on the percentage of injured drivers  
testing positive for cannabis (continued)
  
 
Reference Jurisdiction Consent 
required
% positive 
cannabis
Comparison group Study group Comments
Logan and 
Schwilke (1996)
Washington State, USA No 11 % No 347 fatally injured drivers 10 % positive for alcohol + drugs; 15 % positive for 
drugs alone; 63 % of cannabis users positive for 
alcohol
Longo et al. 
(2000a,b)
Australia No 10.8 % Yes; non-culpable 
drivers
2 500 injured drivers admitted to an ER 7.1 % tested positive for cannabis-only. Blood tests 
taken — most drivers who tested positive for THC 
acid, the inactive metabolite
McBay (1986) Los Angeles, California, 
USA
No 13.4 % No 2 610 fatally injured drivers 2.8 % of drivers were positive for cannabis without 
any other drug; 28 % positive for drugs + alcohol
McLean et al. 
(1987)
Tasmania, Australia No 6 % of total 
sample
Yes; 387 blood 
donors
194 road users (42 fatally injured, 37 accident 
survivors, 115 breath-tested drivers/riders)
8 % of those positive for alcohol (> 0.5 g/L) had also 
used cannabis. Non-significant differences in drug 
use between groups
Marquet et al. 
(1998)
France No drivers — 13.9 %; 
patients — 7.6 %
Yes; 278 non-injured 
patients, aged 18–35
296 injured drivers, aged 18–35 Prevalence of cannabis among female drivers 
was significantly higher than for female patients 
(P < 0.05)
Mason and 
McBay (1984)
North Carolina, USA No 7.8 % No 600 fatally injured drivers 11 % positive for alcohol + drugs; 2.8 % positive for 
drugs alone
Mercer and 
Jeffery (1995)
British Columbia, 
Canada
No 13 % No 227 fatally injured drivers 11 % positive for alcohol + drugs
Movig et al. 
(2004)
The Netherlands Yes 12 % hospitalised 
drivers; 6 % 
controls
Yes; 816 roadside 
survey controls
110 injured drivers admitted to hospital Urine/blood test determined drug positivity. 39 % of 
injured drivers had urine test versus 85 % of controls 
had urine test. Effect of cannabis on risk of injury 
accident not significant
Mura et al. 
(2003)
France 10 % of drivers, 
5 % of controls
Yes; 900 controls 
admitted to 
emergency room of six 
hospitals
900 injured (non-fatal) drivers 10 % injured drivers positive for THC, 5 % of controls 
positive for THC. Among under-27-year-olds, 
cannabis increased collision risk significantly
Orsay et al. 
(1994)
Chicago, Illinois, USA No 7.4 % of total 
sample
Yes; 300 non-
impaired, injured 
drivers
285 alcohol or drug-impaired, injured 
motorists and motorcyclists
Impaired drivers had higher injury severity scores 
than control drivers (P < 0.001). Impaired drivers 
more frequently involved in collisions, cited for 
moving violations; found to be at fault
Peel and Jeffrey 
(1990)
Canada No 20 % of impaired 
drivers
No 492 cases: 94 injured; 172 impaired and 226 
fatally injured drivers
Of 53 impaired drivers, 4 % positive for cannabis
Poklis et al. 
(1987)
St Louis, Missouri, USA No 47 % No 137 drug positive DUI drivers, Jan. 1983 to 
May 1986
32 different drugs detected
del Rio and 
Alvarez (2000)
Northern Spain No 1.4 % No 285 fatally injured drivers Of all positive for drugs, 19.6 % were also positive 
for alcohol
Risser et al. 
(1998)
Vienna, Austria Yes 47 % of 19 
samples in 1993; 
72 % of 99 
samples in 1996
No 205 reckless drivers from 1993 to 1996, aged 
17–24 years. 199 car drivers; six motorcycle 
drivers
Increase in cannabis use increased significantly over 
time (P < 0.05)
Seymour and 
Oliver (1999)
Strathclyde, Scotland No 39 % of impaired 
drivers
Yes; 151 fatally 
injured drivers
752 drivers suspected of being impaired Drugs were present in 19 % of fatally injured drivers; 
polydrug use was prevalent; alcohol detected in 
33 %
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Table 1: Summary of study results on the percentage of injured drivers  
testing positive for cannabis (continued)
  
 
Reference Jurisdiction Consent 
required
% positive 
cannabis
Comparison group Study group Comments
Soderstrom et 
al. (1995)
Baltimore, Maryland, 
USA
No 12 % No 1 338 injured (1 077 car drivers; 261 
motorcyclists)
Stoduto et al. 
(1993)
Toronto, Ontario, 
Canada
No 13.9 % No 339 injured drivers admitted to trauma unit 
(291 car drivers; 48 motorcyclists)
16.5 % positive for alcohol + drugs
Sugrue et al. 
(1995)
Sydney, Australia No 15.2 % drivers 
(> 100 ng/
dL); 8 % cyclists 
(> 200 ng/dL); 
13 % passengers 
(> 200 ng/dL); 
14% pedestrians 
(> 200 ng/dL)
No Total 262 (164 injured drivers, 12 pedal 
cyclists, 31 pedestrians, 55 passengers)
16 % positive alcohol + drugs
Terhune and 
Fell (1982)
Washington DC, USA No 10 % No 500 injured drivers 25 % positive for alcohol
Williams et al. 
(1985)
California, USA No 37 % No 440 fatally injured male drivers aged 15–34 Percentage of crash responsibility increased 
significantly from zero drugs to two or more 
detected drugs (P > 0.001); 81 % of cannabis users 
positive alcohol
of relative risks could be estimated. The best methodological studies are analytic 
epidemiological studies that utilise the case–control method (Meulemans et al., 1996; 
Marquet et al., 1998; Dussault et al., 2002; Mura et al., 2003). However, these studies 
are very difficult to conduct, and other investigators have used methods based on 
analysis of crash responsibility (e.g. Drummer, 1995; Longo et al., 2000a,b; Dussault 
et al., 2002; Drummer et al., 2004) (see Table 1). The logic of these studies is that if 
a drug increases collision risk, drivers under the influence of the drug are more likely 
to be considered responsible for the collision based on police reports (Terhune and 
Fell, 1982).
In a case–control study conducted in France, 296 injured drivers at emergency room 
departments and 278 non-injured control patients matched by age were urine tested for 
the presence of cannabis (Marquet et al., 1998). Methodologically, this study is unique 
among case–control studies in the field because consent was not required for urine tests 
of either cases or controls and, therefore, the results are free of selection biases. Results 
indicated that drivers testing positive for cannabis were not significantly more likely 
than controls to be involved in collisions. However, when the analyses were restricted to 
women only, the relationship became significant (Marquet et al., 1998).
Findings of another case–control study have recently been reported for 354 fatally 
injured drivers and 5 931 roadside controls in Quebec (Dussault et al., 2002). The odds 
ratio was statistically significant and indicated that fatally injured drivers were 2.2 times 
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Table 1: Summary of study results on the percentage of injured drivers  
testing positive for cannabis (continued)
  
 
Reference Jurisdiction Consent 
required
% positive 
cannabis
Comparison group Study group Comments
Soderstrom et 
al. (1995)
Baltimore, Maryland, 
USA
No 12 % No 1 338 injured (1 077 car drivers; 261 
motorcyclists)
Stoduto et al. 
(1993)
Toronto, Ontario, 
Canada
No 13.9 % No 339 injured drivers admitted to trauma unit 
(291 car drivers; 48 motorcyclists)
16.5 % positive for alcohol + drugs
Sugrue et al. 
(1995)
Sydney, Australia No 15.2 % drivers 
(> 100 ng/
dL); 8 % cyclists 
(> 200 ng/dL); 
13 % passengers 
(> 200 ng/dL); 
14% pedestrians 
(> 200 ng/dL)
No Total 262 (164 injured drivers, 12 pedal 
cyclists, 31 pedestrians, 55 passengers)
16 % positive alcohol + drugs
Terhune and 
Fell (1982)
Washington DC, USA No 10 % No 500 injured drivers 25 % positive for alcohol
Williams et al. 
(1985)
California, USA No 37 % No 440 fatally injured male drivers aged 15–34 Percentage of crash responsibility increased 
significantly from zero drugs to two or more 
detected drugs (P > 0.001); 81 % of cannabis users 
positive alcohol
more likely to test positive for cannabis than controls. However, this result should be 
treated cautiously owing to the possibility of systematic bias in the study. Little bias is 
likely for the proportion testing positive among the fatal drivers (19.5 %); however, for 
the control group, consent was required by participants to provide a urine test. Only 
49.6 % of controls agreed to provide a urine sample. The authors used saliva samples 
to assess the degree of possible bias, with the rationale that the reason drivers refused 
both urine samples and saliva sample would be the same (fear of detection). The 
participation rate for saliva tests was 84.6 %, which suggests that a large proportion of 
people found urine tests more invasive. The high rate of refusal to provide a saliva test 
indicates that the results should be interpreted with caution.
Meulemans et al. (1996) conducted a study where urine tests were taken from injured 
drivers at emergency rooms in Belgium. The authors examined injury severity of those 
in crashes. Being positive for cannabis metabolites was not significantly related to injury 
severity.
Mura et al. (2003) conducted toxicological tests on blood samples from 900 drivers 
involved in a non-fatal collision and 900 controls attending emergency rooms for non-
traumatic reasons in France. Younger drivers (under 27) with cannabis alone in their 
blood were significantly more likely to be involved in collisions (OR = 2.5). This was 
somewhat less than the OR associated with alcohol alone (3.8), and when alcohol and 
cannabis were combined the OR for collision involvement increased to 4.6.
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Several Australian studies have used responsibility analysis techniques and also had 
access to blood samples. Blood samples permit analyses of both the active and inactive 
ingredients of tetrahydrocannabinol (THC) and are the best approach for determining 
likely cannabis impairment. Longo et al. (2000a,b) obtained drug tests from 2 500 
injured drivers. Their analysis found no significant differences in the degree of culpability 
associated with cannabis-positive compared with cannabis-negative drivers. Drummer 
(1995) examined the blood samples of driver fatalities linked with traffic reports in an 
Australian study. Similarly, he found no significant elevation of collision risk associated 
with cannabis use. More recently, Drummer et al. (2003, 2004) reported a responsibility 
analysis of 3 398 drivers killed in collisions in the Australian states of Victoria, New 
South Wales and Western Australia. Cannabis alone increased the likelihood of 
involvement in a fatal collision in a dose-related manner. The odds ratio (OR) for fatal 
collision involvement for those positive for cannabis only was 2.7; however, when 
analyses were restricted to those with concentrations greater than 5 ng/mL, the OR rose 
to 6.6.
A recent study from France employed responsibility analysis methods with a large 
sample of fatally injured drivers for whom blood samples were available. Laumon et 
al. (2005) reported on 10 748 drivers killed in France between October 2001 and 
September 2003. Blood levels of ∆9-tetrahydrocannabinol were compared in 6 766 
drivers considered to be at fault for their collisions and 3 006 drivers, selected from the 
3 982 other drivers, not considered to be at fault. These authors found that cannabis 
increased risk of involvement in a fatal collision in a dose-related manner, after 
controlling for presence of alcohol, age, type of vehicle and time of crash. The adjusted 
odds ratio for fatal collision involvement associated with blood levels of 5 ng/mL or over 
was 2.12. As well, these authors estimated that 2.5 % of fatal crashes in France could be 
attributable to cannabis.
Studies using clinical samples of cannabis abusers in treatment
The characteristics of studies using clinical samples of cannabis users in treatment are 
summarised in Table 2. We know from existing studies that clinical substance abuse 
populations are likely to drive after using cannabis. In one study, of a sample of 210 
users in treatment for heroin dependency, 58 reported driving after drug use, and 62 % 
of these reported driving at least once after using cannabis (Albery et al., 1999). In 
a study of those in treatment for alcohol, cannabis or cocaine abuse, 63 % reported 
driving after use of cannabis (Macdonald et al., 2004a).
Few studies exist that examine collision risks experienced by clinical samples of 
individuals receiving treatment for cannabis. In the first of these studies, Smart et al. 
(1969) observed elevated collision rates in abusers of one or more drugs other than 
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alcohol, but the sample was very small (n = 30). In another study of 144 male substance 
abusers aged 21–40, Mann et al. (1993) examined collision rates in the year before 
entry into treatment and compared these rates to collision rates in the general male 
population of the same age. The subjects estimated that about 50 % of their collisions 
in the preceding year occurred while they were under the influence of alcohol and/or 
drugs. As well, results suggested that the frequency of any substance use, as opposed 
to the use of specific substances, predicted collision involvement and significant 
post-treatment reductions were found in moving violations, DWI convictions, and total 
collisions (Mann et al., 1995).
A recent study examined the driving records of a large sample of cannabis abuse clients 
in treatment (Macdonald et al., 2004b). This study utilised blind linkage procedures a 
note to explain this method to avoid non-respondent bias, and compared the clinical 
sample to a randomly selected, frequency-matched (age, gender, location) control 
group of drivers. Significant elevations in collisions were found for abusers of cannabis 
compared with population controls, both prior and after treatment (Macdonald et al., 
2004b). While this study demonstrates an association between cannabis abuse and 
elevated collision risk, alternative explanations for this relationship cannot yet be ruled 
out.
Studies using general populations of drivers
Recently, Asbridge et al. examined the impact of self-reported DUIC on collision risk 
among high-school students in the four Atlantic provinces of Canada. These authors 
observed a significant elevation of collision risk (OR = 1.84) among students who 
reported DUIC, after controlling for demographic factors, driver experience, and self-
reported driving after drinking. Similarly, Mann et al. (2005) examined the association 
of collision risk with DUIC among a representative sample of adults surveyed in Ontario. 
Reporting DUIC in the past year increased significantly the odds of reporting a collision, 
after controlling for age, gender and other demographic variables (OR = 2.61).
General discussion of cannabis and collision risk
Early reviews of the literature on the association of cannabis use with collision risk 
concluded that conclusive demonstrations of cannabis use as risk factor for collisions 
did not exist (Robbe and O’Hanlon, 1993; Ferrara et al., 1994; Chesher, 1995; 
Christopherson and Morland, 1997; Hunter et al., 1998; Bates and Blakely, 1999; de 
Gier, 2000; Morland, 2000; Vingilis and Macdonald, 2002; Macdonald et al., 2003). 
However, more recent studies clearly suggest that cannabis use increases collision 
risk (e.g. Dussault et al., 2002; Mura et al., 2003; Drummer et al., 2004; Laumon et 
al., 2005;). Recent reviews of this literature are reflecting this growing body of studies 
finding a collision-enhancing effect of recent cannabis use (e.g. Kalant, 2004).
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Numerous epidemiological studies have been found where drug tests were conducted of 
injured drivers. Early analytical epidemiological studies that used responsibility analysis 
or case–control methods did not provide clear proof that cannabis use is related to 
increased injury risk from collisions (Bates and Blakely, 1999). These studies often 
have poor statistical power because the presence of drug metabolites is relatively rare 
and large sample sizes are required to detect significant effects. To demonstrate that 
a relationship exists, much larger sample sizes are likely required with methodological 
approaches free of biases that could inflate odds ratios.
Several methodological issues complicate the use of some types of drug tests. For 
example, urine test results cannot be used to measure drug impairment, only whether 
drug use occurred sometime in the past, up to a few weeks for cannabis (Kapur, 1994). 
Since urine tests are detecting those that are not under the influence of cannabis, the 
measure lacks specificity and, therefore, extremely large sample sizes may be needed 
to find a statistically significant increase in collision rates for those testing positive. 
Blood tests offer a more promising approach for the assessment of whether drivers are 
more likely to be under the influence; however, because of their more intrusive nature, 
they may only be feasible for studies using responsibility analysis of fatally injured 
drivers. Few studies that use drug tests have control groups, thereby making it difficult 
to determine whether drug presence is a risk factor. The likely reason few studies 
include controls is that consent from this group is usually required. Consent is likely to 
discourage the participation of drug users more than non-users, which would translate 
into inflated relative risks or odds ratios. Some studies have used comparison groups 
of pedestrians; however, this approach is likely too conservative because the pedestrian 
could also be at fault.
Some studies have noted that different drugs are used in combination with each other, 
possibly resulting in increased risk for injury. Drug metabolites, for example, are often 
found in combination with alcohol. Therefore, it is important to separate out the relative 
role of other drugs from alcohol. Although many studies reported the proportion of 
collisions that involve alcohol, research has largely failed to separate out the role of 
alcohol from cannabis in collisions.
Under these circumstances other means to assess the contribution of cannabis to 
collision risk are useful. One approach is to examine collision risks of known heavy 
users of cannabis, such as people in treatment for a cannabis abuse problem. A recent 
study found cannabis clients have significantly elevated rates of collisions compared with 
population controls (Macdonald et al., 2004b). Another approach is to examine collision 
risks associated with self-reported DUIC in survey data. Recent studies have found 
that collision risks are significantly elevated in samples on adolescents and adults who 
report DUIC (e.g. Asbridge et al., 2005). However, studies of clinical groups or survey 
samples are limited in their ability to draw causal inferences, or to control for potential 
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confounders. Other factors may be causally related to both drug use and collisions. 
Recent studies and reviews on set variables, such as aggression (Beirness, 1993; 
Deffenbacher et al., 2000; Wiesenthal et al., 2000; Gidron et al., 2001), risk-taking/
impulsiveness (Beirness, 1993; Jonah, 1997; Vavrik, 1997), stress (Veneziano and 
Veneziano, 1992; Simon and Corbett, 1996; Norris et al., 2000), fatigue (Horstmann et 
al., 2000; Masa et al., 2000; Connor et al., 2001) and criminality (Wells-Parker et al., 
1986; Denison et al., 1997) confirm the importance of these characteristics in predicting 
collisions. Studies have found that many of the characteristics described above are over-
represented in substance abuse populations, which might also explain higher collision 
rates. Withdrawal effects from cannabis, such as exhaustion, anxiety, agitation, mood 
swings and depression, and long-term effects of abuse, such as chronic sleep disruption, 
distractibility and depression (Cohen and Sas, 1993; Coambs and McAndrews, 1994; 
Herscovitch, 1996) could also increase risks.
One of the strengths of studies of clinical and survey samples is the accessibility and 
validity of information gathered. Although these studies suffer from the same limitations 
as survey studies of non-clinical samples, the biases related to self-reports are likely 
much less pronounced in the clinical samples. Since those who seek treatment have 
already acknowledged that they have a problem, they are more likely to provide 
accurate accounts regarding that problem. Good validity of self-reports has been 
established among substance users both during and after treatment (Hindin et al., 1994; 
Nelson et al., 1998).
Detecting cannabis in drivers
The availability of accurate and simple-to-use breath tests for alcohol have been 
central to current efforts to reduce drink driving (Mann et al., 2001). There has been a 
continued interest in the development of a breath test for cannabis over the years, but to 
date no scientifically validated tests have been reported (Verstraete, 2000). Blood tests 
are the ‘gold standard’ for assessing levels of cannabis and metabolites in the body. 
Results of blood tests can be influenced by such factors as the temperature at which the 
sample is stored and binding to the inner surface of plastic vials (O’Kane et al., 2002). 
The logistic and legal issues involved in obtaining and testing blood samples from 
drivers suspected of DUIC are complex.
As noted earlier, the mere presence of cannabis in plasma may not indicate impairment. 
A current focus of research is to identify a relationship between THC in blood (and other 
body fluids) and behavioural change, drug influence and impairment (Martin and Cone, 
1999). This has led to the suggestion that per se levels of cannabinoids in plasma may 
be identified for legal purposes, similar to the identification of per se levels for alcohol 
(Martin and Cone, 1999). Ramaekers et al. (2004), in considering this question, note 
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that meta-analyses of laboratory studies indicate that maximal performance impairment 
is seen at THC concentrations greater than 14 ng/mL in plasma or 7 ng/mL in whole 
blood. However, they note that the link between these levels and elevated collision risk 
has not been absolutely established.
Urine tests are used in situations where any relatively recent use of cannabis and other 
drugs is of interest (e.g. in sports, in addictions treatment), regardless of whether that 
use occurred in the previous few hours, days or even weeks. However, urine tests do not 
permit an accurate assessment of when drug use occurred (Kapur, 1994). A driver who 
has a positive urine test for cannabis may have used the drug in the preceding hours or 
days (or even weeks), and, thus, his or her driving skills may not be influenced by the 
drug at the time the sample is taken.
The detection of cannabinoids in saliva and sweat has been an active area of research. 
Current kits to measure saliva involve taking a swab from the mouth and include a 
rapid detection kit (O’Kane et al., 2002). Available data suggest that saliva THC levels 
arise from a drug that has remained in the mouth during smoking or ingestion, and 
initial data suggest that these levels are associated with degree of impairment observed 
(Menkes et al., 1991). The EU has run two projects, Rosita-1 and Rosita-2, to examine 
technology for enabling roadside drug screening. The first Rosita project in 1999–2000 
established criteria for acceptable tests (sensitivity and specificity > 90 %, accuracy 
> 95 %) for amphetamines, benzodiazepines and cannabis. As rapid screening in a 
roadside situation should aim to be as non-invasive as possible, the Rosita-2 project 
aimed to evaluate the useability and analytical reliability of nine on-site oral fluid (saliva) 
drug testing devices between 2003 and 2005. Six European countries and four states 
in the USA took part. At the end of the period, none of those devices met the criteria 
proposed during the Rosita-1 project. Six devices registered a failure rate of greater than 
25 %. The procedure of obtaining the saliva samples varied greatly in terms of handling, 
quantities and acceptance by officials testing and persons tested, sometimes easy to 
perform, sometimes difficult to follow.
Assessing behavioural effects of cannabis
There has been substantial recent interest in programmes involving the training of police 
officers and others to detect the physiological and behavioural effects of cannabis in 
individuals suspected of DUIC, and research on this topic is beginning to appear. Drug 
recognition expert (DRE) programmes have been developed to enable police officers 
to identify an individual who may be under the influence of a drug. These indicators 
can range from pupil size and body sway to the presence of drug paraphernalia in the 
vehicle. Walsh and Cangianelli (2002) reported that, in drivers suspected of driving 
under the influence of drugs (DUID) by DRE-trained police officers, subsequent blood 
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testing revealed that 32.5 % were positive for at least one drug other than alcohol. This 
low level of sensitivity improved to 79.3 % when officers were subsequently given an 
improved training programme. Tzambazis and Stough (2002) presented evidence that 
cannabis-induced impairment of performance on behavioural tests (standardized field 
sobriety tests, SFSTs) was significantly correlated with impairment of driving. Similarly, 
Papafotiou et al. (2004) showed that impairment of SFST performance increased with 
increasing dose of cannabis.
Driving under the influence of cannabis legislation in 
Europe
Currently, European Union countries have legal provisions on driving under the 
influence of drugs but impairment must be proven in court in most countries (Moeller et 
al., 1999; EMCDDA, 2007). Germany (in 1998), Belgium (in 1999), Sweden (in 1999; 
Jones, 2004) and Finland (in 2003; Lillsunde et al., 2004) passed laws that allow for 
sanctions based on detection of drugs alone and other countries have proposed similar 
laws. This type of legislation depends on the police force’s authority to collect human 
specimens at the roadside for testing or for confirmatory analysis, and this authority 
is regulated by other legislation that differs by jurisdiction. Some countries allow the 
police to control and test the public randomly and suspicion is not necessary for testing. 
However, the majority of countries treat roadside testing as an infringement of civil 
rights and suspicion is necessary for testing. Some countries have improved the process 
for initial suspicion by training the police to identify intoxicated drivers on the basis of 
physical and psychomotor signs.
Germany and Belgium currently use roadside testing devices routinely (sweat and urine 
are collected) and some countries have used urine or saliva or sweat test devices on 
an experimental basis with the driver’s consent. Very few European countries have 
regulations prohibiting the use of roadside drug testing devices. However, many do 
not use these devices because of concerns regarding their validity or because of their 
unavailability. The preferred test is a single use, multi-parameter test, which is able to 
provide a clear, unambiguous test result within 5 minutes. According to Moeller et al. 
(1999), saliva is the preferred test specimen for cannabis due to its easy availability, low 
invasiveness and good correlation with impairment. Sweat was the second in preference 
because it allows testing without collaboration of the driver, and its low invasiveness and 
good availability at the roadside. Roadside drug screening is being trialled in a number 
of European Member States at the time of writing (EMCDDA, 2007). There have been 
some teething issues. For example, tests carried out in France in the summer of 2007 
used three different devices and required the presence of a doctor for validating a urine 
sample. Introduction of Drugwipe saliva tests in Luxembourg in 2007 required explicitly 
by the Transport Ministry that the tests would not serve to incriminate drivers taking 
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legal medicines (3). Portuguese police reported problems with a faulty batch of Oratec-3 
testing kits. Nonetheless, there is commitment at ministerial level to introducing saliva-
based drug testing across many Member States.
Conclusions
The impact of cannabis on traffic safety is an issue of substantial public and political 
interest at present and will likely continue to be of interest for some time. As has become 
clear in this review, there is a substantial amount of information available that can shed 
light on this issue, but in many areas the available evidence is sparse or unclear.
First, it appears clear that, in laboratory settings, cannabis impairs the skills thought 
to be necessary for safe driving. This impairment is not restricted to high levels of the 
drug (see earlier note that this dosage level may need some explanation) and occurs 
at the dosage levels that result from typical use of the drug. Tolerance may occur with 
continued use, but even individuals who have acquired tolerance to some of the effects 
of cannabis may demonstrate impairment on task performance. Combining alcohol with 
cannabis will result in an increase in the effects of cannabis, and the interaction could 
be multiplicative.
After alcohol, cannabis is the drug most often found in fatally and non-fatally injured 
drivers. In recent, studies cannabis has been found in up to 27.5 % of dead drivers 
(Macdonald et al., 2003). However, epidemiological studies employing control groups 
are necessary to identify more precisely the contribution of the drug to collision 
causation. While earlier reviews of the literature were unable to conclude that cannabis 
increased collision risk, more recent studies employing larger samples and more 
rigorous methods are demonstrating with more consistency that recent cannabis use 
will increase collision risk (e.g. Mura et al., 2003; Drummer et al., 2004; Laumon et 
al., 2005). Studies employing clinical samples or using survey data provide additional 
indications of an increase in collision risk associated with cannabis use, however, in 
these studies the possibility that the increased risk may be due to factors other than the 
effects of cannabis cannot yet be ruled out.
Central to the problems of assessing the impact of cannabis on collision risk and to 
the problem of detecting cannabis-impaired drivers is the problem of measuring the 
presence of cannabis in the body. Difficulties in measuring cannabis in the body have 
hampered research on the effects of cannabis and the potential development of legal 
initiatives to address cannabis-impaired driving. Research is now assessing issues of 
dose–response effects on skills and behaviour. As well, measures that may assist in the 
 (3) See www.gouvernement.lu/salle_presse/communiques/2007/10/03lux/
Cannabis use and driving: implications for public health and transport policy
192
detection of DUIC (saliva tests, DRE programmes, standardized field sobriety tests) show 
promising results in field trials.
While much information is now available, there is a clear need for more research to 
determine the degree and nature of the association between cannabis use and collision 
risk. The impact of several variables on the cannabis–collision risk relationship needs 
to be examined, including personality characteristics such as risk-taking, aggression, 
criminality and stressful life events. Additional research to discover and validate easily 
administrable measures of cannabis use and impairment is also needed. Nevertheless, 
recent research has provided a much clearer picture of the contribution of cannabis to 
collision risk than was available only a few years ago.
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Setting the context
One of the fears that has accompanied increasing cannabis prevalence in Europe is 
that more people, or rather more vulnerable people, are being exposed to problematic 
use. In particular, there are concerns about cannabis’s role as a potential trigger or 
precipitator of mental health problems such as psychosis, depression, schizophrenia and 
anxiety (see this monograph’s chapters by Witton, Hall and Montanari et al.). Anxiety 
has focused particularly on adolescents and young adults, the core cannabis-using 
demographic.
Few argue that more and more people — and in particular adolescents and young 
adults — are seeking professional help for cannabis problems. Cannabis treatment 
indicators were the topic of a selected issue in EMCDDA’s 2004 Annual Report. Key 
findings were that 12 % of all treatment clients and 30 % of new clients to drug treatment 
recorded using cannabis as their main problem drug, and that a steady rise has been 
seen since the mid-1990s. The most recent data indicates that the share of those seeking 
help for cannabis among treatment clients has increased further to 20 %, although the 
share of new clients has remained stable, at 29 % (EMCDDA, 2007). Concerns about 
youth exposure to problems seem justified: nearly all cannabis clients new to treatment 
are under 30 years old, and the majority are male. Teenagers in specialised drug 
treatment are more likely to report cannabis as the primary drug.
Not surprisingly, health professionals – both specialists and general practitioners – are 
increasingly seeking advice on best practices for treating cannabis problems. While 
Chapter 14 by Rödner Sznitman is descriptive, answering the question ‘What cannabis 
treatment is available in Europe today?’, ideally, this chapter would now be prescriptive, 
detailing ‘What cannabis treatment should be available in Europe today?’
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Yet, this chapter cannot be prescriptive. As with other types of drug treatment, no ‘gold 
standard’ for cannabis exists. Nonetheless, there is some cause for optimism. The 
author finds that as cannabis treatment becomes more commonplace, the evidence 
base for ‘what works’ is likely to improve. What is more, the need to measure efficacy is 
increasingly being ‘built into’ emerging programmes from the start, as opposed to being 
tagged on as an afterthought.
Specialised cannabis treatment centres are being opened in a number of European 
countries — for example, in 2005, France opened 250 cannabis consultation centres, 
while promising psychosocial therapy development projects are underway, such as 
CANDIS in Germany and the five-country INCANT project (Belgium, Germany, France, 
Netherlands, Switzerland), and the Maria Youth Centre Project in Sweden (EMCDDA, 
2007). The EMCDDA organised a Reitox academy in Berlin in March 2007 on cannabis 
prevention and treatment (see link below). Nonetheless, policymakers should perhaps 
bookmark this chapter with a large Post-it note reading ‘research funding needed here’.
Further reading
EMCDDA, Annual reports, published each year in November.
EMCDDA (2007), Presentations at the Reitox Training Academy, on cannabis prevention and 
treatment (29–30 March, Berlin) 
http://academy.emcdda.europa.eu/index.cfm?fuseaction=public.Content&nnodeid=23154
EMCDDA (2004), Annual report 2004 — Selected issue on ‘Cannabis problems in context — 
understanding the increase in European treatment demands on Cannabis treatment, European 
Monitoring Centre for Drugs and Drug Addiction, Lisbon 
http://ar2004.emcdda.europa.eu/en/page155-en.html
Lundqvist, T., Petrell, B., Blomqvist, J. (2007), Improvement in cognitive and social competence in 
adolescent chronic cannabis users — Results from a manual based treatment programme at Maria 
Youth Centre, Stockholm, Sweden, Drug Addiction Treatment Centre, Lund University Hospital, 
Lund.
Projekt CANDIS website (2005–2007), http://candis-projekt.de/cannabis.html
Projekt INCANT website (2006–2007), www.incant.de/
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Treating cannabis use disorders: 
perspectives and best practices
Anders Bergmark
As in most other cases within the field of treatment of substance misuse there is no solid 
consensus concerning the specific effects of different treatment interventions for cannabis 
use disorders. Current cannabis treatment options are limited compared with those for 
alcohol and opiates and have only developed in recent years as the need for treatment 
has become more apparent. To a large extent the available knowledge-base is hard 
to interpret, due to a lack of standardisation of core components in clinical trials (such 
as client characteristics and comparison interventions). This challenge is compounded 
by the small amount of treatment studies to draw upon, and the reliance upon meta-
analysis and reviews of clinical studies, which in itself is subject to flaws.
A digression on the limitations of scientific reviews
When mapping the fast-developing field of cannabis treatment, it is crucial to take 
into account both the immaturity of the existing evidence base and the challenges of 
making clear-cut secondary reviews. So before reviewing current work on cannabis 
treatment, a didactic digression is included here to encourage peers to apply a critical 
eye when dealing with cannabis treatment. It reviews the doubts that have been cast on 
the existing evidence base for alcohol treatment, thus serving as a warning to cannabis 
treatment researchers to avoid similar pitfalls.
Recent years have seen a shift within scientific studies away from original studies and 
towards more ‘exhaustive’ reviews. It is no longer sufficient to underpin a clinical 
position by a single primary study or by synthesising a handful of primary studies, 
but to review all relevant studies. In some cases several hundred studies must be 
analysed. However, the resulting secondary studies need to be read critically, and there 
is considerable discussion on the limitations of reviews in clinical and psychological 
literature (Widiger et al., 1990; Deeks, 1998; Rosenthal and DiMatteo, 2001).
For substance treatment, there are three broad types of scientific review: the ‘narrative 
review’, the ‘box-score review’, and the ‘meta-analysis’.
Narrative reviews are conducted without an explicit systematic approach concerning •	
the synthesis of the results of the primary studies that are included.
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Box-score reviews set out to differentiate between evidence by comparing any given •	
treatment modality’s proportion of positive findings vis-à-vis the total number of 
studies for that modality.
Meta-analyses are built upon ‘effect sizes’ (ES), an index of treatment efficacy that •	
enables the study to determine how a standard deviation in the results for one 
treatment group compares to control groups.
Although guidelines exist for how a review should be conducted, the majority of reviews 
— across many clinical fields — fail to follow them (Widiger et al., 1990; Breslow et 
al., 1998; Wilson, 2000; Altman et al., 2001; Bergmark, 2001). Over time ‘narrative 
reviews’ have become less important. While they are rarely without value — essentially 
relying upon the insight of the authors — they are not fit for analysing a large number 
of original studies and because they lack statistical analysis.
Meanwhile, the difficulties involved in producing valid box-score reviews have been 
underestimated, and this situation is not helped by the existence of competing reviews, 
that is reviews that reach contradictory conclusions from the same primary material 
(Petticrew and Kennedy, 1997). Finney (2000), a leading substance misuse treatment 
researcher, has provided strong arguments to favour pessimistic interpretation of existing 
research in the alcohol treatment field, and points to four major problems connected 
with box-score reviews:
 1 lack of statistical power to identify differences between the intervention and control 
group;
 2 multiple statistical tests for treatment effects;
 3 variable comparison (control) groups across studies;
 4 lack of consistent and adequate data on client characteristics across studies.
The number of clients in alcohol treatment studies is generally limited to a size that 
only gives a 50 % chance to detect a medium-size effect at the P < 0.05 level (Morley 
et al., 1996). This means that there is a substantial risk that conclusions concerning 
treatment effects are dependent on variation in statistical power among studies that are 
included in a review. It has been shown that studies on treatment settings that did detect 
positive differences in effects have an average probability of 77 % to do so, whereas 
studies with negative findings only had a 55 % chance to do the same (Finney et al., 
1996). There is also a trend to compensate for weakness in statistical power; that is, 
the use of small groups of clients in studies by using a large number of tests without 
any regard for the type I error rate (Finney, 2000); that is, for false positive findings 
owing to the fact that a large number of tests will increase the probability for positive 
findings because of chance. In a study of settings effects it was found that studies that 
did identify positive effects had an average of 18.6 tests for the identified treatment 
effects, while those studies that did not identify any treatment effects had an average of 
4.9 tests (Finney et al., 1996). A lack of standard procedure when it comes to the use 
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of comparison groups, that is the fact that there often is a great variation concerning 
what type of control condition is used within different studies, undermines the possibility 
of using original studies in reviews. It has been shown (Floyd et al., 1996) that only 
30 % of treatment studies used comparison groups that were exposed to no or minimal 
treatment, and as a consequence the identification of treatment effects will be dependent 
on which type of intervention the comparison group was subjected to. In a similar 
manner, the lack of information on relevant client characteristics constitutes a serious 
threat against the possibility of making comparisons between different studies. In a 
recent review of methodological issues (Floyd et al., 1996) more than two-thirds of the 
studies lacked information on how many years the clients have had substance misuse 
problems, and only 16 % had any information concerning to what extent clients had 
received previous substance misuse treatment.
Meta-analysis is generally considered to be a better alternative than a box-score 
review. This is mainly because meta-analysis can avoid the serious bias connected to 
limited statistical power in the original studies by establishing so-called combined effect 
sizes. However, all the problems do not go away. As with box-score reviews there are 
substantial problems related to the lack of standardised comparison groups and an 
absence of information on relevant client characteristics. Combined, these problems 
bring Finney to conclude that currently, in the field of alcohol treatment, it is not possible 
to establish any synthesis that could direct an evidence-based practice about alcohol 
treatment.
It is telling that some of the most well-known researchers who have been extensively 
involved in such reviews have radically different views on whether existing reviews are 
inconsistent or not. For example, while Miller and Willbourne (2002) are encouraged by 
what they identify as considerable convergence between different reviews, Finney (2000) 
takes the opposite position.
The scientific knowledge base for treatment of cannabis 
use disorders
Meta-analyses
To date there have been two reviews that are specifically directed towards treatment of 
cannabis use disorders: SBU (2001; The Swedish Council on Technology Assessment in 
Health Care) and Fridell (2003). However, these two reviews, which both make use of 
meta-analytical techniques, arrive at two different qualitative answers to the question 
of whether any effective treatment for cannabis use disorders exist. They are in fact 
strongly related to each other: Fridell’s study is an update of the SBU study (Fridell 
was the author of the chapter in the SBU study that dealt with psychosocial treatment 
for drug dependence). Most treatment approaches to cannabis use disorders involve 
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psychosocial approaches, which may include elements of psychological interventions 
such as cognitive–behavioural therapy or motivational interviewing or aspects of the 
client’s environment, notably in interventions involving the client’s family. But while the 
SBU study concluded ‘there is no documentation of reliable effects for any psychosocial 
treatment for cannabis abuse’ (p. 48, vol. II, author’s translation), Fridell summarises his 
findings as follows: in 4 out of 13 published studies, behaviour therapy (pp. 5, 7) and 
family therapy (pp. 70, 88, 97) had a significant effect compared with control conditions 
for marijuana-smoking teenagers with a still-existing family network (p. 354).
The difference in the conclusion drawn in these reviews does not stem from the inclusion 
of new studies; although Fridell’s study includes 13 studies and SBU 11, the two 
studies that were added to the former analysis were published in 1989 and 1982 (and 
should, according to the inclusion criteria stated in the latter analysis, also have been 
included in the SBU study). While the SBU study directly refers to the effect size (ES) of 
the meta-analysis that was undertaken for all psychosocial interventions, Fridell makes 
no explicit reference to the ES derived from his meta-analysis. Instead, he points to the 
fact that some treatment interventions have support for effects. But this approach begs 
the question why the overall meta-analysis was performed at all. To the extent that 
Fridell intended to evaluate the effects of specific treatment modalities, he should also 
have included the studies with no or weak effects that are included in the meta-analysis, 
otherwise the claim that behaviour and family therapy have support in some studies 
cannot be considered as meaningful (as the treatment modalities that are identified also 
are present in studies with no support for an effect).
While the meta-analysis in the SBU study produced an ES of 0.05 and, thus, points in 
the direction of no effects for psychosocial interventions for cannabis use disorders, 
Fridell’s meta-analysis yields an ES of 0.24, that is, just above the 0.20 level which 
commonly is identified as the lower limit for a low ES (0.20–0.50; Cohen, 1978). The 
difference in ES from the two meta-analyses does not seem to be primarily connected 
to the inclusion of two new studies but to a difference in the estimated ES for three 
studies that are present in both studies. A study by Lewis is assigned an ES of 0.25 in 
SBU, while the corresponding value in Fridell’s analysis is 0.49; a study of Joanning 
et al. (1992) has an ES of 0.63 in SBU and an ES of 1.01 in Fridell’s analysis, and 
finally, a study by Henggeler et al. (1998) has an ES 0.54 in SBU and an ES of 0.93 
in Fridell’s analysis. Taken together, such inconsistencies undermine the possibility of 
interpreting the relationship between these two reviews and drawing conclusions that 
could guide practice. Thus, both the SBU’s and Fridell’s meta-analyses suffer from 
several of the problems dealt with in the preceding section. Neither of them considers 
the effects of the fact that there are important differences between the client groups 
in the studies included. Most importantly, neither distinguish between studies that only 
include adolescents and those directed towards adults. In the same fashion, there are 
no attempts to analyse the effects of the fact that there is a substantial variation in 
comparison groups between the studies that are included.
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Recent treatment studies
Adolescent treatment
There are some new, substantial studies that are not included in SBU’s or Fridell’s 
analyses that underline the difficulties of identifying best practice. The most important is 
the CYT (cannabis youth treatment) study (Dennis et al., 2004). This multisite study sets 
out to analyse the effects of five different treatment interventions for adolescent cannabis 
use disorders. The design of the study aims at an identification of effects of treatment 
intensity as well as of treatment modalities. A combination of motivational enhancement 
treatment (MET) and cognitive–behavioural therapy (CBT) in five sessions was compared 
with the MET/CBT in 12 sessions and family support network (FSN, which was based 
on MET/CBT in 12 sessions and an addition of six parent education group meetings, 
four home visits, and case management). In a second trial of the study the five-session 
version of the MET/CBT intervention was compared with the adolescent community 
reinforcement approach (ACRA) and multidimensional family therapy (MDFT). While all 
the interventions led to improvements measured by days of abstinence and proportion of 
adolescents in recovery, the authors conclude, ‘Overall, the clinical outcomes were very 
similar across sites and conditions’ at 12-month follow-up. The study did not produce 
any support for the idea that an increase of the dosage of treatment had a differential 
effect on cannabis use, and neither did it provide any support for family-based treatment 
to being superior to the other interventions (which has been suggested for drug misuse 
in general, e.g. by Stanton and Shadish, 1997).
Brief interventions for adolescent cannabis users have been tested in a multisite study 
with non-treatment seeking adolescents in 10 educational colleges in London in the 
United Kingdom. At 3-month follow-up, the treatment group receiving a 1-hour face-to-
face motivational interviewing session had reduced their weekly frequency of cannabis 
use by 66 %, while a no-treatment control group had increased the weekly frequency 
of their cannabis use by 27 % (McCambridge and Strang, 2004). These effects had 
diminished at 12-month follow-up, although cannabis use levels were significantly 
reduced from those at baseline (McCambridge and Strang, 2005).
Adult treatment
Concerning treatment for adults with cannabis use disorders, six relevant studies that 
are not included in the analyses from SBU and Fridell have been published: MTP 
Research Group (2004), Copeland et al. (2001), Budney et al. (2000, 2006), Stephens 
et al. (2000), Carroll et al. (2006). The first three of these studies set out to study the 
differential effect of treatment dosage and to compare treatment interventions with 
a delayed treatment control (DTC). All studies establish a significant effect for all 
interventions compared with DTC, but in two of the studies (Copeland and Stephens) 
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there is no significant difference in effect between the minimal intervention and the more 
extensive intervention.
However, methodological aspects of these studies may have detracted from the 
potential benefits of longer treatments. Small numbers of cannabis users were studied 
and recruitment may have resulted in a sample of patients more likely to succeed in 
treatment. Less experienced therapists conducted the interventions in group settings 
rather than tailoring them to individual need, and they had abstinence from cannabis 
use as their goal. The multisite study, involving 450 mostly cannabis-dependent 
treatment seekers from three US states from the MTP Research Group (2004), attempted 
to avoid these shortcomings. In this study, outcomes from two interventions and a 
delayed treatment group were compared. Both interventions involved manual-based 
programmes flexible enough to be directed at individual requirements and included 
a moderation goal as well as abstinence. There was a more positive effect for the 
more intensive treatment intervention involving motivational and cognitive–behavioural 
elements, as well as practical issues such as transport, childcare and housing than 
an intervention involving two motivational enhancement sessions provided a month 
apart. While the study confirmed that brief interventions can lead to improvements, at 
each of the follow-up points at 3, 9 and 15 months those who had received the longer 
therapy showed greater improvements: using cannabis less often; greater reductions 
in symptoms of dependence and attaining abstinence in greater numbers. The results 
suggest that many cannabis-dependent patients might benefit from a one- or two-
session intervention involving motivational interviewing combined with an introduction 
to ways of moderating use, while longer courses of motivational interviewing and 
cognitive–behavioural therapy should be available for those who need it (Ashton, 2005).
In the study by Budney et al. (2000), a contingency management approach was used. 
Contingency management usually involves providing patients with vouchers redeemable 
for goods and services in exchange for the patients provided drug-free urine tests, 
treatment attendance or medication compliance. The value of the vouchers can vary 
in order to reinforce desired outcomes. For example, in the recent Carroll et al. study 
with young cannabis-dependent adults, participants received a voucher worth USD 25 
for the first session attended, with increases of USD 5 increments for each subsequent 
session attended. Participants also received USD 25 for each cannabis-free urine sample 
they provided after testing, which also increased in USD 5 increments to a maximum of 
USD 540 if all urine specimens provided during the course of the study were negative. 
Recent meta-analyses found effective outcomes from interventions using voucher-
based and contingency management approaches compared with a range of control 
conditions (Lussier et al., 2006; Prendergast et al., 2006). The Budney et al. study 
randomised 60 cannabis-dependent adults to four individual sessions of motivational 
enhancement therapy (MET), 14 sessions of a MET and cognitive–behavioural 
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therapy (CBT) combination or a MET/CBT intervention together with contingency 
management. Although this study indicated that monetary incentives in the form of 
vouchers exchangeable for retail items increased abstinence in comparison to MET- and 
CBT-based interventions, the fact that no long-term follow-up was performed made it 
uncertain if this extrinsically motivated abstinence was sustained for a longer period of 
time. A subsequent study of these interventions by the same research group assessed 
outcomes for 12 months after treatment. Monetary incentives led to continuous periods 
of abstinence during treatment. CBT did not add to this during treatment effect but 
results showed that CBT did help with post-treatment maintenance of the initial positive 
effects of the vouchers. However, only half of the people in the study were able to 
achieve abstinence during the treatment and the majority continued to use cannabis 
after treatment and experience cannabis-related problems (Budney et al., 2006).
Another US study tested contingency management with young adults referred to 
treatment by the criminal justice service. Here 136, mainly male, cannabis-dependent 
probationers between the ages of 18 and 25 were randomised to one of four treatment 
conditions: a motivational enhancement/cognitive–behavioural intervention (MET/
CBT) based on the manualised approach of the MTP study, either with or without a 
contingency management element; or individual counselling with or without contingency 
management. Contingency management was provided by incentives in the form of 
vouchers redeemable for goods or services dependent on treatment session attendance 
or submission of cannabis-free urines. The interventions with contingency management 
interventions had a significant positive effect on treatment retention and the number 
of cannabis-free urine specimens, with the motivational enhancement/cognitive–
behavioural intervention with contingency management proving the most effective of 
the interventions. While there were few positive effects of MET/CBT compared with drug 
counselling during the treatment period, the patients receiving the MET/CBT intervention 
showed more signs of continuing improvement after treatment and continued to reduce 
their cannabis use when followed up at 3 and 6 months (Carroll et al., 2006).
In addition to the examination and evaluation of reviews and specific original studies 
with a bearing on treatment effects for cannabis use disorders, it might also be 
worthwhile to consider some results from more general reviews of drug misuse treatment 
interventions (Stanton and Shadish, 1997; Ozechowski and Liddle, 2000; Williams 
and Chang, 2000; Prendergast et al., 2002). The review by Prendergast et al. (2002) 
does not find any differences between treatment modalities, but Stanton and Shadish 
(1997), Ozechowski and Liddle (2000) and Williams and Chang (2000) all find support 
for family therapy (in different forms) as a more effective intervention than non-family 
modalities. But such findings are contradicted by the studies of Dennis et al. (2004) and 
Waldron et al. (2001). Multisystemic therapy (MST) (which must be considered as family 
based) has been cited by NIDA (the US National Institute on Drug Abuse) as an effective, 
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evidence-based treatment intervention, but a recent, Cochrane-based review by Littell 
et al. (2005) on MST comes up with the conclusion that MST has few if any significant 
outcomes compared with usual services or alternative treatments.
There is an ongoing study, Projekt CANDIS (1), Targeted Treatment for Cannabis 
Disorders, at the Dresden University of Technology, due for completion in January 2008. 
CANDIS seeks to develop a modular treatment programme for cannabis use disorders 
based on treatment packages and components that have been shown to be effective 
in previous US and Australian trials (Copeland, 2001), and to adapt these materials 
to the needs of its target population (German-speaking problematic cannabis users 
over 16 years of age). The treatment package includes motivational enhancement, 
cognitive–behavioural and psychosocial problem-solving components. While results are 
not yet available at the time of publication, initial feedback is encouraging, with first 
results expected in November 2007 (2).
Pharmacological treatments
There have been a small number of studies assessing potential medications for the 
amelioration of cannabis withdrawal symptoms, all by the same research group and 
involving adult participants (Hart, 2005). Bupropion, a medication that has been found 
to be successful in treating nicotine dependence, was found to exacerbate some of the 
symptoms of cannabis withdrawal in a laboratory study involving non-treatment seeking 
regular cannabis users (Haney et al., 2001). Another laboratory study using nefazadone, 
an antidepressant with sedative abilities, found that the medication alleviated only some 
of the withdrawal symptoms (Haney et al., 2003). Divalproex, used in the treatment 
of epilepsy, mood disorders and migraine headaches, was found to worsen cannabis-
associated withdrawal mood (Haney et al., 2004). Finally, administering doses of oral 
THC, at doses which did not produce subjective effects, was found to reduce withdrawal 
symptoms and reverse other effects associated with withdrawal, such as weight loss 
(Haney et al., 2004).
Naltrexone, an antagonist medication used in the treatment of opiate dependence, has 
been examined in relation to cannabis dependence. Antagonists block the effects of 
drugs by binding to receptors in the brain, with different antagonists working on different 
receptors and consequently blocking the effects of different drugs. Laboratory studies 
have demonstrated that opiates and cannabis share common receptors and animal 
studies have found that naltrexone can inhibit the development of cannabis dependence. 
However, human studies have found that naltrexone does not alter the subjective effects 
of low-dose oral THC and may also enhance the positive subjective effects of higher 
doses of oral THC (Haney et al., 2003).
 (1) www.candis-projekt.de
 (2) E-mail communication with Dr Eva Hoch, CANDIS project leader, October 2006.
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Conclusion
By and large, it seems as if there is still no conclusive evidence for any specific treatment 
intervention concerning cannabis use disorders. On the other hand, there are indications 
that anything works. That is, that the treatment modality in itself is of less importance 
than the treatment context and the individual’s choice to enter treatment. Support for this 
perspective is provided both by the CYT project (Dennis et al., 2004) and Project MATCH 
(Babor and Del Boca, 2003). In both of these projects, different treatment interventions 
produce the same (desired) outcome, although these outcomes did not seem to be 
facilitated by the stipulated theoretical mechanisms intended to produce these outcomes.
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Setting the context
Cannabis is the most widely consumed illicit drug. It is targeted in one way or another 
by most prevention interventions. However, few interventions have targeted cannabis 
specifically. So cannabis prevention in Europe takes place in a vast and varied 
landscape. What may seem an abstract term — prevention — in practice diffuses 
across all manner of concrete programmes. These range from diplomacy and treaty 
negotiation, through health promotion by ministries and community schemes, to physical 
products such as pamphlets, videos and leaflets.
This chapter attempts to map the diversity of interventions in Europe within the three-tier 
‘Gordon’ classification framework of universal, selective and indicated prevention. The 
chapter is illustrative rather than exhaustive. A general overview of prevention is made 
difficult because of the sheer diversity of prevention projects that have been developed. 
Moreover, the actors and implementers involved are far from uniform across Europe (1).
What is certain is that the evidence base for cannabis prevention in the EU needs 
considerable work. Budgets for prevention campaigns in Europe run into tens of millions 
of euros, yet while considerable effort is spent on describing their scale (number of 
leaflets printed, number of advertisements aired, etc.) more research is needed into their 
effectiveness. Much knowledge originates from alcohol and tobacco prevention and 
from non-European studies (the USA in particular). While the evaluation of programmes 
 (1) An EMCDDA project monitors national drugs strategies across Europe, see www.emcdda.europa.
eu/?nnodeid=1360
Cannabis prevention in the EU
218
has matured in Europe, the evidence base is too small to develop definitive conclusions 
for good practice. Political efforts should focus on evaluation and rigorous outcome 
evaluations.
Further reading
DrugInfo Clearinghouse (2005), Prevention reading and resource list: Cannabis, Melbourne.
EMCDDA (2002), Drugs in focus no. 5: Drug prevention in EU schools — includes a short reading 
list.
EMCDDA (ongoing), Prevention and evaluation resources kit (PERK) 
www.emcdda.europa.eu/themes/prevention/perk
Informa Healthcare (journal: six issues per year), Drugs: Education, Prevention & Policy.
Matthys, N., Van Hal, G., Beutels, P. (2006), Evidence based cannabispreventie in Vlaanderen, 
Onderzoek uitgevoerd in opdracht van Inge Vervotte, Vlaams minister van Welzijn, Volksgezondheid 
en Gezin, Brussels.
UNODC (2006), Monitoring and evaluating youth substance abuse prevention programmes, Vienna.
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Gregor Burkhart and Amador Calafat
This chapter focuses on a number of cannabis-specific prevention programmes 
in Europe. It also provides a brief overview of the rationale behind them. It must, 
nonetheless, be stressed that cannabis prevention rarely takes place in isolation. 
Furthermore, the weighting given to illicit drugs (cannabis included) in universal 
prevention has recently been eroded. Europe has shifted away from interventions that 
divide licit and illicit substances, and has moved towards an approach based on relative 
harms and complementary drugs, with particular focus on alcohol and tobacco in 
combination with illicit drugs prevention (2).
Cannabis in the context of polydrug prevention and 
health education
Cannabis prevention is typically delivered in the context of wider informational activities, 
and shares a platform with prevention for other substances — other illicit drug use, 
alcohol, tobacco and prescription drug misuse. Beyond substance use prevention, 
cannabis interventions are also frequently combined with public health prevention 
programmes that go beyond substance misuse, for example to cover personal health 
(mental health, addiction, healthy lifestyles, eating disorders, safe sex, etc.) and social 
education (citizenship, crime, ethics), particularly in the school environment.
A difficulty when analysing cannabis prevention activities is to identify, in this all-inclusive 
prevention environment, approaches that can offer insights specifically for cannabis. 
Reviews focusing specifically on cannabis prevention (e.g. Matthys et al., 2006) are rare. 
Yet, some formal approaches to analysing prevention have emerged, and prevention 
experts have in the past two decades begun to formalise their approach to analysing 
programmes, and a typology of interventions has emerged (universal, selective, 
indicated — see Box 1). This has enabled a more focused approach to evaluation of 
prevention initiatives.
For example, prevention can be categorised along criteria such as coverage (populations 
targeted), scope, duration, efficacy (what works in research conditions), effectiveness 
(what works in real life), resource-efficiency and cost-efficiency (what offers the best 
return on investment). A number of general evidence-based prevention manuals have 
been produced with European relevance (3). However, cannabis-specific handbooks 
 (2) See EMCDDA (2006c).
 (3) International examples include EU-Dap (2005); van der Stel (1998); UNODC (2002).
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Box 1: Prevention classification systems
Gordon (1987), Mrazek and Haggerty (1994) and Kumpfer and Baxley (1997) 
have proposed a three-tiered preventive intervention classification system: 
universal, selective and indicated prevention. Amongst others, this typology has 
gained favour and has been adopted by the US Institute of Medicine, National 
Institute of Drug Abuse (NIDA) and the EMCDDA.
Universal prevention strategies address the entire population (national, local 
community, school, district) and aim to prevent or delay the onset of alcohol, 
tobacco and other drug use. All individuals, without screening, are provided with 
information and skills necessary to prevent the problem.
Selective prevention focuses on groups who are either known to be drug users or 
at heightened risk of developing problems of substance abuse or dependence. 
The subgroups may be distinguished by characteristics such as age, gender, family 
history or economic status.
Indicated prevention involves a screening process, and aims to identify individuals 
who exhibit early signs of substance abuse and other problem behaviours. 
Identifiers include falling grades among students, known problem consumption or 
conduct disorders, alienation from parents, school and positive peer groups, and 
so on.
Outside the scope of this three-tier model are environmental prevention strategies. 
Environmental approaches are typically managed at the regulatory/legislative 
or community level, and focus on interventions to deter drug consumption. 
While prohibition can be viewed as the ultimate environmental restriction, in 
practice environmental strategies for cannabis include increased policing in 
sensitive settings (near schools, at music festivals), legislative guidelines aimed 
at precipitating punishments (warnings, penalties, fines) and actions to limit the 
prevalence of complementary licit drugs (for example, alcohol advertising bans 
and public place smoking bans).
Another classification scheme is primary, secondary and tertiary prevention. 
Primary prevention aims at preventing drug use and is usually the aim of universal 
programmes. Secondary prevention aims to prevent drug use from becoming 
problematic or leading to addiction. Tertiary prevention aims at preventing the 
harm caused by those who are using drugs.
On the borders of prevention and treatment is the strategy of early intervention. 
Based on detection of harmful alcohol or drug use, early intervention typically 
targets treatment of cases before they are aware that their substance use might 
cause problems or major psychosocial complications.
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and guidelines on specific measures for cannabis are less common, yet do exist (4). And 
despite considerable research effort, the prevention literature is largely weighted towards 
alcohol, smoking and general drug prevention (e.g. Aveyard et al., 2001; Loxley et al., 
2004).
A panel of prevention experts recently commented that ‘(…) what we know about 
effectiveness (of illicit drug prevention) is almost entirely grounded in work with 
alcohol and tobacco’ (Stockwell et al., 2005). This is mostly due to the nature of 
the phenomenon. In order to reach statistical power for prevention effects on a low 
prevalence problem such as cannabis use in pre-teens, a much higher number of cases 
to be treated is needed compared with alcohol and tobacco.
From informal to formalised programmes
As with misuse of other illicit drugs and alcohol, cannabis use is strongly associated 
with psychosocial risk factors that go beyond the drug’s pharmacological properties and 
patterns of use (5). Those who use cannabis occasionally and those who use it frequently 
may have different risk factors, different problems, and may therefore benefit from 
different prevention and supportive approaches. Cannabis components of prevention 
in Europe are increasingly being formulated to reflect such specific needs. With regard 
to schools programmes, more countries than before have introduced, expanded or 
are planning more structured prevention programmes, and quality programmes have 
been prioritised in many Member States (EMCDDA, 2006a). In many respects, the 
information on drugs provided as part of these programmes has evolved in parallel with 
the evidence generated through relevant epidemiology and screening instruments (6). As 
the most recent example in France, a 2005 MILDT/DGESCO addiction prevention guide, 
firmly based on epidemiology (7), was tested at 80 schools and proposes sequencing 
 (4) Exceptions include: in Germany, Schule und Cannabis (BZgA, 2004) and materials for the Bekifft in 
der Schule project (SuchtPräventionsZentrum Hamburg, 2004); in Switzerland, Ecoles et cannabis 
(OFSP, 2004); in France, Repérage précoce de l’usage nocif de Cannabis (INPES, 2006); in the 
UK, School drug policy: a review process (Blueprint, UK Home Office, 2004) and Advice for 
teachers on delivering drug education (Drug Education Forum, 2004); in Belgium, Maat in de 
Shit (CAT Infopunt and VAD, 2006). A number of cannabis-specific prevention manuals have 
emerged in recent years from Australia (DrugInfo Clearinghouse, 2005), New Zealand and the 
USA (NIDA, 2003; see also Sloboda, this monograph).
 (5) For a synthetic review of risk and protective factors, see Coggans, this monograph; Frisher et al. 
(2007); Dillon et al. (2006); Hawkins et al. (1991, 1992); Vázquez and Becoña (2000) and the 
website www.drugsprevention.net.
 (6) See Hibell and Coggans, this monograph, for a discussion of epidemiology in schools and 
psychosocial correlates of cannabis use. See Beck and Legleye, this monograph, for discussion 
of screening instruments. The EMCDDA’s next monograph seeks to address harm reduction in 
general.
 (7) The guide ‘Prévention des conduites addictives: Guide d’intervention en milieu scolaire’ is 
available at: http://eduscol.education.fr/D0190/guide.htm
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prevention according to age group and substance focus: 11–12 years, tobacco; 13–14 
years, alcohol; 15–16 years, cannabis; 17–18 years, polydrug consumption (French 
national report, 2006).
Common ground on prevention
A standard EU approach to prevention is notably absent (see Reitox national reports). 
Nonetheless, the EMCDDA’s annual report and EDDRA database have attempted 
to encourage pan-European awareness of what different Member States are doing. 
Encouragingly, cross-border collaboration is now more commonplace.
Consistency yet gradation
There is a continuum between drug-free society prevention approaches and moderation 
approaches. For example, prevention policies might target younger groups with a just 
say no message (minimising onset and experimentation), experimenting youths with 
a quit message (minimising continuation, e.g. Germany’s Quit the Shit programme), 
regular users with a moderation message (e.g. the UK Talk to Frank Cannabis: Too 
much too often guide, Belgium’s Maat in de Shit peer-based approach), and heavy or 
problematic users with a harm reduction or seek treatment message. Prevention projects 
in Europe now show some gradation in objectives: to postpone (the next) consumption, 
to suspend use for some (extendable) time, to refuse offers, to reduce consumption, to 
distance oneself from consuming peers, etc. (Canning et al., 2004). However, the core 
scientific base remains consistent: all programmes emphasise the substance’s illegality, 
risks and harms.
Heterogeneous actors and settings
Delivery of cannabis prevention in Europe, as elsewhere in the world, may involve a 
range of actors: ministries (health and interior affairs), parliamentarians, teachers, 
police, the judiciary, health professionals, drugs workers, community groups, theatre 
groups, youth services, parents (including parents of former drug users), Scouts, 
churches and religious communities, charities and NGOs, the media and commercial 
publishers. In such a populous environment where materials are freely available, 
‘official’ programmes may compete with programmes which are not officially 
endorsed (8). This is particularly the case for selective programmes. Jones (2004) 
 (8) For a discussion of various non-governmental prevention materials producers and Internet 
materials, see Tammi and Peltoniemi (1999), 39–40. Some controversy has arisen in the 
activities of Narconon, affiliated to the Church of Scientology (Czech Republic national report, 
2005; The Sunday Times, 7 January 2007).
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highlights that moves towards selective prevention constitutes a general shift in which 
European drug prevention programmes have become increasingly expansive in nature 
as they attempt to influence complex social environments of risk. Attention should 
be paid to possible problems which ensue from this. While irresponsibility is rare, 
such competing publications are subject to little public health endorsement, and their 
neutrality depends largely on who publishes them (9). For instance, different agencies 
may have different conceptions of vulnerability and risk behaviours, complicating 
interagency cooperation (Powell et al., 2003). Additionally, complications may arise 
from unsuccessful negotiation of boundaries between prevention, treatment and criminal 
justice agendas (Kimberlee et al., 2003). Indeed, research has shown that programmes 
tend to lose effectiveness as they are rolled out over time and across settings (Buston et 
al., 2002; Dusenbury et al., 2003).
Environmental prevention strategies
Environmental prevention strategies (e.g. legislative and regulatory controls, taxes, bans, 
community and school rules) have gained popularity and are currently being introduced 
for alcohol, tobacco and cannabis in several EU Member States. While blanket 
prohibition could be seen as the strictest form of environmental strategy, there are 
many possible variations. These include: full and partial smoking bans in public places; 
EU-wide tobacco advertising bans; developments at EU level on a European Alcohol 
Forum to develop a code of conduct for reducing alcohol-related harm (10); integration 
of roadside drug screening alongside drink driving tests; EU-wide indexation of existing 
minimum excise duties on alcohol; and alternative measures to criminal prosecution 
for personal cannabis possession. The level of enforcement of anti-smoking policies in 
EU Member States consistently correlates with the level of adolescent smoking (Aspect 
Consortium, 2004; Eurostat, 2002) and, without implying causality, there is appreciable 
correspondence between tolerant tobacco policies, prevalence of tobacco smoking 
among youth and prevalence of cannabis use (EMCDDA, 2006a). The vast majority of 
cannabis consumers are tobacco smokers. Inversely, there seems to be a strong intrinsic 
relationship between cannabis and cigarette smoking, in the sense that cannabis use 
perpetuates cigarette smoking (Amos et al., 2003).
Potential environmental prevention strategies for cannabis are limited by the illegal 
status of the drug (11). Nonetheless, advertising controls on tobacco products or alcohol, 
 (9) Producers of non-official prevention-like materials include pro-drugs lobbyists, church groups 
(Christian, Islamic, Scientologists), parents-against-drugs and similar charities, and groups with 
strong commercial interests (for example, cannabis magazine publishers and seed sellers).
 (10) http://europa.eu/rapid/pressReleasesAction.do?reference=IP/07/774&format=HTML&aged=0&
language=EN&guiLanguage=en
 (11) For discussion of hypothetical environmental measures, see Room, this monograph.
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together with anti-binge measures (such as happy hour restrictions) are proven to 
reduce consumption of these substances, and may have a knock-on effect on comorbid 
cannabis consumption, although little research exists on this topic.
Cannabis advertising is generally indirect in Europe, yet is, nonetheless, present. 
Advertisers include seed suppliers, growshops and head shops, cannabis smoking clubs 
and vendors of paraphernalia such as bongs and hydroponic equipment. Publicity 
channels include a burgeoning cannabis culture media — The High Times, Softsecrets, 
Pot-TV.net and the High Life trade fair — as well as general media (inflight magazines, 
music magazines, etc.). Mirroring the brand-stretching vogue that has accompanied 
tobacco marketing controls (Camel Active, Marlboro Classics) a number of products 
are marketed using cannabis or cannabis-leaf logos in Europe. As well as ‘directly 
associated’ products, such as bongs and cigarette rolling papers, products include 
Cannabis cough drops and Swiss Hemp Ice Tea drinks (Slovakian national report, 
2005), and clothing and accessories, often manufactured with hemp (in France, brands 
include Made in Chanvre and Terre de Chanvre). Yet, controlling such marketing and 
cannabis products is very much a grey area. The Australian Federal Government has 
promoted legislation to ban the sale of bongs and drug equipment, with a ‘bong ban’ 
recently put in place in the state of Queensland, although the effects of such legislation 
need to be measured.
At the ‘micro’ level, structural prevention measures targeting the availability of cannabis 
and the social norms around legal drugs are less developed than the evidence base 
would advise. An advertising ban forms part of the AHOJ-G prosecution guidelines for 
Dutch coffee shops (see Korf, this monograph). Some Dutch municipalities are beginning 
to ensure coffee shops are not established in the vicinity of schools, while overall retail 
outlet density has decreased. Policing of smart shops and growshops has tended to 
maintain vigilance for any shops that cross legal boundaries and actually sell cannabis: 
a recent parliamentary proposal in Spain called for regulating cañamerias (growshops). 
Meanwhile, some structural strategies have targeted the ‘periphery’ of substance use 
(e.g. municipal bans on drinking or drug-taking in public). Nonetheless, the apparent 
contradiction persists in Europe where advertisements for a legal product (e.g. tobacco) 
are banned yet not those for products relating to cannabis, an illegal drug.
Universal prevention: school-based approaches and mass media 
campaigns
Universal, multi-substance prevention programmes are the norm across Europe, with the 
predominant focus on school-based and mass media approaches (EMCDDA, 2006a).
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Rationale
An important prevention rationale for universal school-based approaches is the gateway 
hypothesis, whereby delaying onset of adolescent alcohol, tobacco and cannabis use 
is hypothesised to reduce rates of subsequent illicit drug consumption and problematic 
use and other comorbid harms (e.g. truancy, delinquency). Other rationales include 
general health promotion and preventing comorbid behaviour such as harmful alcohol 
use, school drop-out rates, risky sexual behaviour, early sexual activity or pregnancies, 
violence and social exclusion. There is some evidence that preventing or delaying 
tobacco or alcohol use can reduce subsequent use of cannabis (Botvin, 2000; Caulkins 
et al. 2002, 2004; Ellickson et al., 2003), yet strong proof for reductions for ‘harder’ 
illicit drug use has proved both elusive and heavily contended in the USA (Gerstein and 
Green, 1993; Manski et al., 2001).
The political rationale for general universal prevention is robust (12). Economies of scale 
are gained as the targeted population is large, while the health objectives — smoking, 
alcohol, drugs and obesity — are wide (Roe and Becker, 2005). By targeting youths 
and young adults, school-based and young adult-oriented programmes target a 
demographic where prevalence is highest, potential lifetime benefits the strongest, and, 
in many Member States at least, cannabis use is growing (EMCDDA, 2006a; Hibell 
et al. (ESPAD), 2003). Nonetheless, large-scale universal programmes also lead to 
high absolute cost, while covering large populations (low per-capita costs). Economic 
research into prevention cost-effectiveness remains both rare and perhaps politically 
sensitive in Europe.
Content considerations
A typology of different kinds of universal prevention interventions has been produced for 
the EMCDDA’s PERK project and reflects the developments of the last two decades (13). 
It divides content into (Burkhart and Crusellas, 2002; McGrath et al., 2006; EMCDDA, 
2007):
knowledge of drugs (prevention by providing health information to influence •	
decision-making);
personal skills (clarification of values and encouragement of responsible decision-•	
making);
social skills (in particular, peer resistance);•	
 (12) Political commitment to school-based prevention is intuitive, as seen in a recent letter to Addiction: 
‘If we do not have up-to-date evidence then we must fall back upon rationality and human and 
societal values, and I tend to agree (…) that alcohol education, in the absence of evidence, 
should continue to be valued.’ (Foxcroft, D., Addiction 101: 1057–1059).
 (13) www.emcdda.europa.eu/index.cfm?fuseaction=public.Content&nNodeID=9753
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normative beliefs (myth correction, correcting overestimation of the ‘acceptability of •	
use’);
alternatives to drug use (activities that are deemed incompatible with drug use);•	
structural or regulatory measures (reducing acceptance and availability of •	
complementary substances such as tobacco and alcohol); and
multi-component (a combination of these).•	
Debate is strong about the effectiveness of each approach, and there has been a shift 
away from ‘traditional’ or ‘intuitive’ prevention (knowledge and affective) to social skills, 
competence enhancement, and structural/regulatory and multi-component approaches 
based on scientific theory (Burkhart and Crusellas, 2002). Typical prevention approaches 
include theatre-based approaches (Canning et al., 2004) and, increasingly, IT- and 
Internet-based approaches (Tammi and Peltoniemi, 1999; Drugscope, 2006).
In terms of evaluating effectiveness of cannabis prevention programmes, Europe is, to 
a large degree, forced to look at US reviews which are furthermore focused on general 
substance prevention and not cannabis-specific prevention (Skara and Sussman, 2003; 
Faggiano et al., 2005; Thomas and Pereira, 2006). School-based approaches have 
generally been found to have scarce effects but — considering the methodological 
difficulties of implementation and research — they should not be underestimated 
(Milford et al., 2000; Gorman, 2002; Tucker et al., 2002; Coggans et al., 2003; 
Ellickson et al., 2003; Bühler and Kröger, 2006, Thomas and Pereira, 2006; Faggiano 
et al., 2005). Studies from Europe represent a small minority among those aimed at 
preventing drug use. For example, only one small study (Hurry and McGurk, 1997) was 
included in the Faggiano review. Among those aimed at preventing tobacco use, some 
failed to detect any effect (Eveyard et al., 2001) while others show inconsistent results 
across centres (de Vries et al., 2003) or no long-term yet limited short-term effects 
(Thomas and Pereira, 2006).
Beyond objections of societal comparability and applicability of general substance 
findings to cannabis, the US evidence is far from conclusive on programme content. 
The Cochrane (Faggiano) review suggests that skills-based approaches can reduce 
subsequent drug use compared with normal curricula. Another review in the USA (Skara 
and Sussman, 2003) found that 8 out of 25 studies examined programme effects on 
cannabis and all showed positive interim effects (3–24 months). However, only one 
study reported data that allowed the calculation of the percentage reduction compared 
with control groups and other studies did not have enough data to determine relative 
differences with control groups. Four studies provided long-term outcomes (24 months), 
of which two showed positive outcomes and two showed no significant differences. The 
programmes that showed positive outcomes for cannabis use were all based on the 
social influence model and the majority had more than one type of intervention. About 
half of these programmes used peer educators, as well as adults. Most had booster 
Chapter 11
227
sessions or a long-term component and the length of follow-up varied between 27 and 
72 months.
Best practices
Prevention research tends to be descriptive and available proof of effectiveness is 
limited. While the literature is almost universally cautious on making recommendations, 
there are several examples of organisations that have distilled research into actionable 
materials. Practice is informed by a number of international manuals (van der Stel, 
1998; WHO, 2000; UNODC, 2002, 2006), synthetic monographs in the field (e.g. 
EMCDDA, 1997; Bukowski and Sloboda, 2003) and exemplary projects (Ferrer-Wreder 
et al., 2004; the EMCDDA EDDRA database and PERK). The EMCDDA’s PERK project, 
the Prevention and Evaluation Resources Kit, aims to provide an online resource in the 
area.
NIDA’s Red Book recommendations (NIDA, 2003) recur in many European publications. 
These are:
target all forms of drug misuse, including alcohol and tobacco;•	
be family-focused, including a component for parents;•	
be long term across a school career;•	
be age specific and culturally sensitive;•	
address local problems and seek to strengthen community norms against drug use.•	
A study of prevention reviews (Cuijpers, 2002; Gottfredson and Wilson, 2003; Kumpfer 
et al., 2003; Skara and Sussman, 2003; Shepard and Carlson, 2003) lists the following 
guidelines, although with some caveats on the strength of recommendations (McGrath et 
al., 2006):
Interactive approaches are preferable to didactic (ex cathedra) approaches.•	
Peer-led approaches offer a mild increase in effectiveness.•	
Social skills approaches are generally more effective, although resistance skills •	
training offers little evidence of effectiveness.
Booster sessions may help effectiveness, particularly for cannabis.•	
Higher programme intensity (e.g. 10 lessons or more) offers little added benefit.•	
Weak evidence suggests that programmes are best delivered to students 11–14 •	
years old (14).
 (14) Frisher et al. (2007) suggest that the evidence for an ‘optimal age group’ for prevention is unclear, 
although results of late-teen interventions (> 17 years) are generally weaker. They also suggest 
that as problematic patterns of use typically appear in later adolescence (15–16 years), ‘attempts 
to modify behaviour at this age may be more productive’. A case for gradation in prevention 
campaigns (early ages: abstentionism, older groups: less use and quitting) would require more 
research.
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The evidence base for favouring family-based programmes over other approaches •	
is weak, although where used with behavioural parent training, family-skills training 
and family therapy offer some benefits.
Recent trends in universal prevention in Europe
Standardised programmes
In terms of recent European trends at the universal prevention level, a general trend is 
the increased reliance on standardised programmes (EMCDDA, 2006a) and inclusion 
or prioritisation of alcohol and tobacco within general substance prevention (EMCDDA, 
2006c). For example, the EU-Dap trial to develop and evaluate a European school 
prevention programme has reported encouraging results for cannabis, finding that its 
programme reduced occasional cannabis use by 23 % and 24 % respectively (EU-Dap, 
2006). The programme, implemented in a considerable number of countries (Belgium, 
Germany, Greece, Spain, Italy, Austria and Sweden, now joined by Poland and the 
Czech Republic), involves 143 schools, 345 classes and 7 079 students. The early 
findings after one year need long-term validation during phase II of the project (begun 
in October 2006). Still, it is worthy of mention that the EU-Dap project has strong initial 
results while also straddling different prevention and drug consumption cultures.
Gender focus
Gender aspects are increasingly being taken into account in prevention, although 
there is a trend in many countries in Europe for gender consumption patterns for 
cannabis to be eroded, notably in Ireland (EMCDDA, 2006a; Frisher et al., 2007). 
Male gender predicts more intense use (Butters, 2005), while a study suggests that 
girls are more responsive to parental disapproval and are more cautious in selection 
of their peers (Butters, 2004). For girls, the programmes that are most effective in 
sustaining positive effects on substance use prevention after their completion focus 
on behaviourally orientated life skills. In contrast, methods of delivery that involve 
interaction with peers or adults are particularly effective in boys (Springer et al., 2004). 
Competence enhancement approaches, for example, can target gender differences. 
For boys, a number of European projects (e.g. Beer-Group in Germany, Risflecting 
in Austria, Bagmaendene in Denmark) focus on the lack of flirting skills among boys 
which may be related to intensive use of alcohol or cannabis in order to feel able to 
approach girls. Nonetheless, across Member States, gender-specific programmes remain 
underdeveloped (EMCDDA, 2006b).
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Recreational settings
A number of prevention programmes have targeted cannabis in the context of other 
recreational settings. These include campaigns at music festivals, Dutch coffee shops 
and nightlife settings. As with general community prevention programmes, reports 
emphasise the importance of engaging various actors in the process (police, licensees, 
staff, organisers) (EMCDDA, 2006d; Reitox national reports).
Risk perception and normative beliefs
Risk perception is a complex but important factor in prevention. Risk perception is not 
easy to modify with knowledge approaches alone. Own experiences, observation of 
others and common myths associated with cannabis modulate perception more than 
knowledge itself (Springer et al., 1996). Normative beliefs are particularly important 
as cannabis-using youth tend to extrapolate the level of use of their immediate peers 
to ‘normality’ and overestimate the prevalence of drug use (Page and Roland, 2004). 
This might also happen through drug-using peer selection. Recently, considerable 
symbolism or ‘brand value’ surrounding cannabis has emerged, which encourages 
acceptance. Cannabis is often associated with ideas such as ecology, alternative culture, 
non-conformism and left-wing attitudes. While some prevention programmes focus 
on deconstructing or neutralising such ‘marketing’ of cannabis, research is needed on 
their effectiveness. Some Member States have reported attempts to reverse the social 
perception of cannabis use as normative behaviour, that is to correct the misconception 
that the majority of adults and adolescents use drugs (EMCDDA, 2004; McGrath et 
al., 2006). The recent introduction in Europe of ‘strong’ public place smoking bans is 
also being monitored for any knock-on effects on cannabis, particularly with regards to 
adolescent smoking.
At the schools level, structural and regulatory policies — school rules — have an even 
higher impact than universal prevention programmes on preventing or delaying legal 
and illegal substance use (Hawks et al., 2002). Tobacco smoking is a good predictor for 
cannabis use and its escalation (Duncan et al., 1998, Vázquez and Becoña, 2000) and 
prior experiences with legal substances may be a significant risk factor for later illegal 
drug use (von Sydow et al., 2002). Consequently, some Member States encourage 
that schools have drug policies in place which define procedures and rules about use 
and availability of cannabis as well as dealing with legal and illegal substances in 
and around school premises. A number of countries have focused on guiding school 
drugs policy, and in particular approaches to ‘problem students’ and dealing with 
those found using drugs. These include the UK’s Drugs: guidance for schools (DfES, 
2004) and School drug policy: a review process (Blueprint, 2004), Ireland’s Guidelines 
for developing a school substance use policy (Department of Education and Science, 
2003), and France’s Prévention des conduites addictives: guide d’intervention en milieu 
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scolaire (CNDP-MILDT, 2006). Some Member States have introduced drug testing in 
schools, although this practice is contested on ethical grounds (McKeganey, 2005) 
and because either no preventive effect has been demonstrated in the extant research 
literature (Council of Europe, 2005; Drug Education Forum, 2006) or the evidence base 
is insufficient (UK Home Office, 2007). Further research on the subject is part of the 
Pompidou Group’s current work programme.
Family approaches
The family has an influence on drug use, and pro-social family processes have a 
significant impact on children’s peer association, decreasing involvement with antisocial 
peers, and a significant negative effect on substance use initiation (Oxford et al., 2000; 
Ferrer-Wreder et al., 2004). A recent review of risk factors found that parental discipline, 
family cohesion and parental monitoring are among the strongest (Frisher et al., 2007). 
Compared with alcohol, parents have more difficulties to talk and address cannabis use 
of their children openly and to negotiate disciplinary boundaries (Highet, 2005). There 
are not many examples of structured and evaluated family-based prevention approaches 
in Europe, although parenting programmes with positive evaluation based on US studies 
(Kumpfer et al., 2003) have been introduced in Spain, Norway and the United Kingdom. 
Prevention programmes (websites, books, workshops, helplines) aimed specifically at 
assisting parents with children’s drug problems have long been part of the European 
prevention landscape. Publications dealing exclusively with adolescent cannabis use are 
rarer, although examples exist (15).
Mass media campaigns
Mass media campaigns have been a popular option in prevention and especially in 
cannabis prevention. Recent major cannabis campaigns include the UK’s 2006 Brain 
Warehouse campaign, Spain’s Drogas: hay trenes que es mejor no coger and France’s 
Cannabis et Conduite campaign (16), with a trend to use mass media within multi-
component programmes (McGrath et al., 2002, updated 2006, citing Flay, 2000). 
Research — again, broadly drawn from non-European sources — suggests, however, 
that their effectiveness, and especially efficiency, is limited and largely depend on the 
objectives. They can have effects on attitudes and knowledge (Carroll et al., 2000), but 
rarely on behaviour (Derzon and Lipsey, 2002). The overall evidence for the impact of 
 (15) Examples include: in the USA, Marijuana: facts parents need to know (NIDA, 2004); in Switzerland, 
Cannabis: mit Jugendlichten darüber sprechen (SFA/ISPA, 2005); in France, Cannabis: les risques 
expliqués aux parents (MILDT, 2005) (www.inpes.sante.fr/CFESBases/catalogue/pdf/806.pdf).
 (16) The Brain Warehouse cannabis campaign (www.brainwarehouse.tv) included a TV advertisement, 
scratchcards, leaflets and a dedicated website. The EUR 2.2 million Drogas: hay trenes… 
campaign included a TV and radio spot and posters. The Cannabis et conduite (www.
cannabisetconduite.fr) campaign included a website and radio campaign.
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mass media campaigns on consumption patterns is not strong and has mainly focused 
on how many people were reached by campaign messages (Paglia and Room, 1999; 
Hall and Pacula, 2003). Isolated studies provide evidence that recall of anti-drug 
advertising was associated with a lower probability of cannabis and cocaine/crack use 
(Block et al., 2002) or have shown that mass media campaigns aimed at high sensation 
seekers may be effective (Stephenson, 2003). However, the large-scale evaluation of 
the US billion-dollar National Youth Anti-Drug Media Campaign showed no or even 
negative behavioural outcomes, suggesting a ‘boomerang effect’ whereby those exposed 
to the campaign were more likely to consume (EMCDDA, 2007).
Selective prevention
Selective prevention is led by risk factor-specific research allowing for the identification 
of risk groups (see Coggans, this monograph) mostly by social and demographic 
variables. An understanding of risk factors associated with cannabis use and its adverse 
consequences has immediate benefits for the design, targeting and implementation of 
drug prevention (Kandel et al., 1978; Susser, 1987; Daugherty and Leukfeld, 1998).
Contrary to the traditional approach of secondary prevention, which targets those 
who already use drugs because they consume, more recent strategies acknowledge 
that cannabis consumption alone is not a useful predictor for the problems to be 
prevented (see Coggans, this monograph). The strength of selective prevention is that 
it is not guided by the idea that risk equals substance use, but by social and personal 
vulnerability factors for problematic drug use. If drug use alone is to be used as a 
criterion of the need for prevention, the danger is high that youths with transitory drug 
experimentation are wrongly classified and stigmatised as a high-risk group (Schmidt, 
2001).
Selective prevention in the school setting
The most convenient setting for selective prevention interventions targeting experimenting 
or vulnerable youth is while they are still attending school. There are, however, 
challenges in selectively addressing vulnerable adolescents when the mainstream 
prevention messages are health promotion and non-use and when teachers are (if at all) 
only trained in universal prevention methods but are not prepared to deal with ‘difficult’ 
or experimenting youngsters (Parker and Eggington, 2002).
The main subgroups at which selective prevention in schools is aimed are students 
with social behavioural problems such as anti-social behaviour (Tarter et al., 2002), 
academic underachievement (Lynskey and Hall, 2000), low bonding, infrequent school 
attendance, and impaired learning because of drug use (Hawkins et al., 1991, 1992; 
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Lloyd, 1998). Targets may also include pupils with high truancy or who have been 
excluded from school (Goulden and Sondhi, 2001; Powis and Griffiths, 2001), students 
with family problems (e.g. running away from home), immigrant students and those 
belonging to ethnic minorities (17). Academic performance and school attendance are 
good predictors for drug problems, and monitoring these enables early and accurate 
intervention (EMCDDA, 2006a). Other strong patterns include early adolescent smoking 
and heavy drinking (Gil et al., 2002; de Vries et al., 2003; Orlando et al., 2005; 
Paddock, 2005), with tobacco having strong associations with later cannabis use 
(Duncan et al., 1998; Vázquez and Becoña Iglesias, 2000).
Social vulnerability factors
Formerly, it was believed that elements from social influence and life skills programmes 
would not work well in selective prevention approaches (e.g. Tobler et al., 2000). 
However, several elements of such programmes are suggested as moderately effective 
for vulnerable youth (Sussman et al., 2004; Roe and Becker, 2005; McGrath et al., 
2006). The associated contents — normative restructuring (e.g. learning that most 
peers and the opposite sex disapprove of use), assertiveness training, motivation and 
goal-setting, as well as myth correction — are still not included in the typical contents of 
European selective prevention intervention for cannabis. The focus is instead generally 
placed on knowledge approaches.
Selective prevention within the criminal justice system
The association between cannabis use and crime or delinquency is well documented 
(Fergusson et al, 2002; Hall and Pacula, 2003). A study in Spain by the Centro de 
Estudios sobre Promoción de la Salud (CEPS, 2004) of a sample of youths at protection 
and reform centres found approximately one-third reported weekly cannabis use. A 
UK study of youth arrest referrals reported the following use of substances: cannabis 
(30 %), tobacco (30 %) and alcohol (23 %), with other drugs much lower (cocaine, 4 %, 
crack, 1 %, heroin, 1 %) (UK Home Office, 2007). Two Dutch studies (Vreugdenhil et 
al., 2003; Korf et al., 2005) also reported a high prevalence of cannabis use among 
youths in detention centres (see Netherlands national report, 2006). However, caution 
must be applied in that (i) there is consensus that there are associations, not causal 
links, between cannabis and offending; (ii) many studies embrace all types of drug use 
(illicit drugs, alcohol) not cannabis in isolation, with persistent offending associated 
with harder drugs (Flood-Page et al., 2000); (iii) ‘crime’ runs the gamut, from serious 
offences to delinquency and misbehaviour; and (iv) consumption is an offence per se. 
 (17) For an overview of screening instruments for assessing cannabis use, see Beck and Legleye, this 
monograph.
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A recent study suggests that the gateway effect of ‘soft’ drug use for later progression 
into delinquency may be overplayed (Pudney, 2003). Moreover, studies have illustrated 
the importance of situational, social and peer influences in contrast to individual 
psychological problems in initiating drug use among young people (Rhodes et al., 2003; 
Butters, 2004).
While the ethics of coercion into compulsory treatment have been debated, the criminal 
justice system represents an important setting for selective prevention in the form of 
referrals. In most Member States, corresponding legal provisions exist for referral 
of prisoners and offenders. Young offenders (especially those first notified for drugs 
offences) are treated with particular consideration. Drug testing for adult and (less 
commonly) young arrestees has been introduced in some countries. However, specific 
guidelines are often missing and the cooperation and coordination between social 
(prevention) services and judicial services, although of key importance, are considered 
difficult (Newburn, 1999; UK Home Office, 2007). Selective prevention programmes in 
the criminal justice system (see Box 2 for examples) rely on the fact that cannabis use 
and possession are illegal, opening up a referral opportunity for targeted intervention 
for young people at risk. The evaluation of the Austrian project Way Out showed that 
it could be introduced successfully in schools and by public health officers as well as 
school doctors, although the main channel for referrals was the police. The evaluation 
found fewer personality deficits among youngsters first notified for cannabis offences 
than expected.
Selective prevention in informal settings
A recurrent question is how to get in touch with those youngsters at risk of developing 
problematic consumption patterns but who are not reached at school or in other formal 
settings. There are many situations where it is only possible to approach adolescents in 
informal or recreational settings. Haas et al. (2001) point out that in Austria youngsters 
who experiment with drugs are frequently excluded from youth services, thereby 
increasing their social exclusion. As a result, occasions for selective and indicated 
prevention are missed. Attractive drop-in and counselling facilities with a judgement-free 
attitude is one strategy option. In some Member States, pro-active approaches — called 
‘interventionist tracking’ — for vulnerable youth are applied, mostly through cooperation 
of different services (Green et al., 2001) and social actors (Arbex Sanchez et al., 2002).
Many strategies and projects focus on identifying, approaching and attracting vulnerable 
young people in order to intervene at an early stage of problem development and to 
provide counselling or referral to specialised services. Outreach work (18) traditionally 
reaches out to obviously problematic drug users and is less associated with approaching 
 (18) The EMCDDA’s web page on outreach work is at www.emcdda.europa.eu/?nnodeid=1576
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Box 2: Selective prevention for cannabis/illicit drug use – examples from Exchange on 
Drug Demand Reduction Action (EDDRA)
The EMCDDA’s EDDRA database offers information on a broad range of 
evaluated drug demand reduction actions in the EU Member States. Selection 
criteria for this small sample were outcome-evaluated interventions with a 
predominant focus on cannabis. None has a control group design and outcome 
variables are not necessarily drug use related.
Step by Step (Austria and Germany) is a computer program for early diagnosis of 
drug-related problems and for possible interventions at schools. It helps teachers 
who are confronted with problem pupils to find out whether or not these pupils 
use drugs.
www.emcdda.europa.eu/html.cfm/index52035EN.html?project_id=5957&tab=overview
FreD (Austria and Germany) is a programme that targets first-time offenders up 
to the age of 25 who have been arrested due to the consumption of illegal drugs. 
They are referred to a course which motivates them to change their drug use.
www.emcdda.europa.eu/html.cfm/index52035EN.html?project_id=2091&tab=overview
Way out (Austria) is an early intervention for young drug-using first offenders. 
Support is offered over a period of approximately 6 months with the aim of 
encouraging abstinence for illegal drugs, moderation for legal substances and 
avoidance of drug-related problems.
www.emcdda.europa.eu/html.cfm/index52035EN.html?project_id=5038&tab=overview
MSF — Solidarite Jeunes (Luxembourg) provides therapy to youths consuming 
drugs and to their families referred from judicial or educational systems.
www.emcdda.europa.eu/html.cfm/index52035EN.html?project_id=3656&tab=overview
Ámbits-Esport (Catalonia, Spain) provides a sport-based programme for 
immigrant youths from North Africa, sub-Saharan Africa and Latin America 
aimed at reducing smoking and illicit drug consumption (in particular, cannabis), 
together with integration with Catalan peers.
www.emcdda.europa.eu/html.cfm/index52035EN.html?project_id=2918&tab=overview
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vulnerable youth and cannabis users who are not addicted. From some Member States, 
centres for mobile youth or street work are reported, which closely cooperate with 
relevant help organisations so that assistance may be provided at the earliest stage 
possible. Such measures and their relevance for vulnerable and experimenting youth are 
intensively discussed, for example in Austria, and are foreseen to attain an increasing 
geographical coverage (Haas et al., 2001, 2002).
Indicated prevention
There are some conditions that have been identified as potentially increasing the risk 
for intense cannabis use, such as attention deficit disorder (ADD) (Giedd, 2003), and 
affect dysregulation (Simons and Carey, 2002) in the sense of emotional instability 
and impulsivity. Children and adolescents with ADD might seek to relieve their state of 
anxiety, tension and dysphoric mood and the sensation of ‘noise’ in the brain (due to the 
low synaptic dopamine availability in the essential brain areas) through ‘self-treatment’ 
with cannabis. However, systematic early detection, treatment and follow-up involving 
general health services and paediatricians are reported only from Germany, Italy and 
Sweden in their national reports. An increase in cannabis-related psychoses is reported 
from psychiatric services (see Witton, this monograph, volume 2), and according 
to recent reviews there is evidence that cannabis is a risk factor for schizophrenia 
(Arseneault et al., 2004; Smit et al., 2004). There seems to be a strong case to pay 
increased attention to reducing the intensity of consumption in order to respond to 
cannabis-related public health problems. Motivational interviewing, for instance, has 
shown to reduce the intensity of consumption without formal treatment (McCambridge 
and Strang, 2004), although there is evidence to suggest that short-term gains are not 
maintained at 1-year follow-up (McCambridge and Strang, 2004).
Between prevention and treatment
While provision of drug treatment is often the most immediate reaction of policymakers 
to drug use, a strategy of expanding counselling or early intervention offers for cannabis 
users in cone structures may have difficulties in reaching the target population. These 
problems might be increased if the services for cannabis clients are offered in the 
same setting as for heroin users. There is a reluctance of cannabis users to consider 
themselves as drug users or as having a drug problem and to seek help and advice for 
themselves.
Member States are increasingly acknowledging this need to reach out to a wider 
vulnerable population. Approaches which are less treatment-focused stress the 
importance of literacy, academic capacities, employment, gender, social integration, 
body (self) perception, rationality, social networks, and the functionality of use (Boys 
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and Marsden, 2003). Some municipalities in Denmark have been successful in offering 
help to groups of young people with an emerging cannabis problem via day centres, 
where they gather in small groups (up to 10) and are supported by a therapist or 
social worker. They are offered space and time to talk about their life, problems 
and drug use. Supportive methods are favoured: offering help, for example, to plan 
for the future, to pursue their education or to get a job. Evaluation shows that the 
participants profit greatly from contact with adults who offer support, respect and who 
accept them on their own conditions. Results also suggest that the increasing but not 
yet full-blown drug problem ‘solves itself’ if help with other problems (school, family, 
friends) is offered (Danish national report, 2005). The specific support for integration 
into the educational system or the workplace has shown to be of great importance in 
preventing further social exclusion. Several Member States have similar projects. The 
German web-based counselling programme Quit the Shit (19) is another example of an 
innovative approach for cannabis users who want to reduce or stop using cannabis. It 
comprises a 50-day programme, based on cognitive–behavioural principles, including 
information and featuring a diary that is submitted to an intervention team for regular 
feedback. Those who made use of the online support to quit using cannabis had their 
average consumption quantity reduced by a third 3 months after the completion of the 
programme. The number of days on which cannabis was consumed went down by 50 % 
(Die Drogenbeauftragte der Bundesregierung, 2005).
Conclusions and challenges
Cannabis use prevalence is generally increasing among youth in the EU and the 
perception of its risks has generally decreased in recent years (20). The large majority of 
European cannabis smokers have already smoked tobacco, and there is an association 
between a tolerant tobacco policy, smoking prevalence and cannabis consumption. This 
suggests that there is considerable scope of action for structural prevention, directed at 
attitudes and normative frameworks in respect to legal substances as well as cannabis. 
The effects of current public place smoking bans in Europe should be monitored to look 
specifically at knock-on effects on cannabis.
Cannabis use is mostly experimental, but compared with other illegal drugs, the number 
of regular and daily users is higher (EMCDDA, 2006a). About 9 out of 10 persons 
who have ever used cannabis began at around 14 and stopped before the age of 
24. This implies that there is a ‘vulnerability window’ where prevention interventions 
should focus on preventing experimenters beginning to develop cannabis-related 
problems and where entering regular consumption patterns. Even if the majority will 
 (19) www.drugcom.de/
 (20) See Hibell, this monograph.
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never develop problematic use, the opportunity for selective and indicated prevention 
or early intervention to identify those at risk and to be able to assist them with targeted 
interventions is considerable. Appropriate offers of early intervention and support at the 
border between prevention and treatment might be more attractive to this group than 
traditional drug help facilities.
Even regular cannabis users rarely seek support, help or treatment on their own 
initiative. Counselling or early intervention services are not likely to be appropriate when 
there is no problem awareness among the users themselves. However, the illegal status 
of cannabis may sometimes be strategically helpful in the sense that cannabis users 
are being brought into contact with cannabis counselling or other interventions through 
contact with the criminal justice system for possession offences. Reports that very young 
people sometimes appear in treatment centres with advanced cannabis use patterns 
after only a short period of use indicates that some powerful personal and social risk 
factors can lead to rapid progression of cannabis-related problems. Supporting such 
children at an early stage is a challenge for indicated prevention.
The majority of available projects in the EU publicised through EDDRA do not have 
sufficient evaluation, which makes European intervention planning still largely dependent 
on US research and evaluation findings (Matthys et al., 2006). Consumption reduction 
is rarely assessed as an outcome, and the cost-effectiveness of programmes is difficult to 
calculate (Matthys et al., 2006). Moreover, while there has been a search for evidence-
based universal intervention in the USA, the notion of what works is fraught with 
questions about the philosophy, objectives and measures of effectiveness (Cohen, 2001; 
Gorman, 2002; Ashton, 2003).
There is some cause for optimism: a recent Scottish literature review of school-based 
drug prevention programmes concluded that prevention, ‘in general can be effective 
[and] that some types and features of drug education are more effective than others. 
In particular, drug education using highly interactive methods and social influences 
approaches, specifically including resistance skills and normative education elements, is 
consistently shown to be more effective’ (Stead and Angus, 2007). Moreover, there is an 
increased understanding of common risk and protective factors and trajectories of drug 
use (e.g. Advisory Council on the Misuse of Drugs, 2006), and some of this has been 
translated into practical instruments and materials. A particularly prescriptive report is 
Australia’s National Cannabis Strategy 2006–2009, albeit in a non-European context. 
Yet, there are also challenges to face. A Belgian study concludes that ‘Researchers 
continue to come up against substantial methodological, practical and ethical problems 
if they want to put in place effectiveness evaluations relating to drug prevention’ (Matthys 
et al., 2006).
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Setting the context
As mentioned in the previous chapter, a significant amount of what we know about 
drugs prevention is based on research from the USA. This chapter — written by the 
former Director of the Division of Epidemiology and Prevention Research of the National 
Institute on Drug Abuse (NIDA) — provides a useful overview of recent experiences in 
school-based prevention in the USA, together with a presentation of a number of more 
prescriptive studies of ‘what works’ in the US context.
One of the questions that may arise from this chapter is the transferability of the US 
experiences within the European — or universal — context. We have seen in the first 
chapter of this volume (Vicente et al.) that the USA not only has relatively high cannabis 
prevalence in comparison with European countries. On a generational level, use of the 
drug became more widespread around 10 to 20 years earlier than in the majority of 
Western European countries.
To a considerable extent, we have also seen throughout this monograph that there 
remains the issue of diversity within Europe as regards cannabis and other drugs. A 
Europe approaching 500 million citizens is far from a monolithic society from most 
perspectives — economic, political, linguistic, sociocultural. European drug use patterns 
remain similarly heterogeneous. While there may be some approximation of US levels 
of cannabis prevalence among young adults in high-prevalence countries in Europe 
— such as the United Kingdom, Spain and Italy — many European countries report 
extremely low levels of cannabis use. Differences persist even among neighbours in 
Europe: one need only compare reported last month prevalence among 15- to 24-year-
olds in the Czech Republic (15.4 %) and Slovakia (3.9 %), Spain (18.6 %) and Portugal 
(5.5 %), Denmark (8.2 %) and Sweden (1.6 %). If prevention is to be tailored to the needs 
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of a schools population, and given priority over other items within a school curriculum, 
it should reflect the likelihood of students to both experiment and progress to more 
intensive use of drugs.
Universalism should not, however, be dismissed. The promising early experiences 
of some transnational prevention projects across very different drug-using countries 
and cultures — such as EU-Dap — suggest that good practice can cross borders 
successfully. There are several early intervention initiatives — such as the HIT and 
Jellinek knowcannabis self-help site — that have resulted from international cooperation. 
Moreover, as we have seen, European knowledge of prevention practice is subjected 
to increasing study, data collection and cooperation. While, historically, prevention 
knowledge has benefited from much borrowing from the US literature, increasingly there 
is scope for transatlantic dialogue, with European studies contributing new experiences 
and ideas to the debate.
Further reading
EMCDDA, Annual reports, published each year in November.
Journals
Drugs: Education, Prevention and Policy
Journal of Alcohol and Drug Education
Websites
NIDA website on preventing drug abuse among children and adolescents 
www.nida.nih.gov/Prevention/Prevopen.html
EELDA website on School-based drug prevention 
http://en.eelda.org/index.aspx?o=1076
See also the grey literature list in the Appendix to Volume 1 of this monograph.
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Introduction
Prior to the 1970s there was little knowledge on which to base the development of 
prevention programming in the USA (Sloboda, 2003). As is the case today in much 
of Europe, efforts in schools to prevent or delay initiation of smoking, alcohol or drug 
use lacked any research basis. However, the creation of the National Institute on Drug 
Abuse (NIDA) in 1974 began a period of important research that served to move 
prevention from an art to a science (Bukoski, 2003). Longitudinal cohort studies that 
followed children and adolescents over time and national surveys that were administered 
at regular intervals were funded. These research efforts not only gave more accurate 
assessments of trends in substance use in the country but also specification of those 
biological, individual, family, school, peer and community factors that increased the 
susceptibility of some children and adolescents to the use of alcohol, tobacco, marijuana 
and other drugs (Kandel, 1975; Hawkins et al., 1992). In addition, the longitudinal 
cohort studies (e.g. Kandel, 1975; Newcomb and Bentler, 1986) showed a progression 
from ‘legal’ substances (tobacco and alcohol) to illicit drugs (marijuana and cocaine) 
(Kandel, 1988; Kandel and Yamaguchi, 1999). These epidemiological findings greatly 
influenced prevention programme developers and researchers. The vast predominance 
of substance abuse prevention programmes that were evaluated and found effective 
grew from the research on the initiation of use. As such, these programmes target all 
children and adolescents no matter their level of susceptibility and specifically address 
the use of tobacco and alcohol, as well as marijuana and other illicit drugs (to include 
inhalants).
Furthermore, as the research also indicated that the initiation of most substance 
use among adolescents takes place through peer influence, prevention researchers 
based their programmes on social learning incorporating the concept of self-efficacy 
(Bandura, 1977). These programmes are centred around social resistance skills training 
(Botvin and Griffin, 2003) as they increase students’ resistance to those influences 
that encourage substance use and they focus on providing students with the skills 
they need to resist offers to use alcohol, tobacco or illicit drugs and to practise these 
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resistance skills in ‘virtual’ situations that are realistic to them. Most of these universal (1) 
programmes are delivered in schools as curricula. Other prevention programmes 
address the needs of more vulnerable children and adolescents and their families 
through counselling or more in-depth therapies.
Evidence-based school-based prevention programming
Meta-analyses and reviews of evaluation studies of prevention programmes had been 
conducted in the late 1980s and throughout the 1990s to identify the determinants of 
effectiveness. These analyses and reviews, however, were very much restricted by what 
reports were available at the time. For instance, Schaps and his colleagues (1981), 
Bangert-Drowns (1988) and Brunvold and Rundell (1988) found in their analyses that 
prevention programmes of the late 1970s and early 1980s were effective in providing 
knowledge to participants but impacting attitudes and drug-using behaviours were more 
difficult to address and that the use of peer facilitators, use of interactive instructional 
style and high ‘doses’ of exposure to prevention programming led to better outcomes.
Tobler’s work, summarised in her 2000 article, ‘Lessons learned’, used meta-analytic 
approaches using data from studies of 207 school-based drug prevention programs with 
drug use measures that were reported in the literature (1992, 1997 and 2000). Each 
review had subsequently better data, reflecting improvements in measurements and in 
the quality of data collection efforts. Her analyses looked at content, delivery method, 
and programme size. Her findings indicate what works and what doesn’t work. As can 
be seen in Table 1, programmes with content that covers both short- and long-term 
consequences of substance use, address misconceptions regarding the normative nature 
of adolescent substance use, and provide opportunities to learn and practice decision 
making/problem solving, assertiveness and resistance skills had larger effect sizes. In 
addition, delivery or instructional style was found to be important. Adolescents learn best 
when they are actively involved through small group discussions, role play, and given 
sufficient time to practise their new skills. These elements were also found by Tobler and 
her colleagues to be important specifically for the prevention of marijuana use (Tobler 
et al., 1999). Other reviewers of prevention programmes have had similar findings 
even when using other analytical techniques (e.g. Brunvold, 1993; Harachi et al., 1999; 
Cuijpers, 2002; Nation et al., 2003). Elements added through these reviews included 
having a theoretical framework and addressing commitment or intentions not to use.
 (1) In 1994, the mental health and substance abuse fields adopted a classification system for 
prevention programming depending on the level of risk of the targeted group. Universal 
programmes address general populations while selective programmes target those segments 
of the population that present greater than normal risk to develop a disorder and indicated 
programmes focus on those subgroups that exhibit signs or symptoms of developing a 
disorder.
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Table 1: Tobler (2000) findings of what works and what doesn’t work
Works Doesn’t work
Content Content
Short-term effects
Long-term health consequences
Feedback on peer use from school surveys
Addressing media and social influences that 
promote pro-drug attitudes and behaviours
Adjustment of perceptions regarding peer 
substance use
Provide/practise drug refusal skills, 
assertiveness skills, communication skills, safety 
skills, coping skills, goal-setting, decision-
making/problem-solving skills
Not including short-term consequences
Not addressing perceptions of peer substance use
Not addressing media and social influences
Allowing values or moral and ethical decision-
making
Not developing interpersonal skills or drug refusal 
skills
Focusing primarily on intrapersonal aspects
Focusing only on self-esteem building
Delivery Delivery
Active involvement of everyone in class
Active participation between peers
Role plays around scenarios generated by 
students
Developmentally appropriate activities to 
promote bonding
Eliciting positive/supportive comments from 
peers
Rehearsal of resistance/refusal skills with 
modelling of appropriate behaviours
Lots of practice time
Allowing passive participation on the parts of the 
students
Teacher-centred discussions and lecturing solely
Dialogues without structure
Use of effective classroom management 
techniques without a drug programme
In another review of school-based prevention programmes conducted under the 
Cochrane Collaboration, only evaluations using randomised controlled trials (RCTs) or 
controlled prospective studies (CPSs) were reviewed. Of the 32 selected for review, 28 
were from the USA. Most of the studies used post-test or intervention assessments and 
focused on students in the sixth and seventh grades, i.e. around 12–14 years of age. 
Separate reviews were made for RCT (n = 29) and CPS (n = 3) evaluations. No significant 
results were found among the CPS while the RCT programmes that offered skills training 
had the best outcomes (Faggiano et al., 2005).
The movement from examining the elements or principles of prevention to a focus on 
programmes and practices began when NIDA sponsored the first conference on drug 
abuse prevention in 1996 (Putting Research to Work for the Community). The goal of 
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the conference was to introduce the findings from prevention research in a user-friendly 
style to practitioners. The outcome of the conference was a booklet, Preventing drug use 
among children and adolescents: a research-based guide (Sloboda and David, 1997) 
written in a question–answer format that presented how research findings could be used 
to plan and develop prevention programming and practices for the community. The 
approach taken was to present ‘principles’ of prevention related to content, structure 
and delivery. The result was a list of 13 underlying principles drawn from commonalities 
found in both epidemiological and prevention research (an updated version of these 
principles is presented in Table 2).
In addition, however, the booklet summarised the findings from evaluations of 
prevention interventions funded through NIDA that had significant outcomes at least 1 
year after the intervention. At the time, 10 programmes were described (six considered 
universal, two selected, one indicated and one addressing all three levels of risk). The 
publication of this booklet stimulated other groups to develop their own criteria for 
effectiveness and their own lists.
Most dominant of these groups are the federal funding agencies for school- and 
community-based prevention efforts, the Education Department’s Safe and Drug-Free 
Schools and Communities programme (SDFSC) and the Center for Substance Abuse 
Prevention (CSAP). There are a number of interesting similarities and differences in how 
each of these agencies addresses the issue and as a result, the lists that have been 
compiled have very little overlap (Table 3 and Figure 1). Another important difference 
between these two listings is that while procedures are in place to update and add newly 
evaluated prevention strategies to the CSAP list, there are no such procedures in place 
for the SDFSC list. The fact that funding is tied to selecting only from these listings has 
both positive and negative effects. The positive impact of implementing strategies with 
demonstrated successful outcomes has made communities more accountable and, thus, 
more concerned about delivering prevention strategies that have demonstrated success. 
On the other hand, the lack of consistent criteria and listings both confuses and upsets 
community groups, particularly those that may have prevention programming already 
in place. Furthermore, not only is there a heavy emphasis on selecting ‘evidence-
based’ strategies but funding is also dependent on demonstrating need or defining the 
community drug abuse problem. Often communities will identify their needs but find that 
there are no evidence-based strategies available on the lists to meet them.
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Table 2: National Institute on Drug Abuse — principles of prevention
Prevention programmes should enhance protective 
factors and reverse or reduce risk factors
Prevention programmes should address all forms 
of drug abuse, alone or in combination, including 
the underage use of legal drugs (e.g. tobacco or 
alcohol); the use of illegal drugs (e.g. marijuana 
or heroin); and the inappropriate use of legally 
obtained substances (e.g. inhalants), prescription 
medicines or over-the-counter drugs
Family-based prevention programmes should 
enhance family bonding and relationships and 
include parenting skills; practice in developing, 
discussing and enforcing family policies on 
substance abuse; and training in drug education 
and information
Prevention programmes can be designed to 
intervene as early as pre-school to address 
risk factors for drug abuse, such as aggressive 
behaviour, poor social skills and academic 
difficulties
Prevention programmes for elementary school 
children should target improving academic 
and social–emotional learning to address risk 
factors for drug abuse, such as early aggression, 
academic failure and school drop-out
Prevention programmes for middle or junior 
high and high school students should increase 
academic and social competence
Prevention programmes aimed at general 
populations at key transition points, such as the 
transition to middle school, can produce beneficial 
effects even among high-risk families and 
children. Such interventions do not single out risk 
populations and, therefore, reduce labelling and 
promote bonding to school and community
Community prevention programmes that 
combine two or more effective programmes, 
such as family-based and school-based 
programmes, can be more effective than a 
single programme alone
Community prevention programmes 
reaching populations in multiple settings 
— for example, schools, clubs, faith-based 
organisations and the media — are most 
effective when they present consistent, 
community-wide messages in each setting
When communities adapt programmes to 
match their needs, community norms or 
different cultural requirements, they should 
retain core elements of the original research-
based intervention
Prevention programmes should be long-
term with repeated interventions (i.e. booster 
programmes) to reinforce the original 
prevention goals. Research shows that the 
benefits from middle-school prevention 
programmes diminish without follow-up 
programmes in high school
Prevention programmes should include 
teacher training on good classroom 
management practices, such as rewarding 
appropriate student behaviour. Such 
techniques help to foster students’ positive 
behaviour, achievement, academic motivation 
and school bonding
Prevention programmes are most effective 
when they employ interactive techniques, such 
as peer discussion groups and parent role-
playing, that allow for active involvement in 
learning about drug abuse and reinforcing 
skills
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EVIDENCE-BASED PROGRAMMES
Conceptually sound and internally consistent
programme activities related to conceptualisation
reasonably well implemented and evaluated
PROMISING
? Some positive outcomes
EFFECTIVE
? Consistently positive outcomes
? Strongly implemented and evaluated
MODEL
? Available for dissemination
? Technical assistance available from
research/developer
Figure 1: Substance Abuse and Mental Health Services Administration (SAMHSA) national 
registry of evidence-based programmes
Table 3: United States Department of Education — safe, disciplined and drug-
free schools: exemplary and promising programmes
Criterion
Evidence of efficacy The programme reports relevant evidence of efficacy/effectiveness based 
on a methodologically sound evaluation
Quality of programme The programme’s goal with respect to changing behaviour and/or 
risk and protective factors are clear and appropriate for the intended 
population and setting
The rationale underlying the programme is clearly stated, and the 
programme’s content and processes are aligned with its goals
The programme’s content takes into consideration the characteristics 
of the intended population and setting and the needs implied by these 
characteristics
The programme implementation process effectively engages the intended 
population
Educational significance The application describes how the programme is integrated into schools’ 
educational missions
Usefulness to others The programme provides necessary information and guidance for 
replication in other appropriate settings
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What types of prevention approaches are deemed 
effective?
The school-based programmes target children generally in middle school when they 
are around 8–10 years old and have booster sessions that are delivered over a number 
of years. Several include a homework component that allows students to involve their 
parents.
The school is an appropriate setting for prevention strategies for a number of reasons. 
The most obvious is that it is in the schools where children in the USA spend a great 
proportion of their time. In addition, the school remains a major socialisation institution 
to reinforce societal values, norms and acceptable behaviours. The school is a protective 
environment for children (Schaps and Solomon, 2003). Translating these aspects 
of the school for prevention suggests several approaches that can be taken. As a 
socialisation agent, the school provides children with knowledge and skills to become 
competent citizens and it reinforces pro-social attitudes and behaviours. As a protective 
environment, most schools are substance- or drug-free, provide supervised after-school 
programmes, and have activities to connect parents and families to school personnel. 
Of these aspects of the school environment that lend themselves specifically to substance 
use prevention, it is the cognitive approach to prevention that is the most common and, 
therefore, the most often evaluated. However, altering the school culture to create an 
environment that supports anti-drug use norms, beliefs and expectancies and school 
bonding, that is, connecting the individual to the school experience and community, and 
implementing appropriate school policy have not been as extensively assessed.
Prevention programmes that target the school culture intend to make the school 
environment more attractive to students and to help students succeed within the school 
setting to engage in more pro-social behaviours and in this indirect way reduce the 
likelihood that students will use alcohol, tobacco or other drugs. The common elements 
of strategies that attempt to take advantage of and/or impact school culture to provide 
a positive normative environment for children include: creating anti-/non-substance-
using settings (including tobacco, alcohol and other drugs); dispelling misconceptions 
regarding expectancies (positive experiences) associated with the use of tobacco, alcohol 
and other drugs; and establishing comprehensive programmes that involve students, 
school administration and, when appropriate, parents/caregivers (e.g. the Caring School 
Community; Battistich et al., 2000).
In addition, programmes that address school-bonding share common elements or 
principles that include: focusing on early years, that is, pre-school to middle school; 
enhancing competency in reading and mathematics; providing interpersonal skills 
to relate positively with peers and adults; involving parents in communication and 
parenting skills and in school activities. Among school-bonding programmes that are 
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viewed as promising are the Skills, Opportunities and Recognition (SOAR) programme 
(Hawkins et al., 1999), Incredible Years (Webster-Stratton et al., 2001) and Early Risers 
Skills for Success (August et al., 2003).
An interesting new area for prevention examines policies related to substance use 
within the school building. There is a special appeal to developing policies that reach 
greater numbers of the target population and minimise costs. Common elements 
or principles of effective school policy approaches include: reducing or eliminating 
access to and availability of tobacco, alcohol or other drugs; addressing infractions of 
policies by providing counselling or treatment and special services to the students rather 
than punishing them through suspension or expulsion; selecting policies that do not 
disrupt normal school functioning and those that address the full range of drug-using 
behaviours, from initiation to progression to abuse and dependence and relapse; 
specification of the substances that are targeted; and reflect other community prevention 
efforts.
The challenge of disseminating effective prevention 
programming
A recent conference sponsored by NIDA and CSAP, ‘What do schools really think about 
prevention research? Blending research and reality’ (Kaftarian et al., 2004) brought 
both researchers and practitioners together to discuss the challenges of diffusing and 
disseminating effective prevention strategies. Among the greatest mentioned were 
implementation fidelity (or faithfulness of delivery) and adaptation (Botvin, 2004; 
Greenberg, 2004; Pentz, 2004).
These concerns arise from studies (Hallfors and Godette, 2002; Ennett et al., 2003) that 
found that evidence- or research-based programmes taken ‘to scale’ at the community 
level often are not implemented as they were designed and evaluated. Although 
fidelity of implementation is recognised as important, few studies have examined the 
relationship between level of fidelity and programme outcomes. Tobler and Stratton 
(1997) suggest that decreases in the effect sizes they found in their meta-analyses of 
school-based substance abuse prevention programmes taken to scale may be due 
to implementation issues. Pentz and Trebow (1991) found that children exposed to a 
programme delivered by instructors who maintained high implementation fidelity had 
better outcomes than those exposed to the programme delivered by instructors who 
implemented the programme with low fidelity. Furthermore, children exposed to the 
programme delivered by low implementers had better outcomes than children in the 
control condition.
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As the field of prevention continues to develop theory- and research-based interventions, 
the combined issues of fidelity and reinvention will become increasingly important. 
However, as Dusenbury et al. (2003: 240) emphasise, although the field has fair 
agreement on the definition of fidelity (‘… the degree to which teachers and other 
program providers implement programs as intended by the program developers’), there 
does not appear to be a consensus regarding the specific dimensions of fidelity nor 
on their measurements. Similarly, the degree of adaptation that may take place in the 
community has not been well studied.
Conclusions
So where does this leave us? Professionals in the field of substance abuse prevention in 
the USA have experienced a period of exciting new developments. After a long period of 
limited success, the 1990s brought the field to a new level of prominence that engaged 
researcher, practitioner and policymaker to strategically address substance use among 
our children and adolescents. After rapid dissemination and diffusion of evidence-based 
prevention strategies, the field has now entered a new period of deliberations and 
discussions around improving both the extent of prevention programming within the 
community and the specificity of this programming to meet each community’s needs 
in terms of problem identification, available resources (i.e. social capital and funding), 
and priorities. Governmental demands for fiscal accountability pose both opportunities 
and challenges. On one hand, communities are required to deliver ‘evidence-based’ 
prevention programming, while on the other hand researchers and practitioners are 
not in agreement as to what that means. To further complicate the issue, the proposed 
federal budget for fiscal year 2006 shows reduced funding for demand reduction 
activities, particularly prevention, placing a greater load on states and local governments 
and the private sector for support. Funding for the much-needed research, now solely 
the responsibility of NIDA, will remain flat or will increase negligibly. Given the costs for 
conducting rigorous evaluation research studies, these potential obstacles portend that 
few, if any, much needed new prevention strategies will be forthcoming.
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Chapter 13
Cannabis users in drug treatment 
in Europe: an analysis from 
treatment demand data
Keywords: cannabis – EMCDDA – epidemiology – treatment – treatment 
demand
Setting the context
This chapter analyses the 2005 data on people entering drug treatment for primary 
cannabis use in the Member States. For several years, the EMCDDA has reported an 
increasing number of people reported as seeking treatment for cannabis use. Although 
definitive reasons for this are difficult to specify, it is clear that the explanation is multi-
faceted and requires careful study before drawing firm conclusions (Simon, 2004).
Cannabis treatment, like cannabis use, is usually a young person’s phenomenon. As 
with the use of other types of drugs, treatment for cannabis attracts more males than 
females. While most cannabis treatment clients begin use early in their lives, the spread 
of ages amongst those now entering treatment is much broader, and their drug use 
reaches beyond cannabis to include other illicit drugs also, such as cocaine, other 
stimulants and, occasionally, opiates (EMCDDA, 2003a).
Recent years have shown an increase in demand for cannabis treatment in most 
Member States, even though there are important differences between the countries. In 
particular, there has been an increase in the number of adolescents reporting social 
and psychological problems related to cannabis use, for which they themselves, their 
families or their school request specialised help (EMCDDA, 2003a). A number of factors 
may explain the reported increase, for example a simple improvement of data coverage 
in the EMCDDA reporting system, expansion of treatment availability, or an increased 
number of referrals to treatment by the criminal justice system and by the client’s social 
networks. The reported pattern of use of cannabis in the period immediately prior to 
treatment has been changing, and this does not just mean an increase in the number of 
users reporting frequent use.
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People seeking treatment specifically for cannabis use now represent a significant 
proportion of overall drug treatment requests across Europe, though differences between 
countries are substantial. Some countries, such as France, Germany, Hungary and 
Denmark, currently have very high percentages of cannabis clients among people in 
treatment. Other countries, such as Lithuania, Luxembourg, Romania and Portugal, 
report low percentages.
This chapter argues that further investigation of cannabis consumption patterns and 
related problems could identify areas where specialised drug services might provide 
interventions, targeted not only at regular cannabis users but also at any other 
adolescent cannabis users with social, behavioural or psychological problems.
Further reading
Copeland, J. (2004), ‘Developments in the treatment of cannabis use disorder’, Current Opinion in 
Psychiatry 17(3): 161–167.
EMCDDA, Annual report, published each year in November.
UNODC and EMCDDA (2006), Guidance for the measurement of drug treatment demand, United 
Nations Office on Drugs and Crime and European Monitoring Centre for Drugs and Drug 
Addiction, Vienna and Lisbon.
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Cannabis users in drug treatment 
in Europe: an analysis from 
treatment demand data
Linda Montanari, Colin Taylor and Paul Griffiths
Introduction
Cannabis is the most widely used illicit drug in Europe and its use is one of the most 
frequent reasons cited for entering drug treatment. In 2005, 20 % of all drug clients and 
29 % of new drug clients (EMCDDA, 2007a, b) (1) entered treatment for problems related 
to their primary cannabis use. In recent years, drug services in the European Union 
have reported a more or less steady increase in the number of people seeking treatment 
because of problems related to their cannabis use, making cannabis-related treatment 
an increasingly larger proportion of drug treatment demands. In terms of overall 
treatment demand, cannabis now lies behind only the main problem drug type, opiates, 
and is ahead of demands for cocaine-related treatment.
In this chapter, the increase in treatment demand and its implications are analysed 
through data collected under the treatment demand indicator (TDI), a pan-European 
instrument used to monitor data on people entering treatment for drug use (EMCDDA 
and Pompidou Group, 2000) (2).
This chapter highlights a number of key questions arising from the increase in the 
reported demand for cannabis treatment. To build a clear picture of the changing 
situation, it is fundamental to understand how each of these questions is driving the 
current changes in treatment demand.
Does this increase in reported demand represent an increase in the number of •	
people in need of help for cannabis use?
If so, to what extent does it result from an increase in use of cannabis in the •	
general population — in particular, regular and intensive use?
 (1) See figure TDI-G02 in the Statistical bulletin 2007.
 (2) The TDI is called the treatment demand indicator protocol, but in fact it counts the number of 
people starting a drug treatment for their drug use, as written in the TDI definition. The people 
asking for, but not receiving treatment, are not recorded. People sent to treatment centres not 
on their own initiative are also included in the reported data.
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If so, to what extent is it related to other changing factors among drug users, •	
such as their changing patterns of drug use? To what extent is it related to 
physical, social or psychological problems among cannabis users themselves?
Can this increase be explained by factors independent of an increased need for •	
help? Explanations might include:
improvements in the coverage of the treatment reporting system;•	
expansion of the types of treatment facilities available, and, in particular, •	
specific treatment services targeting adolescents and young people, that reach 
out to and attract the cannabis user population more effectively than before;
an increase in referrals to treatment, affecting cannabis users who would not •	
otherwise have sought help spontaneously; and
linked to the above, an increase resulting from changes in the way cannabis or •	
other drug use is dealt with by the criminal justice system, within schools, or by 
agencies working with young people.
The analysis presented here is a broad one, describing trends across several countries 
in the EU. The chapter questions the extent to which the overall European picture 
is reflected in each of the individual countries, and whether some countries have a 
different pattern of change in treatment demand.
Method and sources for data collection
The data presented in this chapter are primarily obtained through a standard protocol 
used by all EU countries, the TDI, a joint EMCDDA–Pompidou Group Protocol (EMCDDA 
and Pompidou Group, 2000). The protocol establishes harmonised definitions across 20 
questionnaire items. These items relate to drug-related information, socio-demographic 
data and use of services, and aim to obtain consistent information on the number, 
characteristics and patterns of use of people entering treatment for drug use. From 
2000 onwards, European Member States have collected data using the TDI to provide 
information on trends in the treatment of problem drug use. The indicator serves several 
purposes: prevalence estimation; identification of patterns of drug use and use of 
services; service planning; and service evaluation.
TDI data can be regarded as providing a reasonably robust and useful representation of 
the characteristics of clients referred to specialised drug services within the EU. However, 
there are limitations that must be borne in mind, as achieving comparability in data 
from all EU Member States is not easy. While departures from EU comparability persist, 
they are believed not to distort the broader picture of drug treatment patterns.
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One limitation of the EMCDDA’s data is the extent of ‘double-counting’ of clients. The 
number of people entering treatment each year is defined so as to count only one 
episode — that is, a single treatment demand — each year. The task of excluding 
‘repeat’ treatment episodes should therefore ideally be controlled centrally in each 
country, yet in practice some countries’ collection procedures cannot use controls at a 
national level, resulting in a slightly higher count of people. A further potential lack of 
comparability is that treatment for cannabis as the primary drug of abuse is defined 
in the protocol as cannabis being ‘the drug that causes the client the most problems’. 
Different treatment systems may interpret this differently. Reporting can be based on 
problems as defined by clients themselves, or on short diagnoses based on the ICD-10. 
When the primary drug is unclear, usually what is reported is the drug most frequently 
used, or the drug considered most important for the potential consequences on the 
health and social situation of the client.
A stronger caveat must be voiced on how far we can generalise from the consolidated 
European data set. The single factor that impacts most heavily on interpreting the 
findings is the potential for under-reporting, which arises from the varying extent to 
which the reporting system succeeds in covering, each year, all the relevant treatment 
facilities in each Member State. It must be remembered that treatment facilities are not 
fixed: new agencies might enter the reporting system and old ones leave it. Monitoring 
the effect of these changes is a continuing part of data collection, and is the subject of 
current work (see, for example, Simon, this monograph, on the German situation).
The EMCDDA’s TDI data nonetheless remains the major pan-European body of data 
on treatment. The discussion based on this information source will focus on four main 
areas:
profiling cannabis treatment clients — their socio-demographic characteristics (age, •	
gender, living and social conditions);
describing patterns of drug use amongst treatment clients (age at first use, •	
frequency of use and combination with other drugs);
incidence of client treatment in Europe, and a comparison with general population •	
data on cannabis use; and
referral routes into treatment for cannabis.•	
The TDI provides good short-term trend information in these four areas, although 
longer-term longitudinal data — 1999 to 2005 — on treatment demand in 20 European 
countries are available (3). For some socio-demographic characteristics (education, 
labour and living status) — and for information on source of referral — only two years 
 (3) See figure TDI-01 in the Statistical bulletin 2007, which provides methodological details on trends 
calculations.
Cannabis users in drug treatment in Europe: an analysis from treatment demand data
266
of data (2001/2002) are available, for seven countries. In these seven countries, a 
specific exercise, not available for other years, was conducted.
Discussion of patterns of drug use, profile of clients and sources of referrals to treatment 
is restricted to outpatient clinics, since these data have the most consistent coverage of 
clinics and individuals.
Cannabis treatment clients
Overall, cannabis is the most used illicit drug in Europe and, over recent years, it has 
risen to become the second most frequently cited drug reported as the primary reason 
for entering specialised drug treatment, after opiates. According to the TDI data in 
2005, around 20 % of all treatment clients and 29 % of first-time treatment clients were 
recorded as having a primary cannabis problem (4) (EMCDDA, 2007a, b).
Polydrug use is often reported among cannabis users. Among drug clients, cannabis can 
be registered as a primary drug, or a secondary drug used along with other substances. 
Among all drug clients entering treatment for primary cannabis use, alcohol (37 %) or 
amphetamines or ecstasy (28 %) were reported as the most frequent secondary drugs 
(5). However, a proportion of clients reported cocaine use (15 %) and/or other opioid 
use (7 %) as secondary drugs, with cannabis reported as the primary drug for treatment. 
Although few in number, these clients are an interesting group who could be more 
carefully examined to better understand patterns of drug use and related problems.
Among all outpatient treatment clients reported by a clinic’s staff, cannabis may also 
be cited as a secondary problematic drug. After alcohol (38 %), cannabis is reported 
as the second most frequently cited secondary substance (17 %) by those receiving drug 
treatment (6). When treatment clients cite cannabis as a secondary drug, analysis shows 
that overall cannabis use is frequently reported as a secondary reason for entering 
treatment among primary cocaine users (28 %), primary users of other stimulants (26 %) 
and primary opiate users (17 %). Similar drug combinations are also found in the 
American treatment data. Analysis of American treatment data shows that marijuana 
appears to be the secondary reason for seeking treatment among clients using alcohol 
(56 %), cocaine (21 %), stimulants (11 %) and opiates (10 %) (DASIS, 2003).
Thus it seems that a group of primary cannabis clients exists which also uses other drugs 
in combination with cannabis. Cannabis can be combined with alcohol, amphetamines 
or ecstasy, but also with other, ‘harder’, drugs such as cocaine or heroin. Among 
 (4) See figure TDI-02 in the Statistical bulletin 2007.
 (5) See table TDI-23 in the Statistical bulletin 2007.
 (6) See table TDI-22 in the Statistical bulletin 2007.
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polydrug users including cannabis, and especially in those clients reporting use of the 
‘hard’ drugs, it is not clear what the role of cannabis is in the request for treatment. 
Polydrug use has became more common in recent years and cannabis might be just one 
among other substances that gives rise to users entering treatment. Limitations in data 
recording, and the small number of absolute cases reported in some countries should be 
considered also.
For simplicity, to analyse changes and trends we have considered here only the group of 
clients reporting cannabis as the primary drug for the first time in their life. Nevertheless, 
this information must be seen in the context of a changing and expanding reporting 
system, the implications of which are discussed below.
When looking at socio-demographic characteristics of cannabis clients, the following 
picture emerges. Cannabis clients new to treatment are predominantly young males. 
The highest male to female ratio among all drugs clients is found among these new 
outpatient clients (6 males:1 female) (7). Higher male to female ratios are found in Italy, 
Portugal, Hungary, Germany, with lower ratios in the Czech Republic, Sweden, Finland 
and the United Kingdom. These differences in the male to female ratios among countries 
is quite similar across the other primary drugs of use. Almost all new clients entering 
treatment for primary cannabis use are younger than 30, and almost 40 % are younger 
than 20. The mean age of cannabis clients is 24 years, whereas in the case of other 
drugs, this age is generally higher. Country differences are found in the age distribution 
of cannabis clients (8). Among the group of people under 20 years old receiving drug 
treatment, the vast majority reports using cannabis as the primary drug (80 % among 
people under 15, 67 % among those aged 15–19) (9).
The age of first cannabis use — onset — is important, since it has been reported 
that the younger the age at which users first consume cannabis, the higher the risk 
of developing drug problems in the future (Kraus et al., 2003). Compared with other 
drug types, which show considerable variation across countries, age of first cannabis 
use among clients requesting treatment for cannabis is quite similar across countries 
in Europe. In the TDI data for cannabis clients starting treatment for the first time, the 
mean age of starting cannabis use is 17 years. Virtually all new cannabis clients start 
their drug use before they are 20 and 33 % before they are 15. The corresponding 
figures for opiates are 45 % before 20 years old, and 5 % before 15 years old, and for 
cocaine, 48 % and 6 %, respectively (10). A comparison of age of onset with age first 
treated shows that there is a time lag of around 7 years between first cannabis use 
 (7) See table TDI-22 in the Statistical bulletin 2007.
 (8) See tables TDI-10 and TDI-102 in the Statistical bulletin 2007.
 (9) See table TDI-10 in the Statistical bulletin 2007.
 (10) See table TDI-11 in the Statistical bulletin 2007.
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and first drug treatment, regardless of where treatment is sought (that is, in different 
countries and in different types of treatment centre).
Finally, looking at available data on other social characteristics in 2002 (11), the 
relatively young age of cannabis clients means that a large proportion, 45 %, are still 
in education, compared with only 8 % amongst clients being treated for problems with 
other drugs. A further 24 % of those being treated for cannabis problems are in regular 
employment, equal to the percentage who are unemployed. This is in stark contrast to 
clients using drugs such as heroin, among whom very few are employed. In addition, 
cannabis clients more often report living in stable accommodation than those being 
treated for problems with other drugs, reflecting the fact that many are young people, 
students, or living with their parents (Agosti and Levin, 2004). However, a few countries, 
such as Greece, also report a number of primary cannabis clients who are older, 
in more precarious social conditions and using other drugs together with cannabis 
(EMCDDA, 2004).
To conclude, the most common characteristics of cannabis clients are that they are 
young male, a student/school pupil and living with parents. However, there are also 
indications of cannabis clients who are older or less socially well-integrated. The same 
patterns were found in the recent review of cannabis specialised treatment reported by 
Rødner Sznitman (this monograph).
Incidence of demands for cannabis treatment
Based on data that were available in 19 EU countries, there are on average 41 persons 
per 100 000 young adults (aged 15–34) each year who enter treatment for cannabis 
use for the first time. Only a tiny proportion — 1 in 200 — last-month cannabis users 
in the young adult population (aged 15–34) report entering specialised drug treatment 
for cannabis use (Table 1). A 2004 detailed review of cannabis treatment demand, 
conducted by the Dutch National Alcohol and Drugs Information System (LADIS), 
confirms that only a small proportion of regular cannabis users in the Netherlands 
receives drug treatment.
Major differences are found between countries in the TDI data set in the proportion of 
clients seeking treatment for cannabis. This varies considerably, from 3 % in Bulgaria 
to 48 % in France and 36 % in Hungary. In terms of new clients, there are also large 
differences between countries, with cannabis clients reaching an almost 70 % share 
of new clients entering drug treatment in France (12). In general, a high prevalence of 
 (11) An ad hoc data collection on social characteristics of cannabis clients was done in 2002, yet is not 
available for other years.
 (12) See tables TDI-04 and TDI-05 in the Statistical bulletin 2007.
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cannabis use reported in the general population is associated with a high percentage of 
primary cannabis users among treatment clients. In particular, the available data show 
that countries with high or low last-month prevalence in the young adult population 
(15–34 years) have correspondingly high or low incidence of cannabis as a share of 
treatment demand. However, there are a few exceptions: in some countries, high levels 
of last-month cannabis prevalence in the young adult population contrast with low levels 
of treatment demand for cannabis and vice versa (Cyprus, Hungary, France, Portugal — 
see Table 1).
The reasons for discrepancies between use and treatment across countries are 
presumably historically rooted, in both the development of treatment centres and in 
attitudes to treatment, as well as prevalence and patterns of cannabis use. In cases 
where high levels of recent cannabis prevalence contrast with low proportions of 
treatment demand, this could imply that treatment availability for cannabis is insufficient 
or not appropriate. On the other hand, it could simply be because there is no perceived 
need for drug treatment. As shown elsewhere (Corrigan, Beck and Legleye, this 
monograph), it is uncertain to what extent cannabis use triggers a need for treatment. 
In other cases, where high demand for cannabis treatment contrasts with low recent 
cannabis prevalence, this might arise from more restrictive national legislation, or a 
widespread medical approach to dealing with cannabis problems.
Even if cannabis is the most used drug in Europe, only a minor part of the population 
uses it on a regular basis, and an even smaller proportion demands drug treatment 
(Agosti and Levin, 2004; Toxibase and Crips, 2004). One of the various observations 
that may be made from this is that demand for cannabis treatment does not always 
mirror, in a logical and straightforward way, the cannabis prevalence rates in the 
general population. Instead, it is clear that the extent of demand for cannabis treatment 
is a complex issue that is probably related to several factors which lie beyond variations 
in reporting coverage. Contenders for explaining this phenomenon include prevalence of 
intensive cannabis users in the general population, availability of treatment, patterns of 
referral to treatment and national legislation.
Trends in treatment incidence
Between 1999 and 2005, according to the TDI information from 20 countries, the 
number of new clients entering treatment for cannabis as a primary drug increased by 
28 000, from around 15 000 to almost 44 000 reported cases. In 1999 the proportion 
of new cannabis clients represented around 12 % of the total of the new clients, while 
in 2005 it reached almost 28 % (Figure 1). In 11 countries there was an increase in 
the proportion of cannabis clients, and in 11 countries a stable or slightly decreasing 
trend was noted. The highest growth was reported in Hungary (+ 40 %) and France 
(+ 37 %), followed by Slovakia, Germany, Malta, Denmark and The Netherlands (around 
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Figure 1: Trends in new cannabis treatment demands from 1999 to 2005 (proportion of 
total clients and absolute numbers)
Notes: Missing data were interpolated by assigning for the respective country the EU average year-on-
year trend from available data. Altogether, 14 % of data points and 21 % of the number of clients 
were interpolated. Countries included: Bulgaria, Czech Republic, Denmark, Germany, Greece, 
Spain, Ireland, France, Italy, Hungary, Malta, Netherlands, Poland, Portugal, Romania, Slovenia, 
Slovakia, Finland, Sweden, United Kingdom. In the case of Romania, the 2001 proportion of 
heroin clients among all new clients was used to estimate their 2000 and 1999 number based on 
all new clients number.
Source: 2006 Reitox National reports – Standard Table 4 – New clients.
+ 20 %) while the smallest growth was found in Poland, Portugal, the Czech Republic 
and Romania (13). An analysis carried out in England on cannabis treatment demand 
confirmed this upward trend (DMRD, 2004).
Compared with other substances, primary cannabis treatment demands increased 
faster than demands for treatment of other drugs. In the same time period, new heroin 
clients decreased by 32 %, cocaine clients increased by 11 % and other stimulant users 
increased by 4 %. This reported increase in cannabis treatment demand is not restricted 
to Europe. In the USA, where a different drug treatment registration system is used (14), 
 (13) See table TDI-03 in the Statistical bulletin 2007.
 (14) In the USA, admissions to treatment rather than individuals are registered. In addition, in contrast 
to Europe, alcohol is included among the substances of abuse. See the SAMHSA website 
(www.samhsa.gov); note that in the USA, Canada and Australia the term ‘marijuana’ is used 
because the term ‘hashish’ (cannabis resin) is not common.
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treatment admissions for marijuana increased from around 20 000 in 1992 to nearly 
90 000 in 2000 (SAMHSA, 2003; EMCDDA, 2003b).
Looking at the factors that might have influenced the reported trends, changes are seen 
in the following areas:
reporting system and data coverage;•	
drug services organisation;•	
sources of referrals to treatment;•	
socio-demographic characteristics; and•	
patterns of drug use and, in particular, frequency of cannabis use.•	
The coverage of the European reporting system has expanded in recent years, with an 
increase in number of units and clients recorded by the system. It is unclear to what 
extent this represents a genuine expansion in treatment offering, as opposed to simply 
the coverage of the treatment reporting system. It is also unclear how treatment offering 
and reporting coverage may have affected the increase in cannabis treatment demands. 
Nevertheless, this growth is not sufficient to explain the increase in cannabis treatment 
demands (EMCDDA, 2003b) (15).
The organisation of drug treatment services has changed in recent years. Because of 
the decrease in proportion of heroin clients, centres have adapted treatment offerings 
to embrace a differentiated client population that includes cocaine and cannabis users. 
This shift in targeted clients might have influenced demand for treatment. In particular, 
countries such as France — where a high proportion of cannabis users is found 
among all treated clients — have created treatment centres for target groups, such 
as adolescents, and these have reported a substantial proportion of cannabis clients 
(EMCDDA, 2003b). Overall, such centres might have added ‘weight’ to the share of 
cannabis users among all treatment clients.
Referral routes into treatment
It is important to identify the channels through which people enter treatment. A number 
of standard options are available in the TDI schedule for recording the source of referral 
for drug users entering treatment. These distinguish (i) drug users who have referred 
themselves and (ii) those who have been referred through other agencies such as health, 
social or criminal justice agencies. Most cannabis clients are referred by family and 
friends, social services or the criminal justice system. In comparison with users of other 
drugs, a smaller proportion of cannabis clients are self-referrals (EMCDDA, 2004). 
A similar picture is also seen in the USA and Canada, where treatment demand for 
 (15) See table TDI-02 in the Statistical bulletin 2007.
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marijuana as a primary substance is largely found not to be self-initiated (EMCDDA, 
2003b). In countries with significant percentages of primary cannabis clients, legal 
authorities and schools play an important role in referring cannabis clients (EMCDDA, 
2003a). In an American analysis of marijuana admissions to treatment based on source 
of referral (DASIS, 2005), marijuana admissions referred by criminal justice were 
also reported to have a different profile from non-criminal justice referrals: they were 
younger, with a higher presence of males, and often occasional users of cannabis with 
no other additional drugs.
Some understanding of the reasons for increases in treatment uptake may be found in 
analysing the changes in the sources of referral to treatment. Between 2001 and 2002, 
in those countries reporting data (16), the total number of cannabis clients referred 
to treatment services by hospital/medical sources and by legal authorities increased 
by 79 % and 58 % respectively, while the known base of clients increased by 37 %. 
By comparison, from 1992 to 2002 the USA also reported increases in marijuana 
admissions referred by the criminal justice system (EMCDDA, 2004).
One of the more problematic measures in the EMCDDA’s TDI is the frequency of use 
of the primary drug in the period immediately before entering treatment. Intended to 
give insight into, amongst other things, the severity of problem to be treated, in practice 
this measure can be strongly tied to the route of referral and how treatment entry 
comes about. Often this ‘frequency of use’ item records, strangely, no or little use of 
the primary drug in the period in question — a phenomenon that might be related to 
referrals from criminal justice, or from a health agency positioned earlier in a referral 
chain. As such, it is difficult to separate its interpretation from referral patterns. For 
example, among clients in treatment for a primary cannabis problem in 2005, 30 % 
of new cannabis clients use the drug occasionally or have not used in the month prior 
to treatment, while 40 % use it daily (17). There are again large differences between 
countries: the highest proportion of daily cannabis users is found in the Netherlands, 
Denmark and Spain, and the highest proportion of occasional users — including clients 
who may not have used in the past month — are found in Hungary, Germany and Italy. 
Compared with the other drugs, in the case of cannabis there is a higher polarisation of 
patterns of use between occasional users — including non-users — and daily users. The 
same patterns are also found in American analysis (NSDUH, 2004).
Among new cannabis users presenting to treatment between 2003 and 2005, the 
proportion of daily users increased by more than 10 % (18). A number of factors may 
be behind this increase, for example artefacts of reporting measures, polydrug use, 
 (16) The countries reporting in these years were Finland, Germany, Greece, Norway, Sweden and the 
United Kingdom.
 (17) See table TDI-18 in the Statistical bulletin 2007.
 (18) See table TDI-18 in the Statistical bulletin 2007.
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and mental health problems among cannabis clients. A number of countries report 
polydrug use where cannabis is reported as the primary substance, yet accompanied 
by the use of alcohol and other drugs. In these cases, it is not totally clear which 
drug precipitates treatment-seeking, even though cannabis might be declared as the 
primary problem. Some countries have examined a purported relationship between 
mental health problems and cannabis use, and specific research has been carried out 
to investigate this relation. The scientific literature indicates that it is not always clear 
whether problematic cannabis use comes before a mental health problem, contributing 
to its appearance or discovery, or whether cannabis is used as a kind of medication for 
pre-existing mental health problems (see Witton, this monograph). However, there is a 
group of people that regularly uses cannabis and seeks help for problems that may be 
related to their cannabis use. This should be seriously taken into consideration by the 
treatment system, and be better investigated by researchers.
Conclusions
The objective of this review has been to describe the observed increase in reported 
cannabis treatment demand, and to analyse the changing reporting environment to 
better understand the trend. In doing so, it has become apparent that many important 
questions that are fundamental to an informed policy debate on this controversial topic 
remain unanswered. What is also apparent is that the available evidence justifies neither 
an alarmist position nor complacency on cannabis treatment demand.
People with cannabis-related problems constitute a non-trivial proportion of treatment 
demands in specialised facilities in some countries, and form an important subgroup 
within the larger treatment population. Most are young males, typically around 20 years 
old, and most started using cannabis at around 17 years of age.
Cannabis clients have different patterns of drug use from those consuming other 
substances. Moreover, there are important differences between cannabis clients, and 
the profiles of different subgroups of cannabis users in treatment are likely to be directly 
relevant to understanding their needs and the provision of appropriate responses. 
Important dimensions for service provision include frequency of use, current and past 
use of other drugs, and referral source. In broad terms, summarising the available 
information at EU level, two client profiles can be postulated (EMCDDA, 2004):
at one extreme, younger users, often students, referred to treatment services by •	
family or school, and consuming only cannabis or sometimes together with alcohol 
or stimulants; and
at the other extreme, polydrug users who are typically older and less socially well-•	
integrated, and who are referred to treatment more often by legal authorities or 
health and social services, and who overlap with the chronic drug-using population.
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In reflecting on changes in the characteristics of primary cannabis treatment demand 
over time, the available information suggests that there were increases in:
numbers of clients referred from the criminal justice system;•	
referrals from family and other social support networks (family, friends, social •	
services, school);
the proportion of people using cannabis intensively (daily cannabis use), although •	
daily users remain in the minority; and
levels of social and educational problems in some countries (although data in this •	
area are still weak).
In considering the increase in treatment demand, it appears that changes in referral 
practice have an impact, and a substantial proportion of those referred appear not to 
be intensive drug users. Nonetheless, in some countries at least, a significant number 
of treatment demands come from individuals whose use of cannabis is intensive. The 
problems experienced by this group remain poorly understood, and research in this area 
is urgently needed. The observation that a majority of treatment demands made by the 
very young are for cannabis suggests that special consideration of the needs, referral 
pathways and responses of this group is required.
It is also important to recognise that treatment demand is not a direct indicator of the 
scale and nature of cannabis problems. General population survey data suggest that, 
compared with occasional use, intensive cannabis use is relatively uncommon. However, 
the widespread general use of cannabis means that considerable numbers of people 
may be using the drug intensively — at least for some part of their life (EMCDDA, 
2004).
Although the effects of cannabis dependence or abuse are less severe than those of 
other drugs, this may, nevertheless, have a considerable public health impact. This is 
because of the scale of cannabis use, and the fact that many of those most affected are 
young and may be using the drug intensively during important developmental stages, 
or when they are particularly vulnerable. Among socially disadvantaged families or 
communities, cannabis dependence or abuse may compound individuals’ problems by 
harming education or employment opportunities.
In summary, there remains a critical need for research to provide an understanding 
of the relationship between different patterns of cannabis use and the development of 
problems. The extent to which cannabis users experience problems and the nature of the 
problems that may be found still remain poorly understood. Methodological tools are 
required to assess problems at the population level. Such information is a prerequisite 
to the development, targeting and implementation of effective public health responses to 
cannabis use in Europe.
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Setting the context
Scientific literature on the treatment of cannabis-related disorders is scarce, particularly 
when compared with opioid treatment. While there have been some synthetic overviews 
(Hall et al., 2001; Steinberg et al., 2002; Loxley et al., 2004), analysis has generally 
been peripheral to wider works on cannabis or restricted to adolescents (e.g. SAMHSA’s 
Cannabis Youth Treatment series in the USA; Elliott et al., 2002; Liddle et al., 2002). 
Scarcity also seems to characterise research on the treatment of cannabis-related 
problems in the European Union. This could be explained by a common belief that 
cannabis problems are not a primary problem for people in drug treatment. Yet Europe, 
like the USA, is recording a trend in which cannabis is mentioned at an increasing rate 
in the context of treatment demand indicators (EMCDDA, 2004, 2006; UNODC, 2006). 
Another explanation is that cannabis does not produce the pharmacological dependence 
syndrome associated with alcohol, nicotine and opioid use. However, as the chapters by 
Witton and Hall in Volume 2 of this monograph indicate, somatic and mental problems 
related to cannabis use affect thousands of people.
Indications do, however, exist, which point towards new directions in regards to cannabis 
treatment. At the level of healthcare policy, domestic and international research, 
cannabis treatment has for some years been gaining a higher level of visibility and 
public funding. In July 2004, the European Council adopted a resolution on cannabis 
proposed by the Horizontal Working Party on Drugs, which called for the EMCDDA to 
continue to monitor ‘conditions for effective prevention and treatment, and examples of 
best practice’ and encourages Member States to ‘promote networking’. 
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In many ways, EU-wide monitoring into cannabis treatment has already benefited from 
scientific collaboration, both in terms of defining a ‘PCU’ (problematic cannabis user) 
and establishing standard treatment indicators. In June 2003, EMCDDA hosted expert 
meetings on the ‘Quality and coverage of TDI and analysis of cannabis client profiles’ 
(1) and ‘The profile of cannabis clients in different regions of the world’(2). In parallel, 
the EMCDDA commissioned a report on ‘Regular and intensive use of cannabis and 
related problems: conceptual framework and data analysis in the EU member states’ 
(Simon, 2004). The Centre also published a selected issue, titled ‘Cannabis problems in 
context: understanding the increase in European treatment demands’ in its 2004 Annual 
Report (EMCDDA, 2004).
Supranational networking is taking place on a number of levels, and is increasingly 
crossing the linguistic barriers which have at times acted as an obstacle to collaboration. 
Cannabis is increasingly mentioned in EMCDDA’s EDDRA  (3) database, including 
specialised cannabis treatment in Lund, Sweden (4), and Berlin, Germany (5). A 
supranational project focused on adolescent therapy, INCANT (International Cannabis 
Need of Treatment Study) has completed pilot phases at centres in Belgium, Germany, 
France, the Netherlands and Switzerland, with the main phase being run from 2006 to 
2009. Cannabis mental health issues and treatment options were covered in a 2006 
Beckley Foundation report (6). Meanwhile, recent forums for international research have 
included the annual HIT Perspectives on cannabis conference in the United Kingdom, 
Therapieladen’s Cannabis — Quo vadis (7) conference in 2005 in Germany, not to 
mention cannabis presentations within general drug treatment conferences, such as 
ICTAB (the International Conference on Treatment of Addictive Behaviors). In terms of 
best practice, Germany’s CaRED (8) project, managed from 2002 to 2004, represents a 
thorough analysis of cannabis treatment, albeit with a domestic focus, and in turn has 
helped stimulate innovative cannabis treatment provision studies, such as CANDIS (9).
 (1) www.emcdda.europa.eu/?nnodeid=1861
 (2) www.emcdda.europa.eu/?nnodeid=1881
 (3) www.emcdda.europa.eu/themes/best-practice
 (4) EDDRA link: 
www.emcdda.europa.eu/html.cfm/index52035EN.html?project_id=1293&tab=overview 
Home page: www.droginfo.com/
 (5) EDDRA link: 
www.emcdda.europa.eu/html.cfm/index52035EN.html?project_id=2915&tab=overview 
Home page: www.drogen-und-du.de
 (6) www.internationaldrugpolicy.net/reports/BeckleyFoundation_Report_08.pdf
 (7) www.therapieladen.de/
 (8) Simon, R., Sonntag, D. (2004), Cannabisbezogene störungen: umfang, behandlungsbedarf 
und behandlungsangebot [Cannabis-related disorders (CareD): prevalence, service needs 
and treatment provision], Bundesministerium für Gesundheit und soziale Sicherung, Munich 
www.bmg.bund.de/nn_604826/SharedDocs/Download/DE/Themenschwerpunkte/Drogen-
und-Sucht/Cannabis/cannabisbezogene-stoerungen,templateId=raw,property=publicationFile.
pdf/cannabisbezogene-stoerungen.pdf
 (9) www.candis-projekt.de/
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This chapter is based on a survey that answered the basic question: What type of 
treatment is available for cannabis use disorders in Europe today? While the results are 
not exhaustive, they help to inform the road ahead.
Further reading
Copeland, J. (2004), ‘Developments in the treatment of cannabis use disorder’, Current Opinion in 
Psychiatry 17(3): 161–167.
EMCDDA, Annual reports, published each year in November.
UNODC and EMCDDA (2006), Guidance for the measurement of drug treatment demand, UNODC and 
EMCDDA, Vienna and Lisbon.
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Cannabis treatment in Europe:  
a survey of services
Sharon Rödner Sznitman
Introduction
In response to an identified lack of data about cannabis treatment provision in Europe, 
the Centre for Social Research on Alcohol and Drugs (SoRAD), in cooperation with 
EMCDDA, conducted a survey on cannabis treatment provision in Europe in 2005. 
The study was designed to provide a base for a preliminary description of cannabis 
treatment in Europe, to examine the availability and nature of different specialist 
treatments for cannabis users, and to profile their clients’ characteristics.
Research method and sample design
The study was conducted in two phases. In phase I, key informants were contacted 
through the EMCDDA’s coordinating network of national focal points. This provided 
access to informants from the 25 Member States and Norway; Switzerland also 
participated. A questionnaire was emailed to these informants in which they were asked 
to provide contact information for key position holders in treatment centres which are 
likely to see cannabis cases. Informants for phase II were thus identified and these were 
contacted by email.
The criterion for including a key expert in the study was ‘any person who is a holder 
of a key position at any centre offering treatment for patients with cannabis use as the 
primary problem’. Respondents were asked to indicate whether their service treated 
cannabis as the primary drug problem but also included other drugs, or solely treated 
cannabis-related problems. The questionnaire asked for information regarding the 
particular treatment offered to the cannabis clients and for summary data on agency’s 
clients.
Problematic issues
Methodological limitations should be considered: since the survey was voluntary only 
some countries responded and they are not proportionately represented in the survey 
(e.g. Sweden returned eight questionnaires, Norway six, while some countries returned 
only one and others did not reply).
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Over 100 questionnaires were sent out in Phase II of the survey, yet only 45 were 
returned. The results of the survey should, thus, be read with caution. They cannot claim 
to be representative of cannabis treatment in Europe overall. In the questionnaires, 
cannabis cases were defined as people who receive treatment mainly due to their 
cannabis use. This definition does not include polydrug users who use cannabis as a 
secondary drug together with other substances (e.g. heroin). The total number of people 
using cannabis is, therefore, underestimated.
Important definitions
For the purposes of the survey a treatment programme for cannabis cases is defined 
as any treatment at the agency for persons who are receiving treatment primarily for 
problems related to their cannabis consumption. Cannabis cases are defined as persons 
who are enrolled at the agencies mainly for their cannabis consumption and do not 
include patients with, for instance, heroin problems who also use cannabis.
Results
Responses were received from 45 individuals representing 45 different treatment 
agencies, from 19 EU Member States, Norway and Switzerland. Member States which 
did not respond and are hence not included in the study are: Estonia, Spain, Ireland, 
Slovenia, Luxembourg and the Netherlands. The respondents hold a wide range 
of positions in their treatment centres, including therapists, coordinators, heads of 
treatment centres, social workers, psychologists and nurses.
Description of the treatment centres
The majority of the responding treatment centres deal with a range of drug-related 
problems, and most of the treatment centres were fairly large. Six centres saw under 
100 clients per year. Twenty-one centres saw between 100 and 500 patients per year, 
with the remainder treating over 500 patients per year. The majority, 72 % (31), of the 
centres treated all or many patients in outpatient ambulatory counselling settings. A 
total of 36 % of the centres treated all or some of their patients in long-term inpatient 
treatment. Short-term, inpatient treatment, treatment in a day clinic or in the community 
was less common.
Table 1 reports respondents’ rating of the importance of modalities provided by their 
service. Short-term psychosocial interventions, long-term psychosocial interventions and 
long-term rehabilitative drug therapy were seen as the most important. In addition, 
on-the-spot psychosocial crisis intervention was rated as a very important or important 
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Table 1: Key informant rating of the importance of the different tasks at the 
agencies
n 1: very 
important 
task, % (n)
2: important 
task, % (n)
3: relatively 
unimportant 
task, % (n)
4: no task 
at all/not on 
offer, % (n)
a On-the-spot psychosocial 
crisis intervention
(42) 24 (10) 38 (16) 31 (13) 7 (3)
b Short-term psychosocial 
interventions: short-term 
counselling
(43) 41 (18) 52 (23) 7 (3) 0
c Long-term psychosocial 
interventions: long-term 
counselling
(45) 49 (22) 45 (20) 5 (2) 2 (1)
d Long-term rehabilitative 
drug therapy: long-term 
psychotherapy 
(43) 40 (17) 42 (18) 7 (3) 12 (5)
e Medical intervention for 
somatic problems
(42) 12 (5) 26 (11) 29 (12) 33 (14)
f Detoxification (42) 24 (10) 26 (11) 21 (9) 29 (12)
g Harm reduction (e.g. 
syringe exchange, 
educating safer-use 
strategies, etc.)
(42) 31 (13) 17 (7) 24 (10) 29 (12)
h Methadone or 
buprenorphine 
substitution
(43) 30 (13) 19 (8) 9 (4) 42 (18)
i Heroin prescription (42) 2 (1) 0 0 98 (41)
j Naltrexone prescription (41) 5 (2) 11 (5) 17 (7) 66 (27)
task by many informants. Fewer identified detoxification, harm reduction, medical 
intervention for somatic problems, methadone or buprenorphine substitution, heroin and 
naltrexone prescription as very important or important tasks of their agencies.
Description of cannabis treatment
Although the recruitment strategy of the study attempted to ensure that questionnaires 
were sent to treatment agencies that include cannabis cases, four of the centres included 
in the study did not currently have any cannabis cases. Thus, the following results are 
based on only 41 treatment centres.
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It is evident from the survey results that cannabis cases for the most part represented 
a minority of the overall clientele in the agencies. In 63 % (25) of the centres cannabis 
cases represented 0–25 % of the entire patient case load. Some centres did, however, 
seem to exclusively treat cannabis cases. In six centres (15 %) — from Belgium, 
Denmark, Sweden, Cyprus and Germany — cannabis cases represented 75–100 % of 
the patient case load.
Out of all the treatment centres, nine (23 %) treated at least some of the cannabis cases 
in a programme within a unit not exclusively for cannabis cases. Fourteen centres (35 %) 
treated the cannabis cases as individual cases among drug users of all sorts. Thus, it 
is evident that a substantial proportion of the agencies do not have a specific cannabis 
treatment programme. It is, however, also evident that treatment programmes exist 
which have an exclusive focus on cannabis cases. Six of the centres (15 %) treated the 
cannabis cases in a unit exclusively for cannabis cases. Three of these were located in 
Sweden, and there was one such unit in each of Belgium, Germany and Italy.
Evidently, units exclusively for cannabis clients exist in Europe, but these must be 
regarded as a scarce phenomenon. This claim is further evidenced by the fact that only 
10 of the respondents knew of only one treatment unit exclusively for cannabis in their 
city while three respondents reported that there were two such units in their city. One 
respondent reported that there were none and 14 respondents did not know how many 
there were.
Treatment
Most of the treatment provided to cannabis cases lasts no longer than 20 sessions. 
Fifteen of the treatment centres treated cannabis cases on average in 1 to 10 treatment 
sessions. Fifteen centres treated the clients in 11 to 20 treatment sessions. Treatment 
over 20 sessions was rare. As such, current treatment seems to correspond well with the 
literature on evidence-based cannabis treatment. Although the literature is scarce, the 
few existing studies mainly indicate that the most useful treatment for cannabis users is 
brief intervention (Stephens et al., 2000; Babor et al., 2004).
The aims of cannabis treatment reported as very important by most of the agencies 
were abstinence (20 agencies, 50 %) and reduction of cannabis use (19 agencies, 48 %). 
Seven agencies (18 %) reported harm reduction (e.g. solving practical life problems 
and no attempt to change cannabis consumption) as a very important aim. Quite a few 
agencies (15), however, reported that harm reduction was an important, but not a very 
important, aim of the cannabis treatment.
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In terms of what type of treatment is offered to cannabis cases, there seems to be a 
wide range of interventions available. As Table 2 shows, the main treatments reported 
by most of the agencies were: individual counselling, talk therapy/counselling about 
cannabis, relapse and treatment, and talk therapy/counselling about conditions of life. 
Also a regular part of treatment in many agencies were detox (10) from cannabis, family 
therapy, therapeutic community (11) and mutual help groups.
 (10) Detox refers to the process of abstinence to clear cannabis from the body, accompanied by social 
and environmental support during the associated physiological and psychological changes.
 (11) Therapeutic community is a term applied to a participative, group-based approach to drug 
treatment that includes group psychotherapy and practical activities, and which may or may not 
be residential.
Table 2: Content breakdown of cannabis interventions, based on number of 
respondents reporting specific treatment types
n 1: main part of 
treatment, % (n)
2: regular part of 
treatment, % (n)
3: not a part of 
treatment, % (n)
a Detox from cannabis (41) 24 (10) 42 (17) 34 (14)
b Peer group counselling (40) 13 (5) 24 (11) 77 (24)
c Individual counselling (41) 78 (32) 22 (9) 0
d Family therapy/
counselling
(41) 22 (9) 71 (29) 7 (3)
e Milieu therapy/
therapeutic community
(37) 0 24 (9) 76 (28)
f Talk therapy/counselling 
about cannabis, relapse 
and treatment
(41) 73 (30) 24 (10) 2 (1)
g Talk therapy/counselling 
about conditions of life 
(relationship problems, 
aggression training, etc.)
(41) 63 (26) 37 (15) 0
h Practical help with 
daily life (to get social 
allowances, clothes, 
housing, education, job)
(40) 13 (5) 48 (19) 40 (16)
i In-patient treatment (39) 8 (3) 21 (8) 72 (28)
j Mutual help group (e.g. 
Narcotics Anonymous)
(41) 0 15 (6) 85 (35)
Chapter 14
287
Characteristics of cannabis cases
Gender
As in drug treatment in general, cannabis cases are predominantly male. Only one 
treatment agency reported having less than 50 % males. Four agencies reported only 
a slight male dominance (51–59 % of all cannabis cases). Nine agencies reported 
that 60–69 % were male, 13 agencies reported that 70–79 % were male, 10 agencies 
reported that 80–89 % were male and six agencies reported that 90–99 % were male.
Age
The majority of cannabis cases are fairly young. Sixteen agencies (39 %) reported that all 
or the majority of their cannabis cases were 20 years old or younger. Thirteen agencies 
(32 %) reported that all or the majority of their cannabis cases were between 21 and 30 
years old. Only four (8 %) of the agencies reported that the majority of their cannabis 
cases were over 30 years old.
Referral channels
Worries have been expressed concerning increasing demand for cannabis treatment 
evident in many parts of the EU. It has, however, been pointed out that the rise might 
not be due to an increase in cannabis problems or dependence in the population. 
Instead, the rise might, among other things, be due to policy changes, which in turn 
lead to more referrals to treatment by police and school systems. While this study is 
unable to measure any trends over time, it provides indications of which are the most 
common referral channels to treatment for cannabis cases (Table 3).
The most common source of referrals reported was the client’s family and friends. Many 
agencies also reported that self-referrals were most common. However, more agencies 
than not reported that cannabis clients do not enter treatment on their own initiative. 
Other referral sources were also reported; among them the most common were the 
criminal justice system, schools, psychiatrists, psychologists, social workers and general 
practitioners. It must, however, be noted that the separation between self-referrals and 
external referral channels is far from clear-cut. Research from Sweden, for instance, has 
shown that there is a large overlap between reporting self-motivation to treatment and 
reporting pressure from unofficial or official sources to enter treatment (Storbjörk, 2004).
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Table 3: Reported common referral channels for cannabis cases
n 1: most 
common, % (n)
2: common, % 
(n)
3: not at all 
common, % (n)
a Self-referrals (39) 31 (12) 33 (13) 36 (14)
b Client’s/patient’s family/
friends
(39) 38 (15) 53 (21) 8 (3)
c School (40) 8 (3) 40 (16) 52 (21)
d Work (38) 3 (1) 18 (7) 80 (31)
e General practitioner 
(family doctors)
(41) 12 (5) 32 (13) 56 (23)
f Psychiatrist/psychologist/
social worker (out-
patient or private 
practice)
(39) 8 (3) 67 (26) 26 (10)
g Courts, probation, 
parole, police
(39) 18 (7) 41 (16) 41 (16)
h Drug counselling agency 
or drug treatment units
(40) 5 (2) 24 (11) 68 (27)
Twenty-eight respondents reported that 50 % or more of the cannabis clients received 
treatment for their substance abuse for the first time in their life when they came into 
contact with the agency. In fact, as many as 12 respondents reported that 90 % or more 
of their cannabis cases received help for their substance abuse for the first time.
Lifestyles
Most cannabis cases in treatment had a socially well-integrated life before entering 
treatment. A large majority of the agencies reported that it was not at all common 
that the cannabis cases had been homeless or lived in a sheltered environment before 
entering treatment. The most common living conditions among the cannabis cases were 
living with parents or living alone.
A majority of the agencies reported that it was common that the cannabis cases had 
attended school or university or had been employed before entering treatment. There 
were, however, slightly more agencies that reported that it was common that cannabis 
cases were school drop-outs or unemployed prior to treatment.
In terms of mental well-being, less than a majority (30 %) (Table 4) of the respondents 
reported that it was common that cannabis cases had psychiatric problems (based on 
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Table 4: Reported situations for cannabis treatment before entry to treatment
n 1: most common, 
% (n)
2: common, % (n) 3: not at all 
common, % (n)
a Were homeless (41) 0 7 (3) 93 (38)
b Lived in a sheltered 
environment (e.g. 
home for psychiatric 
cases)
(41) 0 7 (3) 93 (38)
c Lived with their 
parent(s) or 
guardian(s)
(41) 46 (19) 46 (19) 7 (3)
d Lived alone (40) 30 (12) 48 (19) 23 (9)
e Lived with friends (40) 3 (1) 28 (11) 70 (28)
f Lived with their own 
family
(41) 10 (4) 49 (20) 42 (17)
g Went to school/
university
(41) 15 (6) 63 (26) 22 (9)
h Dropped out of 
school
(41) 7 (3) 73 (30) 20 (8)
i Worked (41) 7 (3) 61 (25) 32 (13)
j Were unemployed (41) 15 (6) 66 (27) 20 (8)
k Had psychiatric 
problems
(40) 23 (9) 30 (20) 28 (11)
l Had health problems (41) 5 (2) 29 (12) 66 (27)
m Had problems with 
the criminal justice 
system
(40) 23 (9) 65 (26) 13 (5)
n Had family problems (41) 42 (17) 59 (24) 0
o Had financial 
problems
(40) 15 (6) 58 (23) 28 (11)
an affirmative response ‘had psychiatric problems’ to the question ‘According to your 
experience, how common are the following situations for cannabis cases before they 
enter treatment at your agency?’). Many agencies, but less than the majority, also 
reported that it was common for cannabis cases to have problems with the criminal 
justice system prior to treatment entry. Family problems were rated as common for 
cannabis clients by slightly more than half of the respondents. Lastly, most agencies 
(66 %, see Table 4) reported that it was not at all common that the cannabis clients had 
health problems (12).
 (12) The questionnaire is annexed to this chapter.
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Cannabis use and polydrug use
The study shows that cannabis cases for the most part have been using cannabis for 
more than 5 years before entering treatment. Fifteen respondents (37 %) reported that 
all or the majority of the cannabis cases had been using for 5 years or more before 
entering treatment. Nevertheless, cannabis use for less than 5 years was also reported. 
Two respondents reported that the majority of their cannabis cases had used cannabis 
for less than a year and seven respondents (22 %) reported that half of their cannabis 
cases had used cannabis for this period.
In this study the respondents were asked to report on cannabis cases, meaning people 
in their agencies who received treatment mainly for their cannabis consumption. This 
does, however, not exclude the possibility that the cannabis cases also use other drugs. 
Indeed, as shown in the epidemiological section of this issue, polydrug use is far from 
the exception in regards to cannabis consumption (Table 5).
In terms of substance use other than cannabis, the majority of the respondents reported 
that heavy use of cigarettes (more than 20 per day) occurred very often among their 
cannabis cases. Heavy use of alcohol was reported very often by slightly fewer agencies. 
Only one respondent reported that heavy use of cigarettes never occurred, and no 
agency reported that heavy use of alcohol never occurred among their clients.
All other substances were reported as less often used. Cocaine, for instance, was 
reported as very often used by only two of the agencies. This substance was, however, 
reported as sometimes used by the majority of the agencies. Nine agencies also 
reported that cocaine was never used by the cannabis clients.
Table 5: Reported level of other substance use than cannabis among the 
cannabis cases
n 1: very often 
used, % (n)
2: sometimes 
used, % (n)
3: never used, 
% (n)
a Heavy use of alcohol (38) 45 (18) 55 (20) 0
b Heavy use of cigarettes 
(more than 20 cigarettes 
per day)
(40) 63 (25) 35 (14) 3 (1)
c Cocaine (40) 5 (2) 73 (29) 23 (9)
d Amphetamines (40) 20 (8) 68 (27) 13 (5)
e Ecstasy/hallucinogens (40) 15 (6) 80 (32) 5 (2)
f Heroin (40) 8 (3) 50 (20) 43 (17)
g More than three different 
substances
(39) 8 (3) 64 (25) 28 (11)
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Use of amphetamines, hallucinogens and ecstasy were also more often reported as 
sometimes used than very often used. A majority reported that amphetamines were 
sometimes used by the cannabis clients and almost all the agencies reported that 
hallucinogens and ecstasy were sometimes used by the cannabis clients. Also important 
to note is that five agencies reported that amphetamines were never used, and two 
agencies reported that hallucinogens and ecstasy were never used by the cannabis 
cases.
Heroin use seems to be less prevalent among the cannabis cases, but still a substantial 
part of cannabis users seems to use heroin sometimes. Half of the respondents reported 
that the substance was sometimes used by cannabis clients. Nevertheless, also a 
substantial amount reported that heroin was never used by the cannabis clients.
Evidently, cannabis users in treatment tend to be polydrug users, although 11 informants 
indicated that three or more different substances were never used at the same time.
General trends in cannabis cases
According to the informants’ evaluation, there has not been a decrease in cannabis 
cases in the agencies. Twenty-nine respondents (67 %) reported that there had been an 
increase the last 5 years, and 14 respondents (33 %) reported that there had been a 
stable number of cannabis cases in their agencies.
Thirty respondents (67 %) reported that there had been policy changes in their country 
towards cannabis use during the previous 5 years. These changes were overall reported 
as an increasing treatment emphasis and less emphasis on punitive approaches to 
cannabis users. Eighteen respondents reported that there had been more emphasis 
on treatment for cannabis users. Sixteen respondents reported there had been more 
attention to cannabis in treatment agencies, while 14 respondents reported that there 
had been emphasis on less punitive approaches. The policy changes do not, however, 
seem to follow a clear-cut unidirectional trend across Europe. Nine of the respondents 
described the policy changes in terms of more emphasis on punitive approaches 
(including respondents from Belgium, the Czech Republic, Denmark, France, Latvia, 
Austria, Poland and Switzerland).
Summary and conclusion
In this report, various themes in connection with cannabis treatment and cases in Europe 
have been discussed. Based on a small sample of treatment centres, this study is only 
meant to provide a few indicators concerning the current state of cannabis treatment 
in Europe, and the material is not suited for generalisations or comprehensive in-depth 
analysis.
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Overall, it seems that specialised cannabis treatment is a rare phenomenon in Europe 
today. Of the 41 centres which had cannabis cases, 23 had no programme exclusively 
for them. Thus, it can be concluded that many cannabis cases across Europe are treated 
within the same setting as persons with other drug problems. This may be regarded as 
problematic, especially in view of the above findings which indicate that cannabis cases 
are relatively young. Research shows that much drug treatment is built for the adult 
population and does not thereby fit younger ages, and supporting material is often 
based on adult patterns of substance use (regular alcohol use, heroin, cocaine) rather 
than adolescent patterns (primary use of cannabis and alcohol bingeing). It is also 
based on adult experiences (parenting, health problems and adult dialogue examples) 
rather than adolescent experiences (peer pressure and adolescent dialogue examples) 
(Dennis et al., 2002a,b). Another problem which may arise when cannabis cases are 
placed in the same setting as other drug users is stigmatisation and exclusion (Sloboda, 
1999).
While most people who use cannabis do not end up in treatment, there are those who 
do. Furthermore, it is evident that the demand for cannabis treatment is increasing. This 
may be due to any number of reasons: increased availability of treatment; an increased 
pressure to seek treatment; increased cannabis-related problems in the general 
population. Indeed, for the people who do end up in treatment it is not totally evident 
whether or not they actually have a cannabis problem. People might enter treatment due 
to pressures from friends, family or the criminal justice system. These complex issues 
are addressed in more detail by Simon (this monograph) but are also shortly touched 
upon in this study as the above findings indicate that there are many different referral 
channels of cannabis cases. Although there may be many cannabis cases that require 
treatment after awareness of personal cannabis problems, self-referral is not necessarily 
easily interpreted as such, as a person might seek treatment by himself after receiving 
demands from family, friends or the criminal justice system to do so.
Furthermore, it cannot be disregarded that increased cannabis treatment demand is 
an artefact of reporting measures. From this study, it is evident that polydrug use is 
common among cannabis cases, which is important in terms of how cannabis cases are 
registered. Indeed, since cannabis users also use other drugs, it cannot be discounted 
that the cannabis cases may have a complex substance use problem not derived solely 
from one substance. Many might be registered as cannabis cases, based on the criteria 
that cannabis is the drug used most frequently and most heavily. This criterion does, 
however, not exclude the possibility that they also receive or should receive treatment for 
other drug use.
According to the above results, cannabis treatment in Europe focuses on counselling 
about conditions in life in addition to counselling about cannabis use and relapse. 
Furthermore, a substantial proportion of the agencies reported that family therapy was 
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an important part of the treatment offered. In view of the heterogeneous make-up of 
cannabis cases, a variety of treatment offers is probably a useful approach, particularly 
as cannabis cases may have problems which are not directly related to cannabis use. 
Nevertheless, the effect of type of treatment offered should not be overemphasised. 
Indeed, as Bergmark (this monograph) highlights, there is no conclusive evidence for 
any specific treatment intervention for cannabis cases.
There are indications, on the other hand, that anything works, that the context of 
treatment and the individual’s choice to enter treatment is important to treatment 
outcome. A summary of cannabis treatment studies by the Beckley Foundation notes 
that the effectiveness of cannabis treatment is not yet clear, but that there is growing 
evidence that it may fulfil a useful role (Hunt et al., 2006). The report further remarks 
that there is evidence which notes that there may be reason to move towards individual 
and targeted treatment through focusing on ‘high risk’ groups and even genetic 
screening. Indeed, it is a seductive idea that screening and targeting individuals may 
create cannabis treatment effectiveness. In light of the above result, and in light of the 
scarce available information, it does, however, seem that individualised solutions is 
a simplistic way forward that overlooks the complicated horizon related to cannabis 
treatment indicators, embedded in societal disapproval, in criminalisation of cannabis 
use, polydrug use and the highly heterogeneous make-up of the relevant clientele. In 
sum, this report, together with other evidence, suggests that our current understanding 
of and available cannabis treatment is scarce and a much more in-depth understanding 
of the relevant issues is needed.
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Questionnaire
Section A: Information on the agency and key-informant
In this section we would like to ask you some questions about your agency, and yourself 
and your position in the agency.
 A1 Please give your agency’s name and address.
 A2 Please give your position in the agency.
 A3 What is your profession?
a Nurse
b Social worker/youth worker
c Clinical psychologist
d Psychiatrist
e Other medical doctor
f Other (please specify):                           
Section B: Information on the treatment programmes
In this section we would like to get information on the structure and the type of treatment 
agency you are working in.
 B1 How many patients/clients does your agency treat? You can answer this in whichever 
way you have the data:
a Number of ‘active’ patients/clients (currently in a treatment episode)
b Number of patients/clients seen in a week
c Number of patients/clients seen in a 12-month period
 B2 How many of the patients/clients at your agency do you treat in one of the following 
settings? Please tick off for each setting.
1: All 2: Many 
but not 
all
3: 
Approximately 
half 
4: A few 5: None
a In the field (e.g. street work, 
prison work)
b Ambulatory (e.g. outpatient, 
ambulatory counselling)
c Day clinic (at least 3 hours per 
visit)
d Short-term inpatient (≤ 1 month)
e Long-term inpatient (> 1 month)
f Other (please specify) 
Chapter 14
297
B3 Please specify the importance of the different tasks at your agency. Please tick off for 
each task.
1: Very 
important 
task
2: Important 
task
3: Relatively 
unimportant 
task
4: No task 
at all/not on 
offer
a On-the-spot psychosocial 
crisis intervention
b Short-term psychosocial 
interventions: short-term 
counselling
c Long-term psychosocial 
interventions: long-term 
counselling
d Long-term rehabilitative 
drug therapy: long-term 
psychotherapy 
e Medical intervention for 
somatic problems
f Detoxification
g Harm reduction (e.g. syringe 
exchange, educating safer-use 
strategies, etc.)
h Methadone or buprenorphine 
substitution
i Heroin prescription
j Naltrexone prescription
k Other (please specify)           
Section C: Information on cannabis treatment
In this section we would like to get information on treatment programmes for cannabis 
cases at your treatment centre. A treatment programme for cannabis cases is defined 
as any treatment at your agency directed towards persons who are receiving treatment 
first of all for their cannabis consumption. By cannabis cases we mean persons who are 
enrolled at your agency mainly for their cannabis consumption. Hence, we do not want 
you to include patients with, for instance, heroin abuse problems who also use cannabis.
 C1a At your treatment centre, are there currently any cannabis cases?
Yes
No
C1b If no, please jump to section E of the questionnaire. If yes, please proceed to the next 
question.
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C2 Approximately what proportion of the patient case load at your agency are cannabis 
cases?
a 0–10 %
b 11–25 %
c 26–50 %
d 51–75 %
e 76–100 %
C3 In which setting(s) are cannabis cases at your agency treated? More than one option 
is possible.
a In a unit/service exclusively for cannabis cases
b In a programme within a unit not exclusively for cannabis cases
c As individual cases among drug users of all sorts
d Other (please specify) ______________
C4 What is the average number of treatment sessions that cannabis cases at your 
treatment centre attend in the course of a treatment episode?
________sessions per client/patient
C5 What are the aims for treatment of cannabis cases at your agency? Please tick off one 
box for each aim.
1: very 
important aim
2: important 
aim
3: relatively 
unimportant aim
4: no 
aim at all
a Abstinence
b Reduction of cannabis 
use
c Harm reduction or 
solving practical life 
problems (no attempt 
to change cannabis 
consumption)
d Other (please specify)  
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C6 To what extent does the treatment centre emphasise the following interventions for 
cannabis cases? Please tick off for each intervention.
1: Main part of 
treatment
2: Regular part of 
treatment
3: Not a part of 
treatment
a Detox from cannabis
b Peer group counselling
c Individual counselling
d Family therapy/counselling
e Milieu therapy/therapeutic 
community
f Talk therapy/counselling about 
cannabis, relapse and treatment
g Talk therapy/counselling about 
conditions of life (relationship 
problems, aggression training, 
etc.)
h Practical help with daily life (to 
get social allowances, clothes, 
housing, education, job)
i In-patient treatment
j Mutual help group (e.g. Narcotics 
Anonymous)
k Other (please specify)  
        
Section D: Information on the ‘typical’ cannabis case
In this section we wish to obtain information about how your typical cannabis cases can 
be characterised.
D1 What is typically the percentage of males among cannabis cases at your agency?
Male: ______ %
D2 According to your experience, how many cannabis cases are receiving help for their 
substance use for the first time in their life when they come in contact with your 
agency?
_________ % of cannabis cases treated in our agency.
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D3 How many of the cannabis cases at your agency…
1: All 2: Majority 3: Half 4: Minority 5: None
a Are 20 years old or 
younger?
b Are between 21 and 30 
years old?
c Are 31 years old or 
older?
d Have been using 
cannabis for less than a 
year?
e Have been using 
cannabis for 5 years or 
longer?
D4 Typically, how common is it that the cannabis cases are referred from the following 
sources? Please tick off for each source.
1: Most common 2: Common 3: Not at all 
common
a Self-referral
b Client’s/patient’s family/friend
c School
d Work
e General practitioner (family doctor)
f Psychiatrist/psychologist/social 
worker (out-patient or private 
practice)
g Courts, probation, parole, police
h Drug counselling agency or drug 
treatment unit
i Other (please specify)  
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D5 According to your experience, how common are the following situations for cannabis 
cases before they enter treatment at your agency? Please tick off for each situation.
1: Most 
common
2: Common 3: Not at all 
common
a Were homeless
b Lived in a sheltered environment (e.g. 
home for psychiatric cases)
c Lived with their parent(s) or guardian(s)
d Lived alone
e Lived with friends
f Lived with their own family
g Went to school/university
h Dropped out of school
i Worked
j Were unemployed
k Had psychiatric problems
l Had health problems
m Had problems with the criminal justice 
system
n Had family problems
o Had financial problems
D6 Apart from cannabis, what are the most often used substances by cannabis cases? 
Please tick off for each substance.
1: Very often 
used
2: Sometimes 
used
3: Never used
a Heavy use of alcohol
b Heavy use of cigarettes  
(more than 20 cigarettes per day)
c Cocaine
d Amphetamines
e Ecstasy/hallucinogens
f Heroin
g More than three different substances
h Other substances
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Section E: Information on general cannabis-related trends
In this section we would like to obtain more general information related to cannabis 
than the above sections.
E1a According to your knowledge, how many units exclusively for cannabis cases are 
there in your city?
  (enter number)
E1b Please guess how many cannabis cases they treat altogether at one time.
   per week
I cannot even guess
E2 Please provide contact information for one or two other centres in your country that 
treat cannabis cases.
E3 Please evaluate the trend over the last 5 years. In regard to your agency, has there 
been:
a An increase in numbers of cannabis cases
b Stable numbers of cannabis cases
c A decrease in numbers of cannabis cases
E4a Please evaluate the trend over the last 5 years. In your country, has there been any 
policy change towards cannabis use?
Yes
No
E4b If yes, which of the following options best describe the change? More than one option 
is possible.
a More emphasis on treatment for cannabis users
b Less emphasis on treatment for cannabis users
c More emphasis on punitive approaches towards cannabis users
d Less emphasis on punitive approaches towards cannabis users
e More attention to cannabis in treatment agencies
f Less attention to cannabis in treatment agencies
E5 In your opinion, which alterations or developments would be desirable for a better 
treatment of your cannabis cases?
E6 We would be grateful for any further comments or observations. If you have any 
please indicate them below.
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Chapter 15
Has treatment demand for 
cannabis-related disorders 
increased in Germany?
Keywords: cannabis – epidemiology – Germany – treatment – treatment demand
Setting the context
In Europe around 65 000 treatment demands were reported in 2005 where cannabis 
was cited as the primary reason for entering treatment (1). Cannabis use is the primary 
reason for entering drug treatment in about 20 % of all cases and 29 % of new treatment 
demands, making it the next most commonly reported drug in European treatment 
centres, after heroin. There are interesting variations between countries, with cannabis 
being cited by less than 5 % of all clients reported as entering treatment in Bulgaria, 
Lithuania, Poland and Romania and by more than 30 % in Hungary and France. For 
the remaining countries, in 12 European countries, the proportion of cannabis clients is 
between 5 and 20 % and in seven it is between 21 and 29 % (EMCDDA, 2007).
What has fuelled anxiety among policymakers is not that treatment demands are 
unmanageable. A figure of 65 000 treatment demands is a relatively small proportion 
of current cannabis users (13.4 million last month cannabis users in Europe), amounting 
to less than one in every 200 last month cannabis users. Moreover, the risk of entering 
treatment would seem to increase as cannabis use becomes more intensive. Cannabis 
clients in treatment in Europe can be divided into three groups: those who use it 
occasionally (34 %), those using it once to several times a week (27 %) and those using 
it daily (39 %). On a more general level, the 65 000 cannabis treatment demands may 
be compared with the 130 000 treatment demands for opioid use, from an estimated 
population of 1.3–1.7 million problem drug users in Europe: a demand rate of 
approximately 1 in 10. Additionally, given the resource-intensive treatment required by 
opioid clients, as opposed to the outpatient/short intervention norm for cannabis (see 
Rödner Sznitman, this monograph), it is clear that drug treatment should reflect the 
proportional risks of different licit and illicit substances.
 (1) Source: EMCDDA Statistical Bulletin 2007. Data available from 21 countries.
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That said, a worrying trend is that, between 1999 and 2005, the total numbers of 
both new and all reported cannabis treatment demands in Europe have approximately 
trebled. And while the most recent data suggest that this trend may be stabilising in 
some countries, the fact remains that an increasing number of cannabis clients are 
entering drug treatment services. While cannabis-specific treatment options are available 
in Europe today, many drug treatment services have been developed to target ‘problem 
drug users’; that is, those injecting opioids or reporting long-term dependence with 
amphetamines, crack and cocaine. The surge in demand for cannabis treatment thus 
implies a need to develop or adapt existing services towards cannabis client profiles (see 
Montanari, Griffiths and Taylor, this monograph).
The rise in treatment demands is not easy to explain on a European level. Nonetheless, 
some countries have sought to examine, and re-examine, the nature of cannabis 
treatment demand in more detail. One of these countries is Germany. This chapter 
suggests that the reported 500 % increase in cannabis treatment demand between 1992 
and 2003 in Germany reflects a genuine increase in clinically diagnosable cases of 
cannabis use disorders. Alternative hypotheses to explain a rise in treatment demand 
— which might have included changing drug policy priorities, misdiagnosis, ‘coercion’ 
into treatment via referrals, new reporting mechanisms and data collection — were not 
considered significant. The chapter also reveals the type of problems experienced by 
those in treatment for cannabis problems in Germany.
Such a far-reaching ‘revisit’ of treatment demand data is useful for building a clearer 
picture of treatment populations, for validating results, for challenging assumptions and 
for checking the quality of data. One cause for optimism is that such ‘deep’, secondary 
analyses of treatment demand are increasingly common across Europe, enabling higher 
responsiveness to changing drug consumption patterns, both for cannabis and other 
drugs.
Further reading
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Has treatment demand for 
cannabis-related disorders 
increased in Germany?
Roland Simon and Ludwig Kraus
Summary
First indications in Germany suggested an increase in treatment demand for primary 
cannabis-related problems. These led the German National Addiction Aid Statistics 
(DSHS) and a research study (CARED) to analyse treatment demands. The results showed 
an increase of roughly 500 % in treatment admissions in outpatient treatment for this 
group in Germany between 1992 and 2003. Three-quarters of these cases fulfilled the 
clinical criteria of a cannabis-related disorder as defined by ICD-10 (F12.1, F12.2x). The 
remaining cases did not reach this level of clinical significance, but might indicate minor 
cannabis-related problems. Where multiple diagnoses exist, no indication was found 
that cannabis was assigned as primary drug incorrectly. As the increase in treatment 
admissions was similar for most types of referrals, changes in treatment admissions 
were very likely not caused by changing treatment availability or external pressure but 
by a genuine increase in treatment need. While last year prevalence of cannabis use 
increased considerably in the population between 1992 and 2003, treatment admissions 
in outpatient centres grew even faster, and it will be necessary to adapt the treatment 
system in Germany to this increasing group of clients.
Introduction
While for decades cannabis use has not been perceived as a problem by many 
addiction therapists and researchers, recent results from basic research as well as from 
clinical and social epidemiology support a more cautious position, which assumes a 
higher risk potential of cannabis, at least for some subgroups of users (Hall and Solowij, 
1997; INSERM 2001; Witton, this monograph, vol. 2). Hall, Degenhardt and Teesson 
(2004), for example, reported that while there is no support for the hypothesis that 
cannabis causes psychotic disorders, there is evidence that cannabis use can precipitate 
schizophrenia and that cannabis use exacerbates psychoses. Patton et al. (2002) found 
a fourfold increase in the risk of depression and anxiety disorders among girls using 
cannabis on a daily basis.
First indications that outpatient treatment demands for primary cannabis-related 
problems might increase were reported by the German National Addiction Aid Statistics 
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(DSHS) in 2000 (Welsch, 2001). An increase in treatment demand could reflect the 
parallel rise in treatment need resulting from an increase in cannabis use as reported 
by population surveys (Kraus, Augustin and Orth, 2005). It is well known that drug 
treatment in Germany primarily focuses on injecting heroin users. Changes in treatment 
needs for cannabis-related problems would, therefore, require modifications in the type 
and organisation of treatment services provided. Increases in treatment demands within 
this group would also have implications for cannabis policy.
A number of possible factors that may have influenced treatment statistics were analysed 
to validate the assumption of a genuine and not artificial increase in treatment demand 
for cannabis-related disorders in outpatient care. The data analysed were derived from 
the DSHS, results from a recent epidemiological survey (Kraus and Augustin, 2005) and 
from a study on cannabis-related disorders (CARED), conducted between 2001 and 
2004 (Simon et al., 2004). Artificial effects might have arisen from invalid diagnoses 
assigned by therapists in their daily work. As most of the staff have social work or 
psychology as a professional background, but no medical training, incorrect diagnoses 
might be assigned to clients. Other external factors might have explained the increase 
in treatment demand, such as increases in availability or accessibility of treatment, or 
increased judicial referrals into treatment. The main questions to be addressed were:
Had there been an increase in treatment demand for primary cannabis-related •	
problems?
Were diagnoses for cannabis-related problems valid?•	
Were there other external or confounding factors that could have caused the •	
observed increase?
How was the increase in treatment demand related to drug use trends in the •	
population?
Methodology
German Addiction Aid Statistics (DSHS)
In Germany, national monitoring of drug treatment is based on the German core item 
set (Kerndatensatz, referred to below as ‘KDS’). Within the ‘client and treatment’ module, 
the complete set of items from the EMCDDA’s treatment demand indicator (TDI) protocol 
are used (EMCDDA, 2000). Drug use is assessed on the basis of ICD-10 criteria (WHO, 
1994). Under the KDS, diagnoses can be made for each psychoactive substance 
(ICD-10, F10–F18), provided the criteria of harmful use or dependence syndrome are 
fulfilled. In case of multiple diagnoses the diagnosis related to the drug that causes the 
most severe problems (‘primary drug’) is selected as the ‘main diagnosis’. The choice 
of diagnosis must be based on the intensity and frequency of use of the drug as well as 
on its negative consequences. Full operationalisation of such classifications, however, is 
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not part of the KDS standards. In addition, for the classification of clients the code F19.x 
(multiple drug use) was generally avoided in the German monitoring system when the 
study took place.
Aggregate data from the treatment centres are collected on an annual basis and were 
reported by the German Addiction Aid Statistics (DSHS) for the years 2001 to 2003 
(Welsch, 2002; Welsch and Sonntag, 2003, 2004), while EBIS statistics were reported for 
the years before 1999 (e.g. Türk and Welsch, 2000). Analysis started in 1992 because 
changes in classification of disorders and substances were introduced in that year. In 
addition, data from the new Länder (2) of the former German Democratic Republic were 
included in the common statistics from 1992 onwards, making comparisons with data 
from earlier years impossible.
The CARED study
The study on cannabis-related disorders (CARED) was conducted in a random sample of 
52 outpatient treatment centres participating in the DSHS. All of them used a common 
technical system for data collection (EBIS). All clients (n = 223), who had been treated 
in these centres during the year 2001 and who fulfilled the criteria of a ‘cannabis 
client’ (referred to below as ‘CC’), were included in a paper-based retrospective survey. 
Inclusion criteria were:
 1 A diagnosis of ‘harmful use’ or ‘dependence syndrome’ related to cannabis (ICD-10, 
F12.1 or F12.2) provided by the DSHS
 2 Cannabis being the only or the primary drug (‘main diagnosis’).
A second group (n = 51) of ‘cannabis clients’ (CCs), who had been in treatment between 
December 2002 and October 2003 in the same units, was assessed during treatment 
using a computer-based clinical interview. Diagnoses were based on ICD-10 and 
DSM-IV as assessed by DIA-X (Wittchen and Pfister, 1997). The participation rate in the 
first group was 40 %. For the second group a rate could not be calculated as the total 
number of cannabis clients in treatment during this time period had not been reported 
by the treatment facilities. As part of the CARED study, therapists (n = 183) from the 
participating centres were also asked in a questionnaire about details of the process of 
assigning diagnoses and their experience with cannabis clients.
 (2) Germany is divided into 16 federal states, or Bundesländer. The six Länder of the former East 
Germany that joined in 1990 are Berlin, Brandenburg, Mecklenburg-Vorpommern, Sachsen, 
Sachsen-Anhalt and Thüringen.
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Results
Increase in treatment admissions
The absolute number of clients starting outpatient treatment with a primary cannabis-
related problem (CCs) was examined for the years 1992–2003, as well as the 
proportion of this group among the total group of clients. In 2003, 699 treatment 
centres reported main diagnoses for 106 816 clients to the national treatment 
monitoring system (DSHS), of whom 10 169 or 9.5 % were diagnosed as CCs. This 
group comes third behind alcohol (59.6 %) and opiates (19.8 %). The absolute number 
of CCs increased over this 12-year period and the proportion within the treated clients 
reached 9.5 %, starting at only 2.1 % in 1992 (Table 1).
Participation in the DSHS being voluntary, the number of reporting facilities varied over 
time, ranging from 170 in 1992 to 699 in 2003. In order to make absolute numbers 
of cases comparable between reporting years, the number of clients reported was 
extrapolated to the total number of 1 049 outpatient treatment centres in Germany as 
reported for 2001 (Bundesministerium für Gesundheit, 2002) (3).
The estimated total numbers of admissions for all outpatient treatment centres in 
Germany show an increase in CCs of nearly 600 % between 1992 (n = 2 561) and 2003 
(n = 15 261). A breakdown by gender, which was possible for the years 1999–2003, 
indicates similar developments for male and female clients. The proportion of women 
among CCs increased slightly from 16.8 % in 1999 to 18 % in 2003 (Figure 1). Thus, 
between 1992 and 2003 a clear increase in total treatment admissions was found in 
Germany for clients with a primary cannabis-related problem.
 (3) Two limitations need to be mentioned with regard to the calculations. The total number of 
facilities only includes units which are financially supported by the Länder, which results in an 
underestimation of total demand for Germany as a whole. The majority of units in Germany, 
however, are funded by the Länder (Welsch and Sonntag, 2004) and, thus, the resulting total 
should not be significantly below the real number of CCs. In the same way, using the number of 
units for 2001 as an estimated total, as opposed to the annual figures, might cause errors. Exact 
data were available only for the years 1996–2003. Inspection of this period shows no major 
trend in number of reporting units and, apart from the year 2002, the totals range between 951 
and 1 049 units. No general legal or financial changes took place during this period that might 
have changed the number of treatment units. Given all these facts, the number of facilities in 
2001 may serve as a proxy for this calculation.
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Validity of diagnoses
Diagnosis according to ICD-10
The validity of the observed trend in treatment admissions strongly depends on the 
quality of diagnoses based on the DSHS. This system requires an ICD-10-based 
classification of substance-related disorders. As part of the CARED study the diagnoses 
assigned by the treatment centres’ staff were validated by comparing them to diagnoses 
reassessed by standard instruments (CIDI, DIA-X). For this purpose, questionnaires 
(n = 223) and clinical computerised interviews (n = 51) were conducted and diagnoses 
assigned in compliance with the ICD-10 criteria.
In validation studies the results of a diagnostic instrument (test) are generally compared 
with an observed outcome (e.g. disease). Presented in a two-by-two table, results can 
be assessed for (i) correct classifications, that is, cases that were correctly identified to 
have or not to have the disease, and (ii) incorrect classifications, that is, cases that were 
incorrectly classified by the test instrument as having the disease (false positives) and 
those cases that were incorrectly classified as not having the disease (false negatives). 
In this validation, the test instrument was defined as the ‘gold standard’ (i.e. for 
ascertaining the presence or absence of cannabis-related disorders) and the diagnoses 
selected by the treatment centres as the instrument to be validated. Since the monitoring 
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Figure 1: Admissions of clients with primary cannabis-related problems in German 
outpatient treatment centres, 1992 to 2003
Source: EBIS reports 1994–2001 (Türk and Welsch, 2000); German Addiction Aid Statistics (Welsch, 
2001, 2002; Welsch and Sonntag, 2003, 2004).
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Table 2: Diagnoses in standard monitoring of treatment centres compared to 
diagnoses based on questionnaires or clinical interviews (ICD-10)
No diagnoses  
(%)
Harmful use ICD-10 
(%)
Dependence ICD-10 
(%)
Validation diagnoses based on
 Questionnaire 
(n = 136)
14.1 17.0 69.6
 Interview (n = 39) 25.6 15.4 59.0
Source: Simon et al. (2004).
system only reports positive cases of CCs, the resulting validation is incomplete: only 
those cases can be observed that were correctly or incorrectly (false positives) classified 
by therapists as having the disease (cannabis-related disorder). Self-evidently, the cases 
that were correctly or incorrectly (false negatives) classified by the therapists as not 
having a cannabis-related disorder were not observable.
Table 2 shows the results of the validation analysis. Overall, 25.6 % of the clients were 
classified as not having a diagnosis of either harmful use or dependence if assessed by 
interview. Looking at the results from the opposite direction, 74.4 % of the cases were 
found to fulfil criteria of a clinical diagnosis.
Compared with the original diagnoses of dependence, where 62.5 % of the diagnoses 
were consistent, assessments were less in accordance with ICD-10 criteria if the client 
had received the diagnosis ‘harmful use’ (14.3 %). Clients with an original diagnosis of 
‘harmful use’ received more frequently a diagnosis of ‘dependence’ than a diagnosis of 
‘harmful use’ (42.9 %). Overall, distinguishing between ‘dependence’ and ‘harmful use’ 
in standard diagnostics is much less reliable than the general decision, whether CCs 
meet clinical criteria or not. On the whole, this might partly be a result of problems with 
the two-dimensional concept of ‘abuse’ or ‘harmful use’ and ‘dependence’ (Fulkerson et 
al., 1999).
For more than 74 % of the CCs, validation showed that clinical criteria with respect to 
cannabis were fulfilled, and either ‘harmful use’ (F12.1) or ‘dependence syndrome’ 
(F12.2x) was the resulting diagnosis. Up to one-quarter of the CCs reported by 
outpatient treatment centres might have cannabis-related problems that are below 
clinical relevance. Discriminating between ‘harmful use’ and ‘dependence’, however, 
does not work well in practice, a problem that can be attributed, at least to some 
degree, to the intrinsic weakness of the concepts themselves.
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Table 3: Multiple diagnoses amongst cannabis clients (tobacco-related 
diagnoses excluded)
Questionnaire based  
(n = 184)
Interview based  
(n = 33)
Substance-related diagnoses % %
Cannabis only 33.7 63.6
+ alcohol 15.2 21.2
+ amphetamines/ecstasy 12.0 6.1
+ cocaine 3.8 0.0
+ alcohol + amphetamines/ecstasy 7.6 6.1
+ alcohol + cocaine 2.2 3.0
+ alcohol + amphetamines/ecstasy + cocaine 8.2 0.0
Other combinations 17.4 0.0
Source: Simon et al. (2004).
Main diagnosis and other psychoactive substances
CCs classified with a cannabis-related diagnosis need not only fulfil ICD-10 criteria. 
Cannabis should also be the main substance in cases where other substance-related 
diagnoses are present, and the possibility that cannabis is used as a ‘label’ for clients 
with other problems should be ruled out. In order to examine this question, the 
validation analysed the prevalence of other substance-related diagnoses in the group of 
CCs, and the criteria used to determine the main diagnosis.
This analysis of multiple diagnoses of primary cannabis clients revealed that no other 
substance-related disorders were found in almost two-thirds of the clients. A combination 
of cannabis- and alcohol-related disorders was found in 21.2 % of clients. While in most 
cases alcohol was involved, disorders related to stimulants without alcohol problems 
accounted for roughly 16 % of multiple diagnoses (Table 3).
Therapists reported that the decision about the main diagnosis was based on the 
consequences (65.7 %), patterns (59.3 %) and frequency of cannabis use (41.3 %). This is 
in line with the criteria that are also defined in the KDS for this classification. As no exact 
algorithm has been defined by the standards, validation cannot go beyond this basic 
check.
A considerable number of CCs (nearly two out of three) showed an exclusive cannabis-
related diagnosis. The substance which plays the most important role after cannabis 
in the group of CCs is alcohol. It is not very likely that a cannabis-related diagnosis 
is used to hide alcohol problems. In the diagnostic process, therapists apply criteria 
as defined by ICD-10 and the national KDS. Thus, the classification of cannabis as a 
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main substance seems to be based on empirical evidence and appropriate procedures. 
While single cases of misclassifications may be possible, CCs may not be judged as 
mislabelled in relation to other psychoactive substances.
Main diagnosis and other mental disorders
The same type of misclassification as discussed for substance-related diagnoses could 
also take place in relation to non substance-related mental disorders. In such cases, the 
main problem of the clients in treatment might for example be psychosis, while cannabis 
problems might be only marginal. In order to analyse this question, prevalence of such 
diagnoses amongst CCs, as well as the correlation between disorders and the severity of 
cannabis-related disorders was analysed. Data are sourced from the clinical interviews 
of the CARED study which assessed a number of mental disorders (last 12 months) 
which are well known to be correlated with cannabis consumption (Hall and Solowij, 
1997).
For CCs a number of such disorders was found. Close to 40 % showed mood disorders, 
most often dysthymia (17.3 %). More than one-third of the clients showed phobic 
disorders, and one out of eight showed anxiety disorders. There was a high rate of 
social phobia (17.3 %) and nearly 11 % of the clients suffered from psychotic disorders. 
Diagnoses F06.X were exclusively based on organic factors, including acute effects of 
drugs (Wittchen and Pfister, 1997). The majority of psychotic disorders and about one-
third of the anxiety disorders and affective disorders were, therefore, more closely linked 
to drug use and may have been only of a short-term nature (Table 4).
Besides psychotic disorders, all diagnoses showed a high correlation with the severity of 
the cannabis diagnosis. Only a few cases of ‘phobia’ and ‘mood disorder’ were found 
where a cannabis-related diagnosis could not be validated. For these cases the basic 
problem might not be a cannabis-related disorder but another psychiatric problem 
(Table 5).
There is considerable prevalence of other psychiatric disorders amongst clients, which 
reflects a close relationship between cannabis use and psychiatric comorbidity found 
elsewhere (Hall and Solowij, 1997). As the majority of cases are linked to a validated 
classification of ‘cannabis dependence’, no misclassification arises from this, but rather 
these cases show additional problems which need to be taken into account and treated 
for this group of clients.
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Table 4: Other mental disorders according to DSM-IV (clinical interview, n = 51)
Group of disorders DSM-IV 
code
Diagnoses %
Psychotic disorders 10.9
F06.0 Psychotic disorder with hallucination 4.3
F06.2 Psychotic disorders with delusion 7.8
F23 Short psychotic disorders 2.2
Mood disorders/depression 39.1
F06.32 Affective disorders with characteristics of 
depression
10.9
F32.x MDD, single episode 4.4
F33.x MDD, multiple episodes 13.0
F34.1 Dysthymia 17.3
Anxiety disorders 15.2
F06.4 Anxiety disorder 4.3
F06.42 Panic attacks 10.9
F41.0 Panic attacks without agoraphobia 2.2
F41.1 Generalised anxiety disorder 0.0
Phobia 37.0
F40.0 Agoraphobia without panic attacks 10.9
F40.01 Panic disorders with agoraphobia 13.0
F40.1 Social phobia 17.3
F40.21 Animal phobia 6.5
F40.22 Environmental phobia 6.5
F40.23 Blood phobia 6.5
F40.24 Specific phobia 4.3
Source: Simon et al., 2004.
Table 5: Groups of other mental disorders (DSM-IV) and cannabis diagnosis 
(ICD-10) (clinical interview, n = 46)
Cannabis-related diagnoses
Disorders (DSM-IV) Total (%) None (%) Harmful use (%) Dependence (%)
Psychotic disorders 10.9 16.7 14.8
Mood disorders 39.1 7.7 33.3 55.6
Anxiety disorders 15.2 25.9
Phobia 37.0 23.1 51.9
Source: Simon et al. (2004).
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Figure 2: Client admissions in outpatient treatment by main drug, 1992 to 2003 
(1992 = 100 %)
Source: EBIS reports 1994–2001 (Türk and Welsch, 2000); German Addiction Aid Statistics (Welsch, 
2001, 2002; Welsch and Sonntag, 2003, 2004).
Other factors
Two external factors were discussed, which might have influenced the increase in CCs: 
one relates to a general increase in treatment admissions, the other to changes in 
referral procedures.
Overall increases in treatment admissions
Possible explanations for the increase in cannabis-related treatment admissions could 
be an overall improvement in (i) treatment availability; (ii) accessibility; or (iii) quality 
of services provided. For the years under inspection no general changes in drug policy, 
treatment standards or funding conditions could be observed in Germany, which may 
have increased the availability of or accessibility to treatment for drug users. So, the 
increase in cannabis-related treatment admissions cannot be attributed to these external 
factors.
This position is supported by data on treatment admissions for other substance-
related disorders involving other drugs. A general positive shift in treatment quality 
or availability would most likely have increased the number of clients for all different 
substances alike. However, as shown in Figure 2, relative to the year 1992, the number 
of cannabis clients in 2003 increased sixfold, the number of clients with stimulants-
related problems more than fourfold, while the number of clients with alcohol- and 
opioid-related problems — the main focus of treatment services up to that time — only 
showed a slight increase.
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This clear increase found for CCs clearly exceeds the general trend for total treatment 
admissions and exceeds all other substances besides ecstasy. Apart from the fact that 
the absolute numbers of ecstasy-related disorders are still small, ecstasy was frequently 
miscoded by the treatment centres under ‘other substances’, which might have inflated 
the rates artificially. This means that there is no indication of a general increase in 
treatment availability. Staff measured in full-time staff member equivalents between 
1996 and 2003 only increased by 1.2 %, which also makes it clear that treatment 
availability did not change dramatically during the reporting period.
Changes in referral procedures
An increase in treatment admissions might also be the consequence of changes 
in referral procedures. If, for example, the Narcotic Drugs Act was enforced more 
rigorously than before, treatment admissions would rise without any changes taking 
place in the underlying medical or psychological treatment needs in the population. In 
order to examine this type of effect, data on treatment referrals from the years 1998 to 
2003 were examined.
In 2003 more than 70 % of all clients entered treatment through three main pathways: 
20 % were ‘internally motivated’ (self-motivated) and came directly to the treatment 
facilities; 25 % were motivated by family or friends and 27 % were referred through 
judicial or police authorities. While compared with 1998 the total number of cannabis 
clients in 2003 increased by 118 %, the number of clients who came directly into 
treatment increased by 96 %, referrals through justice or police by 109 %. The biggest 
increase was due to referrals through other counselling services (Table 6).
Table 6: Access to outpatient treatment for cannabis clients
Compared with 1998 (= 100 %)
Referrals into treatment 2000 2001 2002 2003 Referrals in 
2003 (%)
No referrals/direct access 129 141 161 196 21.5
Relatives/friends 141 153 178 195 24.5
Job/school 118 151 175 214 6.4
GP/psychotherapist 127 158 195 195 3.4
Hospital 158 182 240 236 1.7
Inpatient addiction facility 141 86 166 244 1.9
Drug counselling 149 137 239 338 1.5
Other counselling services 296 412 514 514 8.8
Justice/social administration 105 114 196 209 26.3
Others 161 207 275 286 4.1
Sources: EBIS reports 1994–2001 (Türk and Welsch, 2000); German Addiction Aid Statistics (Welsch, 2001, 2002; 
Welsch and Sonntag, 2003, 2004).
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The hypothesis that the increase in treatment admissions of CCs was caused to a large 
extent by increasing pressure from law enforcement and social administration is not 
supported by these data. Instead, treatment admissions have increased more or less at 
the same extent for a number of types of referring institutions. The biggest increase was 
found for referrals by other counselling services, which might indicate better networking 
that facilitated access to drug treatment for cannabis users though these channels.
Trends in treatment demand and prevalence of cannabis 
use in the population
Survey data indicate that the observed increase in treatment admissions for cannabis-
related disorders was accompanied by a constant increase in the prevalence of 
cannabis use in the general population. Between 1992 (15 %) and 2003 (33 %), lifetime 
prevalence of cannabis use was found to have significantly increased by a factor of two. 
In the same time, last year prevalence (4 % in 1992, 12 % in 2003) increased by a factor 
of three (Kraus, Augustin and Orth, 2005).
Population estimates of recent users (last 12 months) aged 18–29 years derived from 
cross-sectional surveys in 1990/92, 1995/97, 2000 and 2003 were compared with the 
estimated number of cannabis clients for the respective years. Survey data for 1990 
were taken as proxy for 1992. The number of recent cannabis users increased from 
935 000 in 1992 up to 2 105 000 in 2003. In the same period the number of clients 
treated for cannabis-related problems within a 1-year reporting period (admissions plus 
takeover from the year before) increased from 4 353 to 25 485 cases. The ratio of recent 
users in contact with outpatient treatment did not remain constant but increased at a 
disproportional rate. While, in 1992, 4.7 clients per 1 000 recent users were admitted 
for treatment, in 2003 12.1 users had entered treatment (Table 7).
Another way of comparing trends of recent cannabis use and treatment admissions 
is shown in Figure 2. Normalising the numbers of cannabis users and treatment 
Table 7: Estimated number of annual cannabis users and clients
1992 1995 2000 2003
Cannabis users (12-month 
prevalence, 18–29 years)a
935 000b 1 590 000 1 918 000 2 105 000
Cannabis clientsc 4 353 5 246 16 112 25 485
Number of clients per 1 000 users 4.7 3.3 8.4 12.1
aSource: Kraus, Augustin and Orth, 2005.
b1990 survey.
cSource: EBIS reports 1994–2001 (Türk and Welsch, 2000); German Addiction Aid Statistics (Welsch, 2001, 2002; 
Welsch and Sonntag, 2003, 2004).
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Figure 3: Prevalence of last year cannabis use and cannabis clients since 1992
Source: EBIS reports 1994–2001 (Türk and Welsch, 2000); German Addiction Aid Statistics (Welsch, 
2001, 2002; Welsch and Sonntag, 2003, 2004).
admissions for the year 1992 to an index value of 100, the changes for the consecutive 
years can be presented as percentages relative to the year 1992. While treatment 
admissions increased by 500 %, the prevalence of recent use increased by only 190 % 
(Figure 3).
Both analyses show that the number of clients with primary cannabis-related problems 
in treatment (CCs) grew faster than the prevalence of recent cannabis use in the 
population. A direct comparison, however, is too simple a model, since a delay of 8 
years on average between start of use and entering treatment needs to be considered 
(Strobl et al., 2007).
Conclusions
A clear increase in treatment admissions for primary cannabis-related disorders in 
outpatient treatment was found in Germany between 1992 and 2003. The number 
of cases increased roughly by 500 %. Three-quarters of persons with cannabis-related 
diagnoses in the treatment statistics were diagnosed appropriately as cannabis-related 
disorders fulfilling clinical criteria. The remaining cases may have had cannabis-related 
problems, but did not reach the level of clinical significance. In cases where multiple 
diagnoses exist, information on the diagnostic process as well as prevalence of such 
diagnoses showed no indication that cannabis was assigned as main drug incorrectly. 
For logical reasons there is also no reason to call into question cannabis as main 
diagnosis for the majority of cases.
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Other factors which might have influenced treatment admissions have not been analysed 
here. In particular, a change in the perception of risks linked to cannabis might have 
increased cannabis users’ willingness to enrol in treatment. This, and other, hypotheses 
might be evaluated by future research. While in Germany and other countries cannabis-
related problems were historically seen as minor and of limited relevance for public 
health, public debate in recent years has begun to take this topic more seriously. It will 
be necessary to find a new balance for a treatment system that was tailored in the past 
mainly to serve the needs of injecting users of heroin. In this respect, the outcome of the 
CARED study is in line with the results of a city-based evaluation of treatment services in 
Hamburg (FOGS, 2006) as well as a regional study on treatment provision in Munich 
(Perkonigg et al., 2004). Given the high and partly still rising prevalence of cannabis 
use in many European countries, this might become a problem for other countries as 
well (EMCDDA, 2005, 2007).
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Chapter 16
Risk factors for cannabis use
Keywords: cannabis – prevention – protective factors – risk factors – sociology
Setting the context
Lists of risk factors and protective factors are common features in the prevention and 
treatment literature on cannabis and other illicit drugs. Both groups of factors could 
relate to an individual’s genetic make-up and personality, or to their familial, social and 
physical environment. It is beneficial to understand the range of factors that have been 
identified for cannabis. Moreover, it is not always easy to judge which factors carry more 
weight for cannabis, or to exclude factors that may not be relevant to a specific group of 
users’ context. The diagram below (Figure 1), adapted from a UK Home Office report, 
offers a simplified overview of risk and protective factors.
This chapter explores the risk factors associated with cannabis use. In doing so, a 
distinction is drawn between cannabis use per se and the development of problematic 
cannabis use. The chapter reveals that many factors are linked with problematic 
cannabis use, including genetic vulnerability to certain psychological conditions, early 
use of tobacco and alcohol, dysfunctional family relationships, behavioural problems, 
peer associations, family substance use and early initiation.
Further reading
UK Home Office (2007), Identifying and exploring young people’s experiences of risk, protective 
factors and resilience to drug use, Home Office Development and Practice Report, Stationery 
Office, London.
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Motivations not to use Other people’s motivations to use
Contextual riskFactors making it easier/more
difficult to refuse
Other people’s disapproval
Legal consequences
Alternative source of ‘buzz’
Personal experiences with drugs
Fear of losing control
Fear of affect on health
Alternative sources of
support/coping mechanisms
Role as a parent Following example
of others
Peer pressure
Alleviate boredom
‘To look hard’
To fit in
‘The buzz’
Reputation as
resilient to drug use With friends who
(don’t) use
when offeredType of drug offered
Reputation as a smoker/drinker
Being ‘drunk’
Offered by a friend/stranger
Age
‘Happy to be the odd one out’
In trouble with
the police/school
Familial substance use
Alcohol use
Problematic family
relationships
Boredom
Mental health issues
Frequenter of recreational
settings where drugs are sold
Unemployment Member of subgroup/
youth ‘tribe’ (e.g. clubber)
Feel more confident
Ease physical pain
Escape Curiosity about the effects
Fear of addiction
Financial cost
Financial cost
Role as a parent
Career aspirations
Figure 1: Overview of risk and protective factors
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Risk factors for cannabis use
Niall Coggans
Introduction
Much effort has gone into researching the factors that increase the likelihood of using 
drugs (risk factors) and the factors that decrease the likelihood (protective factors) (e.g. 
Hawkins et al., 1992; Lloyd, 1998; Rhodes et al., 2003). The factors that influence 
individuals and groups to use cannabis are numerous and operate at all levels, from the 
individual to the social. Greater awareness of these various factors should lead to more 
effective and more precisely targeted educational and health promotion interventions. 
The purpose of this chapter is to highlight the risk factors for cannabis use.
There are two issues in relation to the title of this chapter, risk factors for cannabis use, 
that require clarification: (i) what is a risk factor and (ii) in what way or to what extent is 
cannabis use a problem? First, the nature of risk factors. The term risk factor is widely 
used in public health to identify and describe individual or social predictors of disease or 
undesirable conditions/behaviour. Of particular interest from a public health perspective 
are those factors which it is possible to reduce through prevention interventions. This 
is also true for drug-related health problems, including cannabis-related problems. 
However, do risk factors cause drug use and/or drug-related problems, or are risk 
factors predictive in that they are statistically associated with the behaviour in question?
A cause of a drug-related problem is something that exists prior to the drug-related 
problem (the effect) and the occurrence of a prior event or state of affairs would ensure, 
or increase the likelihood, of the drug-related problem happening. An association, on 
the other hand, is where there is a relationship between a drug-related problem and 
some other event or state of affairs. The key distinction between cause and association 
is that an association does not imply causation. It may be that there is a causal 
relationship between two associated phenomena or that the association is due to a 
third factor. Where an association between a risk factor and a drug-related problem 
has been found, a number of issues need to be investigated to assess the relationship 
for causality, including consistency with other studies, plausibility, temporal sequence, 
dose–response and strength of association (Campbell and Machin, 1999).
Taken individually, risk factors are unlikely to be causal in a direct ‘if A then B’ manner. 
Moreover, individual risk factors for drug use are unlikely to be either necessary or 
sufficient for the emergence of drug use and/or drug-related problems. Many of the 
risk factors for drug problems are mediated through individual development and social 
interaction. Problematic drug use is therefore the result of a complex of different risk 
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factors which cumulatively increase the likelihood of drug use and/or problems. In other 
words, risk factors do not cause, but are associated with problematic cannabis use.
Second, to what extent is cannabis use a problem? In this discussion of risk factors 
related to cannabis use a distinction is made between experimental or recreational use 
of cannabis and cannabis use that is problematic. Problematic cannabis use is usually 
defined in terms of diagnosed cannabis dependence or substance use disorders using 
standard diagnostic criteria (for more detail see Beck and Legleye, this monograph), and 
often includes people in treatment programmes for their cannabis-related problems. 
Experimental or recreational cannabis use, on the other hand, is often understood as 
use which is not bound up in adverse social, mental or physical health effects for the 
user (Coggans et al., 2004).
The extent to which drug use is actually or potentially harmful to individuals will depend 
on the nature and purity of the drug concerned, mode of ingestion, and the pattern of 
its use by the individual. Cannabis use will not necessarily continue once started, as 
many will stop after a period of recreational use. For example, in a longitudinal study 
of a sample of German cannabis users, half stopped of their own accord in their 20s 
(von Sydow et al., 2001). Moreover, the majority of young people who smoke cannabis 
do not experience cannabis-related problems (see Witton, this monograph, vol. 2). It 
could be argued that the term ‘risk factor’ is inappropriate in relation to this apparently 
non-problematic form of cannabis use. While it might devalue the concept of risk factors 
by referring to risk factors in relation to behaviour that is seen as undesirable by some 
people, rather than behaviour with clearly manifested problems, there remains the need 
to recognise that those who do develop cannabis-related problems will emerge from the 
wider population of cannabis users. From a prevention perspective, there is, therefore, a 
need to work with existing cannabis users who may not have developed cannabis-related 
problems in order to reduce the likelihood of their doing so. It is important to distinguish 
between predictive factors related to cannabis use that is non-problematic and factors 
that predict cannabis-related problems.
Those who use cannabis heavily and for a substantial period of their lives are 
considerably fewer than those who have ever used cannabis (House of Lords Select 
Committee on Science and Technology, 1998). While those who do use cannabis heavily 
over long periods of time in adulthood may develop cannabis-related problems, such as 
dependence, it is not the case that such use will necessarily be perceived as problematic 
by the users concerned (Coggans et al., 2004). Although it is a truism that there is no 
such thing as a safe drug, occasional ‘light’ use of cannabis will carry little risk for large 
numbers of people. Nonetheless, some people do experience problems with cannabis. 
Moreover, there is also concern over the potential for cannabis use among young 
people to compromise healthy development.
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This chapter is not intended to be an exhaustive review of the field, but to provide 
an overview of the nature and scope of the risk factors that predispose people to 
problematic cannabis use, including routes to cannabis use, early initiation, social 
environment (family and peers), psychological risk factors, and the growing evidence of 
genetic risk factors. When reviewing the relevant literature, however, a problem arises, 
as much research on risk factors shows little concern for distinguishing harmful drug 
use from drug use in its own right. Moreover, it is argued here that there is a need 
for a coherent view of the difference between risky or non-risky cannabis use, or what 
constitutes problematic or non-problematic cannabis use. Thus, this chapter includes 
risk factors for different types of cannabis use, and this is a limitation to which more 
attention should be paid in future research.
The term ‘problematic cannabis use’ is employed here to mean cannabis use that gives 
rise to psychological, physiological or behavioural problems. It is not meant here to 
reflect only specific diagnostic criteria such as ICD-10 or DSM-IV. Nor is the term used 
here to reflect frequency and intensity of use beyond arbitrary cut-off points. Here, 
problematic cannabis use refers to cannabis use which results in health problems with 
substantive impacts on the individual’s functioning. Potential problems include, for 
example, early school leaving (Lynskey et al., 2003a), mental health (Henquet et al., 
2004), depression (Bovasso, 2001), dependence (Swift et al., 1998), impairment of 
memory and attention (Solowij et al., 2002), and respiratory functioning (Taylor et al., 
2000).
Routes to cannabis use and cannabis dependence
Cannabis is often described as a ‘gateway’ drug to the use of other, more harmful 
drugs such as heroin and cocaine. While there is considerable debate over the nature of 
this gateway effect, if any (e.g. Morral et al., 2002), there are discernible associations 
between early use of tobacco, alcohol and cannabis.
Patterns of drug use progression
Kandel’s stage theory of drug use — that substance use initiation and progression, 
in those cases where progression occurs, follows predictable stages — has informed 
prevention efforts (Kandel and Faust, 1975; Kandel et al., 1992). However, such 
predictable progression, and with it the possibility of preventive interventions, may not 
be the case for those more at risk of developing problematic patterns of drug use. 
Contrary to the Kandel model, in some cases those at risk of developing problematic 
drug use are more likely to have used cannabis before using alcohol and more likely 
to have used other illicit drugs before using cannabis (Mackesy-Amiti et al., 1997). The 
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point here is that the typical pattern of progression described by Kandel and others may 
relate more to those for whom progression to problematic use is less likely. Moreover, 
routes into drug use may not be as one-way as per Kandel’s stage theory. For example, 
there is evidence that cannabis can lead to nicotine dependence (Patton et al., 2005; 
Amos et al., 2004).
The nature of the relationships between use of alcohol, tobacco and cannabis is the 
subject of ongoing debate. The Kandel stage model can be interpreted as implying 
a sequence of causal relationships, such that use of a prior substance is (somehow) 
causally related to the next substance in the sequence. More plausibly, the model is 
more of a description than an explanation of stages of drug use, with no implication 
of causality intended in its original formulation. What is less in doubt is that there are 
correlations between the use of cannabis and drug use progression (e.g. Blaze-Temple 
and Lo, 1992; Fergusson and Horwood, 2000; Lynskey et al., 2003b), and between the 
use of alcohol, tobacco and cannabis in adolescent populations (see also Monshouwer, 
Smit and Verdurmen, this monograph). Nonetheless, Lynskey et al. (2003b) noted that 
while there were associations between cannabis use and progression to other drugs and 
drug dependence, it was not possible to draw strong causal inferences about the role of 
cannabis.
What might explain these associations between cannabis use and use of other drugs? 
Lynskey et al. (1998) reported that the correlations between alcohol, tobacco and 
cannabis use could be explained by a general ‘vulnerability to substance use’ factor, 
based on connections with delinquent or substance-user peers, novelty seeking and 
parents’ drug use. More recently, Morral et al. (2002) concluded that users of any drug 
have a greater inclination to use other drugs and argued that this general propensity 
theory could adequately explain apparent gateway effects.
Alcohol and tobacco
In addition to correlations between use of cannabis and more harmful drugs, there are 
also associations between adolescent alcohol and tobacco use, on the one hand, and 
cannabis use on the other. In a sample of 11- to 16-year-olds, illicit drug use (primarily 
cannabis for the majority of regular users of drugs) and cigarette smoking were related 
to alcohol use. Those who had been drunk more often were more likely to smoke 
cigarettes and to use other drugs (Sutherland and Willner, 1998). The associations 
between number of episodes of drunkenness and either cigarette use or other drug use 
were not age dependent. Of those who had been drunk less often, from one to five 
times, 13 % reported other drug use, while of those who had been drunk more than 20 
times 58 % reported other drug use. Adolescents who drank more than three times in the 
previous week and who drank five or more units of alcohol were more likely to begin 
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cannabis use (Coffey et al., 2000). But another study found that there was no statistically 
significant relationship between drinking in adolescence and cannabis dependence in 
early adulthood, after possible confounding factors had been taken into account (Wells 
et al., 2004).
Adolescents who smoke tobacco are at greater risk of developing cannabis 
dependence by their mid-20s (Lewinsohn et al., 1999; Coffey et al., 2000). A recent 
longitudinal study in which data were gathered from participants at 11 years and 
20 years of age reported that ‘persistent’ tobacco smokers were more likely to use 
cannabis and to develop dependence on cannabis, as well as to use other drugs and 
develop dependence on other drugs (Vega and Gil, 2005). Coffey et al. (2000) also 
demonstrated that tobacco smoking and not alcohol was a risk factor for the transition 
from experimental cannabis use to a more established cannabis habit, with greater 
degree of tobacco smoking being predictive of subsequent greater cannabis use.
A fundamental issue with cannabis, alcohol and tobacco is whether the gateway 
theory is anything other than an artefact of patterns of typical drug use initiation and 
progression. It has been argued that the overriding trend in drug use over time is for 
young people to reduce their illicit drug use and that problematic drug use is best 
predicted by family, social and psychological deficits (Peele and Brodsky, 1997).
In many ways the numerous studies of drug initiation and progression provide 
descriptions of routes to drug use. For the more fundamental issue of explanation 
there is a need to consider the individual and social context in which these routes are 
recorded.
Age of initiation
Social, childhood and behavioural problems are associated with early onset of cannabis 
use, which in turn can lead to later association with substance users and educational 
disengagement. In turn, these latter risk factors can lead to development of a range 
of psychosocial risk factors that increase the likelihood of substance-related problems 
(Fergusson and Horwood, 1997). Comparison of recent-cannabis-onset adolescents 
and adults found that those who start to use cannabis in adolescence are more likely to 
develop cannabis dependence than adults who initiate cannabis use (Chen and Anthony, 
2003). Children who manifest behavioural disinhibition are at elevated risk of starting 
to drink alcohol at an early age (King et al., 2004). Moreover, early initiation of alcohol 
use is associated with increased risk of substance use disorders (McGue et al., 2001). 
Cannabis users who began using cannabis before late adolescence, and had used 
three or more other drugs before starting cannabis, were at higher risk of developing 
cannabis dependence within 2 years of onset (Chen et al., 2005).
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An investigation of the early onset cannabis users, who started using before they were 
17 years old, revealed an association with reduced measures of verbal IQ. One possible 
explanation for this is that cannabis adversely, and durably, affects cognitive faculties in 
younger people whose brains are still developing (Pope et al., 2003). It is also possible, 
however, that poorer verbal IQ is a consequence of disengagement from mainstream 
education, which is a risk factor for early cannabis use. Such disengagement from the 
educational mainstream may be reinforced by cannabis use. Indeed, Pope et al. (2003) 
speculate that the early onset users in this study had lower verbal IQs because they were 
less motivated to engage with education. Although far from conclusive, these data are 
consistent with other studies that show an association between poor educational status 
and early onset of cannabis use (Lynskey et al., 2003b).
Adolescents with substance use disorders and adults with substance use disorders who 
had initiated cannabis use in adolescence were quicker to develop dependence, have 
behavioural problems and major depression, than comparison groups who started 
cannabis use in early or later adulthood (Clark et al., 1998b).
Young people who are exposed to drug use may be more likely to initiate drug use 
themselves, at least on the basis of the argument that exposure provides both drug-using 
models (parents, siblings, peers) and availability of drugs. The younger children are 
when they experience such models and availability, the greater the risk of initiation at 
an early age, with a consequent elevated risk of developing problematic use in later 
years. One study of Scottish pre-adolescents (10–12 years of age) found that over a 
third had been exposed to drug use and one in seven had been offered drugs (McIntosh 
et al., 2003). McKeganey et al. (2004) found that those 10- to 12-year-olds who had 
initiated drug use (in most cases cannabis) were more likely to use tobacco and alcohol, 
and have problem behaviour and family difficulties. Pre-adolescents (defined as 10–12 
years of age) who used tobacco and had behavioural problems were at risk of early 
adolescent cannabis use (Clark et al., 1998a).
Evident from the research findings, which show an association between early onset and 
later problematic cannabis use, is that the association may not be causative. Indeed, 
as highlighted by Lloyd (1998), early onset use may only be an indicator of other risk 
factors that predict later problematic drug use. Thus, age itself might be less the issue 
than the interplay of other risk factors.
Other risk factors that have to be taken into account are the influences of family and 
peers, psychological risk factors and genetic factors.
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Social environment: family
The family and peer networks have received great attention in risk factor research 
(Rhodes et al., 2003). A study of 14- to 15-year-olds across five European cities 
concluded that ‘attachment to mothers’ inhibited drug use, an aspect of family 
relationships that appears to be more important for boys than girls. This protective factor 
was more important than living with both parents. However, this protective factor does 
not extend to antisocial young people (McArdle et al., 2002).
Kosterman et al. (2000) studied initiation of alcohol and cannabis use among 
adolescents and found that exposure to others who use drugs increases the risk of early 
initiation of cannabis use; as do parents who are not ‘proactive’ and/or parents who 
fail to set clear ‘family standards’. Chen et al. (2004) make the point that initiation to 
tobacco use is more likely to occur in a social environment that is tolerant of smoking.
Foxcroft and Lowe (1995) found relationships between adolescents’ perceptions of 
parent-centred authoritarian or neglectful family life and use of alcohol, tobacco and 
some illicit drugs. However, this was not observed for cannabis use. In other words, 
cannabis use per se was not related to pathological family relations in the way that 
other drug use was. In light of what is known about the risks of dysfunctional family 
relationships for elevation of risk for problematic use, it may be that cannabis use in this 
sample was non-problematic.
Young people exposed to stressors in the family, such as disrupted family structure and 
poor quality of family relationships, are more likely to use cannabis and to develop 
problematic patterns of cannabis use (Butters, 2002). Moreover, a compounding 
effect in terms of school problems was found in this study: family disruption elevated 
the likelihood of school problems, which in turn increased the chances of developing 
problematic cannabis use. The confounding nature of the risk factors delinquency and 
school problems with cannabis use was also highlighted in an American study of nearly 
14 000 11- to 21-year-olds (van den Bree and Pickworth, 2005). Children with social 
disadvantage, dysfunctional family life and behavioural problems are more likely to 
become adolescents who associate with delinquent or drug-using peers (Fergusson 
and Horwood, 2000). A recent study of a sample of adolescents in Turkey noted the 
significant statistical association between cannabis use and cannabis-using peers (Tot et 
al., 2004).
The extent of parental monitoring of children’s activities may influence likelihood of 
substance use, such that lower levels of monitoring increased the risk of initiation of 
drug use (Chilcoat et al., 1995; Bukstein, 1995; Kandel, 1996). Lack of closeness in 
parents’ relationships with their children, and inadequate time spent by parents with 
their children are risk factors (Bukstein, 1995; Hawkins et al., 1992; Kandel, 1996). To 
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some extent, this implies that the causal direction is one-way. It is likely that the process 
is more complex, with some degree of influence of children’s behaviour on their parents 
or carers.
There is much about the precise nature of the relationships within high-risk families 
that is not known, such as the characteristics of the parents and the ways in which 
they interact with their children. A study of the comorbidity of drug misuse and anxiety 
disorders in families found that young adolescents’ drug use was more strongly 
associated with parental drug misuse (diagnosed as having alcohol or drug disorders) 
than with diagnosed parental anxiety disorders. Children of drug misusers were, along 
with controls, less likely to manifest anxiety disorders than children of parents with 
anxiety disorders. Children of drug misusers were more likely to have behavioural 
problems, itself a risk factor for drug use and drug problems (Merikangas et al., 1998).
It is evident that the quality of relationships within the family is important in terms 
of emotional support, parenting style, control and family disruption. However, the 
relationship between these factors and cannabis use or problematic cannabis use is 
probably indirect in the sense that the presence of such factors increase the likelihood 
of young people developing emotional and behavioural problems in general. And it is 
the development of these problems that increase the chances of developing problematic 
patterns of drugs use.
As young people grow and develop, the influence of the family wanes in many cases as 
the influence of peers increases.
Social environment: peers
That cannabis users’ peers are more likely to smoke cannabis than the peers of non-
users is a commonplace of the literature. There is a need for considerable caution in 
going beyond the data when interpreting statistical associations between cannabis users 
and their peers’ cannabis use. In many cases it is not possible to specify the nature 
of the association: that is, does A cause B, vice versa, or neither? Yet, on the basis 
of such data it has often been asserted that drug-using peers somehow pressure or 
encourage drug use in their non-drug-using peers. Peer preference is a more plausible 
interpretation, such that those inclined to the use of cannabis deliberately associate 
with others who do so (Coggans and McKellar, 1994). For example, peers may in 
some instances encourage or even coerce others to take drugs, but there is a need to 
recognise that peer influences can take different forms, ranging from tolerance of drug 
use, through support of drug use to active encouragement of drug use. Often young 
people actively assort themselves to form groups which share similar interests and 
aspirations, which do not fit with (bad) pusher and (innocent) victim stereotypes.
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Changes of frequency in adolescent drug use have been found to precede changes in 
peer variables (Farrell and Danish, 1993). These researchers also analysed their data 
in different ways in order to compare three different hypothetical models, namely, a) 
drug use was a consequence of emotional restraint (ability to deal with negative affect) 
and peer variables (drug using peers and peer pressure); b) drug use was a cause 
of changes in emotional restraint and peer variables; and c) a reciprocal model that 
included both causes and consequences of drug use. While all three models ‘fit the data 
fairly well’, the reciprocal model was the best fit. Of particular note was their conclusion 
that ‘peer drug models and peer pressure were not related to subsequent changes in 
gateway drug use’ and ‘changes in peer drug models were … predicted by previous 
levels of gateway drug use’ (Farrell and Danish, 1993: 327). The authors also drew 
attention to the need for caution with data of this kind and emphasised the importance 
of studying dynamic models that address both the causes and the consequences of drug 
use.
Dobkin et al. (1995) examined the antecedents of early onset substance use in male 
adolescents and reported that individual characteristics were better predictors than 
association with deviant friends. They concluded that the argument that deviant youth 
seek out like-minded friends was plausible. Kandel (1996) suggested that the influence 
of peers on adolescent substance use has generally been overestimated, that this 
overestimate has tended to be at least double the actual effect, and that selection 
is at least as important as influence, if not more. Other researchers concluded from 
their review of the literature that selection ‘may make a substantial contribution to the 
association between drug behaviors of friends, and that failure to control for selection 
may overestimate the contribution of influence’ (Bauman and Ennett, 1996: 188). All of 
which emphasises the need to understand the factors that predispose young people to 
select drug-using associates.
A risk factor for cannabis users’ transition to problematic cannabis use is having more 
friends who use drugs and less perceived parental disapproval of cannabis, with the 
effects found to be greater for adolescent females than males (Butters, 2004). Not all 
cannabis users with cannabis-using peers will progress to problematic cannabis use. 
Progression to problematic cannabis use will depend on other risk factors and how these 
interact with the risks associated with cannabis-using peers.
Interactions within the school environment have been identified as important, although 
it can be difficult to disentangle the relative contribution of social relationships 
and educational experience as potential risk factors. For example, poor academic 
performance and classroom behaviour were found to be important risk factors for boys 
in particular (Hops et al., 1999). Lower attachment to school has been associated with 
higher levels of substance use (Ennett et al., 1997) and academic performance linked 
with subsequent academic and home self-esteem (Filozof et al., 1998). However, others 
Risk factors for cannabis use
336
have cautioned against too great an emphasis on self-esteem in prevention initiatives, 
due to uncertainty over the relationship between (low) self-esteem and substance use 
(Schroeder et al., 1993). Nonetheless, academic failure is a risk factor for adolescent 
drug use, as is low commitment to school (Hawkins et al., 1992).
The influence of peer pressure, especially when perceived as some form of coercion, has 
been overstated. More subtle forms of peer influence, such as attractive role models, 
are likely to have an influence. When young people with emotional or behavioural 
problems perceive cannabis-using others as attractive role models then they may be 
more likely to adopt similar behaviours. The difference between a young person who, 
with cannabis-using role models, becomes a cannabis user, on the one hand, and a 
problematic cannabis user, on the other hand, is explicable by presence of other risk 
factors described in earlier sections.
Psychological risk factors
Rhodes et al. (2003) point out that within the European literature, there is considerable 
agreement that there are correlations between problematic drug use and a variety of 
problematic behaviours. Conduct problems precede and influence early initiation of 
cannabis, the onset of which is greater where there is also early tobacco use (Pederson 
et al., 2001). There are also gender-specific influences of different aspects of problem 
behaviour prior to cannabis initiation. More serious conduct problems were an important 
predictor of cannabis initiation in boys, while aggressive and covert conduct problems 
predicted cannabis initiation in girls.
In a study of 15- to 16-year-olds, the heavier users of cannabis were characterised 
in three groups, according to a range of behavioural, relationship and psychological 
measures: namely, ‘antisocial’, ‘unhappy’ or ‘ordinary’ (Miller and Plant, 2002). While 
the antisocial and unhappy groups of young heavy cannabis users had already exhibited 
negative behaviours, including other substance use, the ordinary group were less likely 
to be heavy users of other substances. All of which is a reminder that cannabis use and 
even heavy cannabis use is not in itself sufficient to lead to problematic use of other 
drugs.
In a sample of 12- to 18-year-olds in treatment for cannabis abuse or dependence, 
most had a range of psychological and behavioural problems (Tims et al., 2002). 
Those with higher levels of drug misuse had problems with relationships, and with their 
psychological and physical health. The extent to which cannabis use, on the one hand, 
and individual and social circumstance (historical or present) on the other, are causal 
is difficult to specify. There is every likelihood that those with personal difficulties who 
subsequently use cannabis will exacerbate these problems.
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In a study of French 15- to 22-year-olds, ‘borderline symptomatology’ for a range of 
personality problems appeared to influence motivations for cannabis use, in particular 
expansion of awareness. However, mood enhancement for boys and expansion 
of awareness for girls were better predictors of cannabis use than psychological 
problems. While cannabis dependence in boys was related to psychological problems, 
it was related to motivation for expanded awareness in girls (Chabrol et al., 2005). 
‘Permissive’ beliefs about the nature and utility of cannabis is associated with cannabis 
use but not dependence, while beliefs that cannabis would ameliorate anxiety, boredom 
and ‘suffering’, and improve mood, were the only predictors of cannabis dependence 
(Chabrol et al., 2004).
In a similar vein, a study that related perceived functions of cannabis to cannabis use 
and to amount of use found that those who used for respite from negative moods 
were at risk of developing problems with cannabis. This contrasts with those who used 
cannabis for social functions, which was not related to degree of cannabis use (Boys and 
Marsden, 2003).
There is much current debate about the potential for cannabis to exacerbate or 
precipitate psychosis (see Witton, this monograph, vol. 2). However, psychotic symptoms 
can also precede cannabis use. While the debate over common vulnerability versus 
bidirectional causal pathways between cannabis and psychosis continues, psychotic 
symptoms were found to be a risk factor for subsequent cannabis use in a recent 
14-year follow-up study in the Netherlands (Ferdinand et al., 2005).
A recent study in Germany found that, in a sample of mid- to late adolescents, use 
of cannabis was predicted by a personality construct defined as ‘addiction’. However, 
cannabis use was more likely among young people who scored low on a measure of 
anxiety–depression and that those who had a positive self-image were more likely to 
use cannabis (Kirkcaldy et al., 2004). The cannabis use measure in these analyses was 
lifetime use.
Investigation of 13- to 19-year-olds with diagnosed major depression, conduct disorder 
and substance dependence found that adolescents with major depression were more 
likely to develop cannabis dependence than adolescents whose depression manifested at 
the same time as substance dependence or whose depression developed subsequent to 
cannabis substance use disorder (Libby et al., 2005).
There are associations between various psychological and behavioural problems and 
problematic drug use including problematic cannabis use. In such cases, problematic 
cannabis use is in part symptomatic of psychological and behavioural problems and in 
part likely to exacerbate psychological and behavioural problems.
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Genetic factors
The epidemiology of drug use is increasingly informed by research into genetic 
influences and it appears that the role of genetic influences is greater for drug problems 
than for drug use (Kendler et al., 2003). But this is a complex issue and the specific 
genes involved and the nature of their interactions with environmental factors are issues 
for further research. Nonetheless, the distinction between drug use and escalation 
to drug problems appears to be in terms of the relative influence of genetic and 
environmental factors. Genetic risk factors are vulnerabilities for conditions that in turn 
increase the likelihood of developing drug problems (Moss et al., 2002). Both genetic 
and environmental influences are non-specific in their influence in terms of drugs that 
are used or with which users develop problems (Kendler et al., 2003).
Genetic factors interacted with family environmental factors in the origins of disruptive 
behaviour in a study of sons of substance and non-substance misusing families 
(Majumnder et al., 1998). In substance-misusing families, sons with disruptive behaviour 
were influenced by parental dysfunction and family environment, while in non-
substance-misusing families sons with disruptive behaviour were influenced by family 
environment. Family and social factors were related to cannabis initiation, while genetic 
factors influenced progression to problematic cannabis use in a study of twin girls 
(Kendler and Prescott, 1998).
Genetic influences account more for cannabis dependence than they do for cannabis 
use, while common environmental influences explained more cannabis use than 
cannabis dependence, supporting an individual vulnerability perspective on development 
of cannabis problems (van den Bree et al., 1998). Miles et al. (2001) found broadly 
equivalent genetic and environmental influences on cannabis use.
The genetic influence on cannabis use may be in terms of a genetic basis for sensation-
seeking or problem behaviour, while genetic influence on problematic cannabis use may 
be in terms of a genetic basis for drug sensitivity and/or subjective reactions to cannabis 
(Agrawal and Lynskey, 2006). Genetic factors may explain in part why many cannabis 
users develop problematic cannabis use or escalation to drug problems of other kinds. 
While there will also be people with problematic cannabis use who are not at elevated 
genetic risk of substance-related problems, better understanding of how genetic factors 
are expressed and how they interact with environmental factors is a potentially valuable 
area of future research.
Implications for prevention
In order to be successful, prevention interventions should address risk factors, taking 
into account the distinctions between cannabis use and problematic cannabis use, with 
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recognition that different kinds of prevention interventions will be required depending 
on the risk factors being tackled. Universal (primary prevention) programmes will in all 
likelihood not work with young people whose risk factor load is greater. Such young 
people, whose backgrounds include family strife, behavioural difficulties, and so on, will 
not only be less likely to gain from universal programmes due to their nature, they will 
be less likely to participate in them by, for example, being less likely to attend school.
Prevention of cannabis initiation has been attempted for many years in the context 
of universal drug education programmes with little or no success. These universal 
prevention interventions typically target entire populations of school pupils of specific 
ages, usually in early adolescence and more recently in pre-adolescence. Evaluation 
of the success of such programmes is usually defined as prevention of onset (primary 
prevention). Even the most successful of universal primary prevention drug education 
programmes have notably poor outcomes, with, at best, small-scale success (Coggans 
and Watson, 1995; Coggans et al., 2002; Tobler and Stratton, 1997; Advisory Council 
on the Misuse of Drugs, 2006). The more successful of these interventions attempt 
to influence aspects of social competence and self-esteem as well as drug-related 
knowledge and attitudes. Such attempts to promote social competence (life skills) 
could, in theory, ameliorate the risks of cannabis and other drug use by equipping 
young people with the skills to cope with a social environment that facilitates drug use. 
However, this type of primary prevention may work best with those young people who 
are less likely to escalate cannabis use to problematic levels. Moreover, at least one 
such programme does not impact on mediating life skills as expected (Coggans et al., 
2002).
Given that the risk factors for experimental and recreational cannabis use are in many 
ways qualitatively different from the risk factors for problematic cannabis use, this lack 
of impact on cannabis initiation and on putative mediating factors is perhaps to be 
expected. However, those at risk of progression to problematic use may well benefit 
from interventions that aim to prevent escalation by addressing the psychological and 
behavioural factors that are risk factors for problematic use. However, such interventions 
require approaches targeted precisely at the individuals and groups at risk.
The recent report from the Advisory Council on the Misuse of Drugs (ACMD) (2006) 
concluded that the risk factors for hazardous drug use are early life experiences, family 
relationships and circumstances, and parental attitudes and behaviour. The ACMD 
also noted that it is not easy to predict who will develop serious problems. The role of 
parents is important, and many will not realise the extent of their potential role in the 
prevention of drug use problems and, most importantly, how to relate to their children 
in ways that maximise the influence of this central protective factor. While there is a 
growing awareness of the need for parent-oriented interventions, there have been 
few evaluations of drug education interventions aimed at parents. Positive impact 
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on mediating variables such as parent–child communication, normative beliefs and 
intentions to use has been reported, but there are also problems of low uptake and 
potential stigmatisation of higher-risk parents (Allot et al., 1999).
Summary and conclusions
There is a complex of potential risk factors that interact with each other to compound 
and increase the risk of cannabis- and other drug-related problems. The weight of 
evidence is that risk factors for problematic cannabis use are, in large part, to be 
found in the interactions between genetic factors, the early nurturing of people and 
their circumstances. In many ways these are risk factors for substance-related problems 
generally. The evidence is accumulating for individual vulnerability to drug-related 
problems. While most cannabis users restrict their preferred drug use and can do so 
presumably on the basis of the absence of risk factors/presence of protective factors, 
others develop problematic relationships with drugs. Such problematic relationships with 
drugs include drug effects as risk factors for intensifying or precipitating psychological or 
social problems in turn.
The influence of risk factors is cumulative, both in terms of interaction with each other 
and in terms of time. The more that multiple risk factors accumulate over time the more 
likely that developmental and behavioural problems will become evident (Loxley et al., 
2004). Behavioural problems, association with delinquent or deviant drug-using peers, 
dysfunctional family relationships, exposure to family substance misuse and genetic 
vulnerability to psychological conditions that increase the likelihood of drug problems all 
contribute to this complex of risk factors for problematic cannabis use. In the light of the 
varied, interactive and potentially confounding nature of risk factors for cannabis-related 
problems, prevention efforts need to be diverse. Universal programmes have a role to 
play in communicating key information and raising awareness of risks, but are unlikely 
to have any substantial impact on problematic cannabis users. Vulnerable groups and 
individuals require more precise targeting and delivery of programmes that will address 
their specific needs (see Burkhart, this monograph).
This chapter has drawn on a wide range of research literature assessing the role of 
various factors from the genetic to the social. Full justice will not have been done to 
the social and cultural differences across all the different settings in which the data 
were gathered for these research reports. To what extent are the conclusions justified 
without exploring these social and cultural contexts further? This is an empirical 
question. However, given the need to distinguish between recreational and problematic 
cannabis use in relation to the utility of the risk factors approach, it may be that there 
is a need to make the same distinction for other drugs as well. The potential for the risk 
factors approach to inform prevention efforts will depend in many respects on greater 
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understanding of the social norms and cultural factors related to recreational and 
problematic patterns of drug use.
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Approaching cannabis research — a quick guide
During the editing of this monograph, the EMCDDA soon realised that the publication 
was entering a crowded arena. Cannabis monographs appear several times a year in 
different languages. The core information they contain is being continuously revamped, 
revised, reworked, remixed or just repeated.
A concern for the Centre was to avoid the near-instant obsolescence of many cannabis 
monographs. This is why the publication takes a ‘reader’ approach, mapping current 
publication flows; sketching the history of cannabis monographs and identifying key 
sources for information. This appendix aims to (i) identify the main producers of 
literature on cannabis and (ii) illustrate the range in thematic focus of publications. In 
particular, it will help researchers who are new to the area or who are entering cannabis 
research from other disciplines (law, medicine, politics, sociology, etc.).
Information overload on cannabis, and the need for a 
trusted guide
Any researcher requiring definitive, accurate information on cannabis needs to be 
forearmed. In the age of the Internet, any taboos that may previously have hushed 
discussion on illicit drugs have vanished. On the contrary, researchers are overwhelmed 
with data (Table 1). Like drinking water from a firehose, it becomes impossible to 
manage the sheer volume of insider guides, reports and general punditry on cannabis. 
Cannabis has even evolved to have its own portal on Wikipedia, alongside such all-
encompassing subjects as science, history and medicine. A recent Spanish study on the 
use of the Internet for finding drugs over several months found that Spanish search 
engine registered 31 800 000 searches for the word ‘cannabis’, 481 000 for ‘marihuana 
efectos’ and 358 000 for ‘cultivo de marihuana’.
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Table 1: Basic internet search results (October 2006)
Internet search used Search terms Hits
Google ‘cannabis’, ‘marihuana’, ‘marijuana’ 18 400 000; 7 030 000; 26 900 000
Google Books ‘Cannabis’, ‘marihuana’, ‘marijuana’ 66 000; 46 400; 148 000
Google Books ‘Cannabis 2006’ 1 140
Google Scholar ‘Cannabis’, ‘marihuana’, ‘marijuana’ 94 500; 9 570; 112 000
PubMed ‘Cannabis’, ‘marihuana’, ‘marijuana’ 9 099; 6 000; 10 812
Bireme ‘Cannabis’ 3 723 (Medline); 462 (Cochrane); 
270 (LILACS); 23 (SciELO)
Amazon.com books ‘Cannabis’, ‘marihuana’, ‘marijuana’ 8 539 
Yahoo ‘Cannabis’, ‘marihuana/marijuana’ (1) 14 400 000; 30 500 000
(1) Yahoo tracks ‘marihuana’ and ‘marijuana’ as a single search term.
Information exchange among cannabis experts: journals, 
conferences and community
Faced with such a huge amount of information, where does one begin? The first 
step is to be able to identify the producers of quality scientific information. Scientific 
publications on cannabis are by-and-large the product of constant information exchange 
among academics and governments. In addition to standard forums for research (e.g. 
PubMed- and Medline-listed journals (1), HON-accredited websites) and annual cyclical 
publications (2), there exists a well-attended circuit of face-to-face meetings with a 
domestic, regional and international scope (3). An overview of websites focusing on drugs 
issues (NGOs, government campaigns) in Europe is provided by the Elisad Gateway. 
Some of these events focus purely on cannabis, but the majority discuss cannabis 
together with other illicit drugs, legal or healthcare topics. These cyclical meetings are 
increasingly bolstered by one-off conferences focusing on selected cannabis issues 
(legislation, treatment, medicinal cannabis, cannabinoid research). The result is a 
sizeable, yet close-knit network of global cannabis experts.
 (1) An invaluable tool for the preparation of this monograph has been the open source referencing 
tool, Jabref, which offers fast searches and abstracts of Medline literature.
 (2) Annual publications include: the UNODC’s World Drugs Report, EMCDDA’s Annual Report and 
Reitox national focal point reports, the ONDCP Annual report, SAMSHA’s National Survey on 
Drug Use and Health and the NDIC’s annual National Drug Threat Assessment in the USA.
 (3) A useful information source for meetings with a European focus is the events section of EMCDDA’s 
quarterly newsletter, DrugNet Europe.
Appendix: Approaching cannabis research — a quick guide
349
A hierarchy in expertise: the ‘cannabis research pyramid’
A three-tier pyramid can be created in terms of global expertise on the subject. On the 
bottom tier there are tens of thousands of practitioners: various healthcare and drugs 
professionals, together with employees of think tanks, charities and governments. To 
some extent, established lobbyist groups, for example NORML and EURAD, can be 
included in this tier. In the middle tier, there are some 2000 to 3000 cannabis experts 
working in research institutions. The majority of these are working directly with drugs 
issues. The top tier comprises around 200 to 300 leading authorities who are generally 
working at centres of excellence in cannabis research and playing an active role in 
informing government policy. The middle and top tiers are the typical publishers of 
general monographs on cannabis.
Top tier: several hundred experts
Centres of excellence in cannabis research.
National and international drugs coordination centres.
International cannabis research societies, e.g. National Drug and Alcohol Research 
Centre, Australia; National Addiction Centre, UK; Trimbos Institute, the Netherlands; 
National Institute of Drugs Dependence, China; Centre for Addictions Research, 
Canada; Addiction Research Centre, Canada; The Institute for Clinical Research, 
Germany; Sociedad Española De Investigación Sobre Cannaboides, Spain; International 
Association for Cannabis as Medicine; European Association of Addiction Therapy; 
National Institute on Drug Abuse, USA.
Middle tier: several thousand people worldwide
Drugs professionals specialising in cannabis: predominantly at national treatment 
centres and domestic centres of excellence.
Educational institutions involved in cannabis RCTs and testing.
Psychiatrists/treatment professionals working in a national advisory role on cannabis 
issues.
Commercial research laboratories involved in cannabis therapeutics.
Appendix: Approaching cannabis research — a quick guide
350
Government policymakers working specifically on drugs control and legislation.
Law enforcement professionals with experience in cannabis control, arrests and seizures.
Bottom tier: tens of thousands of people worldwide
Drugs professionals: local and regional treatment centres and clinics, prevention 
campaigns, drugs charities.
Healthcare practitioners: general practitioners, psychiatrists, psychologists.
Civil servants: working at government ministries, international organisations (UNODC, 
EMCDDA, WHO), healthcare providers.
Law enforcement: police, customs, international police organisations (Interpol, Europol), 
drug enforcement units (DEA).
Educational institutions: teaching centres, postgraduate and postdoctoral researchers.
Commercial research: medicinal cannabis and hemp industries.
Lobbyists: international think tanks (e.g. Pompidou Group, Senlis Council, RAND), 
domestic think tanks (e.g. Rowntree Foundation), legalisation lobbyists (NORML) and 
anti-legalisation lobbyists.
Core outputs of the pyramid: journals, commercial 
publishing, grey literature
Outputs from this research pyramid are dominated by the so-called ‘grey literature’ — 
that is, publications by government departments, NGOs and international organisations 
(this monograph being no exception). Other publications include special issues in 
academic journals, publications by lobbyists, as well as commercially oriented books. 
On a more passive level, the pyramid also helps to inform the several hundred 
journalistic articles on cannabis published each day in the world’s media by providing 
expert opinions, background information and quotes to the press. As such, the cannabis 
experts in the pyramid provide a useful calmative influence on a subject that is often 
discussed in alarmist, confrontational or heavily politicised tones. The outputs can 
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broadly be categorised into academic journals, commercial publications and grey 
literature.
Journals
Scholarly research into cannabis appears many times per month across a variety of 
academic journals, in particular journals focused on drugs, psychiatry, public health, 
science and medicine, and increasingly those focusing on sociology, law and media 
studies (Table 2). There occasionally appear ‘special focus’ editions on cannabis 
in journals. Examples include SWAPS — Spéciale Cannabis (Pialoux (ed.), 2003), 
Monográfico Cannabis — Revista Española de Drogodependencias Vol. 30 (AESED, 
2003). A useful list of scientific journals publishing on drugs issues can be found using 
the members list of the International Society of Addiction Journal Editors (http://www.
parint.org/isajewebsite/).
Table 2: A selection of academic journals regularly covering cannabis
Subject area Journal titles
Drugs and addiction Addiction, Addictive Behaviours, American Journal of Addictions, British 
Journal of Addiction, Bulletin on Narcotics, Drug and Alcohol Dependence, 
Drug and Alcohol Review, Drugs: education, prevention and policy; European 
Addiction Research, Harm Reduction Journal, International Journal of Drug 
Policy, Italian Journal on Drug Addiction and Alcoholism (Bollettino per 
le Farmacodipendenze e L’alcoolismo), The International Journal of the 
Addictions, International Journal of Mental Health & Addiction, Journal of 
Drug Issues, Prevention & Policy, Journal of Substance Abuse Treatment, 
SWAPS, Revista Española de Drogodependencias, Substance Use and Misuse, 
THS — La revue des addictions, The Cannabis Health Journal, Wiener 
Zeitschrift für Suchtforschung
Psychiatry British Journal of Psychiatry, The American Journal of Psychiatry, Psychotropes
Neurology Brain, Neurology, Neuropharmacology, Psychopharmacology
Science Nature, New Scientist
Medicine and 
pharmacology
Annales de toxicologie analytique, Annales pharmaceutiques françaises, 
Clinical Pharmacology and Therapeutics, Journal of the American Medical 
Association, Journal of Cannabis Therapeutics, Cannabinoids: The Journal 
of the International Association for Cannabis as Medicine (2001–2004), 
Journal of Pharmacy and Pharmacology, The Lancet, British Medical Journal, 
European Journal of Clinical Pharmacology
Sociology The Humanist, Journal of Sociology and Social Welfare
Law and 
criminology
The Cambridge Law Journal, European Journal on Criminal Policy and 
Research, Forensic Science International, International Journal of Drug Testing, 
Journal of Police Science and Management, European Review, Policy Review, 
Vanderbilt Journal of Transnational Law
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Commercial publishing
Outside academia, cannabis has sparked what can only be termed a publishing 
phenomenon in the past two decades, embracing all bookselling genres (Table 3). There 
have been novels and literary anthologies, political tracts, dedicated magazines such as 
The High Times, connoisseurship columns in mainstream magazines and newspapers, 
product and cultural histories, biographies (by traffickers, drugs detectives, musicians, 
actors), practical growguides, cannabis-oriented travel guides and cookbooks, not to 
mention a wealth of educational and harm reduction materials. While some of these are 
found only at headshops and specialised booksellers, others have entered bestseller lists. 
Cannabis, it seems, is a mainstream topic that attracts a commercially viable readership. 
Grey literature
As mentioned above, grey literature producers, such as NGOs and government 
agencies, are significant publishers of information on cannabis. The appendix to 
Volume 1 of this monograph provides a selection of key grey literature publications on 
cannabis published in recent years. Naturally, this list is non-exhaustive, yet it remains 
valuable for researchers. Just as this monograph is unlikely to be the last specialised 
publication on cannabis for the EMCDDA, so will peer organisations revisit the topic as 
issues of science, data and policy evolve.
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Table 3: A selection of recent books published on cannabis in three genres and 
three languages (genres: history, society/politics, health/medicine; languages: 
English (EN), French (FR), German (DE))
History Cannabis: a history (Booth, 2003) (EN)
Cannabis: from pariah to prescription (Russo (ed), 2003) (EN)
Cannabis. Hanf, Hemp, Chanvre, Canamo (Bröckers, 2002) (DE)
Cannabis Britannica: empire, trade, and prohibition (Mills, 2003) (EN)
Cannabis on the brain (Smith, 2002) (EN)
Marijuana for dopes: a pop culture history of cannabis (Romain, 2001) (EN)
Society/politics Cannabis (Green, 2002) (EN)
Cannabis: le dossier (Chollet-Przednowed, 2003) (FR)
Cannabis. Neue beiträge zu einer alten diskussion (Gaßmann, 2004) (EN)
Cannabis, ecstasy: du stigmate au déni. Les deux morales des usages récréatifs de 
drogues illicites (Peretti-Watel, 2005) (FR)
Cannabis ist immer anders (Kuntz, 2005) (DE)
Cannabis use and dependence: public health and public policy (Hall and Pacula, 
2002) (EN)
Le cannabis en question (Palazzolo, 2006) (FR)
Orgies of the hemp eaters: cuisine, slang, literature and ritual of cannabis culture 
(Bey and Zug (ed.), 2005) (EN)
Spliffs: a celebration of cannabis culture (Jones, 2004) (EN)
Spliffs 2: further adventures in cannabis culture (Pilcher, 2005) (EN)
The cannabis debate (Donnellan (ed.), 2004) (EN)
The complete illustrated guide to cannabis (Brownlee, 2003) (EN)
Un écran de fumée: le cannabis dans la famille (Bantman and Hefez, 2005) (FR)
Understanding marijuana: a new look at the scientific evidence (Earlywine, 2005) 
(EN)
Health/
medicine
Cannabinoids as therapeutics (Mechoulam (ed.), 2005) (EN)
Cannabis et santé (Raynaud, 2004) (FR)
Cannabis und cannabinoide. pharmakologie, toxikologie und therapeutisches 
potenzial (Grotenhermen, 2005) (DE)
Halte au cannabis (Costentin,2006) (FR)
Le cannabis: et les autres drogues (Benyamina and de Paillette, 2005) (FR)
Management of alcohol and drug problems (Hulse, White and Cape, 2002) (EN)
Marijuana and madness (Castle and Murray (eds), 2004) (EN)
Wenn cannabis der seele schadet: Hilfe bei Sucht und psychischen Störungen 
(Lindberg and Haasen, 2005) (DE)
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